index	sentence	label
10064839.T49.T56	Binding of dimemorfan to @CHEMICAL$ and its anticonvulsant and locomotor effects in mice, compared with @GENE$ and dextrorphan.	false
10064839.T50.T56	Binding of @CHEMICAL$ to @GENE$ and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.	false
10064839.T51.T56	Binding of dimemorfan to @CHEMICAL$ and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and @GENE$.	false
10064839.T40.T54	This study therefore characterized the binding of @CHEMICAL$ to the @GENE$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR.	false
10064839.T41.T54	This study therefore characterized the binding of DF to the @CHEMICAL$ and @GENE$-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR.	false
10064839.T42.T54	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked @GENE$ sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR.	false
10064839.T43.T54	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of @GENE$ in mice in comparison with those of DM and DR.	false
10064839.T44.T54	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of @GENE$ and DR.	false
10064839.T45.T54	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and @GENE$.	false
10064839.T46.T52	We found that @CHEMICAL$, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at @GENE$ (Ki=4-11 microM).	false
10064839.T46.T55	We found that @CHEMICAL$, DM, and DR were relative high-affinity ligands at @GENE$ (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	false
10064839.T47.T52	We found that DF, @CHEMICAL$, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at @GENE$ (Ki=4-11 microM).	false
10064839.T47.T55	We found that DF, @CHEMICAL$, and DR were relative high-affinity ligands at @GENE$ (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	false
10064839.T48.T52	We found that DF, DM, and @CHEMICAL$ were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at @GENE$ (Ki=4-11 microM).	false
10064839.T48.T55	We found that DF, DM, and @CHEMICAL$ were relative high-affinity ligands at @GENE$ (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	false
10064839.T18.T53	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of @GENE$ at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.	false
10064839.T19.T53	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of DF at @GENE$ sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.	false
10064839.T20.T53	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of DF at PCP sites may suggest that acting on the @GENE$ sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.	false
10064839.T21.T53	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of DF at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these @GENE$ analogs.	false
10082498.T21.T33	@CHEM-GENE$ blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.	false
10082498.T21.T34	@CHEMICAL$ receptor blockade in normotensive subjects: A direct comparison of three @GENE$ antagonists.	false
10082498.T14.T28	Use of @CHEM-GENE$ antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-angiotensin system in humans are lacking.	false
10082498.T8.T28	Use of @CHEM-GENE$ antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-angiotensin system in humans are lacking.	false
10082498.T9.T25	In this study, the @CHEM-GENE$ blockade induced by the recommended starting dose of 3 antagonists was evaluated in normotensive subjects in a double-blind, placebo-controlled, randomized, 4-way crossover study.	false
10082498.T13.T30	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @GENE$ assay, and reactive changes in plasma Ang II levels.	false
10082498.T13.T26	Blockade of the @CHEMICAL$-@GENE$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T13.T27	Blockade of the renin-@CHEM-GENE$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T13.T29	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T13.T31	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T15.T30	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro @GENE$ assay, and reactive changes in plasma Ang II levels.	false
10082498.T15.T26	Blockade of the @CHEMICAL$-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T15.T27	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T15.T29	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEM-GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T15.T31	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T16.T30	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @CHEM-GENE$ assay, and reactive changes in plasma Ang II levels.	false
10082498.T16.T26	Blockade of the @CHEMICAL$-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @GENE$ receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T16.T27	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @GENE$ receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T16.T29	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro @GENE$ receptor assay, and reactive changes in plasma Ang II levels.	false
10082498.T16.T31	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @CHEMICAL$ receptor assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T17.T30	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @CHEMICAL$ assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T17.T26	Blockade of the @CHEMICAL$-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T17.T27	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T17.T29	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.	false
10082498.T17.T31	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @CHEM-GENE$ levels.	false
10082498.T18.T32	At 4 hours, losartan blocked 43% of the @CHEM-GENE$-induced systolic blood pressure increase; valsartan, 51%; and irbesartan, 88% (P<0.01 between drugs).	false
10082498.T19.T32	At 4 hours, losartan blocked 43% of the @CHEMICAL$-induced systolic blood pressure increase; @GENE$, 51%; and irbesartan, 88% (P<0.01 between drugs).	CPR:4
10082498.T20.T32	At 4 hours, losartan blocked 43% of the @CHEMICAL$-induced systolic blood pressure increase; valsartan, 51%; and @GENE$, 88% (P<0.01 between drugs).	CPR:4
10082498.T2.T22	Similar results were obtained when @CHEM-GENE$ blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma Ang II levels.	false
10082498.T2.T23	Similar results were obtained when @CHEMICAL$ receptor blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma @GENE$ levels.	false
10082498.T3.T22	Similar results were obtained when @CHEMICAL$ blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma @GENE$ levels.	false
10082498.T3.T23	Similar results were obtained when Ang II receptor blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma @CHEM-GENE$ levels.	false
10082498.T4.T24	This study thus demonstrates that the first administration of the recommended starting dose of @CHEMICAL$ induces a greater and longer lasting @GENE$ blockade than that of valsartan and losartan in normotensive subjects.	CPR:4
10082498.T5.T24	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting @CHEM-GENE$ blockade than that of valsartan and losartan in normotensive subjects.	false
10082498.T6.T24	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting @CHEMICAL$ blockade than that of @GENE$ and losartan in normotensive subjects.	CPR:4
10082498.T7.T24	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting @CHEMICAL$ blockade than that of valsartan and @GENE$ in normotensive subjects.	CPR:4
10193663.T17.T35	Characterisation of the @CHEM-GENE$ binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.	false
10193663.T17.T33	Characterisation of the @CHEMICAL$ receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at @GENE$ and 5-HT1D receptors.	false
10193663.T17.T34	Characterisation of the @CHEMICAL$ receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and @GENE$ receptors.	false
10193663.T18.T35	Characterisation of the @CHEMICAL$ binding profile of @GENE$ and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.	false
10193663.T18.T33	Characterisation of the 5-HT receptor binding profile of @CHEMICAL$ and kinetics of [3H]eletriptan binding at @GENE$ and 5-HT1D receptors.	false
10193663.T18.T34	Characterisation of the 5-HT receptor binding profile of @CHEMICAL$ and kinetics of [3H]eletriptan binding at human 5-HT1B and @GENE$ receptors.	false
10193663.T19.T35	Characterisation of the @CHEMICAL$ binding profile of eletriptan and kinetics of @GENE$ binding at human 5-HT1B and 5-HT1D receptors.	false
10193663.T19.T33	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of @CHEMICAL$ binding at @GENE$ and 5-HT1D receptors.	false
10193663.T19.T34	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of @CHEMICAL$ binding at human 5-HT1B and @GENE$ receptors.	false
10193663.T3.T21	The affinity of eletriptan ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of @CHEM-GENE$ was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.	false
10193663.T3.T25	The affinity of eletriptan ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of @CHEMICAL$ receptors was compared to values obtained for other @GENE$ receptor agonists known to be effective in the treatment of migraine.	false
10193663.T5.T21	The affinity of @CHEMICAL$ ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of @GENE$ was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.	false
10193663.T5.T25	The affinity of @CHEMICAL$ ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of 5-HT receptors was compared to values obtained for other @GENE$ receptor agonists known to be effective in the treatment of migraine.	false
10193663.T8.T21	The affinity of eletriptan (@CHEMICAL$) for a range of @GENE$ was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.	false
10193663.T8.T25	The affinity of eletriptan (@CHEMICAL$) for a range of 5-HT receptors was compared to values obtained for other @GENE$ receptor agonists known to be effective in the treatment of migraine.	false
10193663.T10.T26	Eletriptan, like sumatriptan, zolmitriptan, @CHEMICAL$ and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.	false
10193663.T10.T27	Eletriptan, like sumatriptan, zolmitriptan, @CHEMICAL$ and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.	false
10193663.T10.T28	Eletriptan, like sumatriptan, zolmitriptan, @CHEMICAL$ and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.	false
10193663.T11.T26	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and @CHEMICAL$ had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.	false
10193663.T11.T27	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and @CHEMICAL$ had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.	false
10193663.T11.T28	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and @CHEMICAL$ had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.	false
10193663.T6.T26	@CHEMICAL$, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.	false
10193663.T6.T27	@CHEMICAL$, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.	false
10193663.T6.T28	@CHEMICAL$, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.	false
10193663.T7.T26	Eletriptan, like @CHEMICAL$, zolmitriptan, naratriptan and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.	false
10193663.T7.T27	Eletriptan, like @CHEMICAL$, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.	false
10193663.T7.T28	Eletriptan, like @CHEMICAL$, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.	false
10193663.T9.T26	Eletriptan, like sumatriptan, @CHEMICAL$, naratriptan and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.	false
10193663.T9.T27	Eletriptan, like sumatriptan, @CHEMICAL$, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.	false
10193663.T9.T28	Eletriptan, like sumatriptan, @CHEMICAL$, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.	false
10193663.T12.T29	Kinetic studies comparing the binding of @CHEMICAL$ and [3H]sumatriptan to the @GENE$ and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	false
10193663.T12.T30	Kinetic studies comparing the binding of @CHEMICAL$ and [3H]sumatriptan to the human recombinant 5-HT1B and @GENE$ receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	false
10193663.T13.T29	Kinetic studies comparing the binding of [3H]eletriptan and @CHEMICAL$ to the @GENE$ and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	false
10193663.T13.T30	Kinetic studies comparing the binding of [3H]eletriptan and @CHEMICAL$ to the human recombinant 5-HT1B and @GENE$ receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	false
10193663.T14.T31	However, @CHEMICAL$ had over 6-fold higher affinity than [3H]sumatriptan at the @GENE$ receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).	false
10193663.T14.T32	However, @CHEMICAL$ had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the @GENE$ receptor (K(D): 3.14 and 11.07 nM, respectively).	false
10193663.T15.T31	However, [3H]eletriptan had over 6-fold higher affinity than @CHEMICAL$ at the @GENE$ receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).	false
10193663.T15.T32	However, [3H]eletriptan had over 6-fold higher affinity than @CHEMICAL$ at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the @GENE$ receptor (K(D): 3.14 and 11.07 nM, respectively).	false
10193663.T16.T31	However, [3H]eletriptan had over 6-fold higher affinity than [3H]sumatriptan at the @CHEMICAL$ receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than @GENE$ at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).	false
10193663.T16.T32	However, [3H]eletriptan had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than @CHEMICAL$ at the @GENE$ receptor (K(D): 3.14 and 11.07 nM, respectively).	false
10193663.T1.T20	Association and dissociation rates for both radioligands could only be accurately determined at the @CHEMICAL$ receptor and then only at 4 degrees C. At this temperature, @GENE$ had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than [3H]sumatriptan (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for [3H]sumatriptan).	false
10193663.T2.T20	Association and dissociation rates for both radioligands could only be accurately determined at the @CHEMICAL$ receptor and then only at 4 degrees C. At this temperature, [3H]eletriptan had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than @GENE$ (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for [3H]sumatriptan).	false
10193663.T4.T20	Association and dissociation rates for both radioligands could only be accurately determined at the @CHEMICAL$ receptor and then only at 4 degrees C. At this temperature, [3H]eletriptan had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than [3H]sumatriptan (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for @GENE$).	false
10193665.T24.T30	Pharmacological profile of @CHEMICAL$ at @GENE$.	false
10193665.T25.T30	Pharmacological profile of neuroleptics at @CHEM-GENE$.	false
10193665.T1.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 @CHEMICAL$ and one metabolite of a neuroleptic (haloperidol metabolite) for the @GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	false
10193665.T2.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (@CHEMICAL$ metabolite) for the @GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	false
10193665.T3.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEM-GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	false
10193665.T4.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEM-GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	false
10193665.T5.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEM-GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	false
10193665.T6.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEMICAL$ with @GENE$, [3H]nisoxetine, and [3H]WIN35428, respectively.	false
10193665.T7.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEMICAL$ with [3H]imipramine, @GENE$, and [3H]WIN35428, respectively.	false
10193665.T8.T26	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEMICAL$ with [3H]imipramine, [3H]nisoxetine, and @GENE$, respectively.	false
10193665.T10.T27	Among neuroleptics, the four most potent compounds at the @CHEM-GENE$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T10.T28	Among neuroleptics, the four most potent compounds at the human @CHEMICAL$ transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T11.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were @GENE$, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T11.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were @CHEMICAL$, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T12.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, @GENE$, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T12.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, @CHEMICAL$, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T13.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, @GENE$, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T13.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, @CHEMICAL$, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T14.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and @GENE$ (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T14.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and @CHEMICAL$ (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T15.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$ transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T15.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEM-GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T16.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, @GENE$, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T16.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, @GENE$, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T17.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, @GENE$, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T17.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, chlorpromazine, @GENE$, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T18.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, @GENE$, and promazine (K(D) 19-25 nM).	false
10193665.T18.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, chlorpromazine, zotepine, @GENE$, and promazine (K(D) 19-25 nM).	false
10193665.T19.T27	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and @GENE$ (K(D) 19-25 nM).	false
10193665.T19.T28	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, chlorpromazine, zotepine, chlorprothixene, and @GENE$ (K(D) 19-25 nM).	false
10193665.T9.T27	Among @CHEMICAL$, the four most potent compounds at the @GENE$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T9.T28	Among @CHEMICAL$, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	false
10193665.T20.T29	At the @CHEM-GENE$, only pimozide (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.	false
10193665.T21.T29	At the @CHEMICAL$, only @GENE$ (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.	false
10193665.T22.T29	At the @CHEMICAL$, only pimozide (K(D) = 69+/-3) @GENE$ (K(D) = 76+/-5) had notable potency.	false
10226872.T17.T31	@CHEMICAL$ does not prevent terbutaline-induced desensitization of @GENE$-mediated cardiovascular in vivo functions in human volunteers.	false
10226872.T18.T31	Disodium cromoglycate does not prevent @CHEMICAL$-induced desensitization of @GENE$-mediated cardiovascular in vivo functions in human volunteers.	false
10226872.T10.T20	In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of @CHEMICAL$-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug @GENE$.	false
10226872.T10.T27	In humans, prolonged administration of the @CHEMICAL$ agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug @GENE$.	false
10226872.T15.T20	In humans, prolonged administration of the beta 2-adrenoceptor agonist @CHEMICAL$ leads to a desensitization of @GENE$-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.	false
10226872.T15.T27	In humans, prolonged administration of the @CHEMICAL$ agonist @GENE$ leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.	CPR:5
10226872.T11.T26	This study investigated the effect of @CHEMICAL$, another antiallergic drug, on terbutaline-induced desensitization of @GENE$-mediated cardiovascular and noncardiovascular responses.	false
10226872.T12.T26	This study investigated the effect of disodium cromoglycate, another antiallergic drug, on @CHEMICAL$-induced desensitization of @GENE$-mediated cardiovascular and noncardiovascular responses.	false
10226872.T16.T29	beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective @CHEMICAL$ agonist @GENE$; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.	CPR:5
10226872.T16.T28	@CHEMICAL$ cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist @GENE$; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.	false
10226872.T16.T30	beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist @CHEMICAL$; @GENE$ cardiovascular function was assessed by exercise-induced tachycardia.	false
10226872.T4.T21	@CHEMICAL$ affected neither the rightward shift of @GENE$-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of terbutaline.	false
10226872.T4.T22	@CHEMICAL$ affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in @GENE$-mediated exercise tachycardia after 2 weeks' administration of terbutaline.	false
10226872.T5.T21	Disodium cromoglycate affected neither the rightward shift of @CHEMICAL$-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of @GENE$.	false
10226872.T5.T22	Disodium cromoglycate affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in @CHEMICAL$-mediated exercise tachycardia after 2 weeks' administration of @GENE$.	false
10226872.T6.T23	Tremulousness observed during the first few days of @CHEMICAL$ administration disappeared after 4 to 8 days, indicating development of desensitization of @GENE$-mediated noncardiovascular responses.	false
10362188.T12.T15	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @CHEMICAL$, on reperfusion induced by @GENE$ (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T12.T17	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @CHEMICAL$, on reperfusion induced by tissue plasminogen activator (@GENE$) in patients with acute myocardial infarction (AMI).	false
10362188.T12.T22	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct @CHEMICAL$ inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	CPR:4
10362188.T12.T23	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (@CHEMICAL$) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T12.T24	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and @CHEMICAL$ (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T12.T25	A multicenter, randomized study of argatroban versus heparin as adjunct to @CHEMICAL$ (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T13.T15	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by @GENE$ (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T13.T17	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (@GENE$) in patients with acute myocardial infarction (AMI).	false
10362188.T13.T22	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct @GENE$ inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T13.T23	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (@CHEMICAL$) in acute myocardial infarction: myocardial infarction with @GENE$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T13.T24	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and @GENE$ (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T13.T25	A multicenter, randomized study of argatroban versus heparin as adjunct to @CHEMICAL$ (TPA) in acute myocardial infarction: myocardial infarction with @GENE$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T14.T15	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by @GENE$ (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T14.T17	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (@GENE$) in patients with acute myocardial infarction (AMI).	false
10362188.T14.T22	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct @GENE$ inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T14.T23	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (@GENE$) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T14.T24	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and @GENE$ (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T14.T25	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to @GENE$ (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	false
10362188.T7.T19	In vitro and in vivo studies have shown that @CHEMICAL$ has advantages over heparin for the inhibition of clot-bound @GENE$ and for the enhancement of thrombolysis with TPA.	CPR:4
10362188.T7.T20	In vitro and in vivo studies have shown that @CHEMICAL$ has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with @GENE$.	false
10362188.T8.T21	METHODS: One hundred and twenty-five patients with AMI within 6 h were randomized to heparin, low-dose @CHEMICAL$ or high-dose argatroban in addition to @GENE$.	false
10362188.T9.T21	METHODS: One hundred and twenty-five patients with AMI within 6 h were randomized to heparin, low-dose argatroban or high-dose @CHEMICAL$ in addition to @GENE$.	false
10362188.T5.T16	CONCLUSIONS: @CHEMICAL$, as compared with heparin, appears to enhance reperfusion with @GENE$ in patients with AMI, particularly in those patients with delayed presentation.	false
10373224.T14.T31	The functional inhibitory characteristics of the @CHEM-GENE$ blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	false
10373224.T1.T31	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; @GENE$; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
10373224.T24.T31	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) @GENE$; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
10373224.T3.T31	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; irbesartan; and @GENE$ and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
10373224.T8.T31	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite @GENE$ (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
10373224.T9.T31	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (@GENE$) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
10373224.T15.T32	In both vascular preparations, @CHEMICAL$ caused a marked decrease in the maximal contractile response of the @GENE$ (Ang II) concentration-response curve.	CPR:4
10373224.T15.T33	In both vascular preparations, @CHEMICAL$ caused a marked decrease in the maximal contractile response of the angiotensin II (@GENE$) concentration-response curve.	CPR:4
10373224.T16.T32	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the @CHEM-GENE$ (Ang II) concentration-response curve.	false
10373224.T16.T33	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the @CHEMICAL$ (@GENE$) concentration-response curve.	false
10373224.T17.T32	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the @CHEMICAL$ (@GENE$) concentration-response curve.	false
10373224.T17.T33	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the angiotensin II (@CHEM-GENE$) concentration-response curve.	false
10373224.T18.T34	@CHEMICAL$, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to @GENE$.	false
10373224.T19.T34	Losartan, @CHEMICAL$, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to @GENE$.	false
10373224.T20.T34	Losartan, EXP, and @CHEMICAL$ caused a rightward parallel shift without any major effects on the maximal response to @GENE$.	false
10373224.T21.T34	Losartan, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to @CHEM-GENE$.	false
10373224.T2.T27	Cooling of the rat portal vein preparations to 4 degrees C before administration of @CHEMICAL$ prevented the persistent inhibition of @GENE$ response seen at 37 degrees C.	false
10373224.T4.T27	Cooling of the rat portal vein preparations to 4 degrees C before administration of candesartan prevented the persistent inhibition of @CHEM-GENE$ response seen at 37 degrees C.	false
10373224.T5.T28	For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the @CHEM-GENE$ response were independent of the incubation temperature before washing.	false
10373224.T10.T29	In addition, when candesartan was given to conscious rats, the inhibitory effect on @CHEMICAL$-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of @GENE$ at 24 hours.	false
10373224.T6.T29	In addition, when @CHEMICAL$ was given to conscious rats, the inhibitory effect on @GENE$-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.	CPR:4
10373224.T7.T29	In addition, when candesartan was given to conscious rats, the inhibitory effect on @CHEM-GENE$-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.	false
10373224.T12.T30	At clinically relevant concentrations, @CHEMICAL$ is an insurmountable and long-lasting antagonist of the vascular contractile responses to @GENE$.	CPR:4
10373224.T13.T30	At clinically relevant concentrations, candesartan is an insurmountable and long-lasting antagonist of the vascular contractile responses to @CHEM-GENE$.	false
10381787.T11.T21	Dose-dependent inhibition of platelet @CHEMICAL$ and monocyte cyclooxygenase-2 by @GENE$ in healthy subjects.	CPR:4
10381787.T11.T22	Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte @CHEMICAL$ by @GENE$ in healthy subjects.	CPR:4
10381787.T7.T12	We evaluated whether therapeutic blood levels of @CHEMICAL$ are associated with selective inhibition of monocyte @GENE$ in vitro and ex vivo.	false
10381787.T5.T17	Concentration-response curves for the inhibition of monocyte @CHEMICAL$ and platelet COX-1 were obtained in vitro after the incubation of @GENE$ with whole blood samples.	CPR:4
10381787.T5.T18	Concentration-response curves for the inhibition of monocyte COX-2 and platelet @CHEMICAL$ were obtained in vitro after the incubation of @GENE$ with whole blood samples.	CPR:4
10381787.T8.T19	Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and @CHEMICAL$ was measured in plasma as an index of monocyte @GENE$ activity.	CPR:9
10381787.T9.T20	The production of @CHEMICAL$ in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet @GENE$ activity.	CPR:9
10381787.T2.T13	In contrast, the administration of 7.5 and 15 mg of @CHEMICAL$ caused dose-dependent reductions in monocyte @GENE$ activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.	CPR:4
10381787.T2.T14	In contrast, the administration of 7.5 and 15 mg of @CHEMICAL$ caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet @GENE$ activity by 25% and 35%, respectively.	CPR:4
10381787.T3.T15	Although the IC50 value of @CHEMICAL$ for inhibition of @GENE$ was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	CPR:4
10381787.T3.T16	Although the IC50 value of @CHEMICAL$ for inhibition of COX-1 was 10-fold higher than the IC50 value of @GENE$ in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	CPR:4
10381787.T4.T15	Although the IC50 value of meloxicam for inhibition of @CHEMICAL$ was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of @GENE$ on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	false
10381787.T4.T16	Although the IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than the IC50 value of @CHEMICAL$ in vitro, this biochemical selectivity was inadequate to clearly separate the effects of @GENE$ on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	false
10432475.T41.T61	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by @CHEMICAL$ alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.	false
10432475.T41.T62	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by @CHEMICAL$ alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.	false
10432475.T42.T61	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with @CHEMICAL$ reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.	false
10432475.T42.T62	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with @CHEMICAL$ reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.	false
10432475.T43.T61	Modulation of dialysate levels of @CHEMICAL$, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.	false
10432475.T43.T62	Modulation of dialysate levels of @CHEMICAL$, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.	false
10432475.T44.T61	Modulation of dialysate levels of dopamine, @CHEMICAL$, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.	false
10432475.T44.T62	Modulation of dialysate levels of dopamine, @CHEMICAL$, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.	false
10432475.T45.T61	Modulation of dialysate levels of dopamine, noradrenaline, and @CHEMICAL$ (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.	false
10432475.T45.T62	Modulation of dialysate levels of dopamine, noradrenaline, and @CHEMICAL$ (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.	false
10432475.T46.T61	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (@CHEMICAL$) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.	false
10432475.T46.T62	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (@CHEMICAL$) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.	false
10432475.T1.T48	@CHEMICAL$, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @GENE$, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T1.T58	@CHEMICAL$, which possesses significant affinity for 5-HT1A, 5-HT1B, and @GENE$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T1.T54	@CHEMICAL$, which possesses significant affinity for @GENE$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T1.T56	@CHEMICAL$, which possesses significant affinity for 5-HT1A, @GENE$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T21.T48	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T21.T58	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T21.T54	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T21.T56	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T22.T48	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T22.T58	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T22.T54	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T22.T56	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T24.T48	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T24.T58	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T24.T54	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T24.T56	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T25.T48	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T25.T58	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T25.T54	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T25.T56	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T26.T48	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T26.T58	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T26.T54	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T26.T56	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	false
10432475.T27.T52	In distinction, the preferential @CHEMICAL$ antagonist, @GENE$, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.	CPR:6
10432475.T27.T53	In distinction, the preferential beta 1-AR antagonist, @CHEMICAL$, and the preferential @GENE$ antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.	false
10432475.T28.T52	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, @GENE$, did not increase basal levels of DA, NAD, or 5-HT.	false
10432475.T28.T53	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, @GENE$, did not increase basal levels of DA, NAD, or 5-HT.	CPR:6
10432475.T29.T52	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of @GENE$, NAD, or 5-HT.	false
10432475.T29.T53	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, ICI118,551, did not increase basal levels of @GENE$, NAD, or 5-HT.	false
10432475.T30.T52	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, @GENE$, or 5-HT.	false
10432475.T30.T53	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, ICI118,551, did not increase basal levels of DA, @GENE$, or 5-HT.	false
10432475.T31.T52	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or @GENE$.	false
10432475.T31.T53	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, ICI118,551, did not increase basal levels of DA, NAD, or @GENE$.	false
10432475.T35.T55	The selective @CHEMICAL$ receptor antagonist, @GENE$, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	CPR:6
10432475.T35.T57	The selective 5-HT1A receptor antagonist, @CHEMICAL$, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.	false
10432475.T36.T55	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the @GENE$-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	false
10432475.T36.T57	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the @CHEMICAL$-induced increase in DA and NAD levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.	false
10432475.T37.T55	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in @GENE$ and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	false
10432475.T37.T57	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in @CHEMICAL$ and NAD levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.	false
10432475.T38.T55	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and @GENE$ levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	false
10432475.T38.T57	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and @CHEMICAL$ levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.	false
10432475.T39.T55	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, @GENE$, was ineffective.	false
10432475.T39.T57	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective @CHEMICAL$ antagonist, @GENE$, was ineffective.	CPR:6
10432475.T40.T59	These data suggest that @CHEMICAL$ facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of @GENE$ and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas 5-HT1B receptors are not involved.	false
10432475.T40.T47	These data suggest that @CHEMICAL$ facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas @GENE$ receptors are not involved.	false
10432475.T40.T60	These data suggest that @CHEMICAL$ facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of @GENE$ receptors, whereas 5-HT1B receptors are not involved.	false
10432475.T19.T49	In conclusion, @CHEMICAL$ modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at @GENE$, 5-HT1A, and 5-HT1B receptors.	false
10432475.T19.T50	In conclusion, @CHEMICAL$ modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, @GENE$, and 5-HT1B receptors.	false
10432475.T19.T51	In conclusion, @CHEMICAL$ modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and @GENE$ receptors.	false
10432475.T20.T49	In conclusion, (-)-pindolol modulates, both alone and together with @CHEMICAL$ reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at @GENE$, 5-HT1A, and 5-HT1B receptors.	false
10432475.T20.T50	In conclusion, (-)-pindolol modulates, both alone and together with @CHEMICAL$ reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, @GENE$, and 5-HT1B receptors.	false
10432475.T20.T51	In conclusion, (-)-pindolol modulates, both alone and together with @CHEMICAL$ reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and @GENE$ receptors.	false
10439935.T15.T26	UNLABELLED: Entacapone is a potent and specific peripheral @CHEM-GENE$ (COMT) inhibitor.	false
10439935.T15.T28	UNLABELLED: Entacapone is a potent and specific peripheral @CHEMICAL$-O-methyltransferase (@GENE$) inhibitor.	false
10439935.T17.T26	UNLABELLED: Entacapone is a potent and specific peripheral @CHEM-GENE$ (COMT) inhibitor.	false
10439935.T17.T28	UNLABELLED: Entacapone is a potent and specific peripheral catechol-@CHEMICAL$-methyltransferase (@GENE$) inhibitor.	false
10439935.T5.T26	UNLABELLED: @CHEMICAL$ is a potent and specific peripheral @GENE$ (COMT) inhibitor.	CPR:4
10439935.T5.T28	UNLABELLED: @CHEMICAL$ is a potent and specific peripheral catechol-O-methyltransferase (@GENE$) inhibitor.	CPR:4
10439935.T12.T24	It has been shown to improve the clinical benefits of levodopa plus an @CHEMICAL$ inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to @GENE$ (the 'wearing off' phenomenon).	false
10439935.T12.T25	It has been shown to improve the clinical benefits of levodopa plus an aromatic L-amino acid decarboxylase inhibitor (@CHEMICAL$) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to @GENE$ (the 'wearing off' phenomenon).	false
10439935.T7.T24	It has been shown to improve the clinical benefits of @CHEMICAL$ plus an @GENE$ inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).	false
10439935.T7.T25	It has been shown to improve the clinical benefits of @CHEMICAL$ plus an aromatic L-amino acid decarboxylase inhibitor (@GENE$) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).	false
10439935.T9.T24	It has been shown to improve the clinical benefits of levodopa plus an @CHEM-GENE$ inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).	false
10439935.T9.T25	It has been shown to improve the clinical benefits of levodopa plus an @CHEMICAL$ decarboxylase inhibitor (@GENE$) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).	false
10439935.T14.T27	In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with @CHEMICAL$ (200 mg with each dose of levodopa/@GENE$ inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.	false
10439935.T16.T27	In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with entacapone (200 mg with each dose of @CHEMICAL$/@GENE$ inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.	false
10439935.T19.T21	@CHEMICAL$ also provided benefits when given with controlled release levodopa/ @GENE$ inhibitor or with standard levodopa/AADC inhibitor and selegiline in small trials.	false
10439935.T19.T22	@CHEMICAL$ also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard levodopa/@GENE$ inhibitor and selegiline in small trials.	false
10439935.T1.T21	Entacapone also provided benefits when given with controlled release @CHEMICAL$/ @GENE$ inhibitor or with standard levodopa/AADC inhibitor and selegiline in small trials.	false
10439935.T1.T22	Entacapone also provided benefits when given with controlled release @CHEMICAL$/ AADC inhibitor or with standard levodopa/@GENE$ inhibitor and selegiline in small trials.	false
10439935.T2.T21	Entacapone also provided benefits when given with controlled release levodopa/ @CHEMICAL$ inhibitor or with standard @GENE$/AADC inhibitor and selegiline in small trials.	false
10439935.T2.T22	Entacapone also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard @CHEMICAL$/@GENE$ inhibitor and selegiline in small trials.	false
10439935.T3.T21	Entacapone also provided benefits when given with controlled release levodopa/ @CHEMICAL$ inhibitor or with standard levodopa/AADC inhibitor and @GENE$ in small trials.	false
10439935.T3.T22	Entacapone also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard levodopa/@CHEMICAL$ inhibitor and @GENE$ in small trials.	false
10439935.T8.T23	CONCLUSIONS: The efficacy and tolerability of entacapone administered with @CHEMICAL$/@GENE$ inhibitor have not yet been compared with those of other strategies for the treatment of Parkinson's disease.	false
10460702.T22.T44	@CHEMICAL$ evokes @GENE$ activation in bovine aortic endothelial cell cultures.	CPR:3
10460702.T23.T44	5-hydroxytryptamine evokes @CHEM-GENE$ activation in bovine aortic endothelial cell cultures.	false
10460702.T19.T32	Activation of @CHEMICAL$ (eNOS) results in the production of @GENE$ (NO) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
10460702.T19.T38	Activation of endothelial nitric oxide synthase (@CHEMICAL$) results in the production of @GENE$ (NO) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
10460702.T20.T32	Activation of @CHEMICAL$ (eNOS) results in the production of nitric oxide (@GENE$) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
10460702.T20.T38	Activation of endothelial nitric oxide synthase (@CHEMICAL$) results in the production of nitric oxide (@GENE$) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
10460702.T9.T32	Activation of @CHEM-GENE$ (eNOS) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.	false
10460702.T9.T38	Activation of endothelial @CHEMICAL$ synthase (@GENE$) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.	false
10460702.T7.T35	The goal of this project was to address the possibility that @CHEMICAL$ (5-HT) stimulates @GENE$ activity in bovine aortic endothelial cell (BAEC) cultures.	false
10460702.T8.T35	The goal of this project was to address the possibility that 5-hydroxytryptamine (@CHEMICAL$) stimulates @GENE$ activity in bovine aortic endothelial cell (BAEC) cultures.	false
10460702.T10.T36	Here, we tested the hypothesis that @CHEM-GENE$ mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures.	false
10460702.T10.T37	Here, we tested the hypothesis that @CHEMICAL$ receptors mediate @GENE$ activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures.	false
10460702.T11.T36	Here, we tested the hypothesis that @CHEMICAL$ mediate eNOS activation by measuring agonist-stimulated @GENE$ ([3H]L-Cit) formation in BAEC cultures.	false
10460702.T11.T37	Here, we tested the hypothesis that 5-HT receptors mediate @CHEMICAL$ activation by measuring agonist-stimulated @GENE$ ([3H]L-Cit) formation in BAEC cultures.	CPR:9
10460702.T12.T36	Here, we tested the hypothesis that @CHEMICAL$ mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline (@GENE$) formation in BAEC cultures.	false
10460702.T12.T37	Here, we tested the hypothesis that 5-HT receptors mediate @CHEMICAL$ activation by measuring agonist-stimulated [3H]L-citrulline (@GENE$) formation in BAEC cultures.	CPR:9
10460702.T13.T39	We found that @CHEMICAL$ stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating @GENE$ activation.	CPR:3
10460702.T14.T39	We found that 5-HT stimulated the conversion of @CHEMICAL$ ([3H]L-Arg) to [3H]L-Cit, indicating @GENE$ activation.	CPR:9
10460702.T15.T39	We found that 5-HT stimulated the conversion of [3H]L-arginine (@CHEMICAL$) to [3H]L-Cit, indicating @GENE$ activation.	CPR:9
10460702.T16.T39	We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to @CHEMICAL$, indicating @GENE$ activation.	CPR:9
10460702.T17.T40	The high affinity @CHEMICAL$ receptor agonist, @GENE$ (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.	CPR:5
10460702.T18.T40	The high affinity @CHEMICAL$ receptor agonist, 5-nonyloxytryptamine (5-NOT)-stimulated @GENE$ turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.	false
10460702.T1.T43	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T1.T24	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	CPR:6
10460702.T1.T41	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T1.T42	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T21.T43	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, @GENE$, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	CPR:6
10460702.T21.T24	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, @CHEMICAL$, and the @GENE$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T21.T41	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, @GENE$, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T21.T42	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, @GENE$, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	CPR:6
10460702.T2.T43	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T2.T24	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).	CPR:6
10460702.T2.T41	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T2.T42	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).	false
10460702.T3.T43	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).	false
10460702.T3.T24	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).	CPR:6
10460702.T3.T41	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).	false
10460702.T3.T42	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).	false
10460702.T4.T43	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).	false
10460702.T4.T24	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).	CPR:6
10460702.T4.T41	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).	false
10460702.T4.T42	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).	false
10460702.T5.T29	These findings lend evidence of a @CHEMICAL$ receptor/eNOS pathway, accounting in part for the activation of eNOS by @GENE$.	false
10460702.T5.T30	These findings lend evidence of a 5-HT1B receptor/@CHEMICAL$ pathway, accounting in part for the activation of eNOS by @GENE$.	false
10460702.T5.T31	These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of @CHEMICAL$ by @GENE$.	CPR:3
10460702.T6.T33	Further investigation is needed to determine the role of other vascular @CHEM-GENE$ in the stimulation of eNOS activity.	false
10460702.T6.T34	Further investigation is needed to determine the role of other vascular @CHEMICAL$ receptors in the stimulation of @GENE$ activity.	false
10531013.T6.T13	@CHEMICAL$ inhibits the checkpoint @GENE$ ATM.	CPR:4
10531013.T6.T14	@CHEMICAL$ inhibits the checkpoint kinase @GENE$.	CPR:4
10531013.T1.T10	We report that the radiation-induced activation of the @CHEMICAL$ Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by @GENE$ in vitro.	false
10531013.T1.T8	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM @CHEMICAL$ activity is directly inhibited by @GENE$ in vitro.	CPR:4
10531013.T1.T11	We report that the radiation-induced activation of the kinase @CHEMICAL$ [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by @GENE$ in vitro.	false
10531013.T1.T12	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as @CHEMICAL$ [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by @GENE$ in vitro.	false
10531013.T1.T7	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that @CHEMICAL$ kinase activity is directly inhibited by @GENE$ in vitro.	CPR:4
10531013.T5.T10	We report that the radiation-induced activation of the @CHEMICAL$ Cds1 [4] (also known as Chk2 [5]) is inhibited by @GENE$ in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.	CPR:4
10531013.T5.T8	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by @CHEMICAL$ in vivo and that ATM @GENE$ activity is directly inhibited by caffeine in vitro.	false
10531013.T5.T11	We report that the radiation-induced activation of the kinase @CHEMICAL$ [4] (also known as Chk2 [5]) is inhibited by @GENE$ in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.	CPR:4
10531013.T5.T12	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as @CHEMICAL$ [5]) is inhibited by @GENE$ in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.	CPR:4
10531013.T5.T7	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by @CHEMICAL$ in vivo and that @GENE$ kinase activity is directly inhibited by caffeine in vitro.	false
10531013.T2.T9	Inhibition of @CHEMICAL$ provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of @GENE$-treated cells [6] [7] [8].	CPR:4
10546982.T8.T20	@CHEM-GENE$ production and degradation rates: studies with RTI-76.	false
10546982.T9.T20	@CHEMICAL$ production and degradation rates: studies with @GENE$.	false
10546982.T6.T15	The objective of this study was to examine the turnover of the @CHEM-GENE$ (SERT) by determining its production rate (r), degradation rate constant (k) and half-life of recovery (t1/2).	false
10546982.T6.T18	The objective of this study was to examine the turnover of the @CHEMICAL$ transporter (@GENE$) by determining its production rate (r), degradation rate constant (k) and half-life of recovery (t1/2).	false
10546982.T2.T12	The turnover of @CHEMICAL$ was determined from the rate of recovery of binding after administration of @GENE$, an irreversible inhibitor of ligand binding.	CPR:4
10546982.T3.T13	In preliminary studies, in vitro incubation of rat cerebral cortex with @CHEMICAL$ produced a wash and temperature resistant inhibition of @GENE$ binding densities (Bmax).	CPR:4
10546982.T4.T14	@CHEMICAL$ protected against the RTI-76-induced inhibition of @GENE$ binding.	false
10546982.T5.T14	Citalopram protected against the @CHEMICAL$-induced inhibition of @GENE$ binding.	CPR:4
10546982.T7.T16	Following 6 h of in vivo intracerebroventricular injections of 100 nmol of @CHEMICAL$, there was a dose- and time-dependent reduction (- 60%) of @GENE$ binding in hippocampus and striatum, without a change in the Kd.	false
10546982.T1.T11	The decrease and recovery of @CHEMICAL$ uptake correlated highly (r = 0.93) with the recovery of @GENE$ binding.	CPR:9
10579749.T33.T45	Pharmacological properties of @CHEM-GENE$ antagonists.	false
10579749.T16.T37	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-@GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T16.T38	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEM-GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T16.T39	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the @GENE$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T16.T40	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T16.T41	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ inhibitors.	false
10579749.T16.T43	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T17.T37	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-angiotensin-@GENE$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T17.T38	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-@GENE$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T17.T39	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@CHEMICAL$ system at the level of the @GENE$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T17.T40	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@CHEMICAL$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T17.T41	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@CHEMICAL$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ inhibitors.	false
10579749.T17.T43	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@GENE$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T18.T37	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T18.T38	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T18.T39	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the @CHEMICAL$ receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T18.T40	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @CHEM-GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T18.T41	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @CHEMICAL$, and avoid the nonspecificity of the @GENE$ inhibitors.	false
10579749.T18.T43	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T19.T37	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.	false
10579749.T19.T38	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.	false
10579749.T19.T39	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the @CHEMICAL$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.	false
10579749.T19.T40	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @CHEMICAL$, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.	false
10579749.T19.T41	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @CHEM-GENE$ inhibitors.	false
10579749.T19.T43	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.	false
10579749.T29.T37	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @GENE$-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T29.T38	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T29.T39	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the @GENE$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T29.T40	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T29.T41	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ inhibitors.	false
10579749.T29.T43	The availability of selective, potent, orally active and long acting nonpeptide @CHEM-GENE$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	false
10579749.T20.T42	@CHEMICAL$ was the first, but by no means remained the only, @GENE$ receptor antagonist.	CPR:6
10579749.T1.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of @GENE$) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T2.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, @GENE$ 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T30.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: @GENE$ 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T31.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, @GENE$ 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T32.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, @GENE$ (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T3.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, @GENE$ 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T4.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, @GENE$ 100 and the prodrug candesartan cilexetil 280.	CPR:6
10579749.T5.T44	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug @GENE$ 280.	CPR:6
10579749.T10.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, @GENE$, zolasartan, irbesartan, valsartan, telmisartan, E3174).	CPR:6
10579749.T11.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, @GENE$, irbesartan, valsartan, telmisartan, E3174).	CPR:6
10579749.T12.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, @GENE$, valsartan, telmisartan, E3174).	CPR:6
10579749.T13.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, @GENE$, telmisartan, E3174).	CPR:6
10579749.T14.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, @GENE$, E3174).	CPR:6
10579749.T15.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, @GENE$).	CPR:6
10579749.T6.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (@GENE$, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	CPR:6
10579749.T7.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, @GENE$, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	CPR:6
10579749.T8.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, @GENE$) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	CPR:6
10579749.T9.T34	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (@GENE$, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	CPR:6
10637238.T10.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and @GENE$ inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T10.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and @GENE$ inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T10.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and @GENE$ inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T11.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question mark@GENE$; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T11.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question mark@GENE$; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T11.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question mark@GENE$; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T5.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEM-GENE$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T5.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ receptor (@GENE$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T5.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ receptor (ER)-positive or @GENE$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T6.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (@GENE$, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T6.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (@GENE$, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T6.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (@GENE$, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T7.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, @GENE$, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T7.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, @GENE$, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T7.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, @GENE$, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T8.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and @GENE$ inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T8.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and @GENE$ inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T8.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and @GENE$ inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T9.T16	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus @GENE$ and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T9.T17	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus @GENE$ and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10637238.T9.T18	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus @GENE$ and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	false
10683249.T17.T36	Characterization and partial purification of microsomal @CHEM-GENE$.	false
10683249.T18.T36	Characterization and partial purification of microsomal @CHEM-GENE$.	false
10683249.T1.T19	@CHEM-GENE$ are flavoproteins that catalyze two-electron reduction and detoxification of quinones.	false
10683249.T2.T19	@CHEMICAL$ are flavoproteins that catalyze two-electron reduction and detoxification of @GENE$.	CPR:9
10683249.T10.T24	Two cytosolic forms of @CHEMICAL$ [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:@GENE$ oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T10.T25	Two cytosolic forms of quinone oxidoreductases @CHEMICAL$ (NQO1) and NRH:@GENE$ oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T10.T26	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (@CHEMICAL$) and NRH:@GENE$ oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T10.T27	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and @CHEM-GENE$ (NQO2)] were previously identified, purified, and cloned.	false
10683249.T10.T28	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:@CHEMICAL$ oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.	false
10683249.T7.T24	Two cytosolic forms of @CHEM-GENE$ [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T7.T25	Two cytosolic forms of @CHEMICAL$ oxidoreductases @GENE$ (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T7.T26	Two cytosolic forms of @CHEMICAL$ oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (@GENE$) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T7.T27	Two cytosolic forms of @CHEMICAL$ oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and @GENE$ (NQO2)] were previously identified, purified, and cloned.	false
10683249.T7.T28	Two cytosolic forms of @CHEMICAL$ oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.	false
10683249.T8.T24	Two cytosolic forms of @CHEMICAL$ [@GENE$:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T8.T25	Two cytosolic forms of quinone oxidoreductases @CHEM-GENE$ (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T8.T26	Two cytosolic forms of quinone oxidoreductases [@CHEMICAL$:quinone oxidoreductase 1 (@GENE$) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T8.T27	Two cytosolic forms of quinone oxidoreductases [@CHEMICAL$:quinone oxidoreductase 1 (NQO1) and @GENE$ (NQO2)] were previously identified, purified, and cloned.	false
10683249.T8.T28	Two cytosolic forms of quinone oxidoreductases [@CHEMICAL$:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.	false
10683249.T9.T24	Two cytosolic forms of @CHEMICAL$ [NAD(P)H:@GENE$ oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T9.T25	Two cytosolic forms of quinone oxidoreductases @CHEM-GENE$ (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T9.T26	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:@CHEMICAL$ oxidoreductase 1 (@GENE$) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	false
10683249.T9.T27	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:@CHEMICAL$ oxidoreductase 1 (NQO1) and @GENE$ (NQO2)] were previously identified, purified, and cloned.	false
10683249.T9.T28	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:@CHEMICAL$ oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.	false
10683249.T11.T29	A role of cytosolic @CHEMICAL$ in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of @GENE$ was established.	CPR:9
10683249.T12.T33	The @CHEMICAL$ activity showed significantly higher affinity for @GENE$ than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.	false
10683249.T13.T33	The @CHEMICAL$ activity showed significantly higher affinity for NADH than @GENE$ as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.	false
10683249.T14.T33	The @CHEMICAL$ activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of @GENE$ and menadione.	CPR:9
10683249.T15.T33	The @CHEMICAL$ activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and @GENE$.	CPR:9
10683249.T16.T34	The @CHEMICAL$ activity was insensitive to @GENE$, a potent inhibitor of cytosolic NQO1.	false
10683249.T16.T35	The mNQO activity was insensitive to @CHEMICAL$, a potent inhibitor of cytosolic @GENE$.	CPR:4
10683249.T3.T21	The @CHEMICAL$ activity was partially purified by solubilization of microsomes with detergent Chaps, @GENE$ fractionation, and DEAE-Sephacel column chromatography.	false
10683249.T4.T21	The @CHEMICAL$ activity was partially purified by solubilization of microsomes with detergent Chaps, ammonium sulfate fractionation, and @GENE$-Sephacel column chromatography.	false
10683249.T5.T22	The microsomal @CHEMICAL$ proteins are expected to provide additional protection after cytosolic NQOs against @GENE$ toxicity and mutagenicity.	false
10683249.T5.T23	The microsomal mNQO proteins are expected to provide additional protection after cytosolic @CHEMICAL$ against @GENE$ toxicity and mutagenicity.	false
10688973.T4.T31	The affinity and functional profile of opioids possessing activity at the @CHEMICAL$ was determined using [3H]nociceptin and nociceptin-stimulated @GENE$ binding.	false
10688973.T5.T32	The @CHEMICAL$-selective agonist @GENE$ potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).	CPR:5
10688973.T6.T33	@CHEMICAL$ exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant @GENE$ receptors (EC(50) 50 nM).	CPR:5
10688973.T7.T33	Lofentanil exhibited full agonism for enhancement of @CHEMICAL$ binding to human recombinant @GENE$ receptors (EC(50) 50 nM).	false
10688973.T10.T35	The related piperidines ohmefentanyl and @CHEMICAL$ and the nonselective @GENE$ agonist etorphine were less potent nociceptin receptor agonists.	false
10688973.T10.T36	The related piperidines ohmefentanyl and @CHEMICAL$ and the nonselective opioid receptor agonist etorphine were less potent @GENE$ agonists.	CPR:5
10688973.T11.T35	The related piperidines ohmefentanyl and sufentanil and the nonselective @CHEMICAL$ agonist @GENE$ were less potent nociceptin receptor agonists.	CPR:5
10688973.T11.T36	The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist @CHEMICAL$ were less potent @GENE$ agonists.	CPR:5
10688973.T8.T35	The related @CHEMICAL$ ohmefentanyl and sufentanil and the nonselective @GENE$ agonist etorphine were less potent nociceptin receptor agonists.	false
10688973.T8.T36	The related @CHEMICAL$ ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent @GENE$ agonists.	CPR:5
10688973.T9.T35	The related piperidines @CHEMICAL$ and sufentanil and the nonselective @GENE$ agonist etorphine were less potent nociceptin receptor agonists.	false
10688973.T9.T36	The related piperidines @CHEMICAL$ and sufentanil and the nonselective opioid receptor agonist etorphine were less potent @GENE$ agonists.	CPR:5
10688973.T12.T14	The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist @CHEMICAL$ was a pure antagonist at both rat brain and human @GENE$ receptors.	CPR:6
10688973.T12.T37	The kappa(1)+kappa(3)-opioid receptor agonist/@CHEMICAL$ antagonist @GENE$ was a pure antagonist at both rat brain and human ORL1 receptors.	CPR:6
10688973.T1.T15	The nonselective @CHEMICAL$ partial agonist @GENE$ and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	CPR:5
10688973.T1.T16	The nonselective opioid receptor partial agonist @CHEMICAL$ and the nonselective @GENE$ antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	false
10688973.T1.T19	The nonselective opioid receptor partial agonist @CHEMICAL$ and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at @GENE$ receptors.	false
10688973.T2.T15	The nonselective @CHEMICAL$ partial agonist buprenorphine and the nonselective opioid receptor antagonist @GENE$ exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	false
10688973.T2.T16	The nonselective opioid receptor partial agonist buprenorphine and the nonselective @CHEMICAL$ antagonist @GENE$ exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	CPR:6
10688973.T2.T19	The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist @CHEMICAL$ exhibited pure antagonism at rat brain receptors, but displayed partial agonism at @GENE$ receptors.	CPR:5
10688973.T3.T24	In addition, the stereospecificity required at @CHEMICAL$ appears to be retained at the nociceptin receptor, since @GENE$ is inactive at both receptors.	false
10688973.T3.T25	In addition, the stereospecificity required at opioid receptors appears to be retained at the @CHEMICAL$, since @GENE$ is inactive at both receptors.	false
10697523.T1.T20	@CHEM-GENE$ and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.	false
10697523.T1.T22	@CHEMICAL$ synthase and @GENE$ are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.	false
10697523.T2.T20	@CHEMICAL$ and thymidine kinase are key enzymes involved in the de novo and salvage pathways for @GENE$ synthesis, respectively.	CPR:9
10697523.T2.T22	Thymidylate synthase and @CHEMICAL$ are key enzymes involved in the de novo and salvage pathways for @GENE$ synthesis, respectively.	CPR:9
10697523.T5.T20	@CHEMICAL$ and @GENE$ kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.	false
10697523.T5.T22	Thymidylate synthase and @CHEM-GENE$ are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.	false
10697523.T3.T21	@CHEM-GENE$ is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular folate.	false
10697523.T4.T21	@CHEMICAL$ is inhibited by @GENE$, forming an inactive ternary complex with intracellular folate.	CPR:4
10697523.T6.T21	@CHEMICAL$ is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular @GENE$.	false
10697523.T12.T23	Thirty-week administration of @CHEMICAL$ with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @GENE$ inhibition and the decrease of thymidine kinase activity in the tumor cells.	CPR:4
10697523.T12.T24	Thirty-week administration of @CHEMICAL$ with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of @GENE$ activity in the tumor cells.	CPR:4
10697523.T13.T23	Thirty-week administration of UFT with or without @CHEMICAL$ markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @GENE$ inhibition and the decrease of thymidine kinase activity in the tumor cells.	CPR:4
10697523.T13.T24	Thirty-week administration of UFT with or without @CHEMICAL$ markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of @GENE$ activity in the tumor cells.	CPR:4
10697523.T14.T23	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @CHEM-GENE$ inhibition and the decrease of thymidine kinase activity in the tumor cells.	false
10697523.T14.T24	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @CHEMICAL$ synthase inhibition and the decrease of @GENE$ activity in the tumor cells.	false
10697523.T15.T23	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @CHEMICAL$ inhibition and the decrease of @GENE$ kinase activity in the tumor cells.	false
10697523.T15.T24	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of @CHEM-GENE$ activity in the tumor cells.	false
10698696.T5.T28	@CHEMICAL$ is rapidly induced in growth-stimulated mouse fibroblasts and releases @GENE$ decarboxylase from antizyme suppression.	false
10698696.T5.T29	Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases @CHEMICAL$ decarboxylase from @GENE$ suppression.	false
10698696.T5.T30	Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases @CHEM-GENE$ from antizyme suppression.	false
10698696.T1.T13	@CHEMICAL$ decarboxylase (@GENE$) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine.	false
10698696.T1.T6	@CHEM-GENE$ (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine.	false
10698696.T2.T13	Ornithine decarboxylase (@CHEMICAL$) catalyses the first step in the synthesis of the polyamines putrescine, @GENE$ and spermine.	CPR:9
10698696.T2.T6	@CHEMICAL$ (ODC) catalyses the first step in the synthesis of the polyamines putrescine, @GENE$ and spermine.	CPR:9
10698696.T3.T13	Ornithine decarboxylase (@CHEMICAL$) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and @GENE$.	CPR:9
10698696.T3.T6	@CHEMICAL$ (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and @GENE$.	CPR:9
10698696.T4.T13	Ornithine decarboxylase (@CHEMICAL$) catalyses the first step in the synthesis of the polyamines @GENE$, spermidine and spermine.	CPR:9
10698696.T4.T6	@CHEMICAL$ (ODC) catalyses the first step in the synthesis of the polyamines @GENE$, spermidine and spermine.	CPR:9
10742288.T1.T22	In untransfected CHL cells, @CHEMICAL$ had no effect at concentrations up to 100 microM. In @GENE$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	false
10742288.T2.T22	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was @GENE$ (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	CPR:5
10742288.T3.T22	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>@GENE$ (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	CPR:5
10742288.T4.T22	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>@GENE$ (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	CPR:5
10742288.T5.T22	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>@GENE$ (7.05)>noradrenaline (6.92).	CPR:5
10742288.T6.T22	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>@GENE$ (6.92).	CPR:5
10742288.T12.T23	3. The selective @CHEMICAL$ ligand @GENE$ antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43.	false
10742288.T13.T23	3. The selective @CHEMICAL$ ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against @GENE$ was 8.43.	false
10742288.T14.T24	The selective @CHEMICAL$ ligands @GENE$ and doxazosin (each 3 microM) had no effect on noradrenaline responses.	false
10742288.T15.T24	The selective @CHEMICAL$ ligands prazosin and @GENE$ (each 3 microM) had no effect on noradrenaline responses.	false
10742288.T16.T24	The selective @CHEMICAL$ ligands prazosin and doxazosin (each 3 microM) had no effect on @GENE$ responses.	false
10796070.T10.T18	@CHEMICAL$ were activated by @GENE$ as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.	CPR:3
10796070.T2.T11	The @CHEMICAL$ antagonist @GENE$ (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.	CPR:6
10796070.T2.T12	The glucocorticoid receptor antagonist @CHEMICAL$ (mifepristone) significantly counteracted the effect of dexamethasone on @GENE$ activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.	false
10796070.T2.T13	The glucocorticoid receptor antagonist @CHEMICAL$ (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the @GENE$.	false
10796070.T3.T11	The @CHEMICAL$ antagonist RU-486 (@GENE$) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.	CPR:6
10796070.T3.T12	The glucocorticoid receptor antagonist RU-486 (@CHEMICAL$) significantly counteracted the effect of dexamethasone on @GENE$ activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.	false
10796070.T3.T13	The glucocorticoid receptor antagonist RU-486 (@CHEMICAL$) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the @GENE$.	false
10796070.T4.T11	The @CHEMICAL$ antagonist RU-486 (mifepristone) significantly counteracted the effect of @GENE$ on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.	false
10796070.T4.T12	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of @CHEMICAL$ on @GENE$ activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.	false
10796070.T4.T13	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of @CHEMICAL$ on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the @GENE$.	false
10796070.T5.T11	The @CHEMICAL$ antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the @GENE$ effect is specific and is mediated through the glucocorticoid receptor.	false
10796070.T5.T12	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on @CHEMICAL$ activation, indicating that the @GENE$ effect is specific and is mediated through the glucocorticoid receptor.	false
10796070.T5.T13	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the @CHEMICAL$ effect is specific and is mediated through the @GENE$.	false
10796070.T7.T15	The presence of @CHEMICAL$ confers their responsiveness to glucocorticoids and indicates that the airway epithelium may be a target for the anti-inflammatory effects of inhaled @GENE$.	false
10800083.T1.T4	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. @CHEMICAL$, CD15 and CD120b) and increased expression of aminopeptidase-@GENE$ (CD13).	false
10800083.T1.T5	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, @CHEMICAL$ and CD120b) and increased expression of aminopeptidase-@GENE$ (CD13).	false
10800083.T1.T6	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, CD15 and @CHEMICAL$) and increased expression of aminopeptidase-@GENE$ (CD13).	false
10800083.T1.T7	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, CD15 and CD120b) and increased expression of @CHEM-GENE$ (CD13).	false
10800083.T1.T8	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, CD15 and CD120b) and increased expression of aminopeptidase-@CHEMICAL$ (@GENE$).	false
10839333.T8.T21	A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high @CHEM-GENE$ occupancy.	false
10839333.T9.T21	A positron emission tomography study of @CHEMICAL$ in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high @GENE$ occupancy.	false
10839333.T4.T14	As such, relatively little has been published regarding its in vivo effects at the @CHEM-GENE$ (D2) and serotonin type 2a (5-HT2a) receptor systems.	false
10839333.T4.T16	As such, relatively little has been published regarding its in vivo effects at the @CHEMICAL$ type 2 (@GENE$) and serotonin type 2a (5-HT2a) receptor systems.	false
10839333.T4.T17	As such, relatively little has been published regarding its in vivo effects at the @CHEMICAL$ type 2 (D2) and @GENE$ systems.	false
10839333.T5.T14	As such, relatively little has been published regarding its in vivo effects at the @CHEMICAL$ (D2) and @GENE$ type 2a (5-HT2a) receptor systems.	false
10839333.T5.T16	As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (@CHEMICAL$) and @GENE$ type 2a (5-HT2a) receptor systems.	false
10839333.T5.T17	As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (D2) and @CHEM-GENE$ systems.	false
10839333.T7.T20	RESULTS: @CHEMICAL$ was an effective antipsychotic and improved the extrapyramidal symptoms and @GENE$ level elevation noted at baseline.	CPR:3
10839333.T1.T11	Study of the additional subjects revealed that @CHEMICAL$ does give rise to transiently high (58%-64%) @GENE$ occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours.	false
10839333.T3.T12	CONCLUSIONS: @CHEMICAL$ shows a transiently high @GENE$ occupancy, which decreases to very low levels by the end of the dosing interval.	false
10866053.T2.T20	In this study, we compared the @CHEMICAL$ and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T21	In this study, we compared the insulin and @CHEMICAL$ binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T22	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of @CHEMICAL$ aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T23	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp @CHEMICAL$), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T24	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), @CHEMICAL$ lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T25	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro @CHEMICAL$), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T26	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), @CHEMICAL$ glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T27	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg @CHEMICAL$), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T28	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), @CHEMICAL$ detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.	false
10866053.T2.T29	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@CHEMICAL$), desB30 human @GENE$], and reference insulin analogs.	false
10866053.T2.T30	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@CHEMICAL$), desB30 human insulin], and reference @GENE$ analogs.	false
10866053.T1.T14	The attachment of a @CHEMICAL$ chain to LysB29 provided @GENE$ detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.	false
10887187.T11.T27	@CHEMICAL$, an inactivating 2P domain @GENE$ channel.	false
10887187.T11.T28	TWIK-2, an inactivating @CHEM-GENE$.	false
10887187.T5.T17	We cloned human and rat @CHEMICAL$ and expressed this novel 2P domain @GENE$ channel in transiently transfected COS cells.	false
10887187.T5.T21	We cloned human and rat TWIK-2 and expressed this novel @CHEM-GENE$ in transiently transfected COS cells.	false
10887187.T3.T16	@CHEMICAL$ currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological @GENE$ gradient and mild inward rectification in symmetrical K(+) conditions.	false
10887187.T3.T18	Rat TWIK-2 currents are about 15 times larger than @CHEMICAL$ currents, but both exhibit outward rectification in a physiological @GENE$ gradient and mild inward rectification in symmetrical K(+) conditions.	false
10887187.T4.T16	@CHEMICAL$ currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical @GENE$ conditions.	false
10887187.T4.T18	Rat TWIK-2 currents are about 15 times larger than @CHEMICAL$ currents, but both exhibit outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical @GENE$ conditions.	false
10887187.T6.T23	In a physiological @CHEMICAL$ gradient, @GENE$ is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine.	false
10887187.T7.T23	In a physiological K(+) gradient, @CHEMICAL$ is half inhibited by 0.1 mm @GENE$, quinine, and quinidine.	CPR:4
10887187.T8.T23	In a physiological K(+) gradient, @CHEMICAL$ is half inhibited by 0.1 mm Ba(2+), @GENE$, and quinidine.	CPR:4
10887187.T9.T23	In a physiological K(+) gradient, @CHEMICAL$ is half inhibited by 0.1 mm Ba(2+), quinine, and @GENE$.	CPR:4
10887187.T10.T24	Finally, @CHEMICAL$ 53 in the @GENE$ is required for functional expression of TWIK-2 but is not critical for subunit self-assembly.	false
10887187.T10.T25	Finally, @CHEMICAL$ 53 in the M1P1 external loop is required for functional expression of @GENE$ but is not critical for subunit self-assembly.	false
10887187.T1.T12	TWIK-2 is the first reported @CHEM-GENE$ that inactivates.	false
10887187.T1.T26	@CHEMICAL$ is the first reported 2P domain @GENE$ channel that inactivates.	false
10887187.T2.T13	The base-line, transient, and delayed activities of @CHEMICAL$ suggest that this novel 2P domain @GENE$ channel may play an important functional role in cell electrogenesis.	false
10887187.T2.T14	The base-line, transient, and delayed activities of TWIK-2 suggest that this novel @CHEM-GENE$ may play an important functional role in cell electrogenesis.	false
10917903.T21.T32	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of @CHEMICAL$ (EPA) blocked @GENE$ activity, the terminal enzymatic step in AA synthesis.	CPR:4
10917903.T22.T32	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (@CHEMICAL$) blocked @GENE$ activity, the terminal enzymatic step in AA synthesis.	CPR:4
10917903.T23.T32	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked @CHEMICAL$ activity, the terminal enzymatic step in @GENE$ synthesis.	false
10931813.T15.T25	Effects of a @CHEM-GENE$ opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.	false
10931813.T7.T21	BACKGROUND: This study examines the effects of @CHEMICAL$, a @GENE$ opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).	CPR:3
10931813.T9.T21	BACKGROUND: This study examines the effects of nicorandil, a @CHEM-GENE$ opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).	false
10931813.T10.T22	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, @CHEMICAL$ (100 micromol/L) to block @GENE$ (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).	CPR:4
10931813.T10.T23	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, @CHEMICAL$ (100 micromol/L) to block I(Kr) (LQT2 model), and @GENE$ (20 nmol/L) to augment late I(Na) (LQT3 model).	CPR:4
10931813.T11.T22	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block @CHEMICAL$ (LQT2 model), and ATX-II (20 nmol/L) to augment late I(@GENE$) (LQT3 model).	false
10931813.T11.T23	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and @CHEMICAL$ (20 nmol/L) to augment late I(@GENE$) (LQT3 model).	false
10931813.T8.T22	@CHEMICAL$ (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block @GENE$ (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).	CPR:4
10931813.T8.T23	@CHEMICAL$ (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and @GENE$ (20 nmol/L) to augment late I(Na) (LQT3 model).	CPR:4
10931813.T12.T24	@CHEMICAL$+chromanol 293B, d-sotalol, and @GENE$ produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).	false
10931813.T13.T24	Isoproterenol+@CHEMICAL$, d-sotalol, and @GENE$ produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).	false
10931813.T14.T24	Isoproterenol+chromanol 293B, @CHEMICAL$, and @GENE$ produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).	false
10931813.T4.T16	@CHEMICAL$ 20 micromol/L reversed only 50% of the effect of @GENE$ and failed to completely suppress TdP in the LQT3 model (5/6 to 3/6).	false
10931813.T5.T17	CONCLUSIONS: Our data suggest that @CHEM-GENE$ openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or I(Ks) but less so when it is due to augmented late I(Na).	false
10931813.T5.T18	CONCLUSIONS: Our data suggest that @CHEMICAL$ channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced @GENE$ or I(Ks) but less so when it is due to augmented late I(Na).	false
10931813.T5.T19	CONCLUSIONS: Our data suggest that @CHEMICAL$ channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or @GENE$ but less so when it is due to augmented late I(Na).	false
10931813.T6.T17	CONCLUSIONS: Our data suggest that @CHEMICAL$ openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or I(Ks) but less so when it is due to augmented late I(@GENE$).	false
10931813.T6.T18	CONCLUSIONS: Our data suggest that K(+) channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced @CHEMICAL$ or I(Ks) but less so when it is due to augmented late I(@GENE$).	false
10931813.T6.T19	CONCLUSIONS: Our data suggest that K(+) channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or @CHEMICAL$ but less so when it is due to augmented late I(@GENE$).	false
10933891.T10.T14	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. @CHEMICAL$ (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:9
10933891.T10.T18	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (@CHEMICAL$) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:9
10933891.T10.T30	@CHEMICAL$ (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T10.T31	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase @CHEMICAL$ mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T10.T32	Peroxisome proliferator-activated receptor alpha (@CHEMICAL$) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T12.T14	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, @CHEMICAL$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. @GENE$ (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T12.T18	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, @CHEMICAL$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (@GENE$) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T12.T30	@CHEMICAL$ (PPARalpha) activators, @GENE$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:3
10933891.T12.T31	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, @CHEMICAL$ and Wy-14,643, increase @GENE$ mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:3
10933891.T12.T32	Peroxisome proliferator-activated receptor alpha (@CHEMICAL$) activators, @GENE$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:3
10933891.T13.T14	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and @CHEMICAL$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. @GENE$ (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T13.T18	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and @CHEMICAL$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (@GENE$) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	false
10933891.T13.T30	@CHEMICAL$ (PPARalpha) activators, bezafibrate and @GENE$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:3
10933891.T13.T31	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and @CHEMICAL$, increase @GENE$ mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:3
10933891.T13.T32	Peroxisome proliferator-activated receptor alpha (@CHEMICAL$) activators, bezafibrate and @GENE$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	CPR:3
10933891.T7.T19	We have studied the effects of two fibrates, @CHEMICAL$ and Wy-14,643, on @GENE$ and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	false
10933891.T7.T20	We have studied the effects of two fibrates, @CHEMICAL$ and Wy-14,643, on UCP-3 and @GENE$ mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	false
10933891.T8.T19	We have studied the effects of two fibrates, bezafibrate and @CHEMICAL$, on @GENE$ and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	false
10933891.T8.T20	We have studied the effects of two fibrates, bezafibrate and @CHEMICAL$, on UCP-3 and @GENE$ mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	false
10933891.T9.T23	Thus, @CHEMICAL$ treatment resulted in an 8-fold induction in @GENE$ mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.	CPR:3
10933891.T11.T28	In contrast to @CHEMICAL$, UCP-2 mRNA levels were only slightly modified by @GENE$ in adipocytes.	false
10933891.T11.T29	In contrast to UCP-3, @CHEMICAL$ mRNA levels were only slightly modified by @GENE$ in adipocytes.	false
10933891.T1.T15	The induction in @CHEMICAL$ expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after @GENE$ or Wy-14,643 treatment.	CPR:3
10933891.T2.T15	The induction in @CHEMICAL$ expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or @GENE$ treatment.	CPR:3
10933891.T3.T16	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after @GENE$ and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	false
10933891.T3.T17	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after @GENE$ and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	CPR:3
10933891.T4.T16	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and @GENE$ treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	false
10933891.T4.T17	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after bezafibrate and @GENE$ treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	CPR:3
10933891.T5.T16	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of @GENE$, limiting their availability to be stored as triglycerides.	false
10933891.T5.T17	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of @GENE$, limiting their availability to be stored as triglycerides.	false
10933891.T6.T16	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as @GENE$.	false
10933891.T6.T17	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as @GENE$.	false
10939639.T12.T14	@CHEMICAL$ protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T12.T20	@CHEMICAL$ protects against menadione-induced hepatotoxicity by enhancing @GENE$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	CPR:3
10939639.T13.T14	Schisandrin B protects against @CHEMICAL$-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T13.T20	Schisandrin B protects against @CHEMICAL$-induced hepatotoxicity by enhancing @GENE$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T2.T14	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against @CHEMICAL$-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	CPR:4
10939639.T2.T20	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against @GENE$-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T3.T14	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with @CHEMICAL$ (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T3.T20	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with @GENE$ (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T4.T14	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @CHEMICAL$ activity (78%) and hepatic @GENE$ level (70%), when compared with the menadione intoxicated control.	false
10939639.T4.T20	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic @GENE$ level (70%), when compared with the menadione intoxicated control.	false
10939639.T5.T14	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (@CHEMICAL$), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T5.T20	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (@GENE$), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	false
10939639.T6.T14	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @CHEMICAL$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the @GENE$ intoxicated control.	false
10939639.T6.T20	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the @GENE$ intoxicated control.	false
10939639.T7.T15	In order to define the biochemical mechanism involved in the hepatoprotection afforded by @CHEMICAL$ pretreatment, we examined the activity of @GENE$ (DTD) in hepatocytes isolated from Sch B pretreated rats.	false
10939639.T7.T16	In order to define the biochemical mechanism involved in the hepatoprotection afforded by @CHEMICAL$ pretreatment, we examined the activity of DT-diaphorase (@GENE$) in hepatocytes isolated from Sch B pretreated rats.	false
10939639.T8.T15	In order to define the biochemical mechanism involved in the hepatoprotection afforded by Sch B pretreatment, we examined the activity of @CHEMICAL$ (DTD) in hepatocytes isolated from @GENE$ pretreated rats.	false
10939639.T8.T16	In order to define the biochemical mechanism involved in the hepatoprotection afforded by Sch B pretreatment, we examined the activity of DT-diaphorase (@CHEMICAL$) in hepatocytes isolated from @GENE$ pretreated rats.	false
10939639.T9.T17	Hepatocytes isolated from @CHEMICAL$ pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in @GENE$ activity.	CPR:3
10939639.T10.T18	The increase in @CHEMICAL$ activity was associated with the enhanced rate of @GENE$ elimination in the hepatocyte culture.	false
10939639.T11.T19	The ensemble of results suggests that the ability of @CHEMICAL$ pretreatment to enhance hepatocellular @GENE$ activity may at least in part be attributed to the protection against menadione hepatotoxicity.	CPR:3
10939639.T1.T19	The ensemble of results suggests that the ability of Sch B pretreatment to enhance hepatocellular @CHEMICAL$ activity may at least in part be attributed to the protection against @GENE$ hepatotoxicity.	false
10942908.T7.T18	This study was designed to investigate the delayed effects of @CHEMICAL$ and treadmill exercise on @GENE$ activity, lipid peroxidation and histology of peripheral tissues of mice.	false
10942908.T12.T19	The group treated with @CHEMICAL$ alone showed decreased plasma @GENE$ (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.	CPR:4
10942908.T12.T20	The group treated with @CHEMICAL$ alone showed decreased plasma butyrylcholinesterase (@GENE$) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.	CPR:4
10942908.T12.T21	The group treated with @CHEMICAL$ alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the @GENE$ activity (79% of control), indicating an interactive effect of the combination.	false
10942908.T13.T19	The group treated with pyridostigmine alone showed decreased plasma @CHEMICAL$ (BChE) activity (87% of control), whereas @GENE$ plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.	false
10942908.T13.T20	The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (@CHEMICAL$) activity (87% of control), whereas @GENE$ plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.	false
10942908.T13.T21	The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas @CHEMICAL$ plus exercise significantly decreased the @GENE$ activity (79% of control), indicating an interactive effect of the combination.	CPR:4
10942908.T1.T16	However, @CHEMICAL$ activity in triceps muscle decreased significantly (78% of control) in the group treated with @GENE$ plus exercise.	CPR:4
10942908.T2.T17	@CHEM-GENE$ activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	false
10942908.T3.T17	@CHEMICAL$ activity in plasma increased slightly (compared to control, @GENE$ or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	CPR:3
10942908.T4.T17	@CHEMICAL$ activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with @GENE$ plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	CPR:3
11056242.T1.T10	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as @CHEMICAL$ and GnRH agonist, exert direct regulatory action on @GENE$ (MCP-1) expression by endometrial epithelial cells.	false
11056242.T1.T11	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as @CHEMICAL$ and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (@GENE$) expression by endometrial epithelial cells.	false
11056242.T1.T8	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as @CHEMICAL$ and @GENE$ agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells.	false
11056242.T5.T12	DESIGN: Primary cultures of epithelial cells isolated from human endometrium were exposed to different concentrations of @CHEMICAL$ and @GENE$ hormone analogs.	false
11056242.T2.T15	RESULT(S): Buserelin acetate, a @CHEMICAL$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas @GENE$ (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T2.T7	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @CHEMICAL$ expression, whereas @GENE$ (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T2.T9	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas @CHEMICAL$ (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.	CPR:4
11056242.T3.T15	RESULT(S): Buserelin acetate, a @CHEMICAL$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a @GENE$ analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T3.T7	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @CHEMICAL$ expression, whereas danazol (10(-7)-10(-5) M), a @GENE$ analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T3.T9	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a @CHEMICAL$ analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.	CPR:4
11056242.T4.T15	RESULT(S): Buserelin acetate, a @CHEMICAL$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and @GENE$, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T4.T7	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @CHEMICAL$ expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and @GENE$, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T4.T9	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and @CHEMICAL$, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.	CPR:4
11056242.T6.T15	RESULT(S): @CHEMICAL$, a @GENE$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	CPR:5
11056242.T6.T7	RESULT(S): @CHEMICAL$, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @GENE$ expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	false
11056242.T6.T9	RESULT(S): @CHEMICAL$, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.	false
11146120.T14.T33	Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of @CHEMICAL$ receptor and @GENE$ agonists.	false
11146120.T14.T34	Pharmacological modulation of @CHEMICAL$ synthesis: a mechanistic comparison of @GENE$ receptor and beta(2)-adrenoceptor agonists.	false
11146120.T14.T35	Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of @CHEM-GENE$ and beta(2)-adrenoceptor agonists.	false
11146120.T5.T24	The present studies were undertaken to compare two compounds, a @CHEMICAL$ analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting @GENE$ agonist, both of which induce NGF synthesis in vivo.	false
11146120.T5.T26	The present studies were undertaken to compare two compounds, a @CHEMICAL$ analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce @GENE$ synthesis in vivo.	CPR:4
11146120.T6.T24	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (@CHEMICAL$) with minimal calcaemic effects, and clenbuterol, a long-acting @GENE$ agonist, both of which induce NGF synthesis in vivo.	false
11146120.T6.T26	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (@CHEMICAL$) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce @GENE$ synthesis in vivo.	CPR:3
11146120.T7.T24	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and @CHEMICAL$, a long-acting @GENE$ agonist, both of which induce NGF synthesis in vivo.	CPR:5
11146120.T7.T26	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and @CHEMICAL$, a long-acting beta(2)-adrenoceptor agonist, both of which induce @GENE$ synthesis in vivo.	CPR:3
11146120.T8.T27	@CHEMICAL$ caused significant increases in both @GENE$ mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.	CPR:3
11146120.T10.T28	Effects of clenbuterol on @CHEMICAL$ mRNA were antagonized by @GENE$.	false
11146120.T9.T28	Effects of @CHEMICAL$ on @GENE$ mRNA were antagonized by propranolol.	false
11146120.T11.T29	Mobility shift assays on whole cell extracts showed that @CHEMICAL$ increased @GENE$ binding in 3T3 cells prior to increasing NGF synthesis.	false
11146120.T11.T30	Mobility shift assays on whole cell extracts showed that @CHEMICAL$ increased AP1 binding in 3T3 cells prior to increasing @GENE$ synthesis.	CPR:3
11146120.T12.T31	@CHEMICAL$ was without effect on @GENE$ mRNA levels in L929 cells, whereas CB1093 caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells.	false
11146120.T12.T32	@CHEMICAL$ was without effect on NGF mRNA levels in L929 cells, whereas CB1093 caused significant increases in both @GENE$ mRNA and protein levels in both 3T3 and L929 cells.	false
11146120.T13.T31	Clenbuterol was without effect on @CHEMICAL$ mRNA levels in L929 cells, whereas @GENE$ caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells.	false
11146120.T13.T32	Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas @CHEMICAL$ caused significant increases in both @GENE$ mRNA and protein levels in both 3T3 and L929 cells.	CPR:3
11146120.T1.T15	Binding to the @CHEM-GENE$ (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.	false
11146120.T1.T16	Binding to the @CHEMICAL$ nuclear receptor (@GENE$), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.	false
11146120.T1.T18	Binding to the @CHEMICAL$ nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased @GENE$ binding preceded increased NGF mRNA.	false
11146120.T1.T19	Binding to the @CHEMICAL$ nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased @GENE$ mRNA.	false
11146120.T2.T15	Binding to the @CHEMICAL$ (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @GENE$ and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.	false
11146120.T2.T16	Binding to the vitamin D nuclear receptor (@CHEMICAL$), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @GENE$ and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.	false
11146120.T2.T18	Binding to the vitamin D nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @CHEMICAL$ and maintained up to 24 h. Increased @GENE$ binding preceded increased NGF mRNA.	false
11146120.T2.T19	Binding to the vitamin D nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @CHEMICAL$ and maintained up to 24 h. Increased VDR binding preceded increased @GENE$ mRNA.	false
11146120.T3.T21	This study demonstrates that @CHEMICAL$ and clenbuterol stimulate @GENE$ levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.	CPR:3
11146120.T3.T22	This study demonstrates that @CHEMICAL$ and clenbuterol stimulate NGF levels in vitro and that @GENE$ binding could be a commonality between the mechanism of NGF induction of these two compounds.	false
11146120.T3.T23	This study demonstrates that @CHEMICAL$ and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of @GENE$ induction of these two compounds.	CPR:3
11146120.T4.T21	This study demonstrates that CB1093 and @CHEMICAL$ stimulate @GENE$ levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.	CPR:3
11146120.T4.T22	This study demonstrates that CB1093 and @CHEMICAL$ stimulate NGF levels in vitro and that @GENE$ binding could be a commonality between the mechanism of NGF induction of these two compounds.	false
11146120.T4.T23	This study demonstrates that CB1093 and @CHEMICAL$ stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of @GENE$ induction of these two compounds.	CPR:3
11157886.T8.T21	Protective effect of @CHEMICAL$ anesthesia on retinal light damage: inhibition of metabolic @GENE$ regeneration.	CPR:4
11157886.T5.T20	PURPOSE: To determine whether the volatile anesthetic @CHEMICAL$ protects against light-induced @GENE$ degeneration in the rodent retina.	false
11157886.T6.T17	RESULTS: @CHEMICAL$ anesthesia reversibly inhibited metabolic @GENE$ regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.	CPR:4
11157886.T6.T18	RESULTS: @CHEMICAL$ anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented @GENE$ from absorbing high numbers of photons during light exposure.	CPR:4
11157886.T7.T19	Consequently, @CHEMICAL$ of mice and rats anesthetized with @GENE$ were completely protected against degeneration induced by white light.	false
11157886.T2.T10	CONCLUSIONS: After the initial bleach, @CHEMICAL$ impeded photon absorption by rhodopsin by inhibiting metabolic @GENE$ regeneration.	CPR:4
11157886.T2.T9	CONCLUSIONS: After the initial bleach, @CHEMICAL$ impeded photon absorption by @GENE$ by inhibiting metabolic rhodopsin regeneration.	false
11243491.T15.T27	RATIONALE: A recent study suggested that selective @CHEMICAL$ reuptake inhibitors were inactive in 40-week-old male mice in the mouse forced swimming test, possibly because of alteration of @GENE$ receptors.	false
11243491.T14.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@GENE$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T14.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [@GENE$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T14.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T14.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T14.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T14.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T16.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@GENE$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T16.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@GENE$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T16.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T16.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T16.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T16.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T17.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @GENE$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T17.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @GENE$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T17.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T17.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T17.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T17.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T18.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@GENE$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T18.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@GENE$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T18.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T18.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T18.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T18.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T19.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @GENE$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T19.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @GENE$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T19.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T19.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T19.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T19.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T20.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @GENE$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T20.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @GENE$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T20.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T20.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T20.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T20.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T21.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @GENE$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T21.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @GENE$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T21.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T21.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T21.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T21.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T22.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @GENE$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T22.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @GENE$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T22.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T22.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T22.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T22.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T23.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @GENE$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T23.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @GENE$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T23.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T23.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T23.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T23.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T24.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @GENE$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T24.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @GENE$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T24.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T24.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T24.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T24.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T25.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T25.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T25.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @CHEMICAL$ and 5-HT1B receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T25.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @CHEMICAL$ receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T25.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@CHEMICAL$ (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	CPR:5
11243491.T25.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@CHEMICAL$ (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.	false
11243491.T26.T30	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T26.T31	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T26.T32	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @CHEMICAL$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T26.T33	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @CHEMICAL$ receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T26.T34	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @CHEMICAL$ agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.	false
11243491.T26.T35	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @CHEMICAL$ (@GENE$ agonist)] in the mouse forced swimming test.	CPR:5
11246504.T11.T17	@CHEMICAL$, peroxisomal enzymes and @GENE$ cofactors in koala liver.	false
11246504.T2.T14	We have examined hepatic levels of microsomal @CHEM-GENE$ activity and cyanide-insensitive palmitoyl coenzyme A oxidative activity in koala (Phascolarctos cinereus) and tammar wallaby (Macropus eugenii) and compared our results to those determined in rat.	false
11246504.T10.T15	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the @CHEMICAL$ family led to the cloning of a partial, near full length, cDNA clone with approximately 70% nucleotide and deduced @GENE$ sequence identity to human CYP4A11.	false
11246504.T10.T16	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the CYP4A family led to the cloning of a partial, near full length, cDNA clone with approximately 70% nucleotide and deduced @CHEMICAL$ sequence identity to @GENE$.	false
11246504.T9.T15	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the @CHEMICAL$ family led to the cloning of a partial, near full length, cDNA clone with approximately 70% @GENE$ and deduced amino acid sequence identity to human CYP4A11.	false
11246504.T9.T16	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the CYP4A family led to the cloning of a partial, near full length, cDNA clone with approximately 70% @CHEMICAL$ and deduced amino acid sequence identity to @GENE$.	false
11252887.T1.T12	@CHEMICAL$ (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.	CPR:4
11252887.T1.T13	@CHEMICAL$ (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @GENE$.	CPR:4
11252887.T1.T14	@CHEMICAL$ (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	CPR:4
11252887.T2.T12	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @CHEM-GENE$, and glycinamide ribonucleotide formyl transferase.	false
11252887.T2.T13	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @CHEMICAL$ reductase, and @GENE$.	false
11252887.T2.T14	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$, @GENE$ reductase, and glycinamide ribonucleotide formyl transferase.	false
11252887.T3.T12	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @CHEMICAL$, and @GENE$ transferase.	false
11252887.T3.T13	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @CHEM-GENE$.	false
11252887.T3.T14	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$, dihydrofolate reductase, and @GENE$ transferase.	false
11252887.T4.T12	Pemetrexed disodium (@CHEMICAL$, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.	CPR:4
11252887.T4.T13	Pemetrexed disodium (@CHEMICAL$, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @GENE$.	CPR:4
11252887.T4.T14	Pemetrexed disodium (@CHEMICAL$, LY231514) is a novel, multitargeted antifolate that inhibits @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	CPR:4
11252887.T6.T12	Pemetrexed disodium (Alimta, @CHEMICAL$) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.	CPR:4
11252887.T6.T13	Pemetrexed disodium (Alimta, @CHEMICAL$) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @GENE$.	CPR:4
11252887.T6.T14	Pemetrexed disodium (Alimta, @CHEMICAL$) is a novel, multitargeted antifolate that inhibits @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	CPR:4
11252887.T9.T12	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$ synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.	false
11252887.T9.T13	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$ synthase, dihydrofolate reductase, and @GENE$.	false
11252887.T9.T14	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEM-GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	false
11304699.T1.T17	To mechanistically evaluate this regional selectivity, we assessed @CHEMICAL$ (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and @GENE$-treated rats.	CPR:3
11304699.T1.T18	To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (@CHEMICAL$) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and @GENE$-treated rats.	CPR:3
11304699.T4.T15	The striking distal predilection of @CHEMICAL$ may be, at least partially, explained by distal bowel over-expression of @GENE$ and PPAR-delta.	false
11304699.T4.T16	The striking distal predilection of @CHEMICAL$ may be, at least partially, explained by distal bowel over-expression of COX-2 and @GENE$.	false
11309392.T9.T30	Nuclear @CHEMICAL$ kinase-theta is activated in response to @GENE$.	false
11309392.T9.T31	Nuclear @CHEM-GENE$ is activated in response to alpha-thrombin.	false
11309392.T3.T25	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with @CHEMICAL$ leads to the production of two lipid second messengers in the nucleus: an increase in nuclear @GENE$ mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate phosphatidic acid.	false
11309392.T4.T25	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with @CHEMICAL$ leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of @GENE$ to generate phosphatidic acid.	false
11309392.T5.T25	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with @CHEMICAL$ leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate @GENE$.	false
11309392.T6.T26	@CHEM-GENE$ (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component.	false
11309392.T6.T27	@CHEMICAL$ kinase (@GENE$) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component.	false
11309392.T7.T26	@CHEMICAL$ (DGK) catalyzes the conversion of @GENE$ to phosphatidic acid, making it an attractive candidate for a signal transduction component.	CPR:9
11309392.T7.T27	Diacylglycerol kinase (@CHEMICAL$) catalyzes the conversion of @GENE$ to phosphatidic acid, making it an attractive candidate for a signal transduction component.	CPR:9
11309392.T8.T26	@CHEMICAL$ (DGK) catalyzes the conversion of diacylglycerol to @GENE$, making it an attractive candidate for a signal transduction component.	CPR:9
11309392.T8.T27	Diacylglycerol kinase (@CHEMICAL$) catalyzes the conversion of diacylglycerol to @GENE$, making it an attractive candidate for a signal transduction component.	CPR:9
11309392.T1.T12	We took advantage of the previous observations that @CHEMICAL$ inhibits @GENE$ (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol.	CPR:4
11309392.T2.T16	Constitutively active @CHEMICAL$ inhibited the nuclear stimulated activity, whereas @GENE$ did not have an inhibitory effect.	false
11318430.T1.T10	@CHEMICAL$ (NDGA) has been shown to inhibit both 5-lipoxygenase and @GENE$ and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
11318430.T1.T9	@CHEMICAL$ (NDGA) has been shown to inhibit both @GENE$ and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
11318430.T3.T10	Nordihydroguaiaretic acid (@CHEMICAL$) has been shown to inhibit both 5-lipoxygenase and @GENE$ and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
11318430.T3.T9	Nordihydroguaiaretic acid (@CHEMICAL$) has been shown to inhibit both @GENE$ and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
11318430.T7.T10	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and @CHEM-GENE$ and is active against several cancer cell lines and at least one mouse tumor model.	false
11318430.T7.T9	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both @CHEMICAL$ and @GENE$ decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	false
11392054.T24.T25	@CHEMICAL$ (CA) is a zinc enzyme that catalyses the reversible hydration reaction of @GENE$ and plays a major role in the acid-base balance.	CPR:9
11392054.T24.T31	Carbonic anhydrase (@CHEMICAL$) is a zinc enzyme that catalyses the reversible hydration reaction of @GENE$ and plays a major role in the acid-base balance.	CPR:9
11392054.T6.T25	@CHEMICAL$ (CA) is a @GENE$ enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.	false
11392054.T6.T31	Carbonic anhydrase (@CHEMICAL$) is a @GENE$ enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.	false
11392054.T10.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T10.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T10.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T10.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T11.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEM-GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T11.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T11.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T11.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T12.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T12.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEM-GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T12.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T12.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T13.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, @GENE$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T13.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, @GENE$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T13.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, @CHEMICAL$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T13.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, @CHEMICAL$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T14.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, @GENE$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T14.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, @GENE$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T14.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, @CHEMICAL$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T14.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, @CHEMICAL$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T15.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, @GENE$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T15.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, @GENE$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T15.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, @CHEMICAL$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T15.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, @CHEMICAL$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T16.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, @GENE$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T16.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, @GENE$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T16.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, @CHEMICAL$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T16.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, @CHEMICAL$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T17.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, @GENE$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T17.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, @GENE$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T17.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, @CHEMICAL$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T17.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, @CHEMICAL$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T18.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, @GENE$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T18.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, @GENE$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T18.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, @CHEMICAL$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T18.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, @CHEMICAL$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T19.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @GENE$, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T19.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @GENE$, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T19.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @CHEMICAL$, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T19.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @CHEMICAL$, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T20.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @GENE$, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T20.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @GENE$, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T20.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @CHEMICAL$, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T20.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @CHEMICAL$, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T21.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @GENE$, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T21.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @GENE$, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T21.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @CHEMICAL$, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T21.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @CHEMICAL$, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T22.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @GENE$ and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T22.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @GENE$ and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T22.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @CHEMICAL$ and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T22.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @CHEMICAL$ and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T23.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @GENE$ on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T23.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @GENE$ on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T23.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @CHEMICAL$ on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T23.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @CHEMICAL$ on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T7.T35	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T7.T36	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T7.T37	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T7.T38	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T8.T35	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T8.T36	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T8.T37	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T8.T38	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T9.T35	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T9.T36	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T9.T37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.	false
11392054.T9.T38	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.	false
11392054.T1.T26	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: @CHEMICAL$ (group 1), desmopressin (group 2), verapamil (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.	false
11392054.T2.T26	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), @CHEMICAL$ (group 2), verapamil (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.	false
11392054.T3.T26	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), @CHEMICAL$ (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.	false
11392054.T4.T26	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), verapamil (group 3), @CHEMICAL$ (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.	false
11392054.T5.T26	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), verapamil (group 3), irbesartan (group 4), @CHEMICAL$ (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.	false
11393267.T10.T19	Neuroparalysis and oxime efficacy in @CHEMICAL$ poisoning: a study of @GENE$.	false
11393267.T9.T19	Neuroparalysis and @CHEMICAL$ efficacy in organophosphate poisoning: a study of @GENE$.	false
11393267.T2.T14	The temporal profile of @CHEMICAL$ (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 @GENE$-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	false
11393267.T2.T16	The temporal profile of butyrylcholinesterase (@CHEMICAL$) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 @GENE$-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	false
11393267.T2.T18	The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime-reactivated @CHEMICAL$ was studied in a cohort of 25 @GENE$-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	false
11393267.T5.T14	The temporal profile of @CHEMICAL$ (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of @GENE$ treatment.	false
11393267.T5.T16	The temporal profile of butyrylcholinesterase (@CHEMICAL$) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of @GENE$ treatment.	false
11393267.T5.T18	The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime-reactivated @CHEMICAL$ was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of @GENE$ treatment.	false
11393267.T6.T14	The temporal profile of @CHEMICAL$ (BuChE) and in vitro @GENE$-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	false
11393267.T6.T16	The temporal profile of butyrylcholinesterase (@CHEMICAL$) and in vitro @GENE$-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	false
11393267.T6.T18	The temporal profile of butyrylcholinesterase (BuChE) and in vitro @CHEMICAL$-reactivated @GENE$ was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	CPR:3
11393267.T7.T17	Reactivation potentials of @CHEMICAL$ (the difference between @GENE$-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.	CPR:3
11393267.T8.T17	Reactivation potentials of @CHEMICAL$ (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after @GENE$ ingestion.	CPR:4
11393267.T1.T11	Patients who received @CHEMICAL$ prior to hospitalization had a higher rate of intermediate syndrome and lower levels of @GENE$ at admission than those who had not.	CPR:4
11393267.T3.T12	The study suggests that (i) @CHEMICAL$ reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BuChE; and (iii) the lack of @GENE$ efficacy in our patients maybe due to their severity of poisoning and the timing of oxime treatment.	false
11393267.T3.T13	The study suggests that (i) BuChE reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of @CHEMICAL$; and (iii) the lack of @GENE$ efficacy in our patients maybe due to their severity of poisoning and the timing of oxime treatment.	false
11393267.T4.T12	The study suggests that (i) @CHEMICAL$ reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BuChE; and (iii) the lack of oxime efficacy in our patients maybe due to their severity of poisoning and the timing of @GENE$ treatment.	false
11393267.T4.T13	The study suggests that (i) BuChE reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of @CHEMICAL$; and (iii) the lack of oxime efficacy in our patients maybe due to their severity of poisoning and the timing of @GENE$ treatment.	false
11481271.T23.T39	Potent @CHEMICAL$-mediated vasoconstriction by @GENE$ in porcine ciliary arteries.	false
11481271.T16.T29	The segments were contracted with the @CHEMICAL$ agonists @GENE$, apraclonidine, and oxymetazoline.	CPR:5
11481271.T17.T29	The segments were contracted with the @CHEMICAL$ agonists brimonidine, @GENE$, and oxymetazoline.	CPR:5
11481271.T18.T29	The segments were contracted with the @CHEMICAL$ agonists brimonidine, apraclonidine, and @GENE$.	CPR:5
11481271.T19.T30	To determine which subtypes of the @CHEMICAL$ mediate this contraction, antagonists subselective for the different alpha(2)-adrenoceptors were added to the vessel bath before concentration-response curves for @GENE$ were obtained.	false
11481271.T19.T31	To determine which subtypes of the alpha(2)-adrenoceptor mediate this contraction, antagonists subselective for the different @CHEMICAL$ were added to the vessel bath before concentration-response curves for @GENE$ were obtained.	false
11481271.T20.T32	The following @CHEMICAL$ antagonists were applied: @GENE$ (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	false
11481271.T20.T33	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (@GENE$-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	CPR:6
11481271.T20.T34	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (@GENE$- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	false
11481271.T20.T35	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (alpha(2B)- and @GENE$-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	false
11481271.T20.T36	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (@GENE$- and alpha(2C)-selective).	false
11481271.T20.T37	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and @GENE$-selective).	false
11481271.T21.T32	The following @CHEMICAL$ antagonists were applied: BRL44408 (alpha(2A)-selective), @GENE$ (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	false
11481271.T21.T33	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (@CHEMICAL$-selective), @GENE$ (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	false
11481271.T21.T34	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (@GENE$- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	CPR:6
11481271.T21.T35	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (alpha(2B)- and @GENE$-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	CPR:6
11481271.T21.T36	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (alpha(2B)- and alpha(2C)-selective), and prazosin (@GENE$- and alpha(2C)-selective).	false
11481271.T21.T37	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and @GENE$-selective).	false
11481271.T22.T32	The following @CHEMICAL$ antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).	false
11481271.T22.T33	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (@CHEMICAL$-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).	false
11481271.T22.T34	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (@CHEMICAL$- and alpha(2C)-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).	false
11481271.T22.T35	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and @CHEMICAL$-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).	false
11481271.T22.T36	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @CHEMICAL$ (@GENE$- and alpha(2C)-selective).	CPR:6
11481271.T22.T37	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @CHEMICAL$ (alpha(2B)- and @GENE$-selective).	CPR:6
11481271.T1.T38	RESULTS: The @CHEMICAL$ agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: @GENE$ 2.11, oxymetazoline 5.26, and apraclonidine 13.0.	CPR:5
11481271.T2.T38	RESULTS: The @CHEMICAL$ agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, @GENE$ 5.26, and apraclonidine 13.0.	CPR:5
11481271.T3.T38	RESULTS: The @CHEMICAL$ agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and @GENE$ 13.0.	CPR:5
11481271.T10.T24	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for @CHEMICAL$ (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional @GENE$.	CPR:6
11481271.T11.T24	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), @CHEMICAL$ (5.8) and for prazosin (6.0) suggesting the presence of functional @GENE$.	CPR:6
11481271.T12.T24	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for @CHEMICAL$ (6.0) suggesting the presence of functional @GENE$.	CPR:6
11481271.T9.T24	Schild analyses for the antagonists against @CHEMICAL$ yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional @GENE$.	false
11481271.T13.T26	CONCLUSIONS: The @CHEMICAL$ agonists @GENE$, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.	CPR:5
11481271.T14.T26	CONCLUSIONS: The @CHEMICAL$ agonists brimonidine, @GENE$, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.	CPR:5
11481271.T15.T26	CONCLUSIONS: The @CHEMICAL$ agonists brimonidine, apraclonidine, and @GENE$ are potent vasoconstrictors in the porcine ciliary artery.	CPR:5
11742712.T11.T14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three @CHEMICAL$-dependent enzymes, @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.	false
11742712.T11.T15	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three @CHEMICAL$-dependent enzymes, thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.	false
11742712.T11.T16	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three @CHEMICAL$-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @GENE$.	false
11742712.T1.T14	@CHEMICAL$ (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.	CPR:4
11742712.T1.T15	@CHEMICAL$ (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.	CPR:4
11742712.T1.T16	@CHEMICAL$ (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @GENE$.	CPR:4
11742712.T2.T14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEM-GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.	false
11742712.T2.T15	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$ synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.	false
11742712.T2.T16	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$ synthase, dihydrofolate reductase, and @GENE$.	false
11742712.T3.T14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$, @GENE$ reductase, and glycinamide ribonucleotide formyltransferase.	false
11742712.T3.T15	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @CHEM-GENE$, and glycinamide ribonucleotide formyltransferase.	false
11742712.T3.T16	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @CHEMICAL$ reductase, and @GENE$.	false
11742712.T4.T14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$, dihydrofolate reductase, and @GENE$ formyltransferase.	false
11742712.T4.T15	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @CHEMICAL$, and @GENE$ formyltransferase.	false
11742712.T4.T16	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @CHEM-GENE$.	false
11742712.T6.T14	Pemetrexed disodium (@CHEMICAL$) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.	CPR:4
11742712.T6.T15	Pemetrexed disodium (@CHEMICAL$) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.	CPR:4
11742712.T6.T16	Pemetrexed disodium (@CHEMICAL$) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @GENE$.	CPR:4
11752472.T20.T37	@CHEMICAL$ biosynthesis in plants: molecular and functional characterization of dihydrofolate synthetase and three isoforms of @GENE$ in Arabidopsis thaliana.	false
11752472.T20.T38	@CHEMICAL$ biosynthesis in plants: molecular and functional characterization of @GENE$ and three isoforms of folylpolyglutamate synthetase in Arabidopsis thaliana.	false
11752472.T21.T37	Tetrahydrofolate biosynthesis in plants: molecular and functional characterization of @CHEMICAL$ synthetase and three isoforms of @GENE$ in Arabidopsis thaliana.	false
11752472.T21.T38	Tetrahydrofolate biosynthesis in plants: molecular and functional characterization of @CHEM-GENE$ and three isoforms of folylpolyglutamate synthetase in Arabidopsis thaliana.	false
11752472.T11.T28	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEM-GENE$ (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T11.T29	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEMICAL$ synthetase (@GENE$) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T11.T26	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ (DHFS) and @GENE$ synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T11.T27	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (@CHEMICAL$) and @GENE$ synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T12.T28	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEMICAL$ (FPGS) catalyze the attachment of @GENE$ residues to the folate molecule.	false
11752472.T12.T29	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (@CHEMICAL$) catalyze the attachment of @GENE$ residues to the folate molecule.	false
11752472.T12.T26	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of @GENE$ residues to the folate molecule.	false
11752472.T12.T27	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (@CHEMICAL$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of @GENE$ residues to the folate molecule.	false
11752472.T13.T28	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEMICAL$ (FPGS) catalyze the attachment of glutamate residues to the @GENE$ molecule.	false
11752472.T13.T29	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (@CHEMICAL$) catalyze the attachment of glutamate residues to the @GENE$ molecule.	false
11752472.T13.T26	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the @GENE$ molecule.	false
11752472.T13.T27	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (@CHEMICAL$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the @GENE$ molecule.	false
11752472.T5.T28	In organisms that synthesize @CHEMICAL$ de novo, dihydrofolate synthetase (DHFS) and @GENE$ (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T5.T29	In organisms that synthesize @CHEMICAL$ de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (@GENE$) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T5.T26	In organisms that synthesize @CHEMICAL$ de novo, @GENE$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T5.T27	In organisms that synthesize @CHEMICAL$ de novo, dihydrofolate synthetase (@GENE$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T9.T28	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ synthetase (DHFS) and @GENE$ (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T9.T29	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ synthetase (DHFS) and folylpolyglutamate synthetase (@GENE$) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T9.T26	In organisms that synthesize tetrahydrofolate de novo, @CHEM-GENE$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T9.T27	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ synthetase (@GENE$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	false
11752472.T16.T32	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in @CHEMICAL$ or FPGS activity, and by measuring in vitro @GENE$ incorporation into dihydrofolate or tetrahydrofolate.	false
11752472.T16.T33	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or @CHEMICAL$ activity, and by measuring in vitro @GENE$ incorporation into dihydrofolate or tetrahydrofolate.	false
11752472.T17.T32	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in @CHEMICAL$ or FPGS activity, and by measuring in vitro glutamate incorporation into @GENE$ or tetrahydrofolate.	false
11752472.T17.T33	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or @CHEMICAL$ activity, and by measuring in vitro glutamate incorporation into @GENE$ or tetrahydrofolate.	false
11752472.T18.T32	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in @CHEMICAL$ or FPGS activity, and by measuring in vitro glutamate incorporation into dihydrofolate or @GENE$.	false
11752472.T18.T33	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or @CHEMICAL$ activity, and by measuring in vitro glutamate incorporation into dihydrofolate or @GENE$.	false
11752472.T19.T34	@CHEMICAL$ is present exclusively in the mitochondria, making this compartment the sole site of synthesis of @GENE$ in the plant cell.	CPR:9
11752472.T2.T22	The compartmentation of FPGS isoforms is in agreement with the predominance of @CHEMICAL$ derivatives and the presence of @GENE$ and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	false
11752472.T2.T23	The compartmentation of FPGS isoforms is in agreement with the predominance of @CHEMICAL$ derivatives and the presence of serine hydroxymethyltransferase and @GENE$ in the cytosol, the mitochondria, and the plastids.	false
11752472.T2.T36	The compartmentation of @CHEMICAL$ isoforms is in agreement with the predominance of @GENE$ derivatives and the presence of serine hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	false
11752472.T3.T22	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @CHEM-GENE$ and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	false
11752472.T3.T23	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @CHEMICAL$ hydroxymethyltransferase and @GENE$ in the cytosol, the mitochondria, and the plastids.	false
11752472.T3.T36	The compartmentation of @CHEMICAL$ isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @GENE$ hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	false
11752472.T4.T22	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @CHEMICAL$ and @GENE$ interconverting enzymes in the cytosol, the mitochondria, and the plastids.	false
11752472.T4.T23	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of serine hydroxymethyltransferase and @CHEM-GENE$ in the cytosol, the mitochondria, and the plastids.	false
11752472.T4.T36	The compartmentation of @CHEMICAL$ isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of serine hydroxymethyltransferase and @GENE$ interconverting enzymes in the cytosol, the mitochondria, and the plastids.	false
11752472.T6.T24	Thus, the combination of @CHEMICAL$ with these @GENE$-mediated reactions can supply each compartment with the polyglutamylated folate coenzymes required for the reactions of C1 metabolism.	false
11752472.T7.T24	Thus, the combination of @CHEMICAL$ with these folate-mediated reactions can supply each compartment with the polyglutamylated @GENE$ coenzymes required for the reactions of C1 metabolism.	false
11752472.T8.T24	Thus, the combination of @CHEMICAL$ with these folate-mediated reactions can supply each compartment with the polyglutamylated folate coenzymes required for the reactions of @GENE$ metabolism.	false
11752472.T10.T25	Also, the multicompartmentation of @CHEMICAL$ in the plant cell suggests that the transported forms of @GENE$ are unconjugated.	false
11772142.T7.T33	UNLABELLED: @CHEMICAL$ is an inhibitor of the @GENE$.	CPR:4
11772142.T18.T31	CONCLUSION: @CHEMICAL$ is a well tolerated @GENE$ inhibitor.	CPR:4
11799102.T27.T47	@CHEM-GENE$ suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.	false
11799102.T27.T48	@CHEMICAL$ suppression in humans by the orally active @GENE$ inhibitor Aliskiren (SPP100): comparison with enalapril.	false
11799102.T28.T47	@CHEMICAL$ suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with @GENE$.	false
11799102.T28.T48	Angiotensin II suppression in humans by the orally active @CHEMICAL$ inhibitor Aliskiren (SPP100): comparison with @GENE$.	false
11799102.T29.T47	@CHEMICAL$ suppression in humans by the orally active renin inhibitor @GENE$ (SPP100): comparison with enalapril.	CPR:4
11799102.T29.T48	Angiotensin II suppression in humans by the orally active @CHEMICAL$ inhibitor @GENE$ (SPP100): comparison with enalapril.	CPR:4
11799102.T30.T47	@CHEMICAL$ suppression in humans by the orally active renin inhibitor Aliskiren (@GENE$): comparison with enalapril.	CPR:4
11799102.T30.T48	Angiotensin II suppression in humans by the orally active @CHEMICAL$ inhibitor Aliskiren (@GENE$): comparison with enalapril.	CPR:4
11799102.T19.T31	@CHEMICAL$ is the main determinant of @GENE$ levels.	false
11799102.T19.T43	Renin is the main determinant of @CHEM-GENE$ levels.	false
11799102.T2.T33	It, therefore, always appeared desirable to reduce @CHEM-GENE$ levels by direct inhibition of renin.	false
11799102.T2.T35	It, therefore, always appeared desirable to reduce @CHEMICAL$ levels by direct inhibition of @GENE$.	false
11799102.T16.T42	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor @GENE$ (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.	CPR:4
11799102.T17.T42	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor SPP100 (@GENE$, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.	CPR:4
11799102.T18.T42	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor SPP100 (Aliskiren, an @GENE$ with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.	CPR:4
11799102.T20.T42	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d @GENE$ diet using a double-blind, 3-way crossover protocol.	false
11799102.T24.T44	There was a dose-dependent decrease in plasma @CHEMICAL$ activity, @GENE$, and Ang II following single doses of Aliskiren starting with 40 mg.	false
11799102.T24.T45	There was a dose-dependent decrease in plasma renin activity, @CHEM-GENE$, and Ang II following single doses of Aliskiren starting with 40 mg.	false
11799102.T24.T46	There was a dose-dependent decrease in plasma renin activity, @CHEMICAL$, and @GENE$ following single doses of Aliskiren starting with 40 mg.	false
11799102.T25.T44	There was a dose-dependent decrease in plasma @CHEMICAL$ activity, Ang I, and @GENE$ following single doses of Aliskiren starting with 40 mg.	false
11799102.T25.T45	There was a dose-dependent decrease in plasma renin activity, @CHEMICAL$, and @GENE$ following single doses of Aliskiren starting with 40 mg.	false
11799102.T25.T46	There was a dose-dependent decrease in plasma renin activity, Ang I, and @CHEM-GENE$ following single doses of Aliskiren starting with 40 mg.	false
11799102.T26.T44	There was a dose-dependent decrease in plasma @CHEMICAL$ activity, Ang I, and Ang II following single doses of @GENE$ starting with 40 mg.	CPR:4
11799102.T26.T45	There was a dose-dependent decrease in plasma renin activity, @CHEMICAL$, and Ang II following single doses of @GENE$ starting with 40 mg.	CPR:4
11799102.T26.T46	There was a dose-dependent decrease in plasma renin activity, Ang I, and @CHEMICAL$ following single doses of @GENE$ starting with 40 mg.	CPR:4
11799102.T1.T32	Inhibition was still marked and significant after repeated dosing with maximal decreases in @CHEM-GENE$ levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.	false
11799102.T3.T32	Inhibition was still marked and significant after repeated dosing with maximal decreases in @CHEMICAL$ levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of @GENE$ was compared with placebo.	CPR:4
11799102.T4.T34	At the same time, mean plasma active @CHEMICAL$ was increased 16- and 34-fold at the highest dose of @GENE$.	CPR:3
11799102.T11.T37	In conclusion, the @CHEMICAL$ inhibitor @GENE$ dose-dependently decreases Ang II levels in humans following oral administration.	CPR:4
11799102.T11.T38	In conclusion, the renin inhibitor @CHEMICAL$ dose-dependently decreases @GENE$ levels in humans following oral administration.	CPR:4
11799102.T12.T37	In conclusion, the @CHEMICAL$ inhibitor Aliskiren dose-dependently decreases @GENE$ levels in humans following oral administration.	false
11799102.T12.T38	In conclusion, the renin inhibitor Aliskiren dose-dependently decreases @CHEM-GENE$ levels in humans following oral administration.	false
11799102.T14.T41	@CHEMICAL$ has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and @GENE$ antagonists in therapy for hypertension and other cardiovascular and renal diseases.	CPR:6
11799102.T14.T39	@CHEMICAL$ has the potential to become the first orally active @GENE$ inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	CPR:4
11799102.T14.T40	@CHEMICAL$ has the potential to become the first orally active renin inhibitor that provides a true alternative to @GENE$-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	CPR:4
11799102.T15.T41	Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and @CHEM-GENE$ antagonists in therapy for hypertension and other cardiovascular and renal diseases.	false
11799102.T15.T39	Aliskiren has the potential to become the first orally active @CHEMICAL$ inhibitor that provides a true alternative to ACE-inhibitors and @GENE$ receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	false
11799102.T15.T40	Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to @CHEMICAL$-inhibitors and @GENE$ receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	false
11808879.T3.T11	Almost all patients with @CHEMICAL$ (38/41) or KIR6.2 (5/7) mutations were resistant to @GENE$.	false
11808879.T3.T12	Almost all patients with SUR1 (38/41) or @CHEMICAL$ (5/7) mutations were resistant to @GENE$.	false
11808879.T4.T13	Ten patients with hyperinsulinism-hyperammonaemia syndrome had a mutation in the @CHEM-GENE$ gene (three neonates and seven infants) after reverse transcriptase-polymerase chain reaction and sequence analysis of cDNA.	false
11893059.T1.T7	The earliest known @CHEMICAL$ inhibitors, namely, @GENE$ and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).	CPR:4
11893059.T2.T7	The earliest known @CHEMICAL$ inhibitors, namely, physostigmine and @GENE$, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).	CPR:4
11893059.T3.T8	@CHEMICAL$ inaugurates a new class of @GENE$ inhibitors with longer and more selective action and with manageable adverse effects.	CPR:4
11970990.T1.T10	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through @GENE$, but not CD2.	false
11970990.T1.T23	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the @GENE$ that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T24	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact @GENE$ binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T27	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and @GENE$ to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T3	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase @GENE$ phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T9	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and @GENE$ and be mediated through CD16, but not CD2.	false
11970990.T1.T11	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not @GENE$.	false
11970990.T1.T22	Experimentation using isoforms of @CHEMICAL$ engineered to have @GENE$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T25	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that @GENE$ mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T26	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing @GENE$ and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T5	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker @GENE$, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T6	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of @GENE$. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	false
11970990.T1.T8	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to @GENE$ and CD16 and be mediated through CD16, but not CD2.	false
12046682.T1.T4	Thalidomide in multiple myeloma. @CHEMICAL$--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of @GENE$.	CPR:4
12046682.T3.T4	@CHEMICAL$ in multiple myeloma. Thalidomide--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of @GENE$.	false
12063741.T1.T11	As a prodrug @CHEMICAL$ is completely converted to its active metabolite A 77 1726 (M1) which blocks the @GENE$, a key enzyme of the pyrimidine de novo synthesis.	CPR:4
12063741.T2.T11	As a prodrug leflunomide is completely converted to its active metabolite @CHEMICAL$ (M1) which blocks the @GENE$, a key enzyme of the pyrimidine de novo synthesis.	CPR:4
12063741.T3.T11	As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the @CHEM-GENE$, a key enzyme of the pyrimidine de novo synthesis.	false
12063741.T5.T11	As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the @CHEMICAL$, a key enzyme of the @GENE$ de novo synthesis.	false
12080538.T12.T22	Endocrine therapy is first-line therapy for patients with @CHEM-GENE$-positive or progesterone receptor-positive metastatic breast cancer.	false
12080538.T12.T25	Endocrine therapy is first-line therapy for patients with @CHEMICAL$ receptor-positive or @GENE$-positive metastatic breast cancer.	false
12080538.T17.T22	Endocrine therapy is first-line therapy for patients with @CHEMICAL$-positive or @GENE$ receptor-positive metastatic breast cancer.	false
12080538.T17.T25	Endocrine therapy is first-line therapy for patients with estrogen receptor-positive or @CHEM-GENE$-positive metastatic breast cancer.	false
12080538.T6.T20	Commonly used endocrine therapies are @CHEMICAL$, megestrol acetate, and @GENE$ inhibitors.	false
12080538.T7.T20	Commonly used endocrine therapies are tamoxifen, @CHEMICAL$, and @GENE$ inhibitors.	false
12080538.T13.T21	The @CHEMICAL$ inhibitors are currently used as second-line therapy after @GENE$ failure.	false
12080538.T14.T23	A recent study showed that @CHEMICAL$, an @GENE$ inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.	CPR:4
12080538.T15.T23	A recent study showed that anastrozole, an @CHEMICAL$ inhibitor, is as effective or even superior to @GENE$ when used as a first-line therapy.	false
12080538.T16.T24	A new class of drug, the @CHEM-GENE$ downregulators, has been developed.	false
12080538.T18.T19	@CHEMICAL$, the first agent in this new class, not only induces the degradation of the @GENE$ but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.	CPR:4
12080538.T1.T19	Fulvestrant, the first agent in this new class, not only induces the degradation of the @CHEM-GENE$ but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.	false
12080538.T2.T19	Fulvestrant, the first agent in this new class, not only induces the degradation of the @CHEMICAL$ but also is an @GENE$ antagonist; further, its lack of agonist activity provides a better safety profile.	false
12082550.T14.T28	We recently identified @CHEM-GENE$, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC).	false
12082550.T18.T28	We recently identified @CHEM-GENE$, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC).	false
12082550.T16.T29	@CHEMICAL$, a specific inhibitor of @GENE$, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.	CPR:4
12082550.T17.T29	Lovastatin, a specific inhibitor of @CHEM-GENE$, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.	false
12082550.T2.T22	These included @CHEM-GENE$/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T2.T23	These included @CHEMICAL$-binding inhibitor/@GENE$ the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T2.T24	These included @CHEMICAL$-binding inhibitor/acyl-CoA-binding protein, the @GENE$ and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T2.T25	These included @CHEMICAL$-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and @GENE$. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T3.T22	These included @CHEMICAL$/@GENE$-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T3.T23	These included diazepam-binding inhibitor/@CHEM-GENE$ the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T3.T24	These included diazepam-binding inhibitor/@CHEMICAL$-binding protein, the @GENE$ and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T3.T25	These included diazepam-binding inhibitor/@CHEMICAL$-binding protein, the activated transcription factor 4 and @GENE$. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T4.T22	These included @CHEMICAL$/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T4.T23	These included diazepam-binding inhibitor/@CHEMICAL$ the activated transcription factor 4 and rhoA. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T4.T24	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the @CHEMICAL$ and rhoA. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T4.T25	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and @CHEMICAL$. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.	false
12082550.T5.T22	These included @CHEMICAL$/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.	false
12082550.T5.T23	These included diazepam-binding inhibitor/@CHEMICAL$ the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.	false
12082550.T5.T24	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the @CHEMICAL$ and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.	false
12082550.T5.T25	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and @CHEMICAL$. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.	false
12082550.T10.T26	Because @CHEMICAL$ requires @GENE$ for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of lovastatin.	false
12082550.T10.T27	Because rhoA requires @CHEMICAL$ for its function, this links the microarray and biochemical data and identifies @GENE$ as a potential mediator of the anticancer properties of lovastatin.	false
12082550.T11.T26	Because @CHEMICAL$ requires GGPP for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of @GENE$.	false
12082550.T11.T27	Because rhoA requires GGPP for its function, this links the microarray and biochemical data and identifies @CHEMICAL$ as a potential mediator of the anticancer properties of @GENE$.	false
12137927.T13.T31	Regulation of @CHEM-GENE$ abundance by catecholamines and desipramine in vivo.	false
12137927.T14.T31	Regulation of @CHEMICAL$ abundance by @GENE$ and desipramine in vivo.	false
12137927.T15.T31	Regulation of @CHEMICAL$ abundance by catecholamines and @GENE$ in vivo.	false
12137927.T1.T24	The norepinephrine transporter (NET) regulates @CHEMICAL$ signaling by controlling the availability of synaptic @GENE$ (NE), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T1.T20	The norepinephrine transporter (@CHEMICAL$) regulates adrenoreceptor signaling by controlling the availability of synaptic @GENE$ (NE), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T1.T22	The @CHEMICAL$ (NET) regulates adrenoreceptor signaling by controlling the availability of synaptic @GENE$ (NE), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T2.T24	The norepinephrine transporter (NET) regulates @CHEMICAL$ signaling by controlling the availability of synaptic norepinephrine (@GENE$), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T2.T20	The norepinephrine transporter (@CHEMICAL$) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (@GENE$), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T2.T22	The @CHEMICAL$ (NET) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (@GENE$), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T5.T24	The @CHEMICAL$ transporter (NET) regulates @GENE$ signaling by controlling the availability of synaptic norepinephrine (NE), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T5.T20	The @CHEMICAL$ transporter (@GENE$) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (NE), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T5.T22	The @CHEM-GENE$ (NET) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (NE), and it is a direct target for some classes of antidepressant drugs.	false
12137927.T3.T16	@CHEMICAL$ levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack @GENE$, demonstrating that the NET does not require endogenous NE for appropriate regulation under physiological conditions.	false
12137927.T3.T17	NET levels are normal in @CHEMICAL$ knockout (Dbh -/-) mice that lack @GENE$, demonstrating that the NET does not require endogenous NE for appropriate regulation under physiological conditions.	false
12137927.T3.T18	NET levels are normal in dopamine beta-hydroxylase knockout (@CHEMICAL$ -/-) mice that lack @GENE$, demonstrating that the NET does not require endogenous NE for appropriate regulation under physiological conditions.	false
12137927.T3.T19	NET levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack @CHEMICAL$, demonstrating that the @GENE$ does not require endogenous NE for appropriate regulation under physiological conditions.	false
12137927.T4.T16	@CHEMICAL$ levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack NE, demonstrating that the NET does not require endogenous @GENE$ for appropriate regulation under physiological conditions.	false
12137927.T4.T17	NET levels are normal in @CHEMICAL$ knockout (Dbh -/-) mice that lack NE, demonstrating that the NET does not require endogenous @GENE$ for appropriate regulation under physiological conditions.	false
12137927.T4.T18	NET levels are normal in dopamine beta-hydroxylase knockout (@CHEMICAL$ -/-) mice that lack NE, demonstrating that the NET does not require endogenous @GENE$ for appropriate regulation under physiological conditions.	false
12137927.T4.T19	NET levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack NE, demonstrating that the @CHEMICAL$ does not require endogenous @GENE$ for appropriate regulation under physiological conditions.	false
12137927.T10.T21	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not @GENE$ per se.	false
12137927.T10.T23	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not @GENE$ per se.	false
12137927.T10.T25	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of @CHEMICAL$, suggesting that it is down-regulated by a complete absence of catecholamines and not @GENE$ per se.	false
12137927.T6.T21	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both @GENE$ and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T6.T23	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both @GENE$ and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T6.T25	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both @CHEMICAL$ and dopamine (DA) have reduced levels of @GENE$, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T7.T21	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and @GENE$ (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T7.T23	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and @GENE$ (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T7.T25	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and @CHEMICAL$ (DA) have reduced levels of @GENE$, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T8.T21	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and dopamine (@GENE$) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T8.T23	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and dopamine (@GENE$) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T8.T25	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (@CHEMICAL$) have reduced levels of @GENE$, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	false
12137927.T9.T21	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of @GENE$ and not NE per se.	false
12137927.T9.T23	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of @GENE$ and not NE per se.	false
12137927.T9.T25	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of @CHEMICAL$, suggesting that it is down-regulated by a complete absence of @GENE$ and not NE per se.	false
12137927.T11.T26	Chronic treatment with the @CHEMICAL$ inhibitor, @GENE$ (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.	CPR:4
12137927.T11.T27	Chronic treatment with the NET inhibitor, @CHEMICAL$ (DMI), reduced @GENE$ levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.	CPR:4
12137927.T11.T28	Chronic treatment with the NET inhibitor, @CHEMICAL$ (DMI), reduced NET levels in both control and @GENE$ -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.	false
12137927.T11.T29	Chronic treatment with the NET inhibitor, @CHEMICAL$ (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of @GENE$ by antidepressant drugs.	false
12137927.T12.T26	Chronic treatment with the @CHEMICAL$ inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that @GENE$ is not required for the regulation of NET by antidepressant drugs.	false
12137927.T12.T27	Chronic treatment with the NET inhibitor, desipramine (DMI), reduced @CHEMICAL$ levels in both control and Dbh -/- mice, demonstrating that @GENE$ is not required for the regulation of NET by antidepressant drugs.	false
12137927.T12.T28	Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and @CHEMICAL$ -/- mice, demonstrating that @GENE$ is not required for the regulation of NET by antidepressant drugs.	false
12137927.T12.T29	Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that @CHEMICAL$ is not required for the regulation of @GENE$ by antidepressant drugs.	false
12170059.T20.T37	@CHEM-GENE$ regulation of spinal norepinephrine release.	false
12170059.T21.T37	@CHEMICAL$ regulation of spinal @GENE$ release.	false
12170059.T12.T24	BACKGROUND: @CHEM-GENE$ (nAChR) agonists produce antinociception in animals.	false
12170059.T12.T32	BACKGROUND: Neuronal nicotinic @CHEMICAL$ receptor (@GENE$) agonists produce antinociception in animals.	false
12170059.T13.T31	This study tested whether @CHEMICAL$ agonists stimulate spinal release of the neurotransmitter @GENE$ either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce norepinephrine release.	false
12170059.T14.T31	This study tested whether @CHEMICAL$ agonists stimulate spinal release of the neurotransmitter norepinephrine either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce @GENE$ release.	false
12170059.T15.T34	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist @CHEMICAL$, or nicotine plus @GENE$ antagonists and norepinephrine measured in the microdialysates.	false
12170059.T15.T33	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific @CHEMICAL$ agonist @GENE$, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.	CPR:5
12170059.T16.T34	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or @CHEMICAL$ plus @GENE$ antagonists and norepinephrine measured in the microdialysates.	false
12170059.T16.T33	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific @CHEMICAL$ agonist metanicotine, or @GENE$ plus nAChR antagonists and norepinephrine measured in the microdialysates.	CPR:5
12170059.T17.T34	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or nicotine plus @CHEMICAL$ antagonists and @GENE$ measured in the microdialysates.	false
12170059.T17.T33	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific @CHEMICAL$ agonist metanicotine, or nicotine plus nAChR antagonists and @GENE$ measured in the microdialysates.	false
12170059.T18.T35	The effects of specific @CHEM-GENE$ antagonists and nitric oxide synthase inhibitors were also examined.	false
12170059.T18.T36	The effects of specific @CHEMICAL$ receptor antagonists and @GENE$ inhibitors were also examined.	false
12170059.T19.T35	The effects of specific @CHEMICAL$ antagonists and @GENE$ synthase inhibitors were also examined.	false
12170059.T19.T36	The effects of specific glutamate receptor antagonists and @CHEM-GENE$ inhibitors were also examined.	false
12170059.T1.T25	RESULTS: Both @CHEMICAL$ and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @GENE$ inhibitors.	false
12170059.T2.T25	RESULTS: Both nicotine and @CHEMICAL$ induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @GENE$ inhibitors.	false
12170059.T3.T25	RESULTS: Both nicotine and metanicotine induced @CHEMICAL$ release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @GENE$ inhibitors.	false
12170059.T4.T25	RESULTS: Both nicotine and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not @CHEMICAL$ antagonists or @GENE$ inhibitors.	false
12170059.T5.T25	RESULTS: Both nicotine and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @CHEM-GENE$ inhibitors.	false
12170059.T6.T28	Both of the nicotinic agonists stimulated @CHEMICAL$ release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of alpha(4)beta(2*)- than alpha(7*)-preferring @GENE$ antagonists.	false
12170059.T6.T26	Both of the nicotinic agonists stimulated @CHEMICAL$ release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of @GENE$- than alpha(7*)-preferring nAChR antagonists.	false
12170059.T6.T27	Both of the nicotinic agonists stimulated @CHEMICAL$ release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of alpha(4)beta(2*)- than @GENE$-preferring nAChR antagonists.	false
12170059.T7.T28	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of @CHEMICAL$ was blocked at lower concentrations of alpha(4)beta(2*)- than alpha(7*)-preferring @GENE$ antagonists.	false
12170059.T7.T26	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of @CHEMICAL$ was blocked at lower concentrations of @GENE$- than alpha(7*)-preferring nAChR antagonists.	false
12170059.T7.T27	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of @CHEMICAL$ was blocked at lower concentrations of alpha(4)beta(2*)- than @GENE$-preferring nAChR antagonists.	false
12170059.T8.T29	CONCLUSION: These results suggest that one mechanism by which @CHEMICAL$ agonists act for analgesia is to stimulate spinal @GENE$ release.	false
12170059.T10.T30	They do so by actions on @CHEMICAL$, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating norepinephrine release through @GENE$ release or nitric oxide synthesis.	false
12170059.T11.T30	They do so by actions on @CHEMICAL$, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating norepinephrine release through glutamate release or @GENE$ synthesis.	false
12170059.T9.T30	They do so by actions on @CHEMICAL$, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating @GENE$ release through glutamate release or nitric oxide synthesis.	false
12180353.T7.T21	In addition, there is inhibition of @CHEMICAL$ uptake, eventually resulting in changes in cAMP levels, dependent on the type of @GENE$.	false
12180353.T8.T21	In addition, there is inhibition of adenosine uptake, eventually resulting in changes in @CHEMICAL$ levels, dependent on the type of @GENE$.	false
12180353.T9.T21	In addition, there is inhibition of adenosine uptake, eventually resulting in changes in cAMP levels, dependent on the type of @CHEM-GENE$.	false
12180353.T15.T22	@CHEMICAL$ decreases levels of serum triglycerides and causes some increase in @GENE$-cholesterol levels.	CPR:3
12180353.T16.T22	Cilostazol decreases levels of serum triglycerides and causes some increase in @CHEMICAL$-@GENE$ levels.	false
12180353.T3.T18	@CHEMICAL$ undergoes intensive and finally complete hepatic metabolism via the @GENE$ systems.	CPR:9
12181427.T12.T32	Identification of interaction sites of cyclic nucleotide @CHEMICAL$ with milrinone and @GENE$ using molecular modeling and site-directed mutagenesis.	false
12181427.T13.T32	Identification of interaction sites of cyclic @CHEMICAL$ @GENE$ with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.	false
12181427.T14.T32	Identification of interaction sites of cyclic nucleotide @CHEMICAL$ with @GENE$ and cilostazol using molecular modeling and site-directed mutagenesis.	false
12181427.T3.T20	To identify @CHEMICAL$ residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of @GENE$ using a model created on basis of homology to the PDE4B crystal structure.	false
12181427.T3.T21	To identify @CHEMICAL$ residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the @GENE$ crystal structure.	false
12181427.T3.T22	To identify @CHEMICAL$ residues involved in @GENE$-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure.	false
12181427.T5.T23	We changed the residues to @CHEMICAL$ using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of @GENE$.	false
12181427.T6.T23	We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by @CHEMICAL$ and cilostazol, specific inhibitors of @GENE$.	CPR:4
12181427.T7.T23	We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and @CHEMICAL$, specific inhibitors of @GENE$.	CPR:4
12181427.T8.T24	Mutants @CHEMICAL$, D950A, and F1004A had reduced sensitivity to @GENE$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	CPR:4
12181427.T8.T25	Mutants Y751A, @CHEMICAL$, and F1004A had reduced sensitivity to @GENE$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	CPR:4
12181427.T8.T26	Mutants Y751A, D950A, and @CHEMICAL$ had reduced sensitivity to @GENE$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	CPR:4
12181427.T8.T27	Mutants Y751A, D950A, and F1004A had reduced sensitivity to @CHEMICAL$ (K(i) changed from 0.66 microM for the recombinant @GENE$ to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	CPR:4
12181427.T8.T28	Mutants Y751A, D950A, and F1004A had reduced sensitivity to @CHEMICAL$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant @GENE$).	false
12181427.T9.T24	Mutants @CHEMICAL$, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	false
12181427.T9.T25	Mutants Y751A, @CHEMICAL$, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	false
12181427.T9.T26	Mutants Y751A, D950A, and @CHEMICAL$ had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	false
12181427.T9.T27	Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant @CHEMICAL$ to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	false
12181427.T9.T28	Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @CHEMICAL$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant @GENE$).	CPR:4
12181427.T10.T29	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for @GENE$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T10.T30	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for @GENE$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T10.T31	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for @GENE$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T10.T15	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for @CHEMICAL$ but no difference for milrinone from the recombinant @GENE$. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T10.T16	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for @CHEMICAL$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the @GENE$ inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T10.T17	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for @CHEMICAL$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.	false
12181427.T11.T29	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for cilostazol but no difference for @GENE$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T11.T30	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for cilostazol but no difference for @GENE$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T11.T31	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for cilostazol but no difference for @GENE$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T11.T15	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for @CHEMICAL$ from the recombinant @GENE$. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T11.T16	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for @CHEMICAL$ from the recombinant PDE3A. Molecular models show that the @GENE$ inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T11.T17	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for @CHEMICAL$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.	false
12181427.T1.T29	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T1.T30	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T1.T31	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T1.T15	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant @CHEMICAL$. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T1.T16	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the @CHEMICAL$ inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T1.T17	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @CHEMICAL$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.	false
12181427.T2.T29	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T2.T30	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T2.T31	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T2.T15	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant @CHEMICAL$. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	false
12181427.T2.T16	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the @CHEMICAL$ inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.	CPR:4
12181427.T2.T17	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @CHEMICAL$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.	false
12181427.T4.T18	Our study implies that highly conserved residuals Y751, D950 and F1004 in the @CHEMICAL$ families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the @GENE$ selectivity of PDE3A. Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.	CPR:4
12181427.T4.T19	Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the @CHEMICAL$ selectivity of @GENE$. Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.	CPR:4
12217700.T13.T27	The bacterial enzyme @CHEMICAL$ (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as @GENE$ (Glc1P).	CPR:9
12217700.T13.T33	The bacterial enzyme maltodextrin phosphorylase (@CHEMICAL$) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as @GENE$ (Glc1P).	CPR:9
12217700.T14.T27	The bacterial enzyme @CHEMICAL$ (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (@GENE$).	CPR:9
12217700.T14.T33	The bacterial enzyme maltodextrin phosphorylase (@CHEMICAL$) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (@GENE$).	CPR:9
12217700.T5.T27	The bacterial enzyme @CHEMICAL$ (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing @GENE$ residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).	false
12217700.T5.T33	The bacterial enzyme maltodextrin phosphorylase (@CHEMICAL$) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing @GENE$ residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).	false
12217700.T16.T35	The 2.0A crystal structure of the MalP/@CHEMICAL$ binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @GENE$, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T16.T34	The 2.0A crystal structure of the @CHEMICAL$/@GENE$ binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T17.T35	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the @CHEMICAL$ substrate adopts a conformation seen previously with both inactive and active forms of @GENE$, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T17.T34	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the @GENE$ substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T18.T35	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the @GENE$ group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T18.T34	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the @GENE$ group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T19.T35	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the phosphate group not in close contact with the @GENE$ group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T19.T34	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the @GENE$ group of the essential pyridoxal phosphate (PLP) cofactor.	false
12217700.T20.T35	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the phosphate group not in close contact with the 5'-phosphate group of the essential @GENE$ (PLP) cofactor.	false
12217700.T20.T34	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential @GENE$ (PLP) cofactor.	false
12217700.T21.T35	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (@GENE$) cofactor.	false
12217700.T21.T34	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (@GENE$) cofactor.	false
12217700.T22.T36	In the active @CHEMICAL$ enzyme, the residue Arg569 stabilizes the negative-charged @GENE$, whereas in the inactive form of GP this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	false
12217700.T22.T37	In the active MalP enzyme, the residue Arg569 stabilizes the negative-charged @CHEMICAL$, whereas in the inactive form of @GENE$ this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	false
12217700.T1.T23	The comparison between @CHEMICAL$ structures shows that His377, through a hydrogen bond with the @GENE$ group of Glc1P substrate, triggers a conformational change of the 380s loop.	false
12217700.T2.T23	The comparison between @CHEMICAL$ structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of @GENE$ substrate, triggers a conformational change of the 380s loop.	false
12217700.T3.T25	The structures solved after the diffusion of oligosaccharides (either @CHEMICAL$, G4 or maltopentaose, G5) into @GENE$/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.	false
12217700.T4.T25	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or @CHEMICAL$, G5) into @GENE$/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.	false
12217700.T6.T25	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into @CHEMICAL$/@GENE$ crystals show the formation of phosphate and elongation of the oligosaccharide chain.	false
12217700.T7.T25	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into @CHEMICAL$/Glc1P crystals show the formation of @GENE$ and elongation of the oligosaccharide chain.	false
12217700.T12.T26	The relatively large oligosaccharide substrates can diffuse quickly into the @CHEMICAL$/@GENE$ crystals and the enzymatic reaction can occur without significant crystal damage.	false
12383039.T2.T7	OBJECTIVE: @CHEMICAL$ is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to @GENE$.	false
12383039.T2.T8	OBJECTIVE: @CHEMICAL$ is the first in a new class of synthetic @GENE$ inhibitors that binds reversibly with high affinity to antithrombin III.	CPR:4
12409268.T11.T30	Molecular analysis of @CHEMICAL$ gene in Korean patients with @GENE$ acidemia.	false
12409268.T5.T22	It is caused by a deficiency of @CHEM-GENE$ (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T5.T23	It is caused by a deficiency of @CHEMICAL$ carboxylase (@GENE$, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T5.T25	It is caused by a deficiency of @CHEMICAL$ carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T5.T24	It is caused by a deficiency of @CHEMICAL$ carboxylase (PCC, @GENE$), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T6.T22	It is caused by a deficiency of @CHEMICAL$ (PCC, EC 6.4.1.3), a @GENE$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T6.T23	It is caused by a deficiency of propionyl-CoA carboxylase (@CHEMICAL$, EC 6.4.1.3), a @GENE$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T6.T25	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a @CHEMICAL$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T6.T24	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, @CHEMICAL$), a @GENE$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T7.T22	It is caused by a deficiency of @CHEMICAL$ (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of @GENE$ to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	CPR:9
12409268.T7.T23	It is caused by a deficiency of propionyl-CoA carboxylase (@CHEMICAL$, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of @GENE$ to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	CPR:9
12409268.T7.T25	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of @CHEMICAL$ to D-methylmalonyl-CoA. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T7.T24	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, @CHEMICAL$), a biotin-dependent enzyme that catalyzes the carboxylation of @GENE$ to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	CPR:9
12409268.T8.T22	It is caused by a deficiency of @CHEMICAL$ (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @GENE$. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	CPR:9
12409268.T8.T23	It is caused by a deficiency of propionyl-CoA carboxylase (@CHEMICAL$, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @GENE$. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	CPR:9
12409268.T8.T25	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @CHEMICAL$. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.	false
12409268.T8.T24	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, @CHEMICAL$), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @GENE$. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.	CPR:9
12445705.T50.T64	Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and @CHEMICAL$ release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.	false
12445705.T51.T64	Atypical antipsychotic drugs, @CHEMICAL$, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.	false
12445705.T52.T64	Atypical antipsychotic drugs, quetiapine, @CHEMICAL$, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.	false
12445705.T53.T64	Atypical antipsychotic drugs, quetiapine, iloperidone, and @CHEMICAL$, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.	false
12445705.T54.T64	Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase @CHEMICAL$ and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.	false
12445705.T27.T57	Although only @CHEMICAL$ and ziprasidone are directly acting @GENE$ agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	CPR:5
12445705.T27.T58	Although only @CHEMICAL$ and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective @GENE$ antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	false
12445705.T27.T59	Although only @CHEMICAL$ and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined @GENE$ and D(2) blockade.	CPR:4
12445705.T27.T60	Although only @CHEMICAL$ and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and @GENE$ blockade.	CPR:4
12445705.T28.T57	Although only clozapine and @CHEMICAL$ are directly acting @GENE$ agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	CPR:5
12445705.T28.T58	Although only clozapine and @CHEMICAL$ are directly acting 5-HT(1A) agonists, WAY100635, a selective @GENE$ antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	false
12445705.T28.T59	Although only clozapine and @CHEMICAL$ are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined @GENE$ and D(2) blockade.	CPR:4
12445705.T28.T60	Although only clozapine and @CHEMICAL$ are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and @GENE$ blockade.	CPR:4
12445705.T29.T57	Although only clozapine and ziprasidone are directly acting @CHEMICAL$ agonists, @GENE$, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	false
12445705.T29.T58	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, @CHEMICAL$, a selective @GENE$ antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	CPR:6
12445705.T29.T59	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, @CHEMICAL$, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined @GENE$ and D(2) blockade.	CPR:4
12445705.T29.T60	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, @CHEMICAL$, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and @GENE$ blockade.	CPR:4
12445705.T31.T57	Although only clozapine and ziprasidone are directly acting @CHEMICAL$ agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical @GENE$ release that may be due to combined 5-HT(2A) and D(2) blockade.	false
12445705.T31.T58	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective @CHEMICAL$ antagonist, partially attenuates these atypical APD-induced increases in cortical @GENE$ release that may be due to combined 5-HT(2A) and D(2) blockade.	false
12445705.T31.T59	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical @CHEMICAL$ release that may be due to combined @GENE$ and D(2) blockade.	false
12445705.T31.T60	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical @CHEMICAL$ release that may be due to combined 5-HT(2A) and @GENE$ blockade.	false
12445705.T37.T61	The present study determined whether @CHEMICAL$, iloperidone and melperone, @GENE$/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T37.T62	The present study determined whether @CHEMICAL$, iloperidone and melperone, 5-HT(2A)/@GENE$ antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T37.T63	The present study determined whether @CHEMICAL$, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to @GENE$ agonism.	false
12445705.T38.T61	The present study determined whether quetiapine, @CHEMICAL$ and melperone, @GENE$/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T38.T62	The present study determined whether quetiapine, @CHEMICAL$ and melperone, 5-HT(2A)/@GENE$ antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T38.T63	The present study determined whether quetiapine, @CHEMICAL$ and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to @GENE$ agonism.	false
12445705.T39.T61	The present study determined whether quetiapine, iloperidone and @CHEMICAL$, @GENE$/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T39.T62	The present study determined whether quetiapine, iloperidone and @CHEMICAL$, 5-HT(2A)/@GENE$ antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T39.T63	The present study determined whether quetiapine, iloperidone and @CHEMICAL$, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to @GENE$ agonism.	false
12445705.T40.T61	The present study determined whether quetiapine, iloperidone and melperone, @CHEMICAL$/D(2) antagonist atypical APDs, also increase cortical @GENE$ and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T40.T62	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/@CHEMICAL$ antagonist atypical APDs, also increase cortical @GENE$ and ACh release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T40.T63	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical @CHEMICAL$ and ACh release, and whether these effects are related to @GENE$ agonism.	false
12445705.T41.T61	The present study determined whether quetiapine, iloperidone and melperone, @CHEMICAL$/D(2) antagonist atypical APDs, also increase cortical DA and @GENE$ release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T41.T62	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/@CHEMICAL$ antagonist atypical APDs, also increase cortical DA and @GENE$ release, and whether these effects are related to 5-HT(1A) agonism.	false
12445705.T41.T63	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and @CHEMICAL$ release, and whether these effects are related to @GENE$ agonism.	false
12445705.T16.T55	These results indicate that @CHEMICAL$, iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a @GENE$-related mechanism.	false
12445705.T18.T55	These results indicate that quetiapine, @CHEMICAL$ and melperone preferentially increase DA release in the mPFC, compared to the NAC via a @GENE$-related mechanism.	false
12445705.T19.T55	These results indicate that quetiapine, iloperidone and @CHEMICAL$ preferentially increase DA release in the mPFC, compared to the NAC via a @GENE$-related mechanism.	false
12445705.T20.T55	These results indicate that quetiapine, iloperidone and melperone preferentially increase @CHEMICAL$ release in the mPFC, compared to the NAC via a @GENE$-related mechanism.	false
12445705.T22.T56	However, @CHEMICAL$ agonism may be important only for @GENE$-induced ACh release.	CPR:5
12445705.T23.T56	However, @CHEMICAL$ agonism may be important only for quetiapine-induced @GENE$ release.	false
12545144.T13.T15	BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current @CHEMICAL$ channel opener for @GENE$ and KCNQ3/5 channels.	false
12545144.T13.T16	BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current @CHEMICAL$ channel opener for KCNQ2/3 and @GENE$ channels.	false
12545144.T13.T17	BACKGROUND: The novel antiepileptic drug retigabine is the first selective @CHEM-GENE$ opener for KCNQ2/3 and KCNQ3/5 channels.	false
12545144.T8.T15	BACKGROUND: The novel antiepileptic drug @CHEMICAL$ is the first selective M-current potassium channel opener for @GENE$ and KCNQ3/5 channels.	CPR:3
12545144.T8.T16	BACKGROUND: The novel antiepileptic drug @CHEMICAL$ is the first selective M-current potassium channel opener for KCNQ2/3 and @GENE$ channels.	CPR:3
12545144.T8.T17	BACKGROUND: The novel antiepileptic drug @CHEMICAL$ is the first selective @GENE$ opener for KCNQ2/3 and KCNQ3/5 channels.	CPR:3
12588370.T3.T12	OBJECTIVE: Because of these physiological effects and the widespread use of the selective @CHEMICAL$ inhibitor, @GENE$, we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.	CPR:4
12588370.T3.T13	OBJECTIVE: Because of these physiological effects and the widespread use of the selective COX-2 inhibitor, @CHEMICAL$, we wanted to determine if inhibition of @GENE$ would affect incisional skin wound healing.	false
12588370.T4.T16	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective @CHEMICAL$ inhibitor, @GENE$, with a selective COX-2 inhibitor, SC-791.	CPR:4
12588370.T4.T15	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of @CHEMICAL$ in the wound healing process by comparing the effects of a nonselective COX inhibitor, @GENE$, with a selective COX-2 inhibitor, SC-791.	false
12588370.T4.T17	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective COX inhibitor, @CHEMICAL$, with a selective @GENE$ inhibitor, SC-791.	false
12588370.T1.T7	Neither selective COX-2, nor nonselective @CHEMICAL$ inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas @GENE$ treatment resulted in epidermal and granulation tissue atrophy.	false
12588370.T1.T6	Neither selective @CHEMICAL$, nor nonselective COX inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas @GENE$ treatment resulted in epidermal and granulation tissue atrophy.	false
12588370.T2.T9	In addition, neither selective COX-2, nor nonselective @CHEMICAL$ inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas @GENE$ reduced the tensile strength of the wounds by 30-38% throughout the healing period.	false
12588370.T2.T8	In addition, neither selective @CHEMICAL$, nor nonselective COX inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas @GENE$ reduced the tensile strength of the wounds by 30-38% throughout the healing period.	false
12623106.T15.T23	Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the @CHEM-GENE$.	false
12623106.T10.T18	These radiotracers are close analogues of reboxetine, a potent and selective ligand for the @CHEM-GENE$ (NET).	false
12623106.T10.T19	These radiotracers are close analogues of reboxetine, a potent and selective ligand for the @CHEMICAL$ transporter (@GENE$).	false
12623106.T9.T18	These radiotracers are close analogues of @CHEMICAL$, a potent and selective ligand for the @GENE$ (NET).	false
12623106.T9.T19	These radiotracers are close analogues of @CHEMICAL$, a potent and selective ligand for the norepinephrine transporter (@GENE$).	false
12623106.T7.T16	In vitro autoradiography studies (rat brain slices) with @CHEMICAL$ produced a regional distribution pattern that was consistent with the reported distribution of @GENE$.	false
12623106.T8.T17	@CHEMICAL$ has the potential to be the first successful PET ligand to image @GENE$.	false
12657913.T23.T31	@CHEM-GENE$ antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.	false
12657913.T24.T31	@CHEMICAL$ antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of @GENE$ and reduced haloperidol.	false
12657913.T25.T31	@CHEMICAL$ antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced @GENE$.	false
12657913.T26.T31	@CHEMICAL$ antagonists, @GENE$ and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.	CPR:6
12657913.T27.T31	@CHEMICAL$ antagonists, promethazine and @GENE$, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.	CPR:6
12657913.T11.T28	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @CHEMICAL$, on the steady-state plasma concentrations (Css) of @GENE$ and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T11.T29	The effects of @CHEMICAL$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of @GENE$ and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T12.T28	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @CHEMICAL$, on the steady-state plasma concentrations (Css) of haloperidol and reduced @GENE$ were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T12.T29	The effects of @CHEMICAL$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced @GENE$ were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T13.T28	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @CHEMICAL$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving @GENE$, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T13.T29	The effects of @CHEMICAL$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving @GENE$, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T16.T28	The effects of histamine H1-receptor antagonists, @CHEMICAL$ and homochlorcyclizine, both of which are inhibitors of @GENE$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	CPR:4
12657913.T16.T29	The effects of @CHEMICAL$ antagonists, @GENE$ and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	CPR:6
12657913.T19.T28	The effects of histamine H1-receptor antagonists, promethazine and @CHEMICAL$, both of which are inhibitors of @GENE$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	CPR:4
12657913.T19.T29	The effects of @CHEMICAL$ antagonists, promethazine and @GENE$, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	CPR:6
12657913.T4.T28	The effects of @CHEMICAL$ H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @GENE$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T4.T29	The effects of @CHEM-GENE$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	false
12657913.T10.T30	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @CHEMICAL$-catalyzed metabolism of haloperidol and reduced @GENE$.	CPR:9
12657913.T5.T30	Thus, the current study suggests that coadministration of clinical doses of @CHEMICAL$ and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.	CPR:4
12657913.T6.T30	Thus, the current study suggests that coadministration of clinical doses of promethazine and @CHEMICAL$ increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.	CPR:4
12657913.T7.T30	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of @CHEMICAL$ and reduced haloperidol via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.	false
12657913.T8.T30	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced @CHEMICAL$ via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.	false
12657913.T9.T30	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @CHEMICAL$-catalyzed metabolism of @GENE$ and reduced haloperidol.	CPR:9
12679340.T20.T32	@CHEMICAL$ regulation, an enzyme-enzyme activity control: identification of residues of @GENE$ carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities.	false
12679340.T20.T33	Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of @CHEMICAL$ carbamoyltransferase and @GENE$ responsible for enzyme catalytic and regulatory activities.	false
12679340.T20.T34	Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of @CHEM-GENE$ and arginase responsible for enzyme catalytic and regulatory activities.	false
12679340.T3.T23	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of @GENE$ is inhibited whereas arginase remains catalytically active.	false
12679340.T3.T24	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas @GENE$ remains catalytically active.	false
12679340.T3.T25	In the presence of @CHEMICAL$ and arginine, @GENE$ (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T3.T29	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (@GENE$) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T3.T30	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (OTCase) and @GENE$ form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T4.T23	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of @GENE$ is inhibited whereas arginase remains catalytically active.	false
12679340.T4.T24	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas @GENE$ remains catalytically active.	false
12679340.T4.T25	In the presence of ornithine and @CHEMICAL$, @GENE$ (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T4.T29	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (@GENE$) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T4.T30	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (OTCase) and @GENE$ form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T5.T23	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of @GENE$ is inhibited whereas arginase remains catalytically active.	false
12679340.T5.T24	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas @GENE$ remains catalytically active.	false
12679340.T5.T25	In the presence of ornithine and arginine, @CHEM-GENE$ (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T5.T29	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (@GENE$) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T5.T30	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (OTCase) and @GENE$ form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	false
12679340.T6.T26	In @CHEMICAL$, two @GENE$ at the C terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.	false
12679340.T6.T27	In arginase, two @CHEMICAL$ at the C terminus of the protein are crucial for its @GENE$ function but not for its catalytic activity and trimeric structure.	false
12679340.T7.T26	In @CHEMICAL$, two cysteines at the @GENE$ terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.	false
12679340.T7.T27	In arginase, two cysteines at the @CHEMICAL$ terminus of the protein are crucial for its @GENE$ function but not for its catalytic activity and trimeric structure.	false
12679340.T10.T28	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, @GENE$-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	false
12679340.T10.T31	In OTCase, mutations of putative ornithine binding residues, Asp-182, @CHEMICAL$-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.	false
12679340.T11.T28	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, @GENE$-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	false
12679340.T11.T31	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, @CHEMICAL$-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.	false
12679340.T12.T28	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, @GENE$-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	false
12679340.T12.T31	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, @CHEMICAL$-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.	false
12679340.T13.T28	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and @GENE$-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	false
12679340.T13.T31	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and @CHEMICAL$-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.	false
12679340.T14.T28	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for @GENE$ and impaired the interaction with arginase.	false
12679340.T14.T31	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for @CHEMICAL$ and impaired the interaction with @GENE$.	false
12679340.T8.T28	In @CHEMICAL$, mutations of putative @GENE$ binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	false
12679340.T8.T31	In OTCase, mutations of putative @CHEMICAL$ binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.	false
12679340.T9.T28	In @CHEMICAL$, mutations of putative ornithine binding residues, @GENE$-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	false
12679340.T9.T31	In OTCase, mutations of putative ornithine binding residues, @CHEMICAL$-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.	false
12679340.T15.T21	The four @CHEMICAL$ residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T15.T22	The four @CHEMICAL$ residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T16.T21	The four lysine residues located in the SMG loop, @CHEMICAL$-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T16.T22	The four lysine residues located in the SMG loop, @CHEMICAL$-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T17.T21	The four lysine residues located in the SMG loop, Lys-260, @CHEMICAL$-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T17.T22	The four lysine residues located in the SMG loop, Lys-260, @CHEMICAL$-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T18.T21	The four lysine residues located in the SMG loop, Lys-260, Lys-263, @CHEMICAL$-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T18.T22	The four lysine residues located in the SMG loop, Lys-260, Lys-263, @CHEMICAL$-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T19.T21	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and @CHEMICAL$-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T19.T22	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and @CHEMICAL$-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T1.T21	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @CHEMICAL$ to @GENE$ and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	CPR:4
12679340.T1.T22	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to @CHEMICAL$ and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	false
12679340.T2.T21	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @CHEMICAL$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by @GENE$ for the closure of the catalytic domain.	false
12679340.T2.T22	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @CHEMICAL$ and appear to be involved in transducing and enhancing the signal given by @GENE$ for the closure of the catalytic domain.	false
12692940.T6.T13	On the other hand, @CHEMICAL$ did not modify the eosinophil spontaneous adhesion to the resting or @GENE$ plus TNF-alpha-stimulated pulmonary endothelial cells.	false
12692940.T6.T14	On the other hand, @CHEMICAL$ did not modify the eosinophil spontaneous adhesion to the resting or IL-4 plus @GENE$-stimulated pulmonary endothelial cells.	false
12692940.T8.T15	Similarly, @CHEMICAL$ did not modulate @GENE$- or FMLP-activated eosinophil adhesion to the resting endothelial cells.	false
12699389.T1.T10	The @CHEM-GENE$ P-glycoprotein (P-gp) affects the absorption and disposition of many compounds.	false
12699389.T1.T13	The @CHEMICAL$-dependent drug efflux pump P-glycoprotein (@GENE$) affects the absorption and disposition of many compounds.	false
12699389.T1.T8	The @CHEMICAL$-dependent drug efflux pump @GENE$ (P-gp) affects the absorption and disposition of many compounds.	false
12699389.T2.T14	The assays included in @CHEMICAL$ predictions, inhibition assays (based on cellular uptake of rhodamine-123 or calcein AM), and functional assays (@GENE$ activity assay and transcellular transport assay, the latter for a subset of compounds).	false
12699389.T3.T14	The assays included in silico predictions, inhibition assays (based on cellular uptake of @CHEMICAL$ or calcein AM), and functional assays (@GENE$ activity assay and transcellular transport assay, the latter for a subset of compounds).	false
12699389.T4.T14	The assays included in silico predictions, inhibition assays (based on cellular uptake of rhodamine-123 or @CHEMICAL$), and functional assays (@GENE$ activity assay and transcellular transport assay, the latter for a subset of compounds).	false
12783542.T4.T25	@CHEMICAL$ was incorporated into a model target protein, @GENE$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	false
12783542.T4.T26	@CHEMICAL$ was incorporated into a model target protein, murine dihydrofolate reductase (@GENE$), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	false
12783542.T5.T25	5TFI was incorporated into a model target protein, @CHEM-GENE$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	false
12783542.T5.T26	5TFI was incorporated into a model target protein, murine @CHEMICAL$ reductase (@GENE$), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	false
12783542.T6.T25	5TFI was incorporated into a model target protein, @CHEMICAL$ (mDHFR), in an @GENE$ auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	false
12783542.T6.T26	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (@CHEMICAL$), in an @GENE$ auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	false
12783542.T8.T25	5TFI was incorporated into a model target protein, @CHEMICAL$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in @GENE$-supplemented minimal medium depleted of isoleucine.	false
12783542.T8.T26	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (@CHEMICAL$), in an isoleucine auxotrophic Escherichia coli host strain suspended in @GENE$-supplemented minimal medium depleted of isoleucine.	false
12783542.T9.T25	5TFI was incorporated into a model target protein, @CHEMICAL$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of @GENE$.	false
12783542.T9.T26	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (@CHEMICAL$), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of @GENE$.	false
12783542.T15.T27	Measurement of the rate of activation of @CHEMICAL$ by the @GENE$ (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	false
12783542.T15.T28	Measurement of the rate of activation of @CHEMICAL$ by the E. coli isoleucyl-tRNA synthetase (@GENE$) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	false
12783542.T16.T27	Measurement of the rate of activation of 5TFI by the @CHEM-GENE$ (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	false
12783542.T16.T28	Measurement of the rate of activation of 5TFI by the E. coli @CHEMICAL$-tRNA synthetase (@GENE$) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	false
12783542.T17.T27	Measurement of the rate of activation of 5TFI by the @CHEMICAL$ (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for @GENE$.	false
12783542.T17.T28	Measurement of the rate of activation of 5TFI by the E. coli isoleucyl-tRNA synthetase (@CHEMICAL$) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for @GENE$.	false
12783542.T18.T29	@CHEMICAL$ was successfully introduced into the @GENE$ murine interleukin-2 (mIL-2) at the encoded isoleucine positions.	false
12783542.T18.T30	@CHEMICAL$ was successfully introduced into the cytokine @GENE$ (mIL-2) at the encoded isoleucine positions.	false
12783542.T18.T31	@CHEMICAL$ was successfully introduced into the cytokine murine interleukin-2 (@GENE$) at the encoded isoleucine positions.	false
12783542.T20.T29	5TFI was successfully introduced into the @CHEMICAL$ murine interleukin-2 (mIL-2) at the encoded @GENE$ positions.	false
12783542.T20.T30	5TFI was successfully introduced into the cytokine @CHEMICAL$ (mIL-2) at the encoded @GENE$ positions.	false
12783542.T20.T31	5TFI was successfully introduced into the cytokine murine interleukin-2 (@CHEMICAL$) at the encoded @GENE$ positions.	false
12783542.T2.T24	@CHEMICAL$ yielded no evidence for in vivo incorporation into recombinant proteins, and no evidence for activation by @GENE$ in vitro.	false
1280065.T3.T25	This binding was not significantly inhibited by the @CHEMICAL$ analogue epsilon-amino caproic acid (EACA), indicating that @GENE$ binding was not just through lysine binding sites as suggested for other plasminogen binding sites.	false
1280065.T3.T26	This binding was not significantly inhibited by the @CHEMICAL$ analogue epsilon-amino caproic acid (EACA), indicating that plasminogen binding was not just through lysine binding sites as suggested for other @GENE$ binding sites.	false
1280065.T4.T25	This binding was not significantly inhibited by the lysine analogue @CHEMICAL$ (EACA), indicating that @GENE$ binding was not just through lysine binding sites as suggested for other plasminogen binding sites.	false
1280065.T4.T26	This binding was not significantly inhibited by the lysine analogue @CHEMICAL$ (EACA), indicating that plasminogen binding was not just through lysine binding sites as suggested for other @GENE$ binding sites.	false
1280065.T5.T25	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (@CHEMICAL$), indicating that @GENE$ binding was not just through lysine binding sites as suggested for other plasminogen binding sites.	false
1280065.T5.T26	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (@CHEMICAL$), indicating that plasminogen binding was not just through lysine binding sites as suggested for other @GENE$ binding sites.	false
1280065.T6.T25	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (EACA), indicating that @CHEMICAL$ binding was not just through @GENE$ binding sites as suggested for other plasminogen binding sites.	false
1280065.T6.T26	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (EACA), indicating that plasminogen binding was not just through @CHEMICAL$ binding sites as suggested for other @GENE$ binding sites.	false
1280065.T1.T14	Inhibition of binding of both @CHEMICAL$ and plasmin to gp330 by @GENE$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.	CPR:4
1280065.T1.T15	Inhibition of binding of both plasminogen and @CHEMICAL$ to gp330 by @GENE$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.	CPR:4
1280065.T1.T16	Inhibition of binding of both plasminogen and plasmin to @CHEMICAL$ by @GENE$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.	false
1280065.T1.T17	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of @GENE$ to gp330 slightly more than the binding of plasminogen to gp330.	false
1280065.T1.T18	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of plasmin to @GENE$ slightly more than the binding of plasminogen to gp330.	false
1280065.T1.T19	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of @GENE$ to gp330.	false
1280065.T1.T20	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to @GENE$.	false
1280065.T2.T14	Inhibition of binding of both @CHEMICAL$ and plasmin to gp330 by benzamidine was similar, although @GENE$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.	false
1280065.T2.T15	Inhibition of binding of both plasminogen and @CHEMICAL$ to gp330 by benzamidine was similar, although @GENE$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.	false
1280065.T2.T16	Inhibition of binding of both plasminogen and plasmin to @CHEMICAL$ by benzamidine was similar, although @GENE$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.	false
1280065.T2.T17	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of @GENE$ to gp330 slightly more than the binding of plasminogen to gp330.	CPR:4
1280065.T2.T18	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of plasmin to @GENE$ slightly more than the binding of plasminogen to gp330.	false
1280065.T2.T19	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of plasmin to gp330 slightly more than the binding of @GENE$ to gp330.	CPR:4
1280065.T2.T20	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to @GENE$.	false
12818701.T14.T27	Involvement of @CHEMICAL$ was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, @GENE$ (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	false
12818701.T14.T28	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective @CHEMICAL$ antagonists, @GENE$ (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	CPR:6
12818701.T14.T30	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, @CHEMICAL$ (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective @GENE$ antagonist, prazosin (0.3 mg/kg).	false
12818701.T15.T27	Involvement of @CHEMICAL$ was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and @GENE$ (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	false
12818701.T15.T28	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective @CHEMICAL$ antagonists, phentolamine (0.3-3 mg/kg) and @GENE$ (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	CPR:6
12818701.T15.T30	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and @CHEMICAL$ (0.03-0.3 mg/kg), as well as by the selective @GENE$ antagonist, prazosin (0.3 mg/kg).	false
12818701.T16.T27	Involvement of @CHEMICAL$ was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, @GENE$ (0.3 mg/kg).	false
12818701.T16.T28	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective @CHEMICAL$ antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, @GENE$ (0.3 mg/kg).	false
12818701.T16.T30	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective @CHEMICAL$ antagonist, @GENE$ (0.3 mg/kg).	CPR:6
12818701.T17.T22	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T17.T31	The @CHEMICAL$ antagonist, @GENE$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T17.T20	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T17.T21	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T17.T32	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. @GENE$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T18.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @CHEMICAL$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T18.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @GENE$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T18.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @CHEMICAL$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T18.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @CHEMICAL$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T18.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, @GENE$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T19.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@CHEMICAL$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T19.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@GENE$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T19.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@CHEMICAL$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T19.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@CHEMICAL$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T19.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@GENE$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T1.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @CHEMICAL$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T1.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @GENE$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T1.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @CHEMICAL$ (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T1.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @CHEMICAL$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T1.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @GENE$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T2.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @CHEMICAL$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T2.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @GENE$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T2.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, @GENE$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T2.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @CHEMICAL$ (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T2.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @GENE$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T3.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@CHEMICAL$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T3.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@GENE$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T3.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@GENE$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T3.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@CHEMICAL$; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T3.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@GENE$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T4.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @CHEMICAL$ (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T4.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T4.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T4.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @CHEMICAL$ selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T4.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T5.T22	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@CHEMICAL$; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.	false
12818701.T5.T31	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T5.T20	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12818701.T5.T21	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @CHEMICAL$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	CPR:6
12818701.T5.T32	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	false
12824918.T2.T10	To further investigate this positive correlation and its possible therapeutic implications, a selective @CHEMICAL$ inhibitor, @GENE$, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.	CPR:4
12824918.T2.T11	To further investigate this positive correlation and its possible therapeutic implications, a selective COX-2 inhibitor, @CHEMICAL$, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and @GENE$ expression levels.	false
12827214.T25.T42	In human kidney, we found unique @CHEMICAL$-binding sites that were insensitive to phentolamine and were thus unlikely to be @GENE$.	false
12827214.T32.T42	In human kidney, we found unique prazosin-binding sites that were insensitive to @CHEMICAL$ and were thus unlikely to be @GENE$.	false
12827214.T16.T45	As the binding of @CHEMICAL$ to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T19.T45	As the binding of [(3)H]prazosin to @CHEMICAL$-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T23.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM @CHEMICAL$, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T24.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting @CHEMICAL$ binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T26.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM @CHEMICAL$ from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T27.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM @CHEMICAL$. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T28.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. @CHEMICAL$ bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T29.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the @CHEMICAL$-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T30.T45	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the @CHEMICAL$-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	false
12827214.T1.T40	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and @GENE$, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T1.T46	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and @GENE$, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T2.T40	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and noradrenaline, @GENE$ and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T2.T46	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, @GENE$ and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T36.T40	However, other alpha(1)-adrenoceptor antagonists (@CHEMICAL$, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @GENE$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T36.T46	However, other @CHEMICAL$ antagonists (@GENE$, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	CPR:6
12827214.T37.T40	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, @CHEMICAL$ and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @GENE$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T37.T46	However, other @CHEMICAL$ antagonists (tamsulosin, @GENE$ and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	CPR:6
12827214.T38.T40	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and @CHEMICAL$) did not inhibit the binding at a range of concentrations that generally exhibit @GENE$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	false
12827214.T38.T46	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and @GENE$) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	CPR:6
12827214.T3.T40	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and noradrenaline, rauwolscine and @GENE$ were without effect on the [(3)H]prazosin binding.	false
12827214.T3.T46	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and @GENE$ were without effect on the [(3)H]prazosin binding.	false
12827214.T4.T40	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the @GENE$ binding.	false
12827214.T4.T46	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the @GENE$ binding.	false
12827214.T10.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, @GENE$ and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T11.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and @GENE$) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T12.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of @GENE$ to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T13.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to @GENE$-insensitive sites at micromolar concentrations.	false
12827214.T5.T41	On the other hand, ligands for the renal @CHEM-GENE$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T6.T41	On the other hand, ligands for the renal @CHEMICAL$ (@GENE$ and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T7.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and @GENE$) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T8.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for @GENE$ recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T9.T41	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (@GENE$, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	false
12827214.T14.T43	Photoaffinity labeling with @CHEMICAL$ showed phentolamine-insensitive labeling at around 100 kDa, a molecular size larger than that of @GENE$ expressed in 293 cells (50-60 and 70-80 kDa, respectively) on electrophoresis.	false
12827214.T15.T43	Photoaffinity labeling with [(125)I]iodoarylazidoprazosin showed @CHEMICAL$-insensitive labeling at around 100 kDa, a molecular size larger than that of @GENE$ expressed in 293 cells (50-60 and 70-80 kDa, respectively) on electrophoresis.	false
12827214.T17.T44	In contrast, there was no detectable @CHEMICAL$-insensitive binding site but were phentolamine-sensitive @GENE$ in human liver (pK(d)=10.0+/-0.06, B(max)=44+/-6 fmol mg(-1) protein, n=3).	false
12827214.T18.T44	In contrast, there was no detectable phentolamine-insensitive binding site but were @CHEMICAL$-sensitive @GENE$ in human liver (pK(d)=10.0+/-0.06, B(max)=44+/-6 fmol mg(-1) protein, n=3).	false
12837768.T13.T26	chi-Conopeptide MrIA partially overlaps @CHEM-GENE$ on the human norepinephrine transporter.	false
12837768.T13.T27	chi-Conopeptide MrIA partially overlaps @CHEMICAL$ and cocaine binding sites on the @GENE$.	false
12837768.T14.T26	chi-Conopeptide MrIA partially overlaps @CHEM-GENE$ on the human norepinephrine transporter.	false
12837768.T14.T27	chi-Conopeptide MrIA partially overlaps desipramine and @CHEMICAL$ binding sites on the @GENE$.	false
12837768.T15.T26	chi-Conopeptide MrIA partially overlaps @CHEMICAL$ on the human @GENE$ transporter.	false
12837768.T15.T27	chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the @CHEM-GENE$.	false
12837768.T10.T18	The interactions of chi-conopeptide MrIA with the human @CHEMICAL$ transporter (hNET) were investigated by determining the effects of @GENE$ point mutations on the inhibitory potency of MrIA.	false
12837768.T10.T22	The interactions of chi-conopeptide MrIA with the @CHEM-GENE$ (hNET) were investigated by determining the effects of hNET point mutations on the inhibitory potency of MrIA.	false
12837768.T10.T25	The interactions of chi-conopeptide MrIA with the human @CHEMICAL$ transporter (@GENE$) were investigated by determining the effects of hNET point mutations on the inhibitory potency of MrIA.	false
12837768.T5.T19	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of @GENE$ (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).	CPR:9
12837768.T5.T20	The potency of MrIA was greater for inhibition of uptake by hNET of @CHEMICAL$ (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the @GENE$ and serotonin transporter were not inhibited by MrIA (to 7 microM).	false
12837768.T5.T21	The potency of MrIA was greater for inhibition of uptake by hNET of @CHEMICAL$ (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and @GENE$ were not inhibited by MrIA (to 7 microM).	false
12837768.T6.T19	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of [3H]norepinephrine (Ki 1.89 microM) than @GENE$ (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).	CPR:9
12837768.T6.T20	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than @CHEMICAL$ (Ki 4.33 microM), and the @GENE$ and serotonin transporter were not inhibited by MrIA (to 7 microM).	false
12837768.T6.T21	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than @CHEMICAL$ (Ki 4.33 microM), and the human dopamine transporter and @GENE$ were not inhibited by MrIA (to 7 microM).	false
12837768.T7.T19	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human @GENE$ transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).	false
12837768.T7.T20	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the @CHEM-GENE$ and serotonin transporter were not inhibited by MrIA (to 7 microM).	false
12837768.T7.T21	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human @CHEMICAL$ transporter and @GENE$ were not inhibited by MrIA (to 7 microM).	false
12837768.T8.T19	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and @GENE$ transporter were not inhibited by MrIA (to 7 microM).	false
12837768.T8.T20	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the @CHEMICAL$ and @GENE$ transporter were not inhibited by MrIA (to 7 microM).	false
12837768.T8.T21	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and @CHEM-GENE$ were not inhibited by MrIA (to 7 microM).	false
12837768.T11.T23	Of 18 mutations where @CHEMICAL$ amino acid residues were exchanged with those of the human @GENE$ transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	false
12837768.T11.T24	Of 18 mutations where hNET amino acid residues were exchanged with those of the @CHEM-GENE$, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	false
12837768.T12.T23	Of 18 mutations where @CHEMICAL$ amino acid residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of @GENE$ uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	false
12837768.T12.T24	Of 18 mutations where hNET amino acid residues were exchanged with those of the @CHEMICAL$, MrIA had increased potency for inhibition of @GENE$ uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	false
12837768.T9.T23	Of 18 mutations where @CHEMICAL$ @GENE$ residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	false
12837768.T9.T24	Of 18 mutations where hNET @CHEMICAL$ residues were exchanged with those of the @GENE$, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	false
12837768.T1.T16	A comparison of the results with previous data for @CHEMICAL$ and cocaine inhibition of norepinephrine uptake by the mutant @GENE$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	false
12837768.T1.T17	A comparison of the results with previous data for @CHEMICAL$ and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to @GENE$ occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	false
12837768.T2.T16	A comparison of the results with previous data for desipramine and cocaine inhibition of @CHEMICAL$ uptake by the mutant @GENE$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	CPR:9
12837768.T2.T17	A comparison of the results with previous data for desipramine and cocaine inhibition of @CHEMICAL$ uptake by the mutant hNETs reveals that MrIA binding to @GENE$ occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	false
12837768.T3.T16	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant @CHEMICAL$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for @GENE$ antidepressants and cocaine.	false
12837768.T3.T17	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to @CHEMICAL$ occurs at a site that is distinct from but overlaps with the binding sites for @GENE$ antidepressants and cocaine.	false
12837768.T4.T16	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant @CHEMICAL$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and @GENE$.	false
12837768.T4.T17	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to @CHEMICAL$ occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and @GENE$.	false
1284246.T12.T21	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$ aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @GENE$ having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T12.T17	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$ aminohydrolase, @GENE$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T12.T18	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$ aminohydrolase, ACY-1) [@GENE$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T12.T23	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (@GENE$ aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T12.T25	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEM-GENE$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T2.T21	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @CHEMICAL$ having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T2.T17	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @CHEMICAL$) [EC 3.5.1.14], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T2.T18	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@CHEMICAL$], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T2.T23	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T2.T25	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T3.T21	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @CHEMICAL$ having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
1284246.T3.T17	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @CHEMICAL$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
1284246.T3.T18	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@CHEMICAL$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
1284246.T3.T23	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
1284246.T3.T25	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
1284246.T4.T21	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @CHEMICAL$ having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T4.T17	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @CHEMICAL$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T4.T18	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@CHEMICAL$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T4.T23	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T4.T25	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T5.T21	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @GENE$ having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T5.T17	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @GENE$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T5.T18	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@GENE$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T5.T23	A cDNA encoding the complete @CHEMICAL$ sequence of @GENE$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T5.T25	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (@GENE$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	false
1284246.T10.T22	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that @CHEMICAL$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with @GENE$ at the N-terminus.	false
1284246.T11.T22	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that @CHEMICAL$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the @GENE$-terminus.	false
1284246.T6.T22	From sequence analysis of the cDNA and the @CHEMICAL$- and C-terminal amino acid analyses of the purified protein, it is deduced that @GENE$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.	false
1284246.T7.T22	From sequence analysis of the cDNA and the N- and @CHEMICAL$-terminal amino acid analyses of the purified protein, it is deduced that @GENE$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.	false
1284246.T8.T22	From sequence analysis of the cDNA and the N- and C-terminal @CHEMICAL$ analyses of the purified protein, it is deduced that @GENE$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.	false
1284246.T9.T22	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that @CHEMICAL$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 @GENE$ with acetylalanine at the N-terminus.	false
1284246.T13.T26	The @CHEMICAL$ sequence deduced from the nucleotide sequence of the cDNA from porcine liver was identical to that deduced for @GENE$.	false
1284246.T14.T26	The amino acid sequence deduced from the @CHEMICAL$ sequence of the cDNA from porcine liver was identical to that deduced for @GENE$.	false
1284246.T15.T16	Comparison of the @CHEMICAL$ sequence of porcine ACY-1 with those of other @GENE$ showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	false
1284246.T15.T28	Comparison of the @CHEMICAL$ sequence of @GENE$ with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	false
1284246.T1.T16	Comparison of the amino acid sequence of porcine ACY-1 with those of other @CHEM-GENE$ showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	false
1284246.T1.T28	Comparison of the amino acid sequence of @CHEMICAL$ with those of other @GENE$-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	false
12844134.T7.T17	@CHEMICAL$ polymorphisms and antihypertensive response to @GENE$.	false
12844134.T3.T14	OBJECTIVES: Marked interpatient variability exists in blood pressure response to beta-blocker monotherapy. We tested the hypothesis that 2 common polymorphisms in the gene for @CHEMICAL$ are associated with antihypertensive response to @GENE$ in patients with uncomplicated hypertension.	false
12844134.T1.T13	CONCLUSIONS: Our data suggest that @CHEMICAL$ polymorphisms are important determinants of antihypertensive response to @GENE$.	false
12844134.T2.T15	In the future, codon 49 and 389 genotypes or @CHEMICAL$ haplotypes might be used to predict the diastolic blood pressure response to @GENE$ in patients with hypertension.	false
12901032.T14.T22	Patients stable on @CHEMICAL$ therapy and concurrently taking a @GENE$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	false
12901032.T14.T23	Patients stable on @CHEMICAL$ therapy and concurrently taking a cyclooxygenase-2 (@GENE$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	false
12901032.T6.T22	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, @GENE$, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	CPR:4
12901032.T6.T23	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, @GENE$, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	CPR:4
12901032.T7.T22	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or @GENE$) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	CPR:4
12901032.T7.T23	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or @GENE$) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	CPR:4
12901032.T8.T22	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received @GENE$ 200 mg/day or rofecoxib 25 mg/day for three weeks.	CPR:4
12901032.T8.T23	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received @GENE$ 200 mg/day or rofecoxib 25 mg/day for three weeks.	CPR:4
12901032.T9.T22	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or @GENE$ 25 mg/day for three weeks.	CPR:4
12901032.T9.T23	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or @GENE$ 25 mg/day for three weeks.	CPR:4
12901032.T1.T21	Adverse drug reactions were similar for each @CHEMICAL$ inhibitor, but the rate of edema requiring medical intervention was higher in the @GENE$ group.	false
12927226.T12.T24	@CHEMICAL$ antagonism by @GENE$ lowers heart rate variability and baroreflex gain.	CPR:6
12927226.T7.T19	INTRODUCTION: Blockade of the @CHEMICAL$-@GENE$ system (RAS) by ACE inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	false
12927226.T7.T20	INTRODUCTION: Blockade of the renin-@CHEM-GENE$ system (RAS) by ACE inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	false
12927226.T7.T22	INTRODUCTION: Blockade of the renin-@CHEMICAL$ system (RAS) by @GENE$ inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	false
12927226.T8.T21	We sought to assess the effects of the @CHEM-GENE$ blocker eprosartan on HRV and BRG.	false
12927226.T9.T21	We sought to assess the effects of the @CHEMICAL$ blocker @GENE$ on HRV and BRG.	CPR:4
12927226.T11.T13	RESULTS: @CHEMICAL$ tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating @GENE$ levels (p<0.01).	CPR:3
12927226.T1.T13	RESULTS: Eprosartan tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating @CHEM-GENE$ levels (p<0.01).	false
12927226.T3.T14	CONCLUSIONS: @CHEMICAL$ antagonism by @GENE$ lowers heart rate variability and baroreflex gain.	CPR:6
12927226.T4.T15	We speculate that these findings are due to the marked increase in circulating @CHEM-GENE$ (Ang II).	false
12927226.T4.T16	We speculate that these findings are due to the marked increase in circulating @CHEMICAL$ (@GENE$).	false
12927226.T5.T15	We speculate that these findings are due to the marked increase in circulating @CHEMICAL$ (@GENE$).	false
12927226.T5.T16	We speculate that these findings are due to the marked increase in circulating angiotensin II (@CHEM-GENE$).	false
12927226.T6.T17	Further studies are needed to clarify whether @CHEM-GENE$ (AT1) blockers with potential actions inside the blood-brain barrier (BBB) may have different effects on HRV and BRG.	false
12927226.T6.T18	Further studies are needed to clarify whether @CHEMICAL$ type 1 (@GENE$) blockers with potential actions inside the blood-brain barrier (BBB) may have different effects on HRV and BRG.	false
1318989.T17.T28	@CHEMICAL$ did not prevent or reverse that modulatory activity; moreover, pretreatment with the acetylated peptide did not change the pA2 value displayed by the antagonist at the @GENE$.	false
1318989.T18.T29	The antinociceptive activity of the @CHEMICAL$ agonist @GENE$ was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).	CPR:5
1318989.T19.T29	The antinociceptive activity of the @CHEMICAL$ agonist clonidine was also increased in mice treated with alpha @GENE$ beta-endorphin-(1-31).	false
1318989.T1.T22	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon @CHEMICAL$- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of @GENE$/Go transducer proteins.	false
1318989.T1.T23	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon @CHEMICAL$- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of Gi/@GENE$ transducer proteins.	false
1318989.T20.T22	The reducing activity of alpha @CHEMICAL$ beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of @GENE$/Go transducer proteins.	false
1318989.T20.T23	The reducing activity of alpha @CHEMICAL$ beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of Gi/@GENE$ transducer proteins.	false
1318989.T2.T22	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or @CHEMICAL$, agents known to impair the function of @GENE$/Go transducer proteins.	false
1318989.T2.T23	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or @CHEMICAL$, agents known to impair the function of Gi/@GENE$ transducer proteins.	false
1318989.T6.T25	These results confirm and strengthen the idea of alpha @CHEMICAL$ beta-endorphin-(1-31) acting as a non-competitive regulator of mu opioid- and @GENE$-mediated supraspinal antinociception.	false
1318989.T6.T24	These results confirm and strengthen the idea of alpha @CHEMICAL$ beta-endorphin-(1-31) acting as a non-competitive regulator of @GENE$- and alpha 2-adrenoceptor-mediated supraspinal antinociception.	false
1322429.T1.T20	@CHEMICAL$, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress @GENE$ and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.	CPR:4
1322429.T1.T32	@CHEMICAL$, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and cortisol levels in normal subjects, but not in patients with proven @GENE$-dependent Cushing's disease.	false
1322429.T2.T20	Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress @CHEMICAL$ and @GENE$ levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.	false
1322429.T2.T32	Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and @CHEMICAL$ levels in normal subjects, but not in patients with proven @GENE$-dependent Cushing's disease.	false
1322429.T14.T33	In seven normal subjects, basal @CHEMICAL$ plasma levels were significantly suppressed 3 h after @GENE$ administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).	CPR:4
1322429.T15.T37	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T15.T34	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms @GENE$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T15.T35	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEM-GENE$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T15.T36	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms @GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T15.T38	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the @GENE$ peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T15.T39	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T16.T37	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T16.T34	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms GnRH, 100 micrograms @GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T16.T35	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms @GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T16.T36	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEM-GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T16.T38	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms TRH), the @GENE$ peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T16.T39	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T17.T37	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEM-GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T17.T34	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T17.T35	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T17.T36	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T17.T38	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEMICAL$), the @GENE$ peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T17.T39	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEMICAL$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	false
1322429.T18.T37	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEMICAL$), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	CPR:4
1322429.T18.T34	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	CPR:4
1322429.T18.T35	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	CPR:4
1322429.T18.T36	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	CPR:4
1322429.T18.T38	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the @CHEMICAL$ peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	CPR:4
1322429.T18.T39	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @CHEMICAL$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	CPR:4
1322429.T3.T21	In the @CHEMICAL$-hypoglycemia test (0.15 IU/kg BW), neither the ACTH peak nor the area under the curve of ACTH was affected by @GENE$.	false
1322429.T3.T22	In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the @CHEMICAL$ peak nor the area under the curve of ACTH was affected by @GENE$.	false
1322429.T3.T23	In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the ACTH peak nor the area under the curve of @CHEMICAL$ was affected by @GENE$.	false
1322429.T4.T24	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal @CHEMICAL$ and @GENE$ levels nor CRH-stimulated levels were influenced by loperamide.	false
1322429.T4.T25	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and @CHEMICAL$ levels nor @GENE$-stimulated levels were influenced by loperamide.	false
1322429.T5.T24	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal @CHEMICAL$ and cortisol levels nor CRH-stimulated levels were influenced by @GENE$.	false
1322429.T5.T25	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and cortisol levels nor @CHEMICAL$-stimulated levels were influenced by @GENE$.	false
1322429.T6.T26	In four cultured human corticotropic adenomas, @CHEMICAL$ was not able to reduce basal and @GENE$-induced ACTH secretion.	false
1322429.T6.T27	In four cultured human corticotropic adenomas, @CHEMICAL$ was not able to reduce basal and CRH-induced @GENE$ secretion.	false
1322429.T7.T28	In summary, @CHEMICAL$ is able to reduce basal and @GENE$-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	CPR:4
1322429.T7.T29	In summary, @CHEMICAL$ is able to reduce basal and CRH-induced @GENE$ and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	CPR:4
1322429.T8.T28	In summary, loperamide is able to reduce basal and @CHEMICAL$-induced ACTH and @GENE$ levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	false
1322429.T8.T29	In summary, loperamide is able to reduce basal and CRH-induced @CHEMICAL$ and @GENE$ levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	false
1322429.T10.T30	Loperamide has no significant effect on @CHEMICAL$-hypoglycemia-induced ACTH and @GENE$ levels and, therefore, no effect on stress-induced elevation of cortisol levels.	false
1322429.T10.T31	Loperamide has no significant effect on insulin-hypoglycemia-induced @CHEMICAL$ and @GENE$ levels and, therefore, no effect on stress-induced elevation of cortisol levels.	false
1322429.T9.T30	@CHEMICAL$ has no significant effect on @GENE$-hypoglycemia-induced ACTH and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.	false
1322429.T9.T31	@CHEMICAL$ has no significant effect on insulin-hypoglycemia-induced @GENE$ and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.	false
1329582.T5.T18	We also examined the effects of @CHEMICAL$, a @GENE$ antagonist, in parallel.	CPR:6
1359745.T17.T25	The unique role of the enzyme @CHEMICAL$ (5-LO) in the production of @GENE$ (LTs) makes it a likely target for biochemical manipulation.	CPR:9
1359745.T17.T26	The unique role of the enzyme 5-lipoxygenase (@CHEMICAL$) in the production of @GENE$ (LTs) makes it a likely target for biochemical manipulation.	CPR:9
1359745.T21.T25	The unique role of the enzyme @CHEMICAL$ (5-LO) in the production of leukotrienes (@GENE$) makes it a likely target for biochemical manipulation.	CPR:9
1359745.T21.T26	The unique role of the enzyme 5-lipoxygenase (@CHEMICAL$) in the production of leukotrienes (@GENE$) makes it a likely target for biochemical manipulation.	CPR:9
1359745.T11.T24	The rationale for using @CHEMICAL$ inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of @GENE$ in the inflamed mucosa, LTB4 being the most potent chemotactic and chemokinetic metabolite of arachidonic acid.	false
1359745.T12.T24	The rationale for using @CHEMICAL$ inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of LTs in the inflamed mucosa, @GENE$ being the most potent chemotactic and chemokinetic metabolite of arachidonic acid.	false
1359745.T13.T24	The rationale for using @CHEMICAL$ inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of LTs in the inflamed mucosa, LTB4 being the most potent chemotactic and chemokinetic metabolite of @GENE$.	false
1359745.T14.T27	Furthermore, conventional drugs, such as corticosteroids, @CHEMICAL$, and 5-aminosalicylic acid, inhibit LT production and specific @GENE$ inhibition accelerates healing in animal models of acute colitis.	false
1359745.T15.T27	Furthermore, conventional drugs, such as corticosteroids, sulphasalazine, and @CHEMICAL$, inhibit LT production and specific @GENE$ inhibition accelerates healing in animal models of acute colitis.	false
1359745.T16.T27	Furthermore, conventional drugs, such as corticosteroids, sulphasalazine, and 5-aminosalicylic acid, inhibit @CHEMICAL$ production and specific @GENE$ inhibition accelerates healing in animal models of acute colitis.	false
1359745.T18.T28	The compounds identified as @CHEMICAL$ inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where @GENE$ are potent and more selective inhibitors of 5-LO.	false
1359745.T18.T29	The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where @CHEMICAL$ are potent and more selective inhibitors of @GENE$.	CPR:4
1359745.T19.T30	The @CHEMICAL$, zileuton, is the first selective @GENE$ inhibitor evaluated for the treatment of patients with IBD.	CPR:4
1359745.T20.T30	The benzothiophene hydroxyurea, @CHEMICAL$, is the first selective @GENE$ inhibitor evaluated for the treatment of patients with IBD.	CPR:4
1359745.T7.T23	The proof that any putative @CHEMICAL$ inhibitor is blocking @GENE$ production is an important stage in assessing any such drug.	false
14506245.T2.T52	Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun @CHEMICAL$-terminal kinase-1 is critical for @GENE$-induced p21WAF1/CIP1 promoter activity independent of p53.	false
14506245.T2.T53	Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun @CHEMICAL$-terminal kinase-1 is critical for PDGF-induced @GENE$ activity independent of p53.	false
14506245.T2.T51	@CHEMICAL$-activated c-Jun @GENE$-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53.	false
14506245.T2.T54	Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun @CHEMICAL$-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of @GENE$.	false
14506245.T2.T55	Platelet-derived growth factor (PDGF) receptor-alpha-activated @CHEM-GENE$ is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53.	false
14506245.T1.T41	We showed previously that @CHEMICAL$ antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @GENE$-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.	false
14506245.T1.T42	We showed previously that alpha-PDGFR antagonizes @CHEMICAL$-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @GENE$-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.	false
14506245.T1.T43	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of @CHEMICAL$/c-Jun @GENE$-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.	false
14506245.T1.T44	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/@CHEM-GENE$, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.	false
14506245.T1.T45	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @CHEMICAL$-terminal kinase-1, whereas both @GENE$ and beta-PDGFR induce mitogenic signals.	false
14506245.T1.T47	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @CHEMICAL$-terminal kinase-1, whereas both alpha-PDGFR and @GENE$ induce mitogenic signals.	false
14564902.T1.T5	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, @GENE$, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T1.T6	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, von Willebrand factor, @GENE$, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T1.T7	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, von Willebrand factor, anti-thrombin III, @GENE$-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T1.T8	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, von Willebrand factor, anti-thrombin III, t-plasminogen activator-@GENE$-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T2.T5	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, @GENE$, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T2.T6	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, von Willebrand factor, @GENE$, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T2.T7	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, von Willebrand factor, anti-thrombin III, @GENE$-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T2.T8	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, von Willebrand factor, anti-thrombin III, t-plasminogen activator-@GENE$-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T3.T5	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, @CHEMICAL$, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T3.T6	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, @CHEMICAL$, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T3.T7	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, anti-thrombin III, @CHEMICAL$-plasminogen activator inhibitor 1-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14564902.T3.T8	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, anti-thrombin III, t-plasminogen activator-@CHEMICAL$-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.	false
14583450.T6.T52	The human @CHEMICAL$ reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant @GENE$.	false
14583450.T6.T53	The @CHEM-GENE$ complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.	false
14583450.T6.T54	The human @CHEMICAL$ reductase subunit hRRM2 complements @GENE$ in response to UV-induced DNA repair in cells with mutant p53.	false
14583450.T1.T40	@CHEMICAL$ reductase (@GENE$) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.	false
14583450.T1.T7	@CHEM-GENE$ (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.	false
14583450.T2.T40	Ribonucleotide reductase (@CHEMICAL$) is responsible for the de novo conversion of the ribonucleoside diphosphates to @GENE$, which are essential for DNA synthesis and repair.	CPR:9
14583450.T2.T7	@CHEMICAL$ (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to @GENE$, which are essential for DNA synthesis and repair.	CPR:9
14583450.T5.T40	Ribonucleotide reductase (@CHEMICAL$) is responsible for the de novo conversion of the @GENE$ to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.	CPR:9
14583450.T5.T7	@CHEMICAL$ (RR) is responsible for the de novo conversion of the @GENE$ to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.	CPR:9
14583450.T4.T44	In this study, we investigated the expression and function of @CHEMICAL$ and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated @GENE$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	false
14583450.T4.T45	In this study, we investigated the expression and function of p53R2 and @CHEMICAL$ after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated @GENE$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	false
14583450.T4.T46	In this study, we investigated the expression and function of p53R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant @CHEMICAL$ with a truncated @GENE$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	false
14583450.T4.T47	In this study, we investigated the expression and function of p53R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated @CHEMICAL$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type @GENE$.	false
14583450.T3.T26	In PC3 cells, @CHEMICAL$ inhibited @GENE$ and resulted in increased sensitivity to UV irradiation.	CPR:4
14588118.T3.T14	In addition, @CHEMICAL$ treatment significantly reduced the specific @GENE$ activity after SCI as compared to that of vehicle control.	CPR:4
14588118.T4.T15	Furthermore, RT-PCR analyses revealed that @CHEMICAL$ treatment increased expression of @GENE$ mRNA but decreased tumor necrosis factor-alpha expression.	CPR:3
14588118.T4.T16	Furthermore, RT-PCR analyses revealed that @CHEMICAL$ treatment increased expression of interleukin-10 mRNA but decreased @GENE$ expression.	CPR:4
14588118.T5.T17	These data suggest that, after SCI, @CHEMICAL$ treatment modulated expression of @GENE$, attenuated cell death and the size of lesions, and improved functional recovery in the injured rat.	false
14602594.T9.T16	Likewise, the Rif(r) mutant possessed a mutation in the rpoB gene (encoding the @CHEMICAL$ subunit). Increased productivity of @GENE$ in the Str(r) mutant (containing the K88R mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.	false
14602594.T9.T17	Likewise, the Rif(r) mutant possessed a mutation in the rpoB gene (encoding the RNA polymerase beta subunit). Increased productivity of @CHEMICAL$ in the Str(r) mutant (containing the @GENE$ mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.	false
14602594.T9.T15	Likewise, the Rif(r) mutant possessed a mutation in the @CHEMICAL$ gene (encoding the RNA polymerase beta subunit). Increased productivity of @GENE$ in the Str(r) mutant (containing the K88R mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.	false
14602594.T9.T18	Likewise, the Rif(r) mutant possessed a mutation in the rpoB gene (encoding the RNA polymerase beta subunit). Increased productivity of @CHEMICAL$ in the Str(r) mutant (containing the K88R mutation in the @GENE$ protein) may be a result of an aberrant protein synthesis mechanism.	false
14602594.T2.T10	The @CHEMICAL$ mutant ribosome was characterized by increased 70S complex stability in low @GENE$ concentrations.	false
14602594.T2.T11	The K88R mutant ribosome was characterized by increased @CHEMICAL$ stability in low @GENE$ concentrations.	false
14602594.T3.T12	We conclude that this aberrant protein synthesis ability in the Str(r) mutant, which is a result of increased stability of the @CHEMICAL$, is responsible for the remarkable @GENE$ production enhancement obtained.	false
14619588.T10.T19	[The effects of @CHEMICAL$ on @GENE$ of liver and sexual glands in burned rats].	false
14619588.T3.T16	OBJECTIVE: To assess the effects of @CHEMICAL$ (NP) on @GENE$ (AR) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	false
14619588.T3.T18	OBJECTIVE: To assess the effects of @CHEMICAL$ (NP) on androgen receptor (@GENE$) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	false
14619588.T6.T16	OBJECTIVE: To assess the effects of nandrolone phenylpropionate (@CHEMICAL$) on @GENE$ (AR) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	false
14619588.T6.T18	OBJECTIVE: To assess the effects of nandrolone phenylpropionate (@CHEMICAL$) on androgen receptor (@GENE$) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	false
14619588.T7.T15	RESULTS: The density of @CHEMICAL$ in liver tissue in @GENE$ group was higher than that in control group (P < 0.05).	CPR:3
14619588.T8.T17	The density of @CHEMICAL$ in testis and ovary tissues showed no significant difference between @GENE$ group and control group at every time-point (P > 0.05).	false
14619588.T1.T11	CONCLUSION: @CHEMICAL$ up-regulated the density of @GENE$ in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.	CPR:3
14619588.T1.T12	CONCLUSION: @CHEMICAL$ up-regulated the density of AR in liver tissue, whereas it had no significant effects on the density of @GENE$ in testis and ovary tissues.	false
14659797.T8.T14	@CHEM-GENE$ loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.	false
14659797.T9.T14	@CHEMICAL$ loss of function mutation in a patient with @GENE$-associated primary pulmonary hypertension.	false
14659797.T3.T11	A mouse model incriminates the @CHEM-GENE$ but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via nitric oxide production.	false
14659797.T4.T11	A mouse model incriminates the @CHEMICAL$ but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via @GENE$ production.	false
14659797.T1.T10	CONCLUSION: Loss of @CHEMICAL$ @GENE$ function may predispose to fenfluramine-associated PPH in man.	false
14659797.T2.T10	CONCLUSION: Loss of serotonin @CHEMICAL$ function may predispose to @GENE$-associated PPH in man.	false
14722255.T8.T23	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (TBP) were disrupted on @CHEMICAL$ (CldAMP)-substituted @GENE$.	false
14722255.T8.T21	We demonstrated by in vitro gel-shift assays that binding interactions of the @CHEMICAL$ (TBP) were disrupted on @GENE$ (CldAMP)-substituted TATA box consensus sequences.	false
14722255.T8.T22	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (@CHEMICAL$) were disrupted on @GENE$ (CldAMP)-substituted TATA box consensus sequences.	false
14722255.T9.T23	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (TBP) were disrupted on 2-chlorodeoxyadenosine monophosphate (@CHEMICAL$)-substituted @GENE$.	false
14722255.T9.T21	We demonstrated by in vitro gel-shift assays that binding interactions of the @CHEMICAL$ (TBP) were disrupted on 2-chlorodeoxyadenosine monophosphate (@GENE$)-substituted TATA box consensus sequences.	false
14722255.T9.T22	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (@CHEMICAL$) were disrupted on 2-chlorodeoxyadenosine monophosphate (@GENE$)-substituted TATA box consensus sequences.	false
14722255.T12.T24	We hypothesized that @CHEMICAL$ (pol II) transcriptional processes would therefore be affected by @GENE$ (CldATP) incorporation into a promoter TATA element.	false
14722255.T12.T25	We hypothesized that human RNA polymerase II (@CHEMICAL$) transcriptional processes would therefore be affected by @GENE$ (CldATP) incorporation into a promoter TATA element.	false
14722255.T12.T26	We hypothesized that human RNA polymerase II (pol II) transcriptional processes would therefore be affected by @CHEMICAL$ (CldATP) incorporation into a promoter @GENE$.	false
14722255.T13.T24	We hypothesized that @CHEMICAL$ (pol II) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (@GENE$) incorporation into a promoter TATA element.	false
14722255.T13.T25	We hypothesized that human RNA polymerase II (@CHEMICAL$) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (@GENE$) incorporation into a promoter TATA element.	false
14722255.T13.T26	We hypothesized that human RNA polymerase II (pol II) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (@CHEMICAL$) incorporation into a promoter @GENE$.	false
14722255.T15.T17	With increasing amounts of HeLa extract, @CHEMICAL$ substitution for dAMP within the @GENE$ decreased in vitro pol II transcription by approximately 35% compared with control substrates.	false
14722255.T15.T18	With increasing amounts of HeLa extract, @CHEMICAL$ substitution for dAMP within the TATA box decreased in vitro @GENE$ transcription by approximately 35% compared with control substrates.	false
14722255.T1.T17	With increasing amounts of HeLa extract, CldAMP substitution for @CHEMICAL$ within the @GENE$ decreased in vitro pol II transcription by approximately 35% compared with control substrates.	false
14722255.T1.T18	With increasing amounts of HeLa extract, CldAMP substitution for @CHEMICAL$ within the TATA box decreased in vitro @GENE$ transcription by approximately 35% compared with control substrates.	false
14722255.T2.T19	In contrast, transcription on @CHEMICAL$-substituted @GENE$ reached a plateau after 20 min.	false
14722255.T3.T20	Furthermore, @CHEMICAL$-substituted promoter sequences trapped or sequestered TBP, preventing its dissociation from DNA and subsequent binding to additional @GENE$ to reinitiate transcription.	false
14757145.T11.T20	Blockade of @CHEMICAL$- and desensitization of beta 2-adrenoceptors reduce @GENE$-induced cardiac fibrosis.	false
14757145.T11.T21	Blockade of beta 1- and desensitization of @CHEMICAL$ reduce @GENE$-induced cardiac fibrosis.	false
14757145.T10.T17	The aim of the present study was to analyse the role of @CHEMICAL$ in the @GENE$-induced myocardial remodeling, especially the interstitial fibrosis.	false
14757145.T3.T14	Rats received a concomitant treatment with the selective @CHEMICAL$ antagonist, @GENE$ (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.	CPR:6
14757145.T3.T15	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, @CHEMICAL$ (50 mg/kg/day p.o.) or were chronically pretreated with the selective @GENE$ agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.	false
14757145.T3.T16	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, @CHEMICAL$ (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce @GENE$ desensitization.	false
14757145.T4.T14	Rats received a concomitant treatment with the selective @CHEMICAL$ antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist @GENE$ (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.	false
14757145.T4.T15	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective @CHEMICAL$ agonist @GENE$ (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.	CPR:5
14757145.T4.T16	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist @CHEMICAL$ (40 microg/kg/h) for 1 week to induce @GENE$ desensitization.	false
14757145.T5.T18	The pretreatment with @CHEMICAL$ induced a 59% down-regulation of left ventricular @GENE$ compared to control.	CPR:4
14757145.T1.T13	beta(1)-adrenoceptor blockade and beta(2)-adrenoceptors down-regulation provided similar protection against @CHEMICAL$-induced cardiac interstitial fibrosis suggesting that both @GENE$ are involved in such cardiac remodeling process.	false
14757145.T1.T12	beta(1)-adrenoceptor blockade and @CHEMICAL$ down-regulation provided similar protection against @GENE$-induced cardiac interstitial fibrosis suggesting that both beta-adrenoceptors are involved in such cardiac remodeling process.	false
14757145.T1.T19	@CHEMICAL$ blockade and beta(2)-adrenoceptors down-regulation provided similar protection against @GENE$-induced cardiac interstitial fibrosis suggesting that both beta-adrenoceptors are involved in such cardiac remodeling process.	false
14757700.T39.T60	Characterization of the @CHEM-GENE$ TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. 1.	false
14757700.T39.T61	Characterization of the mouse cold-@CHEMICAL$ receptor @GENE$ and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. 1.	false
14757700.T39.T62	Characterization of the mouse cold-@CHEMICAL$ receptor TRPM8 and @GENE$ VR1 using a fluorometric imaging plate reader (FLIPR) assay. 1.	false
14757700.T39.T63	Characterization of the mouse cold-@CHEMICAL$ receptor TRPM8 and vanilloid receptor type-1 @GENE$ using a fluorometric imaging plate reader (FLIPR) assay. 1.	false
14757700.T19.T51	TRPM8 (CMR1) is a @CHEM-GENE$, which can be activated by low temperatures, menthol, eucalyptol and icilin.	false
14757700.T19.T40	TRPM8 (@CHEMICAL$) is a @GENE$-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.	false
14757700.T19.T55	@CHEMICAL$ (CMR1) is a @GENE$-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.	false
14757700.T1.T51	TRPM8 (CMR1) is a @CHEMICAL$, which can be activated by low temperatures, menthol, @GENE$ and icilin.	CPR:3
14757700.T1.T40	TRPM8 (@CHEMICAL$) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, @GENE$ and icilin.	CPR:3
14757700.T1.T55	@CHEMICAL$ (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, @GENE$ and icilin.	CPR:3
14757700.T35.T51	TRPM8 (CMR1) is a @CHEMICAL$, which can be activated by low temperatures, @GENE$, eucalyptol and icilin.	CPR:3
14757700.T35.T40	TRPM8 (@CHEMICAL$) is a Ca(2+)-permeable channel, which can be activated by low temperatures, @GENE$, eucalyptol and icilin.	CPR:3
14757700.T35.T55	@CHEMICAL$ (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, @GENE$, eucalyptol and icilin.	CPR:3
14757700.T7.T51	TRPM8 (CMR1) is a @CHEMICAL$, which can be activated by low temperatures, menthol, eucalyptol and @GENE$.	CPR:3
14757700.T7.T40	TRPM8 (@CHEMICAL$) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and @GENE$.	CPR:3
14757700.T7.T55	@CHEMICAL$ (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and @GENE$.	CPR:3
14757700.T20.T54	We tested whether substances which are structurally related to @CHEMICAL$, or which produce a cooling sensation, could activate @GENE$, and compared the responses of TRPM8 and VR1 to these ligands.	false
14757700.T20.T56	We tested whether substances which are structurally related to @CHEMICAL$, or which produce a cooling sensation, could activate TRPM8, and compared the responses of @GENE$ and VR1 to these ligands.	false
14757700.T20.T57	We tested whether substances which are structurally related to @CHEMICAL$, or which produce a cooling sensation, could activate TRPM8, and compared the responses of TRPM8 and @GENE$ to these ligands.	false
14757700.T21.T58	The effects of 70 odorants and @CHEMICAL$-related substances on recombinant @GENE$ (mTRPM8), expressed in HEK293 cells, were examined using a FLIPR assay.	false
14757700.T21.T59	The effects of 70 odorants and @CHEMICAL$-related substances on recombinant mouse TRPM8 (@GENE$), expressed in HEK293 cells, were examined using a FLIPR assay.	false
14757700.T11.T41	Known @CHEMICAL$ antagonists (@GENE$, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:6
14757700.T11.T42	Known VR1 antagonists (@CHEMICAL$, thio-BCTC and capsazepine) were also able to block the response of @GENE$ to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:4
14757700.T12.T41	Known @CHEMICAL$ antagonists (BCTC, @GENE$ and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:6
14757700.T12.T42	Known VR1 antagonists (BCTC, @CHEMICAL$ and capsazepine) were also able to block the response of @GENE$ to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:4
14757700.T13.T41	Known @CHEMICAL$ antagonists (BCTC, thio-BCTC and @GENE$) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:6
14757700.T13.T42	Known VR1 antagonists (BCTC, thio-BCTC and @CHEMICAL$) were also able to block the response of @GENE$ to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:4
14757700.T14.T41	Known @CHEMICAL$ antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to @GENE$ (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	false
14757700.T14.T42	Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of @CHEMICAL$ to @GENE$ (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	CPR:3
14757700.T15.T44	The @CHEMICAL$ response of @GENE$-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH.	false
14757700.T15.T45	The @CHEMICAL$ response of hVR1-transfected HEK293 cells to the endogenous @GENE$ agonist N-arachidonoyl-dopamine was potentiated by low pH.	false
14757700.T16.T44	The Ca(2+) response of @CHEMICAL$-transfected HEK293 cells to the endogenous VR1 agonist @GENE$ was potentiated by low pH.	CPR:3
14757700.T16.T45	The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous @CHEMICAL$ agonist @GENE$ was potentiated by low pH.	CPR:5
14757700.T17.T46	In contrast, @CHEMICAL$- and icilin-activated @GENE$ currents were suppressed by low pH. 6.	CPR:3
14757700.T18.T46	In contrast, menthol- and @CHEMICAL$-activated @GENE$ currents were suppressed by low pH. 6.	CPR:3
15049511.T7.T25	Inhibitory effects of the @CHEM-GENE$ inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.	false
15049511.T7.T26	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the @GENE$ enzymes CYP2C19, CYP2C9, and CYP2D6.	false
15049511.T7.T22	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes @GENE$, CYP2C9, and CYP2D6.	false
15049511.T7.T23	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, @GENE$, and CYP2D6.	false
15049511.T7.T24	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and @GENE$.	false
15049511.T8.T25	Inhibitory effects of the @CHEMICAL$ inhibitor @GENE$ on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.	CPR:4
15049511.T8.T26	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the @GENE$ enzymes CYP2C19, CYP2C9, and CYP2D6.	false
15049511.T8.T22	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the cytochrome P450 enzymes @GENE$, CYP2C9, and CYP2D6.	false
15049511.T8.T23	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the cytochrome P450 enzymes CYP2C19, @GENE$, and CYP2D6.	false
15049511.T8.T24	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the cytochrome P450 enzymes CYP2C19, CYP2C9, and @GENE$.	false
15049511.T2.T10	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three @GENE$ (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T2.T11	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (@GENE$) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T2.T20	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of @GENE$ (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	CPR:4
15049511.T2.T9	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (@GENE$), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	CPR:4
15049511.T2.T12	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely @GENE$, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T2.T13	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, @GENE$, and CYP2D6, have been evaluated in vitro.	false
15049511.T2.T14	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and @GENE$, have been evaluated in vitro.	false
15049511.T5.T10	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three @GENE$ (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T5.T11	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (@GENE$) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T5.T20	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEM-GENE$ (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T5.T9	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (@GENE$), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T5.T12	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely @GENE$, CYP2C19, and CYP2D6, have been evaluated in vitro.	false
15049511.T5.T13	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, @GENE$, and CYP2D6, have been evaluated in vitro.	false
15049511.T5.T14	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and @GENE$, have been evaluated in vitro.	false
15049511.T3.T16	A range of substrate concentrations was coincubated with a range of @CHEMICAL$ concentrations in the presence of each of the @GENE$ enzymes at 37 degrees C for a predetermined period of time.	false
15049511.T4.T17	The results demonstrated that @CHEMICAL$ is a competitive inhibitor of @GENE$ (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).	CPR:4
15049511.T4.T18	The results demonstrated that @CHEMICAL$ is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and @GENE$ (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).	CPR:4
15049511.T4.T19	The results demonstrated that @CHEMICAL$ is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of @GENE$ (Ki = 56 microM).	CPR:4
15049511.T1.T21	However, in certain situations such as high dose tranylcypromine therapy, or in poor metabolizers of @CHEMICAL$ substrates, clinically significant interactions might occur, particularly when @GENE$ is coadministered with drugs with a narrow therapeutic index.	false
15049511.T6.T21	However, in certain situations such as high dose @CHEMICAL$ therapy, or in poor metabolizers of @GENE$ substrates, clinically significant interactions might occur, particularly when tranylcypromine is coadministered with drugs with a narrow therapeutic index.	false
15058382.T4.T17	Organization and expression of the @CHEM-GENE$ genes.	false
15058382.T1.T5	The @CHEMICAL$ gene, which encodes the lysosomal @GENE$ transporter LYAAT1/PAT1, generates multiple alternative mRNAs, some of which encode truncated proteins.	false
15058382.T1.T6	The human SLC36A1 gene, which encodes the @CHEM-GENE$/PAT1, generates multiple alternative mRNAs, some of which encode truncated proteins.	false
15058382.T1.T7	The human SLC36A1 gene, which encodes the lysosomal @CHEMICAL$ transporter LYAAT1/@GENE$, generates multiple alternative mRNAs, some of which encode truncated proteins.	false
15058382.T3.T10	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @CHEM-GENE$ tramdorinl/PAT2, is most abundant in kidney and muscle.	false
15058382.T3.T11	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @CHEMICAL$ transporter @GENE$/PAT2, is most abundant in kidney and muscle.	false
15058382.T3.T12	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @CHEMICAL$ transporter tramdorinl/@GENE$, is most abundant in kidney and muscle.	false
15058382.T3.T8	@CHEMICAL$ is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @GENE$ transporter tramdorinl/PAT2, is most abundant in kidney and muscle.	false
15058382.T3.T9	SLC36A1 is expressed in numerous tissues, whereas expression of @CHEMICAL$, which encodes the @GENE$ transporter tramdorinl/PAT2, is most abundant in kidney and muscle.	false
15075397.T2.T13	@CHEMICAL$ mutants were hypersensitive to @GENE$ (HU), aphidicolin, and UV-B light but only mildly sensitive to gamma-radiation.	false
15075397.T3.T13	@CHEMICAL$ mutants were hypersensitive to hydroxyurea (@GENE$), aphidicolin, and UV-B light but only mildly sensitive to gamma-radiation.	false
15075397.T4.T13	@CHEMICAL$ mutants were hypersensitive to hydroxyurea (HU), @GENE$, and UV-B light but only mildly sensitive to gamma-radiation.	false
15075397.T5.T16	G2 arrest also was observed in wild-type plants in response to @CHEMICAL$ but was defective in @GENE$ mutants, resulting in compaction of nuclei and subsequent cell death.	false
15109613.T6.T12	The current report describes progress in development of a selective @CHEM-GENE$ modulator, GC-1.	false
15109613.T1.T9	This compound binds selectively to the @CHEM-GENE$, and its uptake into the heart is relatively low.	false
15109613.T2.T11	Studies in rats, mice and monkeys show that GC-1 lowers @CHEMICAL$ with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of triglyceride and @GENE$, and induces loss of fat.	false
15109613.T2.T10	Studies in rats, mice and monkeys show that GC-1 lowers @CHEMICAL$ with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @GENE$. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat.	false
15109613.T3.T11	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than @CHEMICAL$, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of triglyceride and @GENE$, and induces loss of fat.	false
15109613.T3.T10	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than @CHEMICAL$, a compound that blocks @GENE$. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat.	CPR:4
15109613.T4.T11	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @CHEMICAL$ reductase. GC-1 also decreases plasma levels of triglyceride and @GENE$, and induces loss of fat.	false
15109613.T4.T10	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @CHEM-GENE$. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat.	false
15109613.T5.T11	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of @CHEMICAL$ and @GENE$, and induces loss of fat.	false
15109613.T5.T10	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @CHEMICAL$. GC-1 also decreases plasma levels of @GENE$ and lipoprotein (a), and induces loss of fat.	false
15180525.T25.T53	@CHEM-GENE$ as a drug target in leukemia.	false
15180525.T22.T40	The @CHEM-GENE$ (Flk2, STK1) has recently received much attention as a potential drug target.	false
15180525.T22.T46	The hematopoietic class III receptor @CHEMICAL$ kinase (RTK) Flt3 (@GENE$, STK1) has recently received much attention as a potential drug target.	false
15180525.T22.T48	The hematopoietic class III receptor @CHEMICAL$ kinase (RTK) Flt3 (Flk2, @GENE$) has recently received much attention as a potential drug target.	false
15180525.T23.T42	Signal transduction of Flt3 involves activation of several conserved pathways, including the @CHEMICAL$/MAP-Kinase and the @GENE$-3-kinase/Akt signaling cascades.	false
15180525.T23.T43	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/@CHEMICAL$ and the @GENE$-3-kinase/Akt signaling cascades.	false
15180525.T23.T44	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/MAP-Kinase and the @CHEM-GENE$/Akt signaling cascades.	false
15180525.T23.T45	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/MAP-Kinase and the @CHEMICAL$-3-kinase/@GENE$ signaling cascades.	false
15180525.T23.T41	Signal transduction of @CHEMICAL$ involves activation of several conserved pathways, including the RAS/MAP-Kinase and the @GENE$-3-kinase/Akt signaling cascades.	false
15180525.T24.T51	Selective inhibitors of Flt3 @CHEM-GENE$ activity have the potential to suppress aberrant Flt3 signaling.	false
15180525.T24.T50	Selective inhibitors of @CHEMICAL$ @GENE$ kinase activity have the potential to suppress aberrant Flt3 signaling.	false
15180525.T24.T52	Selective inhibitors of Flt3 @CHEMICAL$ kinase activity have the potential to suppress aberrant @GENE$ signaling.	false
15180525.T1.T26	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the @GENE$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T1.T28	Although highly homologous to other class III RTKs, Flt3 is resistant to the @CHEMICAL$ STI571 (Gleevec, Imatinib), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.	CPR:4
15180525.T1.T27	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the @GENE$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T1.T29	Although highly homologous to other class III RTKs, Flt3 is resistant to the @CHEMICAL$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.	CPR:4
15180525.T1.T30	Although highly homologous to other class III RTKs, Flt3 is resistant to the @CHEMICAL$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.	CPR:4
15180525.T2.T26	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the phenylaminopyrimidine @GENE$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T2.T28	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine @CHEMICAL$ (Gleevec, Imatinib), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.	CPR:4
15180525.T2.T27	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the phenylaminopyrimidine @GENE$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T2.T29	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine @CHEMICAL$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.	CPR:4
15180525.T2.T30	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine @CHEMICAL$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.	CPR:4
15180525.T3.T26	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the phenylaminopyrimidine STI571 (@GENE$, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T3.T28	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (@CHEMICAL$, Imatinib), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.	CPR:4
15180525.T3.T27	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the phenylaminopyrimidine STI571 (@GENE$, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T3.T29	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (@CHEMICAL$, Imatinib), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.	CPR:4
15180525.T3.T30	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (@CHEMICAL$, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.	CPR:4
15180525.T4.T26	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @GENE$), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T4.T28	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @CHEMICAL$), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.	CPR:4
15180525.T4.T27	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the phenylaminopyrimidine STI571 (Gleevec, @GENE$), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	false
15180525.T4.T29	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @CHEMICAL$), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.	CPR:4
15180525.T4.T30	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @CHEMICAL$), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.	CPR:4
15180525.T5.T31	@CHEMICAL$ binding to @GENE$ is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.	false
15180525.T5.T32	@CHEMICAL$ binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding @GENE$ mutant sensitive to STI571.	false
15180525.T6.T31	STI571 binding to @CHEMICAL$ is prevented by the @GENE$ 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.	false
15180525.T6.T32	STI571 binding to Flt3 is prevented by the @CHEMICAL$ 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding @GENE$ mutant sensitive to STI571.	false
15180525.T7.T31	STI571 binding to @CHEMICAL$ is prevented by the phenylalanine 691 side-chain in the @GENE$ binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.	false
15180525.T7.T32	STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the @CHEMICAL$ binding center and mutating this site to threonine renders the corresponding @GENE$ mutant sensitive to STI571.	false
15180525.T8.T31	STI571 binding to @CHEMICAL$ is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to @GENE$ renders the corresponding Flt3 mutant sensitive to STI571.	false
15180525.T8.T32	STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to @CHEMICAL$ renders the corresponding @GENE$ mutant sensitive to STI571.	false
15180525.T9.T31	STI571 binding to @CHEMICAL$ is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to @GENE$.	false
15180525.T9.T32	STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding @CHEMICAL$ mutant sensitive to @GENE$.	CPR:4
15180525.T10.T35	Compounds of several other structural families, including the @CHEMICAL$ AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T10.T34	Compounds of several other structural families, including the @CHEMICAL$ AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T11.T35	Compounds of several other structural families, including the quinoxaline @CHEMICAL$, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T11.T34	Compounds of several other structural families, including the quinoxaline @CHEMICAL$, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T12.T35	Compounds of several other structural families, including the quinoxaline AG1296, the @CHEMICAL$ D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T12.T34	Compounds of several other structural families, including the quinoxaline AG1296, the @CHEMICAL$ D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T13.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone @CHEMICAL$, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T13.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone @CHEMICAL$, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T14.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the @CHEMICAL$ SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T14.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the @CHEMICAL$ SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T15.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones @CHEMICAL$ and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T15.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones @CHEMICAL$ and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T16.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and @CHEMICAL$, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T16.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and @CHEMICAL$, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T17.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the @CHEMICAL$ PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T17.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the @CHEMICAL$ PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T18.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles @CHEMICAL$ and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T18.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles @CHEMICAL$ and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T19.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and @CHEMICAL$, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T19.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and @CHEMICAL$, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T20.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the @CHEMICAL$ CT53518, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T20.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the @CHEMICAL$ CT53518, are potent inhibitors of @GENE$ kinase.	CPR:4
15180525.T21.T35	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline @CHEMICAL$, are potent inhibitors of Flt3 @GENE$.	CPR:4
15180525.T21.T34	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline @CHEMICAL$, are potent inhibitors of @GENE$ kinase.	CPR:4
15192023.T13.T37	Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of @CHEM-GENE$.	false
15192023.T13.T38	Novel mechanism of action for hydralazine: induction of @CHEMICAL$, vascular endothelial growth factor, and angiogenesis by inhibition of @GENE$ hydroxylases.	false
15192023.T13.T39	Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, @CHEMICAL$, and angiogenesis by inhibition of @GENE$ hydroxylases.	false
15192023.T14.T37	Novel mechanism of action for @CHEMICAL$: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of @GENE$.	CPR:4
15192023.T14.T38	Novel mechanism of action for @CHEMICAL$: induction of @GENE$, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.	CPR:3
15192023.T14.T39	Novel mechanism of action for @CHEMICAL$: induction of hypoxia-inducible factor-1alpha, @GENE$, and angiogenesis by inhibition of prolyl hydroxylases.	CPR:3
15192023.T6.T19	@CHEM-GENE$ is a known target of hydralazine.	false
15192023.T7.T19	@CHEMICAL$ is a known target of @GENE$.	false
15192023.T8.T20	We therefore investigated whether inhibition of other members of this enzyme family, namely the @CHEMICAL$ (HIF)-regulating @GENE$-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	false
15192023.T8.T21	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (@CHEMICAL$)-regulating @GENE$-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	false
15192023.T8.T22	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating @CHEMICAL$-dependent @GENE$ (PHD) enzymes, could represent a novel mechanism of action.	false
15192023.T8.T23	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating @CHEMICAL$-dependent prolyl hydroxylase domain (@GENE$) enzymes, could represent a novel mechanism of action.	false
15192023.T9.T20	We therefore investigated whether inhibition of other members of this enzyme family, namely the @CHEMICAL$ (HIF)-regulating O2-dependent @GENE$ hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	false
15192023.T9.T21	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (@CHEMICAL$)-regulating O2-dependent @GENE$ hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	false
15192023.T9.T22	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating O2-dependent @CHEM-GENE$ (PHD) enzymes, could represent a novel mechanism of action.	false
15192023.T9.T23	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating O2-dependent @CHEMICAL$ hydroxylase domain (@GENE$) enzymes, could represent a novel mechanism of action.	false
15192023.T10.T25	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of @GENE$ (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T10.T24	@CHEMICAL$ induced rapid and transient expression of @GENE$ and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T10.T26	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (@GENE$, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T10.T27	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, @GENE$, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T10.T28	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, @GENE$, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T10.T29	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and @GENE$ [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T10.T30	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [@GENE$]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	CPR:3
15192023.T11.T31	@CHEMICAL$ dose-dependently inhibited @GENE$ activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.	CPR:4
15192023.T11.T33	@CHEMICAL$ dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for @GENE$ stabilization specifically by inhibition of PHD enzyme activity.	false
15192023.T11.T34	@CHEMICAL$ dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of @GENE$ enzyme activity.	CPR:4
15192023.T11.T32	@CHEMICAL$ dose-dependently inhibited PHD activity and induced nonhydroxylated @GENE$, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.	CPR:3
15192023.T12.T15	In vivo, @CHEMICAL$ induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma @GENE$ levels.	CPR:3
15192023.T12.T35	In vivo, @CHEMICAL$ induced @GENE$ and VEGF protein in tissue extracts and elevated plasma VEGF levels.	CPR:3
15192023.T12.T36	In vivo, @CHEMICAL$ induced HIF-1alpha and @GENE$ protein in tissue extracts and elevated plasma VEGF levels.	CPR:3
15192023.T2.T16	Thus, @CHEMICAL$ activates the @GENE$ pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.	CPR:3
15192023.T2.T17	Thus, @CHEMICAL$ activates the HIF pathway through inhibition of @GENE$ activity and initiates a pro-angiogenic phenotype.	CPR:4
15192023.T3.T18	This represents a novel mechanism of action for @CHEMICAL$ and presents @GENE$ as a potential target for treatment of ischemic disease.	false
15198222.T10.T31	RESULTS: Aspirin, diclofenac, indomethacin, @CHEMICAL$, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T10.T17	RESULTS: Aspirin, diclofenac, indomethacin, @CHEMICAL$, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	false
15198222.T10.T18	RESULTS: Aspirin, diclofenac, indomethacin, @CHEMICAL$, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	false
15198222.T11.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, @CHEMICAL$, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T11.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, @CHEMICAL$, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	false
15198222.T11.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, @CHEMICAL$, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	false
15198222.T12.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and @CHEMICAL$ had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T12.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and @CHEMICAL$ had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	false
15198222.T12.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and @CHEMICAL$ had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	false
15198222.T13.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas @GENE$, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T13.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas @CHEMICAL$, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	CPR:4
15198222.T13.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas @CHEMICAL$, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	CPR:4
15198222.T14.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, @GENE$, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T14.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, @CHEMICAL$, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	CPR:4
15198222.T14.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, @CHEMICAL$, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	CPR:4
15198222.T15.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, carprofen, @GENE$, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T15.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, @CHEMICAL$, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	CPR:4
15198222.T15.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, @CHEMICAL$, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	CPR:4
15198222.T16.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, carprofen, tolfenamic acid, @GENE$, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T16.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, @CHEMICAL$, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	CPR:4
15198222.T16.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, @CHEMICAL$, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	CPR:4
15198222.T1.T31	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and @GENE$ had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T1.T17	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and @CHEMICAL$ had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	CPR:4
15198222.T1.T18	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and @CHEMICAL$ had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	CPR:4
15198222.T7.T31	RESULTS: @CHEMICAL$, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T7.T17	RESULTS: @CHEMICAL$, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	false
15198222.T7.T18	RESULTS: @CHEMICAL$, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	false
15198222.T8.T31	RESULTS: Aspirin, @CHEMICAL$, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T8.T17	RESULTS: Aspirin, @CHEMICAL$, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	false
15198222.T8.T18	RESULTS: Aspirin, @CHEMICAL$, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	false
15198222.T9.T31	RESULTS: Aspirin, diclofenac, @CHEMICAL$, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.	false
15198222.T9.T17	RESULTS: Aspirin, diclofenac, @CHEMICAL$, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.	false
15198222.T9.T18	RESULTS: Aspirin, diclofenac, @CHEMICAL$, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.	false
15198222.T2.T22	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by @GENE$, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	CPR:4
15198222.T2.T23	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by @CHEMICAL$, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.	false
15198222.T3.T22	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, @GENE$, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	CPR:4
15198222.T3.T23	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, @CHEMICAL$, and NS398; tolfenamic acid and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.	false
15198222.T4.T22	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, nimesulide, and @GENE$; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	CPR:4
15198222.T4.T23	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and @CHEMICAL$; tolfenamic acid and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.	false
15198222.T5.T22	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, nimesulide, and NS398; @GENE$ and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	false
15198222.T5.T23	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; @CHEMICAL$ and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.	CPR:4
15198222.T6.T22	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and @GENE$ also appeared to be preferential COX-2 inhibitors in dogs.	false
15198222.T6.T23	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and @CHEMICAL$ also appeared to be preferential @GENE$ inhibitors in dogs.	CPR:4
1526623.T31.T43	@CHEMICAL$ binds to the @GENE$.	false
1526623.T32.T43	Ketoconazole binds to the @CHEM-GENE$.	false
1526623.T17.T38	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @GENE$ (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	false
1526623.T17.T39	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (@GENE$), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	false
1526623.T17.T40	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to @GENE$ (AR) in vitro was also examined.	false
1526623.T17.T41	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (@GENE$) in vitro was also examined.	false
1526623.T18.T38	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for @GENE$ (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	false
1526623.T18.T39	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for sex steroid binding globulin (@GENE$), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	false
1526623.T18.T40	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for sex steroid binding globulin (SSBG), the binding of ketoconazole to @GENE$ (AR) in vitro was also examined.	false
1526623.T18.T41	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (@GENE$) in vitro was also examined.	false
1526623.T19.T38	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @CHEM-GENE$ (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	false
1526623.T19.T39	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex @CHEMICAL$ binding globulin (@GENE$), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	false
1526623.T19.T40	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex @CHEMICAL$ binding globulin (SSBG), the binding of ketoconazole to @GENE$ (AR) in vitro was also examined.	false
1526623.T19.T41	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex @CHEMICAL$ binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (@GENE$) in vitro was also examined.	false
1526623.T20.T38	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @CHEMICAL$ (SSBG), the binding of @GENE$ to human androgen receptors (AR) in vitro was also examined.	false
1526623.T20.T39	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (@CHEMICAL$), the binding of @GENE$ to human androgen receptors (AR) in vitro was also examined.	false
1526623.T20.T40	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of @CHEMICAL$ to @GENE$ (AR) in vitro was also examined.	false
1526623.T20.T41	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of @CHEMICAL$ to human androgen receptors (@GENE$) in vitro was also examined.	false
1526623.T21.T38	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @CHEMICAL$ (SSBG), the binding of ketoconazole to human @GENE$ receptors (AR) in vitro was also examined.	false
1526623.T21.T39	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (@CHEMICAL$), the binding of ketoconazole to human @GENE$ receptors (AR) in vitro was also examined.	false
1526623.T21.T40	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to @CHEM-GENE$ (AR) in vitro was also examined.	false
1526623.T21.T41	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human @CHEMICAL$ receptors (@GENE$) in vitro was also examined.	false
1526623.T22.T42	@CHEMICAL$ competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	false
1526623.T23.T42	Ketoconazole competition with @CHEMICAL$ (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	false
1526623.T24.T42	Ketoconazole competition with [3H]methyltrienolone (@CHEMICAL$) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	false
1526623.T25.T42	Ketoconazole competition with [3H]methyltrienolone (R1881) for @CHEMICAL$ binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	false
1526623.T27.T42	Ketoconazole competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of @CHEMICAL$ binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	false
1526623.T28.T42	Ketoconazole competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @CHEMICAL$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M @GENE$.	false
1526623.T29.T33	Additional binding studies performed with @CHEMICAL$ in the presence of increasing amounts of [3H]R1881 showed that the interaction of ketoconazole with @GENE$ was competitive when the data were analyzed by the Scatchard method.	false
1526623.T2.T33	Additional binding studies performed with ketoconazole in the presence of increasing amounts of [3H]R1881 showed that the interaction of @CHEMICAL$ with @GENE$ was competitive when the data were analyzed by the Scatchard method.	false
1526623.T30.T33	Additional binding studies performed with ketoconazole in the presence of increasing amounts of @CHEMICAL$ showed that the interaction of ketoconazole with @GENE$ was competitive when the data were analyzed by the Scatchard method.	false
1526623.T3.T34	It should be noted, however, that the dose of @CHEMICAL$ required for 50% occupancy of the @GENE$ is not likely to be achieved in vivo, at least in plasma.	false
1526623.T4.T34	It should be noted, however, that the dose of ketoconazole required for 50% occupancy of the @CHEM-GENE$ is not likely to be achieved in vivo, at least in plasma.	false
1526623.T10.T35	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only @CHEMICAL$ appears to interact with the @GENE$.	false
1526623.T11.T35	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @CHEM-GENE$.	false
1526623.T5.T35	Finally, @CHEMICAL$ binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.	false
1526623.T6.T35	Finally, androgen binding studies performed with other @CHEMICAL$, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.	false
1526623.T7.T35	Finally, androgen binding studies performed with other imidazoles, such as @CHEMICAL$, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.	false
1526623.T8.T35	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, @CHEMICAL$, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.	false
1526623.T9.T35	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and @CHEMICAL$, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.	false
1526623.T12.T37	@CHEMICAL$ appears to be the first example of a non-steroidal compound which binds competitively to both SSBG and multiple @GENE$, suggesting that the ligand binding sites of these proteins share some features in common.	false
1526623.T12.T36	@CHEMICAL$ appears to be the first example of a non-steroidal compound which binds competitively to both @GENE$ and multiple steroid hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	false
1526623.T13.T37	Ketoconazole appears to be the first example of a non-@CHEMICAL$ compound which binds competitively to both SSBG and multiple @GENE$, suggesting that the ligand binding sites of these proteins share some features in common.	false
1526623.T13.T36	Ketoconazole appears to be the first example of a non-@CHEMICAL$ compound which binds competitively to both @GENE$ and multiple steroid hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	false
1526623.T14.T37	Ketoconazole appears to be the first example of a non-steroidal compound which binds competitively to both SSBG and multiple @CHEM-GENE$, suggesting that the ligand binding sites of these proteins share some features in common.	false
1526623.T14.T36	Ketoconazole appears to be the first example of a non-steroidal compound which binds competitively to both @CHEMICAL$ and multiple @GENE$ hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	false
15291969.T2.T23	BACKGROUND: Extracellular @CHEMICAL$ (ATP, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.	false
15291969.T2.T26	BACKGROUND: Extracellular @CHEMICAL$ (ATP, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.	false
15291969.T3.T23	BACKGROUND: Extracellular nucleotides (@CHEMICAL$, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.	false
15291969.T3.T26	BACKGROUND: Extracellular nucleotides (@CHEMICAL$, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.	false
15291969.T4.T23	BACKGROUND: Extracellular nucleotides (ATP, @CHEMICAL$, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.	false
15291969.T4.T26	BACKGROUND: Extracellular nucleotides (ATP, @CHEMICAL$, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.	false
15291969.T5.T23	BACKGROUND: Extracellular nucleotides (ATP, ADP, @CHEMICAL$ and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.	false
15291969.T5.T26	BACKGROUND: Extracellular nucleotides (ATP, ADP, @CHEMICAL$ and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.	false
15291969.T6.T23	BACKGROUND: Extracellular nucleotides (ATP, ADP, UTP and @CHEMICAL$) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.	false
15291969.T6.T26	BACKGROUND: Extracellular nucleotides (ATP, ADP, UTP and @CHEMICAL$) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.	false
15291969.T1.T22	CONCLUSIONS: The most interesting findings were the high mRNA expression of @CHEMICAL$ receptors in lymphocytes potentially explaining the anti-inflammatory effects of @GENE$, P2Y13 receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.	false
15291969.T1.T24	CONCLUSIONS: The most interesting findings were the high mRNA expression of P2Y12 receptors in lymphocytes potentially explaining the anti-inflammatory effects of @CHEMICAL$, @GENE$ receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.	false
15291969.T1.T25	CONCLUSIONS: The most interesting findings were the high mRNA expression of P2Y12 receptors in lymphocytes potentially explaining the anti-inflammatory effects of @CHEMICAL$, P2Y13 receptors in monocytes and a previously unrecognised expression of @GENE$ in lymphocytes and monocytes.	false
15292070.T1.T2	@CHEMICAL$ served as inhibitor of an interfering @GENE$ present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.	CPR:4
15299009.T6.T12	A disorder to order transition accompanies catalysis in @CHEM-GENE$.	false
15299009.T1.T7	@CHEM-GENE$ (RalDH2) converts retinal to the transcriptional regulator retinoic acid in the developing embryo.	false
15299009.T1.T9	@CHEMICAL$ dehydrogenase II (@GENE$) converts retinal to the transcriptional regulator retinoic acid in the developing embryo.	false
15299009.T2.T11	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @GENE$ this region forms a well defined wall of the substrate access channel.	false
15299009.T2.T8	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEM-GENE$ of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T2.T10	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @GENE$ is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T3.T11	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-@CHEMICAL$ span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @GENE$ this region forms a well defined wall of the substrate access channel.	false
15299009.T3.T8	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ of the same enzyme superfamily; a 20-@GENE$ span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T3.T10	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-@CHEMICAL$ span in the substrate access channel in @GENE$ is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T4.T11	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @CHEMICAL$ dehydrogenase II is disordered, whereas in other @GENE$ this region forms a well defined wall of the substrate access channel.	false
15299009.T4.T8	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @GENE$ dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T4.T10	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @CHEM-GENE$ is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T5.T11	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @CHEM-GENE$ this region forms a well defined wall of the substrate access channel.	false
15299009.T5.T8	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @GENE$ dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15299009.T5.T10	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @CHEMICAL$ is disordered, whereas in other @GENE$ dehydrogenases this region forms a well defined wall of the substrate access channel.	false
15325927.T7.T14	Effects of @CHEMICAL$ on @GENE$ concentration and symptoms in patients with heart failure and preserved ejection fraction.	false
15325927.T6.T11	After 12 months of treatment, @CHEMICAL$ significantly improved all end points (plasma concentration of @GENE$ [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	CPR:4
15325927.T6.T12	After 12 months of treatment, @CHEMICAL$ significantly improved all end points (plasma concentration of B-type natriuretic peptide [@GENE$] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	CPR:4
15325927.T6.T13	After 12 months of treatment, @CHEMICAL$ significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (@GENE$ concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	false
15325927.T1.T8	Univariate regression analyses showed that only the use of @CHEMICAL$ was correlated with the decrease in @GENE$ concentration (p <0.03).	CPR:4
15325927.T2.T10	Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of BNP (p <0.02), left ventricular dilation (p <0.03), and use of @CHEMICAL$ (p <0.04) at baseline were predictive of a decrease in plasma concentration of @GENE$.	false
15325927.T2.T9	Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of @CHEMICAL$ (p <0.02), left ventricular dilation (p <0.03), and use of @GENE$ (p <0.04) at baseline were predictive of a decrease in plasma concentration of BNP.	false
15367040.T3.T6	Psychopharmacology of anticonvulsants: @CHEMICAL$ as a @GENE$ modulator.	false
15367040.T1.T4	@CHEMICAL$ binds selectively and with high affinity to a @GENE$ known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.	false
15367040.T1.T5	@CHEMICAL$ binds selectively and with high affinity to a synaptic vesicle protein known as @GENE$, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.	false
1543672.T18.T25	@CHEMICAL$: mode of action and properties of the @GENE$ inhibition.	CPR:4
1543672.T19.T25	Terbinafine: mode of action and properties of the @CHEM-GENE$ inhibition.	false
1543672.T1.T20	@CHEMICAL$ (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of @GENE$ inhibition.	CPR:4
1543672.T5.T20	Terbinafine (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of @CHEM-GENE$ inhibition.	false
1543672.T7.T20	Terbinafine (@CHEMICAL$) has primarily fungicidal action against many fungi as a result of its specific mechanism of @GENE$ inhibition.	CPR:4
1543672.T15.T23	@CHEMICAL$ is a potent non-competitive inhibitor of @GENE$ from Candida (Ki = 30 nM).	CPR:4
1543672.T16.T23	Terbinafine is a potent non-competitive inhibitor of @CHEM-GENE$ from Candida (Ki = 30 nM).	false
1543672.T17.T24	In contrast, inhibition of @CHEM-GENE$ only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with squalene.	false
1543672.T2.T24	In contrast, inhibition of @CHEMICAL$ only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with @GENE$.	CPR:4
1543672.T6.T22	@CHEMICAL$ epoxidase is not an enzyme of the @GENE$ type, thereby avoiding potential inhibition of this class of enzymes.	false
1543672.T6.T21	@CHEM-GENE$ is not an enzyme of the cytochrome P-450 type, thereby avoiding potential inhibition of this class of enzymes.	false
15446566.T11.T19	@CHEMICAL$ decreased the stability of @GENE$-mRNA and COX-2 mRNA.	false
15446566.T11.T20	@CHEMICAL$ decreased the stability of TNF-mRNA and @GENE$ mRNA.	false
15446566.T12.T24	Although @CHEMICAL$ inhibits PG biosynthesis, most do not affect the @GENE$ activity of COX, which can generate proximate carcinogens.	false
15446566.T12.T25	Although @CHEMICAL$ inhibits PG biosynthesis, most do not affect the peroxidase activity of @GENE$, which can generate proximate carcinogens.	false
15446566.T13.T26	Because @CHEMICAL$ does not completely inhibit @GENE$ expression or PG biosynthesis, a therapeutic strategy combining celecoxib with thalidomide might be more effective than using either agent alone.	false
15446566.T14.T26	Because thalidomide does not completely inhibit @CHEMICAL$ expression or PG biosynthesis, a therapeutic strategy combining @GENE$ with thalidomide might be more effective than using either agent alone.	false
15446566.T15.T26	Because thalidomide does not completely inhibit @CHEMICAL$ expression or PG biosynthesis, a therapeutic strategy combining celecoxib with @GENE$ might be more effective than using either agent alone.	false
15474503.T16.T41	Effect of @CHEMICAL$ on @GENE$ production in HepG2 cell.	false
15474503.T10.T30	There are few reports describing the mechanism of @CHEMICAL$-elevating action of @GENE$ reductase inhibitors (statins).	false
15474503.T10.T35	There are few reports describing the mechanism of HDL-elevating action of @CHEM-GENE$ inhibitors (statins).	false
15474503.T3.T28	Each statin induced @CHEMICAL$ expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction @GENE$ (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).	false
15474503.T3.T29	Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the @CHEMICAL$ induction @GENE$ (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).	CPR:3
15474503.T4.T28	Each statin induced @CHEMICAL$ expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>@GENE$ (10 microM)>atorvastatin (30 microM).	false
15474503.T4.T29	Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the @CHEMICAL$ induction pitavastatin (3 microM)>@GENE$ (10 microM)>atorvastatin (30 microM).	CPR:3
15474503.T5.T28	Each statin induced @CHEMICAL$ expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>@GENE$ (30 microM).	false
15474503.T5.T29	Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the @CHEMICAL$ induction pitavastatin (3 microM)>simvastatin (10 microM)>@GENE$ (30 microM).	CPR:3
15474503.T6.T31	The induction of @CHEMICAL$ by statins disappeared with addition of @GENE$, which indicates that the effect is HMG-CoA reductase inhibition-dependent.	CPR:4
15474503.T6.T32	The induction of apoA-I by statins disappeared with addition of @CHEMICAL$, which indicates that the effect is @GENE$ inhibition-dependent.	false
15474503.T7.T31	The induction of @CHEMICAL$ by statins disappeared with addition of mevalonate, which indicates that the effect is @GENE$ reductase inhibition-dependent.	false
15474503.T7.T32	The induction of apoA-I by statins disappeared with addition of mevalonate, which indicates that the effect is @CHEM-GENE$ inhibition-dependent.	false
15474503.T11.T33	Based on @CHEMICAL$ inhibition, pitavastatin-induced apoA-I more efficiently than @GENE$ and atorvastatin.	false
15474503.T11.T34	Based on HMG-CoA reductase inhibition, pitavastatin-induced @CHEMICAL$ more efficiently than @GENE$ and atorvastatin.	CPR:3
15474503.T12.T33	Based on @CHEMICAL$ inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and @GENE$.	false
15474503.T12.T34	Based on HMG-CoA reductase inhibition, pitavastatin-induced @CHEMICAL$ more efficiently than simvastatin and @GENE$.	CPR:3
15474503.T8.T33	Based on @CHEM-GENE$ inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and atorvastatin.	false
15474503.T8.T34	Based on @CHEMICAL$ reductase inhibition, pitavastatin-induced @GENE$ more efficiently than simvastatin and atorvastatin.	false
15474503.T9.T33	Based on @CHEMICAL$ inhibition, @GENE$-induced apoA-I more efficiently than simvastatin and atorvastatin.	false
15474503.T9.T34	Based on HMG-CoA reductase inhibition, @CHEMICAL$-induced @GENE$ more efficiently than simvastatin and atorvastatin.	CPR:3
15474503.T13.T38	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that @GENE$ and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T13.T39	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and @GENE$ inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T13.T36	Further study revealed that @CHEMICAL$ increased @GENE$ mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	CPR:3
15474503.T13.T37	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in @GENE$-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T13.T40	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased @GENE$ production in the HepG2 cells.	false
15474503.T14.T38	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$ reductase-dependent manner and that @GENE$ and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T14.T39	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$ reductase-dependent manner and that Rho and @GENE$ inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T14.T36	Further study revealed that pitavastatin increased @CHEMICAL$ mRNA in @GENE$ reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T14.T37	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEM-GENE$-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	false
15474503.T14.T40	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$ reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased @GENE$ production in the HepG2 cells.	false
15474503.T15.T38	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that @CHEMICAL$ and Rho kinase inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.	CPR:4
15474503.T15.T39	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and @CHEMICAL$ inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.	CPR:4
15474503.T15.T36	Further study revealed that pitavastatin increased @CHEMICAL$ mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.	false
15474503.T15.T37	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$-dependent manner and that Rho and Rho kinase inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.	false
15474503.T15.T40	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and @CHEMICAL$) increased @GENE$ production in the HepG2 cells.	CPR:3
15474503.T1.T20	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of @GENE$ activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	CPR:4
15474503.T1.T17	These results suggest that @CHEMICAL$ efficiently increases @GENE$ in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	CPR:3
15474503.T1.T18	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting @GENE$ production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	CPR:3
15474503.T1.T19	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @GENE$ and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	CPR:4
15474503.T1.T21	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting @GENE$ from catabolism through ABCA1 induction and lipidation of apoA-I.	false
15474503.T1.T22	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through @GENE$ induction and lipidation of apoA-I.	CPR:3
15474503.T1.T23	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of @GENE$.	CPR:3
15474503.T2.T20	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of @GENE$ activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	false
15474503.T2.T17	These results suggest that pitavastatin efficiently increases @CHEMICAL$ in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @GENE$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	false
15474503.T2.T18	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting @CHEMICAL$ production through inhibition of @GENE$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	false
15474503.T2.T19	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEM-GENE$ and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	false
15474503.T2.T21	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of Rho activity and by protecting @GENE$ from catabolism through ABCA1 induction and lipidation of apoA-I.	false
15474503.T2.T22	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through @GENE$ induction and lipidation of apoA-I.	false
15474503.T2.T23	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of @GENE$.	false
15557593.T4.T17	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two @CHEM-GENE$ inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	false
15557593.T4.T19	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor @CHEMICAL$ kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or @GENE$ inhibition.	false
15557593.T4.T18	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor @CHEMICAL$ kinase inhibitors, imatinib and SU11248, were used to disrupt @GENE$-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	false
15557593.T5.T17	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two @CHEMICAL$ inhibitors, @GENE$ and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	CPR:4
15557593.T5.T19	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, @CHEMICAL$ and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or @GENE$ inhibition.	CPR:4
15557593.T5.T18	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, @CHEMICAL$ and SU11248, were used to disrupt @GENE$-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	CPR:4
15557593.T6.T17	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two @CHEMICAL$ inhibitors, imatinib and @GENE$, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	CPR:4
15557593.T6.T19	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and @CHEMICAL$, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or @GENE$ inhibition.	CPR:4
15557593.T6.T18	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and @CHEMICAL$, were used to disrupt @GENE$-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	CPR:4
15557593.T7.T8	RESULTS: @CHEMICAL$, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or @GENE$ inhibition.	CPR:4
15563928.T10.T17	Synovitis in horses is frequently treated by administration of non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs), which inhibit @GENE$ isoforms (COX-1 and COX-2).	false
15563928.T10.T18	Synovitis in horses is frequently treated by administration of non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase isoforms (@GENE$ and COX-2).	false
15563928.T10.T19	Synovitis in horses is frequently treated by administration of non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase isoforms (COX-1 and @GENE$).	false
15563928.T9.T25	The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective @CHEMICAL$ inhibitor @GENE$ in horses with lipopolysaccharide (LPS)-induced synovitis.	CPR:4
15563928.T9.T24	The objective of the present study was to compare the anti-inflammatory effects of the preferential @CHEMICAL$ inhibitor etodolac with the non-selective COX inhibitor @GENE$ in horses with lipopolysaccharide (LPS)-induced synovitis.	false
15563928.T2.T16	In addition, both drugs significantly reduced @CHEMICAL$ levels (P<0.05) 6-h following LPS injection, whereas the probable @GENE$ prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	false
15563928.T3.T16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ @GENE$ TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	false
15563928.T4.T16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ prostanoid @GENE$ was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	false
15563928.T5.T16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ prostanoid TXB2 was significantly reduced by @GENE$ (P<0.05), but not etodolac.	CPR:4
15563928.T6.T16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not @GENE$.	false
15612980.T2.T25	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @GENE$ and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T26	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @GENE$; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T29	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @GENE$; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T32	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T23	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [@GENE$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T24	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (@GENE$) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T27	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @GENE$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T28	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (@GENE$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T30	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T2.T31	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T25	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) @GENE$ and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T26	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and @GENE$; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T29	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @GENE$; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T32	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEM-GENE$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (@GENE$) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T27	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; @GENE$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T28	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (@GENE$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T30	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T4.T31	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T25	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @CHEMICAL$ and A1298C; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T26	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @CHEMICAL$; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T29	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) @GENE$; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T32	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) A2756G; methionine synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ (MTHFR) C677T and A1298C; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (@CHEMICAL$) C677T and A1298C; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T27	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEM-GENE$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T28	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (@GENE$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T30	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) A2756G; @GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T6.T31	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) A2756G; methionine synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T25	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @CHEMICAL$ and A1298C; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T26	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @CHEMICAL$; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T29	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @CHEMICAL$; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T32	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEMICAL$ synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (@CHEMICAL$) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T27	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T28	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (@CHEMICAL$) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T30	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEM-GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T7.T31	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEMICAL$ synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T25	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @CHEMICAL$ and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T26	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @CHEMICAL$; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T29	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @CHEMICAL$; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T32	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) @CHEMICAL$] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (@CHEMICAL$) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T27	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T28	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (@CHEMICAL$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T30	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEMICAL$ (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T9.T31	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (@CHEMICAL$) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	false
15612980.T12.T14	However, MS A2756G was significantly associated with @CHEMICAL$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR @GENE$ (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	false
15612980.T12.T36	However, MS @CHEMICAL$ was significantly associated with @GENE$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	false
15612980.T12.T13	However, MS A2756G was significantly associated with @CHEMICAL$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was @GENE$ A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	false
15612980.T12.T35	However, @CHEMICAL$ A2756G was significantly associated with @GENE$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	false
15612980.T1.T20	Differences in @CHEMICAL$ and folate levels with the MTRR @GENE$ and MS A2756G polymorphisms were noted.	false
15612980.T1.T22	Differences in @CHEMICAL$ and folate levels with the MTRR A66G and MS @GENE$ polymorphisms were noted.	false
15612980.T1.T19	Differences in @CHEMICAL$ and folate levels with the @GENE$ A66G and MS A2756G polymorphisms were noted.	false
15612980.T1.T21	Differences in @CHEMICAL$ and folate levels with the MTRR A66G and @GENE$ A2756G polymorphisms were noted.	false
15629255.T10.T23	Effect of @CHEMICAL$ (@GENE$/ETB receptor antagonist) on metabolic changes during stress and diabetes.	CPR:6
15629255.T10.T24	Effect of @CHEMICAL$ (ETA/@GENE$ receptor antagonist) on metabolic changes during stress and diabetes.	CPR:6
15629255.T4.T17	To test this, we studied the possible effect of the @CHEMICAL$ antagonist, @GENE$ (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.	CPR:6
15629255.T4.T18	To test this, we studied the possible effect of the endothelin receptor antagonist, @CHEMICAL$ (50 and 100 mg kg(-1)) on serum glucose and @GENE$ levels as well as on liver glycogen contents in normoglycemic stressed animals.	false
15629255.T5.T17	To test this, we studied the possible effect of the @CHEMICAL$ antagonist, bosentan (50 and 100 mg kg(-1)) on serum @GENE$ and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.	false
15629255.T5.T18	To test this, we studied the possible effect of the endothelin receptor antagonist, bosentan (50 and 100 mg kg(-1)) on serum @CHEMICAL$ and @GENE$ levels as well as on liver glycogen contents in normoglycemic stressed animals.	false
15629255.T6.T19	In addition, the effect of @CHEMICAL$ on serum glucose and @GENE$ levels in both mild and severely diabetic rats and its effect on insulin-induced hypoglycemia were also determined.	false
15629255.T6.T20	In addition, the effect of @CHEMICAL$ on serum glucose and insulin levels in both mild and severely diabetic rats and its effect on @GENE$-induced hypoglycemia were also determined.	false
15629255.T7.T19	In addition, the effect of bosentan on serum @CHEMICAL$ and @GENE$ levels in both mild and severely diabetic rats and its effect on insulin-induced hypoglycemia were also determined.	false
15629255.T7.T20	In addition, the effect of bosentan on serum @CHEMICAL$ and insulin levels in both mild and severely diabetic rats and its effect on @GENE$-induced hypoglycemia were also determined.	false
15629255.T1.T11	@CHEMICAL$ partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in @GENE$ level in normoglycemic stressed rats.	false
15629255.T2.T13	@CHEMICAL$ also decreased serum glucose level without any effect on @GENE$ secretion in mild diabetic rats and potentiated the hypoglycemic action of insulin.	false
15629255.T2.T14	@CHEMICAL$ also decreased serum glucose level without any effect on insulin secretion in mild diabetic rats and potentiated the hypoglycemic action of @GENE$.	false
15629255.T3.T13	Bosentan also decreased serum @CHEMICAL$ level without any effect on @GENE$ secretion in mild diabetic rats and potentiated the hypoglycemic action of insulin.	false
15629255.T3.T14	Bosentan also decreased serum @CHEMICAL$ level without any effect on insulin secretion in mild diabetic rats and potentiated the hypoglycemic action of @GENE$.	false
15646028.T10.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T10.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T10.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T10.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T10.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T10.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T11.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T11.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T11.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T11.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T11.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T11.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T12.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEM-GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T12.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T12.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T12.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T12.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T12.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T13.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$ (complex-I), @GENE$-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T13.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@CHEMICAL$), @GENE$-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T13.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEM-GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T13.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T13.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T13.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T14.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T14.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@CHEMICAL$), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T14.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$ (complex I/II), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T14.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@CHEMICAL$), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T14.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @CHEM-GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T14.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @CHEMICAL$-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T5.T19	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T5.T20	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T5.T21	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T5.T22	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T5.T23	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T5.T24	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T6.T19	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T6.T20	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T6.T21	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T6.T22	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T6.T23	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T6.T24	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T7.T19	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T7.T20	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T7.T21	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T7.T22	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T7.T23	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T7.T24	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T8.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T8.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T8.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T8.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T8.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T8.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T9.T19	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T9.T20	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T9.T21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T9.T22	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T9.T23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T9.T24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	false
15646028.T3.T16	Pre-irradiation administration of RP-1 enhanced levels of @CHEMICAL$ induced increase in @GENE$ (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).	CPR:3
15646028.T3.T17	Pre-irradiation administration of RP-1 enhanced levels of @CHEMICAL$ induced increase in complex I (upto 16 h), @GENE$ (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).	CPR:3
15646028.T3.T18	Pre-irradiation administration of RP-1 enhanced levels of @CHEMICAL$ induced increase in complex I (upto 16 h), complex I/III (4 h) @GENE$ activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).	CPR:3
15665864.T12.T23	Effects of @CHEMICAL$ on @GENE$-mediated fulminant hepatitis in mice. 1.	false
15665864.T5.T20	We investigated the effects of @CHEMICAL$ on fulminant hepatitis in C57BL/6J mice induced by lethal challenge of the activating anti-@GENE$ antibody, Jo2.	false
15665864.T7.T21	Intraperitoneal injection of Jo2 (0.6 microg g(-1)) to mice resulted in fulminant hepatitis, as evidenced by increase of @CHEM-GENE$ activities and histopathological alterations in liver sections, as well as animal death.	false
15665864.T8.T21	Intraperitoneal injection of Jo2 (0.6 microg g(-1)) to mice resulted in fulminant hepatitis, as evidenced by increase of @CHEM-GENE$ activities and histopathological alterations in liver sections, as well as animal death.	false
15665864.T11.T13	Jo2-induced activation of caspase-3 or -9 in liver tissues was inhibited by @CHEMICAL$ pretreatment, and yet the direct addition of minocycline to liver extracts from Jo2-challenged mice failed to block @GENE$ activation in vitro.	false
15665864.T11.T22	Jo2-induced activation of @CHEMICAL$ in liver tissues was inhibited by @GENE$ pretreatment, and yet the direct addition of minocycline to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.	false
15665864.T1.T13	Jo2-induced activation of caspase-3 or -9 in liver tissues was inhibited by minocycline pretreatment, and yet the direct addition of @CHEMICAL$ to liver extracts from Jo2-challenged mice failed to block @GENE$ activation in vitro.	false
15665864.T1.T22	Jo2-induced activation of @CHEMICAL$ in liver tissues was inhibited by minocycline pretreatment, and yet the direct addition of @GENE$ to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.	false
15665864.T2.T14	Moreover, @CHEMICAL$ efficiently suppressed the release of @GENE$ from mitochondria of the liver tissues from Jo2-challenged mice.	CPR:4
15665864.T3.T15	In contrast, @CHEMICAL$ activation and Bid truncation triggered by Jo2 were not diminished by @GENE$ pretreatment in mouse livers.	false
15665864.T3.T16	In contrast, caspase-8 activation and @CHEMICAL$ truncation triggered by Jo2 were not diminished by @GENE$ pretreatment in mouse livers.	false
15665864.T4.T19	Our results suggest that easing of Fas-triggered fulminant hepatitis by @CHEMICAL$ may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream @GENE$ activation.	CPR:4
15665864.T4.T17	Our results suggest that easing of @CHEMICAL$-triggered fulminant hepatitis by @GENE$ may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation.	false
15665864.T4.T18	Our results suggest that easing of Fas-triggered fulminant hepatitis by @CHEMICAL$ may involve a mitochondrial apoptotic pathway, probably through preventing @GENE$ release and thereby blocking downstream caspase activation.	CPR:4
15671155.T10.T26	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T10.T29	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T10.T30	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T10.T32	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize @CHEMICAL$ as substrate to form H2S. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T10.T33	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize @CHEMICAL$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T10.T36	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T16.T26	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T16.T29	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T16.T30	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T16.T32	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @CHEMICAL$. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T16.T33	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @CHEMICAL$. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T16.T36	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	CPR:9
15671155.T17.T26	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T17.T29	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T17.T30	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T17.T32	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @CHEM-GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T17.T33	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @CHEMICAL$-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T17.T36	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T18.T26	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.	false
15671155.T18.T29	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.	false
15671155.T18.T30	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.	false
15671155.T18.T32	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @CHEMICAL$ (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.	CPR:9
15671155.T18.T33	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@CHEMICAL$) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.	CPR:9
15671155.T18.T36	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.	false
15671155.T24.T26	@CHEMICAL$-gamma-lyase (@GENE$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T24.T29	@CHEMICAL$-gamma-lyase (CSE) and @GENE$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T24.T30	@CHEMICAL$-gamma-lyase (CSE) and cystathionine-beta-synthase (@GENE$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T24.T32	@CHEMICAL$-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T24.T33	@CHEMICAL$-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T24.T36	@CHEM-GENE$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T5.T26	Cystathionine-gamma-lyase (@CHEMICAL$) and @GENE$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T5.T29	Cystathionine-gamma-lyase (CSE) and @CHEM-GENE$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T5.T30	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$-beta-synthase (@GENE$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T5.T32	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T5.T33	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T5.T36	@CHEMICAL$ (CSE) and @GENE$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.	false
15671155.T20.T34	In this paper, we report the presence of @CHEMICAL$ synthesizing enzyme activity and @GENE$ (as determined by mRNA signal) in the pancreas.	false
15671155.T11.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T11.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T11.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T11.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T12.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T12.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T12.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T12.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T21.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, @CHEMICAL$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @GENE$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T21.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, @CHEMICAL$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T21.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, @CHEMICAL$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T21.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, @GENE$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	CPR:4
15671155.T22.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (@CHEMICAL$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @GENE$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T22.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (@CHEMICAL$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T22.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (@CHEMICAL$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T22.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (@GENE$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	CPR:4
15671155.T23.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @CHEMICAL$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @GENE$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T23.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @CHEMICAL$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T23.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @CHEMICAL$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T23.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @GENE$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T2.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @GENE$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T2.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @CHEMICAL$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T2.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @CHEMICAL$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T2.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @GENE$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T3.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @GENE$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T3.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @CHEMICAL$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T3.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @CHEMICAL$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T3.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @GENE$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T4.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T4.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @CHEMICAL$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T4.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @CHEMICAL$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T4.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T6.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T6.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	CPR:3
15671155.T6.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	CPR:3
15671155.T6.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T7.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T7.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T7.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T7.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T8.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T8.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T8.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T8.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T9.T37	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T9.T27	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T9.T28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T9.T35	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.	false
15671155.T14.T31	These effects of @CHEMICAL$ blockade suggest an important proinflammatory role of @GENE$ in regulating the severity of pancreatitis and associated lung injury and raise the possibility that H2S may exert similar activity in other forms of inflammation.	false
15671155.T15.T31	These effects of @CHEMICAL$ blockade suggest an important proinflammatory role of H2S in regulating the severity of pancreatitis and associated lung injury and raise the possibility that @GENE$ may exert similar activity in other forms of inflammation.	false
15694653.T10.T12	Atypical and typical antipsychotic drug interactions with the @CHEM-GENE$.	false
15694653.T1.T11	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics @GENE$ and loxapine, and the atypical antipsychotics clozapine and melperone.	false
15694653.T2.T11	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and @GENE$, and the atypical antipsychotics clozapine and melperone.	false
15694653.T3.T11	A model of the @CHEM-GENE$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone.	false
15694653.T4.T11	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics @GENE$ and melperone.	false
15694653.T5.T11	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and @GENE$.	false
15694653.T9.T11	A model of the @CHEMICAL$ was used to study the receptor interactions of @GENE$, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone.	false
15700891.T2.T6	At doses ranging from 0.02 to 0.2 microg/kg, exenatide dose-dependently reduced postprandial plasma @CHEMICAL$ excursion by insulinotropism, suppression of plasma @GENE$, and slowing of gastric emptying.	false
15737409.T19.T37	@CHEM-GENE$: targets of natural sterols and new lipid lowering drugs.	false
15737409.T20.T37	@CHEMICAL$: targets of natural @GENE$ and new lipid lowering drugs.	false
15737409.T10.T24	Recent insights in the role of @CHEM-GENE$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T10.T22	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of @GENE$ (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T10.T23	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@GENE$) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T10.T32	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters @GENE$ and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T10.T34	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters ABCG5 and @GENE$, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T2.T24	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of @GENE$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T2.T22	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of @CHEMICAL$, the first approved direct cholesterol absorption inhibitor, as well as the identification of @GENE$ (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T2.T23	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of @CHEMICAL$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@GENE$) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T2.T32	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of @GENE$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T2.T34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of @GENE$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T7.T24	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct @GENE$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T7.T22	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct @CHEMICAL$ absorption inhibitor, as well as the identification of @GENE$ (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T7.T23	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct @CHEMICAL$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@GENE$) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T7.T32	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of ezetimibe, the first approved direct @GENE$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T7.T34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of ezetimibe, the first approved direct @GENE$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T8.T24	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T8.T22	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of @CHEMICAL$ (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T8.T23	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@CHEMICAL$) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T8.T32	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T8.T34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	false
15737409.T9.T24	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.	false
15737409.T9.T22	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of @CHEMICAL$ (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.	false
15737409.T9.T23	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@CHEMICAL$) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.	false
15737409.T9.T32	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.	false
15737409.T9.T34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.	false
15737409.T11.T27	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEM-GENE$ regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T11.T30	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T11.T31	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T11.T25	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @GENE$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T11.T26	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as @GENE$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T11.T28	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. @GENE$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T11.T29	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and @GENE$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T27	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal @GENE$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T30	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T31	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T25	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @GENE$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T26	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @GENE$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T28	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. @GENE$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T12.T29	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. ABCG5 and @GENE$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T27	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal sterol absorption and the hepatic @GENE$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T30	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T31	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T25	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @GENE$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T26	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @GENE$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T28	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. @GENE$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T13.T29	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. ABCG5 and @GENE$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T27	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T30	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @CHEMICAL$ via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T31	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @CHEMICAL$ via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T25	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T26	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T28	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. @CHEMICAL$ and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T14.T29	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and @CHEMICAL$ themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	false
15737409.T15.T27	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.	false
15737409.T15.T30	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @CHEMICAL$ (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.	false
15737409.T15.T31	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@CHEMICAL$), which are also activated by oxysterols and some derivatives of plant @GENE$.	CPR:3
15737409.T15.T25	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.	false
15737409.T15.T26	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.	false
15737409.T15.T28	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. @CHEMICAL$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.	false
15737409.T15.T29	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and @CHEMICAL$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.	false
15737409.T16.T35	NPC1L1 could recently be identified as a major @CHEM-GENE$ for the intestinal uptake of cholesterol as well as plant sterols.	false
15737409.T16.T33	@CHEMICAL$ could recently be identified as a major @GENE$ transporter for the intestinal uptake of cholesterol as well as plant sterols.	false
15737409.T17.T35	NPC1L1 could recently be identified as a major @CHEMICAL$ for the intestinal uptake of @GENE$ as well as plant sterols.	CPR:9
15737409.T17.T33	@CHEMICAL$ could recently be identified as a major sterol transporter for the intestinal uptake of @GENE$ as well as plant sterols.	CPR:9
15737409.T18.T35	NPC1L1 could recently be identified as a major @CHEMICAL$ for the intestinal uptake of cholesterol as well as plant @GENE$.	CPR:9
15737409.T18.T33	@CHEMICAL$ could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant @GENE$.	CPR:9
15737409.T1.T21	Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of @CHEMICAL$ and that @GENE$ might also be involved in the mechanism of action of ezetimibe.	false
15737409.T1.T36	Studies in @CHEMICAL$ knockout mice indicate that this transporter is essential for the intestinal uptake of @GENE$ and that NPC1L1 might also be involved in the mechanism of action of ezetimibe.	false
15737409.T3.T21	Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that @CHEMICAL$ might also be involved in the mechanism of action of @GENE$.	false
15737409.T3.T36	Studies in @CHEMICAL$ knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that NPC1L1 might also be involved in the mechanism of action of @GENE$.	false
15787205.T6.T12	[Change of @CHEM-GENE$ activity (DAT) during the action of bupropion (in depression)].	false
15787205.T6.T13	[Change of @CHEMICAL$ transporter activity (@GENE$) during the action of bupropion (in depression)].	false
15787205.T7.T12	[Change of @CHEMICAL$ activity (DAT) during the action of @GENE$ (in depression)].	false
15787205.T7.T13	[Change of dopamine transporter activity (@CHEMICAL$) during the action of @GENE$ (in depression)].	false
15787205.T1.T11	@CHEMICAL$ has an antidepressant effect through blocking the @GENE$.	CPR:4
15787205.T5.T11	Bupropion has an antidepressant effect through blocking the @CHEM-GENE$.	false
15787205.T2.T9	After 3 weeks' @CHEMICAL$ treatment we studied the change in @GENE$ activity, which corresponds to the occupancy of bupropion.	false
15787205.T3.T9	After 3 weeks' bupropion treatment we studied the change in @CHEMICAL$ activity, which corresponds to the occupancy of @GENE$.	false
15787205.T4.T10	The average occupancy of @CHEMICAL$ on @GENE$ was similar to the international findings at 20.84% in 9 depressed patients.	false
15811959.T4.T19	In vitro studies demonstrated that the @CHEMICAL$ (RXR) retinoid, @GENE$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	false
15811959.T4.T20	In vitro studies demonstrated that the retinoid X receptor (@CHEMICAL$) retinoid, @GENE$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	false
15811959.T4.T23	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, @CHEMICAL$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the @GENE$ and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	CPR:3
15811959.T4.T21	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, @CHEMICAL$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the @GENE$ and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	CPR:3
15811959.T4.T22	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, @CHEMICAL$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and @GENE$ subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	CPR:3
15811959.T1.T7	Modulation of @CHEMICAL$ expression was observed at or above a @GENE$ dose of 150 mg/day.	false
15811959.T2.T8	Our results demonstrate that the combination of denileukin diftitox and @CHEMICAL$ is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of @GENE$ expression on circulating leukemia cells.	false
15811959.T3.T8	Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of @CHEMICAL$ are capable of in vivo upregulation of @GENE$ expression on circulating leukemia cells.	CPR:3
15837926.T1.T11	PSMA acts as a @CHEM-GENE$ (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	false
15837926.T1.T10	@CHEMICAL$ acts as a @GENE$ carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	false
15837926.T1.T12	PSMA acts as a @CHEMICAL$ carboxypeptidase (@GENE$) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	false
15837926.T2.T11	PSMA acts as a @CHEMICAL$ (GCPII) on small molecule substrates, including @GENE$, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	CPR:9
15837926.T2.T10	@CHEMICAL$ acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including @GENE$, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	CPR:9
15837926.T2.T12	PSMA acts as a glutamate carboxypeptidase (@CHEMICAL$) on small molecule substrates, including @GENE$, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	CPR:9
15837926.T3.T11	PSMA acts as a @CHEMICAL$ (GCPII) on small molecule substrates, including folate, the anticancer drug @GENE$, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	CPR:9
15837926.T3.T10	@CHEMICAL$ acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug @GENE$, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	CPR:9
15837926.T3.T12	PSMA acts as a glutamate carboxypeptidase (@CHEMICAL$) on small molecule substrates, including folate, the anticancer drug @GENE$, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	CPR:9
15837926.T4.T11	PSMA acts as a @CHEMICAL$ (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide @GENE$.	CPR:9
15837926.T4.T10	@CHEMICAL$ acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide @GENE$.	CPR:9
15837926.T4.T12	PSMA acts as a glutamate carboxypeptidase (@CHEMICAL$) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide @GENE$.	false
15837926.T5.T14	Here we present the 3.5-A crystal structure of the @CHEMICAL$, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for @GENE$-loaded transferrin that lacks protease activity.	false
15837926.T5.T15	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to @CHEMICAL$, a receptor for @GENE$-loaded transferrin that lacks protease activity.	false
15837926.T5.T17	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for @CHEMICAL$-loaded transferrin that lacks @GENE$ activity.	false
15837926.T5.T16	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for @CHEMICAL$-loaded @GENE$ that lacks protease activity.	false
15837926.T6.T18	Unlike @CHEMICAL$, the protease domain of PSMA contains a binuclear @GENE$ site, catalytic residues, and a proposed substrate-binding arginine patch.	false
15837926.T6.T19	Unlike transferrin receptor, the @CHEMICAL$ of PSMA contains a binuclear @GENE$ site, catalytic residues, and a proposed substrate-binding arginine patch.	false
15837926.T6.T20	Unlike transferrin receptor, the protease domain of @CHEMICAL$ contains a binuclear @GENE$ site, catalytic residues, and a proposed substrate-binding arginine patch.	false
15837926.T7.T18	Unlike @CHEMICAL$, the protease domain of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding @GENE$ patch.	false
15837926.T7.T19	Unlike transferrin receptor, the @CHEMICAL$ of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding @GENE$ patch.	false
15837926.T7.T20	Unlike transferrin receptor, the protease domain of @CHEMICAL$ contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding @GENE$ patch.	false
15837926.T8.T21	Elucidation of the @CHEMICAL$ structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate @GENE$.	CPR:9
15840827.T12.T27	Conversion of @CHEM-GENE$ into a more active enzyme by linking the two subunits: spectroscopic and kinetic properties.	false
15840827.T10.T19	The two active sites of dimeric @CHEMICAL$ (ALAS), a pyridoxal 5'-phosphate (@GENE$)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	false
15840827.T10.T23	The two active sites of dimeric 5-aminolevulinate synthase (@CHEMICAL$), a pyridoxal 5'-phosphate (@GENE$)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	false
15840827.T5.T19	The two active sites of dimeric @CHEMICAL$ (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential @GENE$ from each subunit.	false
15840827.T5.T23	The two active sites of dimeric 5-aminolevulinate synthase (@CHEMICAL$), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential @GENE$ from each subunit.	false
15840827.T6.T19	The two active sites of dimeric @CHEM-GENE$ (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	false
15840827.T6.T23	The two active sites of dimeric @CHEMICAL$ synthase (@GENE$), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	false
15840827.T7.T19	The two active sites of dimeric @CHEMICAL$ (ALAS), a @GENE$ (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	false
15840827.T7.T23	The two active sites of dimeric 5-aminolevulinate synthase (@CHEMICAL$), a @GENE$ (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	false
15840827.T3.T13	Transient kinetic analysis of the formation and decay of the @CHEMICAL$ intermediate EQ(2) indicated that, although their rates were similar in @GENE$ and 2XALAS, accumulation of this intermediate was greater in the 2XALAS-catalyzed reaction.	false
15840827.T3.T14	Transient kinetic analysis of the formation and decay of the @CHEMICAL$ intermediate EQ(2) indicated that, although their rates were similar in ALAS and @GENE$, accumulation of this intermediate was greater in the 2XALAS-catalyzed reaction.	false
15840827.T3.T15	Transient kinetic analysis of the formation and decay of the @CHEMICAL$ intermediate EQ(2) indicated that, although their rates were similar in ALAS and 2XALAS, accumulation of this intermediate was greater in the @GENE$-catalyzed reaction.	false
15840827.T4.T16	Collectively, these results suggest that @CHEMICAL$ is the active form of the coenzyme and forms a more prominent coenzyme structure in @GENE$ than in ALAS at pH approximately 7.5.	false
15840827.T4.T17	Collectively, these results suggest that @CHEMICAL$ is the active form of the coenzyme and forms a more prominent coenzyme structure in 2XALAS than in @GENE$ at pH approximately 7.5.	false
15854045.T1.T4	@CHEMICAL$ (PAD) convert protein-bound arginine residues into citrulline residues in a @GENE$ ion-dependent manner.	false
15854045.T1.T8	Peptidylarginine deiminases (@CHEMICAL$) convert protein-bound arginine residues into citrulline residues in a @GENE$ ion-dependent manner.	false
15854045.T2.T4	@CHEMICAL$ (PAD) convert protein-bound @GENE$ residues into citrulline residues in a Ca(2+) ion-dependent manner.	false
15854045.T2.T8	Peptidylarginine deiminases (@CHEMICAL$) convert protein-bound @GENE$ residues into citrulline residues in a Ca(2+) ion-dependent manner.	false
15854045.T3.T4	@CHEMICAL$ (PAD) convert protein-bound arginine residues into @GENE$ residues in a Ca(2+) ion-dependent manner.	false
15854045.T3.T8	Peptidylarginine deiminases (@CHEMICAL$) convert protein-bound arginine residues into @GENE$ residues in a Ca(2+) ion-dependent manner.	false
15937104.T6.T27	Activator of G protein signaling 3 regulates opiate activation of @CHEMICAL$ signaling and relapse of @GENE$-seeking behavior.	false
15937104.T6.T26	@CHEMICAL$ regulates opiate activation of protein kinase A signaling and relapse of @GENE$-seeking behavior.	false
15937104.T1.T10	Galpha(i) inhibits @CHEMICAL$ production, but betagamma regulates several molecular pathways, including protein kinase A (@GENE$).	false
15937104.T1.T8	@CHEMICAL$ inhibits @GENE$ production, but betagamma regulates several molecular pathways, including protein kinase A (PKA).	false
15937104.T1.T9	Galpha(i) inhibits @CHEMICAL$ production, but betagamma regulates several molecular pathways, including @GENE$ (PKA).	false
15937104.T3.T20	In rats self-administering @CHEMICAL$, @GENE$ antisense in the NAc core, but not shell, eliminates reinstatement of heroin-seeking behavior, a model of human relapse.	false
15937104.T4.T20	In rats self-administering heroin, @CHEMICAL$ antisense in the NAc core, but not shell, eliminates reinstatement of @GENE$-seeking behavior, a model of human relapse.	false
15937104.T5.T22	Thus, @CHEMICAL$/AGS3 appears to mediate mu opiate receptor activation of PKA signaling as well as @GENE$-seeking behavior.	false
15937104.T5.T25	Thus, Galpha(i3)/betagamma/AGS3 appears to mediate mu opiate receptor activation of @CHEMICAL$ signaling as well as @GENE$-seeking behavior.	false
15937104.T5.T23	Thus, Galpha(i3)/betagamma/@CHEMICAL$ appears to mediate mu opiate receptor activation of PKA signaling as well as @GENE$-seeking behavior.	false
15937104.T5.T24	Thus, Galpha(i3)/betagamma/AGS3 appears to mediate @CHEMICAL$ activation of PKA signaling as well as @GENE$-seeking behavior.	false
15992586.T27.T39	@CHEMICAL$ (A-381393), a selective @GENE$ antagonist.	false
15992586.T28.T39	2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (@CHEMICAL$), a selective @GENE$ antagonist.	false
15992586.T29.T39	2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective @CHEM-GENE$ antagonist.	false
15992586.T1.T30	@CHEMICAL$ (A-381393) was identified as a potent @GENE$ antagonist with excellent receptor selectivity.	false
15992586.T21.T30	2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (@CHEMICAL$) was identified as a potent @GENE$ antagonist with excellent receptor selectivity.	false
15992586.T3.T30	2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393) was identified as a potent @CHEM-GENE$ antagonist with excellent receptor selectivity.	false
15992586.T11.T33	@CHEMICAL$ competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant @GENE$ (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).	false
15992586.T12.T33	[3H]-spiperone competition binding assays showed that @CHEMICAL$ potently bound to membrane from cells expressing recombinant @GENE$ (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).	false
15992586.T13.T33	[3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant @CHEM-GENE$ (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).	false
15992586.T14.T33	[3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant @CHEMICAL$ (Ki=1.5 nM), which was 20-fold higher than that of @GENE$ (Ki=30.4 nM).	false
15992586.T15.T34	@CHEMICAL$ exhibited highly selective binding for the @GENE$ (>2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors.	false
15992586.T15.T35	@CHEMICAL$ exhibited highly selective binding for the dopamine D4.4 receptor (>2700-fold) when compared to @GENE$.	false
15992586.T16.T34	A-381393 exhibited highly selective binding for the @CHEM-GENE$ (>2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors.	false
15992586.T16.T35	A-381393 exhibited highly selective binding for the @CHEMICAL$ D4.4 receptor (>2700-fold) when compared to @GENE$.	false
15992586.T17.T34	A-381393 exhibited highly selective binding for the @CHEMICAL$ (>2700-fold) when compared to D1, D2, D3 and D5 @GENE$ receptors.	false
15992586.T17.T35	A-381393 exhibited highly selective binding for the dopamine D4.4 receptor (>2700-fold) when compared to @CHEM-GENE$.	false
15992586.T18.T37	Furthermore, in comparison to @CHEMICAL$ and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T18.T38	Furthermore, in comparison to @CHEMICAL$ and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T18.T36	Furthermore, in comparison to @CHEMICAL$ and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @GENE$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T19.T37	Furthermore, in comparison to clozapine and @CHEMICAL$, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T19.T38	Furthermore, in comparison to clozapine and @CHEMICAL$, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T19.T36	Furthermore, in comparison to clozapine and @CHEMICAL$, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @GENE$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T20.T37	Furthermore, in comparison to clozapine and L-745870, @CHEMICAL$ exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T20.T38	Furthermore, in comparison to clozapine and L-745870, @CHEMICAL$ exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T20.T36	Furthermore, in comparison to clozapine and L-745870, @CHEMICAL$ exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @GENE$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T22.T37	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). @CHEMICAL$ potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T22.T38	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). @CHEMICAL$ potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T22.T36	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). @GENE$ potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T23.T37	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced @CHEMICAL$-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T23.T38	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced @CHEMICAL$-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T23.T36	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced @GENE$-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T24.T37	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM @CHEMICAL$ induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T24.T38	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM @CHEMICAL$ induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T24.T36	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM @GENE$ induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T25.T37	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-@CHEMICAL$ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T25.T38	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-@CHEMICAL$ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T25.T36	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-@GENE$ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T26.T37	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @CHEM-GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T26.T38	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human @CHEMICAL$ D4.4 receptor expressing cells, but not in @GENE$ cells.	false
15992586.T26.T36	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human @GENE$ D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.	false
15992586.T2.T37	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @CHEMICAL$ expressing cells, but not in human @GENE$ D2L or D3 receptor cells.	false
15992586.T2.T38	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @CHEM-GENE$ cells.	false
15992586.T2.T36	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human @GENE$ D2L or D3 receptor cells.	false
15992586.T4.T31	In contrast to @CHEMICAL$, A-381393 did not exhibit any significant intrinsic activity in a @GENE$.	false
15992586.T5.T31	In contrast to L-745870, @CHEMICAL$ did not exhibit any significant intrinsic activity in a @GENE$.	false
15992586.T10.T32	Thus, A-381393 is a novel selective D4 antagonist that will enhance the ability to study @CHEM-GENE$ both in vitro and in vivo.	false
15992586.T9.T32	Thus, @CHEMICAL$ is a novel selective D4 antagonist that will enhance the ability to study @GENE$ both in vitro and in vivo.	false
1600046.T10.T23	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and @GENE$.	CPR:6
1600046.T6.T23	A number of selective @CHEMICAL$ antagonists have been developed including @GENE$, granisetron, tropisetron renzapride and zacopride.	CPR:6
1600046.T7.T23	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, @GENE$, tropisetron renzapride and zacopride.	CPR:6
1600046.T8.T23	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, granisetron, @GENE$ renzapride and zacopride.	CPR:6
1600046.T9.T23	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, granisetron, tropisetron @GENE$ and zacopride.	CPR:6
1600046.T11.T24	While the substituted @CHEMICAL$ prokinetics (for example, metoclopramide, cisapride) also block @GENE$ receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.	CPR:4
1600046.T11.T25	While the substituted @CHEMICAL$ prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative @GENE$ receptor.	CPR:5
1600046.T12.T24	While the substituted benzamide prokinetics (for example, @CHEMICAL$, cisapride) also block @GENE$ receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.	CPR:4
1600046.T12.T25	While the substituted benzamide prokinetics (for example, @CHEMICAL$, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative @GENE$ receptor.	CPR:5
1600046.T13.T24	While the substituted benzamide prokinetics (for example, metoclopramide, @CHEMICAL$) also block @GENE$ receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.	CPR:4
1600046.T13.T25	While the substituted benzamide prokinetics (for example, metoclopramide, @CHEMICAL$) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative @GENE$ receptor.	CPR:5
1600046.T14.T19	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, @CHEMICAL$, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a @GENE$ antagonist.	false
1600046.T14.T26	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, @GENE$, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	CPR:6
1600046.T14.T27	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, @GENE$, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	CPR:5
1600046.T15.T19	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, @CHEMICAL$) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a @GENE$ antagonist.	false
1600046.T15.T26	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, @GENE$) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	CPR:6
1600046.T15.T27	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, @GENE$) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	CPR:5
1600046.T16.T19	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, @CHEMICAL$, granisetron), while tropisetron in high concentrations is a @GENE$ antagonist.	false
1600046.T16.T26	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, @GENE$, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	false
1600046.T16.T27	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, zacopride) and others do not (for example, @GENE$, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	false
1600046.T17.T19	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, @CHEMICAL$), while tropisetron in high concentrations is a @GENE$ antagonist.	false
1600046.T17.T26	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, @GENE$), while tropisetron in high concentrations is a 5-HT4 antagonist.	false
1600046.T17.T27	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, @GENE$), while tropisetron in high concentrations is a 5-HT4 antagonist.	false
1600046.T2.T19	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while @CHEMICAL$ in high concentrations is a @GENE$ antagonist.	CPR:6
1600046.T2.T26	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while @GENE$ in high concentrations is a 5-HT4 antagonist.	false
1600046.T2.T27	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while @GENE$ in high concentrations is a 5-HT4 antagonist.	false
16018973.T2.T9	Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. A @CHEMICAL$ to @GENE$ (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	false
16018973.T2.T16	Niacin mediates lipolysis in adipose tissue through its @CHEMICAL$. A G-protein coupled receptor to @GENE$ (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	false
16018973.T3.T9	Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. A @CHEMICAL$ to niacin (@GENE$) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	false
16018973.T3.T16	Niacin mediates lipolysis in adipose tissue through its @CHEMICAL$. A G-protein coupled receptor to niacin (@GENE$) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	false
16018973.T6.T9	@CHEMICAL$ mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. A @GENE$ to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	false
16018973.T6.T16	@CHEMICAL$ mediates lipolysis in adipose tissue through its @GENE$. A G-protein coupled receptor to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	false
16018973.T1.T10	We present our studies to demonstrate that HM74A, but not HM74, binds @CHEMICAL$ at high affinities and effectively mediates @GENE$ signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.	CPR:3
16018973.T1.T11	We present our studies to demonstrate that HM74A, but not HM74, binds @CHEMICAL$ at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing @GENE$.	false
16018973.T1.T7	We present our studies to demonstrate that @CHEMICAL$, but not HM74, binds @GENE$ at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.	false
16018973.T1.T8	We present our studies to demonstrate that HM74A, but not @CHEMICAL$, binds @GENE$ at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.	false
16018973.T4.T12	Furthermore, @CHEMICAL$, but not HM74, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by @GENE$.	false
16018973.T4.T13	Furthermore, HM74A, but not @CHEMICAL$, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by @GENE$.	false
16018973.T5.T14	Our results provided direct evidence indicating that @CHEMICAL$, but not HM74, was sufficient to mediate anti-lipolytic effect of @GENE$ in adipose tissue.	false
16018973.T5.T15	Our results provided direct evidence indicating that HM74A, but not @CHEMICAL$, was sufficient to mediate anti-lipolytic effect of @GENE$ in adipose tissue.	false
16232421.T15.T33	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the @GENE$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T15.T34	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the KGD1 (@GENE$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T15.T35	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @GENE$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T15.T36	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T16.T33	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (@GENE$ dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T16.T34	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEM-GENE$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T16.T35	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$ dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @GENE$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T16.T36	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$ dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T17.T33	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of @GENE$ than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	CPR:9
16232421.T17.T34	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$) gene disrupted mutant produced a lower level of @GENE$ than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	CPR:9
16232421.T17.T35	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of @CHEMICAL$ than the wild-type strain, while the @GENE$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T17.T36	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of @CHEMICAL$ than the wild-type strain, while the SDH1 (@GENE$) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T18.T33	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$ dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T18.T34	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$ dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T18.T35	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @CHEMICAL$ (@GENE$ dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T18.T36	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@CHEM-GENE$) gene-disrupted mutant produced an increased level of succinate.	false
16232421.T19.T33	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of @GENE$.	false
16232421.T19.T34	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of @GENE$.	false
16232421.T19.T35	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @CHEMICAL$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of @GENE$.	CPR:9
16232421.T19.T36	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@CHEMICAL$) gene-disrupted mutant produced an increased level of @GENE$.	CPR:9
16232421.T20.T37	On the other hand, the @CHEMICAL$ (fumarase) gene disrupted mutant produced significantly higher levels of @GENE$ but did not form malate at all.	CPR:9
16232421.T20.T38	On the other hand, the FUM1 (@CHEMICAL$) gene disrupted mutant produced significantly higher levels of @GENE$ but did not form malate at all.	CPR:9
16232421.T21.T37	On the other hand, the @CHEMICAL$ (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form @GENE$ at all.	false
16232421.T21.T38	On the other hand, the FUM1 (@CHEMICAL$) gene disrupted mutant produced significantly higher levels of fumarate but did not form @GENE$ at all.	false
16232421.T3.T28	When the growth condition was shifted from aerobic to anaerobic, the increased level of @CHEMICAL$ in @GENE$ disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.	CPR:9
16232421.T3.T29	When the growth condition was shifted from aerobic to anaerobic, the increased level of @CHEMICAL$ in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the @GENE$ diruptant was still observed.	false
16232421.T4.T28	When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in @CHEMICAL$ disruptants was no longer observed, whereas the decreased level of @GENE$ in the KGD1 diruptant was still observed.	false
16232421.T4.T29	When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of @CHEMICAL$ in the @GENE$ diruptant was still observed.	CPR:9
16232421.T5.T30	A double mutant of the two @CHEM-GENE$ isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	false
16232421.T5.T31	A double mutant of the two @CHEMICAL$ reductase isozyme genes (@GENE$ and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	false
16232421.T5.T32	A double mutant of the two @CHEMICAL$ reductase isozyme genes (OSM1 and @GENE$) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	false
16232421.T6.T30	A double mutant of the two @CHEMICAL$ isozyme genes (OSM1 and FRDS) showed a @GENE$ productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	CPR:9
16232421.T6.T31	A double mutant of the two fumarate reductase isozyme genes (@CHEMICAL$ and FRDS) showed a @GENE$ productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	CPR:9
16232421.T6.T32	A double mutant of the two fumarate reductase isozyme genes (OSM1 and @CHEMICAL$) showed a @GENE$ productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	CPR:9
16232421.T8.T30	A double mutant of the two @CHEMICAL$ isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in @GENE$-buffered solution.	false
16232421.T8.T31	A double mutant of the two fumarate reductase isozyme genes (@CHEMICAL$ and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in @GENE$-buffered solution.	false
16232421.T8.T32	A double mutant of the two fumarate reductase isozyme genes (OSM1 and @CHEMICAL$) showed a succinate productivity of 50% as compared to the parent when cells were incubated in @GENE$-buffered solution.	false
16262557.T1.T9	As examples, @CHEMICAL$, flurbiprofen, ketoprofen and indomethacin have increased @GENE$ selectivity when compared with naproxen and ibuprofen.	false
16262557.T2.T9	As examples, ketorolac, @CHEMICAL$, ketoprofen and indomethacin have increased @GENE$ selectivity when compared with naproxen and ibuprofen.	false
16262557.T3.T9	As examples, ketorolac, flurbiprofen, @CHEMICAL$ and indomethacin have increased @GENE$ selectivity when compared with naproxen and ibuprofen.	false
16262557.T4.T9	As examples, ketorolac, flurbiprofen, ketoprofen and @CHEMICAL$ have increased @GENE$ selectivity when compared with naproxen and ibuprofen.	false
16262557.T5.T9	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased @CHEMICAL$ selectivity when compared with @GENE$ and ibuprofen.	false
16262557.T6.T9	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased @CHEMICAL$ selectivity when compared with naproxen and @GENE$.	false
16268464.T12.T32	Association of MTRR@CHEMICAL$ polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T34	Association of MTRRA66G polymorphism (but not of MTHFR @CHEMICAL$ and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T35	Association of MTRRA66G polymorphism (but not of MTHFR C677T and @CHEMICAL$, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T37	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTR@CHEMICAL$, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T38	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, @CHEMICAL$ C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T39	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN @CHEMICAL$) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T31	Association of @CHEMICAL$A66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T33	Association of MTRRA66G polymorphism (but not of @CHEMICAL$ C677T and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T12.T36	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, @CHEMICAL$A2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.	false
16268464.T11.T28	Methylenetetrahydrofolate reductase polymorphism (MTHFR @CHEMICAL$) is an established determinant of @GENE$ plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T11.T13	@CHEMICAL$ polymorphism (MTHFR C677T) is an established determinant of @GENE$ plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T11.T27	Methylenetetrahydrofolate reductase polymorphism (@CHEMICAL$ C677T) is an established determinant of @GENE$ plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T1.T28	@CHEMICAL$ reductase polymorphism (MTHFR @GENE$) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T1.T13	@CHEM-GENE$ polymorphism (MTHFR C677T) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T1.T27	@CHEMICAL$ reductase polymorphism (@GENE$ C677T) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T3.T28	Methylenetetrahydrofolate reductase polymorphism (MTHFR @CHEMICAL$) is an established determinant of homocysteine plasma level (t-@GENE$) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T3.T13	@CHEMICAL$ polymorphism (MTHFR C677T) is an established determinant of homocysteine plasma level (t-@GENE$) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T3.T27	Methylenetetrahydrofolate reductase polymorphism (@CHEMICAL$ C677T) is an established determinant of homocysteine plasma level (t-@GENE$) while its association with coronary artery disease (CAD) seems to be more limited.	false
16268464.T4.T18	In contrast, the association of the substitutions @CHEMICAL$ of @GENE$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T21	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), @GENE$ of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T24	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and @GENE$ of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T25	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of @GENE$ (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T26	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (@GENE$) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T19	In contrast, the association of the substitutions A2756G of @CHEM-GENE$ (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T20	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (@GENE$), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T22	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of @GENE$ (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T4.T23	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (@GENE$) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T18	In contrast, the association of the substitutions @CHEMICAL$ of methionine synthase (MTR), A66G of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T21	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), @CHEMICAL$ of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T24	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (MTRR) and @GENE$ of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T25	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (MTRR) and C776G of @GENE$ (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T26	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (MTRR) and C776G of transcobalamin (@GENE$) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T19	In contrast, the association of the substitutions A2756G of @CHEMICAL$ (MTR), A66G of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T20	In contrast, the association of the substitutions A2756G of methionine synthase (@CHEMICAL$), A66G of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T22	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEM-GENE$ (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T5.T23	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (@GENE$) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	false
16268464.T6.T18	In contrast, the association of the substitutions @CHEMICAL$ of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T21	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), @CHEMICAL$ of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T24	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and @CHEMICAL$ of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T25	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of @CHEMICAL$ (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T26	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (@CHEMICAL$) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T19	In contrast, the association of the substitutions A2756G of @CHEMICAL$ (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T20	In contrast, the association of the substitutions A2756G of methionine synthase (@CHEMICAL$), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T22	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T6.T23	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (@CHEMICAL$) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.	false
16268464.T10.T29	t-@CHEMICAL$ was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of @GENE$AA and MTHFR 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).	false
16268464.T10.T30	t-@CHEMICAL$ was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of MTRRAA and @GENE$ 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).	false
16268464.T2.T16	In multivariate analysis, t-@CHEMICAL$ > median and @GENE$AA genotype were two significant independent predictors of CAD with respective odds ratios of 3.1 (95 % CI: 1.8-5.1, P < 0.0001) and 4.5 (95% CI: 1.5-13.1, P = 0.0051).	false
16292755.T23.T38	@CHEMICAL$ supplementation alters @GENE$-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.	false
16292755.T23.T39	@CHEMICAL$ supplementation alters HDL-cholesterol concentration and @GENE$ activity in rabbits fed high-cholesterol diet: comparison with probucol.	false
16292755.T24.T38	Vitamin E supplementation alters @CHEMICAL$-cholesterol concentration and paraoxonase activity in rabbits fed high-@GENE$ diet: comparison with probucol.	false
16292755.T24.T39	Vitamin E supplementation alters HDL-cholesterol concentration and @CHEMICAL$ activity in rabbits fed high-@GENE$ diet: comparison with probucol.	false
16292755.T25.T38	Vitamin E supplementation alters @CHEMICAL$-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with @GENE$.	false
16292755.T25.T39	Vitamin E supplementation alters HDL-cholesterol concentration and @CHEMICAL$ activity in rabbits fed high-cholesterol diet: comparison with @GENE$.	false
16292755.T26.T38	Vitamin E supplementation alters @CHEMICAL$-@GENE$ concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.	false
16292755.T26.T39	Vitamin E supplementation alters HDL-@CHEMICAL$ concentration and @GENE$ activity in rabbits fed high-cholesterol diet: comparison with probucol.	false
16292755.T10.T31	@CHEMICAL$ and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and @GENE$ cholesterol compared to HC-control group.	CPR:4
16292755.T11.T31	Vitamin E and @CHEMICAL$ significantly suppressed an increase in plasma total-cholesterol (total-C) and @GENE$ cholesterol compared to HC-control group.	CPR:4
16292755.T12.T31	Vitamin E and probucol significantly suppressed an increase in plasma total-@CHEMICAL$ (total-C) and @GENE$ cholesterol compared to HC-control group.	false
16292755.T13.T31	Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and @CHEMICAL$ @GENE$ compared to HC-control group.	false
16292755.T14.T32	However, plasma @CHEMICAL$-@GENE$ (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.	false
16292755.T14.T33	However, plasma high-density lipoprotein-@CHEMICAL$ (@GENE$-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.	false
16292755.T14.T34	However, plasma high-density lipoprotein-@CHEMICAL$ (HDL-C) and @GENE$-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.	false
16292755.T14.T35	However, plasma high-density lipoprotein-@CHEMICAL$ (HDL-C) and HDL-C/total-C ratio levels and plasma @GENE$ activity were only significantly higher in vitamin E group after 8 weeks.	false
16292755.T15.T32	However, plasma @CHEMICAL$-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in @GENE$ group after 8 weeks.	CPR:3
16292755.T15.T33	However, plasma high-density lipoprotein-cholesterol (@CHEMICAL$-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in @GENE$ group after 8 weeks.	CPR:3
16292755.T15.T34	However, plasma high-density lipoprotein-cholesterol (HDL-C) and @CHEMICAL$-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in @GENE$ group after 8 weeks.	CPR:3
16292755.T15.T35	However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma @CHEMICAL$ activity were only significantly higher in @GENE$ group after 8 weeks.	CPR:3
16292755.T16.T36	Hepatic @CHEMICAL$ activity was significantly lower in both @GENE$ and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.	CPR:4
16292755.T16.T37	Hepatic ACAT activity was significantly lower in both @CHEMICAL$ and probucol groups than in HC-control group, while @GENE$ activity was the highest only in the probucol group.	false
16292755.T17.T36	Hepatic @CHEMICAL$ activity was significantly lower in both vitamin E and @GENE$ groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.	CPR:4
16292755.T17.T37	Hepatic ACAT activity was significantly lower in both vitamin E and @CHEMICAL$ groups than in HC-control group, while @GENE$ activity was the highest only in the probucol group.	false
16292755.T18.T36	Hepatic @CHEMICAL$ activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while @GENE$ reductase activity was the highest only in the probucol group.	false
16292755.T18.T37	Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while @CHEM-GENE$ activity was the highest only in the probucol group.	false
16292755.T19.T36	Hepatic @CHEMICAL$ activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the @GENE$ group.	false
16292755.T19.T37	Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while @CHEMICAL$ activity was the highest only in the @GENE$ group.	CPR:3
16292755.T2.T27	Hepatic mRNA expressions of @CHEMICAL$ and apo C-III were significantly lower in @GENE$ group than in other groups.	CPR:4
16292755.T2.T28	Hepatic mRNA expressions of apo B-100 and @CHEMICAL$ were significantly lower in @GENE$ group than in other groups.	CPR:4
16292755.T3.T29	@CHEMICAL$ supplementation was found to alter the plasma @GENE$-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration.	false
16292755.T3.T30	@CHEMICAL$ supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma @GENE$-C concentration.	false
16292755.T4.T29	Vitamin E supplementation was found to alter the plasma @CHEMICAL$-C-related factors; meanwhile, @GENE$ supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration.	false
16292755.T4.T30	Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, @CHEMICAL$ supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma @GENE$-C concentration.	CPR:4
16292755.T5.T29	Vitamin E supplementation was found to alter the plasma @CHEMICAL$-C-related factors; meanwhile, probucol supplementation was very effective in enhancing @GENE$ metabolism, except for a negative effect that reduced plasma HDL-C concentration.	false
16292755.T5.T30	Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing @CHEMICAL$ metabolism, except for a negative effect that reduced plasma @GENE$-C concentration.	false
16298345.T2.T13	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel @CHEMICAL$ antagonists, such as @GENE$ (UK-427,857).	CPR:6
16298345.T3.T13	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel @CHEMICAL$ antagonists, such as maraviroc (@GENE$).	CPR:6
16298345.T4.T16	To do this we cloned and expressed @CHEMICAL$ from rhesus macaque and compared the binding properties of [@GENE$]-MIP-1beta and [3H]-maraviroc with human recombinant CCR5.	false
16298345.T4.T17	To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [@CHEMICAL$]-MIP-1beta and [3H]-maraviroc with @GENE$.	false
16298345.T5.T16	To do this we cloned and expressed @CHEMICAL$ from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and @GENE$ with human recombinant CCR5.	false
16298345.T5.T17	To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and @CHEMICAL$ with @GENE$.	false
16298345.T6.T18	[@CHEMICAL$]-MIP-1beta bound with similar high affinity to @GENE$ from macaque (K(d) = 0.24 +/- 0.05 nM) and human (K(d) = 0.23 +/- 0.05 nM) and with similar kinetic properties.	false
16298345.T7.T21	@CHEMICAL$ inhibited binding of [125I]-MIP-1beta to @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	false
16298345.T7.T22	@CHEMICAL$ inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	CPR:6
16298345.T8.T21	Maraviroc inhibited binding of [@CHEMICAL$]-MIP-1beta to @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	false
16298345.T8.T22	Maraviroc inhibited binding of [@CHEMICAL$]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	false
16298345.T9.T21	Maraviroc inhibited binding of [125I]-MIP-1beta to @CHEMICAL$ from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular @GENE$ release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	false
16298345.T9.T22	Maraviroc inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular @CHEMICAL$ release mediated through @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	false
16298345.T10.T11	@CHEMICAL$ bound with high affinity to @GENE$ from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque CCR5.	false
16298345.T10.T12	@CHEMICAL$ bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from @GENE$.	false
16298345.T1.T14	However, as with the human receptor, @CHEMICAL$ was shown to be a high affinity, potent functional antagonist of @GENE$ thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.	CPR:6
16298345.T1.T15	However, as with the human receptor, @CHEMICAL$ was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel @GENE$ antagonists.	CPR:6
16316409.T8.T37	To better understand the molecular mechanism of @CHEMICAL$ on tumor suppression, we utilized a complementary @GENE$ microarray composed of approximately 6,000 human cancer-related genes to determine the gene expression pattern altered by re-introduction of p75NTR into PC-3 prostate tumor cells.	false
16316409.T8.T39	To better understand the molecular mechanism of p75(NTR) on tumor suppression, we utilized a complementary @CHEMICAL$ microarray composed of approximately 6,000 human cancer-related genes to determine the gene expression pattern altered by re-introduction of @GENE$ into PC-3 prostate tumor cells.	false
16316409.T1.T10	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (@GENE$) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.	false
16316409.T1.T11	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (CRABPI) and @GENE$ protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.	false
16316409.T1.T12	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (CRABPI) and IGFBP5 protein levels and decreased level of @GENE$ protein with increasing p75NTR protein expression.	false
16316409.T1.T13	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (CRABPI) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing @GENE$ protein expression.	false
16316409.T1.T9	Immunoblot analysis further confirmed increased @CHEM-GENE$ (CRABPI) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.	false
16316409.T2.T14	As @CHEMICAL$ was elevated far more than any other genes, we observed that the @GENE$, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T2.T15	As CRABPI was elevated far more than any other genes, we observed that the @CHEMICAL$, all-trans retinoic acid and 9-cis retinoic acid, that bind @GENE$, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T2.T16	As CRABPI was elevated far more than any other genes, we observed that the @CHEMICAL$, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T3.T14	As @CHEMICAL$ was elevated far more than any other genes, we observed that the retinoids, @GENE$ and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T3.T15	As CRABPI was elevated far more than any other genes, we observed that the retinoids, @CHEMICAL$ and 9-cis retinoic acid, that bind @GENE$, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T3.T16	As CRABPI was elevated far more than any other genes, we observed that the retinoids, @CHEMICAL$ and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T4.T14	As @CHEMICAL$ was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and @GENE$, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T4.T15	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and @CHEMICAL$, that bind @GENE$, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T4.T16	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and @CHEMICAL$, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T5.T14	As @CHEMICAL$ was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted @GENE$-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T5.T15	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind @CHEMICAL$, promoted @GENE$-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T5.T16	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted @CHEMICAL$-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.	false
16316409.T6.T17	Subsequent examination of the @CHEM-GENE$ (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	false
16316409.T6.T18	Subsequent examination of the @CHEMICAL$ receptors @GENE$) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	false
16316409.T6.T19	Subsequent examination of the @CHEMICAL$ receptors (RARs) expression levels demonstrated an absence of @GENE$ in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	false
16316409.T6.T20	Subsequent examination of the @CHEMICAL$ receptors (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the @GENE$ expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	false
16316409.T6.T21	Subsequent examination of the @CHEMICAL$ receptors (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where @GENE$ is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	false
16316409.T7.T32	Hence, re-expression of the @CHEMICAL$ appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @GENE$ that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	false
16316409.T7.T33	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of @CHEMICAL$ for localized sequestration of @GENE$ that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	CPR:3
16316409.T7.T34	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @CHEMICAL$ that are available to newly up-regulated @GENE$, RXR-alpha, and RXR-beta.	false
16316409.T7.T35	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @CHEMICAL$ that are available to newly up-regulated RAR-beta, @GENE$, and RXR-beta.	false
16316409.T7.T36	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @CHEMICAL$ that are available to newly up-regulated RAR-beta, RXR-alpha, and @GENE$.	false
16322797.T17.T30	@CHEMICAL$ (PUMA-G/HM74A) mediates @GENE$-induced flushing.	false
16322797.T17.T31	GPR109A (PUMA-G/@CHEMICAL$) mediates @GENE$-induced flushing.	false
16322797.T17.T32	GPR109A (@CHEMICAL$/HM74A) mediates @GENE$-induced flushing.	false
16322797.T4.T21	Its special profile of actions, especially the rise in @CHEMICAL$-@GENE$ levels induced by nicotinic acid, is unique among the currently available pharmacological tools to treat lipid disorders.	false
16322797.T7.T21	Its special profile of actions, especially the rise in @CHEMICAL$-cholesterol levels induced by @GENE$, is unique among the currently available pharmacological tools to treat lipid disorders.	CPR:3
16322797.T9.T22	Recently, a @CHEMICAL$, termed GPR109A (HM74A in humans, PUMA-G in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.	false
16322797.T9.T23	Recently, a G-protein-coupled receptor, termed @CHEMICAL$ (HM74A in humans, PUMA-G in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.	false
16322797.T9.T24	Recently, a G-protein-coupled receptor, termed GPR109A (@CHEMICAL$ in humans, PUMA-G in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.	false
16322797.T9.T25	Recently, a G-protein-coupled receptor, termed GPR109A (HM74A in humans, @CHEMICAL$ in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.	false
16322797.T11.T26	In the present study, we show that mice lacking @CHEMICAL$ did not show @GENE$-induced flushing.	false
16322797.T12.T28	In addition, flushing in response to @CHEMICAL$ was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @GENE$ had reduced flushing responses.	false
16322797.T12.T27	In addition, flushing in response to @CHEMICAL$ was also abrogated in the absence of @GENE$, and mice lacking prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.	false
16322797.T13.T28	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.	false
16322797.T13.T27	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking @GENE$ (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.	false
16322797.T14.T28	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.	false
16322797.T14.T27	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking prostaglandin D(2) (@GENE$) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.	false
16322797.T15.T28	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.	false
16322797.T15.T27	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking prostaglandin D(2) (PGD(2)) and @GENE$ (PGE(2)) receptors had reduced flushing responses.	false
16322797.T16.T28	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.	false
16322797.T16.T27	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (@GENE$) receptors had reduced flushing responses.	false
16322797.T2.T18	The mouse orthologue of GPR109A, @CHEMICAL$, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated PUMA-G-deficient mice restored the @GENE$-induced flushing response.	false
16322797.T2.T19	The mouse orthologue of GPR109A, PUMA-G, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated @CHEMICAL$-deficient mice restored the @GENE$-induced flushing response.	false
16322797.T2.T29	The mouse orthologue of @CHEMICAL$, PUMA-G, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated PUMA-G-deficient mice restored the @GENE$-induced flushing response.	false
16322797.T3.T20	Our data clearly indicate that @CHEMICAL$ mediates @GENE$-induced flushing and that this effect involves release of PGE(2) and PGD(2), most likely from immune cells of the skin.	false
16322797.T5.T20	Our data clearly indicate that @CHEMICAL$ mediates nicotinic acid-induced flushing and that this effect involves release of @GENE$ and PGD(2), most likely from immune cells of the skin.	false
16322797.T6.T20	Our data clearly indicate that @CHEMICAL$ mediates nicotinic acid-induced flushing and that this effect involves release of PGE(2) and @GENE$, most likely from immune cells of the skin.	false
16325050.T10.T28	The @CHEMICAL$ beta1-adrenoceptor polymorphism and @GENE$ effects on plasma-renin activity.	false
16325050.T10.T27	The Arg389Gly @CHEMICAL$ polymorphism and @GENE$ effects on plasma-renin activity.	false
16325050.T10.T29	The Arg389Gly beta1-adrenoceptor polymorphism and @CHEMICAL$ effects on plasma-@GENE$ activity.	false
16325050.T6.T14	OBJECTIVES: The purpose of this research was to find out whether, in humans, @CHEMICAL$-induced hemodynamic effects and increase in plasma-@GENE$ activity (PRA) might be beta1-adrenoceptor (beta1AR) genotype-dependent.	false
16325050.T6.T17	OBJECTIVES: The purpose of this research was to find out whether, in humans, @CHEMICAL$-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be @GENE$ (beta1AR) genotype-dependent.	false
16325050.T6.T18	OBJECTIVES: The purpose of this research was to find out whether, in humans, @CHEMICAL$-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (@GENE$) genotype-dependent.	false
16325050.T5.T24	RESULTS: With regard to PRA, @CHEMICAL$ increased PRA more potently in Arg389-@GENE$ versus Gly389-beta1AR subjects.	false
16325050.T5.T25	RESULTS: With regard to PRA, @CHEMICAL$ increased PRA more potently in Arg389-beta1AR versus Gly389-@GENE$ subjects.	false
16325050.T7.T26	@CHEMICAL$ markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-@GENE$ subjects.	false
16325050.T8.T26	Bisoprolol markedly suppressed the @CHEMICAL$-induced PRA increase in Arg389- but only marginally in Gly389-@GENE$ subjects.	false
16325050.T9.T11	With regard to hemodynamics, @CHEMICAL$ caused larger heart rate and contractility increases and diastolic blood pressure decreases in Arg389- versus Gly389-@GENE$ subjects.	false
16325050.T1.T12	@CHEMICAL$ reduced dobutamine-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-@GENE$ subjects.	false
16325050.T2.T12	Bisoprolol reduced @CHEMICAL$-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-@GENE$ subjects.	false
16344985.T25.T36	@CHEMICAL$ selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by @GENE$: relevance to bipolar disorder.	CPR:4
16344985.T26.T36	Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by @CHEM-GENE$: relevance to bipolar disorder.	false
16344985.T27.T36	Valproic acid selectively inhibits conversion of @CHEMICAL$ to arachidonoyl-CoA by @GENE$: relevance to bipolar disorder.	CPR:9
16344985.T28.T36	Valproic acid selectively inhibits conversion of arachidonic acid to @CHEMICAL$ by @GENE$: relevance to bipolar disorder.	CPR:9
16344985.T11.T31	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not @CHEMICAL$, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.	false
16344985.T12.T31	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an @CHEMICAL$-selective @GENE$.	false
16344985.T16.T31	RATIONALE: Several drugs used to treat bipolar disorder (@CHEMICAL$ and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.	CPR:4
16344985.T19.T31	RATIONALE: Several drugs used to treat bipolar disorder (lithium and @CHEMICAL$), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.	CPR:4
16344985.T7.T31	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of @CHEMICAL$, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.	false
16344985.T13.T32	Although chronic @CHEMICAL$ produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter @GENE$ activity, suggesting that it targets a different enzyme in the turnover pathway.	false
16344985.T14.T32	Although chronic valproic acid produces similar effects on brain @CHEMICAL$ and docosahexaenoic acid turnover, it does not alter @GENE$ activity, suggesting that it targets a different enzyme in the turnover pathway.	false
16344985.T15.T32	Although chronic valproic acid produces similar effects on brain arachidonic acid and @CHEMICAL$ turnover, it does not alter @GENE$ activity, suggesting that it targets a different enzyme in the turnover pathway.	false
16344985.T17.T33	MATERIALS AND METHODS/RESULTS: By isolating @CHEM-GENE$ (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	false
16344985.T17.T34	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal @CHEMICAL$ synthetases (@GENE$), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	false
16344985.T17.T35	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal @CHEMICAL$ synthetases (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of @GENE$, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	false
16344985.T18.T33	MATERIALS AND METHODS/RESULTS: By isolating @CHEMICAL$ (Acsl), we show in vitro that @GENE$ is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	false
16344985.T18.T34	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (@CHEMICAL$), we show in vitro that @GENE$ is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	false
16344985.T18.T35	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that @CHEMICAL$ is a non-competitive inhibitor of @GENE$, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	CPR:4
16344985.T5.T29	Furthermore, @CHEMICAL$ did not produce @GENE$. CONCLUSIONS: This study shows that valproic acid acts as a non-competitive inhibitor of brain microsomal Acsl, and that inhibition is substrate-selective.	false
16344985.T5.T30	Furthermore, brain microsomal Acsl did not produce @CHEMICAL$. CONCLUSIONS: This study shows that valproic acid acts as a non-competitive inhibitor of @GENE$, and that inhibition is substrate-selective.	false
16344985.T6.T29	Furthermore, @CHEMICAL$ did not produce valproyl-CoA. CONCLUSIONS: This study shows that @GENE$ acts as a non-competitive inhibitor of brain microsomal Acsl, and that inhibition is substrate-selective.	false
16344985.T6.T30	Furthermore, brain microsomal Acsl did not produce valproyl-CoA. CONCLUSIONS: This study shows that @CHEMICAL$ acts as a non-competitive inhibitor of @GENE$, and that inhibition is substrate-selective.	CPR:4
16359899.T5.T13	This article summarizes some findings of a research that I have pursued for the past 25 years, whose roots are immersed in the field of inherited metabolic disorders, and deal with different aspects of the vitamin @CHEMICAL$, starting with a patient with multiple @GENE$ deficiency (MCD).	false
16359899.T1.T10	On the other hand, holocarboxylase synthetase (@CHEMICAL$) mRNA levels were markedly low in the deficient animals, and increased upon @GENE$ injection.	CPR:3
16359899.T1.T9	On the other hand, @CHEMICAL$ (HCS) mRNA levels were markedly low in the deficient animals, and increased upon @GENE$ injection.	CPR:3
16359899.T3.T12	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for @CHEMICAL$ effects on specific genes and proteins, such as HCS and @GENE$, and on their proteomes."	false
16359899.T3.T11	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for @CHEMICAL$ effects on specific genes and proteins, such as @GENE$ and hexokinases, and on their proteomes."	false
16359899.T4.T12	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for biotin effects on specific genes and proteins, such as @CHEMICAL$ and @GENE$, and on their proteomes."	false
16359899.T4.T11	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for biotin effects on specific genes and proteins, such as @CHEM-GENE$ and hexokinases, and on their proteomes."	false
16371234.T16.T48	Involvement of @CHEMICAL$ and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced @GENE$ production by microglia.	CPR:9
16371234.T16.T49	Involvement of COX-1 and up-regulated @CHEMICAL$ in phosphatidylserine liposome-induced @GENE$ production by microglia.	CPR:9
16371234.T17.T48	Involvement of @CHEMICAL$ and up-regulated @GENE$ synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia.	false
16371234.T17.T49	Involvement of COX-1 and up-regulated @CHEM-GENE$ in phosphatidylserine liposome-induced prostaglandin E2 production by microglia.	false
16371234.T18.T48	Involvement of @CHEMICAL$ and up-regulated prostaglandin E synthases in @GENE$ liposome-induced prostaglandin E2 production by microglia.	false
16371234.T18.T49	Involvement of COX-1 and up-regulated @CHEMICAL$ in @GENE$ liposome-induced prostaglandin E2 production by microglia.	false
16371234.T14.T42	The specific ligand for @CHEMICAL$ (SR-B), high density lipoprotein, significantly suppressed PS liposome-induced @GENE$ production.	false
16371234.T14.T43	The specific ligand for class B scavenger receptor (@CHEMICAL$), high density lipoprotein, significantly suppressed PS liposome-induced @GENE$ production.	false
16371234.T14.T44	The specific ligand for class B scavenger receptor (SR-B), @CHEMICAL$, significantly suppressed PS liposome-induced @GENE$ production.	false
16371234.T15.T45	@CHEMICAL$ (COX)-2 and membrane-bound @GENE$ synthase-1 (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	false
16371234.T15.T19	Cyclooxygenase (COX)-2 and membrane-bound @CHEMICAL$ synthase-1 (@GENE$) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	false
16371234.T15.T46	Cyclooxygenase @CHEMICAL$ and membrane-bound @GENE$ synthase-1 (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	false
16371234.T15.T47	Cyclooxygenase (COX)-2 and membrane-bound @CHEM-GENE$ (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	false
16371234.T3.T24	Furthermore, PS liposome-induced @CHEMICAL$ production was significantly suppressed by indomethacin, a preferential @GENE$ inhibitor, but not by NS-398, a selective COX-2 inhibitor.	false
16371234.T3.T25	Furthermore, PS liposome-induced @CHEMICAL$ production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by NS-398, a selective @GENE$ inhibitor.	false
16371234.T4.T24	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by @CHEMICAL$, a preferential @GENE$ inhibitor, but not by NS-398, a selective COX-2 inhibitor.	CPR:4
16371234.T4.T25	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by @CHEMICAL$, a preferential COX-1 inhibitor, but not by NS-398, a selective @GENE$ inhibitor.	false
16371234.T5.T24	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential @CHEMICAL$ inhibitor, but not by @GENE$, a selective COX-2 inhibitor.	false
16371234.T5.T25	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by @CHEMICAL$, a selective @GENE$ inhibitor.	CPR:4
16371234.T6.T33	These observations strongly suggest that the up-regulation of terminal @CHEMICAL$ that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced @GENE$ production by microglia.	CPR:9
16371234.T6.T34	These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with @CHEMICAL$, especially mPGES-2, plays the pivotal role in PS liposome-induced @GENE$ production by microglia.	CPR:9
16371234.T6.T35	These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially @CHEMICAL$, plays the pivotal role in PS liposome-induced @GENE$ production by microglia.	CPR:9
16371234.T7.T37	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other @GENE$, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	false
16371234.T7.T38	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly @GENE$, could also promote PGE2 production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	false
16371234.T7.T41	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/p42 @GENE$ after PS liposomes treatment.	false
16371234.T7.T36	Although @CHEMICAL$ plays an essential role in PS liposome-induced @GENE$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	false
16371234.T7.T39	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including @GENE$/p42 ERK after PS liposomes treatment.	false
16371234.T7.T40	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/@GENE$ ERK after PS liposomes treatment.	false
16371234.T8.T37	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other @CHEMICAL$, possibly PS-specific receptor, could also promote @GENE$ production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	false
16371234.T8.T38	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly @CHEMICAL$, could also promote @GENE$ production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	false
16371234.T8.T41	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @CHEMICAL$ production by transducing intracellular signals including p44/p42 @GENE$ after PS liposomes treatment.	false
16371234.T8.T36	Although @CHEMICAL$ plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @GENE$ production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	false
16371234.T8.T39	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @CHEMICAL$ production by transducing intracellular signals including @GENE$/p42 ERK after PS liposomes treatment.	false
16371234.T8.T40	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @CHEMICAL$ production by transducing intracellular signals including p44/@GENE$ ERK after PS liposomes treatment.	false
16425993.T3.T21	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-@CHEMICAL$ inhibitors (MKIs) @GENE$, sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.	CPR:4
16425993.T3.T23	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) @CHEMICAL$, sunitinib, and AG013736, which target multiple @GENE$ as well as PDGFR-beta.	CPR:4
16425993.T3.T24	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) @CHEMICAL$, sunitinib, and AG013736, which target multiple VEGFRs as well as @GENE$.	CPR:4
16425993.T4.T21	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-@CHEMICAL$ inhibitors (MKIs) sorafenib, @GENE$, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.	CPR:4
16425993.T4.T23	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, @CHEMICAL$, and AG013736, which target multiple @GENE$ as well as PDGFR-beta.	CPR:4
16425993.T4.T24	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, @CHEMICAL$, and AG013736, which target multiple VEGFRs as well as @GENE$.	CPR:4
16425993.T5.T21	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-@CHEMICAL$ inhibitors (MKIs) sorafenib, sunitinib, and @GENE$, which target multiple VEGFRs as well as PDGFR-beta.	CPR:4
16425993.T5.T23	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and @CHEMICAL$, which target multiple @GENE$ as well as PDGFR-beta.	CPR:4
16425993.T5.T24	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and @CHEMICAL$, which target multiple VEGFRs as well as @GENE$.	CPR:4
16425993.T6.T28	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of @GENE$ and PDGFR-beta.	CPR:4
16425993.T6.T25	@CHEMICAL$ has the added advantage of inhibiting multiple different @GENE$ isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.	CPR:4
16425993.T6.T26	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target @GENE$/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.	CPR:4
16425993.T6.T27	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/@GENE$ signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.	CPR:4
16425993.T6.T29	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and @GENE$.	CPR:4
16449956.T1.T16	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with @GENE$ and Ex1-1G>A).	false
16449956.T1.T17	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and @GENE$).	false
16449956.T1.T11	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (@GENE$) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T1.T12	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @GENE$ activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T1.T13	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic @GENE$ protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T1.T14	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in @GENE$ gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T1.T9	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum @GENE$ (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T2.T16	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with @GENE$ and Ex1-1G>A).	false
16449956.T2.T17	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and @GENE$).	false
16449956.T2.T11	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (@CHEMICAL$) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @GENE$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T2.T12	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEM-GENE$ activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T2.T13	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic @GENE$ protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T2.T14	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in @GENE$ gene (compound heterozygote with S225X and Ex1-1G>A).	false
16449956.T2.T9	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum @CHEMICAL$ (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @GENE$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	false
16488503.T13.T26	Inhibition of @CHEMICAL$ binding to rat renal brush-border membrane by @GENE$ ligands and basic peptides.	false
16488503.T4.T15	Our previous studies showed that coadministration of cytochrome c and a 20-residue basic peptide, N-WASP181-200 (@CHEMICAL$, pI=10.87) inhibits renal accumulation of @GENE$.	false
16488503.T4.T22	Our previous studies showed that coadministration of @CHEMICAL$ and a 20-residue basic peptide, N-WASP181-200 (NISHTKEKKKGKAKKKRLTK, pI=10.87) inhibits renal accumulation of @GENE$.	false
16488503.T5.T19	In this study, we examined effects of ligands of @CHEMICAL$, an endocytic receptor involved in renal uptake of @GENE$, and basic peptides including N-WASP180-200 and its mutant peptides on gentamicin binding to isolated rat renal brush-border membrane (BBM).	false
16488503.T6.T19	In this study, we examined effects of ligands of @CHEMICAL$, an endocytic receptor involved in renal uptake of gentamicin, and basic peptides including N-WASP180-200 and its mutant peptides on @GENE$ binding to isolated rat renal brush-border membrane (BBM).	false
16488503.T7.T20	@CHEMICAL$ binding to BBM was inhibited by @GENE$ ligands, basic peptide fragments of cytochrome c, and N-WASP181-200 in a concentration-dependent manner.	false
16488503.T7.T21	@CHEMICAL$ binding to BBM was inhibited by megalin ligands, basic peptide fragments of @GENE$, and N-WASP181-200 in a concentration-dependent manner.	false
16488503.T10.T23	By substituting glycines for @CHEMICAL$ in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the @GENE$ content in the peptide.	false
16488503.T11.T23	By substituting glycines for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on @CHEMICAL$ binding to BBM was reduced, which may be related to a decrease in the @GENE$ content in the peptide.	false
16488503.T9.T23	By substituting @CHEMICAL$ for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the @GENE$ content in the peptide.	false
16488503.T12.T24	@CHEMICAL$ binding to BBM treated with @GENE$, in which megalin completely disappeared, was significantly but not completely decreased compared with the native BBM.	false
16488503.T12.T25	@CHEMICAL$ binding to BBM treated with trypsin, in which @GENE$ completely disappeared, was significantly but not completely decreased compared with the native BBM.	false
16488503.T1.T14	In addition, treatment of BBM with @CHEMICAL$ led to a decrease in the inhibitory effect of N-WASP181-200 on @GENE$ binding.	false
16488503.T2.T16	These observations support that @CHEMICAL$ ligands and basic peptides including N-WASP181-200 decrease renal accumulation of @GENE$ by inhibiting its binding to BBM of proximal tubule cells, partly interacting with megalin.	false
16488503.T2.T17	These observations support that megalin ligands and basic peptides including N-WASP181-200 decrease renal accumulation of @CHEMICAL$ by inhibiting its binding to BBM of proximal tubule cells, partly interacting with @GENE$.	false
16488503.T3.T18	In addition, the @CHEMICAL$ conformation may play an important role in the inhibitory effect of N-WASP181-200 on the binding of @GENE$ to BBM.	false
16596248.T6.T13	@CHEM-GENE$ expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.	false
16596248.T7.T13	@CHEMICAL$ expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with @GENE$.	false
16596248.T8.T13	@CHEMICAL$ expression pattern, expression level and single @GENE$ polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.	false
16596248.T1.T10	Several variables associated to @CHEMICAL$ (TS), the biological target of 5-fluorouracil (@GENE$) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	false
16596248.T1.T11	Several variables associated to thymidylate synthase (@CHEMICAL$), the biological target of 5-fluorouracil (@GENE$) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	false
16596248.T3.T10	Several variables associated to @CHEM-GENE$ (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	false
16596248.T3.T11	Several variables associated to @CHEMICAL$ synthase (@GENE$), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	false
16596248.T5.T10	Several variables associated to @CHEMICAL$ (TS), the biological target of @GENE$ (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	false
16596248.T5.T11	Several variables associated to thymidylate synthase (@CHEMICAL$), the biological target of @GENE$ (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	false
16596248.T2.T9	Low @CHEMICAL$ expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with @GENE$.	CPR:4
16597468.T2.T14	Leishmania species express three @CHEMICAL$ enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @GENE$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T2.T10	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEM-GENE$ (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T2.T11	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ phosphoribosyltransferase (@GENE$), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T2.T12	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ phosphoribosyltransferase (APRT), and @GENE$ (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T2.T13	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (@GENE$), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T2.T15	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ (HGPRT), @GENE$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T2.T9	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (@CHEMICAL$), @GENE$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T14	Leishmania species express three @CHEMICAL$ enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T10	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T11	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (@CHEMICAL$), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T12	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @CHEM-GENE$ (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T13	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @CHEMICAL$ phosphoribosyltransferase (@GENE$), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T15	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ (HGPRT), adenine phosphoribosyltransferase (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T3.T9	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (@CHEMICAL$), adenine phosphoribosyltransferase (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T4.T14	Leishmania species express three @CHEMICAL$ enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T4.T10	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T4.T11	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (@CHEMICAL$), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T4.T12	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @CHEMICAL$ (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T4.T13	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (@CHEMICAL$), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T4.T15	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T4.T9	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (@CHEMICAL$), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.	false
16597468.T5.T14	Leishmania species express three @CHEMICAL$ enzymes, @GENE$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T5.T10	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), @GENE$ (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T5.T11	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (@GENE$), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T5.T12	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @GENE$ (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T5.T13	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (@GENE$), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T5.T15	Leishmania species express three phosphoribosyltransferase enzymes, @CHEM-GENE$ (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T5.T9	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (@GENE$), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	false
16597468.T6.T16	These data support the hypothesis that none of the three @CHEMICAL$ is essential for @GENE$ salvage or viability by itself and that purine salvage occurs through multiple anabolic routes in both parasite life cycle stages.	false
16597468.T7.T16	These data support the hypothesis that none of the three @CHEMICAL$ is essential for purine salvage or viability by itself and that @GENE$ salvage occurs through multiple anabolic routes in both parasite life cycle stages.	false
16597468.T1.T8	In addition these studies revealed the presence of an @CHEM-GENE$ enzyme in L. donovani axenic amastigotes, an activity previously thought to be restricted to promastigotes.	false
16597625.T6.T14	In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and @CHEM-GENE$ (aaRS) coded by the nuclear genome, and imported.	false
16597625.T6.T15	In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and @CHEMICAL$-tRNA synthetases (@GENE$) coded by the nuclear genome, and imported.	false
16597625.T7.T18	We have explored here the human mt-@CHEMICAL$ system in which a @GENE$, highly similar to the Escherichia coli enzyme, recognizes a bizarre tRNA(Asp).	false
16597625.T8.T20	This position is otherwise known as the site of a universally conserved major @CHEMICAL$ identity element, @GENE$, also known as a primordial identity signal.	false
16597625.T2.T10	Sequence alignments of various AspRSs allowed placing @CHEMICAL$-269 at a position occupied by Asp-220, the residue contacting @GENE$ in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.	false
16597625.T2.T9	Sequence alignments of various @CHEMICAL$ allowed placing @GENE$-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.	false
16597625.T2.T11	Sequence alignments of various AspRSs allowed placing @CHEMICAL$-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of @GENE$-tRNA(Asp) complex.	false
16597625.T3.T10	Sequence alignments of various AspRSs allowed placing Gly-269 at a position occupied by @CHEMICAL$-220, the residue contacting @GENE$ in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.	false
16597625.T3.T9	Sequence alignments of various @CHEMICAL$ allowed placing Gly-269 at a position occupied by @GENE$-220, the residue contacting G73 in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.	false
16597625.T3.T11	Sequence alignments of various AspRSs allowed placing Gly-269 at a position occupied by @CHEMICAL$-220, the residue contacting G73 in the crystallographic structure of @GENE$-tRNA(Asp) complex.	false
16597625.T4.T13	Replacing this @CHEMICAL$ by an aspartate renders human mt-AspRS more discriminative to @GENE$.	false
16597625.T4.T12	Replacing this @CHEMICAL$ by an aspartate renders @GENE$ more discriminative to G73.	false
16597625.T5.T13	Replacing this glycine by an @CHEMICAL$ renders human mt-AspRS more discriminative to @GENE$.	false
16597625.T5.T12	Replacing this glycine by an @CHEMICAL$ renders @GENE$ more discriminative to G73.	false
16642960.T6.T13	Metabolic syndrome: @CHEM-GENE$ and malonyl coenzyme A. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by insulin resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.	false
16642960.T6.T12	Metabolic syndrome: @CHEMICAL$-activated protein kinase and malonyl coenzyme A. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by @GENE$ resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.	false
16642960.T7.T13	Metabolic syndrome: @CHEMICAL$ and @GENE$. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by insulin resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.	false
16642960.T7.T12	Metabolic syndrome: adenosine monophosphate-activated protein kinase and @CHEMICAL$. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by @GENE$ resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.	false
16642960.T1.T8	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the @CHEM-GENE$ (AMPK)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism.	false
16642960.T1.T9	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the @CHEMICAL$-activated protein kinase (@GENE$)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism.	false
16642960.T2.T8	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the @CHEMICAL$ (AMPK)/@GENE$ (CoA) fuel-sensing and signaling mechanism.	false
16642960.T2.T9	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the adenosine monophosphate-activated protein kinase (@CHEMICAL$)/@GENE$ (CoA) fuel-sensing and signaling mechanism.	false
16642960.T3.T10	Such dysregulation could be reflected by isolated increases in @CHEMICAL$ or by concurrent changes in malonyl CoA and @GENE$, both of which would alter intracellular fatty acid partitioning.	false
16642960.T4.T10	Such dysregulation could be reflected by isolated increases in malonyl CoA or by concurrent changes in @CHEMICAL$ and @GENE$, both of which would alter intracellular fatty acid partitioning.	false
16642960.T5.T11	The possibility is also raised that pharmacological agents and other factors that activate @CHEMICAL$ and/or decrease @GENE$ could be therapeutic targets.	false
1665782.T17.T27	Chronic effect of @CHEMICAL$ on @GENE$.	false
1665782.T10.T20	In previous studies, we have demonstrated that chronic @CHEMICAL$ or [D-Ala2,D-Leu5]enkephalin (DADLE) treatment of rats results in the reduction of @GENE$ binding activities as tolerance develops.	false
1665782.T13.T20	In previous studies, we have demonstrated that chronic etorphine or @CHEMICAL$ (DADLE) treatment of rats results in the reduction of @GENE$ binding activities as tolerance develops.	false
1665782.T16.T20	In previous studies, we have demonstrated that chronic etorphine or [D-Ala2,D-Leu5]enkephalin (@CHEMICAL$) treatment of rats results in the reduction of @GENE$ binding activities as tolerance develops.	false
1665782.T7.T24	As both @CHEMICAL$ and DADLE are relatively non-specific opioid ligands, interacting with both @GENE$, these studies could not determine whether down-regulation of a specific receptor type occurs.	false
1665782.T8.T24	As both etorphine and @CHEMICAL$ are relatively non-specific opioid ligands, interacting with both @GENE$, these studies could not determine whether down-regulation of a specific receptor type occurs.	false
1665782.T11.T25	Therefore, in the present studies, animals were rendered tolerant to the @CHEMICAL$-selective agonist [D-Pen2,D-Pen5]enkephalin (@GENE$), and receptor binding activities were measured.	CPR:5
1665782.T9.T25	Therefore, in the present studies, animals were rendered tolerant to the @CHEMICAL$-selective agonist @GENE$ (DPDPE), and receptor binding activities were measured.	CPR:5
1665782.T15.T26	When @CHEMICAL$ binding was determined by using @GENE$, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.	false
1665782.T1.T26	When @CHEMICAL$ binding was determined by using [3H]DPDPE, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of @GENE$ treatment.	false
1665782.T3.T18	To our surprise, when @CHEMICAL$ binding was determined by using @GENE$ (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.	false
1665782.T4.T18	To our surprise, when @CHEMICAL$ binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (@GENE$), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.	false
1665782.T5.T18	To our surprise, when @CHEMICAL$ binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of @GENE$ treatment.	false
1665782.T6.T19	Our conclusion is that chronic @CHEMICAL$ treatment preferentially reduces @GENE$ binding activity.	CPR:4
1666997.T5.T23	In vitro binding studies showed that both @CHEMICAL$ and amitriptyline interact in the nanomolar range with @GENE$ receptors labelled by [3H]ketanserin in cortical membranes.	false
1666997.T6.T23	In vitro binding studies showed that both amoxapine and @CHEMICAL$ interact in the nanomolar range with @GENE$ receptors labelled by [3H]ketanserin in cortical membranes.	false
1666997.T7.T23	In vitro binding studies showed that both amoxapine and amitriptyline interact in the nanomolar range with @CHEMICAL$ receptors labelled by @GENE$ in cortical membranes.	false
1666997.T10.T24	By contrast, neither amoxapine nor @CHEMICAL$ can be considered as possible ligands of @GENE$ and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).	false
1666997.T10.T25	By contrast, neither amoxapine nor @CHEMICAL$ can be considered as possible ligands of 5-HT1A and @GENE$ receptors because their affinities for these sites are in the micromolar range (or even worse).	false
1666997.T9.T24	By contrast, neither @CHEMICAL$ nor amitriptyline can be considered as possible ligands of @GENE$ and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).	false
1666997.T9.T25	By contrast, neither @CHEMICAL$ nor amitriptyline can be considered as possible ligands of 5-HT1A and @GENE$ receptors because their affinities for these sites are in the micromolar range (or even worse).	false
1666997.T12.T26	Interestingly, @CHEMICAL$ binds with a good affinity (IC50 = 0.30 microM) to @GENE$ receptors labelled by [3H]zacopride in cortical membranes.	false
1666997.T13.T26	Interestingly, amoxapine binds with a good affinity (IC50 = 0.30 microM) to @CHEMICAL$ receptors labelled by @GENE$ in cortical membranes.	false
1666997.T14.T27	Complementary experiments using the @CHEMICAL$-dependent Bezold-Jarisch reflex confirmed that @GENE$ really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.	false
1666997.T14.T28	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that @CHEMICAL$ really acts in vivo as a @GENE$ antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.	CPR:6
1666997.T14.T29	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that @CHEMICAL$ really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on @GENE$ receptors.	false
1666997.T15.T27	Complementary experiments using the @CHEMICAL$-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas @GENE$ is essentially inactive on 5-HT3 receptors.	false
1666997.T15.T28	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a @CHEMICAL$ antagonist (IC50 = 50 micrograms/kg i.v.), whereas @GENE$ is essentially inactive on 5-HT3 receptors.	false
1666997.T15.T29	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas @CHEMICAL$ is essentially inactive on @GENE$ receptors.	false
1666997.T1.T18	The second part of this study consisted of looking for possible changes in central @CHEMICAL$ 24 h after either a single or a repeated (for 14 days) treatment with @GENE$ (10 mg/kg i.p.	false
1666997.T3.T22	Finally we explored whether acute and/or chronic administration of @CHEMICAL$ or amitriptyline affected the levels of opioid peptides and the @GENE$ in various regions of the brain and the spinal cord.(ABSTRACT TRUNCATED AT 250 WORDS)	false
1666997.T4.T22	Finally we explored whether acute and/or chronic administration of amoxapine or @CHEMICAL$ affected the levels of opioid peptides and the @GENE$ in various regions of the brain and the spinal cord.(ABSTRACT TRUNCATED AT 250 WORDS)	false
16675639.T14.T36	Competitive radioligand binding assays were performed using cells expressing either the @CHEM-GENE$ (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T14.T37	Competitive radioligand binding assays were performed using cells expressing either the human @CHEMICAL$ (5-HT) transporter (@GENE$) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T14.T38	Competitive radioligand binding assays were performed using cells expressing either the human @CHEMICAL$ (5-HT) transporter (hSERT) or @GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T14.T39	Competitive radioligand binding assays were performed using cells expressing either the human @CHEMICAL$ (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T15.T36	Competitive radioligand binding assays were performed using cells expressing either the @CHEM-GENE$ (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T15.T37	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (@CHEMICAL$) transporter (@GENE$) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T15.T38	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (@CHEMICAL$) transporter (hSERT) or @GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T15.T39	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (@CHEMICAL$) transporter (hSERT) or norepinephrine (NE) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T16.T36	Competitive radioligand binding assays were performed using cells expressing either the @CHEMICAL$ (hSERT) or @GENE$ (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T16.T37	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (@CHEMICAL$) or @GENE$ (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T16.T38	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEM-GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T16.T39	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEMICAL$ (NE) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T17.T36	Competitive radioligand binding assays were performed using cells expressing either the @CHEMICAL$ (hSERT) or norepinephrine (@GENE$) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T17.T37	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (@CHEMICAL$) or norepinephrine (@GENE$) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T17.T38	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEM-GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T17.T39	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (@CHEMICAL$) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	false
16675639.T18.T36	Competitive radioligand binding assays were performed using cells expressing either the @CHEMICAL$ (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	CPR:4
16675639.T18.T37	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (@CHEMICAL$) or norepinephrine (NE) transporter (hNET) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	CPR:4
16675639.T18.T38	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEMICAL$ (hNET) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	CPR:4
16675639.T18.T39	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (@CHEMICAL$) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	CPR:4
16675639.T19.T40	@CHEMICAL$ showed weak binding affinity (62% inhibition at 100 microM) at the @GENE$.	false
16675639.T20.T40	DVS showed weak binding affinity (62% inhibition at 100 microM) at the @CHEM-GENE$.	false
16675639.T21.T40	DVS showed weak binding affinity (62% inhibition at 100 microM) at the @CHEM-GENE$.	false
16675639.T22.T41	Inhibition of @CHEMICAL$ or [3H]NE uptake by DVS for the @GENE$ or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	CPR:9
16675639.T22.T42	Inhibition of @CHEMICAL$ or [3H]NE uptake by DVS for the hSERT or @GENE$ produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	false
16675639.T23.T41	Inhibition of [3H]5-HT or @CHEMICAL$ uptake by DVS for the @GENE$ or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	false
16675639.T23.T42	Inhibition of [3H]5-HT or @CHEMICAL$ uptake by DVS for the hSERT or @GENE$ produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	CPR:9
16675639.T24.T41	Inhibition of [3H]5-HT or [3H]NE uptake by @CHEMICAL$ for the @GENE$ or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	false
16675639.T24.T42	Inhibition of [3H]5-HT or [3H]NE uptake by @CHEMICAL$ for the hSERT or @GENE$ produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	false
16675639.T3.T34	To mimic chronic selective @CHEMICAL$ reuptake inhibitor treatment and to block the inhibitory @GENE$ autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).	false
16675639.T3.T35	To mimic chronic selective @CHEMICAL$ reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @GENE$ antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).	false
16675639.T4.T34	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory @CHEMICAL$ autoreceptors, a 5-HT(1A) antagonist, @GENE$ (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).	false
16675639.T4.T35	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @CHEMICAL$ antagonist, @GENE$ (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).	CPR:6
16675639.T5.T34	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory @CHEMICAL$ autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (@GENE$) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).	false
16675639.T5.T35	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @CHEMICAL$ antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (@GENE$) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).	CPR:6
16675639.T6.T34	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory @CHEMICAL$ autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with @GENE$ (30 mg/kg orally).	false
16675639.T6.T35	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @CHEMICAL$ antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with @GENE$ (30 mg/kg orally).	false
16719540.T11.T20	The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal @CHEMICAL$ exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and metabolism, and in targets like @GENE$.	false
16719540.T12.T20	The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal fluorouracil exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and metabolism, and in targets like @CHEM-GENE$.	false
16719540.T13.T21	To individualise @CHEMICAL$ administration before the first dose, assessment of the individual @GENE$ (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.	false
16719540.T13.T22	To individualise @CHEMICAL$ administration before the first dose, assessment of the individual dihydropyrimidine dehydrogenase (@GENE$) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.	false
16719540.T14.T21	To individualise fluorouracil administration before the first dose, assessment of the individual @CHEM-GENE$ (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.	false
16719540.T14.T22	To individualise fluorouracil administration before the first dose, assessment of the individual @CHEMICAL$ dehydrogenase (@GENE$) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.	false
16719540.T16.T21	To individualise fluorouracil administration before the first dose, assessment of the individual @CHEMICAL$ (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of @GENE$ elimination.	false
16719540.T16.T22	To individualise fluorouracil administration before the first dose, assessment of the individual dihydropyrimidine dehydrogenase (@CHEMICAL$) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of @GENE$ elimination.	false
16719540.T17.T23	A complete or partial loss of @CHEMICAL$ activity in 0.1 and 3-5% of Caucasians, respectively, leads to increased @GENE$ exposure and toxicity.	false
16719540.T2.T24	Several methods to assess @CHEMICAL$ activity in patients have been proposed (genotyping, various phenotyping methods), but each of them has limitations, as has the @GENE$ test dose approach.	false
16719540.T10.T19	Whether an adaptation of the fluorouracil starting dose to the results of two @CHEMICAL$ activity tests before fluorouracil administration a priori, and the adaptation of doses to @GENE$ exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	false
16719540.T8.T19	Whether an adaptation of the @CHEMICAL$ starting dose to the results of two @GENE$ activity tests before fluorouracil administration a priori, and the adaptation of doses to fluorouracil exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	false
16719540.T9.T19	Whether an adaptation of the fluorouracil starting dose to the results of two @CHEMICAL$ activity tests before @GENE$ administration a priori, and the adaptation of doses to fluorouracil exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	false
16741658.T9.T34	Expression of @CHEMICAL$ correlates with resistance to @GENE$ in human patient tumors.	false
16741658.T6.T19	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between @CHEMICAL$ expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	false
16741658.T6.T18	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that @CHEMICAL$ expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	false
16741658.T6.T20	BACKGROUND: Preclinical results indicate @CHEMICAL$ (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	false
16741658.T6.T21	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (@CHEMICAL$) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	false
16741658.T6.T28	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and @CHEMICAL$ (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	false
16741658.T6.T32	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (@CHEMICAL$) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	false
16741658.T7.T24	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, @GENE$ (Pgp), p53, and bcl-2.	false
16741658.T7.T25	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (@GENE$), p53, and bcl-2.	false
16741658.T7.T22	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of @GENE$, bFGF, P-glycoprotein (Pgp), p53, and bcl-2.	false
16741658.T7.T23	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, @GENE$, P-glycoprotein (Pgp), p53, and bcl-2.	false
16741658.T7.T26	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), @GENE$, and bcl-2.	false
16741658.T7.T27	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), p53, and @GENE$.	false
16741658.T8.T24	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, @GENE$ (Pgp), p53, and bcl-2.	false
16741658.T8.T25	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (@GENE$), p53, and bcl-2.	false
16741658.T8.T22	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of @GENE$, bFGF, P-glycoprotein (Pgp), p53, and bcl-2.	false
16741658.T8.T23	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, @GENE$, P-glycoprotein (Pgp), p53, and bcl-2.	false
16741658.T8.T26	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), @GENE$, and bcl-2.	false
16741658.T8.T27	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), p53, and @GENE$.	false
16741658.T3.T11	@CHEMICAL$ expression did not correlate with tumor sensitivity to @GENE$, whereas bFGF expression showed an inverse correlation (p < 0.01).	false
16741658.T3.T12	aFGF expression did not correlate with tumor sensitivity to @CHEMICAL$, whereas @GENE$ expression showed an inverse correlation (p < 0.01).	false
16741658.T4.T14	bFGF expression was a stronger predictor of @CHEMICAL$ resistance compared to @GENE$, p53, or Bcl-2.	false
16741658.T4.T13	@CHEMICAL$ expression was a stronger predictor of @GENE$ resistance compared to Pgp, p53, or Bcl-2.	false
16741658.T4.T15	bFGF expression was a stronger predictor of @CHEMICAL$ resistance compared to Pgp, @GENE$, or Bcl-2.	false
16741658.T4.T16	bFGF expression was a stronger predictor of @CHEMICAL$ resistance compared to Pgp, p53, or @GENE$.	false
16741658.T5.T17	CONCLUSION: These results support a role of @CHEMICAL$ in @GENE$ resistance in human patient tumors.	false
16741870.T10.T28	@CHEM-GENE$ expression in the obligatory paedomorphic salamander Necturus maculosus.	false
16741870.T1.T17	These hormones induce metamorphosis by controlling gene expression through binding to @CHEM-GENE$ (TRs).	false
16741870.T1.T18	These hormones induce metamorphosis by controlling gene expression through binding to @CHEMICAL$ receptors (@GENE$).	false
16741870.T3.T19	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine @GENE$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T3.T20	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @GENE$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T3.T21	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (@GENE$)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T3.T22	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T3.T23	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T3.T24	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.	false
16741870.T5.T19	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two @GENE$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T5.T20	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: @GENE$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T5.T21	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (@GENE$)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T5.T22	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T5.T23	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T5.T24	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.	false
16741870.T6.T19	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @GENE$-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T6.T20	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @CHEM-GENE$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T6.T21	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (@GENE$)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T6.T22	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (CTHBP)-@GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T6.T23	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T6.T24	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.	false
16741870.T7.T19	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-@GENE$ kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T7.T20	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @CHEMICAL$ (CTHBP)-M2-@GENE$ kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T7.T21	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (@CHEMICAL$)-M2-@GENE$ kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T7.T22	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@CHEM-GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T7.T23	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-@CHEMICAL$ kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T7.T24	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-@CHEMICAL$ kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.	false
16741870.T8.T19	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T8.T20	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @CHEMICAL$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T8.T21	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (@CHEMICAL$)-M2-pyruvate kinase, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T8.T22	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@CHEMICAL$, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T8.T23	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @CHEM-GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.	false
16741870.T8.T24	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic @CHEMICAL$ binding protein and @GENE$, a direct TH target gene in Xenopus laevis.	false
16763553.T4.T22	The tissue @CHEMICAL$ level is maintained through a cascade of metabolic reactions where @GENE$ (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.	false
16763553.T4.T23	The tissue @CHEMICAL$ level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (@GENE$) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.	false
16763553.T6.T22	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEM-GENE$ (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.	false
16763553.T6.T23	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEMICAL$ dehydrogenases (@GENE$) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.	false
16763553.T7.T22	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEMICAL$ (RALDHs) catalyze the terminal reaction of @GENE$ biosynthesis from retinal, a rate-limiting step.	CPR:9
16763553.T7.T23	The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (@CHEMICAL$) catalyze the terminal reaction of @GENE$ biosynthesis from retinal, a rate-limiting step.	CPR:9
16763553.T8.T22	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEMICAL$ (RALDHs) catalyze the terminal reaction of RA biosynthesis from @GENE$, a rate-limiting step.	CPR:9
16763553.T8.T23	The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (@CHEMICAL$) catalyze the terminal reaction of RA biosynthesis from @GENE$, a rate-limiting step.	CPR:9
16763553.T10.T24	We showed that dietary supplement of cholesterol enhanced the expression of @CHEMICAL$ genes and the cellular @GENE$ content in vital organs such as brain, kidney, liver and heart.	false
16763553.T9.T24	We showed that dietary supplement of @CHEMICAL$ enhanced the expression of @GENE$ genes and the cellular RA content in vital organs such as brain, kidney, liver and heart.	false
16763553.T11.T25	Consistently, the @CHEMICAL$-lowering agent (pravastatin sodium) downregulated the expression of @GENE$ genes in several organs especially the liver and in cultured liver cells.	false
16763553.T12.T25	Consistently, the cholesterol-lowering agent (@CHEMICAL$) downregulated the expression of @GENE$ genes in several organs especially the liver and in cultured liver cells.	false
16763553.T14.T26	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for @GENE$ (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T14.T27	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (@GENE$), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T14.T28	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @GENE$ (SREBP-1c) that bound to the regulatory regions of these genes.	CPR:3
16763553.T14.T29	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (@GENE$) that bound to the regulatory regions of these genes.	CPR:3
16763553.T15.T26	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for @GENE$ (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T15.T27	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for liver X receptor (@GENE$), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T15.T28	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @GENE$ (SREBP-1c) that bound to the regulatory regions of these genes.	CPR:3
16763553.T15.T29	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (@GENE$) that bound to the regulatory regions of these genes.	CPR:3
16763553.T16.T26	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for @CHEMICAL$ (LXR), induced these genes via upregulation of @GENE$ regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T16.T27	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (@CHEMICAL$), induced these genes via upregulation of @GENE$ regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T16.T28	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @CHEM-GENE$ (SREBP-1c) that bound to the regulatory regions of these genes.	false
16763553.T16.T29	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @CHEMICAL$ regulatory element binding protein-1c (@GENE$) that bound to the regulatory regions of these genes.	false
16769115.T2.T6	Brain abnormalities in +/rl are similar to psychotic brain and include a reduction in @CHEM-GENE$ (GAD67), dendritic arbors and spine density in cortex and hippocampus, and abnormalities in synaptic function including long-term potentiation (LTP).	false
16769115.T2.T7	Brain abnormalities in +/rl are similar to psychotic brain and include a reduction in @CHEMICAL$ de carboxylase 67 (@GENE$), dendritic arbors and spine density in cortex and hippocampus, and abnormalities in synaptic function including long-term potentiation (LTP).	false
16769115.T1.T11	Hypermethlyation of @CHEMICAL$ can be induced by treating mice with @GENE$, and these mice display brain and behavioral abnormalities similar to +/rl.	CPR:3
16775509.T7.T14	Functional and bioenergetic consequences of @CHEMICAL$ antagonist @GENE$ in hearts with postinfarction LV remodeling.	CPR:6
16775509.T3.T12	The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by @CHEMICAL$ type 1 receptor (@GENE$) blocker.	false
16775509.T3.T9	The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by @CHEM-GENE$ (AT1) blocker.	false
16775509.T4.T10	Animals with heart failure demonstrated reductions in both mitochondrial @CHEMICAL$ expression and myocardial high-energy @GENE$ levels.	false
16775509.T5.T11	Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the @CHEMICAL$ antagonist @GENE$.	CPR:6
16782282.T18.T35	Regulation of @CHEM-GENE$ and retinoid X receptor alpha after sciatic nerve injury.	false
16782282.T18.T36	Regulation of @CHEMICAL$ receptors alpha, beta and @GENE$ after sciatic nerve injury.	false
16782282.T19.T35	Regulation of @CHEMICAL$ and @GENE$ X receptor alpha after sciatic nerve injury.	false
16782282.T19.T36	Regulation of retinoic acid receptors alpha, beta and @CHEM-GENE$ after sciatic nerve injury.	false
16782282.T6.T25	Since the effect of @CHEMICAL$ is mediated via @GENE$ and retinoid X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	false
16782282.T6.T26	Since the effect of @CHEMICAL$ is mediated via retinoic acid receptors and @GENE$, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	false
16782282.T7.T25	Since the effect of retinoic acid is mediated via @CHEM-GENE$ and retinoid X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	false
16782282.T7.T26	Since the effect of retinoic acid is mediated via @CHEMICAL$ receptors and @GENE$, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	false
16782282.T8.T25	Since the effect of retinoic acid is mediated via @CHEMICAL$ and @GENE$ X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	false
16782282.T8.T26	Since the effect of retinoic acid is mediated via retinoic acid receptors and @CHEM-GENE$, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	false
16782282.T10.T27	Seven days after crush injury, transcript concentrations of all @CHEMICAL$ and of @GENE$ X receptor alpha were significantly higher than in non-lesioned nerves.	false
16782282.T10.T28	Seven days after crush injury, transcript concentrations of all retinoic acid receptors and of @CHEM-GENE$ were significantly higher than in non-lesioned nerves.	false
16782282.T9.T27	Seven days after crush injury, transcript concentrations of all @CHEM-GENE$ and of retinoid X receptor alpha were significantly higher than in non-lesioned nerves.	false
16782282.T9.T28	Seven days after crush injury, transcript concentrations of all @CHEMICAL$ receptors and of @GENE$ were significantly higher than in non-lesioned nerves.	false
16782282.T12.T29	Protein levels of @CHEM-GENE$, retinoic acid receptor beta and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.	false
16782282.T12.T30	Protein levels of @CHEMICAL$ receptor alpha, @GENE$ and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.	false
16782282.T12.T31	Protein levels of @CHEMICAL$ receptor alpha, retinoic acid receptor beta and @GENE$ were upregulated 4, 7 and 14 days after injury.	false
16782282.T13.T29	Protein levels of @CHEMICAL$, @GENE$ receptor beta and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.	false
16782282.T13.T30	Protein levels of retinoic acid receptor alpha, @CHEM-GENE$ and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.	false
16782282.T13.T31	Protein levels of retinoic acid receptor alpha, @CHEMICAL$ receptor beta and @GENE$ were upregulated 4, 7 and 14 days after injury.	false
16782282.T14.T29	Protein levels of @CHEMICAL$, retinoic acid receptor beta and @GENE$ X receptor alpha were upregulated 4, 7 and 14 days after injury.	false
16782282.T14.T30	Protein levels of retinoic acid receptor alpha, @CHEMICAL$ and @GENE$ X receptor alpha were upregulated 4, 7 and 14 days after injury.	false
16782282.T14.T31	Protein levels of retinoic acid receptor alpha, retinoic acid receptor beta and @CHEM-GENE$ were upregulated 4, 7 and 14 days after injury.	false
16782282.T15.T32	In degenerating nerves a significant increase of @CHEM-GENE$ was detected 7 and 14 days, and of retinoic acid receptor beta 14 and 21 days after complete transection.	false
16782282.T15.T33	In degenerating nerves a significant increase of @CHEMICAL$ receptor alpha was detected 7 and 14 days, and of @GENE$ 14 and 21 days after complete transection.	false
16782282.T16.T32	In degenerating nerves a significant increase of @CHEMICAL$ was detected 7 and 14 days, and of @GENE$ receptor beta 14 and 21 days after complete transection.	false
16782282.T16.T33	In degenerating nerves a significant increase of retinoic acid receptor alpha was detected 7 and 14 days, and of @CHEM-GENE$ 14 and 21 days after complete transection.	false
16782282.T17.T34	Immunohistochemical staining of @CHEM-GENE$ revealed their expression in Schwann cells and macrophages.	false
16782282.T1.T20	In addition, we observed that @CHEM-GENE$ and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.	false
16782282.T1.T21	In addition, we observed that @CHEMICAL$ receptor alpha and @GENE$ appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.	false
16782282.T1.T22	In addition, we observed that @CHEMICAL$ receptor alpha and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$-staining co-localized with some regenerating axons.	false
16782282.T2.T20	In addition, we observed that @CHEMICAL$ and @GENE$ X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.	false
16782282.T2.T21	In addition, we observed that retinoic acid receptor alpha and @CHEM-GENE$ appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.	false
16782282.T2.T22	In addition, we observed that retinoic acid receptor alpha and @CHEMICAL$ X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$-staining co-localized with some regenerating axons.	false
16782282.T3.T20	In addition, we observed that @CHEMICAL$ and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$ X receptor alpha-staining co-localized with some regenerating axons.	false
16782282.T3.T21	In addition, we observed that retinoic acid receptor alpha and @CHEMICAL$ appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$ X receptor alpha-staining co-localized with some regenerating axons.	false
16782282.T3.T22	In addition, we observed that retinoic acid receptor alpha and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @CHEM-GENE$-staining co-localized with some regenerating axons.	false
16782282.T4.T23	Experiments with Schwann cell primary cultures revealed an effect of @CHEMICAL$ on the expression of the @GENE$ ErbB3, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.	false
16782282.T4.T24	Experiments with Schwann cell primary cultures revealed an effect of @CHEMICAL$ on the expression of the neuregulin receptor @GENE$, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.	false
16782282.T5.T23	Experiments with Schwann cell primary cultures revealed an effect of retinoic acid on the expression of the @CHEMICAL$ ErbB3, suggesting that one function of @GENE$ consists in the regulation of neuroglial interactions after peripheral nerve injury.	false
16782282.T5.T24	Experiments with Schwann cell primary cultures revealed an effect of retinoic acid on the expression of the neuregulin receptor @CHEMICAL$, suggesting that one function of @GENE$ consists in the regulation of neuroglial interactions after peripheral nerve injury.	false
16782438.T13.T27	Cellular effects of @CHEMICAL$ on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated @GENE$ mutations.	false
16782438.T8.T24	BACKGROUND: Activating mutations in the RET gene, which encodes a @CHEM-GENE$, often cause medullary thyroid carcinoma (MTC).	false
16782438.T8.T20	BACKGROUND: Activating mutations in the @CHEMICAL$ gene, which encodes a @GENE$ kinase receptor, often cause medullary thyroid carcinoma (MTC).	false
16782438.T6.T19	We evaluated @CHEMICAL$, a @GENE$ inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.	CPR:4
16782438.T6.T21	We evaluated @CHEMICAL$, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant @GENE$.	false
16782438.T7.T19	We evaluated imatinib, a @CHEM-GENE$ inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.	false
16782438.T7.T21	We evaluated imatinib, a @CHEMICAL$ kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant @GENE$.	false
16782438.T12.T26	RESULTS: @CHEMICAL$ inhibited RET @GENE$ phosphorylation in a dose-dependent manner after 1.5 hours of exposure.	CPR:4
16782438.T12.T25	RESULTS: @CHEMICAL$ inhibited @GENE$ Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.	CPR:4
16782438.T3.T16	CONCLUSIONS: @CHEMICAL$ inhibits @GENE$-mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner.	CPR:4
16782438.T3.T17	CONCLUSIONS: @CHEMICAL$ inhibits RET-mediated MTC cell growth affecting @GENE$ protein levels in vitro in a dose-dependent manner.	CPR:4
16782438.T4.T18	The concentration of @CHEMICAL$ necessary to inhibit @GENE$ in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.	CPR:4
16782438.T5.T18	The concentration of imatinib necessary to inhibit @CHEMICAL$ in vitro, however, makes it impossible to conclude that @GENE$ monotherapy will be a good option for systemic therapy of MTC.	false
16784786.T22.T47	With the exception of @CHEMICAL$, where @GENE$ is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	false
16784786.T23.T47	With the exception of @CHEMICAL$, where Mo is a constituent of the @GENE$-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	false
16784786.T24.T47	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, @GENE$ is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	false
16784786.T25.T47	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a @GENE$, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	false
16784786.T26.T47	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the @GENE$ cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	false
16784786.T27.T47	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other @GENE$-enzymes.	false
16784786.T1.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @CHEM-GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T1.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$ reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T1.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$ reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T1.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$ reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T28.T39	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T28.T48	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) @GENE$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T28.T49	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T28.T50	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T29.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of @CHEMICAL$-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T29.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of @GENE$-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	CPR:9
16784786.T29.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of @CHEMICAL$-containing amino acids and is involved in detoxifying excess sulfite, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T29.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of @CHEMICAL$-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T2.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @CHEMICAL$, which catalyzes the key step in inorganic @GENE$ assimilation.	false
16784786.T2.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic @GENE$ assimilation.	false
16784786.T2.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic @GENE$ assimilation.	false
16784786.T2.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic @GENE$ assimilation.	false
16784786.T30.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing @CHEMICAL$ and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T30.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing @GENE$ and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T30.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing @CHEMICAL$ and is involved in detoxifying excess sulfite, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T30.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing @CHEMICAL$ and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T31.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @CHEMICAL$, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T31.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @GENE$, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T31.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @CHEMICAL$, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T31.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @CHEMICAL$, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T32.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$ dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T32.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @GENE$ dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T32.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEM-GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T32.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$ dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T33.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in @CHEMICAL$ catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T33.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in @GENE$ catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T33.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in @GENE$ catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T33.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in @CHEMICAL$ catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T34.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive @CHEMICAL$ production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T34.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive @GENE$ production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T34.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive @GENE$ production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T34.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive @CHEMICAL$ production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T35.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$ oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T35.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$ oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T35.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$ oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T35.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEM-GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T36.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of @CHEMICAL$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T36.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of @GENE$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T36.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of @GENE$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T36.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of @GENE$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T37.T39	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @CHEMICAL$, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T37.T48	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @GENE$, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T37.T49	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @GENE$, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T37.T50	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @GENE$, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	false
16784786.T3.T40	All @CHEMICAL$-enzymes, except @GENE$, need at least one more redox active center, many of them involving iron in electron transfer.	false
16784786.T4.T40	All Mo-enzymes, except @CHEM-GENE$, need at least one more redox active center, many of them involving iron in electron transfer.	false
16784786.T5.T40	All Mo-enzymes, except @CHEMICAL$, need at least one more redox active center, many of them involving @GENE$ in electron transfer.	false
16784786.T10.T44	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEMICAL$ oxidase and @GENE$, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T10.T41	@CHEMICAL$ and aldehyde oxidase, but not @GENE$ oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T10.T42	Xanthine dehydrogenase and @CHEMICAL$, but not @GENE$ oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T10.T43	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEM-GENE$ and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T11.T44	Xanthine dehydrogenase and aldehyde oxidase, but not sulfite oxidase and @CHEM-GENE$, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T11.T41	@CHEMICAL$ and aldehyde oxidase, but not sulfite oxidase and @GENE$ reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T11.T42	Xanthine dehydrogenase and @CHEMICAL$, but not sulfite oxidase and @GENE$ reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T11.T43	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEMICAL$ and @GENE$ reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T12.T44	Xanthine dehydrogenase and aldehyde oxidase, but not sulfite oxidase and @CHEMICAL$, require the post-translational sulfuration of their @GENE$-site for becoming active.	false
16784786.T12.T41	@CHEMICAL$ and aldehyde oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their @GENE$-site for becoming active.	false
16784786.T12.T42	Xanthine dehydrogenase and @CHEMICAL$, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their @GENE$-site for becoming active.	false
16784786.T12.T43	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEMICAL$ and nitrate reductase, require the post-translational sulfuration of their @GENE$-site for becoming active.	false
16784786.T8.T44	@CHEMICAL$ dehydrogenase and aldehyde oxidase, but not sulfite oxidase and @GENE$, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T8.T41	@CHEM-GENE$ and aldehyde oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T8.T42	@CHEMICAL$ dehydrogenase and @GENE$, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T8.T43	@CHEMICAL$ dehydrogenase and aldehyde oxidase, but not @GENE$ and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T9.T44	Xanthine dehydrogenase and @CHEMICAL$ oxidase, but not sulfite oxidase and @GENE$, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T9.T41	@CHEMICAL$ and @GENE$ oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T9.T42	Xanthine dehydrogenase and @CHEM-GENE$, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T9.T43	Xanthine dehydrogenase and @CHEMICAL$ oxidase, but not @GENE$ and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	false
16784786.T14.T46	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes @CHEMICAL$ from l-cysteine in a pyridoxal phosphate-dependent manner as typical for @GENE$.	false
16784786.T14.T45	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes @GENE$ from l-cysteine in a pyridoxal phosphate-dependent manner as typical for cysteine desulfurases.	false
16784786.T15.T46	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from @CHEMICAL$ in a pyridoxal phosphate-dependent manner as typical for @GENE$.	false
16784786.T15.T45	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes sulfur from @GENE$ in a pyridoxal phosphate-dependent manner as typical for cysteine desulfurases.	false
16784786.T16.T46	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from l-cysteine in a @CHEMICAL$-dependent manner as typical for @GENE$.	false
16784786.T16.T45	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes sulfur from l-cysteine in a @GENE$-dependent manner as typical for cysteine desulfurases.	false
16784786.T18.T46	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from l-cysteine in a pyridoxal phosphate-dependent manner as typical for @CHEM-GENE$.	false
16784786.T18.T45	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes sulfur from l-cysteine in a pyridoxal phosphate-dependent manner as typical for @GENE$ desulfurases.	false
16819260.T1.T12	@CHEMICAL$ is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and @GENE$), members of nuclear hormone receptor superfamily.	false
16819260.T1.T13	@CHEMICAL$ is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of @GENE$ superfamily.	CPR:3
16819260.T1.T19	@CHEMICAL$ is a collective term for compounds which bind to and activate @GENE$ (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.	CPR:3
16819260.T1.T20	@CHEMICAL$ is a collective term for compounds which bind to and activate retinoic acid receptors (@GENE$ and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.	false
16819260.T3.T14	The most important endogeneous @CHEMICAL$ is all-trans-retinoic acid (ATRA) which is an @GENE$ ligand.	false
16819260.T4.T14	The most important endogeneous retinoid is @CHEMICAL$ (ATRA) which is an @GENE$ ligand.	false
16819260.T5.T14	The most important endogeneous retinoid is all-trans-retinoic acid (@CHEMICAL$) which is an @GENE$ ligand.	false
16819260.T7.T18	Among them, @CHEMICAL$ (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and @GENE$-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T7.T15	Among them, @CHEMICAL$ (Am80) is an @GENE$- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T7.T16	Among them, @CHEMICAL$ (Am80) is an RARalpha- and @GENE$-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T7.T17	Among them, @CHEMICAL$ (Am80) is an RARalpha- and RARbeta-specific (but @GENE$- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T8.T18	Among them, tamibarotene (@CHEMICAL$) is an RARalpha- and RARbeta-specific (but RARgamma- and @GENE$-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T8.T15	Among them, tamibarotene (@CHEMICAL$) is an @GENE$- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T8.T16	Among them, tamibarotene (@CHEMICAL$) is an RARalpha- and @GENE$-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T8.T17	Among them, tamibarotene (@CHEMICAL$) is an RARalpha- and RARbeta-specific (but @GENE$- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T9.T18	Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and @CHEMICAL$-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T9.T15	Among them, tamibarotene (Am80) is an @CHEMICAL$- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T9.T16	Among them, tamibarotene (Am80) is an RARalpha- and @CHEMICAL$-specific (but RARgamma- and RXRs-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.	false
16819260.T9.T17	Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but @CHEMICAL$- and RXRs-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.	false
16828882.T11.T30	@CHEMICAL$ regulates non-neuronal cholinergic activity in T lymphocytes via @GENE$-mediated pathways.	false
16828882.T3.T15	We previously showed that @CHEMICAL$ stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in @GENE$ (ACh) synthesis and choline acetyltransferase (ChAT) mRNA expression.	false
16828882.T3.T16	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via @CHEMICAL$-mediated pathways, as evidenced by increases in @GENE$ (ACh) synthesis and choline acetyltransferase (ChAT) mRNA expression.	false
16828882.T3.T17	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in @CHEMICAL$ (ACh) synthesis and @GENE$ (ChAT) mRNA expression.	false
16828882.T3.T18	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in @CHEMICAL$ (ACh) synthesis and choline acetyltransferase (@GENE$) mRNA expression.	false
16828882.T4.T15	We previously showed that @CHEMICAL$ stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (@GENE$) synthesis and choline acetyltransferase (ChAT) mRNA expression.	false
16828882.T4.T16	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via @CHEMICAL$-mediated pathways, as evidenced by increases in acetylcholine (@GENE$) synthesis and choline acetyltransferase (ChAT) mRNA expression.	false
16828882.T4.T17	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (@CHEMICAL$) synthesis and @GENE$ (ChAT) mRNA expression.	false
16828882.T4.T18	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (@CHEMICAL$) synthesis and choline acetyltransferase (@GENE$) mRNA expression.	false
16828882.T5.T20	The @CHEMICAL$-lowering drug simvastatin inhibits @GENE$ signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.	false
16828882.T5.T22	The @CHEMICAL$-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on @GENE$ (LFA-1 alpha chain), which leads to immunomodulation.	false
16828882.T5.T23	The @CHEMICAL$-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (@GENE$), which leads to immunomodulation.	false
16828882.T6.T20	The cholesterol-lowering drug @CHEMICAL$ inhibits @GENE$ signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.	CPR:4
16828882.T6.T22	The cholesterol-lowering drug @CHEMICAL$ inhibits LFA-1 signaling by binding to an allosteric site on @GENE$ (LFA-1 alpha chain), which leads to immunomodulation.	false
16828882.T6.T23	The cholesterol-lowering drug @CHEMICAL$ inhibits LFA-1 signaling by binding to an allosteric site on CD11a (@GENE$), which leads to immunomodulation.	false
16828882.T8.T25	We found that anti-@CHEMICAL$ monoclonal antibody (mAb) increased ChAT activity, @GENE$ synthesis and release, and expression of ChAT and M5 muscarinic ACh receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T8.T26	We found that anti-CD11a monoclonal antibody (mAb) increased @CHEMICAL$ activity, @GENE$ synthesis and release, and expression of ChAT and M5 muscarinic ACh receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T8.T27	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, @CHEMICAL$ synthesis and release, and expression of @GENE$ and M5 muscarinic ACh receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T8.T28	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and @GENE$ mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T9.T25	We found that anti-@CHEMICAL$ monoclonal antibody (mAb) increased ChAT activity, ACh synthesis and release, and expression of ChAT and M5 muscarinic @GENE$ receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T9.T26	We found that anti-CD11a monoclonal antibody (mAb) increased @CHEMICAL$ activity, ACh synthesis and release, and expression of ChAT and M5 muscarinic @GENE$ receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T9.T27	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, ACh synthesis and release, and expression of @CHEMICAL$ and M5 muscarinic @GENE$ receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T9.T28	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, ACh synthesis and release, and expression of ChAT and @CHEM-GENE$ mRNA in MOLT-3 cells, a human leukemic T cell line.	false
16828882.T10.T29	@CHEMICAL$ abolished these anti-@GENE$ mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.	CPR:4
16828882.T1.T29	Simvastatin abolished these anti-@CHEMICAL$ mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its @GENE$-lowering activity.	false
16828882.T2.T13	These results indicate that @CHEMICAL$ contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways, and suggest that @GENE$ exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	false
16828882.T2.T14	These results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via @CHEMICAL$-mediated pathways, and suggest that @GENE$ exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	false
16829128.T1.T11	@CHEMICAL$, popularly known for its cooling effect, activates TRPM8--a cold-activated @GENE$.	CPR:3
16829128.T1.T10	@CHEMICAL$, popularly known for its cooling effect, activates @GENE$--a cold-activated thermoTRP ion channel.	CPR:3
16829128.T2.T12	However, human physiological studies demonstrate a paradoxical role of @CHEMICAL$ in modulation of warm sensation, and here, we show that menthol also activates heat-activated @GENE$.	false
16829128.T3.T12	However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that @CHEMICAL$ also activates heat-activated @GENE$.	CPR:3
16829128.T4.T13	We further show that @CHEMICAL$ inhibits @GENE$, potentially explaining the use of menthol as an analgesic.	CPR:4
16829128.T5.T13	We further show that menthol inhibits @CHEMICAL$, potentially explaining the use of @GENE$ as an analgesic.	false
16829128.T6.T16	Similar to @CHEMICAL$, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other @GENE$.	false
16829128.T6.T14	Similar to @CHEMICAL$, both camphor and cinnamaldehyde (initially reported to be specific activators of @GENE$ and TRPA1, respectively) also modulate other thermoTRPs.	CPR:3
16829128.T6.T15	Similar to @CHEMICAL$, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and @GENE$, respectively) also modulate other thermoTRPs.	CPR:3
16829128.T7.T16	Similar to menthol, both @CHEMICAL$ and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other @GENE$.	false
16829128.T7.T14	Similar to menthol, both @CHEMICAL$ and cinnamaldehyde (initially reported to be specific activators of @GENE$ and TRPA1, respectively) also modulate other thermoTRPs.	CPR:3
16829128.T7.T15	Similar to menthol, both @CHEMICAL$ and cinnamaldehyde (initially reported to be specific activators of TRPV3 and @GENE$, respectively) also modulate other thermoTRPs.	CPR:3
16829128.T8.T16	Similar to menthol, both camphor and @CHEMICAL$ (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other @GENE$.	false
16829128.T8.T14	Similar to menthol, both camphor and @CHEMICAL$ (initially reported to be specific activators of @GENE$ and TRPA1, respectively) also modulate other thermoTRPs.	CPR:3
16829128.T8.T15	Similar to menthol, both camphor and @CHEMICAL$ (initially reported to be specific activators of TRPV3 and @GENE$, respectively) also modulate other thermoTRPs.	CPR:3
16854582.T3.T23	These PCSCs possessed @CHEM-GENE$ and KGFR, but not androgen receptor as determined by RT-PCR and Western blot, respectively.	false
16854582.T3.T25	These PCSCs possessed @CHEMICAL$ receptors and @GENE$, but not androgen receptor as determined by RT-PCR and Western blot, respectively.	false
16854582.T3.T26	These PCSCs possessed @CHEMICAL$ receptors and KGFR, but not @GENE$ as determined by RT-PCR and Western blot, respectively.	false
16854582.T4.T23	These PCSCs possessed @CHEMICAL$ and KGFR, but not @GENE$ receptor as determined by RT-PCR and Western blot, respectively.	false
16854582.T4.T25	These PCSCs possessed estrogen receptors and @CHEMICAL$, but not @GENE$ receptor as determined by RT-PCR and Western blot, respectively.	false
16854582.T4.T26	These PCSCs possessed estrogen receptors and KGFR, but not @CHEM-GENE$ as determined by RT-PCR and Western blot, respectively.	false
16854582.T1.T13	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and @GENE$ expression.	false
16854582.T1.T10	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, @GENE$ prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	false
16854582.T1.T11	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated @GENE$ triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	false
16854582.T1.T12	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating @GENE$ and phospho-Akt expression.	false
16854582.T2.T13	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and @GENE$ expression.	false
16854582.T2.T10	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, @GENE$ prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	false
16854582.T2.T11	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated @GENE$ triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	false
16854582.T2.T12	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating @GENE$ and phospho-Akt expression.	false
16855093.T16.T27	The glutamate-aspartate transporter @CHEMICAL$ mediates @GENE$ uptake at inner hair cell afferent synapses in the mammalian cochlea.	CPR:9
16855093.T16.T28	The @CHEMICAL$ GLAST mediates @GENE$ uptake at inner hair cell afferent synapses in the mammalian cochlea.	CPR:9
16855093.T8.T20	Focal application of the transporter substrate @CHEMICAL$ elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated @GENE$ and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate.	false
16855093.T9.T20	Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated @CHEMICAL$ and blocked by the transporter antagonist @GENE$.	CPR:6
16855093.T10.T21	These currents were produced by @CHEM-GENE$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T10.T22	These currents were produced by @CHEMICAL$-aspartate transporters (@GENE$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T10.T23	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (@GENE$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T10.T24	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T10.T25	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T10.T26	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.	false
16855093.T11.T21	These currents were produced by @CHEM-GENE$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T11.T22	These currents were produced by glutamate-@CHEMICAL$ transporters (@GENE$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T11.T23	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (@GENE$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T11.T24	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T11.T25	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T11.T26	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.	false
16855093.T12.T21	These currents were produced by @CHEMICAL$ (GLAST) (excitatory @GENE$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T12.T22	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory @GENE$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T12.T23	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEM-GENE$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T12.T24	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory @CHEMICAL$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T12.T25	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory @CHEMICAL$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T12.T26	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory @CHEMICAL$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.	false
16855093.T13.T21	These currents were produced by @CHEMICAL$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @GENE$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	CPR:4
16855093.T13.T22	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory amino acid transporter 1) because they were weakly inhibited by @GENE$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	CPR:4
16855093.T13.T23	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEMICAL$) because they were weakly inhibited by @GENE$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	CPR:4
16855093.T13.T24	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @CHEMICAL$, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	CPR:6
16855093.T13.T25	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @CHEMICAL$, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.	CPR:6
16855093.T13.T26	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @CHEMICAL$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.	false
16855093.T14.T21	These currents were produced by @CHEMICAL$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T14.T22	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T14.T23	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEMICAL$) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T14.T24	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEM-GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T14.T25	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEMICAL$ transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T14.T26	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEMICAL$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.	false
16855093.T15.T21	These currents were produced by @CHEMICAL$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T15.T22	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T15.T23	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEMICAL$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T15.T24	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEMICAL$ (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T15.T25	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@CHEM-GENE$) and were absent from IPCs in GLAST-/- cochleas.	false
16855093.T15.T26	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @CHEMICAL$ transporter 2) and were absent from IPCs in @GENE$-/- cochleas.	false
16855093.T1.T17	Furthermore, @CHEMICAL$-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of @GENE$, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	false
16855093.T1.T18	Furthermore, @CHEMICAL$-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of GLAST, and examination of cochlea from @GENE$-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	false
16855093.T2.T17	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by @CHEMICAL$, a prominent feature of @GENE$, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	CPR:9
16855093.T2.T18	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by @CHEMICAL$, a prominent feature of GLAST, and examination of cochlea from @GENE$-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	false
1687367.T19.T27	The @CHEMICAL$ blocking activities of @GENE$ and its RR-SR (50:50) stereoisomers. 1.	false
1687367.T17.T25	We compared the @CHEMICAL$ blocking potencies of @GENE$ with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart.	false
1687367.T12.T26	@CHEMICAL$ 4 and 20 micrograms kg-1 body wt. and propranolol 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at @GENE$, respectively.	false
1687367.T13.T26	Prazosin 4 and 20 micrograms kg-1 body wt. and @CHEMICAL$ 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at @GENE$, respectively.	false
1687367.T2.T20	Following both oral and intravenous dosing, the RR-SR combination was twice potent as @CHEMICAL$ in terms of @GENE$ antagonism at equivalent doses.	false
1687367.T3.T21	@CHEMICAL$ and the enantiomers lacked affinity at @GENE$ while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol.	false
1687367.T3.T22	@CHEMICAL$ and the enantiomers lacked affinity at alpha 2-adrenoceptors while at @GENE$ the order of potency was prazosin much greater than RR-SR greater than labetalol.	false
1687367.T4.T21	Labetalol and the enantiomers lacked affinity at @CHEMICAL$ while at alpha 1-adrenoceptors the order of potency was @GENE$ much greater than RR-SR greater than labetalol.	false
1687367.T4.T22	Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at @CHEMICAL$ the order of potency was @GENE$ much greater than RR-SR greater than labetalol.	false
1687367.T5.T21	Labetalol and the enantiomers lacked affinity at @CHEMICAL$ while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than @GENE$.	false
1687367.T5.T22	Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at @CHEMICAL$ the order of potency was prazosin much greater than RR-SR greater than @GENE$.	false
1687367.T6.T23	At @CHEMICAL$, the affinity of the compound RR-SR was about 3 times that of @GENE$.5.	false
1687367.T7.T24	As @CHEMICAL$ is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of @GENE$ actions), the combination of RR and SR may be a valuable substitute for labetalol in the treatment of systemic hypertension.	false
1687367.T8.T24	As labetalol is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of @CHEMICAL$ actions), the combination of RR and SR may be a valuable substitute for @GENE$ in the treatment of systemic hypertension.	false
16874462.T10.T26	Overexpression of @CHEM-GENE$ induces proline-dependent and mitochondria-mediated apoptosis.	false
16874462.T11.T26	Overexpression of @CHEMICAL$ induces @GENE$-dependent and mitochondria-mediated apoptosis.	CPR:9
16874462.T1.T12	@CHEM-GENE$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).	false
16874462.T1.T14	@CHEMICAL$ oxidase (@GENE$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).	false
16874462.T3.T12	@CHEMICAL$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of @GENE$ to pyrroline- 5-carboxylate (P5C).	CPR:9
16874462.T3.T14	Proline oxidase (@CHEMICAL$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of @GENE$ to pyrroline- 5-carboxylate (P5C).	CPR:9
16874462.T4.T12	@CHEMICAL$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to @GENE$ (P5C).	CPR:9
16874462.T4.T14	Proline oxidase (@CHEMICAL$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to @GENE$ (P5C).	CPR:9
16874462.T5.T12	@CHEMICAL$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (@GENE$).	CPR:9
16874462.T5.T14	Proline oxidase (@CHEMICAL$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (@GENE$).	CPR:9
16874462.T6.T15	Previously we showed that overexpression of @CHEMICAL$ is associated with generation of reactive @GENE$ species (ROS) and apoptosis in POX-inducible colorectal cancer cells, DLD-1.POX.	false
16874462.T6.T16	Previously we showed that overexpression of POX is associated with generation of reactive @CHEMICAL$ species (ROS) and apoptosis in @GENE$-inducible colorectal cancer cells, DLD-1.POX.	false
16874462.T6.T17	Previously we showed that overexpression of POX is associated with generation of reactive @CHEMICAL$ species (ROS) and apoptosis in POX-inducible colorectal cancer cells, DLD-1.@GENE$.	false
16874462.T7.T20	To further investigate the molecular basis of @CHEMICAL$-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an @GENE$-dependent apoptotic response.	false
16874462.T7.T21	To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.@CHEMICAL$ cells to show that cells overproducing POX exhibit an @GENE$-dependent apoptotic response.	false
16874462.T7.T22	To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing @CHEMICAL$ exhibit an @GENE$-dependent apoptotic response.	CPR:9
16874462.T8.T23	The apoptotic effect is specific for @CHEMICAL$, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced @GENE$.	false
16874462.T9.T23	The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of @CHEMICAL$ to cells with maximally induced @GENE$.	CPR:9
16874462.T2.T13	We conclude that in the presence of @CHEMICAL$, high @GENE$ activity is sufficient to induce mitochondria-mediated apoptosis.	CPR:9
16893531.T22.T33	The effects of @CHEM-GENE$ inactivation on locomotor activity in mice.	false
16893531.T13.T30	Because @CHEMICAL$ is an important regulator of spontaneous locomotor activity, we speculated that @GENE$ blockade contributes to the effects of some antidepressants on spontaneous locomotor activity.	false
16893531.T14.T30	Because norepinephrine is an important regulator of spontaneous locomotor activity, we speculated that @CHEM-GENE$ blockade contributes to the effects of some antidepressants on spontaneous locomotor activity.	false
16893531.T15.T31	METHODS: Antidepressant drugs (@CHEMICAL$, desipramine, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	false
16893531.T16.T31	METHODS: Antidepressant drugs (reboxetine, @CHEMICAL$, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	false
16893531.T17.T31	METHODS: Antidepressant drugs (reboxetine, desipramine, @CHEMICAL$, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	false
16893531.T18.T31	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, @CHEMICAL$, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	false
16893531.T19.T31	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, @CHEMICAL$) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	false
16893531.T20.T31	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @CHEM-GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	false
16893531.T21.T32	RESULTS: Acute treatment with most @CHEM-GENE$-blocking antidepressants decreased spontaneous locomotor activity in a novel environment, whereas chronic treatment decreased spontaneous locomotor activity in both novel and familiar environments.	false
16893531.T1.T23	The exception was @CHEMICAL$, a dual @GENE$/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.	CPR:4
16893531.T1.T24	The exception was @CHEMICAL$, a dual norepinephrine transporter/@GENE$ blocker, which tended to increase spontaneous locomotor activity.	CPR:4
16893531.T2.T23	The exception was bupropion, a dual @CHEM-GENE$/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.	false
16893531.T2.T24	The exception was bupropion, a dual @CHEMICAL$ transporter/@GENE$ blocker, which tended to increase spontaneous locomotor activity.	false
16893531.T3.T23	The exception was bupropion, a dual @CHEMICAL$/@GENE$ transporter blocker, which tended to increase spontaneous locomotor activity.	false
16893531.T3.T24	The exception was bupropion, a dual norepinephrine transporter/@CHEM-GENE$ blocker, which tended to increase spontaneous locomotor activity.	false
16893531.T4.T25	Coadministration of @CHEMICAL$ and the @GENE$ blocker GBR 12909 also increased spontaneous locomotor activity.	false
16893531.T5.T25	Coadministration of reboxetine and the @CHEM-GENE$ blocker GBR 12909 also increased spontaneous locomotor activity.	false
16893531.T6.T25	Coadministration of reboxetine and the @CHEMICAL$ blocker @GENE$ also increased spontaneous locomotor activity.	CPR:4
16893531.T10.T26	@CHEMICAL$ knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in @GENE$ transporter knockout mice.	false
16893531.T10.T27	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in @CHEM-GENE$ knockout mice.	false
16893531.T7.T26	@CHEM-GENE$ knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in norepinephrine transporter knockout mice.	false
16893531.T7.T27	@CHEMICAL$ transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in @GENE$ knockout mice.	false
16893531.T8.T26	@CHEMICAL$ knockout mice had low basal spontaneous locomotor activity, which was increased by @GENE$, whereas reboxetine had no effect in norepinephrine transporter knockout mice.	false
16893531.T8.T27	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by @CHEMICAL$, whereas reboxetine had no effect in @GENE$ knockout mice.	false
16893531.T9.T26	@CHEMICAL$ knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas @GENE$ had no effect in norepinephrine transporter knockout mice.	false
16893531.T9.T27	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas @CHEMICAL$ had no effect in @GENE$ knockout mice.	false
16893531.T11.T28	CONCLUSIONS: Acute or chronic inactivation of the @CHEM-GENE$ decreases spontaneous locomotor activity in novel and familiar environments unless coupled with dopamine transporter blockade.	false
16893531.T11.T29	CONCLUSIONS: Acute or chronic inactivation of the @CHEMICAL$ transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with @GENE$ blockade.	false
16893531.T12.T28	CONCLUSIONS: Acute or chronic inactivation of the @CHEMICAL$ decreases spontaneous locomotor activity in novel and familiar environments unless coupled with @GENE$ transporter blockade.	false
16893531.T12.T29	CONCLUSIONS: Acute or chronic inactivation of the norepinephrine transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with @CHEM-GENE$ blockade.	false
16917142.T20.T33	Treatment of Postmenopausal Breast Cancer with Selective @CHEM-GENE$ Modulators (SERMs).	false
16917142.T10.T22	Endocrine therapy that targets the @CHEMICAL$ receptor (ER) is a standard of care for the treatment of postmenopausal women with @GENE$-positive breast cancer.	false
16917142.T10.T29	Endocrine therapy that targets the @CHEM-GENE$ (ER) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer.	false
16917142.T10.T32	Endocrine therapy that targets the @CHEMICAL$ receptor (@GENE$) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer.	false
16917142.T9.T26	The selective @CHEMICAL$ modulator (SERM) @GENE$ has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of ER-positive disease.	false
16917142.T9.T28	The selective ER modulator (SERM) @CHEMICAL$ has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of @GENE$-positive disease.	false
16917142.T11.T30	@CHEMICAL$ blocks the action of estrogen by binding to the @GENE$, and possesses both ER-agonist and antagonist properties.	false
16917142.T11.T31	@CHEMICAL$ blocks the action of estrogen by binding to the ER, and possesses both @GENE$-agonist and antagonist properties.	CPR:6
16917142.T11.T31	@CHEMICAL$ blocks the action of estrogen by binding to the ER, and possesses both @GENE$-agonist and antagonist properties.	CPR:5
16917142.T12.T30	Tamoxifen blocks the action of @CHEMICAL$ by binding to the @GENE$, and possesses both ER-agonist and antagonist properties.	false
16917142.T12.T31	Tamoxifen blocks the action of @CHEMICAL$ by binding to the ER, and possesses both @GENE$-agonist and antagonist properties.	false
16917142.T3.T21	"The subsequent development of the @CHEMICAL$ inhibitors (AIs) is an important therapeutic advance by creating a ""no @GENE$"" environment."	false
16917142.T4.T23	@CHEMICAL$ is a novel @GENE$ antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.	CPR:6
16917142.T4.T24	@CHEMICAL$ is a novel ER antagonist that destroys the @GENE$ and its signaling pathway and is not associated with tamoxifen-like agonist effects.	CPR:4
16917142.T5.T23	Fulvestrant is a novel @CHEMICAL$ antagonist that destroys the ER and its signaling pathway and is not associated with @GENE$-like agonist effects.	false
16917142.T5.T24	Fulvestrant is a novel ER antagonist that destroys the @CHEMICAL$ and its signaling pathway and is not associated with @GENE$-like agonist effects.	false
16917142.T6.T25	It produces high response rates compared with other SERMs and is not cross-resistant to @CHEMICAL$ or @GENE$ inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy.	false
16917142.T7.T25	It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or @CHEMICAL$ inhibitors and is equally as effective as the AI @GENE$ in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy.	false
16917142.T8.T25	It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or @CHEMICAL$ inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant @GENE$ therapy.	false
16926278.T21.T61	A 46-amino acid segment in phosphodiesterase-5 @CHEMICAL$ provides for high vardenafil potency over @GENE$ and tadalafil and is involved in phosphodiesterase-5 dimerization.	false
16926278.T21.T59	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over @CHEMICAL$ and tadalafil and is involved in @GENE$ dimerization.	false
16926278.T21.T60	A 46-amino acid segment in @CHEMICAL$ GAF-B domain provides for high vardenafil potency over @GENE$ and tadalafil and is involved in phosphodiesterase-5 dimerization.	false
16926278.T22.T61	A 46-amino acid segment in phosphodiesterase-5 @CHEMICAL$ provides for high vardenafil potency over sildenafil and @GENE$ and is involved in phosphodiesterase-5 dimerization.	false
16926278.T22.T59	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and @CHEMICAL$ and is involved in @GENE$ dimerization.	false
16926278.T22.T60	A 46-amino acid segment in @CHEMICAL$ GAF-B domain provides for high vardenafil potency over sildenafil and @GENE$ and is involved in phosphodiesterase-5 dimerization.	false
16926278.T23.T61	A 46-@CHEMICAL$ segment in phosphodiesterase-5 @GENE$ provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.	false
16926278.T23.T59	A 46-@CHEMICAL$ segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in @GENE$ dimerization.	false
16926278.T23.T60	A 46-@CHEMICAL$ segment in @GENE$ GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.	false
16926278.T24.T61	A 46-amino acid segment in phosphodiesterase-5 @CHEMICAL$ provides for high @GENE$ potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.	false
16926278.T24.T59	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high @CHEMICAL$ potency over sildenafil and tadalafil and is involved in @GENE$ dimerization.	false
16926278.T24.T60	A 46-amino acid segment in @CHEMICAL$ GAF-B domain provides for high @GENE$ potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.	false
16926278.T13.T32	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two @CHEMICAL$, Anabaena @GENE$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T13.T41	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, Escherichia coli FhlAs @GENE$ and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T13.T42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$ (cNPKs).	false
16926278.T13.T43	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (@GENE$).	false
16926278.T13.T25	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @GENE$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T13.T38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, @CHEM-GENE$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T13.T39	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, @GENE$ (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T13.T40	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @GENE$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T14.T32	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two @CHEMICAL$, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).	false
16926278.T14.T41	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs @CHEMICAL$ and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).	false
16926278.T14.T42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @CHEM-GENE$ (cNPKs).	false
16926278.T14.T43	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @CHEMICAL$-dependent protein kinases (@GENE$).	false
16926278.T14.T25	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).	false
16926278.T14.T38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, @CHEMICAL$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).	false
16926278.T14.T39	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, @CHEMICAL$ (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).	false
16926278.T14.T40	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).	false
16926278.T19.T32	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two @GENE$, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T19.T41	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs @GENE$ and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T19.T42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$ (cNPKs).	false
16926278.T19.T43	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (@GENE$).	false
16926278.T19.T25	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes @GENE$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	CPR:9
16926278.T19.T38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, @GENE$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T19.T39	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, @GENE$ (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T19.T40	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes @GENE$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	CPR:9
16926278.T9.T32	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two @CHEM-GENE$, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T9.T41	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs @GENE$ and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T9.T42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$ (cNPKs).	false
16926278.T9.T43	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (@GENE$).	false
16926278.T9.T25	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @GENE$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T9.T38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, @GENE$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T9.T39	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, @GENE$ (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T9.T40	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @GENE$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	false
16926278.T15.T44	Binding of @CHEMICAL$ to @GENE$ increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.	false
16926278.T15.T45	Binding of @CHEMICAL$ to GAF-A increases @GENE$ phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.	CPR:3
16926278.T15.T46	Binding of @CHEMICAL$ to GAF-A increases cNPK phosphorylation of @GENE$ and improves catalytic site affinity for cGMP or inhibitors.	CPR:3
16926278.T16.T44	Binding of cGMP to @CHEMICAL$ increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for @GENE$ or inhibitors.	false
16926278.T16.T45	Binding of cGMP to GAF-A increases @CHEMICAL$ phosphorylation of PDE5 and improves catalytic site affinity for @GENE$ or inhibitors.	false
16926278.T16.T46	Binding of cGMP to GAF-A increases cNPK phosphorylation of @CHEMICAL$ and improves catalytic site affinity for @GENE$ or inhibitors.	false
16926278.T17.T47	@CHEMICAL$ contributes to dimerization of PDE5, inhibition of @GENE$ binding to GAF-A, and sequestration of the phosphorylation site.	false
16926278.T17.T49	GAF-B contributes to dimerization of PDE5, inhibition of @CHEMICAL$ binding to @GENE$, and sequestration of the phosphorylation site.	false
16926278.T17.T48	GAF-B contributes to dimerization of @CHEMICAL$, inhibition of @GENE$ binding to GAF-A, and sequestration of the phosphorylation site.	false
16926278.T18.T50	To probe potential @CHEMICAL$ effects on catalytic site affinity for certain inhibitors, four @GENE$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T52	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained @GENE$, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T53	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between @GENE$; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T55	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained @GENE$; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T57	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of @GENE$; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T51	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: @GENE$ contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T54	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; @GENE$ contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T56	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; @GENE$ contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T18.T58	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and @GENE$ contained only C domain.	false
16926278.T20.T50	To probe potential @CHEMICAL$ effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T52	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained @CHEMICAL$, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T53	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between @CHEMICAL$; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T55	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained @CHEMICAL$; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T57	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @CHEMICAL$-terminal portion of @GENE$; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T51	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: @CHEMICAL$ contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T54	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; @CHEMICAL$ contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T56	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; @CHEMICAL$ contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	false
16926278.T20.T58	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @CHEMICAL$-terminal portion of GAF-B; and @GENE$ contained only C domain.	false
16926278.T1.T26	Truncated proteins with a complete @CHEMICAL$ were dimers, but those lacking the @GENE$-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.	false
16926278.T1.T27	Truncated proteins with a complete GAF-B were dimers, but those lacking the @CHEMICAL$-terminal 46 amino acids of @GENE$ were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.	false
16926278.T1.T28	Truncated proteins with a complete GAF-B were dimers, but those lacking the @CHEMICAL$-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for @GENE$-mediated PDE5 dimerization.	false
16926278.T1.T29	Truncated proteins with a complete GAF-B were dimers, but those lacking the @CHEMICAL$-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated @GENE$ dimerization.	false
16926278.T2.T26	Truncated proteins with a complete @CHEMICAL$ were dimers, but those lacking the N-terminal 46 @GENE$ of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.	false
16926278.T2.T27	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 @CHEMICAL$ of @GENE$ were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.	false
16926278.T2.T28	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 @CHEMICAL$ of GAF-B were monomers, indicating that these residues are vital for @GENE$-mediated PDE5 dimerization.	false
16926278.T2.T29	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 @CHEMICAL$ of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated @GENE$ dimerization.	false
16926278.T3.T30	K(m) values of the mutants for @CHEMICAL$ were similar to that of full-length @GENE$.	CPR:9
16926278.T10.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the @GENE$-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T10.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @CHEMICAL$. This indicated that the @GENE$-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T10.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the @CHEMICAL$-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.	false
16926278.T10.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the @GENE$-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T11.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 @GENE$ in GAF-B are required for high vardenafil potency.	false
16926278.T11.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @CHEMICAL$. This indicated that the N-terminal 46 @GENE$ in GAF-B are required for high vardenafil potency.	false
16926278.T11.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 @CHEMICAL$ in @GENE$ are required for high vardenafil potency.	false
16926278.T11.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 @GENE$ in GAF-B are required for high vardenafil potency.	false
16926278.T12.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high @GENE$ potency.	false
16926278.T12.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @CHEMICAL$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high @GENE$ potency.	false
16926278.T12.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @CHEMICAL$ are required for high @GENE$ potency.	false
16926278.T12.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high @GENE$ potency.	false
16926278.T4.T33	All PDE5 constructs had similar affinities for @CHEMICAL$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T4.T34	All PDE5 constructs had similar affinities for @CHEMICAL$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T4.T35	All PDE5 constructs had similar affinities for @CHEMICAL$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.	false
16926278.T4.T31	All @CHEMICAL$ constructs had similar affinities for @GENE$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T5.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, @CHEMICAL$, tadalafil, and UK-122764, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T5.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, @CHEMICAL$, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T5.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, @CHEMICAL$, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.	false
16926278.T5.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, @GENE$, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T6.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @CHEMICAL$, and UK-122764, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T6.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @CHEMICAL$, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T6.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @CHEMICAL$, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.	false
16926278.T6.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @GENE$, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T7.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @CHEMICAL$, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T7.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @CHEMICAL$, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T7.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @CHEMICAL$, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.	false
16926278.T7.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @GENE$, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T8.T33	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for @GENE$-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T8.T34	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for @CHEMICAL$-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16926278.T8.T35	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for @CHEMICAL$-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.	false
16926278.T8.T31	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for @GENE$-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.	false
16938288.T11.T37	@CHEMICAL$ downregulates @GENE$ through activation of peroxisome proliferator-activated receptor gamma.	CPR:4
16938288.T11.T38	@CHEMICAL$ downregulates angiotensin II type 1 receptor through activation of @GENE$.	CPR:3
16938288.T3.T19	OBJECTIVE: @CHEMICAL$, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of @GENE$ (PPARgamma).	CPR:5
16938288.T3.T26	OBJECTIVE: @CHEMICAL$, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (@GENE$).	CPR:5
16938288.T3.T28	OBJECTIVE: @CHEMICAL$, an @GENE$ (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).	CPR:6
16938288.T3.T32	OBJECTIVE: @CHEMICAL$, an angiotensin II type 1 receptor (@GENE$) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).	CPR:6
16938288.T8.T27	Since previous studies have demonstrated that @CHEMICAL$ activators suppressed AT1R expression, we examined whether @GENE$ affects AT1R expression in vascular smooth muscle cells.	false
16938288.T8.T29	Since previous studies have demonstrated that PPARgamma activators suppressed @CHEMICAL$ expression, we examined whether @GENE$ affects AT1R expression in vascular smooth muscle cells.	false
16938288.T8.T30	Since previous studies have demonstrated that PPARgamma activators suppressed AT1R expression, we examined whether @CHEMICAL$ affects @GENE$ expression in vascular smooth muscle cells.	false
16938288.T9.T34	RESULTS: @CHEMICAL$ decreased the expression of @GENE$ at the mRNA and protein levels in a dose- and time-dependent manner.	CPR:4
16938288.T10.T35	Decreased @CHEMICAL$ activity with unchanged mRNA stability suggested that @GENE$ suppressed AT1R gene expression at the transcriptional level.	false
16938288.T10.T36	Decreased AT1R promoter activity with unchanged mRNA stability suggested that @CHEMICAL$ suppressed @GENE$ gene expression at the transcriptional level.	CPR:4
16938288.T1.T12	However, the expression of @CHEMICAL$ was not suppressed by other AT1R antagonists such as @GENE$ or olmesartan.	false
16938288.T1.T13	However, the expression of AT1R was not suppressed by other @CHEMICAL$ antagonists such as @GENE$ or olmesartan.	CPR:6
16938288.T2.T12	However, the expression of @CHEMICAL$ was not suppressed by other AT1R antagonists such as candesartan or @GENE$.	false
16938288.T2.T13	However, the expression of AT1R was not suppressed by other @CHEMICAL$ antagonists such as candesartan or @GENE$.	CPR:6
16938288.T4.T14	Since the suppression of @CHEMICAL$ expression was prevented by pretreatment with @GENE$, a PPARgamma antagonist, PPARgamma should have participated in the process.	CPR:3
16938288.T4.T15	Since the suppression of AT1R expression was prevented by pretreatment with @CHEMICAL$, a @GENE$ antagonist, PPARgamma should have participated in the process.	CPR:6
16938288.T4.T16	Since the suppression of AT1R expression was prevented by pretreatment with @CHEMICAL$, a PPARgamma antagonist, @GENE$ should have participated in the process.	false
16938288.T5.T18	The deletion and mutation analysis of the AT1R gene promoter indicated that a @CHEMICAL$ located in the proximal promoter region is responsible for the @GENE$-induced downregulation.	CPR:4
16938288.T5.T17	The deletion and mutation analysis of the @CHEMICAL$ gene promoter indicated that a GC box located in the proximal promoter region is responsible for the @GENE$-induced downregulation.	CPR:4
16938288.T6.T20	CONCLUSION: Our data provides a novel insight into an effect of @CHEMICAL$: telmisartan inhibits @GENE$ gene expression through PPARgamma activation.	false
16938288.T6.T21	CONCLUSION: Our data provides a novel insight into an effect of @CHEMICAL$: telmisartan inhibits AT1R gene expression through @GENE$ activation.	false
16938288.T7.T20	CONCLUSION: Our data provides a novel insight into an effect of telmisartan: @CHEMICAL$ inhibits @GENE$ gene expression through PPARgamma activation.	CPR:4
16938288.T7.T21	CONCLUSION: Our data provides a novel insight into an effect of telmisartan: @CHEMICAL$ inhibits AT1R gene expression through @GENE$ activation.	CPR:3
16957773.T4.T17	Upon differentiation, osteoclasts express @CHEM-GENE$ (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons.	false
16957773.T4.T18	Upon differentiation, osteoclasts express vesicular @CHEMICAL$ transporter 1 (@GENE$), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons.	false
16957773.T5.T17	Upon differentiation, osteoclasts express @CHEMICAL$ (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of @GENE$ in neurons.	CPR:9
16957773.T5.T18	Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (@CHEMICAL$), which is essential for vesicular storage and subsequent exocytosis of @GENE$ in neurons.	CPR:9
16957773.T6.T19	@CHEMICAL$ is localized in transcytotic vesicles and accumulates @GENE$.	CPR:9
16957773.T10.T20	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a @CHEMICAL$-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T11.T20	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. @CHEMICAL$- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T12.T20	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and @CHEMICAL$-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T13.T20	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of @CHEMICAL$ was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T7.T20	Osteoclasts secrete @CHEMICAL$ and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T8.T20	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with @CHEMICAL$ or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T9.T20	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or @CHEMICAL$ in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.	false
16957773.T14.T22	Osteoclasts express mGluR8, a @CHEM-GENE$.	false
16957773.T14.T21	Osteoclasts express @CHEMICAL$, a class III metabotropic @GENE$ receptor.	false
16971132.T4.T12	Synthesis, @CHEMICAL$ inhibition, antitumor testing, and molecular modeling study of some new @GENE$ analogs.	CPR:4
16971132.T5.T12	Synthesis, @CHEM-GENE$ inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.	false
16971132.T1.T7	In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble @CHEMICAL$ (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of @GENE$ activity.	CPR:4
16971132.T2.T7	In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (@CHEMICAL$, 1) structure features and fitted with functional groups believed to enhance inhibition of @GENE$ activity.	CPR:4
16971132.T3.T7	In order to produce potent new leads for anticancer drugs, a new series of @CHEMICAL$ analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of @GENE$ activity.	CPR:4
16973729.T3.T6	@CHEMICAL$ receptor mutant mice consume more food, which leads to late-onset obesity and impaired @GENE$ tolerance.	false
16973729.T1.T7	Administration of @CHEMICAL$ and fenfluramine, both of which induce anorexic effects via @GENE$ receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	false
16973729.T1.T8	Administration of @CHEMICAL$ and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or @GENE$ receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	false
16973729.T2.T7	Administration of m-chlorophenylpiperazine and @CHEMICAL$, both of which induce anorexic effects via @GENE$ receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	false
16973729.T2.T8	Administration of m-chlorophenylpiperazine and @CHEMICAL$, both of which induce anorexic effects via 5-HT2C receptors and/or @GENE$ receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	false
16985933.T1.T6	"When treatment is started, LHRH agonists initially stimulate the release of @CHEMICAL$, causing a surge in serum @GENE$ that can precipitate a ""flare"" phenomenon or worsening of disease, particularly in patients with bone metastatic disease."	false
16985933.T1.T5	"When treatment is started, @CHEMICAL$ agonists initially stimulate the release of LH, causing a surge in serum @GENE$ that can precipitate a ""flare"" phenomenon or worsening of disease, particularly in patients with bone metastatic disease."	false
16985933.T2.T11	Results from 1 phase II and 3 phase III clinical trials demonstrate that abarelix produces medical castration more quickly and without causing @CHEMICAL$ surge, as compared with @GENE$ agonists with or without a nonsteroidal antagonist.	false
16988497.T6.T20	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of delta-6 desaturase (@GENE$) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T6.T23	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of delta-6 desaturase (D6D) and @GENE$ (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T6.T28	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of delta-6 desaturase (D6D) and delta-5 desaturase (@GENE$) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T6.T33	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of @GENE$ (D6D) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T8.T20	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of delta-6 desaturase (@GENE$) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T8.T23	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of delta-6 desaturase (D6D) and @GENE$ (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T8.T28	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of delta-6 desaturase (D6D) and delta-5 desaturase (@GENE$) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T8.T33	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of @GENE$ (D6D) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	false
16988497.T14.T18	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of @CHEMICAL$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC @GENE$ and D5D genes.	CPR:4
16988497.T14.T19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of @CHEMICAL$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and @GENE$ genes.	CPR:4
16988497.T14.T34	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of @GENE$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.	false
16988497.T14.T35	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of @GENE$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.	false
16988497.T15.T18	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (@CHEMICAL$) and alpha-linolenic acid (LNA) and the expression of PBMC @GENE$ and D5D genes.	CPR:4
16988497.T15.T19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (@CHEMICAL$) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and @GENE$ genes.	CPR:4
16988497.T15.T34	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (@GENE$) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.	false
16988497.T15.T35	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of linoleic acid (@GENE$) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.	false
16988497.T16.T18	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @CHEMICAL$ (LNA) and the expression of PBMC @GENE$ and D5D genes.	CPR:4
16988497.T16.T19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @CHEMICAL$ (LNA) and the expression of PBMC D6D and @GENE$ genes.	CPR:4
16988497.T16.T34	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @GENE$ (LNA) and the expression of PBMC D6D and D5D genes.	false
16988497.T16.T35	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @GENE$ (LNA) and the expression of PBMC D6D and D5D genes.	false
16988497.T17.T18	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@CHEMICAL$) and the expression of PBMC @GENE$ and D5D genes.	CPR:4
16988497.T17.T19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@CHEMICAL$) and the expression of PBMC D6D and @GENE$ genes.	CPR:4
16988497.T17.T34	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@GENE$) and the expression of PBMC D6D and D5D genes.	false
16988497.T17.T35	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@GENE$) and the expression of PBMC D6D and D5D genes.	false
16988497.T1.T21	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC @GENE$ and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.	CPR:3
16988497.T1.T22	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC D6D and @GENE$ genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.	CPR:3
16988497.T1.T24	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC @GENE$ and D5D genes.	false
16988497.T1.T25	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and @GENE$ genes.	false
16988497.T2.T21	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC @GENE$ and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.	CPR:3
16988497.T2.T22	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC D6D and @GENE$ genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.	CPR:3
16988497.T2.T24	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC @GENE$ and D5D genes.	false
16988497.T2.T25	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and @GENE$ genes.	false
16988497.T3.T21	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC @CHEMICAL$ and D5D genes, whilst high @GENE$ intake appears to decrease expression of PBMC D6D and D5D genes.	false
16988497.T3.T22	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and @CHEMICAL$ genes, whilst high @GENE$ intake appears to decrease expression of PBMC D6D and D5D genes.	false
16988497.T3.T24	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high @CHEMICAL$ intake appears to decrease expression of PBMC @GENE$ and D5D genes.	CPR:4
16988497.T3.T25	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high @CHEMICAL$ intake appears to decrease expression of PBMC D6D and @GENE$ genes.	CPR:4
16988497.T4.T26	A follow-up study of the expression of @CHEMICAL$ and D5D genes in Chinese who live in European countries with high @GENE$ and MUFA diets would be of interest.	false
16988497.T4.T27	A follow-up study of the expression of D6D and @CHEMICAL$ genes in Chinese who live in European countries with high @GENE$ and MUFA diets would be of interest.	false
16988497.T5.T26	A follow-up study of the expression of @CHEMICAL$ and D5D genes in Chinese who live in European countries with high SFA and @GENE$ diets would be of interest.	false
16988497.T5.T27	A follow-up study of the expression of D6D and @CHEMICAL$ genes in Chinese who live in European countries with high SFA and @GENE$ diets would be of interest.	false
17013809.T9.T15	The evolution of @CHEM-GENE$ ligands.	false
17013809.T1.T12	@CHEMICAL$ is one of the first @GENE$ hormones to be described functionally and subsequently approached as a drug target.	false
17013809.T2.T10	Because @CHEMICAL$ (1) affects both menstruation and gestation via the @GENE$ (PR), research aimed at modulating its activity is usually surrounded by controversy.	false
17013809.T2.T11	Because @CHEMICAL$ (1) affects both menstruation and gestation via the progesterone receptor (@GENE$), research aimed at modulating its activity is usually surrounded by controversy.	false
17013809.T3.T10	Because progesterone (1) affects both menstruation and gestation via the @CHEM-GENE$ (PR), research aimed at modulating its activity is usually surrounded by controversy.	false
17013809.T3.T11	Because progesterone (1) affects both menstruation and gestation via the @CHEMICAL$ receptor (@GENE$), research aimed at modulating its activity is usually surrounded by controversy.	false
17013809.T4.T13	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like @GENE$ that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T4.T14	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like @CHEMICAL$ that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T5.T13	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of @GENE$; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T5.T14	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of @CHEMICAL$; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T6.T13	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like @GENE$ with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T6.T14	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like @CHEMICAL$ with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T7.T13	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from @GENE$ and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T7.T14	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from @CHEMICAL$ and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T8.T13	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-@GENE$ PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17013809.T8.T14	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-@CHEMICAL$ @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	false
17023173.T2.T9	@CHEMICAL$ inhibits @GENE$ and has shown therapeutic effects in patients with hematologic malignancies.	CPR:4
17065601.T14.T23	We investigated the activity and expression of @CHEM-GENE$ in isolated rat Sertoli cells, peritubular cells, pachytene spermatocytes, and early spermatids.	false
17065601.T15.T24	We assessed the @CHEMICAL$ uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of @GENE$, and studied the expression of the genes encoding them by RT-PCR.	false
17065601.T16.T24	We assessed the l-arginine uptake kinetics, @CHEMICAL$ dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of @GENE$, and studied the expression of the genes encoding them by RT-PCR.	false
17065601.T17.T24	We assessed the l-arginine uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral @CHEMICAL$, and sensitivity to trans stimulation of @GENE$, and studied the expression of the genes encoding them by RT-PCR.	false
17065601.T18.T24	We assessed the l-arginine uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of @CHEM-GENE$, and studied the expression of the genes encoding them by RT-PCR.	false
17065601.T19.T25	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (@GENE$/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.	CPR:9
17065601.T19.T26	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/@GENE$) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.	false
17065601.T19.T27	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (@GENE$ and SLC7A2), with system B(0+) making a minor contribution.	false
17065601.T19.T28	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (SLC7A1 and @GENE$), with system B(0+) making a minor contribution.	false
17065601.T2.T29	By contrast, system B(0+), associated with system y(+)L (@CHEMICAL$/SLC7A7 and SLC7A6), made a major contribution to the transport of cationic @GENE$ in pachytene spermatocytes and early spermatids.	false
17065601.T2.T30	By contrast, system B(0+), associated with system y(+)L (SLC3A2/@CHEMICAL$ and SLC7A6), made a major contribution to the transport of cationic @GENE$ in pachytene spermatocytes and early spermatids.	false
17065601.T2.T31	By contrast, system B(0+), associated with system y(+)L (SLC3A2/SLC7A7 and @CHEMICAL$), made a major contribution to the transport of cationic @GENE$ in pachytene spermatocytes and early spermatids.	false
17065601.T10.T21	Furthermore, whereas @CHEMICAL$ induce nitric oxide (@GENE$) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by cytokines was observed in these cells.	false
17065601.T10.T22	Furthermore, whereas cytokines induce nitric oxide (@CHEMICAL$) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by @GENE$ was observed in these cells.	false
17065601.T11.T21	Furthermore, whereas @CHEMICAL$ induce nitric oxide (NO) production in peritubular and Sertoli cells, little or no upregulation of @GENE$ transport by cytokines was observed in these cells.	false
17065601.T11.T22	Furthermore, whereas cytokines induce nitric oxide (NO) production in peritubular and Sertoli cells, little or no upregulation of @CHEMICAL$ transport by @GENE$ was observed in these cells.	false
17065601.T9.T21	Furthermore, whereas @CHEMICAL$ induce @GENE$ (NO) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by cytokines was observed in these cells.	false
17065601.T9.T22	Furthermore, whereas cytokines induce @CHEMICAL$ (NO) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by @GENE$ was observed in these cells.	false
17090056.T27.T33	Transition-state structure of @CHEM-GENE$.	false
17090056.T9.T28	Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of @CHEM-GENE$ (MTAP).	false
17090056.T9.T30	Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human @CHEMICAL$ phosphorylase (@GENE$).	false
17090056.T17.T31	KIEs were measured on the arsenolysis of @CHEMICAL$ (MTA) catalyzed by @GENE$ and were corrected for the forward commitment to catalysis.	CPR:9
17090056.T18.T31	KIEs were measured on the arsenolysis of 5'-methylthioadenosine (@CHEMICAL$) catalyzed by @GENE$ and were corrected for the forward commitment to catalysis.	CPR:9
17090056.T20.T32	The primary intrinsic KIEs (@CHEMICAL$ and 9-(15)N) suggest that @GENE$ has a dissociative S(N)1 transition state with its cationic center at the anomeric carbon and insignificant bond order to the leaving group.	false
17090056.T21.T32	The primary intrinsic KIEs (1'-(14)C and @CHEMICAL$) suggest that @GENE$ has a dissociative S(N)1 transition state with its cationic center at the anomeric carbon and insignificant bond order to the leaving group.	false
17090056.T22.T32	The primary intrinsic KIEs (1'-(14)C and 9-(15)N) suggest that @CHEMICAL$ has a dissociative S(N)1 transition state with its cationic center at the anomeric @GENE$ and insignificant bond order to the leaving group.	false
17090056.T16.T29	@CHEMICAL$ is characterized by a late S(N)1 transition state with significant participation of the @GENE$ nucleophile.	false
17098734.T5.T17	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a @CHEM-GENE$ (Lratb).	false
17098734.T5.T18	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a @CHEMICAL$:retinol acyltransferase (@GENE$).	false
17098734.T6.T17	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a @CHEM-GENE$ (Lratb).	false
17098734.T6.T18	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a leci-thin:@CHEMICAL$ acyltransferase (@GENE$).	false
17098734.T8.T19	During embryogenesis, @CHEMICAL$ is expressed in mostly non-overlapping domains opposite to @GENE$ dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis.	false
17098734.T8.T20	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to @CHEM-GENE$ (raldh2), the key enzyme for retinoic acid synthesis.	false
17098734.T8.T21	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to @CHEMICAL$ dehydrogenase 2 (@GENE$), the key enzyme for retinoic acid synthesis.	false
17098734.T9.T19	During embryogenesis, @CHEMICAL$ is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for @GENE$ synthesis.	false
17098734.T9.T20	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to @CHEMICAL$ (raldh2), the key enzyme for @GENE$ synthesis.	CPR:9
17098734.T9.T21	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (@CHEMICAL$), the key enzyme for @GENE$ synthesis.	CPR:9
17098734.T10.T22	Blocking @CHEMICAL$ formation by a targeted knock down of @GENE$ results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.	CPR:9
17098734.T11.T22	Blocking retinyl ester formation by a targeted knock down of @CHEMICAL$ results in significantly increased @GENE$ levels, which lead to severe embryonic patterning defects.	false
17098734.T12.T23	Thus, we provide evidence that a balanced competition between @CHEMICAL$ and Raldh2 for yolk @GENE$ defines embryonic compartments either for retinyl ester or retinoic acid synthesis.	false
17098734.T12.T24	Thus, we provide evidence that a balanced competition between Lratb and @CHEMICAL$ for yolk @GENE$ defines embryonic compartments either for retinyl ester or retinoic acid synthesis.	false
17098734.T13.T23	Thus, we provide evidence that a balanced competition between @CHEMICAL$ and Raldh2 for yolk vitamin A defines embryonic compartments either for @GENE$ or retinoic acid synthesis.	false
17098734.T13.T24	Thus, we provide evidence that a balanced competition between Lratb and @CHEMICAL$ for yolk vitamin A defines embryonic compartments either for @GENE$ or retinoic acid synthesis.	false
17098734.T14.T23	Thus, we provide evidence that a balanced competition between @CHEMICAL$ and Raldh2 for yolk vitamin A defines embryonic compartments either for retinyl ester or @GENE$ synthesis.	false
17098734.T14.T24	Thus, we provide evidence that a balanced competition between Lratb and @CHEMICAL$ for yolk vitamin A defines embryonic compartments either for retinyl ester or @GENE$ synthesis.	false
17110146.T19.T24	@CHEMICAL$ are a class of cell surface receptors for @GENE$ that prefer ATP or ADP over adenosine.	false
17110146.T20.T24	@CHEMICAL$ are a class of cell surface receptors for purines that prefer @GENE$ or ADP over adenosine.	false
17110146.T21.T24	@CHEMICAL$ are a class of cell surface receptors for purines that prefer ATP or @GENE$ over adenosine.	false
17110146.T23.T24	@CHEMICAL$ are a class of cell surface receptors for purines that prefer ATP or ADP over @GENE$.	false
17110146.T9.T35	The surface receptors for extracellular @CHEMICAL$ are called @GENE$.	false
17110146.T13.T36	@CHEMICAL$ initiates platelet aggregation by 'simultaneous activation of two @GENE$, P2Y1 and P2Y12.	CPR:3
17110146.T13.T37	@CHEMICAL$ initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, @GENE$ and P2Y12.	CPR:3
17110146.T13.T38	@CHEMICAL$ initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and @GENE$.	CPR:3
17110146.T14.T39	@CHEMICAL$ has been shown to be the target of the @GENE$ drugs, ticlopidine and clopidogrel.	false
17110146.T15.T39	@CHEMICAL$ has been shown to be the target of the thienopyridine drugs, @GENE$ and clopidogrel.	false
17110146.T16.T39	@CHEMICAL$ has been shown to be the target of the thienopyridine drugs, ticlopidine and @GENE$.	false
17110146.T17.T40	Here, the active sites of @CHEMICAL$ for @GENE$ as well as ADP are predicted by bioinformatics and molecular modeling.	false
17110146.T18.T40	Here, the active sites of @CHEMICAL$ for ATP as well as @GENE$ are predicted by bioinformatics and molecular modeling.	false
17110146.T1.T26	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEM-GENE$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T1.T27	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (@GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T1.T28	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T1.T29	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T1.T25	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (@GENE$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T2.T26	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (@GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T2.T27	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEM-GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T2.T28	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T2.T29	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T2.T25	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T3.T26	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T3.T27	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T3.T28	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @CHEM-GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T3.T29	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @CHEMICAL$, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T3.T25	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."	false
17110146.T4.T26	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T4.T27	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T4.T28	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @CHEMICAL$, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T4.T29	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@CHEM-GENE$, 222-231)."	false
17110146.T4.T25	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."	false
17110146.T5.T30	Subsequently the structural model of @CHEMICAL$ was docked with @GENE$/ADP in comparison with P2Y1 (PDB code 1ddd).	false
17110146.T5.T31	Subsequently the structural model of P2Y12 was docked with @CHEMICAL$/ADP in comparison with @GENE$ (PDB code 1ddd).	false
17110146.T5.T32	Subsequently the structural model of P2Y12 was docked with @CHEMICAL$/ADP in comparison with P2Y1 (@GENE$).	false
17110146.T6.T30	Subsequently the structural model of @CHEMICAL$ was docked with ATP/@GENE$ in comparison with P2Y1 (PDB code 1ddd).	false
17110146.T6.T31	Subsequently the structural model of P2Y12 was docked with ATP/@CHEMICAL$ in comparison with @GENE$ (PDB code 1ddd).	false
17110146.T6.T32	Subsequently the structural model of P2Y12 was docked with ATP/@CHEMICAL$ in comparison with P2Y1 (@GENE$).	false
17110146.T10.T33	Our results imply that @CHEMICAL$ has the potential to be inhibited by @GENE$/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.	CPR:4
17110146.T10.T34	Our results imply that P2Y12 has the potential to be inhibited by @CHEMICAL$/ATP analogs, and it suggests that @GENE$ acts as a target of new drugs that inhibit platelet aggregation.	false
17110146.T11.T33	Our results imply that @CHEMICAL$ has the potential to be inhibited by ADP/@GENE$ analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.	CPR:4
17110146.T11.T34	Our results imply that P2Y12 has the potential to be inhibited by ADP/@CHEMICAL$ analogs, and it suggests that @GENE$ acts as a target of new drugs that inhibit platelet aggregation.	false
17125913.T13.T43	@CHEMICAL$ induces mitogenic signaling in breast cancer cell by an @GENE$-dependent mechanism.	false
17125913.T6.T18	@CHEMICAL$ (E2) stimulates BC cells proliferation by binding the @GENE$ (ER).	false
17125913.T6.T23	@CHEMICAL$ (E2) stimulates BC cells proliferation by binding the estrogen receptor (@GENE$).	false
17125913.T8.T18	Estradiol (@CHEMICAL$) stimulates BC cells proliferation by binding the @GENE$ (ER).	false
17125913.T8.T23	Estradiol (@CHEMICAL$) stimulates BC cells proliferation by binding the estrogen receptor (@GENE$).	false
17125913.T4.T24	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating @GENE$, Akt and PDGFRalpha kinases.	false
17125913.T4.T25	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating ERK1/2, @GENE$ and PDGFRalpha kinases.	false
17125913.T4.T27	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating ERK1/2, Akt and PDGFRalpha @GENE$.	false
17125913.T4.T26	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating ERK1/2, Akt and @GENE$ kinases.	false
17125913.T5.T28	@CHEMICAL$ increased cell proliferation and the @GENE$-antagonist ICI 182,780 blunted it.	false
17125913.T7.T31	@CHEMICAL$ decreased @GENE$ expression, but not ERbeta.	CPR:4
17125913.T7.T32	@CHEMICAL$ decreased ERalpha expression, but not @GENE$.	false
17125913.T9.T33	@CHEMICAL$ also increased @GENE$, Akt and PDGFRalpha phosphorylation while ICI blocked it.	false
17125913.T9.T34	@CHEMICAL$ also increased ERK1/2, @GENE$ and PDGFRalpha phosphorylation while ICI blocked it.	CPR:3
17125913.T9.T35	@CHEMICAL$ also increased ERK1/2, Akt and @GENE$ phosphorylation while ICI blocked it.	CPR:3
17125913.T10.T39	@CHEMICAL$ rapidly increased @GENE$, c-fos and PDGFA expression.	CPR:3
17125913.T10.T40	@CHEMICAL$ rapidly increased c-jun, @GENE$ and PDGFA expression.	CPR:3
17125913.T10.T41	@CHEMICAL$ rapidly increased c-jun, c-fos and @GENE$ expression.	CPR:3
17125913.T11.T42	Cells were also co-incubated with the @CHEMICAL$ and specific @GENE$ inhibitors, which blocked the Cd-stimulated proliferation.	false
17125913.T12.T42	Cells were also co-incubated with the Cd and specific @CHEMICAL$ inhibitors, which blocked the @GENE$-stimulated proliferation.	false
17125913.T1.T14	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating @GENE$, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	CPR:3
17125913.T1.T15	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, @GENE$ and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	false
17125913.T1.T17	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha @GENE$ activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	CPR:3
17125913.T1.T16	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and @GENE$ kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	CPR:3
17125913.T1.T19	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating @GENE$, c-jun and PDGFA by an ERalpha-dependent mechanism.	CPR:3
17125913.T1.T20	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, @GENE$ and PDGFA by an ERalpha-dependent mechanism.	CPR:3
17125913.T1.T21	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and @GENE$ by an ERalpha-dependent mechanism.	CPR:3
17125913.T1.T22	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an @GENE$-dependent mechanism.	false
17202804.T25.T67	@CHEM-GENE$ functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.	false
17202804.T25.T68	@CHEMICAL$ functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving @GENE$.	false
17202804.T25.T69	@CHEMICAL$ functionally antagonizes testosterone activation of the @GENE$ in prostate cells through focal adhesion complexes involving Hic-5.	CPR:6
17202804.T26.T67	@CHEMICAL$ functionally antagonizes @GENE$ activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.	false
17202804.T26.T68	Gonadotropin-releasing hormone functionally antagonizes @CHEMICAL$ activation of the human androgen receptor in prostate cells through focal adhesion complexes involving @GENE$.	false
17202804.T26.T69	Gonadotropin-releasing hormone functionally antagonizes @CHEMICAL$ activation of the @GENE$ in prostate cells through focal adhesion complexes involving Hic-5.	CPR:3
17202804.T17.T27	@CHEMICAL$ (@GENE$) analogs constitute the most widely employed medical treatment for prostatic cancer.	false
17202804.T17.T54	Gonadotropin-releasing hormone (@CHEM-GENE$) analogs constitute the most widely employed medical treatment for prostatic cancer.	false
17202804.T1.T27	@CHEM-GENE$ (GnRH) analogs constitute the most widely employed medical treatment for prostatic cancer.	false
17202804.T1.T54	@CHEMICAL$ (@GENE$) analogs constitute the most widely employed medical treatment for prostatic cancer.	false
17202804.T16.T53	However, @CHEM-GENE$ analogs have also been shown to directly inhibit prostate cancer cells both in vitro and in vivo through antiproliferative cell cycle arrest and stimulation of apoptosis.	false
17202804.T18.T56	Since the @CHEMICAL$ receptor has been shown to affect @GENE$ function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	false
17202804.T18.T55	Since the @CHEM-GENE$ has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	false
17202804.T18.T57	Since the @CHEMICAL$ receptor has been shown to affect sex steroid hormone receptor function, we considered that part of @GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	false
17202804.T18.T58	Since the @CHEMICAL$ receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the @GENE$.	false
17202804.T19.T56	Since the GnRH receptor has been shown to affect @CHEMICAL$ function, we considered that part of @GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	false
17202804.T19.T55	Since the @CHEMICAL$ has been shown to affect sex steroid hormone receptor function, we considered that part of @GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	false
17202804.T19.T57	Since the GnRH receptor has been shown to affect sex steroid hormone receptor function, we considered that part of @CHEM-GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	false
17202804.T19.T58	Since the GnRH receptor has been shown to affect sex steroid hormone receptor function, we considered that part of @CHEMICAL$ analog actions on prostate cells may be mediated through modulation of the @GENE$.	false
17202804.T20.T59	Using a model HEK293 cell line expressing the @CHEM-GENE$, we demonstrated a novel signalling pathway of the GnRH receptor that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.	false
17202804.T20.T60	Using a model HEK293 cell line expressing the @CHEMICAL$ receptor, we demonstrated a novel signalling pathway of the @GENE$ that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.	false
17202804.T20.T61	Using a model HEK293 cell line expressing the @CHEMICAL$ receptor, we demonstrated a novel signalling pathway of the GnRH receptor that induces nuclear translocation of the @GENE$ that renders it transcriptionally inactive.	false
17202804.T21.T59	Using a model HEK293 cell line expressing the @CHEMICAL$, we demonstrated a novel signalling pathway of the @GENE$ receptor that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.	false
17202804.T21.T60	Using a model HEK293 cell line expressing the GnRH receptor, we demonstrated a novel signalling pathway of the @CHEM-GENE$ that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.	false
17202804.T21.T61	Using a model HEK293 cell line expressing the GnRH receptor, we demonstrated a novel signalling pathway of the @CHEMICAL$ receptor that induces nuclear translocation of the @GENE$ that renders it transcriptionally inactive.	false
17202804.T22.T28	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/@GENE$, Hic-5.	false
17202804.T22.T62	This mechanism involves the @CHEMICAL$-dependent @GENE$ Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T22.T64	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the @GENE$ c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T22.T66	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the @GENE$/steroid receptor co-factor, Hic-5.	false
17202804.T22.T29	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, @GENE$.	false
17202804.T22.T63	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase @GENE$, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T22.T65	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase @GENE$ and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T23.T28	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/@GENE$, Hic-5.	false
17202804.T23.T62	This mechanism involves the calcium-dependent @CHEM-GENE$ Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T23.T64	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the @GENE$ c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T23.T66	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase c-Src and the @GENE$/steroid receptor co-factor, Hic-5.	false
17202804.T23.T29	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, @GENE$.	false
17202804.T23.T63	This mechanism involves the calcium-dependent @CHEMICAL$ kinase @GENE$, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T23.T65	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase @GENE$ and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T24.T28	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase c-Src and the focal adhesion protein/@GENE$, Hic-5.	false
17202804.T24.T62	This mechanism involves the calcium-dependent @CHEMICAL$ Pyk2, the non-receptor @GENE$ kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T24.T64	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the @CHEM-GENE$ c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T24.T66	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase c-Src and the @GENE$/steroid receptor co-factor, Hic-5.	false
17202804.T24.T29	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase c-Src and the focal adhesion protein/steroid receptor co-factor, @GENE$.	false
17202804.T24.T63	This mechanism involves the calcium-dependent tyrosine kinase @CHEMICAL$, the non-receptor @GENE$ kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T24.T65	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase @GENE$ and the focal adhesion protein/steroid receptor co-factor, Hic-5.	false
17202804.T2.T30	In this setting there is a @CHEM-GENE$-induced association and nuclear translocation of the androgen receptor with Hic-5.	false
17202804.T2.T31	In this setting there is a @CHEMICAL$-induced association and nuclear translocation of the @GENE$ with Hic-5.	false
17202804.T2.T32	In this setting there is a @CHEMICAL$-induced association and nuclear translocation of the androgen receptor with @GENE$.	false
17202804.T3.T33	@CHEM-GENE$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T3.T34	@CHEMICAL$-induced @GENE$ activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	CPR:3
17202804.T3.T35	@CHEMICAL$-induced Pyk2 activation opposed the association of @GENE$ with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	CPR:4
17202804.T3.T36	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with @GENE$ as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	CPR:4
17202804.T3.T37	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative @GENE$ enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T3.T38	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T3.T39	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged @GENE$.	false
17202804.T4.T33	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T4.T34	GnRH-induced @CHEMICAL$ activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T4.T35	GnRH-induced Pyk2 activation opposed the association of @CHEMICAL$ with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T4.T36	GnRH-induced Pyk2 activation opposed the association of Hic-5 with @CHEMICAL$ as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T4.T37	GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative @CHEMICAL$ enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T4.T38	GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @CHEM-GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	false
17202804.T4.T39	GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @CHEMICAL$-induced nuclear translocation of a green fluorescent protein-tagged @GENE$.	false
17202804.T5.T40	@CHEM-GENE$-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.	false
17202804.T5.T41	@CHEMICAL$-induced @GENE$ activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.	CPR:3
17202804.T5.T42	@CHEMICAL$-induced c-Src activation resulted in the phosphorylation of expressed @GENE$ and promoted its association with the human androgen receptor.	false
17202804.T5.T43	@CHEMICAL$-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the @GENE$.	false
17202804.T6.T44	In contrast to @CHEMICAL$, @GENE$-induced nuclear translocation did not transcriptionally activate the androgen receptor.	false
17202804.T6.T45	In contrast to @CHEMICAL$, GnRH-induced nuclear translocation did not transcriptionally activate the @GENE$.	CPR:3
17202804.T7.T44	In contrast to testosterone, @CHEM-GENE$-induced nuclear translocation did not transcriptionally activate the androgen receptor.	false
17202804.T7.T45	In contrast to testosterone, @CHEMICAL$-induced nuclear translocation did not transcriptionally activate the @GENE$.	false
17202804.T8.T46	We then demonstrated that @CHEM-GENE$ can also stimulate androgen receptor mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.	false
17202804.T8.T47	We then demonstrated that @CHEMICAL$ can also stimulate @GENE$ mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.	false
17202804.T10.T48	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of @GENE$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T10.T49	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEM-GENE$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T10.T50	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEMICAL$ on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T11.T48	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T11.T49	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEMICAL$ on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T11.T50	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @CHEM-GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T12.T48	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of @GENE$ on prostate cell proliferation and tissue growth.	false
17202804.T12.T49	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEMICAL$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of @GENE$ on prostate cell proliferation and tissue growth.	false
17202804.T12.T50	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @CHEMICAL$ can functionally antagonize the actions of @GENE$ on prostate cell proliferation and tissue growth.	false
17202804.T9.T48	To determine if @CHEM-GENE$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T9.T49	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of @GENE$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T9.T50	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.	false
17202804.T13.T51	This antagonism of @CHEMICAL$ action by @GENE$ may underlie in part the capacity of GnRH receptor activation to inhibit prostate tumor growth.	false
17202804.T13.T52	This antagonism of @CHEMICAL$ action by GnRH may underlie in part the capacity of @GENE$ activation to inhibit prostate tumor growth.	false
17202804.T14.T51	This antagonism of testosterone action by @CHEM-GENE$ may underlie in part the capacity of GnRH receptor activation to inhibit prostate tumor growth.	false
17202804.T14.T52	This antagonism of testosterone action by @CHEMICAL$ may underlie in part the capacity of @GENE$ activation to inhibit prostate tumor growth.	false
17202804.T15.T51	This antagonism of testosterone action by @CHEMICAL$ may underlie in part the capacity of @GENE$ receptor activation to inhibit prostate tumor growth.	false
17202804.T15.T52	This antagonism of testosterone action by GnRH may underlie in part the capacity of @CHEM-GENE$ activation to inhibit prostate tumor growth.	false
17218486.T32.T54	@CHEMICAL$ displays species-dependent stereoselectivity for isomers of methamphetamine, @GENE$, and para-hydroxyamphetamine.	false
17218486.T33.T54	@CHEMICAL$ displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and @GENE$.	false
17218486.T34.T54	@CHEM-GENE$ displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.	false
17218486.T35.T54	@CHEMICAL$ displays species-dependent stereoselectivity for isomers of @GENE$, amphetamine, and para-hydroxyamphetamine.	false
17218486.T11.T47	Recently, it was reported that @CHEMICAL$, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T11.T48	Recently, it was reported that @CHEMICAL$, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T12.T47	Recently, it was reported that METH, @CHEMICAL$, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T12.T48	Recently, it was reported that METH, @CHEMICAL$, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T13.T47	Recently, it was reported that METH, AMPH, @CHEMICAL$, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T13.T48	Recently, it was reported that METH, AMPH, @CHEMICAL$, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T14.T47	Recently, it was reported that METH, AMPH, POHA, and the TAs @CHEMICAL$ (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T14.T48	Recently, it was reported that METH, AMPH, POHA, and the TAs @CHEMICAL$ (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T15.T47	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (@CHEMICAL$) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T15.T48	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (@CHEMICAL$) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T16.T47	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and @CHEMICAL$ (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T16.T48	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and @CHEMICAL$ (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T18.T47	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (@CHEMICAL$) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T18.T48	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (@CHEMICAL$) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T19.T47	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate @CHEMICAL$ production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).	false
17218486.T19.T48	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate @CHEMICAL$ production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).	false
17218486.T21.T47	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @CHEM-GENE$ (rTAAR1).	false
17218486.T21.T48	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace @CHEMICAL$-associated receptor 1 (@GENE$).	false
17218486.T22.T49	The discovery that @CHEMICAL$ and AMPH activate the @GENE$ motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).	CPR:3
17218486.T22.T50	The discovery that @CHEMICAL$ and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the @GENE$ (mTAAR1) and a human-rat chimera (hrChTAAR1).	false
17218486.T22.T51	The discovery that @CHEMICAL$ and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (@GENE$) and a human-rat chimera (hrChTAAR1).	false
17218486.T22.T52	The discovery that @CHEMICAL$ and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (@GENE$).	false
17218486.T23.T49	The discovery that METH and @CHEMICAL$ activate the @GENE$ motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).	CPR:3
17218486.T23.T50	The discovery that METH and @CHEMICAL$ activate the rTAAR1 motivated us to study the effect of these drugs on the @GENE$ (mTAAR1) and a human-rat chimera (hrChTAAR1).	false
17218486.T23.T51	The discovery that METH and @CHEMICAL$ activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (@GENE$) and a human-rat chimera (hrChTAAR1).	false
17218486.T23.T52	The discovery that METH and @CHEMICAL$ activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (@GENE$).	false
17218486.T25.T53	Furthermore, because S-(+)-isomers of @CHEMICAL$ and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of @GENE$.	CPR:3
17218486.T26.T53	Furthermore, because S-(+)-isomers of METH and @CHEMICAL$ are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of @GENE$.	CPR:3
17218486.T28.T36	In response to @CHEMICAL$, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.	false
17218486.T29.T36	In response to METH, @CHEMICAL$, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.	false
17218486.T30.T36	In response to METH, AMPH, or @CHEMICAL$ exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.	false
17218486.T31.T36	In response to METH, AMPH, or POHA exposure, the accumulation of @CHEMICAL$ by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.	false
17218486.T1.T37	EC50 values for @CHEMICAL$ were 0.89, 0.92, and 4.44 microM for @GENE$, mTAAR1, and h-rChTAAR1, respectively.	CPR:3
17218486.T1.T38	EC50 values for @CHEMICAL$ were 0.89, 0.92, and 4.44 microM for rTAAR1, @GENE$, and h-rChTAAR1, respectively.	CPR:3
17218486.T1.T39	EC50 values for @CHEMICAL$ were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and @GENE$, respectively.	CPR:3
17218486.T3.T40	@CHEMICAL$ was a potent and full agonist at each species of @GENE$, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.	CPR:5
17218486.T3.T41	@CHEMICAL$ was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the @GENE$ but was a partial agonist at h-rChTAAR1.	false
17218486.T3.T42	@CHEMICAL$ was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at @GENE$.	false
17218486.T4.T40	PEA was a potent and full agonist at each species of @CHEMICAL$, whereas @GENE$ was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.	false
17218486.T4.T41	PEA was a potent and full agonist at each species of TAAR1, whereas @CHEMICAL$ was a full agonist for the @GENE$ but was a partial agonist at h-rChTAAR1.	CPR:5
17218486.T4.T42	PEA was a potent and full agonist at each species of TAAR1, whereas @CHEMICAL$ was a full agonist for the rodent TAAR1s but was a partial agonist at @GENE$.	CPR:5
17218486.T5.T43	Interestingly, both isomers of @CHEMICAL$ were full agonists at @GENE$ and h-rChTAAR1, whereas both were partial agonists at rTAAR1.	CPR:5
17218486.T5.T44	Interestingly, both isomers of @CHEMICAL$ were full agonists at mTAAR1 and @GENE$, whereas both were partial agonists at rTAAR1.	CPR:5
17218486.T5.T45	Interestingly, both isomers of @CHEMICAL$ were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at @GENE$.	CPR:5
17221210.T1.T27	RESULTS: We first showed that expression of the genes encoding @CHEMICAL$ and heparan @GENE$ 2-sulfotransferase decreased between E13.5 and E17.5.	false
17221210.T1.T10	RESULTS: We first showed that expression of the genes encoding glypicans 1, 2, 3 and 5 and @CHEM-GENE$ decreased between E13.5 and E17.5.	false
17221210.T5.T11	@CHEMICAL$-positive cells that developed in the presence of @GENE$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T12	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: @GENE$ (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T13	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (@GENE$), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T14	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), @GENE$ (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T15	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (@GENE$; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T16	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as @GENE$), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T17	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), @GENE$ (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T18	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (@GENE$; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T19	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as @GENE$) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T20	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and @GENE$ (Slc2a1; previously known as glucose transporter 2).	false
17221210.T5.T21	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (@GENE$; previously known as glucose transporter 2).	false
17221210.T5.T22	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$).	false
17221210.T6.T11	@CHEMICAL$-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T12	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: @CHEMICAL$ (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T13	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (@CHEMICAL$), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T14	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), @CHEMICAL$ (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T15	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (@CHEMICAL$; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T16	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as @CHEMICAL$), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T17	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), @CHEMICAL$ (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T18	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (@CHEMICAL$; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T19	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as @CHEMICAL$) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T20	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and @CHEM-GENE$ (Slc2a1; previously known as glucose transporter 2).	false
17221210.T6.T21	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @CHEMICAL$ transporter), member 2 (@GENE$; previously known as glucose transporter 2).	false
17221210.T6.T22	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @CHEMICAL$ transporter), member 2 (Slc2a1; previously known as @GENE$).	false
17221210.T7.T11	@CHEMICAL$-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T12	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: @CHEMICAL$ (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T13	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (@CHEMICAL$), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T14	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), @CHEMICAL$ (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T15	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (@CHEMICAL$; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T16	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as @CHEMICAL$), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T17	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), @CHEMICAL$ (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T18	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (@CHEMICAL$; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T19	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as @CHEMICAL$) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T20	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and @CHEMICAL$ (Slc2a1; previously known as @GENE$ transporter 2).	false
17221210.T7.T21	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (@CHEMICAL$; previously known as @GENE$ transporter 2).	false
17221210.T7.T22	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @CHEM-GENE$).	false
17221210.T8.T23	Finally, we showed that @CHEMICAL$ activated endocrine cell development by inducing @GENE$ (Neurog3) expression in early endocrine progenitor cells.	CPR:3
17221210.T8.T24	Finally, we showed that @CHEMICAL$ activated endocrine cell development by inducing neurogenin 3 (@GENE$) expression in early endocrine progenitor cells.	CPR:3
17228881.T24.T39	@CHEMICAL$ inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for @GENE$ and sulfamate inhibitors.	false
17228881.T24.T40	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the @CHEMICAL$, a new target for @GENE$ and sulfamate inhibitors.	CPR:4
17228881.T25.T39	@CHEMICAL$ inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and @GENE$ inhibitors.	false
17228881.T25.T40	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the @CHEMICAL$, a new target for sulfonamide and @GENE$ inhibitors.	CPR:4
17228881.T13.T30	The kinetic parameters for the @CHEMICAL$ hydration reaction proved @GENE$ to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C).	CPR:9
17228881.T16.T37	Simple @CHEMICAL$ were rather ineffective @GENE$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, 4-aminomethyl-, or 4-hydroxymethyl moieties or among halogenated sulfanilamides (KI values of 608-955 nM).	false
17228881.T17.T37	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing @GENE$-, 4-aminomethyl-, or 4-hydroxymethyl moieties or among halogenated sulfanilamides (KI values of 608-955 nM).	false
17228881.T18.T37	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, @GENE$-, or 4-hydroxymethyl moieties or among halogenated sulfanilamides (KI values of 608-955 nM).	false
17228881.T19.T37	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, 4-aminomethyl-, or @GENE$ moieties or among halogenated sulfanilamides (KI values of 608-955 nM).	false
17228881.T20.T37	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, 4-aminomethyl-, or 4-hydroxymethyl moieties or among halogenated @GENE$ (KI values of 608-955 nM).	false
17228881.T1.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, @CHEMICAL$, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T1.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, @CHEMICAL$, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T21.T26	Some clinically used compounds, such as @CHEMICAL$, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T21.T27	Some clinically used compounds, such as @CHEMICAL$, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T22.T26	Some clinically used compounds, such as acetazolamide, @CHEMICAL$, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T22.T27	Some clinically used compounds, such as acetazolamide, @CHEMICAL$, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T23.T26	Some clinically used compounds, such as acetazolamide, methazolamide, @CHEMICAL$, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T23.T27	Some clinically used compounds, such as acetazolamide, methazolamide, @CHEMICAL$, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T2.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, @CHEMICAL$, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T2.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, @CHEMICAL$, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T3.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, @CHEMICAL$, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T3.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, @CHEMICAL$, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T4.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, @CHEMICAL$, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T4.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, @CHEMICAL$, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T5.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, @CHEMICAL$, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T5.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, @CHEMICAL$, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T6.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and @CHEMICAL$, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T6.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and @CHEMICAL$, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T7.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug @CHEMICAL$, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	CPR:4
17228881.T7.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug @CHEMICAL$, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	false
17228881.T8.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @CHEMICAL$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were @GENE$ and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	false
17228881.T8.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were @CHEMICAL$ and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	CPR:4
17228881.T9.T26	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @CHEMICAL$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and @GENE$ (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.	false
17228881.T9.T27	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and @CHEMICAL$ (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.	CPR:4
17228881.T10.T28	The metallic taste reported as a side effect after the treatment with systemic @CHEMICAL$ may be due to the inhibition of the @GENE$.	CPR:4
17228881.T11.T29	Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant @CHEMICAL$ hydrase activity of enamel @GENE$, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.	CPR:9
17228881.T12.T29	Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel @CHEMICAL$, which leads to the formation of protons and @GENE$ and may have a role in cariogenesis.	CPR:9
17229090.T10.T48	Role of the @CHEM-GENE$ in the development of the retinal projections.	false
17229090.T11.T48	Role of the @CHEMICAL$ in the development of the @GENE$ projections.	false
17229090.T3.T24	Transmembrane isoforms of @CHEMICAL$ (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate @GENE$ production in response to calcium entry.	CPR:9
17229090.T3.T28	Transmembrane isoforms of adenylate cyclases (@CHEMICAL$) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate @GENE$ production in response to calcium entry.	CPR:9
17229090.T4.T24	Transmembrane isoforms of @CHEMICAL$ (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to @GENE$ entry.	false
17229090.T4.T28	Transmembrane isoforms of adenylate cyclases (@CHEMICAL$) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to @GENE$ entry.	false
17229090.T5.T24	Transmembrane isoforms of @CHEM-GENE$ (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry.	false
17229090.T5.T28	Transmembrane isoforms of @CHEMICAL$ cyclases (@GENE$) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry.	false
17229090.T6.T23	Based on observations in the barrelless mouse strain, the @CHEMICAL$ gene (AC1) was involved in the segregation of binocular @GENE$ inputs.	false
17229090.T6.T25	Based on observations in the barrelless mouse strain, the Adcy1 gene (@CHEMICAL$) was involved in the segregation of binocular @GENE$ inputs.	false
17229090.T7.T44	Using a genetic approach we tested the role of the @CHEM-GENE$ AC1, AC5 and AC8 for the segregation retinal fibres.	false
17229090.T7.T45	Using a genetic approach we tested the role of the @CHEMICAL$ modulated cyclases @GENE$, AC5 and AC8 for the segregation retinal fibres.	false
17229090.T7.T46	Using a genetic approach we tested the role of the @CHEMICAL$ modulated cyclases AC1, @GENE$ and AC8 for the segregation retinal fibres.	false
17229090.T7.T47	Using a genetic approach we tested the role of the @CHEMICAL$ modulated cyclases AC1, AC5 and @GENE$ for the segregation retinal fibres.	false
17229090.T8.T44	Using a genetic approach we tested the role of the @CHEMICAL$ AC1, AC5 and AC8 for the segregation @GENE$ fibres.	false
17229090.T8.T45	Using a genetic approach we tested the role of the calcium modulated cyclases @CHEMICAL$, AC5 and AC8 for the segregation @GENE$ fibres.	false
17229090.T8.T46	Using a genetic approach we tested the role of the calcium modulated cyclases AC1, @CHEMICAL$ and AC8 for the segregation @GENE$ fibres.	false
17229090.T8.T47	Using a genetic approach we tested the role of the calcium modulated cyclases AC1, AC5 and @CHEMICAL$ for the segregation @GENE$ fibres.	false
17229090.T1.T12	Ipsilateral retinal axons remained exuberant in the @CHEMICAL$(-/-) mice, with overlapping @GENE$ projections from both eyes in the superior colliculus and the visual thalamus.	false
17229090.T9.T12	Ipsilateral @CHEMICAL$ axons remained exuberant in the @GENE$(-/-) mice, with overlapping retinal projections from both eyes in the superior colliculus and the visual thalamus.	false
17229090.T2.T18	Thus, only @CHEMICAL$ is required for the maturation of the @GENE$ axon terminals whereas AC5 and AC8 are not needed.	false
17229090.T2.T19	Thus, only AC1 is required for the maturation of the @CHEMICAL$ axon terminals whereas @GENE$ and AC8 are not needed.	false
17229090.T2.T20	Thus, only AC1 is required for the maturation of the @CHEMICAL$ axon terminals whereas AC5 and @GENE$ are not needed.	false
17234158.T9.T25	@CHEMICAL$ inhibits @GENE$ expression in malignant glioma cells.	CPR:4
17234158.T1.T11	Here, we report that the antifibrotic drug @CHEMICAL$ (pirfenidone, PFD) elicits growth-inhibitory effects and reduces @GENE$ protein levels in human glioma cell lines.	CPR:4
17234158.T2.T11	Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (@CHEMICAL$, PFD) elicits growth-inhibitory effects and reduces @GENE$ protein levels in human glioma cell lines.	CPR:4
17234158.T3.T11	Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, @CHEMICAL$) elicits growth-inhibitory effects and reduces @GENE$ protein levels in human glioma cell lines.	CPR:4
17234158.T4.T12	This reduction in @CHEMICAL$ is biologically relevant since @GENE$ treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.	CPR:4
17234158.T4.T14	This reduction in TGF-beta2 is biologically relevant since @CHEMICAL$ treatment reduces the growth inhibition of @GENE$-sensitive CCL-64 cells mediated by conditioned media of glioma cells.	CPR:4
17234158.T5.T20	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta @GENE$ furin.	CPR:4
17234158.T5.T17	@CHEMICAL$ leads to a reduction of @GENE$ mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.	CPR:4
17234158.T5.T18	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature @GENE$ protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.	CPR:4
17234158.T5.T19	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the @GENE$ pro-protein convertase furin.	CPR:4
17234158.T5.T21	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase @GENE$.	CPR:4
17234158.T6.T22	In addition, @CHEMICAL$ reduces the protein levels of the @GENE$, a TGF-beta target gene and furin substrate involved in carcinogenesis.	CPR:4
17234158.T6.T23	In addition, @CHEMICAL$ reduces the protein levels of the matrix metalloproteinase (MMP)-11, a @GENE$ target gene and furin substrate involved in carcinogenesis.	CPR:4
17234158.T6.T24	In addition, @CHEMICAL$ reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and @GENE$ substrate involved in carcinogenesis.	false
17234158.T7.T10	These data define @CHEMICAL$ or PFD-related agents as promising agents for human cancers associated with enhanced @GENE$ activity.	false
17234158.T8.T10	These data define PFD or @CHEMICAL$-related agents as promising agents for human cancers associated with enhanced @GENE$ activity.	false
17256745.T11.T42	Human and rat @CHEMICAL$ are liver-specific peroxisomal enzymes: implications for intracellular @GENE$ transport.	false
17256745.T12.T42	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.	false
17256745.T13.T42	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.	false
17256745.T14.T42	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.	false
17256745.T15.T42	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.	false
17256745.T1.T21	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T1.T32	UNLABELLED: @CHEMICAL$-coenzyme A:amino acid N-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T2.T21	UNLABELLED: @CHEMICAL$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary @GENE$ to taurine and glycine.	CPR:9
17256745.T2.T32	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is the sole enzyme responsible for conjugation of primary and secondary @GENE$ to taurine and glycine.	CPR:9
17256745.T3.T21	UNLABELLED: @CHEMICAL$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to @GENE$ and glycine.	CPR:9
17256745.T3.T32	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to @GENE$ and glycine.	CPR:9
17256745.T5.T21	UNLABELLED: @CHEMICAL$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and @GENE$.	CPR:9
17256745.T5.T32	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and @GENE$.	CPR:9
17256745.T6.T21	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T6.T32	UNLABELLED: Bile acid-@CHEMICAL$:amino acid N-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T7.T21	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T7.T32	UNLABELLED: Bile acid-coenzyme A:@CHEMICAL$ N-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T8.T21	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T8.T32	UNLABELLED: Bile acid-coenzyme A:amino acid @CHEMICAL$-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	false
17256745.T9.T30	The absence or presence of a cytosolic pool of @CHEMICAL$ has important implications for the intracellular transport of unconjugated/deconjugated @GENE$.	CPR:9
17256745.T10.T31	We used immunofluorescence microscopy and @CHEMICAL$ permeabilization assays to determine the subcellular location of endogenous @GENE$ in primary human and rat hepatocytes.	false
17290783.T7.T16	[Construction of the flavinogenic yeast Candida famata strains with high @CHEM-GENE$ activity using gene engineering].	false
17290783.T1.T10	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$ kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated @GENE$ or constitutive TEF1 promoter) were isolated.	false
17290783.T1.T11	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$ kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive @GENE$) were isolated.	false
17290783.T1.T8	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the @CHEMICAL$ gene (encoding the @GENE$ kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	false
17290783.T1.T9	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEM-GENE$, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	false
17290783.T2.T10	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts @CHEMICAL$ to flavinmononucleotide) driven by the strong promoters (the regulated @GENE$ or constitutive TEF1 promoter) were isolated.	false
17290783.T2.T11	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts @CHEMICAL$ to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive @GENE$) were isolated.	false
17290783.T2.T8	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the @CHEMICAL$ gene (encoding the riboflavin kinase, enzyme that converts @GENE$ to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	false
17290783.T2.T9	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$, enzyme that converts @GENE$ to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	CPR:9
17290783.T3.T10	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to @CHEMICAL$) driven by the strong promoters (the regulated @GENE$ or constitutive TEF1 promoter) were isolated.	false
17290783.T3.T11	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to @CHEMICAL$) driven by the strong promoters (the regulated RIB1 or constitutive @GENE$) were isolated.	false
17290783.T3.T8	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the @CHEMICAL$ gene (encoding the riboflavin kinase, enzyme that converts riboflavin to @GENE$) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	false
17290783.T3.T9	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$, enzyme that converts riboflavin to @GENE$) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	CPR:9
17290783.T4.T12	@CHEM-GENE$ activity in the isolated transformants was tested.	false
17290783.T5.T13	The 6-8-fold increase of the @CHEM-GENE$ activity was shown in the recombinant strains containing the integrated Debaryomyces hansenii FMN1 gene under the strong constitutive TEF1 promoter.	false
17290783.T5.T14	The 6-8-fold increase of the @CHEMICAL$ kinase activity was shown in the recombinant strains containing the integrated @GENE$ gene under the strong constitutive TEF1 promoter.	false
17290783.T5.T15	The 6-8-fold increase of the @CHEMICAL$ kinase activity was shown in the recombinant strains containing the integrated Debaryomyces hansenii FMN1 gene under the strong constitutive @GENE$.	false
17303537.T5.T9	The increased @CHEM-GENE$ activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the glutathione reductase activity.	false
17303537.T5.T10	The increased @CHEMICAL$ peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the @GENE$ activity.	false
17303537.T6.T9	The increased @CHEMICAL$ activity in rats suffering from hyperthyroidism was associated with a fall of the reduced @GENE$ in the homogenate and a marked increase in the glutathione reductase activity.	false
17303537.T6.T10	The increased glutathione peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced @CHEMICAL$ in the homogenate and a marked increase in the @GENE$ activity.	false
17303537.T7.T9	The increased @CHEMICAL$ activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the @GENE$ reductase activity.	false
17303537.T7.T10	The increased glutathione peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the @CHEM-GENE$ activity.	false
1730582.T29.T44	Mechanism of the irreversible inactivation of @CHEM-GENE$ by alpha-difluoromethylornithine.	false
1730582.T30.T44	Mechanism of the irreversible inactivation of @CHEMICAL$ by @GENE$.	CPR:4
1730582.T16.T31	@CHEMICAL$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, @GENE$ (DFMO).	CPR:4
1730582.T16.T36	Mouse ornithine decarboxylase (@CHEMICAL$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, @GENE$ (DFMO).	CPR:4
1730582.T17.T31	@CHEMICAL$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (@GENE$).	CPR:4
1730582.T17.T36	Mouse ornithine decarboxylase (@CHEMICAL$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (@GENE$).	CPR:4
1730582.T23.T31	@CHEM-GENE$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	false
1730582.T23.T36	Mouse @CHEMICAL$ decarboxylase (@GENE$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	false
1730582.T6.T31	@CHEMICAL$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for @GENE$ and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	false
1730582.T6.T36	Mouse ornithine decarboxylase (@CHEMICAL$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for @GENE$ and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	false
1730582.T18.T37	The @CHEMICAL$ binding lysine in @GENE$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T18.T38	The @CHEMICAL$ binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T19.T37	The pyridoxal 5'-phosphate binding @CHEMICAL$ in @GENE$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T19.T38	The pyridoxal 5'-phosphate binding @CHEMICAL$ in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T20.T37	The pyridoxal 5'-phosphate binding lysine in @CHEMICAL$ was identified as @GENE$ 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T20.T38	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as @CHEMICAL$ 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T21.T37	The pyridoxal 5'-phosphate binding lysine in @CHEMICAL$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with @GENE$ followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T21.T38	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with @CHEMICAL$ followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T22.T37	The pyridoxal 5'-phosphate binding lysine in @CHEMICAL$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T22.T38	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @CHEM-GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	false
1730582.T24.T39	This @CHEMICAL$ is contained in the sequence @GENE$, which is found in all known ODCs from eukaryotes.	false
1730582.T24.T40	This @CHEMICAL$ is contained in the sequence PFYAVKC, which is found in all known @GENE$ from eukaryotes.	false
1730582.T25.T39	This lysine is contained in the sequence @CHEM-GENE$, which is found in all known ODCs from eukaryotes.	false
1730582.T25.T40	This lysine is contained in the sequence @CHEMICAL$, which is found in all known @GENE$ from eukaryotes.	false
1730582.T26.T41	The preceding @CHEMICAL$ do not conform to the consensus sequence of @GENE$, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including ODCs from E. coli.	false
1730582.T26.T42	The preceding @CHEMICAL$ do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other @GENE$ including ODCs from E. coli.	false
1730582.T26.T43	The preceding @CHEMICAL$ do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including @GENE$ from E. coli.	false
1730582.T27.T41	The preceding amino acids do not conform to the consensus sequence of @CHEMICAL$, which contains the @GENE$ binding lysine in a number of other decarboxylases including ODCs from E. coli.	false
1730582.T27.T42	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the @CHEMICAL$ binding lysine in a number of other @GENE$ including ODCs from E. coli.	false
1730582.T27.T43	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the @CHEMICAL$ binding lysine in a number of other decarboxylases including @GENE$ from E. coli.	false
1730582.T28.T41	The preceding amino acids do not conform to the consensus sequence of @CHEMICAL$, which contains the pyridoxal 5'-phosphate binding @GENE$ in a number of other decarboxylases including ODCs from E. coli.	false
1730582.T28.T42	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding @CHEMICAL$ in a number of other @GENE$ including ODCs from E. coli.	false
1730582.T28.T43	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding @CHEMICAL$ in a number of other decarboxylases including @GENE$ from E. coli.	false
1730582.T1.T32	Using a similar procedure to analyze @CHEMICAL$ labeled by reaction with @GENE$, it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor.	false
1730582.T2.T32	Using a similar procedure to analyze @CHEMICAL$ labeled by reaction with [5-14C]DFMO, it was found that @GENE$ 69 and cysteine 360 formed covalent adducts with the inhibitor.	false
1730582.T3.T32	Using a similar procedure to analyze @CHEMICAL$ labeled by reaction with [5-14C]DFMO, it was found that lysine 69 and @GENE$ 360 formed covalent adducts with the inhibitor.	false
1730582.T4.T33	@CHEMICAL$ 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -@GENE$-, which is present in all known eukaryote ODCs.	false
1730582.T4.T34	@CHEMICAL$ 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -WGPTCDGL(I)D-, which is present in all known @GENE$.	false
1730582.T5.T33	Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -@CHEM-GENE$-, which is present in all known eukaryote ODCs.	false
1730582.T5.T34	Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -@CHEMICAL$-, which is present in all known @GENE$.	false
17311416.T24.T46	Pre-steady-state currents in @CHEM-GENE$ induced by photolysis of a new caged alanine derivative.	false
17311416.T25.T46	Pre-steady-state currents in @CHEMICAL$ induced by photolysis of a new caged @GENE$ derivative.	false
17311416.T10.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine @GENE$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine @GENE$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine @GENE$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEM-GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T10.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T10.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T10.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T11.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine serine @GENE$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine serine @GENE$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine serine @GENE$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEM-GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T11.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T11.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T11.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T12.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @CHEMICAL$ families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@CHEMICAL$), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @CHEMICAL$] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEM-GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T12.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEMICAL$-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T12.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEMICAL$-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T12.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEMICAL$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T13.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @CHEMICAL$ families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@CHEMICAL$), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @CHEMICAL$] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEM-GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T13.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @CHEMICAL$ transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T13.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @CHEMICAL$ transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T13.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @CHEMICAL$ transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T18.T28	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T30	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T31	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T35	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T32	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T33	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T34	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T36	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T18.T37	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	CPR:9
17311416.T18.T38	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	CPR:9
17311416.T18.T39	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	CPR:9
17311416.T1.T28	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T30	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T31	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T35	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T32	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T33	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T34	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T36	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T1.T37	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T1.T38	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T1.T39	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T21.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T21.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	CPR:9
17311416.T21.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	CPR:9
17311416.T21.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	CPR:9
17311416.T23.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T23.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	CPR:9
17311416.T23.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	CPR:9
17311416.T23.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	CPR:9
17311416.T23.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	CPR:9
17311416.T5.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEM-GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T5.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T5.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T5.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T9.T28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, @GENE$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T30	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, @GENE$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T31	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, @GENE$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T35	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T32	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEM-GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T33	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].	false
17311416.T9.T37	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].	false
17311416.T9.T38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].	false
17311416.T9.T39	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].	false
17311416.T15.T40	Here, we describe a new photolabile @CHEMICAL$ derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.	CPR:9
17311416.T15.T41	Here, we describe a new photolabile @CHEMICAL$ derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.	CPR:9
17311416.T15.T42	Here, we describe a new photolabile @CHEMICAL$ derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.	CPR:9
17311416.T16.T40	Here, we describe a new photolabile alanine derivative based on protection of @CHEMICAL$ with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.	CPR:9
17311416.T16.T41	Here, we describe a new photolabile alanine derivative based on protection of @CHEMICAL$ with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.	CPR:9
17311416.T16.T42	Here, we describe a new photolabile alanine derivative based on protection of @CHEMICAL$ with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.	CPR:9
17311416.T17.T40	Here, we describe a new photolabile alanine derivative based on protection of alanine with the @CHEMICAL$ (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.	CPR:9
17311416.T17.T41	Here, we describe a new photolabile alanine derivative based on protection of alanine with the @CHEMICAL$ (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.	CPR:9
17311416.T17.T42	Here, we describe a new photolabile alanine derivative based on protection of alanine with the @CHEMICAL$ (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.	CPR:9
17311416.T19.T40	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (@CHEMICAL$) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.	CPR:9
17311416.T19.T41	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (@CHEMICAL$) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.	CPR:9
17311416.T19.T42	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (@CHEMICAL$) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.	CPR:9
17311416.T22.T43	Photolytic release of free @CHEMICAL$ results in the generation of significant transient current components in HEK293 cells expressing the @GENE$, SNAT1, and SNAT2 proteins.	false
17311416.T22.T44	Photolytic release of free @CHEMICAL$ results in the generation of significant transient current components in HEK293 cells expressing the ASCT2, @GENE$, and SNAT2 proteins.	false
17311416.T22.T45	Photolytic release of free @CHEMICAL$ results in the generation of significant transient current components in HEK293 cells expressing the ASCT2, SNAT1, and @GENE$ proteins.	false
17315258.T16.T42	Histochemical staining and quantification of @CHEMICAL$ dehydrogenase @GENE$ activity using blue native PAGE.	false
17315258.T16.T41	Histochemical staining and quantification of @CHEM-GENE$ diaphorase activity using blue native PAGE.	false
17315258.T10.T26	Mammalian mitochondrial @CHEMICAL$ dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @GENE$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T10.T17	@CHEM-GENE$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T10.T34	Mammalian mitochondrial @CHEMICAL$ dehydrogenase (@GENE$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T10.T35	Mammalian mitochondrial @CHEMICAL$ dehydrogenase (DLDH, @GENE$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T11.T26	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).	false
17315258.T11.T17	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).	false
17315258.T11.T34	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).	false
17315258.T11.T35	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).	false
17315258.T12.T26	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).	false
17315258.T12.T17	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).	false
17315258.T12.T34	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).	false
17315258.T12.T35	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).	false
17315258.T15.T26	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes @CHEMICAL$-dependent oxidation of dihydrolipoamide in vivo and can also act as a @GENE$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T15.T17	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes @GENE$-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T15.T34	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes @GENE$-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T15.T35	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes @GENE$-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T2.T26	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of @CHEMICAL$ in vivo and can also act as a @GENE$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T2.T17	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of @GENE$ in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T2.T34	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of @GENE$ in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T2.T35	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of @GENE$ in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T8.T26	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T8.T17	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T8.T34	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T8.T35	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T9.T26	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T9.T17	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T9.T34	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T9.T35	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	false
17315258.T13.T36	Rat brain mitochondrial extracts, used as the source of DLDH, were resolved by nongradient BN-PAGE (9%), which was followed by @CHEMICAL$ activity staining using @GENE$ as the electron donor and NBT as the electron acceptor.	false
17315258.T13.T33	Rat brain mitochondrial extracts, used as the source of @CHEMICAL$, were resolved by nongradient BN-PAGE (9%), which was followed by diaphorase activity staining using @GENE$ as the electron donor and NBT as the electron acceptor.	false
17315258.T14.T36	Rat brain mitochondrial extracts, used as the source of DLDH, were resolved by nongradient BN-PAGE (9%), which was followed by @CHEMICAL$ activity staining using NADH as the electron donor and @GENE$ as the electron acceptor.	false
17315258.T14.T33	Rat brain mitochondrial extracts, used as the source of @CHEMICAL$, were resolved by nongradient BN-PAGE (9%), which was followed by diaphorase activity staining using NADH as the electron donor and @GENE$ as the electron acceptor.	false
17315258.T1.T40	Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures DLDH @CHEMICAL$ activity using @GENE$ as the substrate.	false
17315258.T1.T39	Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures @CHEMICAL$ dehydrogenase activity using @GENE$ as the substrate.	false
17315258.T3.T23	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T3.T25	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T3.T28	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.	false
17315258.T3.T22	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T3.T24	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T3.T27	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.	false
17315258.T4.T23	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T4.T25	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T4.T28	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.	false
17315258.T4.T22	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T4.T24	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T4.T27	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.	false
17315258.T5.T23	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T5.T25	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T5.T28	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.	false
17315258.T5.T22	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T5.T24	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T5.T27	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.	false
17315258.T6.T23	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T6.T25	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T6.T28	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.	false
17315258.T6.T22	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T6.T24	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T6.T27	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.	false
17315258.T7.T23	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH @CHEMICAL$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T7.T25	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @CHEMICAL$ activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T7.T28	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @CHEMICAL$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.	false
17315258.T7.T22	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on @CHEMICAL$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T7.T24	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @CHEMICAL$ diaphorase activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	false
17315258.T7.T27	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @CHEMICAL$-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.	false
17319904.T11.T27	Reticulated platelets and uninhibited @CHEMICAL$ and COX-2 decrease the antiplatelet effects of @GENE$.	false
17319904.T11.T28	Reticulated platelets and uninhibited COX-1 and @CHEMICAL$ decrease the antiplatelet effects of @GENE$.	false
17319904.T2.T19	Immature (reticulated) platelets may modulate the antiplatelet effects of @CHEMICAL$ through uninhibited @GENE$ (COX)-1 and COX-2.	false
17319904.T2.T20	Immature (reticulated) platelets may modulate the antiplatelet effects of @CHEMICAL$ through uninhibited cyclooxygenase @GENE$ and COX-2.	false
17319904.T2.T21	Immature (reticulated) platelets may modulate the antiplatelet effects of @CHEMICAL$ through uninhibited cyclooxygenase (COX)-1 and @GENE$.	false
17319904.T7.T23	Platelet studies included light transmission aggregometry; P-selectin and @CHEMICAL$ expression, and serum @GENE$ (TxB(2)) levels.	false
17319904.T7.T22	Platelet studies included light transmission aggregometry; @CHEMICAL$ and integrin alpha(IIb)beta(3) expression, and serum @GENE$ (TxB(2)) levels.	false
17319904.T8.T23	Platelet studies included light transmission aggregometry; P-selectin and @CHEMICAL$ expression, and serum thromboxane B(2) (@GENE$) levels.	false
17319904.T8.T22	Platelet studies included light transmission aggregometry; @CHEMICAL$ and integrin alpha(IIb)beta(3) expression, and serum thromboxane B(2) (@GENE$) levels.	false
17319904.T10.T13	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm @CHEMICAL$ and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and @GENE$ expression were also higher in the upper tertile both before and after aspirin.	false
17319904.T10.T25	Baseline platelet aggregation to 1 microg mL(-1) @CHEMICAL$, and postaspirin aggregations to 5 microm and 20 microm @GENE$ and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.	false
17319904.T10.T26	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm @CHEMICAL$ and @GENE$, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.	false
17319904.T10.T12	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm @CHEMICAL$ and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated @GENE$ and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.	false
17319904.T1.T13	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm ADP and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and @CHEMICAL$ expression were also higher in the upper tertile both before and after @GENE$.	CPR:3
17319904.T1.T25	Baseline platelet aggregation to 1 microg mL(-1) @CHEMICAL$, and postaspirin aggregations to 5 microm and 20 microm ADP and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after @GENE$.	false
17319904.T1.T26	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm ADP and @CHEMICAL$, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after @GENE$.	false
17319904.T1.T12	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm ADP and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated @CHEMICAL$ and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after @GENE$.	CPR:3
17319904.T3.T17	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of @CHEMICAL$ and increased aspirin resistance, possibly because of increased reactivity, and uninhibited @GENE$ and COX-2 activity.	false
17319904.T3.T18	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of @CHEMICAL$ and increased aspirin resistance, possibly because of increased reactivity, and uninhibited COX-1 and @GENE$ activity.	false
17319904.T4.T17	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of aspirin and increased @CHEMICAL$ resistance, possibly because of increased reactivity, and uninhibited @GENE$ and COX-2 activity.	false
17319904.T4.T18	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of aspirin and increased @CHEMICAL$ resistance, possibly because of increased reactivity, and uninhibited COX-1 and @GENE$ activity.	false
17320868.T21.T36	Neuroprotection by @CHEMICAL$ against MPP+-induced dopamine neuron death is mediated by @GENE$ in primary cultures of mouse mesencephalon.	false
17320868.T22.T36	Neuroprotection by estrogen against @CHEMICAL$-induced dopamine neuron death is mediated by @GENE$ in primary cultures of mouse mesencephalon.	false
17320868.T23.T36	Neuroprotection by estrogen against MPP+-induced @CHEMICAL$ neuron death is mediated by @GENE$ in primary cultures of mouse mesencephalon.	false
17320868.T11.T26	Utilizing primary mesencephalic neurons, we found expression of both @CHEM-GENE$ (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T11.T27	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (@GENE$) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T11.T28	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (ERalpha) and @GENE$ (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T11.T29	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (ERalpha) and estrogen receptor beta (@GENE$) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T11.T30	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of @GENE$ on both dopamine neurons and astrocytes.	false
17320868.T12.T26	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ (ERalpha) and @GENE$ receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T12.T27	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (@CHEMICAL$) and @GENE$ receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T12.T28	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEM-GENE$ (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T12.T29	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEMICAL$ receptor beta (@GENE$) with a predominance of ERalpha on both dopamine neurons and astrocytes.	false
17320868.T12.T30	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEMICAL$ receptor beta (ERbeta) with a predominance of @GENE$ on both dopamine neurons and astrocytes.	false
17320868.T13.T26	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.	false
17320868.T13.T27	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (@CHEMICAL$) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.	false
17320868.T13.T28	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEMICAL$ (ERbeta) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.	false
17320868.T13.T29	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and estrogen receptor beta (@CHEMICAL$) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.	false
17320868.T13.T30	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of @CHEMICAL$ on both @GENE$ neurons and astrocytes.	false
17320868.T14.T31	We also found that @CHEMICAL$ protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and @GENE$-dependent manner.	false
17320868.T15.T31	We also found that 17beta-estradiol protects @CHEMICAL$ neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and @GENE$-dependent manner.	false
17320868.T16.T31	We also found that 17beta-estradiol protects dopamine neurons from injury induced by the complex I inhibitor, @CHEMICAL$ (MPP(+)) in a time- and @GENE$-dependent manner.	false
17320868.T17.T31	We also found that 17beta-estradiol protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (@CHEMICAL$) in a time- and @GENE$-dependent manner.	false
17320868.T18.T32	At least 4 h of @CHEMICAL$ pre-treatment was required to elicit protection, an effect that was blocked by the @GENE$ antagonist, ICI 182,780.	false
17320868.T19.T32	At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the @CHEMICAL$ antagonist, @GENE$.	CPR:6
17320868.T20.T33	Moreover, @CHEMICAL$ mediated the protection afforded by @GENE$ since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.	false
17320868.T20.T34	Moreover, ERalpha mediated the protection afforded by @CHEMICAL$ since only the @GENE$ agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.	false
17320868.T20.T35	Moreover, ERalpha mediated the protection afforded by @CHEMICAL$ since only the ERalpha agonist, HPTE, but not the @GENE$ agonist, DPN, protected against dopamine cell loss.	false
17320868.T2.T33	Moreover, @CHEMICAL$ mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, @GENE$, protected against dopamine cell loss.	false
17320868.T2.T34	Moreover, ERalpha mediated the protection afforded by estrogen since only the @CHEMICAL$ agonist, HPTE, but not the ERbeta agonist, @GENE$, protected against dopamine cell loss.	false
17320868.T2.T35	Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the @CHEMICAL$ agonist, @GENE$, protected against dopamine cell loss.	CPR:5
17320868.T3.T33	Moreover, @CHEMICAL$ mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against @GENE$ cell loss.	false
17320868.T3.T34	Moreover, ERalpha mediated the protection afforded by estrogen since only the @CHEMICAL$ agonist, HPTE, but not the ERbeta agonist, DPN, protected against @GENE$ cell loss.	false
17320868.T3.T35	Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the @CHEMICAL$ agonist, DPN, protected against @GENE$ cell loss.	false
17320868.T4.T24	Since glial cells were shown to express significant levels of @CHEMICAL$, we investigated a possible indirect mechanism of @GENE$-mediated neuroprotection through glial cell interaction.	false
17320868.T8.T25	These data indicate that neuroprotection provided by @CHEMICAL$ against MPP(+) toxicity is mediated by @GENE$ and involves an interplay among at least two cell types.	false
17320868.T9.T25	These data indicate that neuroprotection provided by estrogen against @CHEMICAL$ toxicity is mediated by @GENE$ and involves an interplay among at least two cell types.	false
17324065.T10.T20	Differential activation of @CHEMICAL$ in discrete nucleus accumbens subregions during early and late @GENE$ sensitization.	CPR:3
17324065.T11.T20	Differential activation of @CHEM-GENE$ in discrete nucleus accumbens subregions during early and late cocaine sensitization.	false
17324065.T1.T15	The present study examined the differential cocaine-induced activation of the cyclic adenosine monophosphate (@CHEMICAL$) response element binding protein (@GENE$) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	false
17324065.T1.T18	The present study examined the differential cocaine-induced activation of the @CHEM-GENE$ (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	false
17324065.T5.T15	The present study examined the differential @CHEMICAL$-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (@GENE$) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	CPR:3
17324065.T5.T18	The present study examined the differential @CHEMICAL$-induced activation of the @GENE$ (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	CPR:3
17324065.T8.T15	The present study examined the differential cocaine-induced activation of the @CHEMICAL$ (cAMP) response element binding protein (@GENE$) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	false
17324065.T8.T18	The present study examined the differential cocaine-induced activation of the @CHEM-GENE$ (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	false
17324065.T4.T16	@CHEMICAL$-dependent gene transcription, which may underlie long-lasting drug-induced changes in behavior and the subjective effects of @GENE$, varies depending on the stage of drug exposure or withdrawal and the cell population involved.	false
17324065.T6.T17	Using immunohistochemistry, the authors analyzed changes in @CHEMICAL$ phosphorylation in the NAc after 5 days of @GENE$, a short or long drug-free period, and a subsequent challenge injection.	CPR:3
17324065.T7.T12	Repeated @CHEMICAL$ resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of @GENE$ in the 3 most dorsomedial zones of the shell.	false
17324065.T7.T19	Repeated @CHEMICAL$ resulted in @GENE$ phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.	CPR:3
17324065.T9.T12	Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated @CHEMICAL$, but rats challenged after 2 drug-free days yielded a more localized activation of @GENE$ in the 3 most dorsomedial zones of the shell.	CPR:3
17324065.T9.T19	Repeated cocaine resulted in @CHEMICAL$ phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated @GENE$, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.	false
17324065.T2.T13	The temporal and anatomical determinants of @CHEMICAL$-induced @GENE$ activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.	CPR:3
17324065.T2.T14	The temporal and anatomical determinants of @CHEMICAL$-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of @GENE$ in early and late cocaine effects.	false
17324065.T3.T13	The temporal and anatomical determinants of cocaine-induced @CHEMICAL$ activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late @GENE$ effects.	false
17324065.T3.T14	The temporal and anatomical determinants of cocaine-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of @CHEMICAL$ in early and late @GENE$ effects.	false
17327402.T7.T20	Fatal hemorrhage in mice lacking @CHEM-GENE$.	false
17327402.T1.T16	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the @CHEM-GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	false
17327402.T1.T9	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent @CHEMICAL$ carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	false
17327402.T2.T16	The carboxylation of @CHEMICAL$ residues to gamma-carboxyglutamic acid (Gla) by the @GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
17327402.T2.T9	The carboxylation of @CHEMICAL$ residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
17327402.T3.T16	The carboxylation of glutamic acid residues to @CHEMICAL$ (Gla) by the @GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
17327402.T3.T9	The carboxylation of glutamic acid residues to @CHEMICAL$ (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
17327402.T5.T16	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (@CHEMICAL$) by the @GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
17327402.T5.T9	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (@CHEMICAL$) by the vitamin K-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
17327402.T6.T16	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the @CHEM-GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	false
17327402.T6.T9	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the @CHEMICAL$-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	false
17327402.T4.T12	Heterozygous mice carrying a null mutation at the gamma-carboxylase (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEM-GENE$, and prothrombin.	false
17327402.T4.T10	Heterozygous mice carrying a null mutation at the @CHEMICAL$ (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @GENE$-dependent clotting factors IX, X, and prothrombin.	false
17327402.T4.T11	Heterozygous mice carrying a null mutation at the gamma-carboxylase (@CHEMICAL$) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @GENE$-dependent clotting factors IX, X, and prothrombin.	false
17327402.T4.T13	Heterozygous mice carrying a null mutation at the gamma-carboxylase (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEMICAL$-dependent clotting factors IX, X, and @GENE$.	false
17333241.T11.T15	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of @GENE$ and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T11.T16	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and @GENE$ were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T11.T21	Genotyping of the single @CHEMICAL$ polymorphisms @GENE$-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T11.T22	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, @GENE$-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T11.T23	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, @GENE$-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T11.T24	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, @GENE$-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T11.T25	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and @GENE$-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	false
17333241.T2.T17	Furthermore, with respect to @CHEMICAL$ and GSTT1 there were statistically significant differences in @GENE$-levels between genotypes among exposed workers but not among controls.	false
17333241.T2.T18	Furthermore, with respect to GSTM1 and @CHEMICAL$ there were statistically significant differences in @GENE$-levels between genotypes among exposed workers but not among controls.	false
17334413.T28.T61	H3 @CHEMICAL$ receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/@GENE$/ELK-1 pathway.	false
17334413.T28.T63	H3 @CHEMICAL$ receptor agonist inhibits biliary growth of BDL rats by downregulation of the @GENE$/ERK1/2/ELK-1 pathway.	false
17334413.T28.T60	@CHEM-GENE$ agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway.	false
17334413.T28.T62	H3 @CHEMICAL$ receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/@GENE$ pathway.	false
17334413.T29.T61	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the @CHEMICAL$-dependent PKA/@GENE$/ELK-1 pathway.	false
17334413.T29.T63	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the @CHEM-GENE$/ERK1/2/ELK-1 pathway.	false
17334413.T29.T60	@CHEMICAL$ agonist inhibits biliary growth of BDL rats by downregulation of the @GENE$-dependent PKA/ERK1/2/ELK-1 pathway.	false
17334413.T29.T62	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the @CHEMICAL$-dependent PKA/ERK1/2/@GENE$ pathway.	false
17334413.T1.T49	@CHEMICAL$ regulates many functions by binding to four @GENE$ (H1R, H2R, H3R and H4R).	false
17334413.T1.T30	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, @GENE$ and H4R).	false
17334413.T1.T31	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and @GENE$).	false
17334413.T1.T57	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (@GENE$, H2R, H3R and H4R).	false
17334413.T1.T59	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, @GENE$, H3R and H4R).	false
17334413.T23.T49	Histamine regulates many functions by binding to four @CHEM-GENE$ (H1R, H2R, H3R and H4R).	false
17334413.T23.T30	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (H1R, H2R, @GENE$ and H4R).	false
17334413.T23.T31	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (H1R, H2R, H3R and @GENE$).	false
17334413.T23.T57	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (@GENE$, H2R, H3R and H4R).	false
17334413.T23.T59	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (H1R, @GENE$, H3R and H4R).	false
17334413.T14.T32	As @CHEMICAL$ exerts their effects by coupling to Galpha(i/o) proteins reducing @GENE$ (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.	false
17334413.T14.T38	As H3R exerts their effects by coupling to @CHEMICAL$ proteins reducing @GENE$ (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.	false
17334413.T14.T46	As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing @CHEMICAL$ (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of @GENE$ in the regulation of biliary growth.	false
17334413.T19.T32	As @CHEMICAL$ exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (@GENE$) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.	false
17334413.T19.T38	As H3R exerts their effects by coupling to @CHEMICAL$ proteins reducing adenosine 3', 5'-monophosphate (@GENE$) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.	false
17334413.T19.T46	As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (@CHEMICAL$) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of @GENE$ in the regulation of biliary growth.	false
17334413.T20.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of @GENE$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T20.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T20.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T20.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T20.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T20.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (@GENE$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	CPR:5
17334413.T20.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (@GENE$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T20.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T20.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T21.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@GENE$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T21.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T21.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T21.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T21.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T21.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (@GENE$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	CPR:5
17334413.T21.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (@GENE$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T21.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T21.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T22.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @GENE$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T22.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T22.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T22.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T22.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T22.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), @GENE$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T22.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (@GENE$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	CPR:6
17334413.T22.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T22.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T24.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @GENE$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or @GENE$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or @GENE$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T24.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T24.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T25.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @GENE$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @GENE$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or histamine, in the absence/presence of @GENE$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T25.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T25.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T26.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @GENE$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @GENE$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @GENE$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T26.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T26.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T27.T47	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @GENE$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T51	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T52	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T53	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T54	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T48	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @GENE$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T50	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @GENE$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	false
17334413.T27.T55	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?	false
17334413.T27.T56	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?	false
17334413.T6.T33	Following in vivo treatment of BDL rats with @CHEMICAL$ for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and @GENE$, ERK1/2 and Elk-1 phosphorylation.	false
17334413.T6.T34	Following in vivo treatment of BDL rats with @CHEMICAL$ for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and PKA, @GENE$ and Elk-1 phosphorylation.	false
17334413.T6.T35	Following in vivo treatment of BDL rats with @CHEMICAL$ for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and @GENE$ phosphorylation.	false
17334413.T7.T33	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with @CHEMICAL$, we evaluated cholangiocyte proliferation, cAMP levels and @GENE$, ERK1/2 and Elk-1 phosphorylation.	false
17334413.T7.T34	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with @CHEMICAL$, we evaluated cholangiocyte proliferation, cAMP levels and PKA, @GENE$ and Elk-1 phosphorylation.	false
17334413.T7.T35	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with @CHEMICAL$, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and @GENE$ phosphorylation.	false
17334413.T8.T33	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, @CHEMICAL$ levels and @GENE$, ERK1/2 and Elk-1 phosphorylation.	false
17334413.T8.T34	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, @CHEMICAL$ levels and PKA, @GENE$ and Elk-1 phosphorylation.	false
17334413.T8.T35	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, @CHEMICAL$ levels and PKA, ERK1/2 and @GENE$ phosphorylation.	false
17334413.T16.T39	@CHEMICAL$ inhibition of cholangiocyte growth was associated with decreased cAMP levels and @GENE$/ERK1/2/Elk-1 phosphorylation.	CPR:4
17334413.T16.T40	@CHEMICAL$ inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/@GENE$/Elk-1 phosphorylation.	CPR:4
17334413.T16.T41	@CHEMICAL$ inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/@GENE$ phosphorylation.	CPR:4
17334413.T17.T39	RAMH inhibition of cholangiocyte growth was associated with decreased @CHEMICAL$ levels and @GENE$/ERK1/2/Elk-1 phosphorylation.	false
17334413.T17.T40	RAMH inhibition of cholangiocyte growth was associated with decreased @CHEMICAL$ levels and PKA/@GENE$/Elk-1 phosphorylation.	false
17334413.T17.T41	RAMH inhibition of cholangiocyte growth was associated with decreased @CHEMICAL$ levels and PKA/ERK1/2/@GENE$ phosphorylation.	false
17334413.T18.T42	Downregulation of @CHEMICAL$-dependent @GENE$/ERK1/2/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.	false
17334413.T18.T43	Downregulation of @CHEMICAL$-dependent PKA/@GENE$/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.	false
17334413.T18.T44	Downregulation of @CHEMICAL$-dependent PKA/ERK1/2/@GENE$ phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.	false
17334413.T18.T45	Downregulation of @CHEMICAL$-dependent PKA/ERK1/2/Elk-1 phosphorylation (by activation of @GENE$) is important in the inhibition of cholangiocyte growth in liver diseases.	false
17344208.T11.T33	Structure and kinetics of monofunctional @CHEM-GENE$ from Thermus thermophilus.	false
17344208.T1.T12	@CHEM-GENE$ (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T1.T19	@CHEMICAL$ dehydrogenase (@GENE$) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T1.T22	@CHEMICAL$ dehydrogenase (PRODH) and @GENE$ (P5CDH) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T1.T29	@CHEMICAL$ dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (@GENE$) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T2.T12	@CHEMICAL$ (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of @GENE$ to glutamate.	CPR:9
17344208.T2.T19	Proline dehydrogenase (@CHEMICAL$) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of @GENE$ to glutamate.	CPR:9
17344208.T2.T22	Proline dehydrogenase (PRODH) and @CHEMICAL$ (P5CDH) catalyze the two-step oxidation of @GENE$ to glutamate.	CPR:9
17344208.T2.T29	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (@CHEMICAL$) catalyze the two-step oxidation of @GENE$ to glutamate.	CPR:9
17344208.T4.T12	@CHEMICAL$ (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to @GENE$.	CPR:9
17344208.T4.T19	Proline dehydrogenase (@CHEMICAL$) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to @GENE$.	CPR:9
17344208.T4.T22	Proline dehydrogenase (PRODH) and @CHEMICAL$ (P5CDH) catalyze the two-step oxidation of proline to @GENE$.	CPR:9
17344208.T4.T29	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (@CHEMICAL$) catalyze the two-step oxidation of proline to @GENE$.	CPR:9
17344208.T9.T12	@CHEMICAL$ (PRODH) and @GENE$ dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T9.T19	Proline dehydrogenase (@CHEMICAL$) and @GENE$ dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T9.T22	Proline dehydrogenase (PRODH) and @CHEM-GENE$ (P5CDH) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T9.T29	Proline dehydrogenase (PRODH) and @CHEMICAL$ dehydrogenase (@GENE$) catalyze the two-step oxidation of proline to glutamate.	false
17344208.T10.T25	The 2.0-A resolution structure of Thermus thermophilus PRODH reveals a distorted @CHEMICAL$ and a hydrophobic alpha-helical domain located above the @GENE$-terminal ends of the strands of the barrel.	false
17344208.T10.T26	The 2.0-A resolution structure of Thermus thermophilus PRODH reveals a distorted (betaalpha)(8) barrel catalytic core domain and a @CHEMICAL$ located above the @GENE$-terminal ends of the strands of the barrel.	false
17344208.T10.T24	The 2.0-A resolution structure of @CHEMICAL$ reveals a distorted (betaalpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the @GENE$-terminal ends of the strands of the barrel.	false
17344208.T6.T15	Finally, we demonstrate that @CHEMICAL$ reacts with @GENE$ producing superoxide.	CPR:9
17344208.T7.T15	Finally, we demonstrate that @CHEMICAL$ reacts with O(2) producing @GENE$.	CPR:9
17344208.T8.T18	This is significant because @CHEMICAL$ production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between @GENE$.	false
17344208.T8.T16	This is significant because @CHEMICAL$ production underlies the role of @GENE$ in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.	CPR:9
17344208.T8.T17	This is significant because @CHEMICAL$ production underlies the role of human PRODH in @GENE$-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.	false
17347380.T27.T35	@CHEMICAL$ uptake in brain and skeletal muscle of mice lacking @GENE$ assessed by magnetic resonance spectroscopy.	false
17347380.T28.T35	Creatine uptake in brain and skeletal muscle of mice lacking @CHEM-GENE$ assessed by magnetic resonance spectroscopy.	false
17347380.T11.T30	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after @GENE$ supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T11.T32	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after @CHEMICAL$ supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T11.T34	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after @GENE$ supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T12.T30	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 @GENE$ for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T12.T32	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 @CHEMICAL$ for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T12.T34	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 @GENE$ for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T13.T30	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized @GENE$ magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T13.T32	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized @CHEMICAL$ magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T13.T34	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized @GENE$ magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T14.T30	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after @GENE$ supplementation and in control (Con) mice.	false
17347380.T14.T32	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @CHEMICAL$-/- mice before and after @GENE$ supplementation and in control (Con) mice.	false
17347380.T14.T34	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after @GENE$ supplementation and in control (Con) mice.	false
17347380.T1.T30	@CHEMICAL$ (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T1.T32	@CHEMICAL$ (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T1.T34	@CHEMICAL$ (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T21.T30	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of @CHEMICAL$ deficiency caused by guanidinoacetate methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T21.T32	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of @CHEMICAL$ deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T21.T34	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of @CHEMICAL$ deficiency caused by @GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T25.T30	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T25.T32	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T25.T34	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEM-GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T3.T30	Creatine (@CHEMICAL$) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T3.T32	Creatine (@CHEMICAL$) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T3.T34	Creatine (@CHEMICAL$) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.	false
17347380.T15.T33	As expected, a signal for @CHEMICAL$ was hardly detectable in MR spectra of @GENE$-/- mice before Cr supplementation.	false
17347380.T16.T33	As expected, a signal for Cr was hardly detectable in MR spectra of @CHEMICAL$-/- mice before @GENE$ supplementation.	false
17347380.T4.T29	Only because of the repeated MRS measurements performed in this longitudinal @CHEMICAL$ supplementation study on @GENE$-/- mice were we able to discover the initial faster uptake of Cr in skeletal muscle compared with brain, which may represent muscular Cr uptake independent of Cr transporter expression.	false
17347380.T5.T29	Only because of the repeated MRS measurements performed in this longitudinal Cr supplementation study on @CHEMICAL$-/- mice were we able to discover the initial faster uptake of @GENE$ in skeletal muscle compared with brain, which may represent muscular Cr uptake independent of Cr transporter expression.	false
17347380.T6.T29	Only because of the repeated MRS measurements performed in this longitudinal Cr supplementation study on @CHEMICAL$-/- mice were we able to discover the initial faster uptake of Cr in skeletal muscle compared with brain, which may represent muscular @GENE$ uptake independent of Cr transporter expression.	false
17347380.T7.T29	Only because of the repeated MRS measurements performed in this longitudinal Cr supplementation study on @CHEMICAL$-/- mice were we able to discover the initial faster uptake of Cr in skeletal muscle compared with brain, which may represent muscular Cr uptake independent of @GENE$ transporter expression.	false
17347380.T10.T31	Our results can provide the basis for additional experiments to optimize Cr supplementation in @CHEMICAL$ deficiency, as increases in brain Cr are slow in patients after @GENE$ supplementation.	false
17347380.T8.T31	Our results can provide the basis for additional experiments to optimize @CHEMICAL$ supplementation in @GENE$ deficiency, as increases in brain Cr are slow in patients after Cr supplementation.	false
17347380.T9.T31	Our results can provide the basis for additional experiments to optimize Cr supplementation in @CHEMICAL$ deficiency, as increases in brain @GENE$ are slow in patients after Cr supplementation.	false
17352685.T5.T15	The @CHEMICAL$ is the predominant @GENE$ degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.	CPR:9
17352685.T6.T18	Consequently, @CHEMICAL$ inhibitors including @GENE$ and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.	CPR:4
17352685.T7.T18	Consequently, @CHEMICAL$ inhibitors including cilomilast and @GENE$ have been tested in several models of allergic and irritant skin inflammation.	CPR:4
17352685.T8.T19	These @CHEMICAL$ inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the @GENE$ induced skin inflammation in mice and in ovalbumin sensitised guinea pigs.	false
17352685.T8.T20	These PDE4 inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the @CHEMICAL$ induced skin inflammation in mice and in @GENE$ sensitised guinea pigs.	false
17352685.T1.T12	Results of early clinical trials with both topically (@CHEMICAL$, CP80,633) and systemically (CC-10004) active @GENE$ inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.	CPR:4
17352685.T2.T12	Results of early clinical trials with both topically (cipamfylline, @CHEMICAL$) and systemically (CC-10004) active @GENE$ inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.	CPR:4
17354225.T9.T28	Aberrant regulation of @CHEM-GENE$ by TNF-alpha in human epithelial ovarian cancer.	false
17354225.T9.T29	Aberrant regulation of @CHEMICAL$ synthetase by @GENE$ in human epithelial ovarian cancer.	false
17354225.T6.T19	Here, we show that @CHEMICAL$ also induces expression of arate-limiting enzyme in @GENE$ synthesis, argininosuccinate synthetase (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T6.T20	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in @CHEMICAL$ synthesis, @GENE$ (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T6.T21	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in @CHEMICAL$ synthesis, argininosuccinate synthetase (@GENE$), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T7.T19	Here, we show that @CHEMICAL$ also induces expression of arate-limiting enzyme in arginine synthesis, @GENE$ synthetase (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T7.T20	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, @CHEM-GENE$ (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T7.T21	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, @CHEMICAL$ synthetase (@GENE$), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T8.T19	Here, we show that @CHEMICAL$ also induces expression of arate-limiting enzyme in arginine synthesis, argininosuccinate synthetase (AS), thereby linking inflammation with several @GENE$-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T8.T20	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, @CHEMICAL$ (AS), thereby linking inflammation with several @GENE$-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T8.T21	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, argininosuccinate synthetase (@CHEMICAL$), thereby linking inflammation with several @GENE$-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	false
17354225.T1.T14	In summary, high levels of @CHEMICAL$ expression, which may be required for several @GENE$-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T1.T15	In summary, high levels of AS expression, which may be required for several @CHEMICAL$-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T2.T14	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of @GENE$, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T2.T15	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of @CHEMICAL$, proline, pyrimidines and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T3.T14	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, @GENE$, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T3.T15	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, @CHEMICAL$, pyrimidines and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T4.T14	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, @GENE$ and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T4.T15	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, @CHEMICAL$ and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T5.T14	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and @GENE$, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17354225.T5.T15	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and @CHEMICAL$, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	false
17367165.T19.T37	Mechanism of specific membrane targeting by @CHEMICAL$: localized pools of target lipids enhance @GENE$ affinity.	false
17367165.T8.T23	Although considerable functional diversity exists, most @CHEMICAL$ are activated by @GENE$ binding and then dock to a specific cellular membrane.	CPR:3
17367165.T11.T27	The @CHEMICAL$ of protein kinase Calpha (PKCalpha) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.	false
17367165.T11.T28	The C2 domains of @CHEMICAL$ (PKCalpha) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.	false
17367165.T11.T29	The C2 domains of protein kinase Calpha (@CHEMICAL$) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.	false
17367165.T11.T30	The C2 domains of protein kinase Calpha (PKCalpha) and @CHEMICAL$ (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.	false
17367165.T11.T31	The C2 domains of protein kinase Calpha (PKCalpha) and cytosolic phospholipase A2alpha (@CHEMICAL$), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.	false
17367165.T12.T34	@CHEMICAL$ activation targets the @GENE$ to the plasma membrane and the cPLA2alpha C2 domain to the internal membranes, with no detectable spatial overlap.	false
17367165.T12.T35	@CHEMICAL$ activation targets the PKCalpha C2 domain to the plasma membrane and the @GENE$ to the internal membranes, with no detectable spatial overlap.	false
17367165.T13.T20	It is crucial to determine how such targeting specificity is achieved at physiological bulk @CHEMICAL$ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T13.T36	It is crucial to determine how such targeting specificity is achieved at physiological bulk @CHEMICAL$ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @GENE$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T14.T20	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological @CHEMICAL$ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T14.T36	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological @GENE$ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T15.T20	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids @CHEMICAL$ (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T15.T36	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids @GENE$ (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T16.T20	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (@CHEMICAL$) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T16.T36	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (@GENE$) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T17.T20	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and @CHEMICAL$ (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T17.T36	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and @GENE$ (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T18.T20	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (@CHEMICAL$) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T18.T36	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (@GENE$) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.	false
17367165.T1.T21	For the @CHEMICAL$, the target lipid @GENE$ (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.	false
17367165.T2.T21	For the @CHEMICAL$, the target lipid phosphatidylcholine (@GENE$) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.	false
17367165.T3.T21	For the @CHEMICAL$, the target lipid phosphatidylcholine (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological @GENE$ levels, although the results do not rule out a second, unknown target molecule.	false
17367165.T5.T22	In principle, @CHEMICAL$-directed intracellular targeting, which requires coincidence detection of multiple signals (@GENE$ and one or more target lipids), can exhibit two different mechanisms: messenger-activated target affinity (MATA) and target-activated messenger affinity (TAMA).	false
17367165.T6.T24	The @CHEMICAL$ studied here both utilize the TAMA mechanism, in which the C2 domain @GENE$ affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.	false
17367165.T6.T25	The C2 domains studied here both utilize the TAMA mechanism, in which the @CHEMICAL$ @GENE$ affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.	false
17367165.T7.T24	The @CHEMICAL$ studied here both utilize the TAMA mechanism, in which the C2 domain Ca2+ affinity is too low to be activated by physiological @GENE$ signals in most regions of the cell.	false
17367165.T7.T25	The C2 domains studied here both utilize the TAMA mechanism, in which the @CHEMICAL$ Ca2+ affinity is too low to be activated by physiological @GENE$ signals in most regions of the cell.	false
17367165.T10.T26	Only when the @CHEMICAL$ nears its target membrane, which provides a high local concentration of target lipid, is the effective Ca2+ affinity increased by the coupled binding equilibrium to a level that enables substantial @GENE$ activation and target docking.	false
17367165.T9.T26	Only when the @CHEMICAL$ nears its target membrane, which provides a high local concentration of target lipid, is the effective @GENE$ affinity increased by the coupled binding equilibrium to a level that enables substantial Ca2+ activation and target docking.	false
17379925.T11.T26	Quantification and regulation of the subcellular distribution of @CHEM-GENE$ activity in rat liver.	false
17379925.T12.T26	Quantification and regulation of the subcellular distribution of @CHEM-GENE$ activity in rat liver.	false
17379925.T13.T26	Quantification and regulation of the subcellular distribution of @CHEM-GENE$ activity in rat liver.	false
17379925.T10.T14	@CHEMICAL$ (BAT) is responsible for the amidation of @GENE$ with the amino acids glycine and taurine.	CPR:9
17379925.T10.T20	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of @GENE$ with the amino acids glycine and taurine.	CPR:9
17379925.T1.T14	@CHEM-GENE$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	false
17379925.T1.T20	@CHEMICAL$ coenzyme A:amino acid N-acyltransferase (@GENE$) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	false
17379925.T2.T14	@CHEM-GENE$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	false
17379925.T2.T20	Bile acid @CHEMICAL$:amino acid N-acyltransferase (@GENE$) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	false
17379925.T4.T14	@CHEMICAL$ (BAT) is responsible for the amidation of bile acids with the @GENE$ glycine and taurine.	false
17379925.T4.T20	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of bile acids with the @GENE$ glycine and taurine.	false
17379925.T5.T14	@CHEMICAL$ (BAT) is responsible for the amidation of bile acids with the amino acids @GENE$ and taurine.	false
17379925.T5.T20	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of bile acids with the amino acids @GENE$ and taurine.	false
17379925.T6.T14	@CHEMICAL$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and @GENE$.	false
17379925.T6.T20	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of bile acids with the amino acids glycine and @GENE$.	false
17379925.T7.T14	@CHEM-GENE$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	false
17379925.T7.T20	Bile acid coenzyme A:@CHEMICAL$ N-acyltransferase (@GENE$) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	false
17379925.T8.T24	Treatment with @CHEMICAL$ or cholestyramine had no effect on @GENE$ activity in any subcellular compartment.	false
17379925.T9.T24	Treatment with rosiglitazone or @CHEMICAL$ had no effect on @GENE$ activity in any subcellular compartment.	false
17379925.T3.T16	These data support the novel finding that @CHEMICAL$ treatment does not directly regulate @GENE$ activity but does alter the subcellular localization of BAT.	false
17379925.T3.T17	These data support the novel finding that @CHEMICAL$ treatment does not directly regulate BAT activity but does alter the subcellular localization of @GENE$.	false
17380207.T3.T11	Because of their low asparagine synthetase (@CHEMICAL$) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to @GENE$ depletion.	false
17380207.T3.T9	Because of their low @CHEMICAL$ (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to @GENE$ depletion.	false
17380207.T4.T11	Because of their low @CHEMICAL$ synthetase (@GENE$) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.	false
17380207.T4.T9	Because of their low @CHEM-GENE$ (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.	false
17380207.T5.T11	Because of their low asparagine synthetase (@CHEMICAL$) expression and @GENE$ biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.	CPR:9
17380207.T5.T9	Because of their low @CHEMICAL$ (ASNS) expression and @GENE$ biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.	CPR:9
17380207.T1.T6	@CHEMICAL$ secretion by MSCs was directly related to their @GENE$ expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.	CPR:9
17380207.T2.T6	Asparagine secretion by MSCs was directly related to their @CHEMICAL$ expression levels, suggesting a mechanism - increased concentrations of @GENE$ in the leukemic cell microenvironment - for the protective effects we observed.	false
17403555.T19.T62	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B @CHEM-GENE$ subunits.	false
17403555.T19.T57	Toxicity of @CHEMICAL$ in HEK293 cells expressing NR1/NR2A or NR1/NR2B @GENE$ receptor subunits.	false
17403555.T19.T58	Toxicity of beta-amyloid in HEK293 cells expressing @CHEMICAL$/NR2A or NR1/NR2B @GENE$ receptor subunits.	false
17403555.T19.T59	Toxicity of beta-amyloid in HEK293 cells expressing NR1/@CHEMICAL$ or NR1/NR2B @GENE$ receptor subunits.	false
17403555.T19.T60	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or @CHEMICAL$/NR2B @GENE$ receptor subunits.	false
17403555.T19.T61	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/@CHEMICAL$ @GENE$ receptor subunits.	false
17403555.T14.T25	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves @CHEMICAL$ toxicity, resulting from overactivation of @GENE$ and elevation of intracellular calcium.	false
17403555.T14.T36	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves @GENE$ toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular calcium.	false
17403555.T14.T45	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves @GENE$ toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular calcium.	false
17403555.T1.T25	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of @CHEM-GENE$ and elevation of intracellular calcium.	false
17403555.T1.T36	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves glutamate toxicity, resulting from overactivation of @GENE$ (NMDA) receptors and elevation of intracellular calcium.	false
17403555.T1.T45	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves glutamate toxicity, resulting from overactivation of @GENE$ (NMDA) receptors and elevation of intracellular calcium.	false
17403555.T6.T25	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of @CHEM-GENE$ and elevation of intracellular calcium.	false
17403555.T6.T36	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (@GENE$) receptors and elevation of intracellular calcium.	false
17403555.T6.T45	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (@GENE$) receptors and elevation of intracellular calcium.	false
17403555.T9.T25	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of @CHEMICAL$ and elevation of intracellular @GENE$.	false
17403555.T9.T36	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular @GENE$.	false
17403555.T9.T45	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular @GENE$.	false
17403555.T10.T35	However, the heterogeneity of the @CHEM-GENE$, frequently composed of NR1 and NR2A-D subunits, has been less studied.	false
17403555.T10.T38	However, the heterogeneity of the @CHEMICAL$ receptors, frequently composed of NR1 and @GENE$ subunits, has been less studied.	false
17403555.T10.T37	However, the heterogeneity of the @CHEMICAL$ receptors, frequently composed of @GENE$ and NR2A-D subunits, has been less studied.	false
17403555.T11.T39	Thus, we determined the contribution of @CHEM-GENE$ subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/NR2B subunits.	false
17403555.T11.T40	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on @GENE$ toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/NR2B subunits.	false
17403555.T11.T41	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing @GENE$/NR2A or NR1/NR2B subunits.	false
17403555.T11.T42	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/@GENE$ or NR1/NR2B subunits.	false
17403555.T11.T43	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or @GENE$/NR2B subunits.	false
17403555.T11.T44	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/@GENE$ subunits.	false
17403555.T12.T46	Analysis of @CHEM-GENE$ (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T12.T47	Analysis of @CHEMICAL$ dehydrogenase (@GENE$) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T12.T48	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in @GENE$ toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T12.T49	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon @GENE$/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T12.T50	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/@GENE$ expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T12.T51	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to @GENE$/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T12.T52	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/@GENE$, indicating loss of plasma membrane integrity.	false
17403555.T13.T46	Analysis of @CHEMICAL$ (LDH) release and @GENE$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T13.T47	Analysis of lactate dehydrogenase (@CHEMICAL$) release and @GENE$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T13.T48	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in @GENE$ toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T13.T49	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon @GENE$/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T13.T50	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/@GENE$ expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T13.T51	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to @GENE$/NR2B, indicating loss of plasma membrane integrity.	false
17403555.T13.T52	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/@GENE$, indicating loss of plasma membrane integrity.	false
17403555.T15.T56	Furthermore, Abeta(1-40) decreased intracellular @CHEMICAL$ in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T15.T53	Furthermore, @CHEMICAL$ decreased intracellular @GENE$ in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T15.T54	Furthermore, Abeta(1-40) decreased intracellular @CHEMICAL$ in cells expressing @GENE$/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T15.T55	Furthermore, Abeta(1-40) decreased intracellular @CHEMICAL$ in cells expressing NR1/@GENE$. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T16.T56	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/NR2A. @CHEMICAL$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.	CPR:6
17403555.T16.T53	Furthermore, @CHEMICAL$ decreased intracellular ATP in cells expressing NR1/NR2A. @GENE$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T16.T54	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing @CHEMICAL$/NR2A. @GENE$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T16.T55	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/@CHEMICAL$. @GENE$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T17.T56	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 (@CHEMICAL$), a noncompetitive @GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.	CPR:6
17403555.T17.T53	Furthermore, @CHEMICAL$ decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 (@GENE$), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T17.T54	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing @CHEMICAL$/NR2A. MK-801 (@GENE$), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T17.T55	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/@CHEMICAL$. MK-801 (@GENE$), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T18.T56	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @CHEM-GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T18.T53	Furthermore, @CHEMICAL$ decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T18.T54	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing @CHEMICAL$/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T18.T55	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/@CHEMICAL$. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.	false
17403555.T2.T21	Functional @CHEMICAL$/NR2A and NR1/NR2B receptor subtypes were further evidenced by single-cell @GENE$ imaging.	false
17403555.T2.T22	Functional NR1/@CHEMICAL$ and NR1/NR2B receptor subtypes were further evidenced by single-cell @GENE$ imaging.	false
17403555.T2.T23	Functional NR1/NR2A and @CHEMICAL$/NR2B receptor subtypes were further evidenced by single-cell @GENE$ imaging.	false
17403555.T2.T24	Functional NR1/NR2A and NR1/@CHEMICAL$ receptor subtypes were further evidenced by single-cell @GENE$ imaging.	false
17403555.T3.T26	Stimulation of @CHEMICAL$/NR2A receptors with @GENE$/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	false
17403555.T3.T27	Stimulation of NR1/@CHEMICAL$ receptors with @GENE$/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	false
17403555.T3.T28	Stimulation of NR1/NR2A receptors with @CHEMICAL$/glycine revealed an increase in intracellular calcium in cells pre-exposed to @GENE$.	false
17403555.T4.T26	Stimulation of @CHEMICAL$/NR2A receptors with NMDA/@GENE$ revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	false
17403555.T4.T27	Stimulation of NR1/@CHEMICAL$ receptors with NMDA/@GENE$ revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	false
17403555.T4.T28	Stimulation of NR1/NR2A receptors with NMDA/@CHEMICAL$ revealed an increase in intracellular calcium in cells pre-exposed to @GENE$.	false
17403555.T5.T26	Stimulation of @CHEMICAL$/NR2A receptors with NMDA/glycine revealed an increase in intracellular @GENE$ in cells pre-exposed to Abeta(1-40).	false
17403555.T5.T27	Stimulation of NR1/@CHEMICAL$ receptors with NMDA/glycine revealed an increase in intracellular @GENE$ in cells pre-exposed to Abeta(1-40).	false
17403555.T5.T28	Stimulation of NR1/NR2A receptors with NMDA/glycine revealed an increase in intracellular @CHEMICAL$ in cells pre-exposed to @GENE$.	false
17403555.T7.T33	These results suggest that NR1/NR2A-composed @CHEM-GENE$ mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.	false
17403555.T7.T31	These results suggest that @CHEMICAL$/NR2A-composed @GENE$ receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.	false
17403555.T7.T32	These results suggest that NR1/@CHEMICAL$-composed @GENE$ receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.	false
17403555.T7.T34	These results suggest that NR1/NR2A-composed @CHEMICAL$ receptors mediate necrotic cell death in HEK293 cells exposed to @GENE$ through changes in calcium homeostasis.	false
17403555.T8.T33	These results suggest that NR1/NR2A-composed @CHEMICAL$ mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in @GENE$ homeostasis.	false
17403555.T8.T31	These results suggest that @CHEMICAL$/NR2A-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in @GENE$ homeostasis.	false
17403555.T8.T32	These results suggest that NR1/@CHEMICAL$-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in @GENE$ homeostasis.	false
17403555.T8.T34	These results suggest that NR1/NR2A-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to @CHEMICAL$ through changes in @GENE$ homeostasis.	false
17409318.T11.T26	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of @GENE$ from ALA.	CPR:9
17409318.T11.T28	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of @GENE$ from ALA.	CPR:9
17409318.T12.T26	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from @GENE$.	CPR:9
17409318.T12.T28	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from @GENE$.	CPR:9
17409318.T19.T26	The use of @CHEMICAL$ (D6D) twice in the conversion of @GENE$ (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T19.T28	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of @GENE$ (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T23.T26	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (@GENE$; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T23.T28	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (@GENE$; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T2.T26	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to @GENE$ (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T2.T28	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to @GENE$ (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T8.T26	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (@GENE$; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T8.T28	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (@GENE$; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	CPR:9
17409318.T20.T29	The accumulation of the post-@CHEMICAL$ products of 22:5n-3, 24:6n-3 and @GENE$, in cell phospholipids was saturated at concentrations of >18 microM ALA.	CPR:9
17409318.T21.T29	The accumulation of the post-@CHEMICAL$ products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of >18 microM @GENE$.	false
17409318.T10.T27	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for @CHEMICAL$ may contribute to the limited accumulation of @GENE$ in cell membranes.	CPR:9
17409318.T6.T27	The parallel pattern of accumulation of 24:6n-3 and @CHEMICAL$ in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for @GENE$ may contribute to the limited accumulation of DHA in cell membranes.	false
17409318.T7.T27	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of @CHEMICAL$ suggests that the competition between 24:5n-3 and ALA for @GENE$ may contribute to the limited accumulation of DHA in cell membranes.	false
17409318.T9.T27	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and @CHEMICAL$ for @GENE$ may contribute to the limited accumulation of DHA in cell membranes.	CPR:9
17413769.T10.T30	Plasma S/R ratio of @CHEMICAL$ co-varies with @GENE$ haplotype.	false
17413769.T9.T17	We recently reported that the low-dose VKORC1*2 haplotype is an important genetic determinant for @CHEMICAL$ dose requirement and is associated with difficulties to attain stable therapeutic @GENE$ time--International Normalized Ratio in patients undergoing anticoagulation therapy.	false
17413769.T9.T19	We recently reported that the low-dose @CHEMICAL$*2 haplotype is an important genetic determinant for @GENE$ dose requirement and is associated with difficulties to attain stable therapeutic prothrombin time--International Normalized Ratio in patients undergoing anticoagulation therapy.	false
17413769.T5.T18	The aim of this study was to investigate whether patients with @CHEMICAL$*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @GENE$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.	false
17413769.T5.T20	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes @CHEMICAL$*3 or VKORC1*4 had different @GENE$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.	false
17413769.T5.T21	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or @CHEMICAL$*4 had different @GENE$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.	false
17413769.T5.T22	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @CHEMICAL$ ratios in their plasma, and whether that was related to @GENE$ variants CYP2C9*2 and CYP2C9*3 or other factors.	false
17413769.T5.T23	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @CHEMICAL$ ratios in their plasma, and whether that was related to CYP2C9 variants @GENE$*2 and CYP2C9*3 or other factors.	false
17413769.T5.T24	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @CHEMICAL$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and @GENE$*3 or other factors.	false
17413769.T6.T25	Samples from patients previously haplotyped for @CHEMICAL$ and measured for plasma @GENE$ concentration were genotyped for the CYP2C9 variants CYP2C9*2 and CYP2C9*3.	false
17413769.T6.T26	Samples from patients previously haplotyped for VKORC1 and measured for plasma @CHEMICAL$ concentration were genotyped for the @GENE$ variants CYP2C9*2 and CYP2C9*3.	false
17413769.T6.T27	Samples from patients previously haplotyped for VKORC1 and measured for plasma @CHEMICAL$ concentration were genotyped for the CYP2C9 variants @GENE$*2 and CYP2C9*3.	false
17413769.T6.T28	Samples from patients previously haplotyped for VKORC1 and measured for plasma @CHEMICAL$ concentration were genotyped for the CYP2C9 variants CYP2C9*2 and @GENE$*3.	false
17413769.T8.T11	Our result shows that there is a significant difference (P<0.01) in @CHEMICAL$ ratios between VKORC1*2 and @GENE$*3 or VKORC1*4 patients.	false
17413769.T8.T12	Our result shows that there is a significant difference (P<0.01) in @CHEMICAL$ ratios between VKORC1*2 and VKORC1*3 or @GENE$*4 patients.	false
17413769.T8.T29	Our result shows that there is a significant difference (P<0.01) in @CHEMICAL$ ratios between @GENE$*2 and VKORC1*3 or VKORC1*4 patients.	false
17413769.T1.T16	We speculate that @CHEMICAL$ haplotypes possibly are linked to some unidentified factors involved in the metabolic clearance of @GENE$ enantiomers.	false
17468175.T14.T26	@CHEM-GENE$ agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.	false
17468175.T14.T27	@CHEMICAL$ D1 receptor agonist and @GENE$ antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.	false
17468175.T15.T26	@CHEMICAL$ agonist and D2 receptor antagonist effects of the natural product @GENE$: molecular modeling and dynamics simulations.	CPR:5
17468175.T15.T27	Dopamine D1 receptor agonist and @CHEMICAL$ antagonist effects of the natural product @GENE$: molecular modeling and dynamics simulations.	CPR:6
17468175.T1.T18	@CHEMICAL$ (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @GENE$ agonist and D2 antagonist.	CPR:5
17468175.T1.T19	@CHEMICAL$ (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and @GENE$ antagonist.	CPR:6
17468175.T4.T18	(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @CHEM-GENE$ agonist and D2 antagonist.	false
17468175.T4.T19	(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @CHEMICAL$ receptor D1 agonist and @GENE$ antagonist.	false
17468175.T8.T18	(-)-Stepholidine (@CHEMICAL$), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @GENE$ agonist and D2 antagonist.	CPR:5
17468175.T8.T19	(-)-Stepholidine (@CHEMICAL$), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and @GENE$ antagonist.	CPR:6
17468175.T10.T20	Insights into dynamical behaviors of @CHEMICAL$ and their interaction modes with SPD are crucial in understanding the structural and functional characteristics of @GENE$ receptors.	false
17468175.T10.T21	Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with SPD are crucial in understanding the structural and functional characteristics of @CHEM-GENE$.	false
17468175.T9.T20	Insights into dynamical behaviors of @CHEMICAL$ and their interaction modes with @GENE$ are crucial in understanding the structural and functional characteristics of dopamine receptors.	false
17468175.T9.T21	Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with @CHEMICAL$ are crucial in understanding the structural and functional characteristics of @GENE$.	false
17468175.T11.T22	In this study a computational approach, integrating protein structure prediction, automated molecular docking, and molecular dynamics simulations were employed to investigate the dual action mechanism of @CHEMICAL$ on the @GENE$, with the eventual aim to develop new drugs for treating diseases affecting the central nervous system such as schizophrenia.	false
17468175.T12.T23	"The dynamics simulations revealed the surface features of the electrostatic potentials and the conformational ""open-closed"" process of the binding entrances of two @CHEM-GENE$."	false
17468175.T13.T24	Potential binding conformations of @CHEMICAL$ were obtained, and the D1-@GENE$ and D2-SPD complexes were generated, which are in good agreement with most of experimental data.	false
17468175.T13.T16	Potential binding conformations of D1 and D2 receptors were obtained, and the D1-@CHEMICAL$ and @GENE$-SPD complexes were generated, which are in good agreement with most of experimental data.	false
17468175.T13.T25	Potential binding conformations of D1 and D2 receptors were obtained, and the @CHEMICAL$-@GENE$ and D2-SPD complexes were generated, which are in good agreement with most of experimental data.	false
17468175.T2.T24	Potential binding conformations of @CHEMICAL$ were obtained, and the D1-SPD and D2-@GENE$ complexes were generated, which are in good agreement with most of experimental data.	false
17468175.T2.T16	Potential binding conformations of D1 and D2 receptors were obtained, and the D1-SPD and @CHEMICAL$-@GENE$ complexes were generated, which are in good agreement with most of experimental data.	false
17468175.T2.T25	Potential binding conformations of D1 and D2 receptors were obtained, and the @CHEMICAL$-SPD and D2-@GENE$ complexes were generated, which are in good agreement with most of experimental data.	false
17468175.T3.T17	The @CHEMICAL$-@GENE$ structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of SPD.	false
17468175.T5.T17	The @CHEMICAL$-SPD structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of @GENE$.	false
17475961.T1.T16	UNLABELLED: Peptide hormone receptors overexpressed in human tumors, such as @CHEM-GENE$, can be used for in vivo targeting for diagnostic and therapeutic purposes.	false
17475961.T1.T3	UNLABELLED: @CHEMICAL$ overexpressed in human tumors, such as @GENE$ receptors, can be used for in vivo targeting for diagnostic and therapeutic purposes.	false
17496727.T11.T26	A novel variant @CHEMICAL$ in human @GENE$ dehydrogenase 2 is associated with diminished enzyme activity.	false
17496727.T11.T27	A novel variant L263F in @CHEM-GENE$ is associated with diminished enzyme activity.	false
17496727.T7.T21	BACKGROUND AND OBJECTIVE: @CHEM-GENE$ is required for purine synthesis in activated lymphocytes.	false
17496727.T8.T16	Variants in the @CHEMICAL$ gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving @GENE$.	false
17496727.T9.T24	Genetic variant was constructed by site-directed mutagenesis and transformed to an @CHEM-GENE$-deficient strain of Escherichia coli h712.	false
17496727.T1.T12	A novel nonsynonymous variant @CHEMICAL$ was identified, and the kinetic assay demonstrated that the @GENE$ dehydrogenase activity of L263F variant was decreased to 10% of the wild-type.	false
17496727.T1.T13	A novel nonsynonymous variant L263F was identified, and the kinetic assay demonstrated that the @CHEM-GENE$ activity of L263F variant was decreased to 10% of the wild-type.	false
17496727.T1.T14	A novel nonsynonymous variant L263F was identified, and the kinetic assay demonstrated that the @CHEMICAL$ dehydrogenase activity of @GENE$ variant was decreased to 10% of the wild-type.	false
17496727.T2.T15	The Ki for @CHEMICAL$ inhibition of the @GENE$ variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.	CPR:4
17496727.T3.T15	The Ki for mycophenolic acid inhibition of the @CHEMICAL$ variant was comparable with the wild-type, and the variant Km for @GENE$ and nicotinamide adenine dinucleotide did not change significantly.	false
17496727.T4.T15	The Ki for mycophenolic acid inhibition of the @CHEMICAL$ variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and @GENE$ did not change significantly.	false
17496727.T5.T18	CONCLUSIONS: IMPDH2 has low genetic diversity, but the nonsynonymous variant @CHEMICAL$ has a significant impact on @GENE$ dehydrogenase activity.	false
17496727.T5.T19	CONCLUSIONS: IMPDH2 has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on @CHEM-GENE$ activity.	false
17496727.T5.T17	CONCLUSIONS: @CHEMICAL$ has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on @GENE$ dehydrogenase activity.	false
17496727.T6.T20	This novel functional variant may be one of the factors contributing to the inter-individual difference of baseline @CHEM-GENE$ activity as well as drug efficacy and adverse events in transplant patients.	false
17498496.T3.T42	[Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and @CHEM-GENE$ after cerebral ischemia-reperfusion in rats].	false
17498496.T3.T43	[Effects of Panax notoginseng saponins on mRNA expressions of @CHEMICAL$, its correlative factors and @GENE$ specific protease after cerebral ischemia-reperfusion in rats].	false
17498496.T4.T42	[Effects of Panax notoginseng @CHEMICAL$ on mRNA expressions of interleukin-1 beta, its correlative factors and @GENE$ after cerebral ischemia-reperfusion in rats].	false
17498496.T4.T43	[Effects of Panax notoginseng @CHEMICAL$ on mRNA expressions of @GENE$, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats].	false
17498496.T1.T12	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (@CHEMICAL$), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T16	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), @CHEMICAL$ (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T18	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (@CHEMICAL$), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T19	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), @CHEMICAL$ (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T25	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (@CHEMICAL$), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T28	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), @CHEMICAL$ (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T29	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (@CHEMICAL$), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T30	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEM-GENE$ (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T31	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEMICAL$ specific protease-1 (@GENE$), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T32	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEMICAL$ specific protease-1 (caspase-1), @GENE$ and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T33	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEMICAL$ specific protease-1 (caspase-1), caspase-3 and @GENE$ after cerebral ischemia-reperfusion in rats.	false
17498496.T1.T41	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of @CHEMICAL$ (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T12	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (@GENE$), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T16	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), @GENE$ (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T18	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (@GENE$), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T19	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), @GENE$ (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T25	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (@GENE$), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T28	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), @GENE$ (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T29	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (@GENE$), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T30	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T31	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (@GENE$), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T32	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), @GENE$ and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T33	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and @GENE$ after cerebral ischemia-reperfusion in rats.	false
17498496.T2.T41	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of @GENE$ (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	false
17512091.T21.T40	Downregulation of @CHEMICAL$ but not @GENE$ loss leads to mitochondrial dysfunction in female mice CNS: implications in excitotoxicity.	false
17512091.T11.T37	We examined the critical roles played by the antioxidant, non-protein @CHEMICAL$, glutathione and related enzyme, @GENE$ in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	false
17512091.T12.T37	We examined the critical roles played by the antioxidant, non-protein thiol, @CHEMICAL$ and related enzyme, @GENE$ in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	false
17512091.T13.T37	We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, @CHEMICAL$ in maintaining mitochondrial function during excitotoxicity caused by @GENE$ (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	false
17512091.T14.T37	We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, @CHEMICAL$ in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (@GENE$), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	false
17512091.T15.T38	@CHEMICAL$ causes loss of GSH and inhibition of @GENE$ in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.	CPR:4
17512091.T16.T38	L-BOAA causes loss of @CHEMICAL$ and inhibition of @GENE$ in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.	false
17512091.T17.T38	L-BOAA causes loss of GSH and inhibition of @CHEMICAL$ in lumbosacral cord of male mice through oxidation of @GENE$ groups, while female mice are resistant.	false
17512091.T18.T39	Reducing @CHEMICAL$ levels in female mice CNS by pretreatment with diethyl maleate or L-propargyl glycine did not result in inhibition of @GENE$ activity, unlike male mice.	false
17512091.T19.T39	Reducing GSH levels in female mice CNS by pretreatment with @CHEMICAL$ or L-propargyl glycine did not result in inhibition of @GENE$ activity, unlike male mice.	false
17512091.T20.T39	Reducing GSH levels in female mice CNS by pretreatment with diethyl maleate or @CHEMICAL$ did not result in inhibition of @GENE$ activity, unlike male mice.	false
17512091.T1.T22	Further, treatment of female mice depleted of @CHEMICAL$ with L-BOAA did not induce inhibition of @GENE$ indicating that GSH levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.	false
17512091.T1.T23	Further, treatment of female mice depleted of @CHEMICAL$ with L-BOAA did not induce inhibition of complex I indicating that GSH levels were not critical for maintaining @GENE$ activity in female mice unlike their male counterpart.	false
17512091.T2.T22	Further, treatment of female mice depleted of GSH with @CHEMICAL$ did not induce inhibition of @GENE$ indicating that GSH levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.	false
17512091.T2.T23	Further, treatment of female mice depleted of GSH with @CHEMICAL$ did not induce inhibition of complex I indicating that GSH levels were not critical for maintaining @GENE$ activity in female mice unlike their male counterpart.	false
17512091.T3.T22	Further, treatment of female mice depleted of GSH with L-BOAA did not induce inhibition of @CHEMICAL$ indicating that @GENE$ levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.	false
17512091.T3.T23	Further, treatment of female mice depleted of GSH with L-BOAA did not induce inhibition of complex I indicating that @CHEMICAL$ levels were not critical for maintaining @GENE$ activity in female mice unlike their male counterpart.	false
17512091.T4.T24	@CHEMICAL$, a thiol @GENE$ oxidoreductase helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of mitochondrial complex I activity.	false
17512091.T4.T25	Glutaredoxin, a @CHEM-GENE$ helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of mitochondrial complex I activity.	false
17512091.T4.T26	Glutaredoxin, a thiol @CHEMICAL$ oxidoreductase helps maintain redox status of proteins and downregulation of @GENE$ results in loss of mitochondrial complex I activity.	false
17512091.T4.T27	Glutaredoxin, a thiol @CHEMICAL$ oxidoreductase helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of @GENE$ activity.	false
17512091.T6.T28	Female mice express higher levels of @CHEMICAL$ in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to @GENE$ toxicity seen as mitochondrial complex I loss.	false
17512091.T6.T29	Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of @CHEMICAL$ using antisense oligonucleotides sensitizes them to @GENE$ toxicity seen as mitochondrial complex I loss.	false
17512091.T6.T30	Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to @CHEMICAL$ toxicity seen as @GENE$ loss.	CPR:4
17512091.T7.T31	Ovariectomy downregulates @CHEMICAL$ and renders female mice vulnerable to @GENE$ toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.	false
17512091.T7.T33	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to @CHEMICAL$ toxicity as evidenced by activation of AP1, loss of GSH and @GENE$ activity indicating the important role of glutaredoxin in neuroprotection.	CPR:3
17512091.T7.T34	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to @CHEMICAL$ toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of @GENE$ in neuroprotection.	false
17512091.T7.T32	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to @CHEMICAL$ toxicity as evidenced by activation of @GENE$, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.	CPR:3
17512091.T8.T31	Ovariectomy downregulates @CHEMICAL$ and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of @GENE$ and complex I activity indicating the important role of glutaredoxin in neuroprotection.	false
17512091.T8.T33	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of @CHEMICAL$ and @GENE$ activity indicating the important role of glutaredoxin in neuroprotection.	false
17512091.T8.T34	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of @CHEMICAL$ and complex I activity indicating the important role of @GENE$ in neuroprotection.	false
17512091.T8.T32	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of @CHEMICAL$, loss of @GENE$ and complex I activity indicating the important role of glutaredoxin in neuroprotection.	false
17512091.T9.T35	@CHEMICAL$ protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of @GENE$ in the CNS.	CPR:3
17550897.T10.T41	The @CHEMICAL$ of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced @GENE$ release in Jurkat T lymphocytes.	false
17550897.T10.T43	The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to @CHEMICAL$-induced @GENE$ release in Jurkat T lymphocytes.	false
17550897.T10.T40	The calponin homology domain of @CHEMICAL$ associates with calmodulin and is prerequisite to T cell antigen receptor-induced @GENE$ release in Jurkat T lymphocytes.	false
17550897.T10.T42	The calponin homology domain of Vav1 associates with @CHEMICAL$ and is prerequisite to T cell antigen receptor-induced @GENE$ release in Jurkat T lymphocytes.	false
17550897.T1.T14	Vav1 is a @CHEM-GENE$ that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation.	false
17550897.T1.T11	@CHEMICAL$ is a @GENE$ exchange factor that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation.	false
17550897.T5.T23	Vav1 consists of multiple structural domains so as to facilitate both its @CHEMICAL$ exchange activity and scaffold function following @GENE$ (TCR) engagement.	false
17550897.T5.T24	Vav1 consists of multiple structural domains so as to facilitate both its @CHEMICAL$ exchange activity and scaffold function following T cell antigen receptor (@GENE$) engagement.	false
17550897.T5.T22	@CHEMICAL$ consists of multiple structural domains so as to facilitate both its @GENE$ exchange activity and scaffold function following T cell antigen receptor (TCR) engagement.	false
17550897.T6.T25	Previous studies demonstrated that the @CHEMICAL$ of Vav1 is required for TCR-stimulated @GENE$ mobilization and thus downstream activation of nuclear factor of activated T cells.	false
17550897.T6.T28	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for TCR-stimulated @CHEMICAL$ mobilization and thus downstream activation of @GENE$.	false
17550897.T6.T26	Previous studies demonstrated that the calponin homology (CH) domain of @CHEMICAL$ is required for TCR-stimulated @GENE$ mobilization and thus downstream activation of nuclear factor of activated T cells.	false
17550897.T6.T27	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for @CHEMICAL$-stimulated @GENE$ mobilization and thus downstream activation of nuclear factor of activated T cells.	false
17550897.T7.T29	However, it remained obscure how @CHEMICAL$ functions in regulating @GENE$ flux.	false
17550897.T8.T33	In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to Vav1 in a @CHEMICAL$-dependent and @GENE$ activation-independent manner.	false
17550897.T8.T30	In an effort to explore molecules interacting with @CHEMICAL$, we found that calmodulin bound to Vav1 in a @GENE$-dependent and TCR activation-independent manner.	false
17550897.T8.T31	In an effort to explore molecules interacting with Vav1, we found that @CHEMICAL$ bound to Vav1 in a @GENE$-dependent and TCR activation-independent manner.	false
17550897.T8.T32	In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to @CHEMICAL$ in a @GENE$-dependent and TCR activation-independent manner.	false
17550897.T9.T38	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with @CHEMICAL$-deleted Vav1 exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.	false
17550897.T9.T12	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in @CHEMICAL$ release to the same extent as that of Jurkat cells treated with the @GENE$ inhibitor or J.Vav1 cells.	false
17550897.T9.T13	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in @CHEMICAL$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.@GENE$ cells.	false
17550897.T9.T36	Reconstitution of @CHEMICAL$-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.	false
17550897.T9.T37	Reconstitution of vav1-null Jurkat T cells (J.@CHEMICAL$) with CH-deleted Vav1 exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.	false
17550897.T9.T39	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted @CHEMICAL$ exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.	false
17550897.T2.T16	The defect persisted even when phospholipase-Cgamma1 was fully activated, indicating a prerequisite role of @CHEMICAL$ in @GENE$ signaling.	false
17550897.T2.T15	The defect persisted even when @CHEMICAL$ was fully activated, indicating a prerequisite role of Vav1 CH domain in @GENE$ signaling.	false
17550897.T3.T19	The results suggest that Vav1 and calmodulin function cooperatively to potentiate @CHEMICAL$-induced @GENE$ release.	false
17550897.T3.T17	The results suggest that @CHEMICAL$ and calmodulin function cooperatively to potentiate TCR-induced @GENE$ release.	false
17550897.T3.T18	The results suggest that Vav1 and @CHEMICAL$ function cooperatively to potentiate TCR-induced @GENE$ release.	false
17550897.T4.T20	This study unveiled a mechanism by which the @CHEMICAL$ is involved in @GENE$ signaling and provides insight into our understanding of the role of Vav1 in T cell activation.	false
17550897.T4.T21	This study unveiled a mechanism by which the Vav1 CH domain is involved in @CHEMICAL$ signaling and provides insight into our understanding of the role of @GENE$ in T cell activation.	false
17554001.T6.T19	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, @CHEMICAL$ and GABA, share the same @GENE$ (VIAAT) and are both present in neurons during postnatal development.	CPR:9
17554001.T6.T20	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, @CHEMICAL$ and GABA, share the same vesicular inhibitory amino acid transporter (@GENE$) and are both present in neurons during postnatal development.	CPR:9
17554001.T7.T19	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and @CHEMICAL$, share the same @GENE$ (VIAAT) and are both present in neurons during postnatal development.	CPR:9
17554001.T7.T20	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and @CHEMICAL$, share the same vesicular inhibitory amino acid transporter (@GENE$) and are both present in neurons during postnatal development.	CPR:9
17554001.T8.T19	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same @CHEM-GENE$ (VIAAT) and are both present in neurons during postnatal development.	false
17554001.T8.T20	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory @CHEMICAL$ transporter (@GENE$) and are both present in neurons during postnatal development.	false
17554001.T10.T22	We have expressed VIAAT and the @CHEMICAL$ for glycine and @GENE$ in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.	CPR:9
17554001.T10.T21	We have expressed @CHEMICAL$ and the plasmalemmal transporters for glycine and @GENE$ in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.	CPR:9
17554001.T11.T22	We have expressed VIAAT and the @CHEMICAL$ for glycine and GABA in a neuroendocrine cell line and measured the quantal release of @GENE$ and GABA using a novel double-sniffer patch-clamp technique.	false
17554001.T11.T21	We have expressed @CHEMICAL$ and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of @GENE$ and GABA using a novel double-sniffer patch-clamp technique.	false
17554001.T12.T22	We have expressed VIAAT and the @CHEMICAL$ for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and @GENE$ using a novel double-sniffer patch-clamp technique.	false
17554001.T12.T21	We have expressed @CHEMICAL$ and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and @GENE$ using a novel double-sniffer patch-clamp technique.	false
17554001.T9.T22	We have expressed VIAAT and the @CHEMICAL$ for @GENE$ and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.	CPR:9
17554001.T9.T21	We have expressed @CHEMICAL$ and the plasmalemmal transporters for @GENE$ and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.	CPR:9
17554001.T13.T24	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the @GENE$ GlyT2 or the glial transporter GlyT1.	false
17554001.T13.T26	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the @GENE$ GlyT1.	false
17554001.T13.T23	We found that @CHEMICAL$ is released from vesicles when @GENE$ is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.	CPR:9
17554001.T13.T25	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the neuronal transporter @GENE$ or the glial transporter GlyT1.	false
17554001.T13.T27	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial transporter @GENE$.	false
17554001.T14.T28	However, @CHEMICAL$ was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @GENE$ concentration required for efficient vesicular loading by VIAAT.	false
17554001.T14.T29	However, GlyT2 was more effective than @CHEMICAL$, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @GENE$ concentration required for efficient vesicular loading by VIAAT.	false
17554001.T14.T30	However, GlyT2 was more effective than GlyT1, probably because @CHEMICAL$ is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @GENE$ concentration required for efficient vesicular loading by VIAAT.	false
17554001.T14.T31	However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @CHEMICAL$ concentration required for efficient vesicular loading by @GENE$.	CPR:9
17554001.T1.T15	The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when @CHEMICAL$ is introduced into the secretory cell and competes for uptake by @GENE$.	CPR:9
17554001.T2.T16	Interestingly, the @CHEMICAL$ ortholog from Caenorhabditis elegans (UNC-47), a species lacking @GENE$ transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.	false
17554001.T2.T17	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking @CHEMICAL$ transmission, also supports glycine exocytosis in the presence of @GENE$, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.	false
17554001.T3.T16	Interestingly, the @CHEMICAL$ ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports @GENE$ exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.	false
17554001.T3.T17	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports @CHEMICAL$ exocytosis in the presence of @GENE$, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.	CPR:9
17554001.T4.T16	Interestingly, the @CHEMICAL$ ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes @GENE$ transmission in the worm confers glycine specificity.	false
17554001.T4.T17	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of @CHEMICAL$, and a point mutation of UNC-47 that abolishes @GENE$ transmission in the worm confers glycine specificity.	false
17554001.T5.T18	Together, these results suggest that an increased cytosolic availability of @CHEMICAL$ in @GENE$-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.	CPR:9
17578749.T1.T10	The following AOD was examined: @CHEMICAL$ dismutase (@GENE$), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T13	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), @GENE$ (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T14	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (@GENE$), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T15	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T17	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).	false
17578749.T1.T9	The following AOD was examined: @CHEM-GENE$ (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T11	The following AOD was examined: @CHEMICAL$ dismutase (SOD), @GENE$ (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T12	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (@GENE$), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T1.T16	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).	false
17578749.T2.T10	The following AOD was examined: superoxide dismutase (@CHEMICAL$), catalase (CAT), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T13	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEM-GENE$ (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T14	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (@GENE$), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T15	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T17	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).	false
17578749.T2.T9	The following AOD was examined: @CHEMICAL$ (SOD), catalase (CAT), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T11	The following AOD was examined: superoxide dismutase (SOD), @CHEMICAL$ (CAT), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T12	The following AOD was examined: superoxide dismutase (SOD), catalase (@CHEMICAL$), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T2.T16	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).	false
17578749.T3.T10	The following AOD was examined: superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T13	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T14	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T15	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), @CHEMICAL$, and vitamin A. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T17	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), @CHEMICAL$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).	false
17578749.T3.T9	The following AOD was examined: @CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T11	The following AOD was examined: superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T12	The following AOD was examined: superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T3.T16	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), @CHEMICAL$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).	false
17578749.T4.T10	The following AOD was examined: superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T13	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T14	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T15	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @CHEMICAL$. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T17	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @CHEMICAL$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).	false
17578749.T4.T9	The following AOD was examined: @CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T11	The following AOD was examined: superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T12	The following AOD was examined: superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	false
17578749.T4.T16	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @CHEMICAL$. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).	false
17581967.T11.T27	@CHEMICAL$/Cl- dipole couples agonist binding to @GENE$ activation.	CPR:3
17581967.T12.T27	Na+/Cl- dipole couples agonist binding to @CHEM-GENE$ activation.	false
17581967.T13.T27	Na+/@CHEMICAL$ dipole couples agonist binding to @GENE$ activation.	CPR:3
17581967.T1.T14	@CHEM-GENE$ (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.	false
17581967.T1.T19	@CHEMICAL$-selective ionotropic glutamate receptors (@GENE$) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.	false
17581967.T2.T14	@CHEMICAL$ (GluRs) require external Na+ and Cl- as well as the neurotransmitter @GENE$ for activation.	CPR:3
17581967.T2.T19	Kainate-selective ionotropic glutamate receptors (@CHEMICAL$) require external Na+ and Cl- as well as the neurotransmitter @GENE$ for activation.	CPR:3
17581967.T4.T14	@CHEM-GENE$ (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.	false
17581967.T4.T19	Kainate-selective ionotropic @CHEMICAL$ receptors (@GENE$) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.	false
17581967.T6.T14	@CHEMICAL$ (GluRs) require external @GENE$ and Cl- as well as the neurotransmitter L-glutamate for activation.	CPR:3
17581967.T6.T19	Kainate-selective ionotropic glutamate receptors (@CHEMICAL$) require external @GENE$ and Cl- as well as the neurotransmitter L-glutamate for activation.	CPR:3
17581967.T7.T14	@CHEMICAL$ (GluRs) require external Na+ and @GENE$ as well as the neurotransmitter L-glutamate for activation.	CPR:3
17581967.T7.T19	Kainate-selective ionotropic glutamate receptors (@CHEMICAL$) require external Na+ and @GENE$ as well as the neurotransmitter L-glutamate for activation.	CPR:3
17581967.T3.T16	Although, external anions and cations apparently coactivate @CHEM-GENE$ (KARs) in an identical manner, it has yet to be established how ions of opposite charge achieve this.	false
17581967.T3.T17	Although, external anions and cations apparently coactivate @CHEMICAL$ receptors (@GENE$) in an identical manner, it has yet to be established how ions of opposite charge achieve this.	false
17581967.T5.T20	Consequently, other cation species may compete with @CHEMICAL$ to regulate the time @GENE$ remain in the open state.	false
17581967.T8.T26	Additionally, @CHEMICAL$ and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on @GENE$.	false
17581967.T8.T25	Additionally, @CHEMICAL$ and Cl- ions coactivate @GENE$ receptors by establishing a dipole, accounting for their common effect on KARs.	CPR:3
17581967.T9.T26	Additionally, Na+ and @CHEMICAL$ ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on @GENE$.	false
17581967.T9.T25	Additionally, Na+ and @CHEMICAL$ ions coactivate @GENE$ receptors by establishing a dipole, accounting for their common effect on KARs.	CPR:3
17590520.T3.T8	@CHEMICAL$ receptor gene @GENE$ modulates early event-related potentials in auditory and visual oddball target detection tasks.	false
17590520.T1.T4	The same sense @CHEMICAL$-to-cytosine polymorphism (c.@GENE$; Ser543Ser) was shown to preferentially modulate early components in both modalities.	false
17590520.T1.T5	The same sense @CHEMICAL$-to-cytosine polymorphism (c.1629T-C; @GENE$) was shown to preferentially modulate early components in both modalities.	false
17590520.T2.T4	The same sense thymine-to-@CHEMICAL$ polymorphism (c.@GENE$; Ser543Ser) was shown to preferentially modulate early components in both modalities.	false
17590520.T2.T5	The same sense thymine-to-@CHEMICAL$ polymorphism (c.1629T-C; @GENE$) was shown to preferentially modulate early components in both modalities.	false
17594192.T1.T16	@CHEMICAL$, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (@GENE$) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
17594192.T1.T27	@CHEMICAL$, a derivative of physostigmine, was first described as an inhibitor of @GENE$ (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
17594192.T7.T16	Phenserine, a derivative of @CHEMICAL$, was first described as an inhibitor of acetylcholinesterase (@GENE$) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
17594192.T7.T27	Phenserine, a derivative of @CHEMICAL$, was first described as an inhibitor of @GENE$ (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
17594192.T8.T20	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting @GENE$, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation.	CPR:4
17594192.T8.T21	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of @GENE$ (APP) in neuronal cell culture by reducing APP translation.	false
17594192.T8.T22	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (@GENE$) in neuronal cell culture by reducing APP translation.	false
17594192.T8.T23	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing @GENE$ translation.	CPR:4
17594192.T9.T24	This effect probably involves interaction of @CHEMICAL$ with a regulatory element in the 5'-untranslated region of the @GENE$ gene that controls APP expression.	false
17594192.T9.T25	This effect probably involves interaction of @CHEMICAL$ with a regulatory element in the 5'-untranslated region of the APP gene that controls @GENE$ expression.	false
17594192.T10.T26	@CHEMICAL$ apparently reduces translational efficiency of @GENE$ mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.	CPR:4
17594192.T11.T26	Phenserine apparently reduces translational efficiency of @CHEMICAL$ mRNA into protein, a process that may involve an interaction with @GENE$ and/or an iron-responsive element.	false
17594192.T12.T26	Phenserine apparently reduces translational efficiency of @CHEMICAL$ mRNA into protein, a process that may involve an interaction with iron and/or an @GENE$-responsive element.	false
17594192.T13.T28	As a consequence, @CHEMICAL$ reduces @GENE$ peptide (Abeta) formation in vitro and in vivo.	CPR:4
17594192.T13.T29	As a consequence, @CHEMICAL$ reduces beta-amyloid peptide (@GENE$) formation in vitro and in vivo.	CPR:4
17594192.T14.T17	@CHEMICAL$ is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of @GENE$, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.	false
17594192.T14.T18	@CHEMICAL$ is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen') has weak activity as an @GENE$ inhibitor and can be dosed much higher.	false
17594192.T2.T17	Phenserine is also unique because of differing actions of its enantiomers: @CHEMICAL$ is the active enantiomer for inhibition of @GENE$, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.	CPR:4
17594192.T2.T18	Phenserine is also unique because of differing actions of its enantiomers: @CHEMICAL$ is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen') has weak activity as an @GENE$ inhibitor and can be dosed much higher.	false
17594192.T3.T17	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of @CHEMICAL$, whereas @GENE$ ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.	false
17594192.T3.T18	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas @CHEMICAL$ ('posiphen') has weak activity as an @GENE$ inhibitor and can be dosed much higher.	CPR:4
17594192.T4.T17	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of @CHEMICAL$, whereas (+)-phenserine ('@GENE$') has weak activity as an AChE inhibitor and can be dosed much higher.	false
17594192.T4.T18	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('@CHEMICAL$') has weak activity as an @GENE$ inhibitor and can be dosed much higher.	CPR:4
17594192.T5.T19	Both enantiomers are equipotent in downregulating @CHEMICAL$ expression. @GENE$ may be a promising drug, either alone or in combination with (-)-phenserine, to attenuate the progression of Alzheimer's disease.	false
17594192.T6.T19	Both enantiomers are equipotent in downregulating @CHEMICAL$ expression. (+)-Posiphen may be a promising drug, either alone or in combination with @GENE$, to attenuate the progression of Alzheimer's disease.	false
17603545.T1.T7	Contractile tension of the vas deferens in response to @CHEMICAL$ was markedly decreased in alpha(1A)-adrenoceptor KO mice, and this contraction was completely abolished in @GENE$ triple-KO mice.	false
17603545.T1.T6	Contractile tension of the vas deferens in response to @CHEMICAL$ was markedly decreased in @GENE$ KO mice, and this contraction was completely abolished in alpha(1)-adrenoceptor triple-KO mice.	false
17603555.T47.T61	Pharmacological activators of @CHEM-GENE$ have different effects on Na+ transport processes across human lung epithelial cells.	false
17603555.T48.T61	Pharmacological activators of @CHEMICAL$ have different effects on @GENE$ transport processes across human lung epithelial cells.	false
17603555.T27.T55	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (@GENE$).	CPR:3
17603555.T27.T57	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (@GENE$).	CPR:3
17603555.T30.T55	BACKGROUND AND PURPOSE: @CHEM-GENE$ (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	false
17603555.T30.T57	BACKGROUND AND PURPOSE: @CHEMICAL$-activated protein kinase (@GENE$) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	false
17603555.T3.T55	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, phenformin, and the @GENE$ mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	false
17603555.T3.T57	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, phenformin, and the @GENE$ mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	false
17603555.T40.T55	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by @GENE$, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	CPR:3
17603555.T40.T57	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by @GENE$, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	CPR:3
17603555.T42.T55	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, @GENE$, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	CPR:3
17603555.T42.T57	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, @GENE$, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	CPR:3
17603555.T8.T55	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, phenformin, and the AMP mimetic, @GENE$ (AICAR).	CPR:3
17603555.T8.T57	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, phenformin, and the AMP mimetic, @GENE$ (AICAR).	CPR:3
17603555.T31.T56	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, @GENE$ concentration, transepithelial amiloride-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	false
17603555.T32.T56	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial @GENE$-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	false
17603555.T33.T56	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(@GENE$)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	false
17603555.T34.T56	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and @GENE$-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	false
17603555.T35.T56	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(@GENE$)) short circuit current in H441 lung epithelial cells.	false
17603555.T38.T58	@CHEMICAL$ activity was measured as the amount of radiolabelled @GENE$ transferred to the SAMS peptide.	false
17603555.T43.T59	KEY RESULTS: @CHEMICAL$, AICAR and metformin increased @GENE$ activity and decreased I(amiloride).	CPR:3
17603555.T44.T59	KEY RESULTS: Phenformin, @CHEMICAL$ and metformin increased @GENE$ activity and decreased I(amiloride).	CPR:3
17603555.T45.T59	KEY RESULTS: Phenformin, AICAR and @CHEMICAL$ increased @GENE$ activity and decreased I(amiloride).	CPR:3
17603555.T46.T59	KEY RESULTS: Phenformin, AICAR and metformin increased @CHEMICAL$ activity and decreased I(@GENE$).	false
17603555.T1.T60	The @CHEMICAL$ inhibitor Compound C prevented the action of @GENE$ and AICAR but not phenformin.	false
17603555.T2.T60	The @CHEMICAL$ inhibitor Compound C prevented the action of metformin and @GENE$ but not phenformin.	false
17603555.T4.T60	The @CHEMICAL$ inhibitor Compound C prevented the action of metformin and AICAR but not @GENE$.	CPR:3
17603555.T20.T50	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEM-GENE$ (ENaC), which has important implications for the clinical use of metformin.	false
17603555.T20.T51	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEMICAL$-sensitive Na(+) channels (@GENE$), which has important implications for the clinical use of metformin.	false
17603555.T20.T49	CONCLUSIONS AND IMPLICATIONS: Activation of @CHEMICAL$ is associated with inhibition of apical @GENE$-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of metformin.	false
17603555.T21.T50	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEM-GENE$ (ENaC), which has important implications for the clinical use of metformin.	false
17603555.T21.T51	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive @CHEMICAL$ channels (@GENE$), which has important implications for the clinical use of metformin.	false
17603555.T21.T49	CONCLUSIONS AND IMPLICATIONS: Activation of @CHEMICAL$ is associated with inhibition of apical amiloride-sensitive @GENE$ channels (ENaC), which has important implications for the clinical use of metformin.	false
17603555.T22.T50	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEMICAL$ (ENaC), which has important implications for the clinical use of @GENE$.	false
17603555.T22.T51	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive Na(+) channels (@CHEMICAL$), which has important implications for the clinical use of @GENE$.	false
17603555.T22.T49	CONCLUSIONS AND IMPLICATIONS: Activation of @CHEMICAL$ is associated with inhibition of apical amiloride-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of @GENE$.	false
17603555.T23.T52	Additional pharmacological effects evoked by @CHEMICAL$ and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	false
17603555.T23.T54	Additional pharmacological effects evoked by @CHEMICAL$ and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.	false
17603555.T23.T53	Additional pharmacological effects evoked by @CHEMICAL$ and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.	CPR:3
17603555.T24.T52	Additional pharmacological effects evoked by AICAR and @CHEMICAL$ on I(ouabain), with potential secondary effects on apical Na+ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	false
17603555.T24.T54	Additional pharmacological effects evoked by AICAR and @CHEMICAL$ on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.	false
17603555.T24.T53	Additional pharmacological effects evoked by AICAR and @CHEMICAL$ on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.	CPR:3
17603555.T25.T52	Additional pharmacological effects evoked by AICAR and phenformin on I(@CHEMICAL$), with potential secondary effects on apical Na+ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	false
17603555.T25.T54	Additional pharmacological effects evoked by AICAR and phenformin on I(@CHEMICAL$), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.	false
17603555.T25.T53	Additional pharmacological effects evoked by AICAR and phenformin on I(@CHEMICAL$), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.	CPR:3
17603555.T26.T52	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical @CHEMICAL$ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	false
17603555.T26.T54	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical @CHEMICAL$ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.	false
17603555.T26.T53	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical @CHEMICAL$ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.	false
17603555.T28.T52	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, @CHEMICAL$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$+K+ATPase is an important component.	false
17603555.T28.T54	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @CHEM-GENE$ is an important component.	false
17603555.T28.T53	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @CHEMICAL$ in cell systems where @GENE$+K+ATPase is an important component.	false
17603555.T29.T52	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, @CHEMICAL$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+@GENE$+ATPase is an important component.	false
17603555.T29.T54	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @CHEM-GENE$ is an important component.	false
17603555.T29.T53	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @CHEMICAL$ in cell systems where Na+@GENE$+ATPase is an important component.	false
17604186.T20.T30	Neuroprotective effect of @CHEMICAL$, a preferential @GENE$ inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.	CPR:4
17604186.T21.T30	Neuroprotective effect of nimesulide, a preferential @CHEMICAL$ inhibitor, against @GENE$ (PTZ)-induced chemical kindling and associated biochemical parameters in mice.	false
17604186.T22.T30	Neuroprotective effect of nimesulide, a preferential @CHEMICAL$ inhibitor, against pentylenetetrazol (@GENE$)-induced chemical kindling and associated biochemical parameters in mice.	false
17604186.T15.T25	Brain cyclooxygenases (@CHEMICAL$), the rate-limiting enzyme in @GENE$ synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.	CPR:9
17604186.T15.T29	Brain @CHEMICAL$ (COX), the rate-limiting enzyme in @GENE$ synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.	CPR:9
17604186.T10.T26	Previous studies have explored the protective effect of naproxen (non-selective @CHEMICAL$-inhibitor) or @GENE$ (selective COX-2 inhibitor) against chemical kindling in mice.	false
17604186.T10.T27	Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or @CHEMICAL$ (selective @GENE$ inhibitor) against chemical kindling in mice.	CPR:4
17604186.T9.T26	Previous studies have explored the protective effect of @CHEMICAL$ (non-selective @GENE$-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.	CPR:4
17604186.T9.T27	Previous studies have explored the protective effect of @CHEMICAL$ (non-selective COX-inhibitor) or rofecoxib (selective @GENE$ inhibitor) against chemical kindling in mice.	false
17604186.T11.T28	With this background, the present study was designed to explore the possible effect of @CHEMICAL$ (a preferential @GENE$ inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.	CPR:4
17604186.T12.T28	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential @CHEMICAL$ inhibitor) against @GENE$ (PTZ)-induced kindling epilepsy in mice.	false
17604186.T13.T28	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential @CHEMICAL$ inhibitor) against pentylenetetrazol (@GENE$)-induced kindling epilepsy in mice.	false
17604186.T1.T23	Compared with normal control group, @CHEMICAL$-kindled mice had significantly higher levels of malondialdehyde, nitrite, @GENE$ but had lower levels of reduced glutathione in the whole brain homogenate.	CPR:3
17604186.T2.T23	Compared with normal control group, PTZ-kindled mice had significantly higher levels of @CHEMICAL$, nitrite, @GENE$ but had lower levels of reduced glutathione in the whole brain homogenate.	false
17604186.T3.T23	Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, @CHEMICAL$, @GENE$ but had lower levels of reduced glutathione in the whole brain homogenate.	false
17604186.T4.T23	Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, nitrite, @CHEMICAL$ but had lower levels of reduced @GENE$ in the whole brain homogenate.	false
17604186.T7.T24	These results suggested that @CHEMICAL$, a preferential @GENE$ inhibitor offered neuroprotection against PTZ-induced kindling in mice.	CPR:4
17604186.T8.T24	These results suggested that nimesulide, a preferential @CHEMICAL$ inhibitor offered neuroprotection against @GENE$-induced kindling in mice.	false
17617661.T5.T20	@CHEM-GENE$ polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study.	false
17617661.T6.T20	@CHEM-GENE$ polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study.	false
17617661.T1.T10	@CHEMICAL$, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @GENE$ (GSTs) before urinary excretion.	false
17617661.T1.T11	@CHEMICAL$, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione S-transferases (@GENE$) before urinary excretion.	false
17617661.T2.T10	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to @CHEMICAL$ by @GENE$ (GSTs) before urinary excretion.	false
17617661.T2.T11	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to @CHEMICAL$ by glutathione S-transferases (@GENE$) before urinary excretion.	false
17617661.T3.T10	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @CHEM-GENE$ (GSTs) before urinary excretion.	false
17617661.T3.T11	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @CHEMICAL$ S-transferases (@GENE$) before urinary excretion.	false
17617661.T4.T10	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @CHEM-GENE$ (GSTs) before urinary excretion.	false
17617661.T4.T11	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione @CHEMICAL$-transferases (@GENE$) before urinary excretion.	false
17627474.T19.T32	Regulated function of the @CHEM-GENE$.	false
17627474.T20.T32	Regulated function of the @CHEM-GENE$.	false
17627474.T12.T24	Cellular oxygen is sensed by @CHEM-GENE$ that hydroxylate hypoxia-inducible factor (HIF) alpha subunits.	false
17627474.T12.T29	Cellular oxygen is sensed by @CHEMICAL$-4-hydroxylase domain (PHD) proteins that hydroxylate @GENE$ subunits.	false
17627474.T14.T24	Cellular oxygen is sensed by @CHEMICAL$ that @GENE$ hypoxia-inducible factor (HIF) alpha subunits.	false
17627474.T14.T29	Cellular oxygen is sensed by prolyl-4-hydroxylase domain (PHD) proteins that @CHEMICAL$ @GENE$ subunits.	false
17627474.T17.T24	Cellular @CHEMICAL$ is sensed by @GENE$ that hydroxylate hypoxia-inducible factor (HIF) alpha subunits.	false
17627474.T17.T29	Cellular @CHEMICAL$ is sensed by prolyl-4-hydroxylase domain (PHD) proteins that hydroxylate @GENE$ subunits.	false
17627474.T13.T28	Thus, the @CHEMICAL$ @GENE$ sensors themselves represent effectors of cellular signalling pathways as well as potential drug targets.	false
17627474.T15.T30	Here, a cell-free in vitro microtiter plate-based peptide hydroxylation assay was used to investigate the influence of @CHEMICAL$, Krebs cycle intermediates, transition metals, and vitamin C and other antioxidants on the activity of purified @GENE$.	false
17627474.T16.T30	Here, a cell-free in vitro microtiter plate-based peptide hydroxylation assay was used to investigate the influence of ferrous iron, Krebs cycle intermediates, transition metals, and @CHEMICAL$ and other antioxidants on the activity of purified @GENE$.	false
17627474.T18.T31	@CHEMICAL$ activity depends not only on @GENE$ availability but is also regulated by iron, vitamin C, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	false
17627474.T1.T31	@CHEMICAL$ activity depends not only on oxygen availability but is also regulated by @GENE$, vitamin C, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	false
17627474.T2.T31	@CHEMICAL$ activity depends not only on oxygen availability but is also regulated by iron, @GENE$, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	false
17627474.T10.T21	While vitamin C is essential for @CHEMICAL$ activity in vitro, N-acetyl-L-cysteine had no effect, and @GENE$ or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.	false
17627474.T10.T22	While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and @CHEMICAL$ or n-propyl gallate efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.	CPR:4
17627474.T11.T21	While vitamin C is essential for @CHEMICAL$ activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or @GENE$ efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.	false
17627474.T11.T22	While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or @CHEMICAL$ efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.	CPR:4
17627474.T8.T21	While @CHEMICAL$ is essential for @GENE$ activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.	false
17627474.T8.T22	While @CHEMICAL$ is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.	false
17627474.T9.T21	While vitamin C is essential for @CHEMICAL$ activity in vitro, @GENE$ had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.	false
17627474.T9.T22	While vitamin C is essential for PHD activity in vitro, @CHEMICAL$ had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.	false
17632548.T17.T39	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @CHEM-GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T17.T40	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @CHEMICAL$ synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T18.T39	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @CHEMICAL$ (LTC4S), the pivotal enzyme for the biosynthesis of @GENE$ (ref.	CPR:9
17632548.T18.T40	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@CHEMICAL$), the pivotal enzyme for the biosynthesis of @GENE$ (ref.	CPR:9
17632548.T19.T39	The cysteinyl leukotrienes, namely @CHEMICAL$ and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T19.T40	The cysteinyl leukotrienes, namely @CHEMICAL$ and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T20.T39	The @CHEMICAL$, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T20.T40	The @CHEMICAL$, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T29.T39	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites @CHEMICAL$ and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T29.T40	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites @CHEMICAL$ and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T30.T39	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and @CHEMICAL$, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T30.T40	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and @CHEMICAL$, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.	false
17632548.T21.T42	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes 5-lipoxygenase-activating protein, @GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	CPR:9
17632548.T21.T43	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.	CPR:9
17632548.T21.T41	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes @GENE$, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T21.T44	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and @GENE$ (ref.	CPR:9
17632548.T22.T42	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes 5-lipoxygenase-activating protein, @GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	CPR:9
17632548.T22.T43	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.	CPR:9
17632548.T22.T41	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes @GENE$, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T22.T44	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and @GENE$ (ref.	CPR:9
17632548.T23.T42	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, @CHEM-GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T23.T43	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal @CHEMICAL$ S-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T23.T41	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes @CHEMICAL$, microsomal @GENE$ S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T23.T44	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal @CHEMICAL$ S-transferases (MGSTs), and @GENE$ (ref.	false
17632548.T24.T42	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, @CHEM-GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T24.T43	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione @CHEMICAL$-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T24.T41	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes @CHEMICAL$, microsomal glutathione @GENE$-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	false
17632548.T24.T44	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione @CHEMICAL$-transferases (MGSTs), and @GENE$ (ref.	false
17632548.T25.T42	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, @CHEMICAL$ (MGSTs), and microsomal @GENE$ synthase 1 (ref.	false
17632548.T25.T43	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (@CHEMICAL$), and microsomal @GENE$ synthase 1 (ref.	false
17632548.T25.T41	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes @CHEMICAL$, microsomal glutathione S-transferases (MGSTs), and microsomal @GENE$ synthase 1 (ref.	false
17632548.T25.T44	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and @CHEM-GENE$ (ref.	false
17632548.T26.T45	@CHEMICAL$ conjugates @GENE$ to LTA4, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway.	false
17632548.T26.T46	LTC4S conjugates @CHEMICAL$ to LTA4, the endogenous substrate derived from arachidonic acid through the @GENE$ pathway.	false
17632548.T27.T45	@CHEMICAL$ conjugates glutathione to @GENE$, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway.	false
17632548.T27.T46	LTC4S conjugates glutathione to @CHEMICAL$, the endogenous substrate derived from arachidonic acid through the @GENE$ pathway.	false
17632548.T28.T45	@CHEMICAL$ conjugates glutathione to LTA4, the endogenous substrate derived from @GENE$ through the 5-lipoxygenase pathway.	false
17632548.T28.T46	LTC4S conjugates glutathione to LTA4, the endogenous substrate derived from @CHEMICAL$ through the @GENE$ pathway.	false
17632548.T31.T47	In contrast with @CHEMICAL$ and MGST3 (refs 15, 16), LTC4S does not conjugate @GENE$ to xenobiotics.	false
17632548.T31.T48	In contrast with MGST2 and @CHEMICAL$ (refs 15, 16), LTC4S does not conjugate @GENE$ to xenobiotics.	false
17632548.T31.T49	In contrast with MGST2 and MGST3 (refs 15, 16), @CHEMICAL$ does not conjugate @GENE$ to xenobiotics.	false
17632548.T1.T35	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for @CHEMICAL$ and LTA4 that distinguishes LTC4S from other @GENE$.	false
17632548.T1.T34	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for @CHEMICAL$ and LTA4 that distinguishes @GENE$ from other MGSTs.	false
17632548.T1.T50	Here we show the atomic structure of @CHEMICAL$ in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for @GENE$ and LTA4 that distinguishes LTC4S from other MGSTs.	false
17632548.T2.T35	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and @CHEMICAL$ that distinguishes LTC4S from other @GENE$.	false
17632548.T2.T34	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and @CHEMICAL$ that distinguishes @GENE$ from other MGSTs.	false
17632548.T2.T50	Here we show the atomic structure of @CHEMICAL$ in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and @GENE$ that distinguishes LTC4S from other MGSTs.	false
17632548.T32.T35	Here we show the atomic structure of human LTC4S in a complex with @CHEMICAL$ at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes LTC4S from other @GENE$.	false
17632548.T32.T34	Here we show the atomic structure of human LTC4S in a complex with @CHEMICAL$ at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes @GENE$ from other MGSTs.	false
17632548.T32.T50	Here we show the atomic structure of @CHEMICAL$ in a complex with @GENE$ at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes LTC4S from other MGSTs.	false
17632548.T15.T38	These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three @CHEMICAL$ ligands whose stability and potency are different and by multiple @GENE$ whose functions may be non-redundant.	false
17632548.T15.T37	These findings provide a structural basis for the development of @CHEMICAL$ inhibitors for a proinflammatory pathway mediated by three @GENE$ ligands whose stability and potency are different and by multiple cysteinyl leukotriene receptors whose functions may be non-redundant.	false
17632548.T16.T38	These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple @CHEM-GENE$ whose functions may be non-redundant.	false
17632548.T16.T37	These findings provide a structural basis for the development of @CHEMICAL$ inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple @GENE$ receptors whose functions may be non-redundant.	false
17704420.T1.T15	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any @GENE$ allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T1.T16	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any @CHEMICAL$ allele, and @GENE$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T1.T17	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any @CHEMICAL$ allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@GENE$ arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T2.T15	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any @GENE$ allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T2.T16	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any @GENE$ allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T2.T17	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any @CHEMICAL$ allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@GENE$ arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T3.T15	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A @GENE$/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T3.T16	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A @GENE$/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T3.T17	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ @GENE$/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T4.T15	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/@GENE$ or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T4.T16	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/@GENE$ or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T4.T17	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ arginine/@GENE$ or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T5.T15	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or @GENE$/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T5.T16	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or @GENE$/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T5.T17	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ arginine/arginine or @GENE$/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T6.T15	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/@GENE$) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T6.T16	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/@GENE$) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17704420.T6.T17	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ arginine/arginine or valine/@GENE$) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	false
17768678.T34.T44	@CHEMICAL$ causes an increase in brain ornithine that is prevented by prior @GENE$ inhibition.	CPR:4
17768678.T35.T44	Phenelzine causes an increase in brain ornithine that is prevented by prior @CHEM-GENE$ inhibition.	false
17768678.T14.T39	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain @GENE$ levels.	false
17768678.T14.T40	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@CHEMICAL$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain @GENE$ levels.	false
17768678.T14.T36	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@CHEMICAL$), markedly increasing brain @GENE$ levels.	false
17768678.T14.T43	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEMICAL$ (GABA-T), markedly increasing brain @GENE$ levels.	false
17768678.T1.T39	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of @GENE$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	CPR:4
17768678.T1.T40	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@GENE$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	CPR:4
17768678.T1.T36	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@GENE$), markedly increasing brain GABA levels.	CPR:4
17768678.T1.T43	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @GENE$ (GABA-T), markedly increasing brain GABA levels.	CPR:4
17768678.T27.T39	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEM-GENE$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	false
17768678.T27.T40	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (@GENE$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	false
17768678.T27.T36	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), also inhibits GABA-transaminase (@GENE$), markedly increasing brain GABA levels.	false
17768678.T27.T43	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), also inhibits @GENE$ (GABA-T), markedly increasing brain GABA levels.	false
17768678.T33.T39	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ (MAO), also inhibits @GENE$-transaminase (GABA-T), markedly increasing brain GABA levels.	false
17768678.T33.T40	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@CHEMICAL$), also inhibits @GENE$-transaminase (GABA-T), markedly increasing brain GABA levels.	false
17768678.T33.T36	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEMICAL$-transaminase (@GENE$), markedly increasing brain GABA levels.	false
17768678.T33.T43	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEM-GENE$ (GABA-T), markedly increasing brain GABA levels.	false
17768678.T5.T39	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ (MAO), also inhibits GABA-transaminase (@GENE$-T), markedly increasing brain GABA levels.	false
17768678.T5.T40	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@CHEMICAL$), also inhibits GABA-transaminase (@GENE$-T), markedly increasing brain GABA levels.	false
17768678.T5.T36	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@CHEM-GENE$), markedly increasing brain GABA levels.	false
17768678.T5.T43	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEMICAL$ (@GENE$-T), markedly increasing brain GABA levels.	false
17768678.T6.T39	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of @GENE$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	CPR:4
17768678.T6.T40	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of monoamine oxidase (@GENE$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	CPR:4
17768678.T6.T36	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@GENE$), markedly increasing brain GABA levels.	CPR:4
17768678.T6.T43	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @GENE$ (GABA-T), markedly increasing brain GABA levels.	CPR:4
17768678.T16.T38	@CHEMICAL$ is also a substrate for @GENE$, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.	CPR:9
17768678.T17.T38	PLZ is also a substrate for @CHEMICAL$, and studies suggest that a metabolite formed by the action of this enzyme on @GENE$ may be responsible for the increase in GABA observed.	false
17768678.T18.T38	PLZ is also a substrate for @CHEMICAL$, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in @GENE$ observed.	false
17768678.T29.T41	To determine whether a metabolite formed by the action of @CHEMICAL$ on @GENE$ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	false
17768678.T29.T42	To determine whether a metabolite formed by the action of MAO on @CHEMICAL$ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @GENE$ inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	false
17768678.T2.T41	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or @GENE$ (15 mg/kg), and brains collected 3 h later.	false
17768678.T2.T42	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @CHEMICAL$ inhibitor tranylcypromine (TCP) before vehicle or @GENE$ (15 mg/kg), and brains collected 3 h later.	false
17768678.T30.T41	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain @GENE$ observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	false
17768678.T30.T42	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain @CHEMICAL$ observed, animals were pretreated with vehicle or the @GENE$ inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	false
17768678.T31.T41	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor @GENE$ (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	false
17768678.T31.T42	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @CHEMICAL$ inhibitor @GENE$ (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	CPR:4
17768678.T32.T41	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (@GENE$) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	false
17768678.T32.T42	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @CHEMICAL$ inhibitor tranylcypromine (@GENE$) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	CPR:4
17768678.T10.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with @CHEMICAL$, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	false
17768678.T11.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of @CHEMICAL$ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	CPR:9
17768678.T12.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @CHEMICAL$ is responsible for the elevation of brain @GENE$ observed.	false
17768678.T3.T37	@CHEMICAL$ levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	false
17768678.T4.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in @CHEMICAL$-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	false
17768678.T7.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with @CHEMICAL$ completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	false
17768678.T8.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the @CHEMICAL$-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	false
17768678.T9.T37	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain @CHEMICAL$, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.	false
17869551.T10.T36	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @CHEM-GENE$ (eNOS).	false
17869551.T10.T37	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial @CHEMICAL$ synthase (@GENE$).	false
17869551.T11.T36	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (@CHEMICAL$) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).	CPR:9
17869551.T11.T37	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (@CHEMICAL$) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).	CPR:9
17869551.T1.T36	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. @CHEMICAL$ (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).	CPR:9
17869551.T1.T37	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. @CHEMICAL$ (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).	CPR:9
17869551.T23.T36	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with @CHEMICAL$ from L-arginine in a reaction catalyzed by @GENE$ (eNOS).	CPR:9
17869551.T23.T37	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with @CHEMICAL$ from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).	CPR:9
17869551.T29.T36	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from @CHEMICAL$ in a reaction catalyzed by @GENE$ (eNOS).	CPR:9
17869551.T29.T37	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from @CHEMICAL$ in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).	CPR:9
17869551.T32.T36	Endothelial @CHEMICAL$ production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).	false
17869551.T32.T37	Endothelial @CHEMICAL$ production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).	false
17869551.T33.T36	Endothelial nitric oxide production is tightly coupled to the @CHEMICAL$ cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).	false
17869551.T33.T37	Endothelial nitric oxide production is tightly coupled to the @CHEMICAL$ cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).	false
17869551.T2.T34	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEM-GENE$ (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	false
17869551.T2.T35	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ synthase (@GENE$), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	false
17869551.T31.T34	As further support, @CHEMICAL$, an inhibitor of @GENE$ (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	CPR:4
17869551.T31.T35	As further support, @CHEMICAL$, an inhibitor of argininosuccinate synthase (@GENE$), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	CPR:4
17869551.T3.T34	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ (AS), a component of the @GENE$-NO cycle, inhibited NO production in a dose-dependent manner.	false
17869551.T3.T35	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (@CHEMICAL$), a component of the @GENE$-NO cycle, inhibited NO production in a dose-dependent manner.	false
17869551.T4.T34	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ (AS), a component of the citrulline-@GENE$ cycle, inhibited NO production in a dose-dependent manner.	false
17869551.T4.T35	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (@CHEMICAL$), a component of the citrulline-@GENE$ cycle, inhibited NO production in a dose-dependent manner.	false
17869551.T5.T34	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ (AS), a component of the citrulline-NO cycle, inhibited @GENE$ production in a dose-dependent manner.	false
17869551.T5.T35	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (@CHEMICAL$), a component of the citrulline-NO cycle, inhibited @GENE$ production in a dose-dependent manner.	false
17916059.T4.T14	It is more potent and selective than @CHEMICAL$ in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and @GENE$.	false
17916059.T4.T13	It is more potent and selective than @CHEMICAL$ in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @GENE$ and muscarinic receptors.	false
17916059.T5.T14	It is more potent and selective than citalopram in inhibiting @CHEMICAL$ re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and @GENE$.	false
17916059.T5.T13	It is more potent and selective than citalopram in inhibiting @CHEMICAL$ re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @GENE$ and muscarinic receptors.	false
17916059.T7.T14	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective @CHEMICAL$ re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and @GENE$.	false
17916059.T7.T13	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective @CHEMICAL$ re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @GENE$ and muscarinic receptors.	false
17916059.T8.T14	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than @CHEMICAL$ in binding to the histamine H1 and @GENE$.	false
17916059.T8.T13	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than @CHEMICAL$ in binding to the @GENE$ and muscarinic receptors.	false
17916059.T9.T14	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @CHEMICAL$ H1 and @GENE$.	false
17916059.T9.T13	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @CHEM-GENE$ and muscarinic receptors.	false
17916059.T11.T16	Caution is necessary only when it is coadministered with drugs metabolised by @CHEMICAL$, such as @GENE$, or administered to the elderly or patients with severe hepatic or renal impairment.	CPR:9
17980251.T27.T30	Inhibition of platelet aggregation by AZD6140, a reversible oral @CHEMICAL$ receptor antagonist, compared with @GENE$ in patients with acute coronary syndromes.	CPR:6
17980251.T28.T30	Inhibition of platelet aggregation by @CHEMICAL$, a reversible oral @GENE$ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.	CPR:6
17980251.T20.T29	@CHEMICAL$ is a reversible oral @GENE$ receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).	CPR:6
17980251.T21.T29	AZD6140 is a reversible oral @CHEMICAL$ receptor antagonist that has been studied in ACS patients in comparison with @GENE$ (DISPERSE-2 study).	CPR:6
18045203.T1.T10	The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. @CHEMICAL$ (1) is a non-selective @GENE$ antagonist that is used clinically for the treatment of urinary incontinence.	CPR:6
18045203.T1.T15	The preparation and @CHEMICAL$ profiling of oxybutynin and N-desethyloxybutynin enantiomers. @GENE$ (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.	false
18045203.T7.T10	The preparation and human muscarinic receptor profiling of @CHEMICAL$ and N-desethyloxybutynin enantiomers. Oxybutynin (1) is a non-selective @GENE$ antagonist that is used clinically for the treatment of urinary incontinence.	false
18045203.T7.T15	The preparation and @CHEMICAL$ profiling of @GENE$ and N-desethyloxybutynin enantiomers. Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.	false
18045203.T8.T10	The preparation and human muscarinic receptor profiling of oxybutynin and @CHEMICAL$ enantiomers. Oxybutynin (1) is a non-selective @GENE$ antagonist that is used clinically for the treatment of urinary incontinence.	false
18045203.T8.T15	The preparation and @CHEMICAL$ profiling of oxybutynin and @GENE$ enantiomers. Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.	false
18045203.T4.T9	We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace @CHEMICAL$ ((3)H-NMS) binding on @GENE$.	false
18045203.T5.T9	We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT(3)-scopolamine chloride (@CHEMICAL$) binding on @GENE$.	false
18045203.T6.T11	Compounds 1 and 2 potently displaced @CHEMICAL$ binding at @GENE$, but were less potent at the m2 and m5 subtypes.	false
18045203.T6.T12	Compounds 1 and 2 potently displaced @CHEMICAL$ binding at m1, m3 and m4 receptors, but were less potent at the @GENE$ and m5 subtypes.	false
18045203.T6.T13	Compounds 1 and 2 potently displaced @CHEMICAL$ binding at m1, m3 and m4 receptors, but were less potent at the m2 and @GENE$ subtypes.	false
18450949.T5.T19	Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by @CHEMICAL$, an @GENE$ agonist.	CPR:5
18450949.T5.T20	Degradation of submandibular gland @CHEMICAL$ by parasympathetic denervation of chorda tympani and its recovery by @GENE$, an M3 muscarinic receptor agonist.	CPR:3
18450949.T1.T10	Administration of @CHEMICAL$, an @GENE$ agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.	CPR:5
18450949.T1.T11	Administration of @CHEMICAL$, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the @GENE$ protein level reduced by CTD and increased the AQP1 protein level above the control one.	CPR:3
18450949.T1.T12	Administration of @CHEMICAL$, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the @GENE$ protein level above the control one.	CPR:3
18450949.T2.T10	Administration of cevimeline hydrochloride, an @CHEMICAL$ agonist (10 mg/kg for 7 days po), but not @GENE$ (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.	false
18450949.T2.T11	Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not @CHEMICAL$ (0.3 mg/kg for 7 days po), recovered the @GENE$ protein level reduced by CTD and increased the AQP1 protein level above the control one.	false
18450949.T2.T12	Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not @CHEMICAL$ (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the @GENE$ protein level above the control one.	false
18450949.T3.T14	The mRNA level of @CHEMICAL$ was scarcely affected by CTD and @GENE$ administration.	false
18450949.T4.T16	Administration of @CHEMICAL$ (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the @GENE$ protein level reduced by CTD.	CPR:3
18466433.T1.T3	There are few prospective clinical trials of @CHEM-GENE$ inhibitors (or proliferation signal inhibitors) combined with CNI inhibitors in de novo pediatric renal transplantation.	false
18480678.T14.T30	threo-methylphenidate inhibits the @CHEM-GENE$ and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.	false
18480678.T14.T31	threo-methylphenidate inhibits the @CHEMICAL$ transporter and the @GENE$, resulting in elevations of these monoamines after impulse release.	false
18480678.T16.T30	threo-methylphenidate inhibits the @CHEMICAL$ and the @GENE$ transporter, resulting in elevations of these monoamines after impulse release.	false
18480678.T16.T31	threo-methylphenidate inhibits the dopamine transporter and the @CHEM-GENE$, resulting in elevations of these monoamines after impulse release.	false
18480678.T17.T30	threo-methylphenidate inhibits the @CHEMICAL$ and the norepinephrine transporter, resulting in elevations of these @GENE$ after impulse release.	CPR:9
18480678.T17.T31	threo-methylphenidate inhibits the dopamine transporter and the @CHEMICAL$, resulting in elevations of these @GENE$ after impulse release.	CPR:9
18480678.T8.T30	@CHEMICAL$ inhibits the @GENE$ and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.	CPR:4
18480678.T8.T31	@CHEMICAL$ inhibits the dopamine transporter and the @GENE$, resulting in elevations of these monoamines after impulse release.	CPR:4
18480678.T24.T32	In both rodent and primate animal models, the binding of radiolabeled @CHEMICAL$ to @GENE$ was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.	false
18480678.T25.T32	In both rodent and primate animal models, the binding of radiolabeled d-MPH to @CHEM-GENE$ was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.	false
18480678.T26.T32	In both rodent and primate animal models, the binding of radiolabeled d-MPH to @CHEMICAL$ was found to be selective, saturable, and reversible, whereas binding of @GENE$ was diffuse and nonspecific.	false
18480678.T10.T29	The importance of MPH chirality to central nervous system @CHEM-GENE$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific.	false
18480678.T11.T29	The importance of MPH chirality to central nervous system @CHEMICAL$ targeting has culminated in human imaging studies revealing that @GENE$ binds specifically to striatal structures, whereas l-MPH binding is nonspecific.	false
18480678.T12.T29	The importance of MPH chirality to central nervous system @CHEMICAL$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas @GENE$ binding is nonspecific.	false
18480678.T9.T29	The importance of @CHEMICAL$ chirality to central nervous system @GENE$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific.	false
18593822.T1.T63	Identification of @CHEMICAL$-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and @GENE$ function.	false
18593822.T1.T64	Identification of @CHEMICAL$-terminal receptor activity-modifying protein residues important for @GENE$, adrenomedullin, and amylin receptor function.	false
18593822.T1.T62	Identification of @CHEMICAL$-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, @GENE$, and amylin receptor function.	false
18593927.T5.T13	We therefore sought to establish a role for @CHEMICAL$ in malignant glioma cell motility, migration, and invasion and determine the effects of @GENE$ on these cell movement-related processes.	false
18593927.T1.T14	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular @CHEMICAL$ levels and in the absence and presence of sublethal nitrosourea ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; @GENE$) concentrations.	false
18593927.T6.T14	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular @CHEMICAL$ levels and in the absence and presence of sublethal @GENE$ ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; CCNU) concentrations.	false
18593927.T7.T14	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular @CHEMICAL$ levels and in the absence and presence of sublethal nitrosourea (@GENE$; CCNU) concentrations.	false
18593927.T3.T9	The direct inhibition of @CHEMICAL$ by @GENE$ is likely a contributing factor.	CPR:4
18604229.T21.T29	Interaction with the @CHEMICAL$ channel and cytotoxicity of @GENE$ and amiodarone analogues.	false
18604229.T22.T29	Interaction with the @CHEMICAL$ channel and cytotoxicity of amiodarone and @GENE$ analogues.	false
18604229.T12.T27	The principal aim of the study was to find @CHEMICAL$ analogues that retained @GENE$ inhibition but with reduced cytotoxicity.	CPR:4
18604229.T6.T23	Pharmacological and in silico investigations concerning the interactions of these compounds with the @CHEMICAL$ channel revealed that compounds carrying a basic @GENE$ in the side chain display a much higher affinity than those lacking such a group.	false
18604229.T7.T24	Specifically, @CHEMICAL$ and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards @GENE$ channels than amiodarone.	false
18604229.T8.T24	Specifically, B2-O-CH(2)-CH(2)-N-piperidine and @CHEMICAL$ revealed a higher affinity towards @GENE$ channels than amiodarone.	false
18604229.T9.T24	Specifically, B2-O-CH(2)-CH(2)-N-piperidine and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards @CHEMICAL$ channels than @GENE$.	false
18604229.T10.T25	CONCLUSIONS AND IMPLICATIONS: @CHEMICAL$ analogues with better @GENE$ channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.	CPR:4
18604229.T10.T26	CONCLUSIONS AND IMPLICATIONS: @CHEMICAL$ analogues with better hERG channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and @GENE$ channel interaction are mechanistically distinct and separable properties of the compounds.	false
18620538.T8.T14	Interaction of @CHEMICAL$ with @GENE$: determination of binding parameters.	false
18620538.T7.T11	The interaction of holo- and apo-forms of @CHEMICAL$ with @GENE$ was studied by a partition equilibrium method.	false
18620538.T1.T9	@CHEMICAL$, obtained by treatment with @GENE$, displays one binding site for fatty acids, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.	false
18620538.T2.T9	@CHEMICAL$, obtained by treatment with EDTA, displays one binding site for @GENE$, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.	false
18620538.T3.T9	@CHEMICAL$, obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for @GENE$ being 1.9.10(6) and 4.2.10(5) M(-1), respectively.	false
18620538.T4.T10	However, @CHEMICAL$ was unable to bind @GENE$ as measured by this technique.	false
18620538.T5.T12	Likewise, no @CHEMICAL$ bound to @GENE$, isolated using nondenaturing conditions, were detected by gas chromatography.	false
18620538.T6.T13	These results demonstrate that the conformational change induced in @CHEMICAL$ by the removal of @GENE$ enables the protein to interact with fatty acids.	false
18655903.T34.T75	Peptide and non-peptide agonists and antagonists for the @CHEM-GENE$ and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T34.T76	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and @GENE$ V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T34.T77	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin @GENE$, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T34.T78	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, @GENE$, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T34.T79	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, V1b, @GENE$ and OT receptors: research tools and potential therapeutic agents.	false
18655903.T34.T80	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, V1b, V2 and @GENE$: research tools and potential therapeutic agents.	false
18655903.T35.T75	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and @GENE$ V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T35.T76	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEM-GENE$ V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T35.T77	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ @GENE$, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T35.T78	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, @GENE$, V2 and OT receptors: research tools and potential therapeutic agents.	false
18655903.T35.T79	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, V1b, @GENE$ and OT receptors: research tools and potential therapeutic agents.	false
18655903.T35.T80	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, V1b, V2 and @GENE$: research tools and potential therapeutic agents.	false
18655903.T36.T75	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, V1b, V2 and @GENE$ receptors: research tools and potential therapeutic agents.	false
18655903.T36.T76	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, V1b, V2 and @GENE$ receptors: research tools and potential therapeutic agents.	false
18655903.T36.T77	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin @CHEMICAL$, V1b, V2 and @GENE$ receptors: research tools and potential therapeutic agents.	false
18655903.T36.T78	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, @CHEMICAL$, V2 and @GENE$ receptors: research tools and potential therapeutic agents.	false
18655903.T36.T79	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, @CHEMICAL$ and @GENE$ receptors: research tools and potential therapeutic agents.	false
18655903.T36.T80	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and @CHEM-GENE$: research tools and potential therapeutic agents.	false
18655903.T1.T67	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.	false
18655903.T1.T37	@CHEM-GENE$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T38	@CHEMICAL$ (@GENE$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T39	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T42	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T43	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T53	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T57	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T59	@CHEMICAL$ (OT) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T1.T64	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T1.T68	@CHEMICAL$ (OT) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T67	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.	false
18655903.T22.T37	@CHEMICAL$ (OT) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T38	Oxytocin (@CHEMICAL$) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T39	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T42	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T43	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T53	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T57	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T59	Oxytocin (OT) and @CHEM-GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T22.T64	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T22.T68	Oxytocin (OT) and @CHEMICAL$ (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T26.T67	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @CHEMICAL$ @GENE$? (vasodilating) receptor.	false
18655903.T26.T37	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T38	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T39	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T42	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T43	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @CHEMICAL$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T53	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @CHEMICAL$ (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T57	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @CHEMICAL$ (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T59	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T64	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @CHEM-GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T26.T68	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T28.T67	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.	false
18655903.T28.T37	@CHEMICAL$ (OT) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T38	Oxytocin (@CHEMICAL$) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T39	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T42	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T43	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T53	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T57	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T59	Oxytocin (OT) and @CHEMICAL$ (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T28.T64	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T28.T68	Oxytocin (OT) and vasopressin (@CHEM-GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T67	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.	false
18655903.T2.T37	@CHEMICAL$ (@GENE$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T38	Oxytocin (@CHEM-GENE$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T39	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T42	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T43	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T53	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T57	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T59	Oxytocin (@CHEMICAL$) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T2.T64	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T2.T68	Oxytocin (@CHEMICAL$) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T67	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.	false
18655903.T3.T37	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T38	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T39	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEM-GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T42	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T43	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T53	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T57	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T59	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T3.T64	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T3.T68	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T67	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.	false
18655903.T6.T37	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T38	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T39	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T42	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEM-GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T43	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T53	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T57	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T59	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T6.T64	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.	false
18655903.T6.T68	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.	false
18655903.T29.T69	The pharmacological properties of promising new selective @CHEM-GENE$ antagonists and V(1b) agonists are also presented.	false
18655903.T29.T70	The pharmacological properties of promising new selective @CHEMICAL$ antagonists and @GENE$ agonists are also presented.	false
18655903.T30.T71	The current status of non-peptide @CHEM-GENE$ and AVP antagonists and agonists is also summarized.	false
18655903.T30.T72	The current status of non-peptide @CHEMICAL$ and @GENE$ antagonists and agonists is also summarized.	false
18655903.T31.T71	The current status of non-peptide @CHEMICAL$ and @GENE$ antagonists and agonists is also summarized.	false
18655903.T31.T72	The current status of non-peptide OT and @CHEM-GENE$ antagonists and agonists is also summarized.	false
18655903.T32.T73	The relative merits of peptide and non-peptide @CHEM-GENE$ and OT agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	false
18655903.T32.T74	The relative merits of peptide and non-peptide @CHEMICAL$ and @GENE$ agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	false
18655903.T33.T73	The relative merits of peptide and non-peptide @CHEMICAL$ and @GENE$ agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	false
18655903.T33.T74	The relative merits of peptide and non-peptide AVP and @CHEM-GENE$ agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	false
18655903.T4.T40	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of @CHEM-GENE$ and AVP than their non-peptide counterparts.	false
18655903.T4.T41	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of @CHEMICAL$ and @GENE$ than their non-peptide counterparts.	false
18655903.T5.T40	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of @CHEMICAL$ and @GENE$ than their non-peptide counterparts.	false
18655903.T5.T41	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of OT and @CHEM-GENE$ than their non-peptide counterparts.	false
18655903.T10.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEM-GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T10.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T11.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	CPR:5
18655903.T11.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T11.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T12.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEM-GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T12.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T13.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	CPR:5
18655903.T13.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T13.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T14.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @CHEMICAL$ (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	CPR:5
18655903.T14.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @CHEMICAL$ (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T14.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @CHEMICAL$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T15.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T15.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @CHEMICAL$ (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	CPR:5
18655903.T15.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @CHEMICAL$ (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T16.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@CHEMICAL$ agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.	false
18655903.T16.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @CHEMICAL$ (Tractocile @GENE$ antagonist) are also in clinical use.	CPR:6
18655903.T17.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@CHEMICAL$ agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.	false
18655903.T17.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@CHEMICAL$ @GENE$ antagonist) are also in clinical use.	CPR:6
18655903.T18.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@CHEMICAL$ agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T18.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @CHEM-GENE$ antagonist) are also in clinical use.	false
18655903.T7.T44	In addition to @CHEM-GENE$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T45	In addition to @CHEMICAL$ and to a lesser extent @GENE$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T46	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T47	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T48	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T49	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T50	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T51	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T52	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T7.T54	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T8.T44	In addition to @CHEMICAL$ and to a lesser extent @GENE$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T45	In addition to OT and to a lesser extent @CHEM-GENE$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T46	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T47	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T48	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T49	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T50	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T51	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T52	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T8.T54	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T9.T44	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T45	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T46	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEM-GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T47	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T48	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T49	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T50	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T51	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T52	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	false
18655903.T9.T54	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.	false
18655903.T19.T58	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, @GENE$, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T19.T60	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, @CHEMICAL$, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @GENE$/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T19.T61	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, @CHEMICAL$, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@GENE$, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T20.T58	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, @GENE$ and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T20.T60	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, @CHEMICAL$ and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @GENE$/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T20.T61	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, @CHEMICAL$ and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@GENE$, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T21.T58	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and @GENE$, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T21.T60	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and @CHEMICAL$, are currently in Phase III clinical trials; to date, only the mixed @GENE$/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T21.T61	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and @CHEMICAL$, are currently in Phase III clinical trials; to date, only the mixed V(2)/@GENE$, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T23.T58	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist @GENE$ (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T23.T60	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @CHEMICAL$/V(1a), antagonist @GENE$ (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T23.T61	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@CHEMICAL$, antagonist @GENE$ (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T24.T58	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (@GENE$), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	false
18655903.T24.T60	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @CHEMICAL$/V(1a), antagonist Conivaptan (@GENE$), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T24.T61	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@CHEMICAL$, antagonist Conivaptan (@GENE$), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
18655903.T25.T62	Promising new non-peptide @CHEMICAL$ and @GENE$ antagonists, as well as non-peptide V(2) and OT agonists are now in pre-clinical development.	false
18655903.T25.T63	Promising new non-peptide V(1b) and @CHEM-GENE$ antagonists, as well as non-peptide V(2) and OT agonists are now in pre-clinical development.	false
18655903.T25.T65	Promising new non-peptide V(1b) and @CHEMICAL$ antagonists, as well as non-peptide @GENE$ and OT agonists are now in pre-clinical development.	false
18655903.T25.T66	Promising new non-peptide V(1b) and @CHEMICAL$ antagonists, as well as non-peptide V(2) and @GENE$ agonists are now in pre-clinical development.	false
18655903.T27.T62	Promising new non-peptide @CHEMICAL$ and OT antagonists, as well as non-peptide V(2) and @GENE$ agonists are now in pre-clinical development.	false
18655903.T27.T63	Promising new non-peptide V(1b) and @CHEMICAL$ antagonists, as well as non-peptide V(2) and @GENE$ agonists are now in pre-clinical development.	false
18655903.T27.T65	Promising new non-peptide V(1b) and OT antagonists, as well as non-peptide @CHEMICAL$ and @GENE$ agonists are now in pre-clinical development.	false
18655903.T27.T66	Promising new non-peptide V(1b) and OT antagonists, as well as non-peptide V(2) and @CHEM-GENE$ agonists are now in pre-clinical development.	false
1868500.T5.T18	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	CPR:4
1868500.T5.T19	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	CPR:4
1868500.T5.T20	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.	CPR:4
1868500.T5.T21	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.	CPR:4
1868500.T5.T17	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, @GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	false
1868500.T6.T18	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	CPR:4
1868500.T6.T19	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	CPR:4
1868500.T6.T20	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.	CPR:4
1868500.T6.T21	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.	CPR:4
1868500.T6.T17	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, @GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	false
1868500.T7.T18	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	CPR:4
1868500.T7.T19	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	CPR:4
1868500.T7.T20	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.	CPR:4
1868500.T7.T21	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.	CPR:4
1868500.T7.T17	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, @GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	false
1868500.T8.T18	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	false
1868500.T8.T19	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	false
1868500.T8.T20	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.	false
1868500.T8.T21	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.	false
1868500.T8.T17	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEM-GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	false
1868500.T9.T22	@CHEMICAL$, in particular, act by stimulating the catabolism of @GENE$ and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.	CPR:4
1868500.T9.T23	@CHEMICAL$, in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving @GENE$ delipidation, thus favoring receptor uptake.	false
1868500.T10.T24	@CHEMICAL$ and acipimox interfere with the biosynthesis of @GENE$ and can also improve the clearance of VLDL/LDL.	false
1868500.T10.T25	@CHEMICAL$ and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of @GENE$/LDL.	false
1868500.T10.T26	@CHEMICAL$ and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of VLDL/@GENE$.	false
1868500.T11.T27	@CHEMICAL$ acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from @GENE$ to lower-density lipoproteins.	false
1868500.T11.T28	@CHEMICAL$ acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to @GENE$.	false
1868500.T12.T27	Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of @CHEMICAL$ from @GENE$ to lower-density lipoproteins.	CPR:9
1868500.T12.T28	Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of @CHEMICAL$ from high-density lipoproteins to @GENE$.	CPR:9
1868500.T13.T15	Finally, @CHEMICAL$ reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity @GENE$.	false
1868500.T13.T29	Finally, @CHEM-GENE$ inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors.	false
1868500.T14.T15	Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of @CHEMICAL$, can induce an increased expression of liver high-affinity @GENE$.	false
1868500.T14.T29	Finally, @CHEMICAL$ inhibitors, interfering with the biosynthesis of @GENE$, can induce an increased expression of liver high-affinity lipoprotein receptors.	false
18803986.T30.T53	@CHEMICAL$: a dual inhibitor of human epidermal growth factor receptor @GENE$.	CPR:4
18803986.T30.T52	@CHEMICAL$: a dual inhibitor of @GENE$ tyrosine kinases.	CPR:4
18803986.T31.T53	Lapatinib: a dual inhibitor of human epidermal growth factor receptor @CHEM-GENE$.	false
18803986.T31.T52	Lapatinib: a dual inhibitor of @CHEMICAL$ @GENE$ kinases.	false
18803986.T5.T37	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) @GENE$, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
18803986.T5.T35	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (@GENE$) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
18803986.T5.T49	BACKGROUND: @CHEMICAL$, the first dual inhibitor of @GENE$ (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
18803986.T5.T50	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (@GENE$) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
18803986.T5.T51	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (EGFR) and @GENE$ (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
18803986.T7.T37	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) @CHEM-GENE$, was approved by the US Food and Drug Administration (FDA) in 2007.	false
18803986.T7.T35	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (@CHEMICAL$) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	false
18803986.T7.T49	BACKGROUND: Lapatinib, the first dual inhibitor of @CHEMICAL$ (EGFR) and human epidermal growth factor receptor 2 (HER2) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	false
18803986.T7.T50	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (@CHEMICAL$) and human epidermal growth factor receptor 2 (HER2) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	false
18803986.T7.T51	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and @CHEMICAL$ (HER2) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	false
18803986.T22.T47	It is indicated for use in combination with @CHEMICAL$ for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress @GENE$ (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.	false
18803986.T22.T48	It is indicated for use in combination with @CHEMICAL$ for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (@GENE$) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.	false
18803986.T27.T47	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress @CHEMICAL$ (ErbB2) and who have received previous treatment that included an @GENE$, a taxane, and trastuzumab.	false
18803986.T27.T48	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (@CHEMICAL$) and who have received previous treatment that included an @GENE$, a taxane, and trastuzumab.	false
18803986.T28.T47	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress @CHEMICAL$ (ErbB2) and who have received previous treatment that included an anthracycline, a @GENE$, and trastuzumab.	false
18803986.T28.T48	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (@CHEMICAL$) and who have received previous treatment that included an anthracycline, a @GENE$, and trastuzumab.	false
18803986.T1.T34	Search terms included @CHEMICAL$, GW572016, HER2, EGFR, @GENE$, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T1.T32	Search terms included @CHEMICAL$, GW572016, @GENE$, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T1.T33	Search terms included @CHEMICAL$, GW572016, HER2, @GENE$, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T2.T34	Search terms included lapatinib, @CHEMICAL$, HER2, EGFR, @GENE$, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T2.T32	Search terms included lapatinib, @CHEMICAL$, @GENE$, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T2.T33	Search terms included lapatinib, @CHEMICAL$, HER2, @GENE$, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T3.T34	Search terms included lapatinib, GW572016, HER2, EGFR, @CHEM-GENE$, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T3.T32	Search terms included lapatinib, GW572016, @CHEMICAL$, EGFR, receptor @GENE$ kinase, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T3.T33	Search terms included lapatinib, GW572016, HER2, @CHEMICAL$, receptor @GENE$ kinase, dual-receptor blockade, adverse events, and clinical trials.	false
18803986.T6.T36	@CHEMICAL$ is metabolized primarily by the @GENE$ isozyme, with 1 metabolite remaining active against EGFR but not HER2.	CPR:9
18803986.T6.T38	@CHEMICAL$ is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against @GENE$ but not HER2.	false
18803986.T6.T39	@CHEMICAL$ is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not @GENE$.	false
18803986.T10.T40	In a Phase III trial comparing lapatinib and @CHEMICAL$ with capecitabine alone in women with @GENE$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T11.T40	In a Phase III trial comparing lapatinib and capecitabine with @CHEMICAL$ alone in women with @GENE$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T12.T40	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an @GENE$, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T13.T40	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a @GENE$, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T14.T40	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of @GENE$ and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T15.T40	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and @GENE$ was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T16.T40	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with @GENE$ alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T9.T40	In a Phase III trial comparing @CHEMICAL$ and capecitabine with capecitabine alone in women with @GENE$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	false
18803986.T24.T43	CONCLUSIONS: @CHEMICAL$ is a dual inhibitor of the EGFR and HER2 @GENE$.	CPR:4
18803986.T24.T41	CONCLUSIONS: @CHEMICAL$ is a dual inhibitor of the @GENE$ and HER2 tyrosine kinases.	CPR:4
18803986.T24.T42	CONCLUSIONS: @CHEMICAL$ is a dual inhibitor of the EGFR and @GENE$ tyrosine kinases.	CPR:4
18803986.T25.T43	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 @CHEM-GENE$.	false
18803986.T25.T41	CONCLUSIONS: Lapatinib is a dual inhibitor of the @CHEMICAL$ and HER2 @GENE$ kinases.	false
18803986.T25.T42	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and @CHEMICAL$ @GENE$ kinases.	false
18803986.T26.T44	It is approved by the FDA for use in combination with @CHEMICAL$ for the treatment of @GENE$-positive MBC that has progressed with standard treatment.	false
1881457.T1.T26	@CHEMICAL$ is a relatively potent inhibitor of @GENE$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	false
1881457.T2.T26	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEM-GENE$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	false
1881457.T3.T26	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of @GENE$ and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	false
1881457.T4.T26	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and @GENE$, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	false
1881457.T5.T26	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in @GENE$, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	false
1881457.T6.T26	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, @GENE$, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	false
1881457.T8.T26	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and @GENE$ after acute i.p.	false
1881457.T10.T27	Phenelzine is a more potent @CHEM-GENE$ inhibitor than is N2-acetylphenelzine.	false
1881457.T11.T27	Phenelzine is a more potent @CHEMICAL$ inhibitor than is @GENE$.	CPR:4
1881457.T9.T27	@CHEMICAL$ is a more potent @GENE$ inhibitor than is N2-acetylphenelzine.	CPR:4
1881457.T17.T28	Acetylation of @CHEMICAL$ at the N2 position presumably interferes with the inhibition of the @GENE$ enzymes for gamma-aminobutyric acid and alanine.	CPR:4
1881457.T18.T28	Acetylation of phenelzine at the @CHEMICAL$ position presumably interferes with the inhibition of the @GENE$ enzymes for gamma-aminobutyric acid and alanine.	CPR:4
1881457.T20.T28	Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the @CHEMICAL$ enzymes for @GENE$ and alanine.	CPR:4
1881457.T21.T28	Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the @CHEMICAL$ enzymes for gamma-aminobutyric acid and @GENE$.	CPR:4
18973551.T22.T38	@CHEMICAL$ D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via @GENE$ phosphorylation.	false
18973551.T22.T37	@CHEM-GENE$-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.	false
18973551.T16.T34	Clinical improvements in Parkinson's disease produced by @CHEM-GENE$-preferring agonists have been related to their neuroprotective actions and, more recently, to their neuroregenerative properties.	false
18973551.T12.T32	However, it is unclear whether @CHEMICAL$ agonists produce their neurotrophic effects by acting directly on receptors expressed by the mesencephalic dopaminergic neurons or indirectly on receptors expressed by astrocytes, via release of @GENE$.	false
18973551.T13.T33	In this study, we investigated the effects of the @CHEM-GENE$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	false
18973551.T13.T35	In this study, we investigated the effects of the @CHEMICAL$ D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).	false
18973551.T13.T36	In this study, we investigated the effects of the @CHEMICAL$ D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).	false
18973551.T14.T33	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists @GENE$ and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	false
18973551.T14.T35	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists @CHEMICAL$ and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).	false
18973551.T14.T36	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists @CHEMICAL$ and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).	false
18973551.T15.T33	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and @GENE$ (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	false
18973551.T15.T35	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and @CHEMICAL$ (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).	false
18973551.T15.T36	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and @CHEMICAL$ (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).	false
18973551.T17.T33	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (@GENE$), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	false
18973551.T17.T35	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (@CHEMICAL$), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).	false
18973551.T17.T36	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (@CHEMICAL$), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).	false
18973551.T18.T33	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist @GENE$, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	false
18973551.T18.T35	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist @CHEMICAL$, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).	false
18973551.T18.T36	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist @CHEMICAL$, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).	false
18973551.T19.T33	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ hydroxylase immunoreactivity (TH-IR).	false
18973551.T19.T35	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @CHEM-GENE$ immunoreactivity (TH-IR).	false
18973551.T19.T36	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @CHEMICAL$ hydroxylase immunoreactivity (@GENE$-IR).	false
18973551.T1.T23	After 3 days of incubation, both quinpirole (1-10 microm) and 7-OH-DPAT (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and @CHEMICAL$ uptake (P < 0.01) of @GENE$-IR-positive mesencephalic neurons.	false
18973551.T20.T23	After 3 days of incubation, both @CHEMICAL$ (1-10 microm) and 7-OH-DPAT (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and [3H]dopamine uptake (P < 0.01) of @GENE$-IR-positive mesencephalic neurons.	false
18973551.T21.T23	After 3 days of incubation, both quinpirole (1-10 microm) and @CHEMICAL$ (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and [3H]dopamine uptake (P < 0.01) of @GENE$-IR-positive mesencephalic neurons.	false
18973551.T3.T24	All neurotrophic effects were blocked by the unselective @CHEMICAL$ antagonist @GENE$ (5 microm) and by the selective D3 receptor antagonist SB-277011-A at a low dose (50 nm).	false
18973551.T3.T25	All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist @CHEMICAL$ (5 microm) and by the selective @GENE$ antagonist SB-277011-A at a low dose (50 nm).	false
18973551.T4.T24	All neurotrophic effects were blocked by the unselective @CHEMICAL$ antagonist sulpiride (5 microm) and by the selective D3 receptor antagonist @GENE$ at a low dose (50 nm).	false
18973551.T4.T25	All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective @CHEMICAL$ antagonist @GENE$ at a low dose (50 nm).	CPR:6
18973551.T10.T26	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.	false
18973551.T10.T27	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.	false
18973551.T10.T28	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @CHEMICAL$ signalling pathway to ERK was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.	false
18973551.T10.T29	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @CHEMICAL$ was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.	false
18973551.T5.T26	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of @GENE$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	CPR:3
18973551.T5.T27	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@GENE$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	CPR:3
18973551.T5.T28	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @GENE$ signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T5.T29	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @GENE$ was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T6.T26	Quinpirole and @CHEMICAL$ also increased the phosphorylation of @GENE$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	CPR:3
18973551.T6.T27	Quinpirole and @CHEMICAL$ also increased the phosphorylation of extracellular signal-regulated kinase (@GENE$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	CPR:3
18973551.T6.T28	Quinpirole and @CHEMICAL$ also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @GENE$ signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T6.T29	Quinpirole and @CHEMICAL$ also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @GENE$ was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T7.T26	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with @GENE$. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	CPR:4
18973551.T7.T27	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with @GENE$. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	CPR:4
18973551.T7.T28	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with @CHEMICAL$. Inhibition of the @GENE$ signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T7.T29	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with @CHEMICAL$. Inhibition of the D2/D3 receptor signalling pathway to @GENE$ was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T8.T26	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T8.T27	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T8.T28	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @CHEMICAL$ signalling pathway to ERK was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T8.T29	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @CHEMICAL$ was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T9.T26	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T9.T27	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T9.T28	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @CHEMICAL$ signalling pathway to ERK was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T9.T29	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @CHEMICAL$ was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.	false
18973551.T11.T30	These data suggest that @CHEMICAL$ agonists increase dendritic arborizations of mesencephalic dopaminergic neurons via a direct effect on @GENE$, preferentially involving D3 receptor-dependent neurotransmission.	false
18973551.T11.T31	These data suggest that @CHEMICAL$ agonists increase dendritic arborizations of mesencephalic dopaminergic neurons via a direct effect on D2/D3 receptors, preferentially involving @GENE$-dependent neurotransmission.	false
18974361.T18.T28	Molecular pharmacology of human Cav3.2 @CHEM-GENE$: block by antihypertensives, antiarrhythmics, and their analogs.	false
18974361.T18.T27	Molecular pharmacology of @CHEMICAL$ T-type @GENE$ channels: block by antihypertensives, antiarrhythmics, and their analogs.	false
18974361.T4.T19	"Antihypertensive drugs of the ""calcium channel blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of @CHEM-GENE$ in vascular smooth muscle."	false
18974361.T4.T22	"Antihypertensive drugs of the ""@CHEMICAL$ blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of L-type @GENE$ channels in vascular smooth muscle."	false
18974361.T6.T19	"Antihypertensive drugs of the ""@CHEMICAL$ channel blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of @GENE$ in vascular smooth muscle."	false
18974361.T6.T22	"Antihypertensive drugs of the ""@CHEM-GENE$ blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of L-type Ca(2+) channels in vascular smooth muscle."	false
18974361.T8.T19	"Antihypertensive drugs of the ""calcium channel blocker"" or ""@CHEMICAL$ antagonist"" class have been used to establish the physiological role of @GENE$ in vascular smooth muscle."	false
18974361.T8.T22	"Antihypertensive drugs of the ""@CHEMICAL$ blocker"" or ""@GENE$ antagonist"" class have been used to establish the physiological role of L-type Ca(2+) channels in vascular smooth muscle."	false
18974361.T5.T20	In contrast, there has been limited progress on the pharmacology @CHEM-GENE$.	false
18974361.T7.T21	@CHEMICAL$ play a role in cardiac pacemaking, @GENE$ secretion, and renal hemodynamics, leading to the hypothesis that mixed T- and L-type blockers may have therapeutic advantages over selective L-type blockers.	false
18974361.T10.T24	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., @GENE$) and dihydropyridines (e.g., efonidipine).	false
18974361.T10.T23	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., @GENE$) and dihydropyridines (e.g., efonidipine).	false
18974361.T11.T24	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and @GENE$ (e.g., efonidipine).	false
18974361.T11.T23	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and @GENE$ (e.g., efonidipine).	false
18974361.T12.T24	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., @GENE$).	false
18974361.T12.T23	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., @GENE$).	false
18974361.T9.T24	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: @GENE$ (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).	false
18974361.T9.T23	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: @GENE$ (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).	false
18974361.T13.T25	Compounds were tested using a validated @CHEMICAL$ influx assay into a cell line expressing recombinant @GENE$ channels.	false
18974361.T14.T26	This study identified four clinically approved antihypertensive drugs (@CHEMICAL$, felodipine, isradipine, and nitrendipine) as potent @GENE$ blockers (IC(50) < 3 microM).	CPR:4
18974361.T15.T26	This study identified four clinically approved antihypertensive drugs (efonidipine, @CHEMICAL$, isradipine, and nitrendipine) as potent @GENE$ blockers (IC(50) < 3 microM).	CPR:4
18974361.T16.T26	This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, @CHEMICAL$, and nitrendipine) as potent @GENE$ blockers (IC(50) < 3 microM).	CPR:4
18974361.T17.T26	This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and @CHEMICAL$) as potent @GENE$ blockers (IC(50) < 3 microM).	CPR:4
19002123.T10.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, @GENE$, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T10.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, @GENE$, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T11.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, @GENE$, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T11.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, @GENE$, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T12.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, @GENE$, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T12.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, @GENE$, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T13.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, @GENE$, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T13.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, @GENE$, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T14.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, @GENE$, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T14.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, @GENE$, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T15.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, @GENE$, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T15.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, @GENE$, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T16.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, @GENE$, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T16.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, @GENE$, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T17.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, @GENE$, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T17.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, @GENE$, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T18.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, @GENE$, vardenafil and tadalafil.	false
19002123.T18.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, @GENE$, vardenafil and tadalafil.	false
19002123.T19.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, @GENE$ and tadalafil.	false
19002123.T19.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, @GENE$ and tadalafil.	false
19002123.T20.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and @GENE$.	false
19002123.T20.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and @GENE$.	false
19002123.T8.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, @GENE$, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T8.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, @GENE$, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T9.T22	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, @GENE$, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19002123.T9.T23	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, @GENE$, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	false
19023039.T13.T20	Pannexin (Panx) 1 is a widely expressed protein that shares structural, but not @CHEMICAL$, homology with gap junction proteins, the @GENE$.	false
19023039.T13.T17	@CHEMICAL$ is a widely expressed protein that shares structural, but not @GENE$, homology with gap junction proteins, the connexins.	false
19023039.T14.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: @GENE$ > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	CPR:4
19023039.T15.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > @GENE$ (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	CPR:4
19023039.T16.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (@GENE$) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	CPR:4
19023039.T1.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately @GENE$ approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	CPR:4
19023039.T2.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately @GENE$ > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	CPR:4
19023039.T3.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > @GENE$ >> probenecid >> flufenamic acid = niflumic acid.	CPR:4
19023039.T4.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> @GENE$ >> flufenamic acid = niflumic acid.	CPR:4
19023039.T5.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> @GENE$ = niflumic acid.	CPR:4
19023039.T6.T39	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = @GENE$.	CPR:4
19023039.T10.T19	Triphosphate nucleotides (ATP, GTP, and @CHEMICAL$) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.	false
19023039.T10.T18	Triphosphate nucleotides (ATP, GTP, and @CHEMICAL$) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.	CPR:4
19023039.T7.T19	@CHEMICAL$ (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.	false
19023039.T7.T18	@CHEMICAL$ (ATP, GTP, and UTP) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.	CPR:4
19023039.T8.T19	Triphosphate nucleotides (@CHEMICAL$, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.	false
19023039.T8.T18	Triphosphate nucleotides (@CHEMICAL$, GTP, and UTP) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.	CPR:4
19023039.T9.T19	Triphosphate nucleotides (ATP, @CHEMICAL$, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.	false
19023039.T9.T18	Triphosphate nucleotides (ATP, @CHEMICAL$, and UTP) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.	CPR:4
19023039.T11.T21	When @CHEMICAL$ was coexpressed with purinergic P2X(7) receptor (P2X(7)R), @GENE$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T11.T22	When Panx1 was coexpressed with @CHEMICAL$ (P2X(7)R), @GENE$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T11.T23	When Panx1 was coexpressed with purinergic P2X(7) receptor (@CHEMICAL$), @GENE$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T11.T24	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), @CHEMICAL$ was found to act as a @GENE$ antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	CPR:6
19023039.T11.T26	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), @CHEMICAL$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited @GENE$ currents.	false
19023039.T12.T21	When @CHEMICAL$ was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T12.T22	When Panx1 was coexpressed with @CHEMICAL$ (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T12.T23	When Panx1 was coexpressed with purinergic P2X(7) receptor (@CHEMICAL$), DIDS was found to act as a P2X(7)R antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T12.T24	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a @CHEMICAL$ antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	false
19023039.T12.T26	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit @CHEMICAL$-evoked currents, but none of the other compounds inhibited @GENE$ currents.	false
19057128.T14.T29	@CHEMICAL$ attenuates @GENE$ in monocrotaline-induced right ventricular hypertrophy in rats.	false
19057128.T15.T29	Captopril attenuates @CHEMICAL$ in @GENE$-induced right ventricular hypertrophy in rats.	false
19057128.T10.T16	Little is known about the influence of @CHEMICAL$ converting enzyme (ACE) inhibitors on matrix metalloproteinase (@GENE$) in right ventricular remodeling.	false
19057128.T10.T28	Little is known about the influence of @CHEMICAL$ converting enzyme (ACE) inhibitors on @GENE$ (MMP) in right ventricular remodeling.	false
19057128.T10.T24	Little is known about the influence of @CHEM-GENE$ (ACE) inhibitors on matrix metalloproteinase (MMP) in right ventricular remodeling.	false
19057128.T10.T27	Little is known about the influence of @CHEMICAL$ converting enzyme (@GENE$) inhibitors on matrix metalloproteinase (MMP) in right ventricular remodeling.	false
19057128.T7.T21	We investigated the effect of @CHEMICAL$, an @GENE$ inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.	CPR:4
19057128.T7.T22	We investigated the effect of @CHEMICAL$, an ACE inhibitor, on @GENE$ and MMP-9 in monocrotaline-induced right ventricular hypertrophy.	false
19057128.T7.T23	We investigated the effect of @CHEMICAL$, an ACE inhibitor, on MMP-2 and @GENE$ in monocrotaline-induced right ventricular hypertrophy.	false
19057128.T8.T21	We investigated the effect of captopril, an @CHEMICAL$ inhibitor, on MMP-2 and MMP-9 in @GENE$-induced right ventricular hypertrophy.	false
19057128.T8.T22	We investigated the effect of captopril, an ACE inhibitor, on @CHEMICAL$ and MMP-9 in @GENE$-induced right ventricular hypertrophy.	false
19057128.T8.T23	We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and @CHEMICAL$ in @GENE$-induced right ventricular hypertrophy.	false
19057128.T2.T17	However, @CHEMICAL$ did not attenuate an increase in pulmonary artery pressure. @GENE$ and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.	false
19057128.T2.T18	However, @CHEMICAL$ did not attenuate an increase in pulmonary artery pressure. MMP-2 and @GENE$ expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.	false
19057128.T3.T17	However, captopril did not attenuate an increase in pulmonary artery pressure. @CHEMICAL$ and MMP-9 expressions and activities in right ventricles increased significantly in @GENE$-injected rats and captopril inhibited them.	CPR:3
19057128.T3.T18	However, captopril did not attenuate an increase in pulmonary artery pressure. MMP-2 and @CHEMICAL$ expressions and activities in right ventricles increased significantly in @GENE$-injected rats and captopril inhibited them.	CPR:3
19057128.T4.T17	However, captopril did not attenuate an increase in pulmonary artery pressure. @CHEMICAL$ and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and @GENE$ inhibited them.	CPR:4
19057128.T4.T18	However, captopril did not attenuate an increase in pulmonary artery pressure. MMP-2 and @CHEMICAL$ expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and @GENE$ inhibited them.	CPR:4
19057128.T5.T19	These findings indicate that @CHEMICAL$ attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of @GENE$ and MMP-9 in rats.	CPR:4
19057128.T5.T20	These findings indicate that @CHEMICAL$ attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and @GENE$ in rats.	CPR:4
19057128.T6.T19	These findings indicate that captopril attenuates the development of @CHEMICAL$-induced right ventricular hypertrophy in association with inhibition of @GENE$ and MMP-9 in rats.	CPR:3
19057128.T6.T20	These findings indicate that captopril attenuates the development of @CHEMICAL$-induced right ventricular hypertrophy in association with inhibition of MMP-2 and @GENE$ in rats.	CPR:3
19119014.T1.T24	@CHEMICAL$ and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@GENE$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.	CPR:4
19119014.T1.T36	@CHEMICAL$ and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @GENE$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.	CPR:4
19119014.T1.T26	@CHEMICAL$ and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @GENE$) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.	CPR:4
19119014.T7.T24	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@CHEMICAL$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as @GENE$, methazolamide, and ethoxzolamide.	CPR:4
19119014.T7.T36	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @CHEMICAL$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as @GENE$, methazolamide, and ethoxzolamide.	CPR:4
19119014.T7.T26	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @CHEMICAL$) with a very different profile as compared to classical inhibitors, such as @GENE$, methazolamide, and ethoxzolamide.	CPR:4
19119014.T8.T24	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@CHEMICAL$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, @GENE$, and ethoxzolamide.	CPR:4
19119014.T8.T36	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @CHEMICAL$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, @GENE$, and ethoxzolamide.	CPR:4
19119014.T8.T26	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @CHEMICAL$) with a very different profile as compared to classical inhibitors, such as acetazolamide, @GENE$, and ethoxzolamide.	CPR:4
19119014.T9.T24	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@CHEMICAL$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and @GENE$.	CPR:4
19119014.T9.T36	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @CHEMICAL$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and @GENE$.	CPR:4
19119014.T9.T26	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @CHEMICAL$) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and @GENE$.	CPR:4
19119014.T10.T29	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with @GENE$, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	false
19119014.T10.T30	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with @CHEMICAL$, trichloromethiazide, and furosemide being efficient inhibitors against @GENE$ (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	CPR:4
19119014.T11.T29	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with chlorthalidone, @GENE$, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	false
19119014.T11.T30	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, @CHEMICAL$, and furosemide being efficient inhibitors against @GENE$ (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	CPR:4
19119014.T12.T29	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with chlorthalidone, trichloromethiazide, and @GENE$ being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	false
19119014.T12.T30	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and @CHEMICAL$ being efficient inhibitors against @GENE$ (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	CPR:4
19119014.T13.T29	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas @GENE$ is a much weaker one (K(I) of 2520 nM).	false
19119014.T13.T30	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against @CHEMICAL$ (K(I)s of 65-138 nM), whereas @GENE$ is a much weaker one (K(I) of 2520 nM).	CPR:4
19119014.T14.T31	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against @GENE$; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	false
19119014.T14.T32	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against hCA VB, VII, IX, and XIII; indapamide against @GENE$, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	false
19119014.T14.T33	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against @GENE$, and furosemide against CA I and XIV.	false
19119014.T14.T34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against @GENE$.	false
19119014.T15.T31	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against @CHEMICAL$; @GENE$ against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	false
19119014.T15.T32	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; @CHEMICAL$ against @GENE$, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	false
19119014.T15.T33	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; @CHEMICAL$ against CA VII, IX, XII, and XIII, trichloromethiazide against @GENE$, and furosemide against CA I and XIV.	false
19119014.T15.T34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; @CHEMICAL$ against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against @GENE$.	false
19119014.T16.T31	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against @CHEMICAL$; indapamide against CA VII, IX, XII, and XIII, @GENE$ against CA VII and IX, and furosemide against CA I and XIV.	false
19119014.T16.T32	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against @CHEMICAL$, @GENE$ against CA VII and IX, and furosemide against CA I and XIV.	false
19119014.T16.T33	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, @CHEMICAL$ against @GENE$, and furosemide against CA I and XIV.	false
19119014.T16.T34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, @CHEMICAL$ against CA VII and IX, and furosemide against @GENE$.	false
19119014.T17.T31	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against @CHEMICAL$; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and @GENE$ against CA I and XIV.	false
19119014.T17.T32	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against @CHEMICAL$, trichloromethiazide against CA VII and IX, and @GENE$ against CA I and XIV.	false
19119014.T17.T33	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against @CHEMICAL$, and @GENE$ against CA I and XIV.	false
19119014.T17.T34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and @CHEMICAL$ against @GENE$.	false
19119014.T18.T35	Examining the four X-ray crystal structures of their @CHEMICAL$ adducts, we observed several (2-3) active site water molecules interacting with the @GENE$, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity.	false
19119014.T19.T35	Examining the four X-ray crystal structures of their @CHEMICAL$ adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, @GENE$, and furosemide scaffolds which may be responsible for this important difference of activity.	false
19119014.T2.T35	Examining the four X-ray crystal structures of their @CHEMICAL$ adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and @GENE$ scaffolds which may be responsible for this important difference of activity.	false
19119014.T3.T25	Indeed, @CHEMICAL$ bound to @GENE$ has no interactions with active site water molecules.	false
19119014.T4.T27	@CHEMICAL$ bound within the @GENE$ active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong hydrogen bonds with Asn67 and a water molecule.	false
19119014.T5.T27	Chlorthalidone bound within the @CHEMICAL$ active site is in an enolic (lactimic) tautomeric form, with the enolic @GENE$ also participating in two strong hydrogen bonds with Asn67 and a water molecule.	false
19119014.T6.T27	Chlorthalidone bound within the @CHEMICAL$ active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong @GENE$ bonds with Asn67 and a water molecule.	false
19281809.T28.T38	@CHEMICAL$, a selective @GENE$ inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.	CPR:4
19281809.T29.T38	Sergliflozin etabonate, a selective @CHEMICAL$ inhibitor, improves glycemic control in @GENE$-induced diabetic rats and Zucker fatty rats.	false
19281809.T11.T32	The low-affinity @CHEM-GENE$ (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	false
19281809.T11.T35	The low-affinity @CHEMICAL$ glucose cotransporter (@GENE$) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	false
19281809.T13.T32	The low-affinity @CHEM-GENE$ (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	false
19281809.T13.T35	The low-affinity sodium @CHEMICAL$ cotransporter (@GENE$) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	false
19281809.T25.T32	The low-affinity @CHEMICAL$ (SGLT2) is responsible for most of the @GENE$ reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	CPR:9
19281809.T25.T35	The low-affinity sodium glucose cotransporter (@CHEMICAL$) is responsible for most of the @GENE$ reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	CPR:9
19281809.T12.T33	We discovered @CHEMICAL$, a novel selective @GENE$ inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.	CPR:4
19281809.T12.T34	We discovered @CHEMICAL$, a novel selective SGLT2 inhibitor, and found that selective inhibition of @GENE$ increased urinary glucose excretion and consequently decreased plasma glucose levels.	CPR:4
19281809.T14.T33	We discovered sergliflozin etabonate, a novel selective @CHEMICAL$ inhibitor, and found that selective inhibition of SGLT2 increased urinary @GENE$ excretion and consequently decreased plasma glucose levels.	false
19281809.T14.T34	We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of @CHEMICAL$ increased urinary @GENE$ excretion and consequently decreased plasma glucose levels.	false
19281809.T15.T33	We discovered sergliflozin etabonate, a novel selective @CHEMICAL$ inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma @GENE$ levels.	false
19281809.T15.T34	We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of @CHEMICAL$ increased urinary glucose excretion and consequently decreased plasma @GENE$ levels.	false
19281809.T16.T36	In this report, we examined the antihyperglycemic effects of @CHEMICAL$ in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an @GENE$ inhibitor (voglibose).	false
19281809.T17.T36	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a @CHEMICAL$ (gliclazide) and an @GENE$ inhibitor (voglibose).	false
19281809.T18.T36	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (@CHEMICAL$) and an @GENE$ inhibitor (voglibose).	false
19281809.T19.T36	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an @CHEMICAL$ inhibitor (@GENE$).	CPR:4
19281809.T20.T37	@CHEMICAL$ increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of @GENE$ secretion in normal rats.	false
19281809.T21.T37	Sergliflozin etabonate increased urinary @CHEMICAL$ excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of @GENE$ secretion in normal rats.	false
19281809.T22.T37	Sergliflozin etabonate increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma @CHEMICAL$ after sucrose loading independently of @GENE$ secretion in normal rats.	false
19281809.T23.T37	Sergliflozin etabonate increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after @CHEMICAL$ loading independently of @GENE$ secretion in normal rats.	false
19281809.T6.T30	Chronic treatment with @CHEMICAL$ reduced the levels of @GENE$ and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.	CPR:4
19281809.T7.T30	Chronic treatment with sergliflozin etabonate reduced the levels of @CHEMICAL$ and fasting plasma @GENE$, and improved the glycemic response after glucose loading in Zucker fatty rats.	false
19281809.T8.T30	Chronic treatment with sergliflozin etabonate reduced the levels of @CHEMICAL$ and fasting plasma glucose, and improved the glycemic response after @GENE$ loading in Zucker fatty rats.	false
19281809.T10.T31	These data indicate that @CHEMICAL$ could improve glycemic control without its use resulting in @GENE$ secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes.	false
19293728.T7.T23	Our previous study showed that the stimulatory effect of @CHEMICAL$ on VSMC proliferation is inhibited by @GENE$ and the D3 dopamine receptor, a member of the D2-like receptor family.	false
19293728.T7.T25	Our previous study showed that the stimulatory effect of @CHEMICAL$ on VSMC proliferation is inhibited by D1-like receptors and the D3 dopamine receptor, a member of the @GENE$ family.	false
19293728.T7.T24	Our previous study showed that the stimulatory effect of @CHEMICAL$ on VSMC proliferation is inhibited by D1-like receptors and the @GENE$, a member of the D2-like receptor family.	false
19293728.T8.T23	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by @CHEMICAL$ and the D3 @GENE$ receptor, a member of the D2-like receptor family.	false
19293728.T8.T25	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by D1-like receptors and the D3 @CHEMICAL$ receptor, a member of the @GENE$ family.	false
19293728.T8.T24	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by D1-like receptors and the @CHEM-GENE$, a member of the D2-like receptor family.	false
19293728.T9.T33	METHODS: VSMC proliferation was determined by @CHEMICAL$ incorporation; @GENE$ mRNA and protein expressions were determined by RT-PCR, immunoblotting, and immunohistochemistry.	false
19293728.T1.T34	RESULTS: @CHEMICAL$ increased VSMC proliferation in immortalized aortic A10 cells, determined by @GENE$ incorporation.	false
19293728.T2.T10	Although the @CHEMICAL$, by itself, had no effect on VSMC proliferation, stimulation with @GENE$, a D1-like receptor agonist, inhibited the stimulatory effect of insulin.	false
19293728.T2.T11	Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with @CHEMICAL$, a @GENE$ agonist, inhibited the stimulatory effect of insulin.	CPR:5
19293728.T2.T12	Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with @CHEMICAL$, a D1-like receptor agonist, inhibited the stimulatory effect of @GENE$.	CPR:4
19293728.T3.T14	The inhibitory effect of @CHEMICAL$ on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a @GENE$ antagonist.	false
19293728.T3.T13	The inhibitory effect of @CHEMICAL$ on @GENE$-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.	CPR:4
19293728.T4.T14	The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by @CHEMICAL$, a @GENE$ antagonist.	CPR:6
19293728.T4.T13	The inhibitory effect of fenoldopam on @CHEMICAL$-mediated VSMC proliferation was receptor specific, because its effect could be blocked by @GENE$, a D1-like receptor antagonist.	false
19293728.T5.T15	@CHEMICAL$ also inhibited @GENE$ mRNA and protein expression, which was time dependent and concentration dependent.	CPR:4
19293728.T6.T16	A @CHEMICAL$ or MAP kinase inhibitor blocked the inhibitory effect of @GENE$ on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.	false
19293728.T6.T17	A PKC or @CHEMICAL$ inhibitor blocked the inhibitory effect of @GENE$ on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.	false
19293728.T6.T19	A PKC or MAP kinase inhibitor blocked the inhibitory effect of @CHEMICAL$ on insulin receptor expression, indicating that @GENE$ and MAP kinase were involved in the signaling pathway.	false
19293728.T6.T20	A PKC or MAP kinase inhibitor blocked the inhibitory effect of @CHEMICAL$ on insulin receptor expression, indicating that PKC and @GENE$ were involved in the signaling pathway.	false
19293728.T6.T18	A PKC or MAP kinase inhibitor blocked the inhibitory effect of @CHEMICAL$ on @GENE$ expression, indicating that PKC and MAP kinase were involved in the signaling pathway.	CPR:4
19399743.T1.T3	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by somatic mutations in the @CHEM-GENE$ gene and the resulting absence of a key complement regulatory protein, CD59.	false
19399743.T1.T4	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by somatic mutations in the @CHEMICAL$ glycan-complementation class A gene and the resulting absence of a key complement regulatory protein, @GENE$.	false
19472276.T4.T11	The progress of the enzymatic reaction of the hydrolysis of @CHEMICAL$ at pH 8 in the presence of @GENE$ and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).	CPR:9
19472276.T5.T11	The progress of the enzymatic reaction of the hydrolysis of acetylthiocholine at pH 8 in the presence of @CHEMICAL$ and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product @GENE$ (TCh).	false
19472276.T6.T12	In the method employed the capillary was first filled with 30 mM @CHEMICAL$-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) @GENE$ solution, (iii) substrate solution with or without inhibitor, (iv) AChE solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	false
19472276.T6.T13	In the method employed the capillary was first filled with 30 mM @CHEMICAL$-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) AChE solution, (iii) substrate solution with or without inhibitor, (iv) @GENE$ solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	false
19472276.T7.T12	In the method employed the capillary was first filled with 30 mM borate-@CHEMICAL$ buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) @GENE$ solution, (iii) substrate solution with or without inhibitor, (iv) AChE solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	false
19472276.T7.T13	In the method employed the capillary was first filled with 30 mM borate-@CHEMICAL$ buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) AChE solution, (iii) substrate solution with or without inhibitor, (iv) @GENE$ solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	false
19496999.T22.T32	@CHEM-GENE$ binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.	false
19496999.T23.T32	@CHEMICAL$ binding potential and occupancy in midbrain and temporal cortex by haloperidol, @GENE$ and clozapine.	false
19496999.T24.T32	@CHEMICAL$ binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and @GENE$.	false
19496999.T25.T32	@CHEMICAL$ binding potential and occupancy in midbrain and temporal cortex by @GENE$, olanzapine and clozapine.	false
19496999.T9.T28	Differences between typical and second-generation antipsychotics in @CHEM-GENE$ modulation within various brain areas remain a topic for debate.	false
19496999.T10.T29	The aim of the present study was therefore to investigate @CHEM-GENE$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, olanzapine- and haloperidol-treated schizophrenia patients.	false
19496999.T11.T29	The aim of the present study was therefore to investigate @CHEMICAL$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among @GENE$-, olanzapine- and haloperidol-treated schizophrenia patients.	false
19496999.T12.T29	The aim of the present study was therefore to investigate @CHEMICAL$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, @GENE$- and haloperidol-treated schizophrenia patients.	false
19496999.T13.T29	The aim of the present study was therefore to investigate @CHEMICAL$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, olanzapine- and @GENE$-treated schizophrenia patients.	false
19496999.T14.T30	METHODS: @CHEM-GENE$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.	false
19496999.T15.T30	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand @GENE$ in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.	false
19496999.T16.T30	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with @GENE$, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.	false
19496999.T17.T30	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with @GENE$ and seven with clozapine), six drug-naive patients and seven healthy controls.	false
19496999.T18.T30	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with @GENE$), six drug-naive patients and seven healthy controls.	false
19496999.T19.T31	RESULTS: Statistically significant differences in midbrain @CHEM-GENE$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, olanzapine and haloperidol groups.	false
19496999.T1.T31	RESULTS: Statistically significant differences in midbrain @CHEMICAL$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, olanzapine and @GENE$ groups.	false
19496999.T20.T31	RESULTS: Statistically significant differences in midbrain @CHEMICAL$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the @GENE$, olanzapine and haloperidol groups.	false
19496999.T21.T31	RESULTS: Statistically significant differences in midbrain @CHEMICAL$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, @GENE$ and haloperidol groups.	false
19496999.T6.T26	CONCLUSION: Both typical and second-generation antipsychotics occupy cortical @CHEM-GENE$, thus mediating therapeutic efficacy.	false
19496999.T7.T27	Observed differences in midbrain @CHEM-GENE$ occupancy between classical antipsychotics and second-generation antipsychotics may have clinical relevance by modulating altered nigrostriatal dopamine neurotransmission during the acute phase of schizophrenia.	false
19496999.T8.T27	Observed differences in midbrain @CHEMICAL$ occupancy between classical antipsychotics and second-generation antipsychotics may have clinical relevance by modulating altered nigrostriatal @GENE$ neurotransmission during the acute phase of schizophrenia.	false
19651196.T17.T27	The mechanism of @CHEMICAL$ poisoning involves inhibition of @GENE$ (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.	CPR:4
19651196.T17.T28	The mechanism of @CHEMICAL$ poisoning involves inhibition of acetylcholinesterase (@GENE$) leading to inactivation of the enzyme which has an important role in neurotransmission.	CPR:4
19651196.T18.T29	@CHEMICAL$ inhibition results in the accumulation of @GENE$ at cholinergic receptor sites, producing continuous stimulation of cholinergic fibers throughout the nervous systems.	false
19651196.T21.T30	They act by reactivation of @CHEMICAL$ inhibited by @GENE$.	CPR:4
19651196.T10.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, @GENE$, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	CPR:3
19651196.T11.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, @GENE$ and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	CPR:3
19651196.T12.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and @GENE$) and diazepam are used for the treatment of OP poisoning in humans.	CPR:3
19651196.T13.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and @GENE$ are used for the treatment of OP poisoning in humans.	CPR:3
19651196.T14.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of @GENE$ poisoning in humans.	CPR:4
19651196.T7.T26	Presently, a combination of an antimuscarinic agent, e.g. @CHEMICAL$, @GENE$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	CPR:3
19651196.T8.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended @GENE$ (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	CPR:3
19651196.T9.T26	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (@GENE$, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	CPR:3
19837759.T9.T22	Preclinical properties of @CHEMICAL$: a PET agent for @GENE$ plaques in the brain.	false
19837759.T3.T16	@CHEMICAL$ ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of @GENE$ plaques in the brain.	false
19837759.T4.T16	(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (@CHEMICAL$) is such as an agent currently in phase III clinical studies for PET of @GENE$ plaques in the brain.	false
19837759.T5.T17	METHODS: In vitro binding of @CHEMICAL$ to @GENE$ plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography.	false
19837759.T6.T18	In vivo biodistribution of @CHEMICAL$ in mice and ex vivo autoradiography of AD transgenic mice (@GENE$/PSEN1) with Abeta aggregates in the brain were performed.	false
19837759.T6.T19	In vivo biodistribution of @CHEMICAL$ in mice and ex vivo autoradiography of AD transgenic mice (APPswe/@GENE$) with Abeta aggregates in the brain were performed.	false
19837759.T6.T20	In vivo biodistribution of @CHEMICAL$ in mice and ex vivo autoradiography of AD transgenic mice (APPswe/PSEN1) with @GENE$ aggregates in the brain were performed.	false
19837759.T8.T10	RESULTS: @CHEMICAL$ displayed a high binding affinity and specificity to @GENE$ plaques (K(d), 3.72 +/- 0.30 nM).	false
19837759.T1.T12	@CHEMICAL$ displayed excellent binding affinity to @GENE$ plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice.	false
19837759.T2.T13	The results lend support that @CHEMICAL$ may be a useful PET agent for detecting @GENE$ plaques in the living human brain.	false
19852528.T15.T23	Palonosetron is a second-generation @CHEMICAL$ 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation @GENE$ antagonists.	false
19852528.T15.T25	Palonosetron is a second-generation @CHEM-GENE$ antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.	false
19852528.T1.T23	@CHEMICAL$ is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation @GENE$ antagonists.	CPR:6
19852528.T1.T25	@CHEMICAL$ is a second-generation @GENE$ antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.	CPR:6
19852528.T12.T24	Oral @CHEMICAL$ is likely to be a useful addition to oral formulations of other @GENE$r antagonists in preventing CINV in patients receiving MEC.	CPR:6
19888521.T1.T6	Besides providing the content of terminal groups and individual @CHEMICAL$ and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.	false
19888521.T2.T6	Besides providing the content of terminal groups and individual glucosamine and @CHEMICAL$ residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.	false
19888521.T3.T6	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different @CHEMICAL$ substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.	false
19888521.T4.T6	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the @CHEMICAL$, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.	false
19888521.T5.T6	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @CHEMICAL$ (AT-bs) through quantification of signals of the @GENE$ sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.	false
20053189.T20.T30	@CHEMICAL$ and other @GENE$ antagonists in prostate cancer.	false
20053189.T21.T30	Abarelix and other @CHEM-GENE$ antagonists in prostate cancer.	false
20053189.T10.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (@CHEMICAL$) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.	false
20053189.T10.T22	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (@GENE$) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	false
20053189.T10.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (@GENE$) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	false
20053189.T10.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEM-GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	false
20053189.T11.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @CHEMICAL$ and @GENE$ levels.	false
20053189.T11.T22	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and @GENE$ levels.	false
20053189.T11.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and @GENE$ levels.	false
20053189.T11.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEMICAL$, ultimately leading to its de-sensitization and subsequent reduction of LH and @GENE$ levels.	false
20053189.T5.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as @CHEMICAL$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.	CPR:4
20053189.T5.T22	@CHEMICAL$ (LHRH) agonists, such as @GENE$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T5.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as @GENE$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T5.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as @CHEMICAL$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:3
20053189.T6.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, @CHEMICAL$, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.	CPR:4
20053189.T6.T22	@CHEMICAL$ (LHRH) agonists, such as buserelin, @GENE$, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T6.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, @GENE$, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T6.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, @CHEMICAL$, leuprorelin and triptorelin, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:3
20053189.T7.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, @CHEMICAL$ and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.	CPR:4
20053189.T7.T22	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, @GENE$ and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T7.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, @GENE$ and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T7.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, @CHEMICAL$ and triptorelin, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:3
20053189.T8.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and @CHEMICAL$, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.	CPR:4
20053189.T8.T22	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and @GENE$, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T8.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and @GENE$, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:5
20053189.T8.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and @CHEMICAL$, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	CPR:3
20053189.T9.T25	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEMICAL$ (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.	false
20053189.T9.T22	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @GENE$ (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	false
20053189.T9.T23	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @GENE$ (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	false
20053189.T9.T24	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEM-GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	false
20053189.T12.T26	However, this reduction is accompanied by a well described increase or 'surge' in @CHEMICAL$ and @GENE$ levels, necessitating the concomitant administration of an antiandrogen to combat the potential effects of transient acceleration in cancer activity.	false
20053189.T13.T27	Two pure @CHEM-GENE$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.	false
20053189.T13.T28	Two pure @CHEMICAL$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @GENE$ and consequently do not result in testosterone flare.	false
20053189.T14.T27	Two pure @CHEMICAL$ antagonists have been developed, @GENE$ and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.	CPR:6
20053189.T14.T28	Two pure GnRH antagonists have been developed, @CHEMICAL$ and degarelix, that are devoid of any agonist effect on the @GENE$ and consequently do not result in testosterone flare.	false
20053189.T15.T27	Two pure @CHEMICAL$ antagonists have been developed, abarelix and @GENE$, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.	CPR:6
20053189.T15.T28	Two pure GnRH antagonists have been developed, abarelix and @CHEMICAL$, that are devoid of any agonist effect on the @GENE$ and consequently do not result in testosterone flare.	false
20053189.T16.T27	Two pure @CHEMICAL$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @GENE$ receptor and consequently do not result in testosterone flare.	false
20053189.T16.T28	Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @CHEM-GENE$ and consequently do not result in testosterone flare.	false
20053189.T17.T27	Two pure @CHEMICAL$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in @GENE$ flare.	false
20053189.T17.T28	Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @CHEMICAL$ and consequently do not result in @GENE$ flare.	false
20053189.T18.T29	@CHEMICAL$ was the first @GENE$ antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.	CPR:6
20053189.T19.T29	Abarelix was the first @CHEM-GENE$ antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.	false
20053189.T1.T29	Abarelix was the first @CHEMICAL$ antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid @GENE$ suppression is necessary.	false
20151846.T5.T14	Pharmacologic advances in the field in the past decades, including @CHEMICAL$ and the @GENE$ inhibitors, have contributed significantly to the reduced mortality of estrogen-sensitive breast cancer.	false
20151846.T6.T14	Pharmacologic advances in the field in the past decades, including tamoxifen and the @CHEMICAL$ inhibitors, have contributed significantly to the reduced mortality of @GENE$-sensitive breast cancer.	false
20151846.T8.T15	@CHEMICAL$, a pure @GENE$ downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.	CPR:4
20151846.T9.T15	Fulvestrant, a pure @CHEM-GENE$ downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.	false
20496522.T5.T7	@CHEMICAL$ mediated hemodynamic profile of @GENE$.	false
21207059.T1.T10	Its pathophysiological process is mainly via the competitive inhibition of @CHEM-GENE$.	false
21207059.T4.T11	Isovaleric acidemia is an autosomal recessive disease of @CHEMICAL$ metabolism due to deficiency of @GENE$.	false
21207059.T5.T11	Isovaleric acidemia is an autosomal recessive disease of leucine metabolism due to deficiency of @CHEM-GENE$.	false
2125244.T6.T15	Stoichiometry of @CHEMICAL$ binding to MAP2 measured by the disassembly of chick brain MAP2:@GENE$ microtubules.	false
2125244.T6.T16	Stoichiometry of @CHEMICAL$ binding to @GENE$ measured by the disassembly of chick brain MAP2:tubulin microtubules.	false
2125244.T6.T17	Stoichiometry of @CHEMICAL$ binding to MAP2 measured by the disassembly of @GENE$:tubulin microtubules.	false
2125244.T1.T8	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of chick brain MAP2:@GENE$ microtubules is markedly dependent upon the microtubule protein concentration.	CPR:4
2125244.T1.T8	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of chick brain MAP2:@GENE$ microtubules is markedly dependent upon the microtubule protein concentration.	CPR:3
2125244.T1.T7	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of @GENE$:tubulin microtubules is markedly dependent upon the microtubule protein concentration.	CPR:4
2125244.T1.T7	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of @GENE$:tubulin microtubules is markedly dependent upon the microtubule protein concentration.	CPR:3
2125244.T2.T9	Analysis of this relationship shows that @CHEMICAL$ and @GENE$ compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.	false
2125244.T2.T10	Analysis of this relationship shows that @CHEMICAL$ and tubulin compete for common @GENE$ sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.	false
2125244.T2.T11	Analysis of this relationship shows that @CHEMICAL$ and tubulin compete for common MAP2 sites, that @GENE$ can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.	false
2125244.T3.T9	Analysis of this relationship shows that estramustine phosphate and @CHEMICAL$ compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 @GENE$, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.	false
2125244.T3.T10	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common @CHEMICAL$ sites, that MAP2 can bind 5-6 moles.mole-1 @GENE$, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.	false
2125244.T3.T11	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common MAP2 sites, that @CHEMICAL$ can bind 5-6 moles.mole-1 @GENE$, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.	false
2125244.T4.T9	Analysis of this relationship shows that estramustine phosphate and @CHEMICAL$ compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM @GENE$.	false
2125244.T4.T10	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common @CHEMICAL$ sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM @GENE$.	false
2125244.T4.T11	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common MAP2 sites, that @CHEMICAL$ can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM @GENE$.	false
2125244.T5.T14	It is proposed that two molecules of @CHEMICAL$ interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:@GENE$ interaction by neutralising two highly conserved basic residues.	CPR:4
2125244.T5.T12	It is proposed that two molecules of @CHEMICAL$ interact with each of the three tubulin-binding sites of @GENE$ and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues.	false
2125244.T5.T13	It is proposed that two molecules of @CHEMICAL$ interact with each of the three tubulin-binding sites of MAP2 and inhibit the @GENE$:tubulin interaction by neutralising two highly conserved basic residues.	CPR:4
21606412.T7.T21	Activity of @CHEMICAL$ (Cabozantinib), an oral @GENE$ inhibitor, in patients with medullary thyroid cancer.	CPR:4
21606412.T8.T21	Activity of XL184 (@CHEMICAL$), an oral @GENE$ inhibitor, in patients with medullary thyroid cancer.	CPR:4
21606412.T9.T21	Activity of XL184 (Cabozantinib), an oral @CHEM-GENE$ inhibitor, in patients with medullary thyroid cancer.	false
21606412.T3.T13	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (@GENE$), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T3.T14	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and @GENE$, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T3.T18	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of @GENE$, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T3.T19	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of MET, @GENE$ (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T6.T13	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (@GENE$), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T6.T14	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and @GENE$, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T6.T18	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of @GENE$, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T6.T19	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of MET, @GENE$ (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	CPR:4
21606412.T2.T15	@CHEMICAL$ may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including @GENE$, VEGFR2, and RET.	false
21606412.T2.T16	@CHEMICAL$ may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, @GENE$, and RET.	false
21606412.T2.T17	@CHEMICAL$ may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and @GENE$.	false
22258629.T6.T10	Blood complete counts, high-sensitive @CHEMICAL$, @GENE$ and routine biochemical tests were carried out by routine procedures.	false
22287617.T7.T24	The activities of @CHEM-GENE$, catalase and glutathione peroxidase were found significantly higher in combined treated than untreated rats.	false
22287617.T7.T26	The activities of @CHEMICAL$ dismutase, catalase and @GENE$ were found significantly higher in combined treated than untreated rats.	false
22287617.T7.T25	The activities of @CHEMICAL$ dismutase, @GENE$ and glutathione peroxidase were found significantly higher in combined treated than untreated rats.	false
22287617.T8.T24	The activities of @CHEMICAL$, catalase and @GENE$ peroxidase were found significantly higher in combined treated than untreated rats.	false
22287617.T8.T26	The activities of superoxide dismutase, catalase and @CHEM-GENE$ were found significantly higher in combined treated than untreated rats.	false
22287617.T8.T25	The activities of superoxide dismutase, @CHEMICAL$ and @GENE$ peroxidase were found significantly higher in combined treated than untreated rats.	false
22370636.T1.T12	Oncogenic mutations in PIK3CA, which encodes the @CHEM-GENE$, occur in ~25% of human breast cancers.	false
22370636.T1.T4	Oncogenic mutations in @CHEMICAL$, which encodes the @GENE$-3-kinase (PI3K) catalytic subunit p110a, occur in ~25% of human breast cancers.	false
22370636.T2.T14	Whole-exome analysis of the Pik3ca(@CHEMICAL$)-driven mammary tumors identified multiple mutations, including @GENE$53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	false
22370636.T2.T13	Whole-exome analysis of the @CHEMICAL$(H1047R)-driven mammary tumors identified multiple mutations, including @GENE$53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	false
22370636.T2.T15	Whole-exome analysis of the Pik3ca(H1047R)-driven mammary tumors identified multiple mutations, including @CHEM-GENE$ mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	false
22370636.T3.T16	Further, we used this model to test the efficacy of @CHEMICAL$, a @GENE$ inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.	CPR:4
22370636.T3.T17	Further, we used this model to test the efficacy of @CHEMICAL$, a PI3K inhibitor, in clinical development, and showed that the tumors respond to @GENE$ inhibition.	CPR:4
22447684.T9.T11	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including @GENE$, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T12	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, @GENE$, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T13	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, @GENE$, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T14	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, @GENE$, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T15	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, @GENE$, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T16	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, @GENE$, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T17	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, @GENE$, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T18	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, @GENE$, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T19	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, @GENE$, Fdft1, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T20	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, @GENE$, and Fasn, relative to those in HFD control mice.	false
22447684.T9.T21	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and @GENE$, relative to those in HFD control mice.	false
22469981.T2.T6	A @CHEMICAL$-inducible transgenic mouse model expressing truncated @GENE$ (DN89b-catenin) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic b-catenin expression both in 3D 'crypt culture' and in vivo.	false
22469981.T2.T7	A @CHEMICAL$-inducible transgenic mouse model expressing truncated b-catenin (DN89@GENE$) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic b-catenin expression both in 3D 'crypt culture' and in vivo.	false
22469981.T2.T8	A @CHEMICAL$-inducible transgenic mouse model expressing truncated b-catenin (DN89b-catenin) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic @GENE$ expression both in 3D 'crypt culture' and in vivo.	false
22578098.T4.T16	The interplay between cardiac sarcoplasmic @CHEM-GENE$ and phospholamban is a key regulating factor of contraction and relaxation in the cardiac muscle.	false
22578098.T4.T19	The interplay between cardiac sarcoplasmic @CHEMICAL$ATPase and @GENE$ is a key regulating factor of contraction and relaxation in the cardiac muscle.	false
22578098.T3.T14	In heart failure, aberrations in the inhibition of sarcoplasmic @CHEM-GENE$ by phospholamban are associated with anomalies in cardiac functions.	false
22578098.T3.T15	In heart failure, aberrations in the inhibition of sarcoplasmic @CHEMICAL$ATPase by @GENE$ are associated with anomalies in cardiac functions.	false
22578098.T5.T18	The aim of our research was to find molecules able to interfere with the inhibitory activity of phospholamban on sarcoplasmic @CHEM-GENE$.	false
22578098.T5.T17	The aim of our research was to find molecules able to interfere with the inhibitory activity of @CHEMICAL$ on sarcoplasmic @GENE$ATPase.	false
22578098.T1.T8	By synthesizing and testing a series of alanine point-mutated @CHEMICAL$, we identified which @GENE$ was important for the inhibition of the phospholamban function.	false
22578098.T1.T9	By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which @CHEMICAL$ was important for the inhibition of the @GENE$ function.	false
22578098.T7.T8	By synthesizing and testing a series of @CHEMICAL$ point-mutated @GENE$, we identified which amino acid was important for the inhibition of the phospholamban function.	false
22578098.T7.T9	By synthesizing and testing a series of @CHEMICAL$ point-mutated cyclic peptides, we identified which amino acid was important for the inhibition of the @GENE$ function.	false
22578098.T2.T10	The structures of active and inactive @CHEMICAL$-mutated @GENE$, and of phospholamban (1-36), were determined by NMR.	false
22578098.T2.T11	The structures of active and inactive @CHEMICAL$-mutated cyclic peptides, and of @GENE$, were determined by NMR.	false
22614014.T1.T2	BMMs are the major source of inflammatory factors and @CHEMICAL$, including @GENE$ protease cathepsin K (CTSK).	false
22614014.T1.T3	BMMs are the major source of inflammatory factors and proteases, including @CHEM-GENE$ cathepsin K (CTSK).	false
22614014.T1.T4	BMMs are the major source of inflammatory factors and proteases, including @CHEMICAL$ protease @GENE$ (CTSK).	false
22614014.T1.T5	BMMs are the major source of inflammatory factors and proteases, including @CHEMICAL$ protease cathepsin K (@GENE$).	false
2268554.T18.T28	Inhibitory effect of synthetic @CHEMICAL$, 4-MA and cyanoketone on @GENE$ activity.	CPR:4
2268554.T19.T28	Inhibitory effect of synthetic progestins, @CHEMICAL$ and cyanoketone on @GENE$ activity.	CPR:4
2268554.T20.T28	Inhibitory effect of synthetic progestins, 4-MA and @CHEMICAL$ on @GENE$ activity.	CPR:4
2268554.T21.T28	Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on @CHEM-GENE$ activity.	false
2268554.T1.T22	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (@GENE$ and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T1.T26	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (@GENE$ and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T2.T22	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and @GENE$) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T2.T26	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and @GENE$) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T3.T22	@CHEM-GENE$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	false
2268554.T3.T26	Human placental @CHEMICAL$ dehydrogenase/5----4-ene isomerase (@GENE$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	false
2268554.T4.T22	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (@GENE$ and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T4.T26	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (@GENE$ and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T5.T22	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and @GENE$) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T5.T26	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and @GENE$) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T6.T22	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding @GENE$ and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T6.T26	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding @GENE$ and is thus involved in the biosynthesis of all classes of hormonal steroids.	CPR:9
2268554.T10.T23	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. @GENE$, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T10.T24	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. @CHEMICAL$, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	CPR:4
2268554.T10.T25	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. @CHEMICAL$, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	CPR:4
2268554.T11.T23	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic @GENE$ compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T11.T24	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @CHEMICAL$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic @GENE$ compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T11.T25	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @CHEMICAL$ with a Ki value of 56 nM. Synthetic @GENE$ compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T12.T23	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as @GENE$ and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T12.T24	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @CHEMICAL$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as @GENE$ and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T12.T25	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @CHEMICAL$ with a Ki value of 56 nM. Synthetic progestin compounds such as @GENE$ and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T13.T23	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and @GENE$ show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T13.T24	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @CHEMICAL$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and @GENE$ show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T13.T25	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @CHEMICAL$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and @GENE$ show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T7.T23	@CHEMICAL$, epostane and cyanoketone are potent inhibitors of @GENE$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	CPR:4
2268554.T7.T24	@CHEMICAL$, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T7.T25	@CHEMICAL$, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T8.T23	Trilostane, @CHEMICAL$ and cyanoketone are potent inhibitors of @GENE$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	CPR:4
2268554.T8.T24	Trilostane, @CHEMICAL$ and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T8.T25	Trilostane, @CHEMICAL$ and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T9.T23	Trilostane, epostane and @CHEMICAL$ are potent inhibitors of @GENE$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	CPR:4
2268554.T9.T24	Trilostane, epostane and @CHEMICAL$ are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T9.T25	Trilostane, epostane and @CHEMICAL$ are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.	false
2268554.T14.T27	@CHEMICAL$, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
2268554.T15.T27	Cyproterone acetate, a @CHEMICAL$ used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
2268554.T16.T27	Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as @CHEMICAL$ and norethindrone that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
2268554.T17.T27	Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and @CHEMICAL$ that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
22709946.T3.T14	We also examined @CHEMICAL$ receptor signaling by in vivo measurement of @GENE$-stimulated polyphosphoinositides hydrolysis.	false
22709946.T4.T14	We also examined @CHEMICAL$ receptor signaling by in vivo measurement of DHPG-stimulated @GENE$ hydrolysis.	false
22709946.T1.T9	However, chronic treatment of cLH rats with @CHEMICAL$ did not reverse learned helplessness, indicating that the enhanced @GENE$ function is not the only player in the behavioral phenotype of this genetic model of depression.	CPR:3
22709946.T2.T10	This article is part of a Special Issue entitled '@CHEM-GENE$'.	false
22722028.T7.T16	Rescue of this impaired extinction consolidation/retrieval was achieved with @CHEMICAL$ (N-methly-d-aspartate partial agonist) or MS-275 (@GENE$ (HDAC) inhibitor), applied after extinction training.	false
22722028.T7.T17	Rescue of this impaired extinction consolidation/retrieval was achieved with @CHEMICAL$ (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (@GENE$) inhibitor), applied after extinction training.	false
22722028.T8.T16	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (@CHEMICAL$ partial agonist) or MS-275 (@GENE$ (HDAC) inhibitor), applied after extinction training.	false
22722028.T8.T17	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (@CHEMICAL$ partial agonist) or MS-275 (histone deacetylase (@GENE$) inhibitor), applied after extinction training.	false
22722028.T9.T16	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or @CHEMICAL$ (@GENE$ (HDAC) inhibitor), applied after extinction training.	CPR:4
22722028.T9.T17	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or @CHEMICAL$ (histone deacetylase (@GENE$) inhibitor), applied after extinction training.	CPR:4
22722028.T1.T10	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and @GENE$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	CPR:4
22722028.T1.T13	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T1.T11	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@GENE$ (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T1.T12	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@GENE$) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T2.T10	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or @GENE$ [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T2.T13	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or @CHEMICAL$ [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T2.T11	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or @CHEMICAL$ [@GENE$ (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	CPR:5
22722028.T2.T12	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or @CHEMICAL$ [metabotropic glutamate receptor 7 (@GENE$) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	CPR:5
22722028.T3.T10	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic @GENE$ receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T3.T13	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic @CHEMICAL$ receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T3.T11	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEM-GENE$ (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T3.T12	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic @CHEMICAL$ receptor 7 (@GENE$) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T4.T10	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while @GENE$ or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T4.T13	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while @CHEMICAL$ or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.	CPR:3
22722028.T4.T11	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEMICAL$ (mGlu7) agonist], while @GENE$ or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T4.T12	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@CHEMICAL$) agonist], while @GENE$ or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T5.T10	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or @GENE$ (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T5.T13	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or @CHEMICAL$ (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.	CPR:3
22722028.T5.T11	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEMICAL$ (mGlu7) agonist], while MS-275 or @GENE$ (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T5.T12	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@CHEMICAL$) agonist], while MS-275 or @GENE$ (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T6.T10	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T6.T13	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@CHEM-GENE$ potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T6.T11	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEMICAL$ (mGlu7) agonist], while MS-275 or PEPA (@GENE$ receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22722028.T6.T12	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@CHEMICAL$) agonist], while MS-275 or PEPA (@GENE$ receptor potentiator) failed to affect extinction acquisition in S1 mice.	false
22749926.T8.T11	Electroencephalographic recordings during substance consumption showed reduced alpha activity and @CHEMICAL$ latencies in the @GENE$ group compared to the control group.	CPR:4
22749926.T2.T10	These findings suggest that oral consumption of @CHEMICAL$ enhances the efficacy of @GENE$.	CPR:3
22749926.T3.T10	These findings suggest that oral consumption of nicotine enhances the efficacy of @CHEM-GENE$.	false
22798247.T1.T4	Rats treated with @CHEMICAL$ plus hCG displayed abnormal estrous cycles with increasing @GENE$ biosynthesis.	false
22798247.T1.T5	Rats treated with insulin plus @CHEMICAL$ displayed abnormal estrous cycles with increasing @GENE$ biosynthesis.	false
22893351.T3.T14	It was hypothesized that because @CHEMICAL$ accumulates in the proximal tubules (PTs), @GENE$ (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T3.T15	It was hypothesized that because @CHEMICAL$ accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T4.T14	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEM-GENE$ (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T4.T15	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEMICAL$-S-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T5.T14	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEM-GENE$ (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T5.T15	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), glutathione-@CHEMICAL$-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T6.T14	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEMICAL$ (suggestive of kidney damage at the level of PT) would be expected to be more related to @GENE$ exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T6.T15	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to @CHEMICAL$ exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).	false
22893351.T7.T16	Our study determined whether there was a significant dose-dependent correlation between increasing @CHEMICAL$ exposure from dental amalgams and @GENE$ and GST-p as biomarkers of kidney integrity.	false
22893351.T7.T17	Our study determined whether there was a significant dose-dependent correlation between increasing @CHEMICAL$ exposure from dental amalgams and GST-a and @GENE$ as biomarkers of kidney integrity.	false
22893351.T1.T11	Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to @CHEMICAL$ from dental amalgams and urinary levels of @GENE$, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of GST-p.	false
22893351.T1.T12	Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to @CHEMICAL$ from dental amalgams and urinary levels of GST-a, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of @GENE$.	false
22923473.T3.T7	Following a 2-h control period during which @CHEMICAL$ infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal @GENE$ (INS) or portal vein glucose infusion (PoG) was measured.	false
22923473.T3.T8	Following a 2-h control period during which @CHEMICAL$ infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal insulin (@GENE$) or portal vein glucose infusion (PoG) was measured.	false
22923473.T4.T7	Following a 2-h control period during which fructose infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal @CHEMICAL$ (INS) or portal vein @GENE$ infusion (PoG) was measured.	false
22923473.T4.T8	Following a 2-h control period during which fructose infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal insulin (@CHEMICAL$) or portal vein @GENE$ infusion (PoG) was measured.	false
22923473.T5.T10	Increased hepatic glycogen reduced the percent of @CHEMICAL$ taken up by the liver that was deposited in glycogen (74 + 3 vs. 53 + 5% in Gly+INS and SCGly+@GENE$, respectively, and 72 + 3 vs. 50 + 6% in Gly+PoG and SCGly+PoG, respectively).	false
22923473.T5.T9	Increased hepatic glycogen reduced the percent of @CHEMICAL$ taken up by the liver that was deposited in glycogen (74 + 3 vs. 53 + 5% in Gly+@GENE$ and SCGly+INS, respectively, and 72 + 3 vs. 50 + 6% in Gly+PoG and SCGly+PoG, respectively).	false
22943130.T1.T8	1. @CHEM-GENE$ (UGTs) are a group of drug-metabolizing enzymes that catalyse the conjugation of endogeonous compounds and xenobiotics to yield hydrophilic glucuronides which subsequently undergo excretion.	false
22943130.T1.T9	1. @CHEMICAL$-glucuronosyltransferases (@GENE$) are a group of drug-metabolizing enzymes that catalyse the conjugation of endogeonous compounds and xenobiotics to yield hydrophilic glucuronides which subsequently undergo excretion.	false
22956632.T5.T24	Toxicity profile of small-molecule @CHEMICAL$ antagonist @GENE$ is linked to TNF-a pharmacology.	CPR:6
22956632.T5.T25	Toxicity profile of small-molecule IAP antagonist @CHEMICAL$ is linked to @GENE$ pharmacology.	false
22956632.T2.T13	@CHEMICAL$ is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing @GENE$.	CPR:6
22956632.T3.T14	@CHEMICAL$ induces @GENE$ transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-a) is the most important for single-agent tumor activity.	CPR:3
22956632.T3.T15	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several @GENE$ and cytokines, of which tumor necrosis factor alpha (TNF-a) is the most important for single-agent tumor activity.	false
22956632.T3.T16	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several chemokines and @GENE$, of which tumor necrosis factor alpha (TNF-a) is the most important for single-agent tumor activity.	false
22956632.T3.T17	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several chemokines and cytokines, of which @GENE$ (TNF-a) is the most important for single-agent tumor activity.	false
22956632.T3.T18	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (@GENE$) is the most important for single-agent tumor activity.	false
22956632.T1.T11	Furthermore, elevations in blood neutrophil count, serum @CHEMICAL$, and other markers of inflammation corresponded to @GENE$ exposure and toxicity and thus may have utility as safety biomarkers.	false
22966070.T4.T27	In the current study, we investigated whether @CHEMICAL$, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @GENE$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).	false
22966070.T4.T30	In the current study, we investigated whether insulin, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @CHEMICAL$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular @GENE$ and leptin, and Tub antisense oligonucleotide (ASO).	false
22966070.T4.T28	In the current study, we investigated whether insulin, @CHEMICAL$, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @GENE$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).	false
22966070.T4.T29	In the current study, we investigated whether insulin, leptin, and obesity can modulate @CHEMICAL$ in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @GENE$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).	false
22966070.T4.T31	In the current study, we investigated whether insulin, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @CHEMICAL$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and @GENE$, and Tub antisense oligonucleotide (ASO).	false
22966070.T4.T32	In the current study, we investigated whether insulin, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @CHEMICAL$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and @GENE$ antisense oligonucleotide (ASO).	false
22966070.T5.T33	@CHEMICAL$ @GENE$ phosphorylation (Tub-p-tyr) is modulated by nutritional status.	false
22966070.T6.T33	@CHEMICAL$ tyrosine phosphorylation (Tub-p-@GENE$) is modulated by nutritional status.	false
22966070.T7.T35	@CHEMICAL$ is a substrate of insulin receptor @GENE$ kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	false
22966070.T7.T36	Tub is a substrate of @CHEM-GENE$ (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	false
22966070.T7.T37	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (@GENE$) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	false
22966070.T7.T38	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and @GENE$ (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	false
22966070.T7.T39	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and leptin receptor (@GENE$)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	false
22966070.T7.T40	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and leptin receptor (LEPR)-@GENE$ (JAK2) in hypothalamic nuclei.	false
22966070.T7.T41	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (@GENE$) in hypothalamic nuclei.	false
22966070.T1.T10	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of @GENE$ or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T1.T11	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or @GENE$ on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T1.T12	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on @GENE$, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T1.T13	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, @GENE$, melanin-concentrating hormone, and orexin expression.	false
22966070.T1.T14	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, @GENE$, and orexin expression.	false
22966070.T1.T15	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and @GENE$ expression.	false
22966070.T1.T45	Inhibition of @CHEMICAL$ expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @GENE$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T8.T10	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of @GENE$ or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T8.T11	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or @GENE$ on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T8.T12	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on @GENE$, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T8.T13	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, @GENE$, melanin-concentrating hormone, and orexin expression.	false
22966070.T8.T14	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, @GENE$, and orexin expression.	false
22966070.T8.T15	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and @GENE$ expression.	false
22966070.T8.T45	Inhibition of @CHEMICAL$ expression in hypothalamus by ASO increased food intake, fasting blood @GENE$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T9.T10	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of @GENE$ or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T9.T11	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or @GENE$ on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T9.T12	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on @GENE$, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T9.T13	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, @GENE$, melanin-concentrating hormone, and orexin expression.	false
22966070.T9.T14	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, @GENE$, and orexin expression.	false
22966070.T9.T15	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and @GENE$ expression.	false
22966070.T9.T45	Inhibition of @CHEMICAL$ expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @GENE$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	false
22966070.T2.T18	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and @CHEMICAL$-induced Tub-p-@GENE$ and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.	false
22966070.T2.T17	In hypothalamus of mice administered a high-fat diet, there is a reduction in @CHEMICAL$ and insulin-induced Tub-p-@GENE$ and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.	false
22966070.T2.T19	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced @CHEMICAL$-p-@GENE$ and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.	false
22966070.T2.T20	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced Tub-p-@CHEMICAL$ and nuclear translocation, which is reversed by reducing @GENE$ expression.	false
22966070.T3.T18	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and @CHEMICAL$-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein @GENE$ phosphatase 1B expression.	false
22966070.T3.T17	In hypothalamus of mice administered a high-fat diet, there is a reduction in @CHEMICAL$ and insulin-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein @GENE$ phosphatase 1B expression.	false
22966070.T3.T19	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced @CHEMICAL$-p-tyr and nuclear translocation, which is reversed by reducing protein @GENE$ phosphatase 1B expression.	false
22966070.T3.T20	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing @CHEM-GENE$ expression.	false
22982218.T7.T23	The @CHEMICAL$ inhibitor @GENE$ modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.	CPR:4
22982218.T7.T22	The PARP inhibitor @CHEMICAL$ modifies proliferation, @GENE$ expression and epigenetic marks in thyroid cancer cell lines.	false
22982218.T1.T9	Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the @CHEMICAL$ inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.	CPR:4
22982218.T1.T13	Since @CHEMICAL$ is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the PARP inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.	false
22982218.T1.T15	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEMICAL$ (NIS) expression, in this study the effect of the PARP inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.	false
22982218.T1.T19	Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (@CHEMICAL$) expression, in this study the effect of the PARP inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.	false
22982218.T6.T9	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEMICAL$ symporter (NIS) expression, in this study the effect of the @GENE$ inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	false
22982218.T6.T13	Since @CHEMICAL$ is supposed to be part of a multimeric repressor of @GENE$ symporter (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	false
22982218.T6.T15	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEM-GENE$ (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	false
22982218.T6.T19	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEMICAL$ symporter (@GENE$) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	false
22982218.T2.T10	In TPC1, BCPAP, FRO, WRO cell lines @CHEMICAL$ induced a strong increase in @GENE$ mRNA levels.	CPR:3
22982218.T4.T11	Accordingly, in transfection experiments performed in TPC1 cells, treatment with @CHEMICAL$ increased @GENE$ activity without affecting PARP-1 binding to the promoter sequence.	CPR:3
22982218.T4.T12	Accordingly, in transfection experiments performed in TPC1 cells, treatment with @CHEMICAL$ increased NIS promoter activity without affecting @GENE$ binding to the promoter sequence.	false
22982218.T5.T14	We also investigated the epigenetic status of @CHEMICAL$ after @GENE$ treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	false
22982218.T5.T16	We also investigated the epigenetic status of NIS promoter after @CHEMICAL$ treatment in TPC1 cell line: in addition to an increase of @GENE$ (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	CPR:3
22982218.T5.T17	We also investigated the epigenetic status of NIS promoter after @CHEMICAL$ treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (@GENE$, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	CPR:3
22982218.T5.T18	We also investigated the epigenetic status of NIS promoter after @CHEMICAL$ treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, @GENE$), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	CPR:3
22989703.T15.T24	Both @CHEMICAL$ also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in @GENE$ and COX-2 expressions caused by CSE.	CPR:4
22989703.T15.T25	Both @CHEMICAL$ also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and @GENE$ expressions caused by CSE.	CPR:4
22989703.T16.T24	Both apo-lycopenoic acids also decreased CSE-induced ROS production, @CHEMICAL$ formation and reduced the increase in @GENE$ and COX-2 expressions caused by CSE.	false
22989703.T16.T25	Both apo-lycopenoic acids also decreased CSE-induced ROS production, @CHEMICAL$ formation and reduced the increase in NOX-4 and @GENE$ expressions caused by CSE.	false
23000451.T7.T17	Plants as a source of butyrylcholinesterase variants designed for enhanced @CHEM-GENE$ activity.	false
23000451.T7.T16	Plants as a source of @CHEMICAL$ variants designed for enhanced @GENE$ hydrolase activity.	false
23000451.T3.T10	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme @CHEMICAL$ (BChE), which is capable of breaking down naturally occurring @GENE$ before the drug can influence the reward centers of the brain or affect other areas of the body.	CPR:9
23000451.T3.T11	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (@CHEMICAL$), which is capable of breaking down naturally occurring @GENE$ before the drug can influence the reward centers of the brain or affect other areas of the body.	CPR:9
23000451.T4.T13	This prompted the design of variants of @CHEMICAL$ which exhibit significantly improved catalytic activity against @GENE$.	CPR:9
23000451.T5.T14	Plants are a promising means to produce large amounts of these @CHEM-GENE$ variants of BChE, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.	false
23000451.T5.T15	Plants are a promising means to produce large amounts of these @CHEMICAL$ hydrolase variants of @GENE$, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.	false
23000451.T2.T8	Here, in expressing @CHEMICAL$-hydrolyzing mutants of @GENE$ in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.	CPR:9
23000451.T2.T9	Here, in expressing @CHEMICAL$-hydrolyzing mutants of BChE in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered @GENE$ proteins with desired properties.	false
23000507.T7.T13	Nerve fibers immunoreactive for not only sensory neuromarkers, such as @CHEMICAL$ (CGRP), but also sympathetic neuromarkers, such as @GENE$ hydroxylase (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	false
23000507.T7.T14	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (@CHEMICAL$), but also sympathetic neuromarkers, such as @GENE$ hydroxylase (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	false
23000507.T7.T15	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEM-GENE$ (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	false
23000507.T7.T16	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEMICAL$ hydroxylase (@GENE$) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	false
23000507.T7.T17	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEMICAL$ hydroxylase (TH) and @GENE$ (NPY) were increased in the periodontal ligament during ETM.	false
23000507.T7.T18	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEMICAL$ hydroxylase (TH) and neuropeptide Y (@GENE$) were increased in the periodontal ligament during ETM.	false
23002036.T7.T64	@CHEMICAL$ knockout mice exhibit impaired adipocyte @GENE$-dependent insulinotropic polypeptide receptor (GIPR) expression.	false
23002036.T7.T65	Resistin knockout mice exhibit impaired adipocyte @CHEMICAL$-dependent insulinotropic polypeptide receptor (@GENE$) expression.	false
23002036.T7.T66	Resistin knockout mice exhibit impaired adipocyte @CHEM-GENE$ (GIPR) expression.	false
23002036.T1.T45	@CHEMICAL$-dependent insulinotropic polypeptide (GIP) is an @GENE$ that also plays a regulatory role in fat metabolism.	false
23002036.T1.T41	@CHEMICAL$-dependent insulinotropic polypeptide (@GENE$) is an incretin hormone that also plays a regulatory role in fat metabolism.	false
23002036.T1.T8	@CHEM-GENE$ (GIP) is an incretin hormone that also plays a regulatory role in fat metabolism.	false
23002036.T5.T24	In 3T3-L1 cells, @CHEMICAL$ was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T31	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of @CHEMICAL$ stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T32	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of @CHEMICAL$ (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T33	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (@CHEMICAL$) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T34	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of @CHEMICAL$ (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T35	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (@CHEMICAL$) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T36	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of @CHEMICAL$ (LKB1) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T37	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (@CHEMICAL$) and @GENE$-activated protein kinase (AMPK).	false
23002036.T5.T38	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @CHEM-GENE$ (AMPK).	false
23002036.T5.T39	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @CHEMICAL$-activated protein kinase (@GENE$).	false
23002036.T6.T43	Analysis of primary adipocytes isolated from @CHEMICAL$(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T44	Analysis of primary adipocytes isolated from Retn(-/-), @CHEMICAL$(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T46	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and @CHEMICAL$(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T47	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that @CHEMICAL$ stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T48	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the @CHEMICAL$/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T49	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/@CHEMICAL$/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T50	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/@CHEMICAL$/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T51	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/@CHEMICAL$ pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T52	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in @GENE$(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T53	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that @GENE$ signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T54	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or @GENE$ responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T55	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in @GENE$(+/-) and Retn(-/-) adipocytes.	false
23002036.T6.T56	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and @GENE$(-/-) adipocytes.	false
23002036.T2.T12	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins @CHEMICAL$ (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T13	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (@CHEMICAL$)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T14	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/@CHEM-GENE$ (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T15	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (@GENE$), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T16	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of @GENE$/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T17	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/@GENE$/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T10	In addition, genes encoding tumor necrosis factor (TNF), @CHEMICAL$ (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T11	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (@CHEMICAL$), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T18	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/@GENE$ were decreased in Retn(-/-) mice.	false
23002036.T2.T19	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in @GENE$(-/-) mice.	false
23002036.T2.T63	In addition, genes encoding @CHEMICAL$ (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T2.T9	In addition, genes encoding tumor necrosis factor (@CHEMICAL$), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	false
23002036.T3.T20	Chromatin immunoprecipitation assays were used to identify a @CHEM-GENE$ (TRE-III) responsible for c-Jun-mediated transcriptional activation of Gipr.	false
23002036.T3.T21	Chromatin immunoprecipitation assays were used to identify a @CHEMICAL$ (TPA)-response element (@GENE$) responsible for c-Jun-mediated transcriptional activation of Gipr.	false
23002036.T3.T22	Chromatin immunoprecipitation assays were used to identify a @CHEMICAL$ (TPA)-response element (TRE-III) responsible for @GENE$-mediated transcriptional activation of Gipr.	false
23002036.T3.T23	Chromatin immunoprecipitation assays were used to identify a @CHEMICAL$ (TPA)-response element (TRE-III) responsible for c-Jun-mediated transcriptional activation of @GENE$.	false
23002036.T4.T20	Chromatin immunoprecipitation assays were used to identify a @CHEM-GENE$ (TRE-III) responsible for c-Jun-mediated transcriptional activation of Gipr.	false
23002036.T4.T21	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (@CHEMICAL$)-response element (@GENE$) responsible for c-Jun-mediated transcriptional activation of Gipr.	false
23002036.T4.T22	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (@CHEMICAL$)-response element (TRE-III) responsible for @GENE$-mediated transcriptional activation of Gipr.	false
23002036.T4.T23	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (@CHEMICAL$)-response element (TRE-III) responsible for c-Jun-mediated transcriptional activation of @GENE$.	false
23008503.T10.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @CHEMICAL$ isoforms and @GENE$ (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T10.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and @CHEMICAL$ (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T10.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and @GENE$ (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T10.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and @GENE$ (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T11.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @CHEMICAL$ isoforms and prostaglandin E(2) (@GENE$) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T11.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (@CHEMICAL$) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T11.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (@GENE$) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T11.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (@GENE$) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T5.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (@CHEMICAL$, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T5.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (@CHEMICAL$, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T5.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (@GENE$, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	CPR:4
23008503.T5.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (@CHEMICAL$, ketorolac) and @GENE$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T6.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, @CHEMICAL$) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T6.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, @CHEMICAL$) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T6.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, @GENE$) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	CPR:4
23008503.T6.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, @CHEMICAL$) and @GENE$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T7.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (@CHEMICAL$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T7.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (@CHEMICAL$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T7.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (@GENE$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T7.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (@GENE$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	CPR:4
23008503.T8.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, @CHEMICAL$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T8.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, @CHEMICAL$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T8.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, @GENE$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T8.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, @GENE$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	CPR:4
23008503.T9.T23	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @CHEMICAL$ on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T9.T24	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @CHEMICAL$ on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.	false
23008503.T9.T21	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @GENE$ on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T9.T22	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @GENE$ on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	false
23008503.T12.T26	Localization and expression of @CHEMICAL$ isoforms (by immunohistochemistry, Western blot) and @GENE$ level (by enzyme immunoassay) were examined.	false
23008503.T3.T14	Second, feeding increased both the expression of @CHEMICAL$ isoforms and @GENE$ level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine.	false
23008503.T4.T14	Second, feeding increased both the expression of @CHEMICAL$ isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with @GENE$.	CPR:4
23019137.T11.T35	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on @GENE$, G protein-coupled receptor kinase, and dynamin.	false
23019137.T11.T36	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, @GENE$, and dynamin.	false
23019137.T11.T37	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and @GENE$.	false
23019137.T11.T38	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by @GENE$-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and dynamin.	false
23019137.T11.T34	Reversal of @CHEM-GENE$ agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and dynamin.	false
23019137.T6.T19	DIR is mediated by @CHEMICAL$ and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.	false
23019137.T6.T20	DIR is mediated by phospholipase C and @CHEMICAL$ (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.	false
23019137.T6.T21	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (@CHEMICAL$) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.	false
23019137.T6.T23	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and @CHEMICAL$, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.	false
23019137.T6.T25	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @CHEM-GENE$ or neurotensin receptors.	false
23019137.T6.T26	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @CHEMICAL$(2) or @GENE$.	false
23019137.T6.T22	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of @CHEMICAL$ and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.	false
23019137.T6.T24	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by @CHEMICAL$ stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.	false
23019137.T7.T19	DIR is mediated by @CHEMICAL$ and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.	false
23019137.T7.T20	DIR is mediated by phospholipase C and @CHEMICAL$ (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.	false
23019137.T7.T21	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (@CHEMICAL$) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.	false
23019137.T7.T23	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and @CHEMICAL$, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.	false
23019137.T7.T25	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @CHEMICAL$ or @GENE$ receptors.	false
23019137.T7.T26	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @CHEM-GENE$.	false
23019137.T7.T22	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of @CHEMICAL$ and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.	false
23019137.T7.T24	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by @CHEMICAL$ stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.	false
23019137.T10.T32	Reversal of inhibition by @CHEMICAL$ agonist quinpirole was produced by serotonin (50 mM) and by @GENE$ (5-10 nM).	CPR:3
23019137.T10.T33	Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 mM) and by @CHEM-GENE$ (5-10 nM).	false
23019137.T8.T32	Reversal of inhibition by @CHEMICAL$ agonist @GENE$ was produced by serotonin (50 mM) and by neurotensin (5-10 nM).	CPR:5
23019137.T8.T33	Reversal of inhibition by D2 agonist @CHEMICAL$ was produced by serotonin (50 mM) and by @GENE$ (5-10 nM).	false
23019137.T9.T32	Reversal of inhibition by @CHEMICAL$ agonist quinpirole was produced by @GENE$ (50 mM) and by neurotensin (5-10 nM).	CPR:3
23019137.T9.T33	Reversal of inhibition by D2 agonist quinpirole was produced by @CHEMICAL$ (50 mM) and by @GENE$ (5-10 nM).	false
23019137.T1.T13	@CHEMICAL$-induced or neurotensin-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @GENE$ antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).	false
23019137.T1.T12	@CHEMICAL$-induced or @GENE$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).	false
23019137.T2.T13	Serotonin-induced or @CHEMICAL$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @GENE$ antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).	false
23019137.T2.T12	Serotonin-induced or @CHEM-GENE$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).	false
23019137.T3.T13	Serotonin-induced or neurotensin-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @CHEMICAL$ antagonist @GENE$ (Go6976).	CPR:6
23019137.T3.T12	Serotonin-induced or @CHEMICAL$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist @GENE$ (Go6976).	false
23019137.T4.T13	Serotonin-induced or neurotensin-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @CHEMICAL$ antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (@GENE$).	CPR:6
23019137.T4.T12	Serotonin-induced or @CHEMICAL$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (@GENE$).	false
23042952.T16.T40	RSV targets and activates the @CHEM-GENE$; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	false
23042952.T16.T41	RSV targets and activates the @CHEMICAL$-dependent protein deacetylase SIRT1; in turn, @GENE$ induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	false
23042952.T16.T42	RSV targets and activates the @CHEMICAL$-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing @GENE$ (SOD2).	false
23042952.T16.T43	RSV targets and activates the @CHEMICAL$-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (@GENE$).	false
23042952.T19.T40	RSV targets and activates the @CHEMICAL$; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial @GENE$ dismutase (SOD2).	false
23042952.T19.T41	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, @CHEMICAL$ induces an intracellular antioxidative mechanism by inducing mitochondrial @GENE$ dismutase (SOD2).	false
23042952.T19.T42	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing @CHEM-GENE$ (SOD2).	false
23042952.T19.T43	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial @CHEMICAL$ dismutase (@GENE$).	false
23042952.T8.T40	@CHEMICAL$ targets and activates the @GENE$; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	CPR:3
23042952.T8.T41	@CHEMICAL$ targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, @GENE$ induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	CPR:3
23042952.T8.T42	@CHEMICAL$ targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing @GENE$ (SOD2).	CPR:3
23042952.T8.T43	@CHEMICAL$ targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (@GENE$).	CPR:3
23042952.T2.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with @GENE$, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T2.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with @CHEMICAL$, @GENE$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T2.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with @GENE$, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T2.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with @GENE$, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T35.T46	However, @CHEMICAL$, but not 3G-RSV, induced SIRT1-dependent @GENE$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T35.T39	However, @CHEMICAL$, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @GENE$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T35.T45	However, @CHEMICAL$, but not 3G-RSV, induced @GENE$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	CPR:3
23042952.T35.T47	However, @CHEMICAL$, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @GENE$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	CPR:3
23042952.T36.T46	However, 4'G-RSV, but not @CHEMICAL$, induced SIRT1-dependent @GENE$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T36.T39	However, 4'G-RSV, but not @CHEMICAL$, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @GENE$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T36.T45	However, 4'G-RSV, but not @CHEMICAL$, induced @GENE$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T36.T47	However, 4'G-RSV, but not @CHEMICAL$, induced SIRT1-dependent histone H3 deacetylation and @GENE$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T3.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T3.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T3.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T3.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T4.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T4.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T4.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T4.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T5.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T5.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T5.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T5.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T6.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T6.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T6.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T6.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T7.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T7.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T7.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T7.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.	false
23042952.T9.T46	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.	false
23042952.T9.T39	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.	false
23042952.T9.T45	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.	false
23042952.T9.T47	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.	false
23042953.T10.T15	Hydrophobic @CHEMICAL$ in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the @GENE$ transporter.	false
23042953.T10.T16	Hydrophobic @CHEMICAL$ in the hinge region of the @GENE$ mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.	false
23042953.T9.T15	Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting @CHEMICAL$ efflux by the @GENE$ transporter.	CPR:9
23042953.T9.T16	Hydrophobic amino acids in the hinge region of the @CHEMICAL$ mimetic peptide are essential for promoting @GENE$ efflux by the ABCA1 transporter.	false
23042953.T5.T12	The bihelical @CHEMICAL$ effluxes @GENE$ from cells and reduces inflammation and atherosclerosis in animal models.	CPR:9
23042953.T7.T14	Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing @CHEMICAL$ by the @GENE$ transporter.	CPR:9
23042953.T3.T11	These results provide a rationale for future design of therapeutic @CHEMICAL$ mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the ABCA1 transporter during the @GENE$ efflux process.	false
23042953.T3.T13	These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the @CHEMICAL$ transporter during the @GENE$ efflux process.	CPR:9
23042954.T12.T18	Efficacy of the GluK1/@CHEM-GENE$ antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	false
23042954.T12.T17	Efficacy of the @CHEMICAL$/@GENE$ receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	false
23042954.T13.T18	Efficacy of the GluK1/@CHEMICAL$ antagonist @GENE$ against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	CPR:6
23042954.T13.T17	Efficacy of the @CHEMICAL$/AMPA receptor antagonist @GENE$ against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	CPR:6
23042954.T10.T16	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEMICAL$ antagonist @GENE$ (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	CPR:6
23042954.T10.T14	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist @GENE$ (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	CPR:6
23042954.T10.T15	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist @GENE$ (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	CPR:6
23042954.T11.T16	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEMICAL$ antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (@GENE$) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	CPR:6
23042954.T11.T14	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (@GENE$) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	CPR:6
23042954.T11.T15	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (@GENE$) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	CPR:6
23042954.T8.T16	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEM-GENE$ antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	false
23042954.T8.T14	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/@GENE$ (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	false
23042954.T8.T15	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/@GENE$ (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	false
23042954.T9.T16	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEM-GENE$ antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	false
23042954.T9.T14	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (@GENE$) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	false
23042954.T9.T15	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (@GENE$) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	false
23044709.T1.T3	@CHEM-GENE$ (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.	false
23044709.T1.T4	@CHEMICAL$-resistant acid phosphatase (@GENE$) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.	false
23044709.T1.T5	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old @GENE$-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.	false
23044709.T1.T6	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-@GENE$ mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.	false
23044709.T1.T7	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with @GENE$-Cnn1 osteoblasts.	false
23044709.T1.T8	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-@GENE$ osteoblasts.	false
23047022.T1.T24	Although acetylcholinesterase (@CHEMICAL$) is primarily a hydrolytic enzyme, metabolising the neurotransmitter @GENE$ in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.	CPR:9
23047022.T1.T36	Although @CHEMICAL$ (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter @GENE$ in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.	CPR:9
23047022.T11.T28	Since AChE does not possess a @CHEMICAL$, its anchorage in the membrane is established via the @GENE$ Rich Membrane Anchor (PRiMA), a transmembrane protein.	false
23047022.T11.T27	Since @CHEMICAL$ does not possess a transmembrane domain, its anchorage in the membrane is established via the @GENE$ Rich Membrane Anchor (PRiMA), a transmembrane protein.	false
23047022.T11.T29	Since AChE does not possess a transmembrane domain, its anchorage in the membrane is established via the @CHEM-GENE$ (PRiMA), a transmembrane protein.	false
23047022.T11.T30	Since AChE does not possess a transmembrane domain, its anchorage in the membrane is established via the @CHEMICAL$ Rich Membrane Anchor (@GENE$), a transmembrane protein.	false
23047022.T2.T13	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an @CHEMICAL$- and batimastat-sensitive, but GM6001-insensitive @GENE$, with the possible additional involvement of a thiol isomerase.	false
23047022.T2.T14	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an @CHEMICAL$- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @GENE$.	false
23047022.T2.T12	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an @GENE$- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.	false
23047022.T3.T13	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and @CHEMICAL$-sensitive, but GM6001-insensitive @GENE$, with the possible additional involvement of a thiol isomerase.	false
23047022.T3.T14	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and @CHEMICAL$-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @GENE$.	false
23047022.T3.T12	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and @GENE$-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.	false
23047022.T4.T13	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but @CHEMICAL$-insensitive @GENE$, with the possible additional involvement of a thiol isomerase.	false
23047022.T4.T14	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but @CHEMICAL$-insensitive metalloprotease, with the possible additional involvement of a @GENE$.	false
23047022.T4.T12	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but @GENE$-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.	false
23047022.T5.T13	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive @CHEMICAL$, with the possible additional involvement of a @GENE$ isomerase.	false
23047022.T5.T14	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @CHEM-GENE$.	false
23047022.T5.T12	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @GENE$ isomerase.	false
23047022.T10.T16	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist @GENE$.	false
23047022.T10.T17	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist @GENE$.	false
23047022.T10.T18	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the @CHEMICAL$ antagonist @GENE$.	CPR:6
23047022.T10.T15	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist @GENE$.	CPR:4
23047022.T6.T16	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEM-GENE$ (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	false
23047022.T6.T17	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic @CHEMICAL$ receptor (@GENE$) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	false
23047022.T6.T18	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic @CHEMICAL$ receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the @GENE$ antagonist atropine.	false
23047022.T6.T15	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic @GENE$ receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	false
23047022.T7.T16	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists @GENE$ or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	CPR:5
23047022.T7.T17	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists @GENE$ or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	CPR:5
23047022.T7.T18	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists @CHEMICAL$ or muscarine, with the effect of carbachol blocked by the @GENE$ antagonist atropine.	false
23047022.T7.T15	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists @GENE$ or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	CPR:3
23047022.T8.T16	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists carbachol or @GENE$, with the effect of carbachol blocked by the mAChR antagonist atropine.	CPR:5
23047022.T8.T17	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists carbachol or @GENE$, with the effect of carbachol blocked by the mAChR antagonist atropine.	CPR:5
23047022.T8.T18	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or @CHEMICAL$, with the effect of carbachol blocked by the @GENE$ antagonist atropine.	false
23047022.T8.T15	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or @GENE$, with the effect of carbachol blocked by the mAChR antagonist atropine.	CPR:3
23047022.T9.T16	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists carbachol or muscarine, with the effect of @GENE$ blocked by the mAChR antagonist atropine.	false
23047022.T9.T17	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists carbachol or muscarine, with the effect of @GENE$ blocked by the mAChR antagonist atropine.	false
23047022.T9.T18	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of @CHEMICAL$ blocked by the @GENE$ antagonist atropine.	false
23047022.T9.T15	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of @GENE$ blocked by the mAChR antagonist atropine.	CPR:3
23047828.T12.T27	Circulating very-@CHEMICAL$ from subjects with impaired glucose tolerance accelerates adrenocortical @GENE$ and aldosterone synthesis.	false
23047828.T13.T27	Circulating very-@CHEMICAL$ from subjects with impaired glucose tolerance accelerates adrenocortical cortisol and @GENE$ synthesis.	false
23047828.T14.T27	Circulating very-@CHEMICAL$ from subjects with impaired @GENE$ tolerance accelerates adrenocortical cortisol and aldosterone synthesis.	false
23047828.T11.T22	Apart from their role in cardiovascular homeostasis and immunomodulation, aldosterone and @CHEMICAL$ are also implicated in the pathogenesis of @GENE$ resistance and type 2 diabetes mellitus (T2DM).	false
23047828.T9.T22	Apart from their role in cardiovascular homeostasis and immunomodulation, @CHEMICAL$ and cortisol are also implicated in the pathogenesis of @GENE$ resistance and type 2 diabetes mellitus (T2DM).	false
23047828.T3.T15	@CHEMICAL$ induced a greater stimulating effect on adrenocortical @GENE$ and cortisol release compared to HDL and LDL.	false
23047828.T3.T16	VLDL induced a greater stimulating effect on adrenocortical @CHEMICAL$ and cortisol release compared to @GENE$ and LDL.	false
23047828.T3.T17	VLDL induced a greater stimulating effect on adrenocortical @CHEMICAL$ and cortisol release compared to HDL and @GENE$.	false
23047828.T4.T15	@CHEMICAL$ induced a greater stimulating effect on adrenocortical aldosterone and @GENE$ release compared to HDL and LDL.	false
23047828.T4.T16	VLDL induced a greater stimulating effect on adrenocortical aldosterone and @CHEMICAL$ release compared to @GENE$ and LDL.	false
23047828.T4.T17	VLDL induced a greater stimulating effect on adrenocortical aldosterone and @CHEMICAL$ release compared to HDL and @GENE$.	false
23047912.T16.T21	@CHEMICAL$ induced ER stress and enhanced @GENE$ cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.	CPR:3
23047912.T15.T17	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, @GENE$ and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2a in SH-SY5Y cells.	CPR:3
23047912.T15.T18	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and @GENE$ activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2a in SH-SY5Y cells.	CPR:3
23047912.T15.T19	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker @GENE$, and enhanced phosphorylation of elf2a in SH-SY5Y cells.	CPR:3
23047912.T15.T20	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of @GENE$ in SH-SY5Y cells.	CPR:3
23050902.T17.T47	@CHEMICAL$-induced intracellular GTP depletion activates transcription elongation in @GENE$ gene expression.	CPR:3
23050902.T18.T47	Ribavirin-induced intracellular @CHEMICAL$ depletion activates transcription elongation in @GENE$ gene expression.	false
23050902.T7.T19	@CHEMICAL$ (Factor VII) is a @GENE$-dependent glycoprotein synthesized in hepatocytes.	false
23050902.T7.T36	Coagulation FVII (@CHEMICAL$) is a @GENE$-dependent glycoprotein synthesized in hepatocytes.	false
23050902.T6.T28	It was reported previously that @CHEMICAL$ gene (F7) expression was up-regulated by @GENE$ treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.	CPR:3
23050902.T6.T34	It was reported previously that FVII gene (@CHEMICAL$) expression was up-regulated by @GENE$ treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.	CPR:3
23050902.T8.T37	In the present study, we investigated the molecular mechanism of @CHEMICAL$-induced up-regulation of @GENE$ expression in HepG2 (human hepatoma cell line).	CPR:3
23050902.T10.T38	We found that intracellular GTP depletion by @CHEMICAL$ as well as other @GENE$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T10.T39	We found that intracellular GTP depletion by @CHEMICAL$ as well as other IMPDH (@GENE$) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T10.T40	We found that intracellular GTP depletion by @CHEMICAL$ as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated @GENE$ expression.	false
23050902.T11.T38	We found that intracellular GTP depletion by ribavirin as well as other @CHEMICAL$ (@GENE$ dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T11.T39	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEM-GENE$) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T11.T40	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEMICAL$ dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated @GENE$ expression.	false
23050902.T12.T38	We found that intracellular GTP depletion by ribavirin as well as other @CHEMICAL$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as @GENE$ and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T12.T39	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEMICAL$) inhibitors, such as @GENE$ and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T12.T40	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as @CHEMICAL$ and 6-mercaptopurine, up-regulated @GENE$ expression.	CPR:3
23050902.T13.T38	We found that intracellular GTP depletion by ribavirin as well as other @CHEMICAL$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and @GENE$, up-regulated F7 expression.	false
23050902.T13.T39	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEMICAL$) inhibitors, such as mycophenolic acid and @GENE$, up-regulated F7 expression.	false
23050902.T13.T40	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and @CHEMICAL$, up-regulated @GENE$ expression.	CPR:3
23050902.T9.T38	We found that intracellular @CHEMICAL$ depletion by ribavirin as well as other @GENE$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T9.T39	We found that intracellular @CHEMICAL$ depletion by ribavirin as well as other IMPDH (@GENE$) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	false
23050902.T9.T40	We found that intracellular @CHEMICAL$ depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated @GENE$ expression.	false
23050902.T14.T44	@CHEMICAL$ unregulated @GENE$ (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.	CPR:3
23050902.T14.T45	@CHEMICAL$ unregulated ELL (@GENE$ mRNA expression before F7 up-regulation.	CPR:3
23050902.T14.T46	@CHEMICAL$ unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before @GENE$ up-regulation.	CPR:3
23050902.T15.T44	Ribavirin unregulated @CHEMICAL$ (eleven-nineteen @GENE$-rich leukaemia) 3 mRNA expression before F7 up-regulation.	false
23050902.T15.T45	Ribavirin unregulated ELL (@CHEM-GENE$ mRNA expression before F7 up-regulation.	false
23050902.T15.T46	Ribavirin unregulated ELL (eleven-nineteen @CHEMICAL$-rich leukaemia) 3 mRNA expression before @GENE$ up-regulation.	false
23050902.T16.T20	We observed that @CHEMICAL$ enhanced @GENE$ recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.	CPR:3
23050902.T16.T21	We observed that @CHEMICAL$ enhanced ELL3 recruitment to @GENE$, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.	CPR:3
23050902.T16.T22	We observed that @CHEMICAL$ enhanced ELL3 recruitment to F7, whereas knockdown of @GENE$ diminished ribavirin-induced FVII mRNA up-regulation.	false
23050902.T16.T23	We observed that @CHEMICAL$ enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced @GENE$ mRNA up-regulation.	false
23050902.T1.T20	We observed that ribavirin enhanced @CHEMICAL$ recruitment to F7, whereas knockdown of ELL3 diminished @GENE$-induced FVII mRNA up-regulation.	false
23050902.T1.T21	We observed that ribavirin enhanced ELL3 recruitment to @CHEMICAL$, whereas knockdown of ELL3 diminished @GENE$-induced FVII mRNA up-regulation.	false
23050902.T1.T22	We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of @CHEMICAL$ diminished @GENE$-induced FVII mRNA up-regulation.	false
23050902.T1.T23	We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished @CHEMICAL$-induced @GENE$ mRNA up-regulation.	CPR:3
23050902.T2.T24	@CHEMICAL$ also enhanced recruitment of @GENE$ (cyclin-dependent kinase 9) and AFF4 to F7.	CPR:3
23050902.T2.T25	@CHEMICAL$ also enhanced recruitment of CDK9 (@GENE$) and AFF4 to F7.	CPR:3
23050902.T2.T26	@CHEMICAL$ also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and @GENE$ to F7.	CPR:3
23050902.T2.T27	@CHEMICAL$ also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to @GENE$.	CPR:3
23050902.T3.T29	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing @GENE$, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.	CPR:3
23050902.T3.T30	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, @GENE$ and ELL3, to F7, and modulates FVII mRNA transcription elongation.	CPR:3
23050902.T3.T31	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and @GENE$, to F7, and modulates FVII mRNA transcription elongation.	CPR:3
23050902.T3.T32	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to @GENE$, and modulates FVII mRNA transcription elongation.	CPR:3
23050902.T3.T33	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates @GENE$ mRNA transcription elongation.	false
23050902.T4.T29	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing @GENE$, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.	false
23050902.T4.T30	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, @GENE$ and ELL3, to F7, and modulates FVII mRNA transcription elongation.	false
23050902.T4.T31	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, AFF4 and @GENE$, to F7, and modulates FVII mRNA transcription elongation.	false
23050902.T4.T32	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to @GENE$, and modulates FVII mRNA transcription elongation.	false
23050902.T4.T33	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates @GENE$ mRNA transcription elongation.	false
23050902.T5.T35	Collectively, we have elucidated a basal mechanism for @CHEMICAL$-induced @GENE$ mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.	CPR:3
23052195.T10.T44	Neuropeptide Y Y1 receptor knockdown can modify @CHEMICAL$ and c-AMP response element-binding protein in @GENE$-treated rats.	false
23052195.T10.T45	Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and @CHEMICAL$ in @GENE$-treated rats.	false
23052195.T10.T43	@CHEMICAL$ knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in @GENE$-treated rats.	false
23052195.T11.T44	Neuropeptide Y Y1 receptor knockdown can modify @CHEM-GENE$ and c-AMP response element-binding protein in phenylpropanolamine-treated rats.	false
23052195.T11.T45	Neuropeptide Y Y1 receptor knockdown can modify @CHEMICAL$ peroxidase and @GENE$ in phenylpropanolamine-treated rats.	false
23052195.T11.T43	@CHEMICAL$ knockdown can modify @GENE$ peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.	false
23052195.T12.T44	Neuropeptide Y Y1 receptor knockdown can modify @CHEMICAL$ and @GENE$ response element-binding protein in phenylpropanolamine-treated rats.	false
23052195.T12.T45	Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and @CHEM-GENE$ in phenylpropanolamine-treated rats.	false
23052195.T12.T43	@CHEMICAL$ knockdown can modify glutathione peroxidase and @GENE$ response element-binding protein in phenylpropanolamine-treated rats.	false
23052195.T3.T17	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (@CHEMICAL$) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.	false
23052195.T3.T34	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEMICAL$ (CREB) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.	false
23052195.T3.T28	It has been reported that antioxidative enzymes, @CHEMICAL$ (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.	false
23052195.T3.T30	It has been reported that antioxidative enzymes, neuropeptide Y (@CHEMICAL$), and c-AMP response element-binding protein (CREB) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.	false
23052195.T4.T17	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (@CHEMICAL$) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.	false
23052195.T4.T34	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEMICAL$ (CREB) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.	false
23052195.T4.T28	It has been reported that antioxidative enzymes, @CHEMICAL$ (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.	false
23052195.T4.T30	It has been reported that antioxidative enzymes, neuropeptide Y (@CHEMICAL$), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.	false
23052195.T8.T17	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEMICAL$ response element-binding protein (@GENE$) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	false
23052195.T8.T34	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEM-GENE$ (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	false
23052195.T8.T28	It has been reported that antioxidative enzymes, @CHEMICAL$ (NPY), and @GENE$ response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	false
23052195.T8.T30	It has been reported that antioxidative enzymes, neuropeptide Y (@CHEMICAL$), and @GENE$ response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	false
23052195.T6.T22	Changes in the contents of NPY, Y1R, @CHEM-GENE$ (GP), and CREB were assessed and compared.	false
23052195.T6.T23	Changes in the contents of NPY, Y1R, @CHEMICAL$ peroxidase (@GENE$), and CREB were assessed and compared.	false
23052195.T6.T24	Changes in the contents of NPY, Y1R, @CHEMICAL$ peroxidase (GP), and @GENE$ were assessed and compared.	false
23052195.T6.T20	Changes in the contents of @CHEMICAL$, Y1R, @GENE$ peroxidase (GP), and CREB were assessed and compared.	false
23052195.T6.T21	Changes in the contents of NPY, @CHEMICAL$, @GENE$ peroxidase (GP), and CREB were assessed and compared.	false
23052195.T7.T32	By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @CHEMICAL$ treatment was opposite to those of Y1R, @GENE$, and CREB.	false
23052195.T7.T33	By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @CHEMICAL$ treatment was opposite to those of Y1R, GP, and @GENE$.	false
23052195.T7.T29	By contrast, @CHEMICAL$ decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @GENE$ treatment was opposite to those of Y1R, GP, and CREB.	false
23052195.T7.T31	By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @CHEMICAL$ treatment was opposite to those of @GENE$, GP, and CREB.	false
23052195.T9.T37	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and @GENE$ (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.	false
23052195.T9.T38	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or @GENE$), revealing an essential role of Y1R in regulating NPY, GP, and CREB.	false
23052195.T9.T41	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, @GENE$, and CREB.	false
23052195.T9.T42	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and @GENE$.	false
23052195.T9.T35	Central knockdown (using antisense) or inhibition (using antagonist) of @CHEMICAL$ expression modulated the anorectic response of @GENE$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.	false
23052195.T9.T36	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between @GENE$ and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.	false
23052195.T9.T39	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of @GENE$ in regulating NPY, GP, and CREB.	false
23052195.T9.T40	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating @GENE$, GP, and CREB.	false
23052195.T1.T15	These results suggest that Y1R participates in the reciprocal regulation of NPY, @CHEMICAL$, and CREB in the hypothalamus during @GENE$ treatment in conscious rats.	false
23052195.T1.T16	These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and @CHEMICAL$ in the hypothalamus during @GENE$ treatment in conscious rats.	false
23052195.T1.T13	These results suggest that @CHEMICAL$ participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during @GENE$ treatment in conscious rats.	false
23052195.T1.T14	These results suggest that Y1R participates in the reciprocal regulation of @CHEMICAL$, GP, and CREB in the hypothalamus during @GENE$ treatment in conscious rats.	false
23066089.T18.T50	Activation of @CHEM-GENE$ potentiates heteromeric kainate receptors.	false
23066089.T18.T51	Activation of group I metabotropic @CHEMICAL$ receptors potentiates heteromeric @GENE$.	false
23066089.T19.T50	Activation of @CHEMICAL$ potentiates heteromeric @GENE$ receptors.	false
23066089.T19.T51	Activation of group I metabotropic glutamate receptors potentiates heteromeric @CHEM-GENE$.	false
23066089.T15.T20	@CHEMICAL$ (KARs), a family of ionotropic @GENE$ receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	false
23066089.T15.T35	Kainate receptors (@CHEMICAL$), a family of ionotropic @GENE$ receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	false
23066089.T15.T40	Kainate receptors (KARs), a family of @CHEM-GENE$, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	false
23066089.T1.T20	@CHEM-GENE$ (KARs), a family of ionotropic glutamate receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	false
23066089.T1.T35	@CHEMICAL$ receptors (@GENE$), a family of ionotropic glutamate receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	false
23066089.T1.T40	@CHEMICAL$ receptors (KARs), a family of @GENE$, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	false
23066089.T14.T34	@CHEMICAL$ activation is influenced by metabotropic @GENE$ receptor (mGlu) signaling, but the underlying mechanisms are not understood.	false
23066089.T14.T36	KAR activation is influenced by @CHEM-GENE$ (mGlu) signaling, but the underlying mechanisms are not understood.	false
23066089.T14.T37	KAR activation is influenced by metabotropic @CHEMICAL$ receptor (@GENE$) signaling, but the underlying mechanisms are not understood.	false
23066089.T16.T43	In hippocampal and cortical cultures, the @CHEMICAL$ signal caused by activation of native @GENE$ was potentiated by activation of group I mGlu receptors.	false
23066089.T16.T44	In hippocampal and cortical cultures, the @CHEMICAL$ signal caused by activation of native KARs was potentiated by activation of @GENE$.	false
23066089.T17.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @GENE$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @GENE$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the @GENE$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T17.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.	false
23066089.T17.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.	false
23066089.T17.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @GENE$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the @GENE$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @GENE$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T2.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator @GENE$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T2.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.	false
23066089.T2.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.	false
23066089.T2.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @GENE$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T3.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the @GENE$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@GENE$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T3.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@GENE$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T3.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.	false
23066089.T3.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.	false
23066089.T3.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@GENE$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T4.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T4.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T4.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T4.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.	false
23066089.T4.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.	false
23066089.T4.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T5.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEM-GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T5.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.	false
23066089.T5.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.	false
23066089.T5.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T6.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T6.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	false
23066089.T6.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.	false
23066089.T6.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.	false
23066089.T6.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	CPR:4
23066089.T7.T21	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T22	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T23	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @CHEMICAL$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T24	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@CHEMICAL$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T28	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @CHEMICAL$ by @GENE$ potentiated GluK2/GluK5.	CPR:3
23066089.T7.T47	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T49	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T25	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @CHEMICAL$ of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T26	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @CHEMICAL$/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T27	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@CHEMICAL$, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T7.T29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @CHEMICAL$ potentiated @GENE$/GluK5.	CPR:3
23066089.T7.T30	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @CHEMICAL$ potentiated GluK2/@GENE$.	CPR:3
23066089.T7.T48	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.	false
23066089.T10.T33	Using site-directed mutagenesis, we identified three serines (Ser833, @CHEMICAL$836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.	false
23066089.T10.T31	Using site-directed mutagenesis, we identified three serines (Ser833, @CHEMICAL$836, and Ser840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	false
23066089.T10.T32	Using site-directed mutagenesis, we identified three serines (Ser833, @CHEMICAL$836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.	false
23066089.T11.T33	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and @CHEMICAL$840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.	false
23066089.T11.T31	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and @CHEMICAL$840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	false
23066089.T11.T32	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and @CHEMICAL$840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.	false
23066089.T12.T33	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 @CHEMICAL$-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.	false
23066089.T12.T31	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the @CHEMICAL$ @GENE$-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	false
23066089.T12.T32	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 @CHEMICAL$-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.	false
23066089.T8.T33	Using site-directed mutagenesis, we identified three @CHEMICAL$ (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.	false
23066089.T8.T31	Using site-directed mutagenesis, we identified three @CHEMICAL$ (Ser833, Ser836, and Ser840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	false
23066089.T8.T32	Using site-directed mutagenesis, we identified three @CHEMICAL$ (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.	false
23066089.T9.T33	Using site-directed mutagenesis, we identified three serines (@CHEMICAL$833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.	false
23066089.T9.T31	Using site-directed mutagenesis, we identified three serines (@CHEMICAL$833, Ser836, and Ser840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	false
23066089.T9.T32	Using site-directed mutagenesis, we identified three serines (@CHEMICAL$833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.	false
23073075.T1.T27	@CHEMICAL$ (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @GENE$ (S1PR) subtypes.	CPR:3
23073075.T1.T28	@CHEMICAL$ (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (@GENE$) subtypes.	CPR:3
23073075.T6.T27	Fingolimod (@CHEMICAL$), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @GENE$ (S1PR) subtypes.	CPR:3
23073075.T6.T28	Fingolimod (@CHEMICAL$), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (@GENE$) subtypes.	CPR:3
23073075.T7.T27	Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @CHEM-GENE$ (S1PR) subtypes.	false
23073075.T7.T28	Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @CHEMICAL$ receptor (@GENE$) subtypes.	false
23073075.T9.T29	However, recent evidence suggests that the action of @CHEMICAL$ involves @GENE$ expressed by cells resident in the CNS, including neurons.	false
23073075.T2.T23	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the @GENE$ (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	false
23073075.T2.T24	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the mitogen associated protein kinase (@GENE$) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	false
23073075.T2.T25	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$ (PtdIns-3-K) pathways.	false
23073075.T2.T26	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (@GENE$) pathways.	false
23073075.T2.T30	Neuroprotection was attenuated by @CHEMICAL$, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @GENE$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	false
23073075.T2.T21	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective @CHEMICAL$ (S1P1R) antagonist, @GENE$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	CPR:6
23073075.T2.T22	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (@CHEMICAL$) antagonist, @GENE$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	CPR:6
23073075.T3.T23	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the @CHEMICAL$ (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.	false
23073075.T3.T24	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (@CHEMICAL$) and the @GENE$-3-kinase (PtdIns-3-K) pathways.	false
23073075.T3.T25	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @CHEM-GENE$ (PtdIns-3-K) pathways.	false
23073075.T3.T26	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @CHEMICAL$-3-kinase (@GENE$) pathways.	false
23073075.T3.T30	Neuroprotection was attenuated by @CHEMICAL$, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.	false
23073075.T3.T21	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective @CHEMICAL$ (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.	false
23073075.T3.T22	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (@CHEMICAL$) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.	false
23075005.T9.T19	Pharmacokinetics and metabolism of @CHEMICAL$, a novel @GENE$ inhibitor, in humans.	CPR:4
23075005.T3.T18	The disposition of anagliptin, an orally active, highly selective @CHEMICAL$ inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq @GENE$ to six healthy men.	false
23075005.T4.T18	The disposition of @CHEMICAL$, an orally active, highly selective @GENE$ inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.	CPR:4
23075005.T1.T10	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of @GENE$, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	false
23075005.T1.T11	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, @GENE$, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	false
23075005.T1.T12	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, @GENE$ and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	false
23075005.T1.T13	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and @GENE$, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	false
23075005.T1.T14	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of @GENE$, BCRP, MRP2 and MRP4.	false
23075005.T1.T15	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, @GENE$, MRP2 and MRP4.	false
23075005.T1.T16	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, @GENE$ and MRP4.	false
23075005.T1.T17	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and @GENE$.	false
23075005.T2.T10	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of @GENE$, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	CPR:9
23075005.T2.T11	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, @GENE$, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	CPR:9
23075005.T2.T12	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, @GENE$ and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	CPR:9
23075005.T2.T13	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and @GENE$, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	CPR:9
23075005.T2.T14	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of @GENE$, BCRP, MRP2 and MRP4.	false
23075005.T2.T15	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, @GENE$, MRP2 and MRP4.	false
23075005.T2.T16	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, @GENE$ and MRP4.	false
23075005.T2.T17	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and @GENE$.	false
23085436.T3.T14	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating @CHEMICAL$ and LDL-@GENE$ (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	false
23085436.T3.T15	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and @CHEMICAL$-@GENE$ (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	false
23085436.T3.T16	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-@CHEMICAL$ (p < 0.001) and improved @GENE$ sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	false
23085436.T3.T13	Twice daily injection of @CHEMICAL$ in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-@GENE$ (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	false
23085436.T4.T14	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating @CHEMICAL$ and LDL-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.	false
23085436.T4.T15	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and @CHEMICAL$-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.	false
23085436.T4.T16	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-cholesterol (p < 0.001) and improved @CHEMICAL$ sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.	false
23085436.T4.T13	Twice daily injection of @CHEMICAL$ in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.	false
23085436.T5.T18	Energy intake, body weight, circulating @CHEMICAL$ and @GENE$ tolerance of (pGlu-Gln)-CCK-8 mice were similar to lean controls.	false
23085436.T5.T19	Energy intake, body weight, circulating insulin and @CHEMICAL$ tolerance of @GENE$ mice were similar to lean controls.	false
23085436.T6.T20	In addition, @CHEMICAL$ prevented the effect of high fat feeding on @GENE$ accumulation in liver and muscle.	false
23085436.T1.T10	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating @CHEMICAL$ (p < 0.05 to p < 0.01) and @GENE$ (p < 0.05 to p < 0.001) and improved glucose tolerance (p < 0.05) and insulin sensitivity (p < 0.001).	false
23085436.T1.T11	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating @CHEMICAL$ (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved glucose tolerance (p < 0.05) and @GENE$ sensitivity (p < 0.001).	false
23085436.T1.T9	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with @CHEMICAL$ for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating @GENE$ (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved glucose tolerance (p < 0.05) and insulin sensitivity (p < 0.001).	false
23085436.T2.T10	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating glucose (p < 0.05 to p < 0.01) and @CHEMICAL$ (p < 0.05 to p < 0.001) and improved @GENE$ tolerance (p < 0.05) and insulin sensitivity (p < 0.001).	false
23085436.T2.T11	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating glucose (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved @CHEMICAL$ tolerance (p < 0.05) and @GENE$ sensitivity (p < 0.001).	false
23085436.T2.T9	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with @CHEMICAL$ for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating glucose (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved @GENE$ tolerance (p < 0.05) and insulin sensitivity (p < 0.001).	false
23091188.T20.T52	Inhibition of the @CHEM-GENE$ (BSEP) can cause intracellular accumulation of bile acids and is a risk factor for drug-induced liver injury in humans.	false
23091188.T20.T54	Inhibition of the @CHEMICAL$ export pump (@GENE$) can cause intracellular accumulation of bile acids and is a risk factor for drug-induced liver injury in humans.	false
23091188.T43.T52	Inhibition of the @CHEMICAL$ (BSEP) can cause intracellular accumulation of @GENE$ and is a risk factor for drug-induced liver injury in humans.	false
23091188.T43.T54	Inhibition of the bile salt export pump (@CHEMICAL$) can cause intracellular accumulation of @GENE$ and is a risk factor for drug-induced liver injury in humans.	false
23091188.T21.T51	Antiretroviral @CHEMICAL$ inhibitors @GENE$ (LPV) and ritonavir (RTV) are reported BSEP inhibitors.	CPR:4
23091188.T21.T53	Antiretroviral protease inhibitors @CHEMICAL$ (LPV) and ritonavir (RTV) are reported @GENE$ inhibitors.	CPR:4
23091188.T22.T51	Antiretroviral @CHEMICAL$ inhibitors lopinavir (@GENE$) and ritonavir (RTV) are reported BSEP inhibitors.	CPR:4
23091188.T22.T53	Antiretroviral protease inhibitors lopinavir (@CHEMICAL$) and ritonavir (RTV) are reported @GENE$ inhibitors.	CPR:4
23091188.T23.T51	Antiretroviral @CHEMICAL$ inhibitors lopinavir (LPV) and @GENE$ (RTV) are reported BSEP inhibitors.	CPR:4
23091188.T23.T53	Antiretroviral protease inhibitors lopinavir (LPV) and @CHEMICAL$ (RTV) are reported @GENE$ inhibitors.	CPR:4
23091188.T24.T51	Antiretroviral @CHEMICAL$ inhibitors lopinavir (LPV) and ritonavir (@GENE$) are reported BSEP inhibitors.	CPR:4
23091188.T24.T53	Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (@CHEMICAL$) are reported @GENE$ inhibitors.	CPR:4
23091188.T19.T50	Quantification of endogenous @CHEMICAL$ in SCRH may reveal important adaptive responses associated with exposure to known @GENE$ inhibitors.	false
23099431.T8.T11	Pharmacokinetic study of @CHEM-GENE$ (GHRP-6) in nine male healthy volunteers.	false
23099431.T9.T11	Pharmacokinetic study of @CHEMICAL$-Releasing Peptide 6 (@GENE$) in nine male healthy volunteers.	false
23099431.T1.T10	@CHEMICAL$ is a @GENE$ secretagogue that also enhances tissue viability in different organs.	CPR:3
23102509.T10.T26	Diabetic rats showed significant (p<0.05) increased in plasma @CHEMICAL$, @GENE$ and significant (p<0.05) decreased in circulating insulin and hemoglobin.	false
23102509.T10.T27	Diabetic rats showed significant (p<0.05) increased in plasma @CHEMICAL$, glycosylated hemoglobin and significant (p<0.05) decreased in circulating @GENE$ and hemoglobin.	false
23102509.T10.T28	Diabetic rats showed significant (p<0.05) increased in plasma @CHEMICAL$, glycosylated hemoglobin and significant (p<0.05) decreased in circulating insulin and @GENE$.	false
23102509.T11.T21	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T22	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T23	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T11.T24	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).	false
23102509.T11.T25	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T11.T31	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @GENE$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T32	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T34	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T29	The altered activities of key enzymes such as @CHEM-GENE$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T30	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and @GENE$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T11.T33	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T21	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T22	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T23	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T12.T24	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).	false
23102509.T12.T25	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T12.T31	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @GENE$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T32	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T34	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T29	The altered activities of key enzymes such as @CHEMICAL$ and @GENE$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T30	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEM-GENE$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T12.T33	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T13.T21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T13.T22	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T13.T23	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T13.T24	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).	false
23102509.T13.T25	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T13.T31	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas @GENE$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T13.T32	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T13.T34	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T13.T29	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of @GENE$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	CPR:9
23102509.T13.T30	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of @GENE$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	CPR:9
23102509.T13.T33	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T22	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T23	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T14.T24	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).	false
23102509.T14.T25	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T14.T31	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, @GENE$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T32	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEM-GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T34	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T29	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T30	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T14.T33	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T22	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T23	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T15.T24	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).	false
23102509.T15.T25	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T15.T31	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, pyruvate kinase, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T32	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T34	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T29	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T30	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T15.T33	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEM-GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T22	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T23	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T16.T24	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).	false
23102509.T16.T25	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T16.T31	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T32	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T34	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEM-GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T29	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T30	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T16.T33	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@CHEMICAL$), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T22	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEM-GENE$ (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T23	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEMICAL$ transaminase (@GENE$) and alkaline phosphatase (ALP).	false
23102509.T2.T24	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEMICAL$ transaminase (ALT) and @GENE$ (ALP).	false
23102509.T2.T25	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEMICAL$ transaminase (ALT) and alkaline phosphatase (@GENE$).	false
23102509.T2.T31	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T32	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T34	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T29	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T30	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23102509.T2.T33	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).	false
23103563.T11.T25	@CHEMICAL$ increases the expression of the pro-apoptotic gene @GENE$ by epigenetic mechanisms in tumor cells.	CPR:3
23103563.T8.T23	Further we found stimulation of @CHEMICAL$-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both @GENE$ and farnesylpyrophosphate.	false
23103563.T8.T24	Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of @CHEMICAL$, which was rescued by re-isoprenylation by both @GENE$ and farnesylpyrophosphate.	CPR:3
23103563.T9.T23	Further we found stimulation of @CHEMICAL$-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and @GENE$.	false
23103563.T9.T24	Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of @CHEMICAL$, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and @GENE$.	CPR:3
23103563.T10.T12	In contrast, @CHEMICAL$ did not affect @GENE$ and DNMT1 expression in MC3T3-E1 non-neoplastic cells.	false
23103563.T10.T13	In contrast, @CHEMICAL$ did not affect FAS and @GENE$ expression in MC3T3-E1 non-neoplastic cells.	false
23103563.T1.T14	Data suggest that @CHEMICAL$ via modulation of the activity of small-@GENE$ induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.	false
23103563.T1.T15	Data suggest that @CHEMICAL$ via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-@GENE$-demethylation and stimulation of FAS-expression.	false
23103563.T1.T16	Data suggest that @CHEMICAL$ via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of @GENE$-expression.	CPR:3
23103563.T2.T14	Data suggest that bisphosphonates via modulation of the activity of small-@CHEMICAL$ induce apoptosis in neoplastic cells by DNA-@GENE$-demethylation and stimulation of FAS-expression.	false
23103563.T2.T15	Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-@CHEM-GENE$-demethylation and stimulation of FAS-expression.	false
23103563.T2.T16	Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-@CHEMICAL$-demethylation and stimulation of @GENE$-expression.	false
23103563.T3.T17	In conclusion the shown epigenetic mechanism underlying the anti-neoplastic activity of @CHEM-GENE$-inhibition, also explains the clinical success of other drugs, which target this pathway.	false
23117151.T13.T33	@CHEMICAL$ receptor @GENE$ length modifies the effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor activity in human prostate cells.	false
23117151.T13.T32	@CHEM-GENE$ CAG repeat length modifies the effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor activity in human prostate cells.	false
23117151.T14.T33	Androgen receptor @CHEMICAL$ length modifies the effect of @GENE$ on receptor activity in human prostate cells.	false
23117151.T14.T32	@CHEMICAL$ CAG repeat length modifies the effect of @GENE$ on receptor activity in human prostate cells.	false
23117151.T2.T15	@CHEMICAL$ acts through the @GENE$ (AhR), which interacts with the androgen receptor (AR).	false
23117151.T2.T16	@CHEMICAL$ acts through the aryl hydrocarbon receptor (@GENE$), which interacts with the androgen receptor (AR).	false
23117151.T2.T17	@CHEMICAL$ acts through the aryl hydrocarbon receptor (AhR), which interacts with the @GENE$ (AR).	false
23117151.T2.T18	@CHEMICAL$ acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (@GENE$).	false
23117151.T3.T15	TCDD acts through the @CHEM-GENE$ (AhR), which interacts with the androgen receptor (AR).	false
23117151.T3.T16	TCDD acts through the @CHEMICAL$ receptor (@GENE$), which interacts with the androgen receptor (AR).	false
23117151.T3.T17	TCDD acts through the @CHEMICAL$ receptor (AhR), which interacts with the @GENE$ (AR).	false
23117151.T3.T18	TCDD acts through the @CHEMICAL$ receptor (AhR), which interacts with the androgen receptor (@GENE$).	false
23117151.T4.T15	TCDD acts through the @CHEMICAL$ (AhR), which interacts with the @GENE$ receptor (AR).	false
23117151.T4.T16	TCDD acts through the aryl hydrocarbon receptor (@CHEMICAL$), which interacts with the @GENE$ receptor (AR).	false
23117151.T4.T17	TCDD acts through the aryl hydrocarbon receptor (AhR), which interacts with the @CHEM-GENE$ (AR).	false
23117151.T4.T18	TCDD acts through the aryl hydrocarbon receptor (AhR), which interacts with the @CHEMICAL$ receptor (@GENE$).	false
23117151.T5.T22	We investigated the influence of @CHEMICAL$ on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on 5a-dihydrotestosterone-activated ARs containing @GENE$ within normal length range (16, 22, and 28).	false
23117151.T5.T21	We investigated the influence of @CHEMICAL$ on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on 5a-dihydrotestosterone-activated @GENE$ containing CAG repeats within normal length range (16, 22, and 28).	false
23117151.T6.T22	We investigated the influence of TCDD on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on @CHEMICAL$-activated ARs containing @GENE$ within normal length range (16, 22, and 28).	false
23117151.T6.T21	We investigated the influence of TCDD on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on @CHEMICAL$-activated @GENE$ containing CAG repeats within normal length range (16, 22, and 28).	false
23117151.T7.T26	The AhR target gene CYP1A1 mRNA expression was induced by @CHEMICAL$, but was not affected by the AR @GENE$ length.	false
23117151.T7.T23	The @CHEMICAL$ target gene CYP1A1 mRNA expression was induced by @GENE$, but was not affected by the AR CAG length.	false
23117151.T7.T24	The AhR target gene @CHEMICAL$ mRNA expression was induced by @GENE$, but was not affected by the AR CAG length.	CPR:3
23117151.T7.T25	The AhR target gene CYP1A1 mRNA expression was induced by @CHEMICAL$, but was not affected by the @GENE$ CAG length.	false
23117151.T8.T27	@CHEMICAL$ had no effect on @GENE$ activity in PC-3 cells, whereas the shortest AR variant was induced by TCDD in PNT1A cells.	false
23117151.T8.T28	@CHEMICAL$ had no effect on AR activity in PC-3 cells, whereas the shortest @GENE$ variant was induced by TCDD in PNT1A cells.	false
23117151.T9.T27	TCDD had no effect on @CHEMICAL$ activity in PC-3 cells, whereas the shortest AR variant was induced by @GENE$ in PNT1A cells.	false
23117151.T9.T28	TCDD had no effect on AR activity in PC-3 cells, whereas the shortest @CHEMICAL$ variant was induced by @GENE$ in PNT1A cells.	CPR:3
23117151.T11.T29	In conclusion, the @CHEMICAL$ length dependent effect of @GENE$ on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on AR activity.	false
23117151.T11.T30	In conclusion, the CAG length dependent effect of @CHEMICAL$ on @GENE$ activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on AR activity.	false
23117151.T11.T31	In conclusion, the CAG length dependent effect of @CHEMICAL$ on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on @GENE$ activity.	false
23117151.T12.T29	In conclusion, the @CHEMICAL$ length dependent effect of TCDD on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of @GENE$ on AR activity.	false
23117151.T12.T30	In conclusion, the CAG length dependent effect of TCDD on @CHEMICAL$ activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of @GENE$ on AR activity.	false
23117151.T12.T31	In conclusion, the CAG length dependent effect of TCDD on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of @CHEMICAL$ on @GENE$ activity.	false
23123257.T1.T5	Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several @CHEMICAL$ in mice and replacement of plasmid by @GENE$ reduced the elevation of all assayed cytokines.	false
23123257.T1.T6	Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by @CHEMICAL$ reduced the elevation of all assayed @GENE$.	CPR:4
23123298.T6.T17	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as @GENE$, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).	CPR:3
23123298.T6.T18	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, @GENE$ (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).	CPR:3
23123298.T6.T19	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (@GENE$) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).	CPR:3
23123298.T6.T20	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the @GENE$ (CHOP).	CPR:3
23123298.T6.T21	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (@GENE$).	CPR:3
23123298.T7.T22	However, down-regulation of @CHEMICAL$ and/or CHOP expression by siRNA had no effect on @GENE$-induced apoptosis in Caki and HCT116 cells.	false
23123298.T7.T23	However, down-regulation of ATF4 and/or @CHEMICAL$ expression by siRNA had no effect on @GENE$-induced apoptosis in Caki and HCT116 cells.	false
23123662.T28.T43	Contributions of @CHEMICAL$ to the uptake and toxicity of @GENE$ and platinum anticancer drugs in dorsal root ganglion neurons.	CPR:9
23123662.T29.T43	Contributions of @CHEMICAL$ to the uptake and toxicity of copper and @GENE$ anticancer drugs in dorsal root ganglion neurons.	CPR:9
23123662.T14.T35	This study aimed to understand the role of @CHEM-GENE$ (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T14.T36	This study aimed to understand the role of @CHEMICAL$ transporter 1 (@GENE$) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T14.T37	This study aimed to understand the role of @CHEMICAL$ transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of @GENE$ (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T14.T38	This study aimed to understand the role of @CHEMICAL$ transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@GENE$) as a membrane transporter of copper and platinum drugs.	false
23123662.T15.T35	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of @GENE$ and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T15.T36	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of @GENE$ and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T15.T37	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of @CHEMICAL$ and platinum drugs in cultured rat DRG neurons, and the functional activities of @GENE$ (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T15.T38	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of @CHEMICAL$ and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@GENE$) as a membrane transporter of copper and platinum drugs.	false
23123662.T16.T35	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of copper and @GENE$ drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T16.T36	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of copper and @GENE$ drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T16.T37	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and @CHEMICAL$ drugs in cultured rat DRG neurons, and the functional activities of @GENE$ (rCtr1) as a membrane transporter of copper and platinum drugs.	false
23123662.T16.T38	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and @CHEMICAL$ drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@GENE$) as a membrane transporter of copper and platinum drugs.	false
23123662.T17.T35	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of @GENE$ and platinum drugs.	false
23123662.T17.T36	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of @GENE$ and platinum drugs.	false
23123662.T17.T37	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of @CHEMICAL$ (rCtr1) as a membrane transporter of @GENE$ and platinum drugs.	false
23123662.T17.T38	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@CHEMICAL$) as a membrane transporter of @GENE$ and platinum drugs.	false
23123662.T18.T35	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and @GENE$ drugs.	false
23123662.T18.T36	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and @GENE$ drugs.	false
23123662.T18.T37	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of @CHEMICAL$ (rCtr1) as a membrane transporter of copper and @GENE$ drugs.	false
23123662.T18.T38	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@CHEMICAL$) as a membrane transporter of copper and @GENE$ drugs.	false
23123662.T20.T39	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of @GENE$, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T20.T40	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of @GENE$, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T21.T39	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, @GENE$, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T21.T40	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of copper, @GENE$, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T22.T39	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, @GENE$ and carboplatin, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T22.T40	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of copper, oxaliplatin, @GENE$ and carboplatin, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T23.T39	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and @GENE$, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T23.T40	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and @GENE$, in comparison to isogenic vector-transfected control cells.	CPR:9
23123662.T24.T41	Cultured rat DRG neurons endogenously expressed @CHEMICAL$ protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up @GENE$, but were resistant to copper toxicity.	CPR:9
23123662.T25.T41	Cultured rat DRG neurons endogenously expressed @CHEMICAL$ protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up copper, but were resistant to @GENE$ toxicity.	false
23123662.T1.T30	The uptake of copper by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, silver and @CHEMICAL$, consistent with it being mediated by @GENE$.	false
23123662.T1.T42	The uptake of copper by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells was saturable and inhibited by cold temperature, silver and @GENE$, consistent with it being mediated by rCtr1.	false
23123662.T26.T30	The uptake of @CHEMICAL$ by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by @GENE$.	false
23123662.T26.T42	The uptake of @CHEMICAL$ by both cultured rat DRG neurons and HEK/@GENE$ cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.	CPR:9
23123662.T27.T30	The uptake of copper by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, @CHEMICAL$ and zinc, consistent with it being mediated by @GENE$.	false
23123662.T27.T42	The uptake of copper by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells was saturable and inhibited by cold temperature, @GENE$ and zinc, consistent with it being mediated by rCtr1.	false
23123662.T5.T31	The accumulation of @CHEMICAL$ by both cultured rat DRG neurons and HEK/@GENE$ cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.	false
23123662.T5.T32	The accumulation of @CHEMICAL$ by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/@GENE$ cells.	false
23123662.T6.T31	The accumulation of platinum by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells, during @GENE$ exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.	false
23123662.T6.T32	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during @CHEMICAL$ exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/@GENE$ cells.	false
23123662.T7.T31	The accumulation of platinum by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by @GENE$ only in HEK/rCtr1 cells.	false
23123662.T7.T32	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by @CHEMICAL$ only in HEK/@GENE$ cells.	false
23123662.T10.T33	In conclusion, @CHEMICAL$ can transport copper and @GENE$ drugs, and sensitizes cells to their cytotoxicities.	CPR:9
23123662.T9.T33	In conclusion, @CHEMICAL$ can transport @GENE$ and platinum drugs, and sensitizes cells to their cytotoxicities.	CPR:9
23123662.T11.T34	DRG neurons display substantial capacity for accumulating @CHEMICAL$ via a transport process mediated by @GENE$, but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.	CPR:9
23123662.T12.T34	DRG neurons display substantial capacity for accumulating copper via a transport process mediated by @CHEMICAL$, but appear able to resist @GENE$ toxicity and use alternative mechanisms to take up oxaliplatin.	false
23123662.T13.T34	DRG neurons display substantial capacity for accumulating copper via a transport process mediated by @CHEMICAL$, but appear able to resist copper toxicity and use alternative mechanisms to take up @GENE$.	CPR:9
23128353.T10.T20	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of @CHEMICAL$ and @GENE$ oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	false
23128353.T10.T19	Examination of phosphorylation in @CHEMICAL$, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @GENE$ oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	false
23128353.T10.T21	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @CHEM-GENE$ (HO-1), but also caused a reduction in p21 protein expression.	false
23128353.T10.T22	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @CHEMICAL$ oxygenase-1 (@GENE$), but also caused a reduction in p21 protein expression.	false
23128353.T10.T23	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @CHEMICAL$ oxygenase-1 (HO-1), but also caused a reduction in @GENE$ protein expression.	false
23128353.T8.T20	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of @GENE$ and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	false
23128353.T8.T19	Examination of phosphorylation in @CHEMICAL$, we found an inhibitory effect by @GENE$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	CPR:4
23128353.T8.T21	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @GENE$ (HO-1), but also caused a reduction in p21 protein expression.	false
23128353.T8.T22	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (@GENE$), but also caused a reduction in p21 protein expression.	false
23128353.T8.T23	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in @GENE$ protein expression.	false
23128353.T9.T20	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of @GENE$ and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	CPR:3
23128353.T9.T19	Examination of phosphorylation in @CHEMICAL$, we found an inhibitory effect by glucosamine at 20 and 50 mM. @GENE$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	false
23128353.T9.T21	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @GENE$ (HO-1), but also caused a reduction in p21 protein expression.	CPR:3
23128353.T9.T22	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (@GENE$), but also caused a reduction in p21 protein expression.	false
23128353.T9.T23	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in @GENE$ protein expression.	CPR:4
23128353.T1.T12	In addition, @CHEMICAL$ attenuated @GENE$ protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.	CPR:4
23128353.T1.T13	In addition, @CHEMICAL$ attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing @GENE$ nuclear accumulation.	CPR:3
23128353.T2.T16	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, @GENE$ and HO-1 expression, and nuclear p21 accumulation.	false
23128353.T2.T14	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in @GENE$ phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.	CPR:4
23128353.T2.T15	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of @GENE$, p53 and HO-1 expression, and nuclear p21 accumulation.	false
23128353.T2.T17	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and @GENE$ expression, and nuclear p21 accumulation.	false
23128353.T2.T18	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear @GENE$ accumulation.	CPR:3
23131177.T12.T28	Characterization of substituted @CHEMICAL$ as highly selective agonists at the @GENE$.	CPR:5
23131177.T13.T28	Characterization of substituted phenylpropylamides as highly selective agonists at the @CHEM-GENE$.	false
23131177.T5.T22	The two subtypes of @CHEMICAL$ are primarily responsible for mediating the actions of @GENE$.	false
23131177.T6.T23	Because synthetic @CHEM-GENE$ agonists have considerable therapeutic potentials in modulating insomnia and circadian- related sleep disorders, it is highly desirable to develop subtype-selective melatoninergic compounds.	false
23131177.T7.T26	The pharmacological potencies of a series of substituted @CHEMICAL$ towards human melatonin MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with @GENE$ phosphorylation and cAMP assays.	false
23131177.T7.T24	The pharmacological potencies of a series of substituted @CHEMICAL$ towards @GENE$ and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	false
23131177.T7.T25	The pharmacological potencies of a series of substituted @CHEMICAL$ towards human melatonin MT(1) and @GENE$ were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	false
23131177.T8.T26	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human @CHEMICAL$ MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with @GENE$ phosphorylation and cAMP assays.	false
23131177.T8.T24	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards @CHEM-GENE$ and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	false
23131177.T8.T25	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human @CHEMICAL$ MT(1) and @GENE$ were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	false
23131177.T9.T26	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human melatonin MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with @CHEMICAL$ phosphorylation and @GENE$ assays.	false
23131177.T9.T24	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards @CHEMICAL$ and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and @GENE$ assays.	false
23131177.T9.T25	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human melatonin MT(1) and @CHEMICAL$ were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and @GENE$ assays.	false
23131177.T10.T14	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a @CHEMICAL$ substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the @GENE$ potency and at the same time decreased MT(1) potency.	false
23131177.T10.T15	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a @CHEMICAL$ substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased @GENE$ potency.	false
23131177.T10.T27	Structure-activity relationship analysis of highly potent subtype-selective ligands (@CHEMICAL$ EC(50) 10-90 pM) revealed that a @GENE$ substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased MT(1) potency.	false
23131177.T11.T14	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the @CHEMICAL$ ring dramatically enhanced the @GENE$ potency and at the same time decreased MT(1) potency.	false
23131177.T11.T15	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the @CHEMICAL$ ring dramatically enhanced the MT(2) potency and at the same time decreased @GENE$ potency.	false
23131177.T11.T27	Structure-activity relationship analysis of highly potent subtype-selective ligands (@CHEMICAL$ EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the @GENE$ ring dramatically enhanced the MT(2) potency and at the same time decreased MT(1) potency.	false
23131177.T2.T17	The most potent subtype-selective ligand, 2q had a substantially higher potency for @CHEMICAL$ than @GENE$ for elevation of [Ca(2+)]i and inhibition of forskolin-elevated cAMP.	false
23131177.T3.T17	The most potent subtype-selective ligand, 2q had a substantially higher potency for @CHEMICAL$ than melatonin for elevation of [@GENE$]i and inhibition of forskolin-elevated cAMP.	false
23131177.T4.T21	These ligands represent invaluable tools for delineating the functional roles of distinct @CHEM-GENE$ subtypes and are viable candidates for drug development.	false
23142699.T3.T19	@CHEMICAL$ PIM-1 is a novel @GENE$ receptor target associating with high grade breast tumors.	false
23142699.T3.T20	Proto-oncogene @CHEMICAL$ is a novel @GENE$ receptor target associating with high grade breast tumors.	false
23142699.T3.T21	Proto-oncogene PIM-1 is a novel @CHEM-GENE$ target associating with high grade breast tumors.	false
23142699.T1.T7	We show that the expression of @CHEMICAL$ is induced in response to @GENE$ in MCF-7 cells and that the induction is mediated by ERa-regulated enhancers located distally upstream from the gene.	CPR:3
23142699.T1.T8	We show that the expression of PIM-1 is induced in response to @CHEMICAL$ in MCF-7 cells and that the induction is mediated by @GENE$-regulated enhancers located distally upstream from the gene.	CPR:3
23142699.T2.T16	In sum, identification of @CHEMICAL$ as an ERa target gene adds a novel potential mechanism by which @GENE$ can contribute to breast cancer cell proliferation and carcinogenesis.	false
23142699.T2.T17	In sum, identification of PIM-1 as an @CHEMICAL$ target gene adds a novel potential mechanism by which @GENE$ can contribute to breast cancer cell proliferation and carcinogenesis.	false
23143891.T14.T24	In this work, the metabolism of four frequently prescribed inhaled GCs, @CHEMICAL$, flunisolide, budesonide, and fluticasone propionate, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
23143891.T15.T24	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, @CHEMICAL$, budesonide, and fluticasone propionate, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
23143891.T16.T24	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, @CHEMICAL$, and fluticasone propionate, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
23143891.T17.T24	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and @CHEMICAL$, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
23143891.T1.T19	@CHEMICAL$, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize @GENE$, budesonide, and fluticasone propionate.	CPR:9
23143891.T2.T19	@CHEMICAL$, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, @GENE$, and fluticasone propionate.	CPR:9
23143891.T3.T19	@CHEMICAL$, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and @GENE$.	CPR:9
23143891.T4.T20	In contrast, @CHEMICAL$ was only metabolized via @GENE$, with no significant turnover by CYP3A5 or CYP3A7.	CPR:9
23143891.T4.T21	In contrast, @CHEMICAL$ was only metabolized via CYP3A4, with no significant turnover by @GENE$ or CYP3A7.	false
23143891.T4.T22	In contrast, @CHEMICAL$ was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or @GENE$.	false
23159329.T11.T24	Distinct roles of @CHEMICAL$ in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of @GENE$ and CREB activation in hippocampus and prefrontal cortex.	CPR:3
23159329.T11.T25	Distinct roles of @CHEMICAL$ in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and @GENE$ activation in hippocampus and prefrontal cortex.	CPR:3
23159329.T5.T12	The @CHEMICAL$ (ERK) and the transcription factor @GENE$ response element-binding protein (CREB) were involved in neuroplastic changes associated with learning and memory.	false
23159329.T5.T17	The extracellular signal-regulated kinase (@CHEMICAL$) and the transcription factor @GENE$ response element-binding protein (CREB) were involved in neuroplastic changes associated with learning and memory.	false
23159329.T5.T18	The extracellular signal-regulated kinase (ERK) and the transcription factor @CHEM-GENE$ (CREB) were involved in neuroplastic changes associated with learning and memory.	false
23159329.T5.T19	The extracellular signal-regulated kinase (ERK) and the transcription factor @CHEMICAL$ response element-binding protein (@GENE$) were involved in neuroplastic changes associated with learning and memory.	false
23159329.T10.T22	Furthermore, 1.0 mg/kg dose of @CHEMICAL$ injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both @GENE$ and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in METH-treated mouse groups.	false
23159329.T10.T23	Furthermore, 1.0 mg/kg dose of @CHEMICAL$ injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both ERK and @GENE$ in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in METH-treated mouse groups.	false
23159329.T1.T22	Furthermore, 1.0 mg/kg dose of METH injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both @CHEMICAL$ and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in @GENE$-treated mouse groups.	false
23159329.T1.T23	Furthermore, 1.0 mg/kg dose of METH injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both ERK and @CHEMICAL$ in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in @GENE$-treated mouse groups.	false
23159329.T2.T13	In contrast, activation of both @CHEMICAL$ and CREB in the PFC was found following memory retrieval but not other processes in @GENE$-treated mouse groups.	CPR:3
23159329.T2.T14	In contrast, activation of both ERK and @CHEMICAL$ in the PFC was found following memory retrieval but not other processes in @GENE$-treated mouse groups.	CPR:3
23159329.T4.T15	Moreover, activation of the @CHEMICAL$ and CREB signaling pathway in the hippocampus might be involved in @GENE$-induced spatial memory changes.	CPR:3
23159329.T4.T16	Moreover, activation of the ERK and @CHEMICAL$ signaling pathway in the hippocampus might be involved in @GENE$-induced spatial memory changes.	CPR:3
23159479.T6.T12	The impact of @CHEM-GENE$ administration and maternal love withdrawal on event-related potential (ERP) responses to emotional faces with performance feedback.	false
23159479.T2.T8	This is the first experimental study on the effect of @CHEM-GENE$ administration on the neural processing of facial stimuli conducted with female participants that uses event-related potentials (ERPs).	false
23159479.T1.T7	Using a double-blind, placebo-controlled within-subjects design, we studied the effects of 16 IU of intranasal @CHEM-GENE$ on ERPs to pictures combining performance feedback with emotional facial expressions in 48 female undergraduate students.	false
23159479.T3.T9	Vertex positive potential (VPP) and late positive potential (LPP) amplitudes were more positive after @CHEM-GENE$ compared to placebo administration.	false
23159479.T4.T10	This suggests that @CHEM-GENE$ increased attention to the feedback stimuli (LPP) and enhanced the processing of emotional faces (VPP).	false
23159479.T5.T11	@CHEM-GENE$ heightened processing of the happy and disgusted faces primarily for those reporting less love withdrawal.	false
23161868.T1.T4	A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative @CHEMICAL$ and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by @GENE$.	CPR:3
23161868.T1.T5	A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential @CHEMICAL$, was highly activated in embryonic pituitary cells and up-regulated by @GENE$.	CPR:3
23161868.T1.T3	A reporter construct driven by 4 kb of the @CHEMICAL$ 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by @GENE$.	CPR:3
23161868.T2.T10	However, mutating putative @CHEMICAL$ did not substantially reduce induction of ras-dva promoter activity by @GENE$, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.	CPR:3
23161868.T2.T11	However, mutating putative GR binding sites did not substantially reduce induction of @CHEMICAL$ activity by @GENE$, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.	CPR:3
23161868.T2.T12	However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by @CHEMICAL$, suggesting additional @GENE$ within the 5'-flanking region are responsible for glucocorticoid regulation.	false
23164615.T8.T15	Differential modulation of retinal ganglion cell light responses by orthosteric and allosteric @CHEM-GENE$ compounds.	false
23164615.T1.T10	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of @CHEMICAL$, @GENE$ (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).	false
23164615.T1.T11	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, @CHEMICAL$ (AZ) and the @GENE$-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).	false
23164615.T1.T12	To investigate the role of @CHEMICAL$ in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, @GENE$ (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).	false
23164615.T2.T10	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of @CHEMICAL$, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist @GENE$ (DCPG).	false
23164615.T2.T11	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the @CHEMICAL$-specific orthosteric agonist @GENE$ (DCPG).	CPR:5
23164615.T2.T12	To investigate the role of @CHEMICAL$ in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist @GENE$ (DCPG).	false
23164615.T3.T10	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of @CHEMICAL$, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (@GENE$).	false
23164615.T3.T11	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the @CHEMICAL$-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (@GENE$).	CPR:5
23164615.T3.T12	To investigate the role of @CHEMICAL$ in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (@GENE$).	false
23164615.T5.T13	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous @CHEMICAL$ being stronger during bright light stimulation and with @GENE$ receptors mainly being localized away from glutamate release sites, immuno-labeled with VGLUT1.	false
23164615.T5.T14	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous @CHEMICAL$ being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from glutamate release sites, immuno-labeled with @GENE$.	false
23164615.T6.T13	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous glutamate being stronger during bright light stimulation and with @CHEMICAL$ receptors mainly being localized away from @GENE$ release sites, immuno-labeled with VGLUT1.	false
23164615.T6.T14	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous glutamate being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from @CHEMICAL$ release sites, immuno-labeled with @GENE$.	false
23164615.T7.T9	The differential sensitivity of ganglion cell light responses to @CHEMICAL$ and AZ supports multiple sites where @GENE$ modulates the light responses of ganglion cells.	false
23178182.T16.T40	@CHEMICAL$, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the @GENE$ antagonist MK-801.	false
23178182.T17.T40	UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the @CHEM-GENE$ antagonist MK-801.	false
23178182.T18.T40	UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the @CHEMICAL$ antagonist @GENE$.	CPR:6
23178182.T12.T19	Excessive @CHEMICAL$ (NMDAR)-dependent production of @GENE$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	false
23178182.T12.T30	Excessive N-Methyl-d-aspartate receptor (@CHEMICAL$)-dependent production of @GENE$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	false
23178182.T12.T22	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of @CHEMICAL$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by @GENE$ (PSD-95).	false
23178182.T12.T23	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of @CHEMICAL$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (@GENE$).	false
23178182.T15.T19	Excessive @CHEMICAL$ (NMDAR)-dependent production of nitric oxide (@GENE$) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	false
23178182.T15.T30	Excessive N-Methyl-d-aspartate receptor (@CHEMICAL$)-dependent production of nitric oxide (@GENE$) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	false
23178182.T15.T22	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (@CHEMICAL$) is involved in the development and maintenance of chronic pain states, and is mediated by @GENE$ (PSD-95).	false
23178182.T15.T23	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (@CHEMICAL$) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (@GENE$).	false
23178182.T2.T19	Excessive @CHEM-GENE$ (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	false
23178182.T2.T30	Excessive @CHEMICAL$ receptor (@GENE$)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	false
23178182.T2.T22	Excessive @CHEMICAL$ receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by @GENE$ (PSD-95).	false
23178182.T2.T23	Excessive @CHEMICAL$ receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (@GENE$).	false
23178182.T10.T24	By binding to both the @CHEMICAL$ and neuronal NO synthase (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and @GENE$ production.	false
23178182.T10.T28	By binding to both the NMDAR and neuronal NO synthase (nNOS), PSD-95 mediates a specific coupling between @CHEMICAL$ activation and @GENE$ production.	false
23178182.T10.T25	By binding to both the NMDAR and @CHEMICAL$ (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and @GENE$ production.	false
23178182.T10.T26	By binding to both the NMDAR and neuronal NO synthase (@CHEMICAL$), PSD-95 mediates a specific coupling between NMDAR activation and @GENE$ production.	false
23178182.T10.T27	By binding to both the NMDAR and neuronal NO synthase (nNOS), @CHEMICAL$ mediates a specific coupling between NMDAR activation and @GENE$ production.	false
23178182.T9.T24	By binding to both the @CHEMICAL$ and neuronal @GENE$ synthase (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and NO production.	false
23178182.T9.T28	By binding to both the NMDAR and neuronal @CHEMICAL$ synthase (nNOS), PSD-95 mediates a specific coupling between @GENE$ activation and NO production.	false
23178182.T9.T25	By binding to both the NMDAR and @CHEM-GENE$ (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and NO production.	false
23178182.T9.T26	By binding to both the NMDAR and neuronal @CHEMICAL$ synthase (@GENE$), PSD-95 mediates a specific coupling between NMDAR activation and NO production.	false
23178182.T9.T27	By binding to both the NMDAR and neuronal @CHEMICAL$ synthase (nNOS), @GENE$ mediates a specific coupling between NMDAR activation and NO production.	false
23178182.T11.T31	An alternative approach to modulate the @CHEMICAL$-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.	false
23178182.T11.T32	An alternative approach to modulate the NMDAR-related activity is to perturb the @CHEMICAL$/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.	false
23178182.T11.T35	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting @CHEMICAL$, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.	false
23178182.T11.T36	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @CHEMICAL$ production without interfering with the @GENE$ ion channel function.	false
23178182.T11.T37	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @CHEMICAL$ production without interfering with the NMDAR @GENE$ function.	false
23178182.T11.T33	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/@CHEMICAL$/nNOS complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.	false
23178182.T11.T34	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/@CHEMICAL$ complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.	false
23178182.T13.T39	Here, we compared the effects of a dimeric PSD-95 inhibitor, @CHEMICAL$, and the @GENE$ antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	false
23178182.T13.T38	Here, we compared the effects of a dimeric @CHEMICAL$ inhibitor, @GENE$, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	CPR:4
23178182.T14.T39	Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the @CHEMICAL$ antagonist, @GENE$, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	CPR:6
23178182.T14.T38	Here, we compared the effects of a dimeric @CHEMICAL$ inhibitor, UCCB01-125, and the NMDAR antagonist, @GENE$, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	false
23182766.T13.T21	Control of hypercholesterolemia and atherosclerosis using the @CHEMICAL$ recognition/interaction amino acid sequence of the @GENE$.	false
23182766.T14.T21	Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction @CHEMICAL$ sequence of the @GENE$.	false
23182766.T9.T18	The @CHEMICAL$ is an ubiquitous high affinity @GENE$-binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.	false
23182766.T5.T17	A domain in the @CHEMICAL$-terminus of @GENE$ was identified and characterized as the cholesterol recognition/interaction amino acid consensus (CRAC).	false
23182766.T6.T17	A domain in the carboxy-terminus of @CHEMICAL$ was identified and characterized as the @GENE$ recognition/interaction amino acid consensus (CRAC).	false
23182766.T7.T17	A domain in the carboxy-terminus of @CHEMICAL$ was identified and characterized as the cholesterol recognition/interaction @GENE$ consensus (CRAC).	false
23182766.T10.T19	We report herein the therapeutic benefit that resulted for the administration of the VLNYYVWR human CRAC sequence to guinea pigs fed with a high @CHEMICAL$ diet and @GENE$ knock-out B6.129P2-Apoetm1Unc/J mice.	false
23182766.T11.T20	CRAC treatment (3 and 30mg/kg once daily for 6 weeks) resulted in reduced circulating @CHEMICAL$ levels in guinea pigs fed with 2% high cholesterol diet and @GENE$ knock-out B6.129P2-Apoetm1Unc/J mice.	false
23182766.T12.T20	CRAC treatment (3 and 30mg/kg once daily for 6 weeks) resulted in reduced circulating cholesterol levels in guinea pigs fed with 2% high @CHEMICAL$ diet and @GENE$ knock-out B6.129P2-Apoetm1Unc/J mice.	false
23182766.T3.T15	The treatment also prevented the high @CHEMICAL$ diet-induced increase in serum @GENE$, total and isoforms, markers of neurological, cardiac and muscular damage.	CPR:3
23182766.T4.T15	The treatment also prevented the high cholesterol diet-induced increase in serum @CHEM-GENE$, total and isoforms, markers of neurological, cardiac and muscular damage.	false
23192339.T1.T13	GIP potentiates @CHEMICAL$-stimulated @GENE$ secretion and induces energy accumulation into adipose tissue, resulting in obesity.	CPR:3
23192339.T1.T9	@CHEMICAL$ potentiates @GENE$-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity.	false
23194076.T8.T24	Diet, physical exercise and @CHEMICAL$ administration increase serum @GENE$ (AMH) levels in women with polycystic ovary syndrome (PCOS).	CPR:3
23194076.T8.T25	Diet, physical exercise and @CHEMICAL$ administration increase serum Anti-Mullerian Hormone (@GENE$) levels in women with polycystic ovary syndrome (PCOS).	CPR:3
23194076.T6.T12	The present study investigates the combined effect of diet, physical exercise and @CHEMICAL$ for 24 weeks, on serum Anti-Mullerian Hormone (@GENE$) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.	false
23194076.T6.T9	The present study investigates the combined effect of diet, physical exercise and @CHEMICAL$ for 24 weeks, on serum @GENE$e (AMH) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.	false
23194076.T2.T14	At baseline, week 12 and week 24, serum levels of AMH, @CHEMICAL$, LH, PRL, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T15	At baseline, week 12 and week 24, serum levels of AMH, FSH, @CHEMICAL$, PRL, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T13	At baseline, week 12 and week 24, serum levels of @CHEMICAL$, FSH, LH, PRL, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T16	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, @CHEMICAL$, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T17	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, @GENE$ (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T18	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, sex hormone-binding globulin (@GENE$), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T19	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, sex hormone-binding globulin (SHBG), glucose, and @GENE$ were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T2.T20	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and @GENE$ Resistance (IR) indices were calculated.	false
23194076.T3.T14	At baseline, week 12 and week 24, serum levels of AMH, @CHEMICAL$, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T15	At baseline, week 12 and week 24, serum levels of AMH, FSH, @CHEMICAL$, PRL, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T13	At baseline, week 12 and week 24, serum levels of @CHEMICAL$, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T16	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, @CHEMICAL$, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T17	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, @CHEMICAL$ (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T18	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (@CHEMICAL$), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T19	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @CHEMICAL$, and @GENE$ were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T3.T20	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @CHEMICAL$, and insulin were measured and Free Androgen Index (FAI) and @GENE$ Resistance (IR) indices were calculated.	false
23194076.T4.T14	At baseline, week 12 and week 24, serum levels of AMH, @CHEMICAL$, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T15	At baseline, week 12 and week 24, serum levels of AMH, FSH, @CHEMICAL$, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T13	At baseline, week 12 and week 24, serum levels of @CHEMICAL$, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T16	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, @CHEMICAL$, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T17	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, @CHEMICAL$ (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T18	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (@CHEMICAL$), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T19	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and @CHEMICAL$ were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.	false
23194076.T4.T20	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @CHEMICAL$ Index (FAI) and @GENE$ Resistance (IR) indices were calculated.	false
23194076.T5.T22	After 12 weeks @CHEMICAL$ and SHBG were increased, while @GENE$ decreased.	false
23194076.T5.T23	After 12 weeks LH and @CHEMICAL$ were increased, while @GENE$ decreased.	false
23194076.T7.T10	We concluded that in overweight and obese women with PCOS @CHEMICAL$ administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and @GENE$ sensitivity, and increased serum AMH levels.	false
23194076.T7.T11	We concluded that in overweight and obese women with PCOS @CHEMICAL$ administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum @GENE$ levels.	CPR:3
23200732.T8.T22	Lessons from the dissection of the @CHEMICAL$ (AF-1 and AF-2) of the @GENE$ receptor alpha in vivo.	false
23200732.T8.T23	Lessons from the dissection of the activation functions (@CHEMICAL$ and AF-2) of the @GENE$ receptor alpha in vivo.	false
23200732.T8.T24	Lessons from the dissection of the activation functions (AF-1 and @CHEMICAL$) of the @GENE$ receptor alpha in vivo.	false
23200732.T8.T25	Lessons from the dissection of the activation functions (AF-1 and AF-2) of the @CHEM-GENE$ in vivo.	false
23200732.T6.T14	These actions are mediated by the activation of @CHEM-GENE$ (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	false
23200732.T6.T16	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent @GENE$ (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	false
23200732.T6.T17	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions @GENE$ and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	false
23200732.T6.T18	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and @GENE$, but can also elicit rapid membrane initiated steroid signals (MISS).	false
23200732.T6.T15	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (@GENE$), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	false
23200732.T7.T14	These actions are mediated by the activation of @CHEMICAL$ (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).	false
23200732.T7.T16	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent @CHEMICAL$ (AF)-1 and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).	false
23200732.T7.T17	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions @CHEMICAL$ and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).	false
23200732.T7.T18	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and @CHEMICAL$, but can also elicit rapid membrane initiated @GENE$ signals (MISS).	false
23200732.T7.T15	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (@CHEMICAL$), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).	false
23200732.T2.T11	However, the use of these @CHEMICAL$ or selective @GENE$ modulators (SERMs) have also induced undesired effects.	false
23200732.T3.T11	However, the use of these estrogens or selective @CHEM-GENE$ modulators (SERMs) have also induced undesired effects.	false
23201003.T20.T28	Inhibitory effect of @CHEMICAL$ on excretion of JBP485 via @GENE$ in rats.	false
23201003.T21.T28	Inhibitory effect of 1a,25-dihydroxyvitamin D3 on excretion of @CHEMICAL$ via @GENE$ in rats.	false
23201003.T13.T25	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of @CHEMICAL$ (Oat)1 and Oat3 in rat kidney in response to @GENE$ treatment.	false
23201003.T13.T26	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter @CHEMICAL$ and Oat3 in rat kidney in response to @GENE$ treatment.	false
23201003.T13.T27	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter (Oat)1 and @CHEMICAL$ in rat kidney in response to @GENE$ treatment.	false
23201003.T2.T22	Moreover, @CHEMICAL$ decreased expression of @GENE$ and Oat3 in rat kidney.	CPR:4
23201003.T2.T23	Moreover, @CHEMICAL$ decreased expression of Oat1 and @GENE$ in rat kidney.	CPR:4
23201003.T6.T24	The mechanism of interaction between @CHEMICAL$ and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of @GENE$ in rat kidney.	false
23201003.T7.T24	The mechanism of interaction between JBP485 and @CHEMICAL$ could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of @GENE$ in rat kidney.	false
23201003.T8.T24	The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of @CHEMICAL$ on expression of @GENE$ in rat kidney.	CPR:4
23210662.T1.T12	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of @GENE$-G2.0-PAMAM or ethynyl-G3.0-PAMAM dendrons.	false
23210662.T1.T14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of @GENE$-G2.0-PAMAM or ethynyl-G3.0-PAMAM dendrons.	false
23210662.T2.T12	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-@GENE$ or ethynyl-G3.0-PAMAM dendrons.	false
23210662.T2.T14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-@GENE$ or ethynyl-G3.0-PAMAM dendrons.	false
23210662.T3.T12	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or @GENE$-G3.0-PAMAM dendrons.	false
23210662.T3.T14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or @GENE$-G3.0-PAMAM dendrons.	false
23210662.T4.T12	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or ethynyl-G3.0-@GENE$ dendrons.	false
23210662.T4.T14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or ethynyl-G3.0-@GENE$ dendrons.	false
23210662.T5.T11	The attachment of @CHEMICAL$-G2.0-PAMAM dendrons to @GENE$ yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic PAMAM shell.	false
23210662.T6.T11	The attachment of ethynyl-G2.0-@CHEMICAL$ dendrons to @GENE$ yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic PAMAM shell.	false
23210662.T7.T11	The attachment of ethynyl-G2.0-PAMAM dendrons to @CHEMICAL$ yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic @GENE$ shell.	false
23210662.T8.T13	Significantly higher loading of @CHEMICAL$ was observed for dendronized G2-DHSA compared with the native protein due to the availability of binding pockets of the @GENE$ core, and interaction with the dendritic shell.	false
23212306.T10.T22	The present study investigated the effect of neonatal exposure to diazinon on hippocampus-dependent novel object recognition test performance and the expression of the @CHEM-GENE$ and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.	false
23212306.T11.T22	The present study investigated the effect of neonatal exposure to diazinon on hippocampus-dependent novel object recognition test performance and the expression of the @CHEM-GENE$ and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.	false
23212306.T9.T22	The present study investigated the effect of neonatal exposure to @CHEMICAL$ on hippocampus-dependent novel object recognition test performance and the expression of the @GENE$ and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.	false
23212306.T13.T23	The hippocampi were collected on PND 50 or PND 85 after the completion of the novel object recognition test, and the expression levels of @CHEMICAL$ and the @GENE$ receptor and its signal transduction pathway-related genes were examined using real-time RT-PCR.	false
23212306.T13.T24	The hippocampi were collected on PND 50 or PND 85 after the completion of the novel object recognition test, and the expression levels of neurotrophins and the @CHEM-GENE$ and its signal transduction pathway-related genes were examined using real-time RT-PCR.	false
23212306.T2.T16	The @CHEM-GENE$ and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T2.T17	The @CHEMICAL$ receptor subunits NR1 and NR2B and the related protein @GENE$ calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T2.T18	The @CHEMICAL$ receptor subunits NR1 and NR2B and the related protein kinase @GENE$ and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T2.T19	The @CHEMICAL$ receptor subunits NR1 and NR2B and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ mRNA levels were reduced in the PND 50 mice.	false
23212306.T3.T16	The @CHEMICAL$ and the related protein kinase @GENE$/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T3.T17	The NMDA receptor subunits NR1 and NR2B and the related protein @CHEMICAL$ @GENE$/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T3.T18	The NMDA receptor subunits NR1 and NR2B and the related protein kinase @CHEM-GENE$ and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T3.T19	The NMDA receptor subunits NR1 and NR2B and the related protein kinase @CHEMICAL$/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ mRNA levels were reduced in the PND 50 mice.	false
23212306.T4.T16	The @CHEMICAL$ and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T4.T17	The NMDA receptor subunits NR1 and NR2B and the related protein @CHEMICAL$ calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T4.T18	The NMDA receptor subunits NR1 and NR2B and the related protein kinase @CHEMICAL$ and the transcription factor @GENE$ responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	false
23212306.T4.T19	The NMDA receptor subunits NR1 and NR2B and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @CHEM-GENE$ mRNA levels were reduced in the PND 50 mice.	false
23212306.T7.T21	These results indicate that neonatal @CHEMICAL$ exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the @GENE$ and neurotrophin in young adult and adult mice.	false
23212306.T8.T21	These results indicate that neonatal diazinon exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the @CHEM-GENE$ and neurotrophin in young adult and adult mice.	false
23215039.T1.T3	Legumain is a lysosomal @CHEM-GENE$ whose biological function remains poorly defined.	false
23215039.T1.T2	@CHEMICAL$ is a lysosomal @GENE$ protease whose biological function remains poorly defined.	false
23218950.T3.T23	The accuracy of DNA synthesis depends on the accuracy of the @CHEMICAL$ as well as the quality and concentration(s) of the available @GENE$ DNA precursors (dNTPs).	false
23218950.T7.T23	The accuracy of DNA synthesis depends on the accuracy of the @CHEMICAL$ as well as the quality and concentration(s) of the available 5'-deoxynucleoside-triphosphate DNA precursors (@GENE$).	false
23218950.T10.T21	These strains, defective in @CHEMICAL$ and @GENE$ kinase, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.	false
23218950.T10.T22	These strains, defective in dCTP deaminase and @CHEM-GENE$, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.	false
23218950.T11.T21	These strains, defective in @CHEMICAL$ and nucleoside diphosphate kinase, respectively, are characterized by both disturbances of @GENE$ pools and a mutator phenotype.	false
23218950.T11.T22	These strains, defective in dCTP deaminase and @CHEMICAL$, respectively, are characterized by both disturbances of @GENE$ pools and a mutator phenotype.	false
23218950.T9.T21	These strains, defective in @CHEM-GENE$ and nucleoside diphosphate kinase, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.	false
23218950.T9.T22	These strains, defective in @CHEMICAL$ deaminase and @GENE$, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.	false
23218950.T12.T14	We show that dcd strains suffer from increased intracellular levels of @CHEMICAL$ (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for @GENE$ and A*T>T*A transversions (27- and 42-fold enhancement, respectively).	false
23218950.T12.T15	We show that dcd strains suffer from increased intracellular levels of @CHEMICAL$ (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and @GENE$ transversions (27- and 42-fold enhancement, respectively).	false
23218950.T12.T25	We show that @CHEMICAL$ strains suffer from increased intracellular levels of @GENE$ (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and A*T>T*A transversions (27- and 42-fold enhancement, respectively).	false
23218950.T13.T14	We show that dcd strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of @CHEMICAL$ (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for @GENE$ and A*T>T*A transversions (27- and 42-fold enhancement, respectively).	false
23218950.T13.T15	We show that dcd strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of @CHEMICAL$ (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and @GENE$ transversions (27- and 42-fold enhancement, respectively).	false
23218950.T13.T25	We show that @CHEMICAL$ strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of @GENE$ (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and A*T>T*A transversions (27- and 42-fold enhancement, respectively).	false
23218950.T1.T17	In contrast, ndk strains possess a lowered @CHEMICAL$ level (4-fold) and modestly enhanced dCTP level (2-fold), while its mutator effect is specific for just the @GENE$ transversions.	false
23218950.T1.T16	In contrast, @CHEMICAL$ strains possess a lowered @GENE$ level (4-fold) and modestly enhanced dCTP level (2-fold), while its mutator effect is specific for just the A*T>T*A transversions.	false
23218950.T2.T17	In contrast, ndk strains possess a lowered dATP level (4-fold) and modestly enhanced @CHEMICAL$ level (2-fold), while its mutator effect is specific for just the @GENE$ transversions.	false
23218950.T2.T16	In contrast, @CHEMICAL$ strains possess a lowered dATP level (4-fold) and modestly enhanced @GENE$ level (2-fold), while its mutator effect is specific for just the A*T>T*A transversions.	false
23218950.T5.T18	Overall, our analysis reveals for both strains a satisfactory correlation between @CHEMICAL$ pool alterations and the replication error rates, and also suggests that a minimal explanation for the @GENE$ mutator does not require assumptions beyond the predicted effect of the dNTP pools.	false
23218950.T6.T18	Overall, our analysis reveals for both strains a satisfactory correlation between dNTP pool alterations and the replication error rates, and also suggests that a minimal explanation for the @CHEMICAL$ mutator does not require assumptions beyond the predicted effect of the @GENE$ pools.	false
23220614.T23.T49	@CHEMICAL$ signaling pathways regulate mitochondrial-mediated apoptosis induced by @GENE$ in human hepatoblastoma cancer cells.	false
23220614.T13.T35	@CHEMICAL$ is able to induce apoptosis through mitochondrial dysfunction and inhibition of @GENE$/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.	CPR:4
23220614.T13.T36	@CHEMICAL$ is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/@GENE$ signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.	CPR:4
23220614.T13.T37	@CHEMICAL$ is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on @GENE$ signaling pathways remain unknown.	false
23220614.T15.T35	ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of @CHEMICAL$/Akt signaling pathway in HepG2 cells, however, the effects of @GENE$ on MAPK signaling pathways remain unknown.	false
23220614.T15.T36	ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/@CHEMICAL$ signaling pathway in HepG2 cells, however, the effects of @GENE$ on MAPK signaling pathways remain unknown.	false
23220614.T15.T37	ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of @CHEMICAL$ on @GENE$ signaling pathways remain unknown.	false
23220614.T16.T38	The present study investigated the effects of @CHEMICAL$ on this pathway, and the roles of @GENE$ kinases on mitochondrial-mediated apoptosis in HepG2 cells.	false
23220614.T16.T39	The present study investigated the effects of @CHEMICAL$ on this pathway, and the roles of MAPK @GENE$ on mitochondrial-mediated apoptosis in HepG2 cells.	false
23220614.T20.T40	@CHEMICAL$ significantly inhibited the levels of @GENE$ kinase and increased the expression of JNK and p38 kinases.	false
23220614.T20.T41	@CHEMICAL$ significantly inhibited the levels of ERK1/2 kinase and increased the expression of @GENE$ and p38 kinases.	CPR:3
23220614.T20.T42	@CHEMICAL$ significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and @GENE$ kinases.	CPR:3
23220614.T20.T43	@CHEMICAL$ significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38 @GENE$.	CPR:3
23220614.T21.T44	Furthermore, @CHEMICAL$ (an @GENE$ inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	false
23220614.T21.T45	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the @GENE$/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	CPR:3
23220614.T21.T46	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/@GENE$ ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	CPR:3
23220614.T21.T47	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of @GENE$ to the cytosol fraction, and the levels of cleaved caspase-3.	false
23220614.T21.T48	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved @GENE$.	false
23220614.T22.T44	Furthermore, U0126 (an @CHEMICAL$ inhibitor) significantly enhanced the @GENE$-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	false
23220614.T22.T45	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the @GENE$/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	CPR:3
23220614.T22.T46	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the Bax/@GENE$ ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	CPR:3
23220614.T22.T47	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the Bax/Bcl-2 ratio, the release of @GENE$ to the cytosol fraction, and the levels of cleaved caspase-3.	false
23220614.T22.T48	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved @GENE$.	false
23220614.T2.T24	While @CHEMICAL$ (a @GENE$ inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.	CPR:4
23220614.T2.T25	While @CHEMICAL$ (a JNK inhibitor) and SB203580 (a @GENE$ inhibitor) markedly prevented the expression of these proteins induced by ISO.	false
23220614.T3.T24	While SP600125 (a @CHEMICAL$ inhibitor) and @GENE$ (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.	false
23220614.T3.T25	While SP600125 (a JNK inhibitor) and @CHEMICAL$ (a @GENE$ inhibitor) markedly prevented the expression of these proteins induced by ISO.	CPR:4
23220614.T4.T24	While SP600125 (a @CHEMICAL$ inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by @GENE$.	CPR:3
23220614.T4.T25	While SP600125 (a JNK inhibitor) and SB203580 (a @CHEMICAL$ inhibitor) markedly prevented the expression of these proteins induced by @GENE$.	CPR:3
23220614.T5.T26	Furthermore, the ROS inhibitor (@CHEMICAL$) notably promoted the inhibited effect of ISO on the @GENE$ kinase.	false
23220614.T6.T26	Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of @CHEMICAL$ on the @GENE$ kinase.	false
23220614.T7.T27	@CHEMICAL$ also suppressed the p-@GENE$ and p-p38, but failed to reverse the effects of ISO.	CPR:4
23220614.T7.T28	@CHEMICAL$ also suppressed the p-JNK and @GENE$, but failed to reverse the effects of ISO.	CPR:4
23220614.T8.T27	NAC also suppressed the p-@CHEMICAL$ and p-p38, but failed to reverse the effects of @GENE$.	false
23220614.T8.T28	NAC also suppressed the p-JNK and @CHEMICAL$, but failed to reverse the effects of @GENE$.	false
23220614.T10.T29	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating @GENE$ kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.	false
23220614.T10.T30	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating @GENE$ and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.	CPR:3
23220614.T10.T31	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and @GENE$ kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.	CPR:3
23220614.T10.T32	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 @GENE$, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.	CPR:3
23220614.T10.T33	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the @GENE$ singaling pathway as the upstream signaling molecules.	false
23220614.T11.T29	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating @CHEMICAL$ kinase and activating JNK and p38 kinases, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.	false
23220614.T11.T30	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating @CHEMICAL$ and p38 kinases, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.	false
23220614.T11.T31	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and @CHEMICAL$ kinases, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.	false
23220614.T11.T32	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 @CHEMICAL$, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.	false
23220614.T11.T33	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by @CHEMICAL$ is able to activate the @GENE$ singaling pathway as the upstream signaling molecules.	CPR:3
23220614.T12.T34	Initiating event of the mitochondrial-mediated apoptosis induced by @CHEMICAL$ is @GENE$ signals.	false
23220618.T10.T33	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of @GENE$ and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.	CPR:4
23220618.T10.T34	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @GENE$, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.	CPR:4
23220618.T10.T35	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of @GENE$ and FXa in HUVECs.	false
23220618.T10.T36	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and @GENE$ in HUVECs.	false
23220618.T11.T33	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of @GENE$ and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.	CPR:4
23220618.T11.T34	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @GENE$, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.	CPR:4
23220618.T11.T35	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of @GENE$ and FXa in HUVECs.	false
23220618.T11.T36	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and @GENE$ in HUVECs.	false
23220618.T12.T33	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of @CHEMICAL$ and FXa, and @GENE$ or hyperoside inhibited production of thrombin and FXa in HUVECs.	false
23220618.T12.T34	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @CHEMICAL$, and @GENE$ or hyperoside inhibited production of thrombin and FXa in HUVECs.	false
23220618.T12.T35	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and @CHEMICAL$ or hyperoside inhibited production of @GENE$ and FXa in HUVECs.	CPR:3
23220618.T12.T36	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and @CHEMICAL$ or hyperoside inhibited production of thrombin and @GENE$ in HUVECs.	CPR:4
23220618.T13.T33	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of @CHEMICAL$ and FXa, and IMG or @GENE$ inhibited production of thrombin and FXa in HUVECs.	false
23220618.T13.T34	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @CHEMICAL$, and IMG or @GENE$ inhibited production of thrombin and FXa in HUVECs.	false
23220618.T13.T35	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or @CHEMICAL$ inhibited production of @GENE$ and FXa in HUVECs.	CPR:4
23220618.T13.T36	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or @CHEMICAL$ inhibited production of thrombin and @GENE$ in HUVECs.	CPR:4
23220618.T15.T19	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of @GENE$-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.	CPR:4
23220618.T15.T20	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of TNF-a-induced production of @GENE$, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.	CPR:4
23220618.T15.T21	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the @GENE$ to t-PA ratio.	false
23220618.T15.T22	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to @GENE$ ratio.	false
23220618.T16.T19	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of @GENE$-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.	CPR:4
23220618.T16.T20	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of TNF-a-induced production of @GENE$, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.	CPR:4
23220618.T16.T21	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the @GENE$ to t-PA ratio.	false
23220618.T16.T22	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to @GENE$ ratio.	false
23220618.T2.T19	In addition, treatment with IMG and hyperoside resulted in inhibition of @CHEMICAL$-induced production of PAI-1, and treatment with @GENE$ resulted in significant reduction of the PAI-1 to t-PA ratio.	false
23220618.T2.T20	In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-a-induced production of @CHEMICAL$, and treatment with @GENE$ resulted in significant reduction of the PAI-1 to t-PA ratio.	false
23220618.T2.T21	In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with @CHEMICAL$ resulted in significant reduction of the @GENE$ to t-PA ratio.	CPR:4
23220618.T2.T22	In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with @CHEMICAL$ resulted in significant reduction of the PAI-1 to @GENE$ ratio.	CPR:4
23220644.T6.T17	Optimization of @CHEMICAL$ as dual function inhibitors targeting @GENE$ and leukotriene A4 hydrolase.	CPR:4
23220644.T6.T18	Optimization of @CHEMICAL$ as dual function inhibitors targeting phospholipase A2 and @GENE$.	CPR:4
23220644.T1.T12	Dual function inhibitors targeting phospholipase A(2) (@CHEMICAL$) and leukotriene A(4) hydrolase (LTA(4)H) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.	CPR:9
23220644.T1.T8	Dual function inhibitors targeting @CHEMICAL$ (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.	CPR:9
23220644.T1.T13	Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and @CHEMICAL$ (LTA(4)H) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.	CPR:9
23220644.T1.T16	Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (@CHEMICAL$) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.	CPR:9
23220644.T2.T10	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and @GENE$ (LTA(4)H-h) was found.	CPR:4
23220644.T2.T11	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (@GENE$) was found.	CPR:4
23220644.T2.T7	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for @GENE$ (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.	CPR:4
23220644.T2.T9	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for human nonpancreatic secretory phospholipase A(2) (@GENE$) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.	CPR:4
23220749.T13.T28	@CHEMICAL$ is a bimodal modulator of @GENE$ channels.	false
23220749.T7.T18	We wanted to test whether sensory @CHEMICAL$ are a molecular target for @GENE$.	false
23220749.T9.T19	Here, we show that @CHEMICAL$, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.	false
23220749.T9.T20	Here, we show that rTRPV1, @CHEMICAL$, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.	false
23220749.T9.T21	Here, we show that rTRPV1, rTRPV2, @CHEMICAL$, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.	false
23220749.T9.T22	Here, we show that rTRPV1, rTRPV2, rTRPV3, and @CHEMICAL$, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.	false
23220749.T9.T23	Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as @CHEMICAL$, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.	false
23220749.T9.T24	Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and @CHEMICAL$, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.	false
23220749.T11.T26	On the contrary, @CHEMICAL$ could be concentration-dependently modulated by @GENE$.	false
23220749.T12.T27	Whereas the addition of @CHEMICAL$ in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed @GENE$ channels, resulting from a reduction of single-channel open times.	CPR:4
23220749.T2.T14	In addition, we provide evidence that @CHEMICAL$ also acts on endogenous @GENE$ in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1.	false
23220749.T2.T15	In addition, we provide evidence that @CHEMICAL$ also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of @GENE$.	CPR:3
23220749.T3.T14	In addition, we provide evidence that apomorphine also acts on endogenous @CHEMICAL$ in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which @GENE$ is released upon activation of TRPA1.	false
23220749.T3.T15	In addition, we provide evidence that apomorphine also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which @CHEMICAL$ is released upon activation of @GENE$.	false
23220749.T4.T16	Our study shows that @CHEMICAL$ is a target for @GENE$, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.	false
23220749.T4.T17	Our study shows that human TRPA1 is a target for @CHEMICAL$, suggesting that an activation of @GENE$ might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.	CPR:3
23220749.T5.T16	Our study shows that @CHEMICAL$ is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with @GENE$.	false
23220749.T5.T17	Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of @CHEMICAL$ might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with @GENE$.	CPR:3
23221600.T7.T34	Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of @CHEM-GENE$ to the gene promoter.	false
23221600.T7.T33	@CHEMICAL$ (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of @GENE$ receptor to the gene promoter.	false
23221600.T7.T35	Human stearoyl-CoA desaturase 1 (@CHEMICAL$) gene expression is negatively regulated by thyroid hormone without direct binding of @GENE$ receptor to the gene promoter.	false
23221600.T8.T34	Human @CHEMICAL$ desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of @GENE$ to the gene promoter.	false
23221600.T8.T33	@CHEM-GENE$ (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter.	false
23221600.T8.T35	Human @CHEMICAL$ desaturase 1 (@GENE$) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter.	false
23221600.T9.T34	Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by @CHEMICAL$ without direct binding of @GENE$ to the gene promoter.	false
23221600.T9.T33	@CHEMICAL$ (SCD-1) gene expression is negatively regulated by @GENE$ without direct binding of thyroid hormone receptor to the gene promoter.	CPR:4
23221600.T9.T35	Human stearoyl-CoA desaturase 1 (@CHEMICAL$) gene expression is negatively regulated by @GENE$ without direct binding of thyroid hormone receptor to the gene promoter.	CPR:4
23221600.T1.T10	@CHEM-GENE$ (SCD-1) plays a pivotal role in an increase of triglyceride by an excess of dietary carbohydrate intake.	false
23221600.T1.T22	@CHEMICAL$ desaturase-1 (@GENE$) plays a pivotal role in an increase of triglyceride by an excess of dietary carbohydrate intake.	false
23221600.T2.T10	@CHEMICAL$ (SCD-1) plays a pivotal role in an increase of triglyceride by an excess of dietary @GENE$ intake.	false
23221600.T2.T22	Stearoyl-CoA desaturase-1 (@CHEMICAL$) plays a pivotal role in an increase of triglyceride by an excess of dietary @GENE$ intake.	false
23221600.T6.T10	@CHEMICAL$ (SCD-1) plays a pivotal role in an increase of @GENE$ by an excess of dietary carbohydrate intake.	false
23221600.T6.T22	Stearoyl-CoA desaturase-1 (@CHEMICAL$) plays a pivotal role in an increase of @GENE$ by an excess of dietary carbohydrate intake.	false
23221600.T3.T19	Dietary @CHEMICAL$ increase @GENE$ gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.	CPR:3
23221600.T3.T20	Dietary @CHEMICAL$ increase SCD-1 gene expression in liver by @GENE$-dependent and SREBP-1c -independent pathways.	false
23221600.T3.T21	Dietary @CHEMICAL$ increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and @GENE$ -independent pathways.	false
23221600.T4.T19	Dietary carbohydrates increase @CHEMICAL$ gene expression in liver by @GENE$ response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.	false
23221600.T4.T20	Dietary carbohydrates increase SCD-1 gene expression in liver by @CHEM-GENE$-dependent and SREBP-1c -independent pathways.	false
23221600.T4.T21	Dietary carbohydrates increase SCD-1 gene expression in liver by @CHEMICAL$ response element binding protein (SREBP)-1c-dependent and @GENE$ -independent pathways.	false
23221600.T5.T23	Previous report demonstrated that @CHEMICAL$ (TH) negatively regulates @GENE$ before SREBP-1c was revealed.	CPR:4
23221600.T5.T24	Previous report demonstrated that @CHEMICAL$ (TH) negatively regulates mouse SCD-1 gene promoter before @GENE$ was revealed.	false
23223177.T6.T11	Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of @CHEMICAL$-activated protein kinase (@GENE$) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism.	false
23223177.T6.T32	Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of @CHEM-GENE$ (AMPK) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism.	false
23223177.T2.T15	We hypothesized that @CHEMICAL$-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.	false
23223177.T2.T16	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of @CHEMICAL$ on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.	false
23223177.T2.T17	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between @CHEMICAL$ and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.	false
23223177.T2.T18	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and @CHEMICAL$, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.	false
23223177.T3.T19	Exposure of H9c2 cells to high @CHEMICAL$ reduced @GENE$ activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	CPR:4
23223177.T3.T20	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited @GENE$ (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	CPR:4
23223177.T3.T21	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (@GENE$)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	CPR:4
23223177.T3.T22	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-@GENE$ (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	CPR:4
23223177.T3.T23	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (@GENE$) signaling, and promoted Beclin1 binding to Bcl-2.	CPR:4
23223177.T3.T24	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted @GENE$ binding to Bcl-2.	false
23223177.T3.T25	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to @GENE$.	false
23223177.T4.T19	Exposure of H9c2 cells to high glucose reduced @CHEMICAL$ activity, inhibited Jun @GENE$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	false
23223177.T4.T20	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited @CHEM-GENE$ (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	false
23223177.T4.T21	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (@GENE$)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	false
23223177.T4.T22	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-@GENE$ (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	false
23223177.T4.T23	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (@GENE$) signaling, and promoted Beclin1 binding to Bcl-2.	false
23223177.T4.T24	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted @GENE$ binding to Bcl-2.	false
23223177.T4.T25	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to @GENE$.	false
23223177.T5.T31	Activation of @CHEMICAL$, which normalized cardiac autophagy, attenuated high @GENE$-induced apoptosis in cultured H9c2 cells.	false
23223177.T1.T10	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and @GENE$.	false
23223177.T1.T7	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating @GENE$-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.	CPR:3
23223177.T1.T8	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating JNK1-@GENE$ pathways and dissociating Beclin1 and Bcl-2.	CPR:3
23223177.T1.T9	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating @GENE$ and Bcl-2.	false
23228696.T16.T40	@CHEMICAL$-mediated downregulation of @GENE$ mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.	CPR:4
23228696.T16.T41	@CHEMICAL$-mediated downregulation of p38 @GENE$-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.	CPR:4
23228696.T17.T40	Metformin-mediated downregulation of @CHEMICAL$ mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to @GENE$.	false
23228696.T17.T41	Metformin-mediated downregulation of p38 @CHEMICAL$-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to @GENE$.	false
23228696.T12.T28	High expression levels of @CHEMICAL$ (ERCC1) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with @GENE$-containing chemotherapy.	false
23228696.T12.T29	High expression levels of excision repair cross-complementary 1 (@CHEMICAL$) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with @GENE$-containing chemotherapy.	false
23228696.T13.T30	In this current study, @CHEMICAL$ was found to increase phosphorylation of @GENE$ (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	CPR:3
23228696.T13.T31	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (@GENE$)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	false
23228696.T13.T32	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-@GENE$ MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	CPR:3
23228696.T13.T33	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 @GENE$ as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	CPR:3
23228696.T13.T34	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of @GENE$ in H1650 and H1703 cells.	CPR:3
23228696.T14.T36	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of @GENE$ activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	false
23228696.T14.T37	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a @GENE$ MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	false
23228696.T14.T38	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 @GENE$ inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	false
23228696.T14.T39	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or @GENE$ knockdown with specific small interfering RNA (siRNA).	false
23228696.T14.T35	Moreover, @CHEMICAL$-induced @GENE$ protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	CPR:3
23228696.T15.T36	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of @CHEMICAL$ activity by either a p38 MAPK inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).	CPR:4
23228696.T15.T37	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a @CHEMICAL$ MAPK inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).	CPR:4
23228696.T15.T38	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 @CHEMICAL$ inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).	CPR:4
23228696.T15.T39	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor @CHEMICAL$ or @GENE$ knockdown with specific small interfering RNA (siRNA).	false
23228696.T15.T35	Moreover, paclitaxel-induced @CHEMICAL$ protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).	false
23228696.T2.T18	Specific inhibition of @CHEMICAL$ with siRNA was found to enhance the @GENE$-induced cytotoxic effect and growth inhibition.	false
23228696.T3.T19	Furthermore, @CHEMICAL$ was able to not only decrease the paclitaxel-induced @GENE$ MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	CPR:4
23228696.T3.T20	Furthermore, @CHEMICAL$ was able to not only decrease the paclitaxel-induced p38 @GENE$-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	CPR:4
23228696.T3.T21	Furthermore, @CHEMICAL$ was able to not only decrease the paclitaxel-induced p38 MAPK-mediated @GENE$ expression, but also augment the cytotoxic effect induced by paclitaxel.	CPR:4
23228696.T4.T19	Furthermore, metformin was able to not only decrease the @CHEMICAL$-induced @GENE$ MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	CPR:3
23228696.T4.T20	Furthermore, metformin was able to not only decrease the @CHEMICAL$-induced p38 @GENE$-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	CPR:3
23228696.T4.T21	Furthermore, metformin was able to not only decrease the @CHEMICAL$-induced p38 MAPK-mediated @GENE$ expression, but also augment the cytotoxic effect induced by paclitaxel.	CPR:3
23228696.T5.T19	Furthermore, metformin was able to not only decrease the paclitaxel-induced @CHEMICAL$ MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by @GENE$.	false
23228696.T5.T20	Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 @CHEMICAL$-mediated ERCC1 expression, but also augment the cytotoxic effect induced by @GENE$.	false
23228696.T5.T21	Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated @CHEMICAL$ expression, but also augment the cytotoxic effect induced by @GENE$.	false
23228696.T6.T23	Finally, expression of constitutive activate MKK6 or HA-@CHEMICAL$ MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.	false
23228696.T6.T24	Finally, expression of constitutive activate MKK6 or HA-p38 @CHEMICAL$ vectors in lung cancer cells was able to abrogate ERCC1 downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.	false
23228696.T6.T22	Finally, expression of constitutive activate @CHEMICAL$ or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.	false
23228696.T6.T25	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate @CHEMICAL$ downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.	CPR:4
23228696.T7.T23	Finally, expression of constitutive activate MKK6 or HA-@CHEMICAL$ MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.	false
23228696.T7.T24	Finally, expression of constitutive activate MKK6 or HA-p38 @CHEMICAL$ vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.	false
23228696.T7.T22	Finally, expression of constitutive activate @CHEMICAL$ or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.	false
23228696.T7.T25	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate @CHEMICAL$ downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.	CPR:4
23228696.T8.T26	Overall, our results suggest that inhibition of the @CHEMICAL$ MAPK signaling by @GENE$ coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	CPR:4
23228696.T8.T27	Overall, our results suggest that inhibition of the p38 @CHEMICAL$ signaling by @GENE$ coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	CPR:4
23228696.T9.T26	Overall, our results suggest that inhibition of the @CHEMICAL$ MAPK signaling by metformin coupled with @GENE$ therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	false
23228696.T9.T27	Overall, our results suggest that inhibition of the p38 @CHEMICAL$ signaling by metformin coupled with @GENE$ therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	false
23228697.T13.T35	@CHEMICAL$ is a highly sensitive target of the antiobesity agent @GENE$ with profound implications in the activation of anticancer prodrugs.	false
23228697.T1.T17	@CHEMICAL$ has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal @GENE$.	CPR:4
23228697.T6.T25	This study was designed to test the hypothesis that @CHEMICAL$ inhibits @GENE$ with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.	CPR:4
23228697.T6.T28	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward CES1 than CES2, a @GENE$ with little lipase activity.	CPR:4
23228697.T6.T29	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little @GENE$ activity.	CPR:4
23228697.T6.T26	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward @GENE$ than CES2, a carboxylesterase with little lipase activity.	CPR:4
23228697.T6.T27	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward CES1 than @GENE$, a carboxylesterase with little lipase activity.	CPR:4
23228697.T10.T30	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of doxazolidine (@GENE$) and irinotecan.	false
23228697.T11.T30	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of doxazolidine (PPD) and @GENE$.	false
23228697.T7.T30	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs @GENE$ of p-aminobenzyl carbamate of doxazolidine (PPD) and irinotecan.	false
23228697.T8.T30	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of @GENE$ of doxazolidine (PPD) and irinotecan.	false
23228697.T9.T30	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of @GENE$ (PPD) and irinotecan.	false
23228697.T12.T31	Contrary to the hypothesis, orlistat at 1 nM inhibited @CHEMICAL$ activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of @GENE$.	CPR:4
23228697.T12.T32	Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on @CHEMICAL$, placing CES2 one of the most sensitive targets of @GENE$.	false
23228697.T12.T33	Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing @CHEMICAL$ one of the most sensitive targets of @GENE$.	CPR:4
23228697.T4.T16	Inhibition of this @CHEMICAL$ probably presents a major source for altered therapeutic activity of these medicines if co-administered with @GENE$.	CPR:4
23229509.T6.T25	Regions on @CHEM-GENE$ required for selective regulation by the G13 pathway.	false
23229509.T6.T26	Regions on @CHEMICAL$ cyclase VII required for selective regulation by the @GENE$ pathway.	false
23229509.T1.T10	Regulation of multiple @CHEM-GENE$ (AC) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function.	false
23229509.T1.T13	Regulation of multiple @CHEMICAL$ cyclases (@GENE$) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function.	false
23229509.T5.T10	Regulation of multiple @CHEMICAL$ (AC) provides unique inputs to mediate the synthesis of @GENE$, a ubiquitous second messenger that controls many aspects of cellular function.	CPR:9
23229509.T5.T13	Regulation of multiple adenylyl cyclases (@CHEMICAL$) provides unique inputs to mediate the synthesis of @GENE$, a ubiquitous second messenger that controls many aspects of cellular function.	CPR:9
23229509.T2.T8	On stimulation by @CHEMICAL$, the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular @GENE$ responses to specific stimuli.	false
23229509.T2.T9	On stimulation by G(s), the activities of @CHEMICAL$ can be further selectively modulated by other pathways to ensure precise control of intracellular @GENE$ responses to specific stimuli.	CPR:9
23229509.T3.T18	Although both enzymes could fully restore regulation of @CHEMICAL$ by @GENE$, activation of the G(13) pathway preferentially synergized with AC7.	false
23229509.T3.T19	Although both enzymes could fully restore regulation of @CHEMICAL$ by Gbg, activation of the @GENE$ pathway preferentially synergized with AC7.	false
23229509.T3.T20	Although both enzymes could fully restore regulation of @CHEMICAL$ by Gbg, activation of the G(13) pathway preferentially synergized with @GENE$.	false
23229509.T4.T21	Exchange of domains between the two isoforms indicates that the @CHEMICAL$ and the @GENE$-terminus of the C1a domain are important for directing selective regulation of AC7 by the G(13) pathway.	false
23229509.T4.T22	Exchange of domains between the two isoforms indicates that the C1b domain and the @CHEMICAL$-terminus of the @GENE$ are important for directing selective regulation of AC7 by the G(13) pathway.	false
23229509.T4.T23	Exchange of domains between the two isoforms indicates that the C1b domain and the @CHEMICAL$-terminus of the C1a domain are important for directing selective regulation of @GENE$ by the G(13) pathway.	false
23229509.T4.T24	Exchange of domains between the two isoforms indicates that the C1b domain and the @CHEMICAL$-terminus of the C1a domain are important for directing selective regulation of AC7 by the @GENE$ pathway.	false
23229510.T10.T22	An important effector of the ISR is @CHEMICAL$ (ATF4), a transcription factor that regulates genes involved in redox homeostasis and @GENE$ metabolism and transport.	false
23229510.T10.T23	An important effector of the ISR is activating transcription factor 4 (@CHEMICAL$), a transcription factor that regulates genes involved in redox homeostasis and @GENE$ metabolism and transport.	false
23229510.T11.T26	We identified one compound, @CHEMICAL$ (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of @GENE$ in transformed cells.	CPR:3
23229510.T12.T26	We identified one compound, E235 @CHEMICAL$, that activated the ISR and dose-dependently increased levels of @GENE$ in transformed cells.	CPR:3
23229510.T1.T27	A dose-dependent decrease in viability was observed in several mouse and human tumor cell lines, and knockdown of @CHEMICAL$ significantly increased the antiproliferative effects of @GENE$.	false
23229510.T3.T13	@CHEMICAL$-mediated induction of senescence was not dependent on @GENE$ or p53; however, p21 conferred protection against the growth inhibitory effects of E235.	false
23229510.T3.T14	@CHEMICAL$-mediated induction of senescence was not dependent on p21 or @GENE$; however, p21 conferred protection against the growth inhibitory effects of E235.	false
23229510.T3.T15	@CHEMICAL$-mediated induction of senescence was not dependent on p21 or p53; however, @GENE$ conferred protection against the growth inhibitory effects of E235.	false
23229510.T4.T13	E235-mediated induction of senescence was not dependent on @CHEMICAL$ or p53; however, p21 conferred protection against the growth inhibitory effects of @GENE$.	false
23229510.T4.T14	E235-mediated induction of senescence was not dependent on p21 or @CHEMICAL$; however, p21 conferred protection against the growth inhibitory effects of @GENE$.	false
23229510.T4.T15	E235-mediated induction of senescence was not dependent on p21 or p53; however, @CHEMICAL$ conferred protection against the growth inhibitory effects of @GENE$.	false
23229510.T6.T16	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-@GENE$, g-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.	CPR:3
23229510.T6.T17	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, @GENE$, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.	CPR:3
23229510.T6.T18	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and @GENE$ (Chk2), although E235 does not appear to cause physical DNA damage.	CPR:3
23229510.T6.T19	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and phosphorylated checkpoint kinase 2 (@GENE$), although E235 does not appear to cause physical DNA damage.	CPR:3
23229510.T7.T16	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-@GENE$, g-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.	false
23229510.T7.T17	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-phosphorylated p53, @GENE$, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.	false
23229510.T7.T18	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-phosphorylated p53, g-H2AX, and @GENE$ (Chk2), although E235 does not appear to cause physical DNA damage.	false
23229510.T7.T19	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-phosphorylated p53, g-H2AX, and phosphorylated checkpoint kinase 2 (@GENE$), although E235 does not appear to cause physical DNA damage.	false
23229510.T8.T16	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-@CHEMICAL$, g-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although @GENE$ does not appear to cause physical DNA damage.	false
23229510.T8.T17	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, @CHEMICAL$, and phosphorylated checkpoint kinase 2 (Chk2), although @GENE$ does not appear to cause physical DNA damage.	false
23229510.T8.T18	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and @CHEMICAL$ (Chk2), although @GENE$ does not appear to cause physical DNA damage.	false
23229510.T8.T19	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and phosphorylated checkpoint kinase 2 (@CHEMICAL$), although @GENE$ does not appear to cause physical DNA damage.	false
23231492.T1.T10	"We aim to ""tilt"" the stability of the @CHEMICAL$ structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the @GENE$ sequence of the H1, H2, and proximal residues."	false
23231492.T1.T11	"We aim to ""tilt"" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the @CHEMICAL$ sequence of the @GENE$, H2, and proximal residues."	false
23231492.T1.T12	"We aim to ""tilt"" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the @CHEMICAL$ sequence of the H1, @GENE$, and proximal residues."	false
23240892.T15.T17	Cell culture studies demonstrated that @CHEMICAL$ is capable of delivering anti-TNF (tumor necrosis factor)-a siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of @GENE$.	CPR:4
23240892.T15.T21	Cell culture studies demonstrated that @CHEMICAL$ is capable of delivering anti-@GENE$ (tumor necrosis factor)-a siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-a.	false
23240892.T15.T22	Cell culture studies demonstrated that @CHEMICAL$ is capable of delivering anti-TNF @GENE$ siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-a.	false
23240892.T4.T19	@CHEMICAL$/anti-TNF-a siRNA nanocomplexes significantly reduced the @GENE$ (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	CPR:4
23240892.T4.T20	@CHEMICAL$/anti-TNF-a siRNA nanocomplexes significantly reduced the ALT (@GENE$) and the hepatic cellular damages in APAP-intoxicated mice.	CPR:4
23240892.T4.T18	@CHEMICAL$/anti-@GENE$ siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	false
23240892.T5.T19	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the @CHEMICAL$ (@GENE$ transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	false
23240892.T5.T20	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the ALT (@CHEM-GENE$) and the hepatic cellular damages in APAP-intoxicated mice.	false
23240892.T5.T18	PKAA/anti-@CHEMICAL$ siRNA nanocomplexes significantly reduced the ALT (@GENE$ transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	false
23240892.T6.T19	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the @CHEMICAL$ (alanine transaminase) and the hepatic cellular damages in @GENE$-intoxicated mice.	false
23240892.T6.T20	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the ALT (@CHEMICAL$) and the hepatic cellular damages in @GENE$-intoxicated mice.	false
23240892.T6.T18	PKAA/anti-@CHEMICAL$ siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in @GENE$-intoxicated mice.	false
23246481.T14.T25	@CHEMICAL$ inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of @GENE$.	CPR:4
23246481.T15.T25	Wogonin inhibits @CHEMICAL$-induced vascular permeability through suppressing the phosphorylation of @GENE$.	CPR:3
23246481.T6.T16	We found that @CHEMICAL$ can suppress the H2O2-stimulated @GENE$ remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	CPR:4
23246481.T6.T17	We found that @CHEMICAL$ can suppress the H2O2-stimulated actin remodeling and @GENE$ uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	CPR:4
23246481.T7.T16	We found that wogonin can suppress the @CHEMICAL$-stimulated @GENE$ remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	CPR:3
23246481.T7.T17	We found that wogonin can suppress the @CHEMICAL$-stimulated actin remodeling and @GENE$ uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	CPR:3
23246481.T8.T18	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of @GENE$ (cav-1) associating with the suppression of stabilization of VE-cadherin and b-catenin.	CPR:4
23246481.T8.T19	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of caveolin-1 (@GENE$) associating with the suppression of stabilization of VE-cadherin and b-catenin.	CPR:4
23246481.T8.T20	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of @GENE$ and b-catenin.	CPR:4
23246481.T8.T21	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and @GENE$.	CPR:4
23246481.T9.T18	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of @GENE$ (cav-1) associating with the suppression of stabilization of VE-cadherin and b-catenin.	CPR:3
23246481.T9.T19	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of caveolin-1 (@GENE$) associating with the suppression of stabilization of VE-cadherin and b-catenin.	CPR:3
23246481.T9.T20	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of @GENE$ and b-catenin.	false
23246481.T9.T21	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and @GENE$.	false
23246481.T10.T22	Moreover, @CHEMICAL$ repressed anisomycin-induced phosphorylation of @GENE$, cav-1 and vascular permeability.	CPR:4
23246481.T10.T23	Moreover, @CHEMICAL$ repressed anisomycin-induced phosphorylation of p38, @GENE$ and vascular permeability.	CPR:4
23246481.T11.T22	Moreover, wogonin repressed @CHEMICAL$-induced phosphorylation of @GENE$, cav-1 and vascular permeability.	CPR:3
23246481.T11.T23	Moreover, wogonin repressed @CHEMICAL$-induced phosphorylation of p38, @GENE$ and vascular permeability.	CPR:3
23246481.T12.T24	These results suggested that @CHEMICAL$ could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of @GENE$, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.	CPR:4
23246481.T13.T24	These results suggested that wogonin could inhibit @CHEMICAL$-induced vascular permeability by downregulating the phosphorylation of @GENE$, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.	CPR:3
23253441.T3.T6	The discovery of fused @CHEMICAL$ as @GENE$ modulators for treatment of Alzheimer's disease.	false
23253441.T1.T4	In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the @CHEMICAL$ activity, conformational modifications of the core structure resulted in the identification of fused @GENE$ such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	false
23253441.T1.T5	In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused @CHEMICAL$ such as 7i which had an improved @GENE$ inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	CPR:4
23253441.T2.T4	In an attempt to further improve overall profiles of the @CHEMICAL$ series of GSMs, in particular the @GENE$ activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	false
23253441.T2.T5	In an attempt to further improve overall profiles of the @CHEMICAL$ series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved @GENE$ inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	false
23254198.T14.T22	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of @CHEMICAL$, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.	CPR:4
23254198.T14.T23	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, @CHEMICAL$, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.	CPR:4
23254198.T14.T24	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and @CHEMICAL$ and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.	CPR:4
23254198.T14.T25	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors @CHEMICAL$, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.	CPR:4
23254198.T14.T26	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, @CHEMICAL$, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.	CPR:4
23254198.T14.T27	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and @CHEMICAL$, These effects could be completely blocked by @GENE$.	CPR:4
23254198.T1.T17	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of @CHEMICAL$, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @GENE$ receptor and amphiregulin expression were weaker than E(2).	false
23254198.T1.T18	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, @CHEMICAL$, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @GENE$ receptor and amphiregulin expression were weaker than E(2).	false
23254198.T1.T19	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and @CHEMICAL$, whereas the stimulatory effects of CE on @GENE$ receptor and amphiregulin expression were weaker than E(2).	false
23254198.T1.T20	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @CHEM-GENE$ and amphiregulin expression were weaker than E(2).	false
23254198.T1.T21	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @CHEMICAL$ receptor and @GENE$ expression were weaker than E(2).	false
23261524.T2.T21	We used @CHEMICAL$, a well-known disruptor of @GENE$-Mdm2 interaction, to validate the specificity of the assay.	CPR:4
23261524.T2.T22	We used @CHEMICAL$, a well-known disruptor of p53-@GENE$ interaction, to validate the specificity of the assay.	CPR:4
23261524.T1.T5	The reduction of BiFC signal mediated by @CHEMICAL$ was correlated with an increase in Puma transactivation, @GENE$ cleavage, and cell death.	CPR:3
23261524.T1.T4	The reduction of BiFC signal mediated by @CHEMICAL$ was correlated with an increase in @GENE$ transactivation, PARP cleavage, and cell death.	CPR:3
23261589.T15.T32	@CHEMICAL$ induced apoptotic changes in neural stem cells: amelioration by @GENE$ support.	false
23261589.T14.T31	In this study we explored the toxicity of @CHEMICAL$ toward NSCs focusing on apoptosis and status of @GENE$ survival signaling.	false
23261589.T5.T19	@CHEMICAL$ toxicity coincided with reduced @GENE$ level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T5.T20	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: @GENE$, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T5.T23	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and @GENE$ GDNF, BDNF suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T5.T26	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed @GENE$/Akt signaling.	CPR:4
23261589.T5.T27	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/@GENE$ signaling.	CPR:4
23261589.T5.T21	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, @GENE$, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T5.T22	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, @GENE$ and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T5.T24	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins @GENE$, BDNF suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T5.T25	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, @GENE$ suggesting repressed PI3K/Akt signaling.	CPR:4
23261589.T7.T28	Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against @CHEMICAL$ through activating @GENE$/Akt pathway.	false
23261589.T7.T29	Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against @CHEMICAL$ through activating PI3K/@GENE$ pathway.	false
23261589.T8.T30	This was confirmed on adding @CHEMICAL$ the @GENE$ inhibitor which abolished the protection.	CPR:4
23261676.T15.T31	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @GENE$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	CPR:4
23261676.T15.T33	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	CPR:4
23261676.T15.T34	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	CPR:4
23261676.T15.T32	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	CPR:4
23261676.T16.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial @GENE$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T16.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T16.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T16.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T17.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEM-GENE$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T17.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$ peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T17.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$ peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T17.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$ peroxidase, @GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T18.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, @GENE$ reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T18.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$ reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T18.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$ reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T18.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEM-GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T19.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, @GENE$, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T19.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, @CHEMICAL$, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T19.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, @CHEMICAL$, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T19.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, @GENE$, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T20.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, @GENE$, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T20.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, @CHEMICAL$, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T20.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, @CHEMICAL$, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T20.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, @GENE$, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T21.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, @GENE$, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T21.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, @CHEMICAL$, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T21.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, @CHEMICAL$, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T21.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, @GENE$, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T22.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, @GENE$, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T22.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, @CHEMICAL$, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T22.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, @CHEMICAL$, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T22.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, @GENE$, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T23.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, @GENE$ and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T23.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, @CHEMICAL$ and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T23.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, @CHEMICAL$ and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T23.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, malate, @GENE$ and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T24.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T24.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @CHEM-GENE$, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T24.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @CHEMICAL$-dehydrogenases, @GENE$ and adenosine triphosphate.	false
23261676.T24.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	false
23261676.T25.T31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and @GENE$.	false
23261676.T25.T33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @CHEMICAL$, cytochrome-C-oxidase and @GENE$.	false
23261676.T25.T34	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @CHEMICAL$ and @GENE$.	false
23261676.T25.T32	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and @GENE$.	false
23261757.T6.T11	Increased urinary excretion of @CHEMICAL$, hemopexin, transferrin and VDBP correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.	CPR:3
23261757.T6.T12	Increased urinary excretion of albumin, @CHEMICAL$, transferrin and VDBP correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.	CPR:3
23261757.T6.T13	Increased urinary excretion of albumin, hemopexin, @CHEMICAL$ and VDBP correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.	CPR:3
23261757.T6.T14	Increased urinary excretion of albumin, hemopexin, transferrin and @CHEMICAL$ correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.	CPR:3
23261757.T1.T7	Four proteins, namely @CHEMICAL$, hemopexin, transferrin and @GENE$ binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	false
23261757.T1.T10	Four proteins, namely albumin, hemopexin, transferrin and @CHEM-GENE$ were increased in the urine in temporal association with the appearance of chronic predisposition.	false
23261757.T1.T8	Four proteins, namely albumin, @CHEMICAL$, transferrin and @GENE$ binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	false
23261757.T1.T9	Four proteins, namely albumin, hemopexin, @CHEMICAL$ and @GENE$ binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	false
23265459.T10.T22	They also increased catalase (CAT), @CHEMICAL$ (SOD) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T10.T23	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T10.T24	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEM-GENE$ (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T10.T25	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ peroxidase (@GENE$) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T10.T20	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T10.T21	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T11.T22	They also increased catalase (CAT), @CHEMICAL$ (SOD) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T11.T23	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T11.T24	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T11.T25	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@CHEM-GENE$) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T11.T20	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T11.T21	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T12.T22	They also increased catalase (CAT), @CHEMICAL$ (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.	false
23265459.T12.T23	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.	false
23265459.T12.T24	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.	false
23265459.T12.T25	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@CHEMICAL$) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.	false
23265459.T12.T20	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.	false
23265459.T12.T21	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.	false
23265459.T13.T22	They also increased catalase (CAT), @CHEMICAL$ (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.	false
23265459.T13.T23	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.	false
23265459.T13.T24	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.	false
23265459.T13.T25	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@CHEMICAL$) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.	false
23265459.T13.T20	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.	false
23265459.T13.T21	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.	false
23265459.T9.T22	They also increased catalase (CAT), @CHEM-GENE$ (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T9.T23	They also increased catalase (CAT), @CHEMICAL$ dismutase (@GENE$) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T9.T24	They also increased catalase (CAT), @CHEMICAL$ dismutase (SOD) and @GENE$ (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T9.T25	They also increased catalase (CAT), @CHEMICAL$ dismutase (SOD) and glutathione peroxidase (@GENE$) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T9.T20	They also increased @CHEMICAL$ (CAT), @GENE$ dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265459.T9.T21	They also increased catalase (@CHEMICAL$), @GENE$ dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	false
23265905.T2.T9	Design and synthesis of novel @CHEMICAL$ derivatives as @GENE$ inhibitors.	CPR:4
23266270.T2.T19	@CHEMICAL$ induced dose-dependent reduction of the protein levels of @GENE$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	CPR:4
23266270.T2.T20	@CHEMICAL$ induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@GENE$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	CPR:4
23266270.T2.T21	@CHEMICAL$ induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @GENE$ (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	CPR:4
23266270.T2.T22	@CHEMICAL$ induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@GENE$) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	CPR:4
23266270.T3.T19	DPEP induced dose-dependent reduction of the protein levels of @CHEM-GENE$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	false
23266270.T3.T20	DPEP induced dose-dependent reduction of the protein levels of inducible @CHEMICAL$ synthase (@GENE$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	false
23266270.T3.T21	DPEP induced dose-dependent reduction of the protein levels of inducible @CHEMICAL$ synthase (iNOS) and @GENE$ (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	false
23266270.T3.T22	DPEP induced dose-dependent reduction of the protein levels of inducible @CHEMICAL$ synthase (iNOS) and cyclooxygenase-2 (@GENE$) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	false
23266270.T4.T19	DPEP induced dose-dependent reduction of the protein levels of @CHEMICAL$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).	false
23266270.T4.T20	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@CHEMICAL$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).	false
23266270.T4.T21	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @CHEMICAL$ (COX-2) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).	false
23266270.T4.T22	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@CHEMICAL$) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).	false
23266270.T5.T19	DPEP induced dose-dependent reduction of the protein levels of @CHEMICAL$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).	false
23266270.T5.T20	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@CHEMICAL$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).	false
23266270.T5.T21	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @CHEMICAL$ (COX-2) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).	false
23266270.T5.T22	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@CHEMICAL$) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).	false
23266270.T6.T19	DPEP induced dose-dependent reduction of the protein levels of @CHEMICAL$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).	false
23266270.T6.T20	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@CHEMICAL$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).	false
23266270.T6.T21	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @CHEMICAL$ (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).	false
23266270.T6.T22	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@CHEMICAL$) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).	false
23266270.T7.T23	Additionally, @CHEMICAL$ suppressed the production of inflammatory @GENE$, including tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, and IL-6.	CPR:4
23266270.T7.T24	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including @GENE$ (TNF-a), interleukin (IL)-1b, and IL-6.	CPR:4
23266270.T7.T25	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including tumor necrosis factor-a (@GENE$), interleukin (IL)-1b, and IL-6.	CPR:4
23266270.T7.T26	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including tumor necrosis factor-a (TNF-a), @GENE$, and IL-6.	CPR:4
23266270.T7.T27	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, and @GENE$.	CPR:4
23266270.T10.T28	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of @GENE$ (NF-kB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T10.T29	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of nuclear factor-kB (@GENE$) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T10.T30	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the @GENE$ (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T10.T31	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the mitogen-activated protein kinase (@GENE$) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T11.T28	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of @GENE$ (NF-kB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T11.T29	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of nuclear factor-kB (@GENE$) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T11.T30	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of nuclear factor-kB (NF-kB) activation within the @GENE$ (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T11.T31	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of nuclear factor-kB (NF-kB) activation within the mitogen-activated protein kinase (@GENE$) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T9.T28	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of @GENE$ (NF-kB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T9.T29	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of nuclear factor-kB (@GENE$) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T9.T30	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the @GENE$ (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T9.T31	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the mitogen-activated protein kinase (@GENE$) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	false
23266270.T12.T32	@CHEMICAL$ inhibited LPS-induced phosphorylation of @GENE$, JNK, and p38.	CPR:4
23266270.T12.T33	@CHEMICAL$ inhibited LPS-induced phosphorylation of ERK, @GENE$, and p38.	CPR:4
23266270.T12.T34	@CHEMICAL$ inhibited LPS-induced phosphorylation of ERK, JNK, and @GENE$.	CPR:4
23266270.T13.T36	Furthermore, @CHEMICAL$ inhibited the LPS-induced phosphorylation of inhibitor kB (IkB)-a and @GENE$ p50.	CPR:4
23266270.T13.T16	Furthermore, @CHEMICAL$ inhibited the LPS-induced phosphorylation of inhibitor kB (IkB)-a and NF-kB @GENE$.	CPR:4
23266270.T13.T35	Furthermore, @CHEMICAL$ inhibited the LPS-induced phosphorylation of @GENE$ and NF-kB p50.	CPR:4
23266270.T1.T17	Taken together, the results of this study demonstrate that @CHEMICAL$ inhibits LPS-stimulated inflammation by blocking the @GENE$ and MAPK pathways in macrophages.	CPR:4
23266270.T1.T18	Taken together, the results of this study demonstrate that @CHEMICAL$ inhibits LPS-stimulated inflammation by blocking the NF-kB and @GENE$ pathways in macrophages.	CPR:4
23267011.T22.T32	@CHEMICAL$ interactions modulate mutagenic bypass of a templating @GENE$ lesion.	false
23267011.T14.T29	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite @CHEMICAL$. To determine how pol b discriminates between anti- and syn-8-oxoG, we introduced a point mutation (@GENE$) to alter insertion specificity.	false
23267011.T14.T27	During base excision repair of this mispair, @CHEMICAL$ is confronted with gap filling opposite @GENE$. To determine how pol b discriminates between anti- and syn-8-oxoG, we introduced a point mutation (R283K) to alter insertion specificity.	false
23267011.T14.T28	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite @CHEMICAL$. To determine how @GENE$ discriminates between anti- and syn-8-oxoG, we introduced a point mutation (R283K) to alter insertion specificity.	false
23267011.T16.T29	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite 8-oxoG. To determine how pol b discriminates between @CHEMICAL$, we introduced a point mutation (@GENE$) to alter insertion specificity.	false
23267011.T16.T27	During base excision repair of this mispair, @CHEMICAL$ is confronted with gap filling opposite 8-oxoG. To determine how pol b discriminates between @GENE$, we introduced a point mutation (R283K) to alter insertion specificity.	false
23267011.T16.T28	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite 8-oxoG. To determine how @CHEMICAL$ discriminates between @GENE$, we introduced a point mutation (R283K) to alter insertion specificity.	false
23267011.T17.T30	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite @CHEMICAL$. Structural studies with @GENE$ pol b show that the binary DNA complex has 8-oxoG in equilibrium between anti- and syn-forms.	false
23267011.T17.T31	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite @CHEMICAL$. Structural studies with R283K @GENE$ show that the binary DNA complex has 8-oxoG in equilibrium between anti- and syn-forms.	false
23267011.T18.T30	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite 8-oxoG. Structural studies with @CHEMICAL$ pol b show that the binary DNA complex has @GENE$ in equilibrium between anti- and syn-forms.	false
23267011.T18.T31	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite 8-oxoG. Structural studies with R283K @CHEMICAL$ show that the binary DNA complex has @GENE$ in equilibrium between anti- and syn-forms.	false
23267011.T2.T24	In contrast to wild-type pol b, the ternary complex of the @CHEMICAL$ mutant with an incoming @GENE$-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.	false
23267011.T2.T23	In contrast to wild-type @CHEMICAL$, the ternary complex of the R283K mutant with an incoming @GENE$-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.	false
23267011.T3.T24	In contrast to wild-type pol b, the ternary complex of the @CHEMICAL$ mutant with an incoming dATP-analogue and templating @GENE$ resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.	false
23267011.T3.T23	In contrast to wild-type @CHEMICAL$, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating @GENE$ resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.	false
23267011.T4.T24	In contrast to wild-type pol b, the ternary complex of the @CHEMICAL$ mutant with an incoming dATP-analogue and templating 8-oxoG resembles a G-A mismatched structure with @GENE$ adopting an anti-conformation.	false
23267011.T4.T23	In contrast to wild-type @CHEMICAL$, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating 8-oxoG resembles a G-A mismatched structure with @GENE$ adopting an anti-conformation.	false
23267011.T5.T25	These results demonstrate that the incoming @CHEMICAL$ is unable to induce a syn-8-oxoG conformation without @GENE$ DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	false
23267011.T5.T26	These results demonstrate that the incoming @CHEMICAL$ is unable to induce a syn-8-oxoG conformation without minor groove @GENE$ interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	false
23267011.T6.T25	These results demonstrate that the incoming nucleotide is unable to induce a @CHEMICAL$ conformation without @GENE$ DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	false
23267011.T6.T26	These results demonstrate that the incoming nucleotide is unable to induce a @CHEMICAL$ conformation without minor groove @GENE$ interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	false
23267011.T7.T25	These results demonstrate that the incoming nucleotide is unable to induce a syn-8-oxoG conformation without @CHEMICAL$ DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of @GENE$ while modulating fidelity.	false
23267011.T7.T26	These results demonstrate that the incoming nucleotide is unable to induce a syn-8-oxoG conformation without minor groove @CHEMICAL$ interactions that influence templating (anti-/syn-equilibrium) of @GENE$ while modulating fidelity.	false
23267840.T15.T28	@CHEM-GENE$ mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of curcumin.	false
23267840.T16.T28	@CHEMICAL$ mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of @GENE$.	false
23267840.T17.T28	@CHEMICAL$ mediated excitotoxicity in cerebral cortex of @GENE$ induced diabetic rat: ameliorating effects of curcumin.	false
23267840.T18.T28	@CHEM-GENE$ mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of curcumin.	false
23267840.T6.T21	Gene expression studies in diabetic rats showed a down regulation of @CHEM-GENE$ mRNA leading to accumulation of glutamate.	false
23267840.T7.T21	Gene expression studies in diabetic rats showed a down regulation of @CHEMICAL$ mRNA leading to accumulation of @GENE$.	false
23267840.T8.T22	Radioreceptor binding assays showed a significant increase in @CHEM-GENE$ density which was confirmed by immunohistochemical studies.	false
23267840.T9.T22	Radioreceptor binding assays showed a significant increase in @CHEM-GENE$ density which was confirmed by immunohistochemical studies.	false
23267840.T10.T23	Decreased @CHEM-GENE$ gene expression indicates enhanced oxidative stress in diabetic rats.	false
23267840.T11.T24	This leads to decreased expression of @CHEM-GENE$, which in turn reduces glutamate transport.	false
23267840.T12.T24	This leads to decreased expression of @CHEM-GENE$, which in turn reduces glutamate transport.	false
23267840.T13.T24	This leads to decreased expression of @CHEMICAL$, which in turn reduces @GENE$ transport.	CPR:9
23267840.T14.T19	@CHEMICAL$ and @GENE$ treatment reversed these altered parameters to near control.	false
23274086.T1.T9	Inactivation of @CHEMICAL$ in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of @GENE$ carbon into lipids, and biomass accumulation.	false
23274086.T2.T9	Inactivation of @CHEMICAL$ in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of glucose @GENE$ into lipids, and biomass accumulation.	false
23281812.T6.T20	@CHEMICAL$ type dual inhibitors of @GENE$/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.	CPR:4
23281812.T6.T21	@CHEMICAL$ type dual inhibitors of aromatase/@GENE$ as a novel strategy for breast cancer patients with elevated cardiovascular risks.	CPR:4
23281812.T7.T20	Tetrahydropyrroloquinolinone type dual inhibitors of @CHEMICAL$/@GENE$ synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.	false
23281812.T7.T21	Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/@CHEM-GENE$ as a novel strategy for breast cancer patients with elevated cardiovascular risks.	false
23281812.T3.T14	Dual inhibitors of @CHEMICAL$ (CYP19) and @GENE$ synthase (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	false
23281812.T3.T15	Dual inhibitors of aromatase (@CHEMICAL$) and @GENE$ synthase (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	false
23281812.T3.T16	Dual inhibitors of aromatase (CYP19) and @CHEM-GENE$ (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	false
23281812.T3.T17	Dual inhibitors of aromatase (CYP19) and @CHEMICAL$ synthase (@GENE$) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	false
23281812.T4.T18	By combining decisive structural features of @CHEMICAL$ and CYP19 inhibitors into a common template, a series of @GENE$ were designed and synthesized.	false
23281812.T4.T19	By combining decisive structural features of CYP11B2 and @CHEMICAL$ inhibitors into a common template, a series of @GENE$ were designed and synthesized.	false
23282066.T12.T16	Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by @CHEMICAL$ enzymes via in vivo and in vitro oxidation of @GENE$ and triazolam.	false
23282066.T13.T16	Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by @CHEMICAL$ enzymes via in vivo and in vitro oxidation of midazolam and @GENE$.	false
23282066.T1.T14	Furthermore, @CHEMICAL$ caused mechanism-based inactivation of @GENE$-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.	CPR:4
23282066.T2.T14	Furthermore, MDZ caused mechanism-based inactivation of @CHEMICAL$-dependent @GENE$ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.	CPR:9
23294326.T2.T10	We previously found that the @CHEMICAL$-enriched microdomains (ganglioside clusters) in presynaptic neuronal membranes play a key role in the initiation of the @GENE$ assembly process.	false
23294326.T3.T10	We previously found that the ganglioside-enriched microdomains (@CHEMICAL$ clusters) in presynaptic neuronal membranes play a key role in the initiation of the @GENE$ assembly process.	false
23294326.T4.T11	However, not all @CHEMICAL$ clusters accelerate @GENE$ assembly.	false
23294326.T5.T15	The Ab assembly was generated on a distinctive @CHEMICAL$, which was characterized as the Ab-sensitive @GENE$ nanocluster (ASIGN).	false
23294326.T5.T14	The @CHEMICAL$ assembly was generated on a distinctive GM1 domain, which was characterized as the Ab-sensitive @GENE$ nanocluster (ASIGN).	false
23294326.T5.T16	The Ab assembly was generated on a distinctive GM1 domain, which was characterized as the @CHEMICAL$-sensitive @GENE$ nanocluster (ASIGN).	false
23294326.T1.T6	These results suggest that @CHEMICAL$-bound @GENE$ (GAb), which acts as an endogenous seed for Ab fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	false
23294326.T1.T7	These results suggest that @CHEMICAL$-bound Ab (G@GENE$), which acts as an endogenous seed for Ab fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	false
23294326.T1.T8	These results suggest that @CHEMICAL$-bound Ab (GAb), which acts as an endogenous seed for @GENE$ fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	false
23295740.T15.T31	@CHEMICAL$ represses @GENE$ microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.	CPR:4
23295740.T15.T30	@CHEMICAL$ represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating @GENE$ in endometrial carcinoma cell lines.	CPR:3
23295740.T10.T22	Although tamoxifen (TAM), a selective @CHEM-GENE$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.	false
23295740.T14.T22	Although @CHEMICAL$ (TAM), a selective @GENE$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.	false
23295740.T5.T22	Although tamoxifen (TAM), a selective @CHEMICAL$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its @GENE$-like effect increases the risk of endometrial cancer.	false
23295740.T7.T22	Although tamoxifen (@CHEMICAL$), a selective @GENE$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.	false
23295740.T9.T23	In this report, we explored the role of microRNAs (miRNAs) in @CHEMICAL$-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found @GENE$ is involved in this process via the regulation of c-Myc.	false
23295740.T9.T24	In this report, we explored the role of microRNAs (miRNAs) in @CHEMICAL$-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found miR-200 is involved in this process via the regulation of @GENE$.	false
23295740.T12.T25	@CHEMICAL$, a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to @GENE$ treatment.	CPR:4
23295740.T13.T16	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas @GENE$ decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T13.T26	Consistent with @CHEM-GENE$, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T13.T27	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of @GENE$ in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T13.T28	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as @GENE$ and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T13.T29	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and @GENE$ increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T1.T16	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas @CHEMICAL$ decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	CPR:4
23295740.T1.T26	Consistent with @CHEMICAL$, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T1.T27	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of @CHEMICAL$ in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	false
23295740.T1.T28	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as @CHEMICAL$ and N-cadherin increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	CPR:3
23295740.T1.T29	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and @CHEMICAL$ increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	CPR:3
23295740.T2.T16	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas @CHEMICAL$ decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.	false
23295740.T2.T26	Consistent with @CHEMICAL$, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.	false
23295740.T2.T27	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of @CHEMICAL$ in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.	false
23295740.T2.T28	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as @CHEMICAL$ and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.	false
23295740.T2.T29	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and @CHEMICAL$ increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.	false
23295740.T3.T18	In addition, we showed that c-Myc directly binds to and represses the promoter of @CHEMICAL$ miRNAs, and its up-regulation in @GENE$-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT.	false
23295740.T3.T19	In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in @CHEMICAL$-treated endometrial cancer cells leads to the down-regulation of @GENE$ and eventually to EMT.	CPR:4
23295740.T3.T17	In addition, we showed that @CHEMICAL$ directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in @GENE$-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT.	false
23295740.T4.T20	Collectively, our data suggest that @CHEMICAL$ can repress the @GENE$ family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.	CPR:4
23295740.T4.T21	Collectively, our data suggest that @CHEMICAL$ can repress the miR-200 family and induce EMT via the up-regulation of @GENE$ in endometrial cancer cells.	CPR:3
23297412.T7.T25	@CHEMICAL$ improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of @GENE$ protein.	false
23297412.T7.T26	@CHEMICAL$ improves cardiomyopathy in @GENE$-deficient mice through SIRT1 protein-mediated modulation of p300 protein.	false
23297412.T7.T27	@CHEMICAL$ improves cardiomyopathy in dystrophin-deficient mice through @GENE$ protein-mediated modulation of p300 protein.	false
23297412.T1.T10	Here, we show that oral administration of @CHEMICAL$, which leads to activation of an @GENE$, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.	CPR:3
23297412.T1.T11	Here, we show that oral administration of @CHEMICAL$, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in @GENE$-deficient mdx mice.	false
23297412.T2.T10	Here, we show that oral administration of resveratrol, which leads to activation of an @CHEM-GENE$, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.	false
23297412.T2.T11	Here, we show that oral administration of resveratrol, which leads to activation of an @CHEMICAL$-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in @GENE$-deficient mdx mice.	false
23297412.T3.T12	The pro-hypertrophic co-activator @CHEMICAL$ protein but not p300 mRNA was up-regulated in the mdx heart, and @GENE$ administration down-regulated the p300 protein level.	false
23297412.T3.T13	The pro-hypertrophic co-activator p300 protein but not @CHEMICAL$ mRNA was up-regulated in the mdx heart, and @GENE$ administration down-regulated the p300 protein level.	false
23297412.T3.T14	The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and @CHEMICAL$ administration down-regulated the @GENE$ protein level.	CPR:4
23297412.T4.T15	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist @CHEMICAL$ was inhibited by the overexpression of @GENE$ as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels.	false
23297412.T4.T16	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist @CHEMICAL$ was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated @GENE$ protein levels but not p300 mRNA levels.	false
23297412.T4.T17	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist @CHEMICAL$ was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated p300 protein levels but not @GENE$ mRNA levels.	false
23297412.T5.T15	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist phenylephrine was inhibited by the overexpression of @CHEMICAL$ as well as @GENE$, both of which down-regulated p300 protein levels but not p300 mRNA levels.	false
23297412.T5.T16	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as @CHEMICAL$, both of which down-regulated @GENE$ protein levels but not p300 mRNA levels.	CPR:4
23297412.T5.T17	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as @CHEMICAL$, both of which down-regulated p300 protein levels but not @GENE$ mRNA levels.	false
23297412.T6.T23	We found that SIRT1 induced p300 down-regulation via the @CHEMICAL$-proteasome pathway by deacetylation of @GENE$ residues for ubiquitination.	false
23297412.T6.T24	We found that SIRT1 induced p300 down-regulation via the ubiquitin-@CHEMICAL$ pathway by deacetylation of @GENE$ residues for ubiquitination.	false
23297412.T6.T21	We found that @CHEMICAL$ induced p300 down-regulation via the ubiquitin-proteasome pathway by deacetylation of @GENE$ residues for ubiquitination.	false
23297412.T6.T22	We found that SIRT1 induced @CHEMICAL$ down-regulation via the ubiquitin-proteasome pathway by deacetylation of @GENE$ residues for ubiquitination.	false
23298577.T3.T24	The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards sialoadhesin and @CHEM-GENE$.	false
23298577.T3.T23	The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards @CHEMICAL$ and @GENE$ receptors.	false
23299080.T1.T8	The @CHEMICAL$ constitutive @GENE$ receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T1.T12	The nuclear receptors constitutive @CHEMICAL$ receptor (@GENE$), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T1.T13	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), @GENE$ (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T1.T18	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), pregnane X receptor (@GENE$) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T1.T19	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), pregnane X receptor (PXR) and @GENE$ (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T1.T4	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (@GENE$) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T1.T5	The nuclear receptors @CHEM-GENE$ (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T8	The @CHEMICAL$ constitutive androstane receptor (CAR), @GENE$ X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T12	The nuclear receptors constitutive androstane receptor (@CHEMICAL$), @GENE$ X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T13	The nuclear receptors constitutive androstane receptor (CAR), @CHEM-GENE$ (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T18	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ X receptor (@GENE$) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T19	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ X receptor (PXR) and @GENE$ (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T4	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ X receptor (PXR) and vitamin D receptor (@GENE$) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T2.T5	The nuclear receptors @CHEMICAL$ (CAR), @GENE$ X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T8	The @CHEMICAL$ constitutive androstane receptor (CAR), pregnane X receptor (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T12	The nuclear receptors constitutive androstane receptor (@CHEMICAL$), pregnane X receptor (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T13	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T18	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (@CHEMICAL$) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T19	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and @CHEM-GENE$ (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T4	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and @CHEMICAL$ receptor (@GENE$) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23299080.T3.T5	The nuclear receptors @CHEMICAL$ (CAR), pregnane X receptor (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	false
23305921.T23.T28	Synthesis and dual biological effects of @CHEMICAL$/prolyl hydroxamic acid derivatives as @GENE$ inhibitor and antioxidant.	CPR:4
23305921.T24.T28	Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/@CHEMICAL$ derivatives as @GENE$ inhibitor and antioxidant.	CPR:4
23305921.T15.T25	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (@CHEMICAL$) acted as both a good antioxidant and @GENE$ inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.	CPR:4
23305921.T1.T25	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when @GENE$ was conjugated with proline or amino acids having aromatic ring like phenylalanine.	false
23305921.T2.T25	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when caffeic acid was conjugated with @GENE$ or amino acids having aromatic ring like phenylalanine.	false
23305921.T3.T25	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when caffeic acid was conjugated with proline or @GENE$ having aromatic ring like phenylalanine.	false
23305921.T4.T25	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like @GENE$.	false
23305921.T6.T25	We previously reported that @CHEMICAL$ (CA-Xaa-NHOH) acted as both a good antioxidant and @GENE$ inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.	CPR:4
23305921.T10.T26	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (@CHEMICAL$ and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.	false
23305921.T11.T26	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and @CHEMICAL$) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.	false
23305921.T5.T26	Here, various @CHEMICAL$ (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.	false
23305921.T7.T26	Here, various hydroxycinnamic acid (@CHEMICAL$) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.	false
23305921.T8.T26	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with @CHEMICAL$ and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.	false
23305921.T9.T26	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and @CHEMICAL$ (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.	false
23305921.T21.T27	In addition, derivatives of @CHEMICAL$ and sinapic acid efficiently inhibited @GENE$ activity and reduced melanin content in melanocytes Mel-Ab cell.	CPR:4
23305921.T22.T27	In addition, derivatives of caffeic acid and @CHEMICAL$ efficiently inhibited @GENE$ activity and reduced melanin content in melanocytes Mel-Ab cell.	CPR:4
23307549.T1.T13	@CHEMICAL$ is a small-molecule inhibitor of @GENE$ and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	CPR:4
23307549.T1.T14	@CHEMICAL$ is a small-molecule inhibitor of JAK1 and @GENE$ and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	CPR:4
23312278.T1.T3	Stenesen and colleagues (2012) activate @CHEMICAL$ both directly and indirectly by altering @GENE$ biosynthesis to slow aging in Drosophila, highlighting AMPK as a conserved life span modulator that links energy sensing to longevity.	false
23312278.T1.T4	Stenesen and colleagues (2012) activate AMPK both directly and indirectly by altering @CHEMICAL$ biosynthesis to slow aging in Drosophila, highlighting @GENE$ as a conserved life span modulator that links energy sensing to longevity.	false
23318731.T12.T25	Ex vivo samples of human oral mucosa were exposed to @CHEMICAL$ or BaP, and immunohistochemical staining was performed to evaluate active @GENE$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).	false
23318731.T13.T25	Ex vivo samples of human oral mucosa were exposed to Pb or @CHEMICAL$, and immunohistochemical staining was performed to evaluate active @GENE$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).	false
23318731.T15.T25	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, @GENE$ (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).	false
23318731.T16.T25	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, 8-epi-prostaglandin F2 alpha (@GENE$), and 3-nitrotyrosine (3-NT).	false
23318731.T17.T25	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and @GENE$ (3-NT).	false
23318731.T18.T25	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (@GENE$).	false
23318731.T19.T26	@CHEMICAL$ and BaP treatments significantly increased active @GENE$ levels in a time-dependent manner.	CPR:3
23318731.T20.T26	Pb and @CHEMICAL$ treatments significantly increased active @GENE$ levels in a time-dependent manner.	CPR:3
23318833.T10.T26	TAA increased the number and area of @CHEM-GENE$ (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	false
23318833.T10.T27	TAA increased the number and area of glutathione @CHEMICAL$-transferase placental form (@GENE$)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	false
23318833.T8.T26	@CHEMICAL$ increased the number and area of @GENE$ (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	CPR:3
23318833.T8.T27	@CHEMICAL$ increased the number and area of glutathione S-transferase placental form (@GENE$)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	CPR:3
23318833.T9.T26	TAA increased the number and area of @CHEM-GENE$ (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	false
23318833.T9.T27	TAA increased the number and area of @CHEMICAL$ S-transferase placental form (@GENE$)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	false
23318833.T12.T30	@CHEMICAL$ also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of @GENE$(+) lymphocytes.	CPR:4
23318833.T12.T28	@CHEMICAL$ also increased the numbers of ED2(+), @GENE$(+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.	CPR:4
23318833.T12.T29	@CHEMICAL$ also increased the numbers of ED2(+), cyclooxygenase-2(+), and @GENE$(+) liver cells, as well as the number of CD3(+) lymphocytes.	CPR:4
23318833.T13.T30	TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and @CHEMICAL$ oxygenase-1(+) liver cells, as well as the number of @GENE$(+) lymphocytes.	false
23318833.T13.T28	TAA also increased the numbers of ED2(+), @CHEMICAL$(+), and @GENE$ oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.	false
23318833.T13.T29	TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and @CHEM-GENE$(+) liver cells, as well as the number of CD3(+) lymphocytes.	false
23318833.T14.T19	EMIQ increased liver levels of @CHEMICAL$-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within @GENE$(+) foci.	false
23318833.T14.T17	EMIQ increased liver levels of @CHEMICAL$-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, @GENE$ (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	false
23318833.T14.T18	EMIQ increased liver levels of @CHEMICAL$-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (@GENE$)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	false
23318833.T1.T19	EMIQ increased liver levels of thiobarbituric acid-reactive substance and @CHEMICAL$, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within @GENE$(+) foci.	false
23318833.T1.T17	EMIQ increased liver levels of thiobarbituric acid-reactive substance and @CHEMICAL$, and TUNEL(+) apoptotic cells, @GENE$ (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	false
23318833.T1.T18	EMIQ increased liver levels of thiobarbituric acid-reactive substance and @CHEMICAL$, and TUNEL(+) apoptotic cells, death receptor 5 (@GENE$)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	false
23318833.T2.T19	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and @CHEMICAL$(+) cells within @GENE$(+) foci.	false
23318833.T2.T17	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, @CHEMICAL$ (DR5)(+) cells and @GENE$(+) cells within GST-P(+) foci.	false
23318833.T2.T18	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (@CHEMICAL$)(+) cells and @GENE$(+) cells within GST-P(+) foci.	false
23319419.T18.T41	@CHEMICAL$ interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG @GENE$.	CPR:3
23319419.T18.T39	@CHEMICAL$ interacts with a common binding site to elicit opposite effects on inactivation gating of @GENE$ and ERG potassium channels.	CPR:3
23319419.T18.T40	@CHEMICAL$ interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and @GENE$ potassium channels.	CPR:3
23319419.T19.T41	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG @CHEM-GENE$.	false
23319419.T19.T39	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of @CHEMICAL$ and ERG @GENE$ channels.	false
23319419.T19.T40	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and @CHEMICAL$ @GENE$ channels.	false
23319419.T15.T24	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEMICAL$-a-go-go-related gene (ERG) @GENE$.	false
23319419.T15.T23	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEMICAL$-a-go-go-related gene (@GENE$) K(+) channels.	false
23319419.T15.T38	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEM-GENE$ (ERG) K(+) channels.	false
23319419.T1.T24	Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (ERG) @CHEM-GENE$.	false
23319419.T1.T23	Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (@CHEMICAL$) @GENE$ channels.	false
23319419.T1.T38	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEMICAL$ (ERG) @GENE$ channels.	false
23319419.T7.T33	In contrast, inactivation of related @CHEMICAL$-a-go-go (EAG) @GENE$ is very slow and minimally reduces outward currents.	false
23319419.T7.T31	In contrast, inactivation of related @CHEM-GENE$ (EAG) K(+) channels is very slow and minimally reduces outward currents.	false
23319419.T7.T32	In contrast, inactivation of related @CHEMICAL$-a-go-go (@GENE$) K(+) channels is very slow and minimally reduces outward currents.	false
23319419.T8.T33	In contrast, inactivation of related ether-a-go-go (EAG) @CHEM-GENE$ is very slow and minimally reduces outward currents.	false
23319419.T8.T31	In contrast, inactivation of related @CHEMICAL$ (EAG) @GENE$ channels is very slow and minimally reduces outward currents.	false
23319419.T8.T32	In contrast, inactivation of related ether-a-go-go (@CHEMICAL$) @GENE$ channels is very slow and minimally reduces outward currents.	false
23319419.T12.T34	Although @CHEMICAL$ greatly attenuates @GENE$ inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.	CPR:3
23319419.T12.T35	Although @CHEMICAL$ greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of @GENE$ inactivation without altering its voltage dependence.	CPR:4
23319419.T13.T36	Here, we investigate whether the inverse functional response to @CHEMICAL$ in @GENE$ and ERG channels is related to differences in ICA binding site or to intrinsic mechanisms of inactivation.	false
23319419.T13.T37	Here, we investigate whether the inverse functional response to @CHEMICAL$ in EAG and @GENE$ channels is related to differences in ICA binding site or to intrinsic mechanisms of inactivation.	false
23319419.T14.T36	Here, we investigate whether the inverse functional response to ICA in @CHEMICAL$ and ERG channels is related to differences in @GENE$ binding site or to intrinsic mechanisms of inactivation.	false
23319419.T14.T37	Here, we investigate whether the inverse functional response to ICA in EAG and @CHEMICAL$ channels is related to differences in @GENE$ binding site or to intrinsic mechanisms of inactivation.	false
23319419.T17.T20	@CHEMICAL$ is a mixed agonist of mutant @GENE$ and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.	CPR:5
23319419.T17.T21	@CHEMICAL$ is a mixed agonist of mutant EAG and @GENE$/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.	CPR:5
23319419.T17.T22	@CHEMICAL$ is a mixed agonist of mutant EAG and EAG/@GENE$ chimera channels that inactivate by a combination of slow and fast mechanisms.	CPR:5
23319419.T2.T25	With the exception of three residues, the specific @CHEMICAL$ that form the putative binding pocket for ICA in @GENE$ are conserved in EAG.	false
23319419.T2.T26	With the exception of three residues, the specific @CHEMICAL$ that form the putative binding pocket for ICA in ERG are conserved in @GENE$.	false
23319419.T3.T25	With the exception of three residues, the specific amino acids that form the putative binding pocket for @CHEMICAL$ in @GENE$ are conserved in EAG.	false
23319419.T3.T26	With the exception of three residues, the specific amino acids that form the putative binding pocket for @CHEMICAL$ in ERG are conserved in @GENE$.	false
23319419.T4.T27	Mutations introduced into @CHEMICAL$ to replicate the @GENE$ binding site in ERG did not alter the functional response to ICA.	false
23319419.T4.T28	Mutations introduced into EAG to replicate the @CHEMICAL$ binding site in @GENE$ did not alter the functional response to ICA.	false
23319419.T5.T27	Mutations introduced into @CHEMICAL$ to replicate the ICA binding site in ERG did not alter the functional response to @GENE$.	false
23319419.T5.T28	Mutations introduced into EAG to replicate the ICA binding site in @CHEMICAL$ did not alter the functional response to @GENE$.	false
23319419.T6.T29	Together these findings suggest that @CHEMICAL$ binds to the same site in @GENE$ and ERG channels to elicit opposite functional effects.	false
23319419.T6.T30	Together these findings suggest that @CHEMICAL$ binds to the same site in EAG and @GENE$ channels to elicit opposite functional effects.	false
23319591.T1.T17	Methylation of @CHEMICAL$ on @GENE$ 4 by the lysine methyltransferase SET1 protein is needed for normal clock gene expression.	false
23319591.T1.T18	Methylation of histone H3 on @CHEMICAL$ 4 by the @GENE$ SET1 protein is needed for normal clock gene expression.	false
23319591.T1.T19	Methylation of histone H3 on @CHEMICAL$ 4 by the lysine methyltransferase @GENE$ protein is needed for normal clock gene expression.	false
23319591.T2.T17	Methylation of @CHEMICAL$ on lysine 4 by the @GENE$ methyltransferase SET1 protein is needed for normal clock gene expression.	false
23319591.T2.T18	Methylation of histone H3 on lysine 4 by the @CHEM-GENE$ SET1 protein is needed for normal clock gene expression.	false
23319591.T2.T19	Methylation of histone H3 on lysine 4 by the @CHEMICAL$ methyltransferase @GENE$ protein is needed for normal clock gene expression.	false
23321689.T5.T21	The a7 nicotinic @CHEMICAL$ receptor (@GENE$) is highly expressed in different regions of the brain and is associated with cognitive function as well as anxiety.	false
23321689.T5.T22	The @CHEM-GENE$ (nAChR) is highly expressed in different regions of the brain and is associated with cognitive function as well as anxiety.	false
23321689.T6.T20	Previously @CHEMICAL$, which activates both @GENE$, has been shown to have an anxiogenic effect in behavioral tests.	false
23321689.T1.T15	@CHEMICAL$ on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the @GENE$ antagonist WAY-100135.	false
23321689.T2.T15	PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the @CHEMICAL$ antagonist @GENE$.	CPR:6
23321689.T3.T16	However the @CHEMICAL$ antagonist @GENE$ was unable to reverse these anxiety-like effects seen with PNU-282987.	CPR:6
23321689.T4.T16	However the @CHEMICAL$ antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with @GENE$.	false
23322164.T22.T46	@CHEM-GENE$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T22.T47	@CHEMICAL$ palmitoyltransferase 2 and @GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T23.T46	@CHEMICAL$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.	CPR:9
23322164.T23.T47	Carnitine palmitoyltransferase 2 and @CHEMICAL$ are involved in the mitochondrial synthesis and export of @GENE$.	CPR:9
23322164.T24.T46	@CHEMICAL$ and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T24.T47	Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T25.T46	@CHEMICAL$ and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T25.T47	Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T12.T42	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T36	We used lentiviral shRNA to knock down the expression of @CHEM-GENE$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T37	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (@GENE$) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T38	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and @GENE$ (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T39	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@GENE$)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T40	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T41	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T12.T43	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.	false
23322164.T13.T42	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T36	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and @GENE$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T37	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and @GENE$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T38	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEM-GENE$ (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T39	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (@GENE$)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T40	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, @GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T41	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T13.T43	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.	false
23322164.T14.T42	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T36	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T37	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and carnitine palmitoyltransferase 2 (CPT2)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T38	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ (CPT2)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T39	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@CHEMICAL$)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T40	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEM-GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T41	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$/acylcarnitine translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T14.T43	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.	false
23322164.T15.T42	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@CHEMICAL$ translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T36	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T37	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T38	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ (CPT2)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T39	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@CHEMICAL$)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T40	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEM-GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T41	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@CHEMICAL$ translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T15.T43	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@CHEMICAL$ translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.	false
23322164.T16.T42	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @CHEM-GENE$ (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T36	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T37	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T38	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T39	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@CHEMICAL$)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T40	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$ (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T41	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (@CHEMICAL$)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.	false
23322164.T16.T43	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @CHEMICAL$ transporter (@GENE$)-deficient human fibroblasts.	false
23322164.T21.T44	In control fibroblasts, @CHEMICAL$ knockdown markedly increased the production of @GENE$ (3-fold, P<0.01).	false
23322164.T2.T26	OCTN2-deficient cell lines also showed extracellular accumulation of @CHEMICAL$ (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on @GENE$.	false
23322164.T2.T45	@CHEMICAL$-deficient cell lines also showed extracellular accumulation of @GENE$ (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on OCTN2.	false
23322164.T3.T26	OCTN2-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of @CHEMICAL$ does not depend on @GENE$.	false
23322164.T3.T45	@CHEMICAL$-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of @GENE$ does not depend on OCTN2.	false
23322164.T4.T27	In contrast, in @CHEMICAL$- and CACT-deficient cells, the accumulation of @GENE$ in the medium did not significantly increase in the MCAD knockdown.	false
23322164.T4.T28	In contrast, in CPT2- and @CHEMICAL$-deficient cells, the accumulation of @GENE$ in the medium did not significantly increase in the MCAD knockdown.	false
23322164.T4.T29	In contrast, in CPT2- and CACT-deficient cells, the accumulation of @CHEMICAL$ in the medium did not significantly increase in the @GENE$ knockdown.	false
23322164.T10.T32	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.	false
23322164.T10.T33	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.	false
23322164.T10.T34	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.	CPR:9
23322164.T10.T35	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @CHEMICAL$ are involved in the mitochondrial synthesis and export of @GENE$.	CPR:9
23322164.T5.T32	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial @GENE$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	CPR:9
23322164.T5.T33	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial @GENE$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	CPR:9
23322164.T5.T34	This shows that CPT2 and CACT are crucial for mitochondrial @CHEMICAL$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @GENE$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T5.T35	This shows that CPT2 and CACT are crucial for mitochondrial @CHEMICAL$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T7.T32	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @GENE$ palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T7.T33	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @GENE$ palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T7.T34	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEM-GENE$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T7.T35	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ palmitoyltransferase 2 and @GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T8.T32	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T8.T33	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T8.T34	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T8.T35	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T9.T32	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T9.T33	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T9.T34	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23322164.T9.T35	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.	false
23327794.T8.T11	When evaluated for their effects on @CHEM-GENE$ (nAChRs), several of these compounds were shown to be active as nAChR antagonists.	false
23327794.T8.T12	When evaluated for their effects on human a3b4 or a4b2 nicotinic @CHEMICAL$ receptors (@GENE$), several of these compounds were shown to be active as nAChR antagonists.	false
23327794.T8.T13	When evaluated for their effects on human a3b4 or a4b2 nicotinic @CHEMICAL$ receptors (nAChRs), several of these compounds were shown to be active as @GENE$ antagonists.	false
23327794.T9.T10	As a result of this study, @CHEMICAL$ (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit nicotinic receptor antagonistic activity for both the @GENE$ subtypes.	false
23327794.T9.T14	As a result of this study, @CHEMICAL$ (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit @GENE$ antagonistic activity for both the ha3b4 and ha4b2 receptor subtypes.	CPR:6
23331067.T4.T19	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express calbindin-D28k, a @CHEM-GENE$ previously associated with resistance to injury in PD and in animal models.	false
23331067.T4.T17	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express @CHEMICAL$-D28k, a @GENE$-binding protein previously associated with resistance to injury in PD and in animal models.	false
23331067.T4.T18	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express calbindin-@CHEMICAL$, a @GENE$-binding protein previously associated with resistance to injury in PD and in animal models.	false
23331067.T5.T20	Cell-mapping studies in wild-type mice revealed that @CHEMICAL$ is primarily expressed in the ventral SN, a region particularly susceptible to @GENE$ and other dopaminergic neurotoxins.	false
23331067.T1.T21	Furthermore, @CHEMICAL$-expressing SN cells are preferentially lost following @GENE$ treatment.	false
23331067.T2.T6	Finally, SN mDA neurons in @CHEMICAL$ hemizygous mice show increased sensitivity when exposed to @GENE$.	false
23331067.T3.T10	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant Pitx3-autonomous, calbindin-positive neurons, and @GENE$-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	false
23331067.T3.T11	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant Pitx3-autonomous, calbindin-positive neurons, and calbindin-negative @GENE$-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	false
23331067.T3.T8	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant @GENE$-autonomous, calbindin-positive neurons, and calbindin-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	false
23331067.T3.T9	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant Pitx3-autonomous, @GENE$-positive neurons, and calbindin-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	false
23332762.T1.T23	@CHEMICAL$ phosphorylates BAD at @GENE$-26 (Ser26) and primes it for inactivation.	false
23332762.T1.T24	IKK phosphorylates @CHEMICAL$ at @GENE$-26 (Ser26) and primes it for inactivation.	false
23332762.T2.T23	@CHEMICAL$ phosphorylates BAD at serine-26 (@GENE$26) and primes it for inactivation.	false
23332762.T2.T24	IKK phosphorylates @CHEMICAL$ at serine-26 (@GENE$26) and primes it for inactivation.	false
23332762.T3.T25	Elimination of @CHEMICAL$26 phosphorylation promotes @GENE$ proapoptotic activity, thereby accelerating TNFa-induced apoptosis in cultured cells and increasing mortality in animals.	false
23332762.T3.T26	Elimination of @CHEMICAL$26 phosphorylation promotes BAD proapoptotic activity, thereby accelerating @GENE$-induced apoptosis in cultured cells and increasing mortality in animals.	false
23334403.T19.T27	@CHEMICAL$ effects on @GENE$ activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.	false
23334403.T20.T27	Almorexant effects on @CHEMICAL$ activity studied by its simultaneous and time-separated administration with @GENE$ and atorvastatin.	false
23334403.T21.T27	Almorexant effects on @CHEMICAL$ activity studied by its simultaneous and time-separated administration with simvastatin and @GENE$.	false
23334403.T5.T22	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual @CHEMICAL$ antagonist @GENE$.	CPR:6
23334403.T5.T25	PURPOSE: To characterise further the previously observed @CHEMICAL$ (CYP3A4) interaction of the dual orexin receptor antagonist @GENE$.	false
23334403.T5.T26	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (@CHEMICAL$) interaction of the dual orexin receptor antagonist @GENE$.	false
23334403.T10.T23	This suggests that the observed interaction of almorexant with @CHEMICAL$ is mainly caused by intestinal @GENE$ inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.	false
23334403.T10.T24	This suggests that the observed interaction of almorexant with @CHEMICAL$ is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic @GENE$ inhibition.	false
23334403.T11.T23	This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal @CHEMICAL$ inhibition, whereas the interaction with @GENE$ is more due to hepatic CYP3A4 inhibition.	false
23334403.T11.T24	This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with @CHEMICAL$ is more due to hepatic @GENE$ inhibition.	false
23334403.T9.T23	This suggests that the observed interaction of @CHEMICAL$ with simvastatin is mainly caused by intestinal @GENE$ inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.	false
23334403.T9.T24	This suggests that the observed interaction of @CHEMICAL$ with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic @GENE$ inhibition.	false
23339682.T1.T10	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T1.T11	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T1.T12	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T1.T13	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T1.T9	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T2.T10	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T2.T11	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T2.T12	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T2.T13	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T2.T9	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.	false
23339682.T3.T10	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.	false
23339682.T3.T11	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.	false
23339682.T3.T12	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.	false
23339682.T3.T13	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.	false
23339682.T3.T9	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.	false
23339682.T4.T10	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.	false
23339682.T4.T11	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.	false
23339682.T4.T12	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.	false
23339682.T4.T13	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.	false
23339682.T4.T9	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.	false
23339682.T5.T10	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.	false
23339682.T5.T11	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.	false
23339682.T5.T12	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.	false
23339682.T5.T13	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.	false
23339682.T5.T9	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.	false
23341458.T1.T43	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).	false
23341458.T1.T45	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$ of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).	false
23341458.T1.T11	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @CHEMICAL$ peptide (@GENE$(289)<Lys(290)).	false
23341458.T1.T41	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).	false
23341458.T1.T42	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).	false
23341458.T1.T44	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).	false
23341458.T1.T46	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @CHEMICAL$, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).	false
23341458.T2.T43	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).	false
23341458.T2.T45	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).	false
23341458.T2.T11	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @CHEMICAL$ peptide (Arg(289)<@GENE$(290)).	false
23341458.T2.T41	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).	false
23341458.T2.T42	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).	false
23341458.T2.T44	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).	false
23341458.T2.T46	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @CHEMICAL$, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).	false
23341458.T6.T43	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @GENE$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T6.T45	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T6.T11	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).	false
23341458.T6.T41	@CHEMICAL$-terminal sequencing indicated that @GENE$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T6.T42	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by @GENE$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T6.T44	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @GENE$ (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T6.T46	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T7.T43	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T7.T45	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@CHEMICAL$(282)<Gln(283)), as well as in the @GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T7.T11	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@CHEMICAL$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).	false
23341458.T7.T41	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T7.T42	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T7.T44	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T7.T46	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@CHEMICAL$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T8.T43	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T8.T45	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@CHEMICAL$(283)), as well as in the @GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T8.T11	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@CHEMICAL$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).	false
23341458.T8.T41	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T8.T42	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T8.T44	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T8.T46	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@CHEMICAL$(283)), as well as in the N-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T9.T43	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T9.T45	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEM-GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T9.T11	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).	false
23341458.T9.T41	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T9.T42	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T9.T44	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T9.T46	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).	false
23341458.T3.T12	Similarly, mature @CHEMICAL$ was also cleaved to a truncated peptide within its @GENE$-terminal region (Arg(289)<Lys(290)).	false
23341458.T4.T12	Similarly, mature @CHEMICAL$ was also cleaved to a truncated peptide within its N-terminal region (@GENE$(289)<Lys(290)).	false
23341458.T5.T12	Similarly, mature @CHEMICAL$ was also cleaved to a truncated peptide within its N-terminal region (Arg(289)<@GENE$(290)).	false
23348754.T15.T24	A brief history of @CHEM-GENE$ and its role in modulating psychostimulant effects.	false
23348754.T8.T19	Over the past century, the polypeptide @CHEM-GENE$ has played an important role in medicine with major highlights including the identification of its involvement in parturition and the milk let-down reflex.	false
23348754.T7.T18	@CHEM-GENE$ is now implicated in an extensive range of psychological phenomena including reward and memory processes and has been investigated as a treatment for several psychiatric disorders including addiction, anxiety, autism, and schizophrenia.	false
23348754.T9.T20	In this review, we first provide an historical overview of @CHEM-GENE$ and describe key aspects of its physiological activity.	false
23348754.T10.T21	We then outline some pharmacological limitations in this field of research before highlighting the role of @CHEM-GENE$ in a wide range of behavioral and neuronal processes.	false
23348754.T11.T22	Finally, we review evidence for a modulatory role of @CHEM-GENE$ with regard to psychostimulant effects.	false
23348754.T12.T23	Key findings suggest that @CHEM-GENE$ attenuates a broad number of cocaine and methamphetamine induced behaviors and associated neuronal activity in rodents.	false
23348754.T13.T23	Key findings suggest that @CHEMICAL$ attenuates a broad number of @GENE$ and methamphetamine induced behaviors and associated neuronal activity in rodents.	false
23348754.T14.T23	Key findings suggest that @CHEMICAL$ attenuates a broad number of cocaine and @GENE$ induced behaviors and associated neuronal activity in rodents.	false
23348754.T1.T16	Evidence also outlines a role for @CHEM-GENE$ in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in both rodents and humans.	false
23348754.T2.T16	Evidence also outlines a role for @CHEMICAL$ in the prosocial effects of @GENE$ (MDMA, Ecstasy) in both rodents and humans.	false
23348754.T3.T16	Evidence also outlines a role for @CHEMICAL$ in the prosocial effects of 3,4-methylenedioxymethamphetamine (@GENE$, Ecstasy) in both rodents and humans.	false
23348754.T4.T16	Evidence also outlines a role for @CHEMICAL$ in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, @GENE$) in both rodents and humans.	false
23348754.T5.T17	Clinical trials should now investigate the effectiveness of @CHEM-GENE$ as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of MDMA that are currently being investigated.	false
23348754.T6.T17	Clinical trials should now investigate the effectiveness of @CHEMICAL$ as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of @GENE$ that are currently being investigated.	false
23349488.T1.T6	The @CHEMICAL$/IDE T2D locus is associated with decreased insulin secretion in response to oral @GENE$ stimulation in humans.	false
23349488.T1.T7	The HHEX/@CHEMICAL$ T2D locus is associated with decreased insulin secretion in response to oral @GENE$ stimulation in humans.	false
23349488.T1.T8	The HHEX/IDE T2D locus is associated with decreased @CHEMICAL$ secretion in response to oral @GENE$ stimulation in humans.	false
23349488.T2.T10	We find that @CHEMICAL$ stimulated @GENE$ secretion (GSIS) is decreased in Ide KO mice due to impaired replenishment of the releasable pool of granules and that the Ide gene is haploinsufficient.	false
23349488.T2.T11	We find that @CHEMICAL$ stimulated insulin secretion (GSIS) is decreased in @GENE$ KO mice due to impaired replenishment of the releasable pool of granules and that the Ide gene is haploinsufficient.	false
23349488.T2.T12	We find that @CHEMICAL$ stimulated insulin secretion (GSIS) is decreased in Ide KO mice due to impaired replenishment of the releasable pool of granules and that the @GENE$ gene is haploinsufficient.	false
23349489.T1.T2	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven @GENE$-lox, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the b-cell lineage.	false
23349489.T1.T3	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven cre-@GENE$, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the b-cell lineage.	false
23349489.T1.T4	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven cre-lox, and low-frequency ubiquitous @GENE$-lox reveal that PDL does not convert progenitors to the b-cell lineage.	false
23349489.T1.T5	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven cre-lox, and low-frequency ubiquitous cre-@GENE$ reveal that PDL does not convert progenitors to the b-cell lineage.	false
23349489.T1.T7	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, @GENE$-driven cre-lox, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the b-cell lineage.	false
23353901.T24.T48	Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective @CHEMICAL$ receptor ligands and the @GENE$ elicited head-twitch response model.	false
23353901.T24.T49	Support for @CHEMICAL$ receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the @GENE$ elicited head-twitch response model.	false
23353901.T10.T32	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @CHEMICAL$ agonist 2,5-dimethoxy-4-iodoamphetamine (@GENE$).	false
23353901.T10.T46	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) @CHEMICAL$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (@GENE$).	false
23353901.T17.T32	There are seemingly conflicting data in the literature regarding the role of @CHEMICAL$ (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @GENE$ agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	false
23353901.T17.T46	There are seemingly conflicting data in the literature regarding the role of @CHEMICAL$ (5-HT) @GENE$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	false
23353901.T20.T32	There are seemingly conflicting data in the literature regarding the role of serotonin (@CHEMICAL$) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @GENE$ agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	false
23353901.T20.T46	There are seemingly conflicting data in the literature regarding the role of serotonin (@CHEMICAL$) @GENE$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	false
23353901.T9.T32	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @CHEMICAL$ agonist @GENE$ (DOI).	false
23353901.T9.T46	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) @CHEMICAL$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist @GENE$ (DOI).	false
23353901.T11.T40	The present experiments tested the hypothesis that both classes of @CHEMICAL$ receptor compounds could attenuate the @GENE$-elicited-HTR in a single strain of mice, C57Bl/6J. The expected results were considered in accordance with ligand functional selectivity.	false
23353901.T12.T43	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T12.T47	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T12.T41	Commercially-available @CHEMICAL$ agonists (@GENE$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T12.T42	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T12.T44	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T12.T45	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T13.T43	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T13.T47	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T13.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, @GENE$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T13.T42	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T13.T44	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T13.T45	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T14.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T14.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T14.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, @GENE$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T14.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T14.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T14.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T15.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T15.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T15.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, @GENE$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T15.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T15.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T15.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T16.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T16.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T16.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @GENE$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T16.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T16.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T16.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T18.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T18.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T18.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @GENE$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T18.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T18.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T18.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T19.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T19.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T19.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@GENE$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T19.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:5
23353901.T19.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T19.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T1.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.	false
23353901.T1.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @CHEMICAL$ (SB-206553) receptors attenuated the @GENE$-elicited-HTR.	false
23353901.T1.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.	false
23353901.T1.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.	false
23353901.T1.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.	false
23353901.T1.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @CHEMICAL$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.	false
23353901.T21.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T21.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@CHEMICAL$), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T21.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T21.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T21.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:6
23353901.T21.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@CHEMICAL$), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T22.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T22.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@CHEMICAL$), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T22.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T22.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T22.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	false
23353901.T22.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @CHEMICAL$ (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	CPR:6
23353901.T23.T43	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.	false
23353901.T23.T47	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @CHEMICAL$ (@GENE$) receptors attenuated the DOI-elicited-HTR.	false
23353901.T23.T41	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.	false
23353901.T23.T42	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.	false
23353901.T23.T44	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.	false
23353901.T23.T45	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @CHEMICAL$ (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.	false
23353901.T2.T25	The @CHEMICAL$ agonists and @GENE$ decreased locomotion, SB-242084 increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	false
23353901.T3.T25	The @CHEMICAL$ agonists and M100907 decreased locomotion, @GENE$ increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	false
23353901.T4.T25	The @CHEMICAL$ agonists and M100907 decreased locomotion, SB-242084 increased locomotion, @GENE$ resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	false
23353901.T5.T28	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the @CHEMICAL$-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated @GENE$ signaling in HEK cells.	false
23353901.T5.T26	In vitro molecular pharmacology studies showed that @CHEMICAL$ agonists potent for attenuating the @GENE$-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated PLC signaling in HEK cells.	false
23353901.T5.T27	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the @CHEMICAL$-elicited-HTR also reduced the efficacy of DOI to activate @GENE$ receptor-mediated PLC signaling in HEK cells.	false
23353901.T6.T28	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of @CHEMICAL$ to activate mouse 5-HT2C receptor-mediated @GENE$ signaling in HEK cells.	false
23353901.T6.T26	In vitro molecular pharmacology studies showed that @CHEMICAL$ agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of @GENE$ to activate mouse 5-HT2C receptor-mediated PLC signaling in HEK cells.	false
23353901.T6.T27	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of @CHEMICAL$ to activate @GENE$ receptor-mediated PLC signaling in HEK cells.	CPR:3
23353901.T7.T31	Results indicate that @CHEMICAL$ receptor agonists and antagonists attenuate the @GENE$-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different 5-HT2C receptor signaling outcomes compared to DOI.	false
23353901.T7.T33	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the @CHEMICAL$-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse @GENE$ ligands result in different 5-HT2C receptor signaling outcomes compared to DOI.	false
23353901.T7.T34	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the @CHEMICAL$-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different @GENE$ receptor signaling outcomes compared to DOI.	false
23353901.T8.T31	Results indicate that @CHEMICAL$ receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different 5-HT2C receptor signaling outcomes compared to @GENE$.	false
23353901.T8.T33	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse @CHEMICAL$ ligands result in different 5-HT2C receptor signaling outcomes compared to @GENE$.	false
23353901.T8.T34	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different @CHEMICAL$ receptor signaling outcomes compared to @GENE$.	false
23361846.T21.T33	Role of @CHEMICAL$ in @GENE$ metabolism and clearance.	false
23361846.T1.T24	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to @GENE$.	CPR:9
23361846.T1.T30	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic @GENE$ (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	CPR:9
23361846.T1.T31	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (@GENE$) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	CPR:9
23361846.T1.T32	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and @GENE$, but clinical disposition is often attributed to CYP3A4.	CPR:9
23361846.T2.T24	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to @GENE$.	CPR:9
23361846.T2.T30	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic @GENE$ (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	CPR:9
23361846.T2.T31	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (@GENE$) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	CPR:9
23361846.T2.T32	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and @GENE$, but clinical disposition is often attributed to CYP3A4.	CPR:9
23361846.T7.T26	This investigation tested the hypothesis that CYP2B6 is a prominent @CHEMICAL$ isoform responsible for clinical @GENE$ N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.	CPR:9
23361846.T7.T25	This investigation tested the hypothesis that @CHEMICAL$ is a prominent CYP isoform responsible for clinical @GENE$ N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.	CPR:9
23361846.T7.T27	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical @CHEMICAL$ N-demethylation and clearance, using the in vivo mechanism-based @GENE$ inhibitor ticlopidine, given orally for 4 days.	false
23361846.T8.T26	This investigation tested the hypothesis that CYP2B6 is a prominent @CHEMICAL$ isoform responsible for clinical methadone @GENE$-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.	CPR:9
23361846.T8.T25	This investigation tested the hypothesis that @CHEMICAL$ is a prominent CYP isoform responsible for clinical methadone @GENE$-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.	CPR:9
23361846.T8.T27	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone @CHEMICAL$-demethylation and clearance, using the in vivo mechanism-based @GENE$ inhibitor ticlopidine, given orally for 4 days.	false
23361846.T9.T26	This investigation tested the hypothesis that CYP2B6 is a prominent @CHEMICAL$ isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor @GENE$, given orally for 4 days.	false
23361846.T9.T25	This investigation tested the hypothesis that @CHEMICAL$ is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor @GENE$, given orally for 4 days.	false
23361846.T9.T27	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based @CHEMICAL$ inhibitor @GENE$, given orally for 4 days.	CPR:4
23361846.T10.T28	A preliminary clinical investigation with the @CHEMICAL$ substrate probe @GENE$ established that ticlopidine did not inhibit intestinal or hepatic CYP3A4/5.	false
23361846.T10.T29	A preliminary clinical investigation with the CYP3A4/5 substrate probe @CHEMICAL$ established that ticlopidine did not inhibit intestinal or hepatic @GENE$.	false
23361846.T11.T28	A preliminary clinical investigation with the @CHEMICAL$ substrate probe alfentanil established that @GENE$ did not inhibit intestinal or hepatic CYP3A4/5.	false
23361846.T11.T29	A preliminary clinical investigation with the CYP3A4/5 substrate probe alfentanil established that @CHEMICAL$ did not inhibit intestinal or hepatic @GENE$.	false
23361846.T3.T22	@CHEMICAL$ inhibition reduces @GENE$ N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.	false
23361846.T3.T23	CYP2B6 inhibition reduces @CHEMICAL$ N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for @GENE$ in clinical methadone disposition.	false
23361846.T4.T22	@CHEMICAL$ inhibition reduces methadone @GENE$-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.	false
23361846.T4.T23	CYP2B6 inhibition reduces methadone @CHEMICAL$-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for @GENE$ in clinical methadone disposition.	false
23361846.T5.T22	@CHEMICAL$ inhibition reduces methadone N-demethylation and clearance, and alters @GENE$ concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.	false
23361846.T5.T23	CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters @CHEMICAL$ concentrations, demonstrating an important role for @GENE$ in clinical methadone disposition.	false
23361846.T6.T22	@CHEMICAL$ inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical @GENE$ disposition.	false
23361846.T6.T23	CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for @CHEMICAL$ in clinical @GENE$ disposition.	CPR:9
23373701.T7.T35	@CHEMICAL$ D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gbg-@GENE$-dependent induction of Zif268.	false
23373701.T7.T34	@CHEM-GENE$ activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gbg-Erk1/2-dependent induction of Zif268.	false
23373701.T7.T36	@CHEMICAL$ D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gbg-Erk1/2-dependent induction of @GENE$.	false
23373701.T7.T37	@CHEMICAL$ D2 receptor activation leads to an up-regulation of @GENE$ via Gbg-Erk1/2-dependent induction of Zif268.	false
23373701.T1.T23	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEM-GENE$ (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T1.T25	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (@GENE$) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T1.T26	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of @GENE$ that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T1.T27	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$ (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T1.T28	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (@GENE$), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T2.T23	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ (D2R) agonist, @GENE$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	CPR:5
23373701.T2.T25	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (@CHEMICAL$) agonist, @GENE$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	CPR:5
23373701.T2.T26	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, @CHEMICAL$, triggered an increase in the expression of @GENE$ that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	CPR:3
23373701.T2.T27	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, @CHEMICAL$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$ (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	CPR:3
23373701.T2.T28	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, @CHEMICAL$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (@GENE$), a DNA-binding transcription factor encoded by an immediate-early gene.	CPR:3
23373701.T3.T23	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T3.T25	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (@CHEMICAL$) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T3.T26	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of @CHEMICAL$ that was temporally preceded by an increase in the levels of @GENE$-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T3.T27	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @CHEM-GENE$ (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T3.T28	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @CHEMICAL$-finger protein 268 (@GENE$), a DNA-binding transcription factor encoded by an immediate-early gene.	false
23373701.T4.T29	Moreover, the @CHEMICAL$ inhibitor @GENE$ blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.	CPR:4
23373701.T4.T30	Moreover, the D2R inhibitor @CHEMICAL$ blocked the increase of both @GENE$ and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.	CPR:4
23373701.T4.T31	Moreover, the D2R inhibitor @CHEMICAL$ blocked the increase of both GDNF and @GENE$ expression following potassium-evoked dopamine release in SH-SY5Y cells.	CPR:4
23373701.T5.T29	Moreover, the @CHEMICAL$ inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following @GENE$-evoked dopamine release in SH-SY5Y cells.	false
23373701.T5.T30	Moreover, the D2R inhibitor raclopride blocked the increase of both @CHEMICAL$ and Zif268 expression following @GENE$-evoked dopamine release in SH-SY5Y cells.	false
23373701.T5.T31	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and @CHEMICAL$ expression following @GENE$-evoked dopamine release in SH-SY5Y cells.	false
23373701.T6.T29	Moreover, the @CHEMICAL$ inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked @GENE$ release in SH-SY5Y cells.	false
23373701.T6.T30	Moreover, the D2R inhibitor raclopride blocked the increase of both @CHEMICAL$ and Zif268 expression following potassium-evoked @GENE$ release in SH-SY5Y cells.	false
23373701.T6.T31	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and @CHEMICAL$ expression following potassium-evoked @GENE$ release in SH-SY5Y cells.	false
23373704.T4.T10	Here, we have perturbed vibrational motions in @CHEMICAL$ reductase (@GENE$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and (2)H).	false
23373704.T4.T9	Here, we have perturbed vibrational motions in @CHEM-GENE$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and (2)H).	false
23373704.T5.T10	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (@CHEMICAL$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope (@GENE$, (15)N, and (2)H).	false
23373704.T5.T9	Here, we have perturbed vibrational motions in @CHEMICAL$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope (@GENE$, (15)N, and (2)H).	false
23373704.T6.T10	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (@CHEMICAL$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, @GENE$, and (2)H).	false
23373704.T6.T9	Here, we have perturbed vibrational motions in @CHEMICAL$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, @GENE$, and (2)H).	false
23373704.T7.T10	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (@CHEMICAL$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and @GENE$).	false
23373704.T7.T9	Here, we have perturbed vibrational motions in @CHEMICAL$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and @GENE$).	false
23376217.T5.T24	Characterization of the mouse promoter region of the @CHEMICAL$ synthetase 4 gene: role of Sp1 and @GENE$.	false
23376217.T5.T22	Characterization of the mouse promoter region of the @CHEM-GENE$ gene: role of Sp1 and CREB.	false
23376217.T5.T23	Characterization of the mouse promoter region of the @CHEMICAL$ synthetase 4 gene: role of @GENE$ and CREB.	false
23376217.T1.T6	@CHEM-GENE$ (Acsl4) is involved in several cellular functions including steroidogenesis, synaptic development and cancer metastasis.	false
23376217.T1.T9	@CHEMICAL$ synthetase 4 (@GENE$) is involved in several cellular functions including steroidogenesis, synaptic development and cancer metastasis.	false
23376217.T3.T10	We demonstrated @CHEMICAL$ and @GENE$ regulation of Acsl4 mRNA in mouse steroidogenic MA-10 Leydig cells.	false
23376217.T3.T11	We demonstrated hCG and @CHEMICAL$ regulation of @GENE$ mRNA in mouse steroidogenic MA-10 Leydig cells.	false
23376217.T2.T18	Functional characterization revealed that the @CHEMICAL$/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @GENE$ stimulation of Acsl4 transcription.	false
23376217.T2.T19	Functional characterization revealed that the specificity protein/@CHEMICAL$ Sp1 binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @GENE$ stimulation of Acsl4 transcription.	false
23376217.T2.T21	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @CHEMICAL$-binding site is involved in @GENE$ stimulation of Acsl4 transcription.	false
23376217.T2.T20	Functional characterization revealed that the specificity protein/Kruppel-like factor @CHEMICAL$ binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @GENE$ stimulation of Acsl4 transcription.	false
23376217.T2.T7	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @CHEMICAL$ stimulation of @GENE$ transcription.	false
23376217.T4.T18	Functional characterization revealed that the @CHEMICAL$/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @GENE$ response element-binding site is involved in cAMP stimulation of Acsl4 transcription.	false
23376217.T4.T19	Functional characterization revealed that the specificity protein/@CHEMICAL$ Sp1 binding site in the proximal promoter is involved in basal activity and that the @GENE$ response element-binding site is involved in cAMP stimulation of Acsl4 transcription.	false
23376217.T4.T21	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @CHEM-GENE$-binding site is involved in cAMP stimulation of Acsl4 transcription.	false
23376217.T4.T20	Functional characterization revealed that the specificity protein/Kruppel-like factor @CHEMICAL$ binding site in the proximal promoter is involved in basal activity and that the @GENE$ response element-binding site is involved in cAMP stimulation of Acsl4 transcription.	false
23376217.T4.T7	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @CHEMICAL$ response element-binding site is involved in cAMP stimulation of @GENE$ transcription.	false
23376249.T3.T13	Synthesis and biological evaluation of @CHEMICAL$ analogues as novel @GENE$ and BuChE inhibitors.	CPR:4
23376249.T3.T14	Synthesis and biological evaluation of @CHEMICAL$ analogues as novel AChE and @GENE$ inhibitors.	CPR:4
23376249.T1.T4	In this paper a series of new 1,3,4-thiadiazole derivatives has been designed, synthesized and evaluated as the @CHEM-GENE$ inhibitors.	false
23376249.T2.T4	In this paper a series of new @CHEMICAL$ derivatives has been designed, synthesized and evaluated as the @GENE$ inhibitors.	CPR:4
23376356.T1.T15	@CHEMICAL$, a specific @GENE$/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	CPR:4
23376356.T1.T16	@CHEMICAL$, a specific PI3K/@GENE$ inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	CPR:4
23376356.T1.T17	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the @GENE$ MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	CPR:3
23376356.T1.T18	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 @GENE$ kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	CPR:3
23376356.T1.T19	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK @GENE$ pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	CPR:3
23376356.T1.T21	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate @GENE$.	false
23376356.T1.T20	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced @GENE$ phosphorylation, but did not activate JNK.	CPR:3
23376356.T2.T22	The pharmacological inhibitors @CHEMICAL$ (@GENE$ inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	CPR:4
23376356.T2.T23	The pharmacological inhibitors @CHEMICAL$ (p38 inhibitor) and SP600125 (a @GENE$ inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	false
23376356.T3.T22	The pharmacological inhibitors SB203580 (@CHEMICAL$ inhibitor) and @GENE$ (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	false
23376356.T3.T23	The pharmacological inhibitors SB203580 (p38 inhibitor) and @CHEMICAL$ (a @GENE$ inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	CPR:4
23376356.T4.T22	The pharmacological inhibitors SB203580 (@CHEMICAL$ inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from @GENE$-induced apoptosis.	false
23376356.T4.T23	The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a @CHEMICAL$ inhibitor) protected primary cultures of rat CGCs from @GENE$-induced apoptosis.	false
23376546.T20.T34	We previously demonstrated that @CHEMICAL$ (P-gp) modulation at the blood-brain barrier (BBB) contributes highly to @GENE$-related respiratory toxicity, by limiting NBUP entrance into the brain.	false
23376546.T20.T35	We previously demonstrated that P-glycoprotein (@CHEMICAL$) modulation at the blood-brain barrier (BBB) contributes highly to @GENE$-related respiratory toxicity, by limiting NBUP entrance into the brain.	false
23376546.T21.T34	We previously demonstrated that @CHEMICAL$ (P-gp) modulation at the blood-brain barrier (BBB) contributes highly to BUP-related respiratory toxicity, by limiting @GENE$ entrance into the brain.	false
23376546.T21.T35	We previously demonstrated that P-glycoprotein (@CHEMICAL$) modulation at the blood-brain barrier (BBB) contributes highly to BUP-related respiratory toxicity, by limiting @GENE$ entrance into the brain.	false
23376546.T23.T36	In this work, we sought to investigate the role of @CHEMICAL$-mediated transport at the BBB in gender and strain-related variability of @GENE$ and NBUP-induced respiratory effects in mice.	false
23376546.T24.T36	In this work, we sought to investigate the role of @CHEMICAL$-mediated transport at the BBB in gender and strain-related variability of BUP and @GENE$-induced respiratory effects in mice.	false
23376546.T12.T32	No differences in @CHEMICAL$ expression or @GENE$ and NBUP transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.	false
23376546.T13.T32	No differences in @CHEMICAL$ expression or BUP and @GENE$ transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.	false
23376546.T15.T33	Our results suggest that @CHEMICAL$-mediated transport across the BBB does not play a key-role in gender and strain-related variability in @GENE$ and NBUP-induced respiratory toxicity in mice.	false
23376546.T16.T33	Our results suggest that @CHEMICAL$-mediated transport across the BBB does not play a key-role in gender and strain-related variability in BUP and @GENE$-induced respiratory toxicity in mice.	false
23380477.T5.T21	Autophagy takes place in mutated @CHEMICAL$ neuroblastoma cells in response to hypoxia mimetic @GENE$.	false
23380477.T1.T15	Today, we used @CHEMICAL$, a hypoxia mimetic that inhibits proteasomal @GENE$ degradation and generates reactive oxygen species (ROS).	CPR:3
23380477.T2.T15	Today, we used cobalt chloride, a hypoxia mimetic that inhibits proteasomal @CHEMICAL$ degradation and generates reactive @GENE$ species (ROS).	false
23380477.T3.T16	We focused on @CHEMICAL$-induced cell death in a DNA-binding mutated @GENE$ neuroblastoma cell line (SKNBE(2c)).	false
23380477.T4.T18	An autophagic signaling was evidenced by an increase of Beclin-1, @CHEMICAL$, and LC3-II expression whereas the p53(mut) presence decreased with @GENE$ time exposure.	false
23380477.T4.T17	An autophagic signaling was evidenced by an increase of @CHEMICAL$, ATG 5-12, and LC3-II expression whereas the p53(mut) presence decreased with @GENE$ time exposure.	false
23380477.T4.T19	An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and @CHEMICAL$ expression whereas the p53(mut) presence decreased with @GENE$ time exposure.	false
23380477.T4.T20	An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the @CHEMICAL$(mut) presence decreased with @GENE$ time exposure.	CPR:4
23382379.T6.T17	The myosin-18Aa isoform, additionally, has an @CHEMICAL$-terminal @GENE$.	false
23382379.T6.T16	The @CHEMICAL$ isoform, additionally, has an @GENE$-terminal PDZ domain.	false
23382379.T1.T21	@CHEMICAL$ binding was unchanged by presence of @GENE$.	false
23382379.T2.T8	Both myosin-18A isoforms bound @CHEMICAL$, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by @GENE$.	false
23382379.T2.T7	Both @CHEMICAL$ isoforms bound @GENE$, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.	false
23382379.T3.T8	Both myosin-18A isoforms bound N-methylanthraniloyl-nucleotides, but the rate of @CHEMICAL$ hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by @GENE$.	false
23382379.T3.T7	Both @CHEMICAL$ isoforms bound N-methylanthraniloyl-nucleotides, but the rate of @GENE$ hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.	false
23382379.T4.T9	Phosphorylation of the regulatory light chain had no effect on @CHEMICAL$ hydrolysis, and neither did the addition of tropomyosin or of GOLPH3, a @GENE$ binding partner.	false
23382379.T5.T10	Electron microscopy of @CHEMICAL$-S1 showed that the lever is strongly angled with respect to the long axis of the motor domain, suggesting a pre-power stroke conformation regardless of the presence of @GENE$.	false
23382381.T2.T28	Cellular responses to DNA damage induced by @CHEMICAL$ or doxorubicin include down-regulation of endogenous @GENE$ coincident with increases in p53.	CPR:4
23382381.T2.T29	Cellular responses to DNA damage induced by @CHEMICAL$ or doxorubicin include down-regulation of endogenous supervillin coincident with increases in @GENE$.	CPR:3
23382381.T3.T28	Cellular responses to DNA damage induced by etoposide or @CHEMICAL$ include down-regulation of endogenous @GENE$ coincident with increases in p53.	CPR:4
23382381.T3.T29	Cellular responses to DNA damage induced by etoposide or @CHEMICAL$ include down-regulation of endogenous supervillin coincident with increases in @GENE$.	CPR:3
23382381.T1.T12	@CHEMICAL$ binds directly to the supervillin @GENE$ terminus and can deubiquitinate and stabilize supervillin.	false
23382381.T1.T13	USP7 binds directly to the @CHEMICAL$ @GENE$ terminus and can deubiquitinate and stabilize supervillin.	false
23382381.T1.T14	USP7 binds directly to the supervillin @CHEMICAL$ terminus and can deubiquitinate and stabilize @GENE$.	false
23384387.T11.T21	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (@GENE$) and/or decreased neuropeptide Y (NPY).	CPR:3
23384387.T11.T22	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased @GENE$ (NPY).	CPR:4
23384387.T11.T23	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (@GENE$).	CPR:4
23384387.T11.T24	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic @GENE$ (POMC) and/or decreased neuropeptide Y (NPY).	CPR:3
23384387.T10.T12	Effects of @CHEMICAL$ on weight were dose-dependent, and it could be given orally. 1, 2, 4, 5 down-regulated @GENE$ mRNA expression.	false
23384447.T10.T24	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and @CHEMICAL$ exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @GENE$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	false
23384447.T10.T25	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and @CHEMICAL$ exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @GENE$ (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	false
23384447.T11.T24	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @CHEMICAL$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and @GENE$ (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	false
23384447.T11.T25	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @CHEMICAL$ (1.0mg/ml) and @GENE$ (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	false
23384447.T12.T24	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @CHEMICAL$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% @GENE$.	false
23384447.T12.T25	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @CHEMICAL$ (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% @GENE$.	false
23384447.T9.T24	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and @CHEMICAL$ diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @GENE$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	false
23384447.T9.T25	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and @CHEMICAL$ diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @GENE$ (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	false
23384447.T1.T17	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and @CHEMICAL$ (PAI), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.	false
23384447.T1.T18	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (@CHEMICAL$), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.	false
23384447.T1.T15	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of @CHEMICAL$ (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.	false
23384447.T1.T16	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (@CHEMICAL$) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.	false
23384447.T1.T19	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in @CHEM-GENE$ (eNOS) protein expression and nitric oxide (NO) release.	false
23384447.T1.T20	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial @CHEMICAL$ synthase (@GENE$) protein expression and nitric oxide (NO) release.	false
23384447.T2.T17	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and @CHEMICAL$ (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.	false
23384447.T2.T18	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (@CHEMICAL$), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.	false
23384447.T2.T15	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of @CHEMICAL$ (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.	false
23384447.T2.T16	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (@CHEMICAL$) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.	false
23384447.T2.T19	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in @CHEMICAL$ (eNOS) protein expression and @GENE$ (NO) release.	false
23384447.T2.T20	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (@CHEMICAL$) protein expression and @GENE$ (NO) release.	false
23384447.T3.T17	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and @CHEMICAL$ (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.	false
23384447.T3.T18	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (@CHEMICAL$), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.	false
23384447.T3.T15	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of @CHEMICAL$ (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.	false
23384447.T3.T16	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (@CHEMICAL$) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.	false
23384447.T3.T19	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in @CHEMICAL$ (eNOS) protein expression and nitric oxide (@GENE$) release.	false
23384447.T3.T20	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (@CHEMICAL$) protein expression and nitric oxide (@GENE$) release.	false
23384447.T4.T23	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and @CHEMICAL$ release and caused membrane damage, but caused no changes in the secretion of ET-1, prostacyclin and @GENE$.	false
23384447.T4.T21	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, @CHEMICAL$ protein expression, and @GENE$ release and caused membrane damage, but caused no changes in the secretion of ET-1, prostacyclin and PAI.	false
23384447.T4.T22	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and @CHEMICAL$ release and caused membrane damage, but caused no changes in the secretion of @GENE$, prostacyclin and PAI.	false
23384447.T5.T23	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of ET-1, @CHEMICAL$ and @GENE$.	false
23384447.T5.T21	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, @CHEMICAL$ protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of ET-1, @GENE$ and PAI.	false
23384447.T5.T22	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of @CHEMICAL$, @GENE$ and PAI.	false
23385325.T6.T11	We apply DFTB in a QM/MM framework to perform vibrational analysis of buried @CHEMICAL$ in @GENE$ and channelrhodopsin-2.	false
23385325.T6.T12	We apply DFTB in a QM/MM framework to perform vibrational analysis of buried @CHEMICAL$ in bacteriorhodopsin and @GENE$.	false
23386248.T12.T26	Refining the @CHEMICAL$ haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with @GENE$/irinotecan-based regimens.	false
23386248.T13.T26	Refining the @CHEMICAL$ haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/@GENE$-based regimens.	false
23386248.T14.T26	Refining the @CHEMICAL$ haplotype associated with @GENE$-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.	false
23386248.T10.T20	Despite the importance of @CHEMICAL$*28 in @GENE$ pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.	false
23386248.T3.T20	Despite the importance of @CHEM-GENE$*28 in irinotecan pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.	false
23386248.T1.T18	Our results suggest that specific SNPs in @CHEMICAL$, other than UGT1A1*28, may influence @GENE$ toxicity and should be considered to refine pharmacogenetic testing.	false
23386248.T1.T19	Our results suggest that specific SNPs in UGT1A, other than @CHEMICAL$*28, may influence @GENE$ toxicity and should be considered to refine pharmacogenetic testing.	false
23386417.T13.T26	@CHEM-GENE$ mRNA Measured by Quantitative Real Time PCR is Decreased in the Urethral Mucosa of Patients with Middle Idiopathic Hypospadias.	false
23386417.T1.T22	@CHEMICAL$ action is exerted through the @GENE$.	false
23386417.T9.T22	Androgen action is exerted through the @CHEM-GENE$.	false
23386417.T3.T15	The normal 46,XY genital virilization depends on @CHEM-GENE$ gene expression, which is tissue specific, and requires normal androgen receptor mRNA levels in androgen sensitive tissues.	false
23386417.T3.T21	The normal 46,XY genital virilization depends on @CHEMICAL$ receptor gene expression, which is tissue specific, and requires normal @GENE$ mRNA levels in androgen sensitive tissues.	false
23386417.T6.T15	The normal 46,XY genital virilization depends on @CHEMICAL$ gene expression, which is tissue specific, and requires normal @GENE$ receptor mRNA levels in androgen sensitive tissues.	false
23386417.T6.T21	The normal 46,XY genital virilization depends on androgen receptor gene expression, which is tissue specific, and requires normal @CHEM-GENE$ mRNA levels in androgen sensitive tissues.	false
23386417.T7.T15	The normal 46,XY genital virilization depends on @CHEMICAL$ gene expression, which is tissue specific, and requires normal androgen receptor mRNA levels in @GENE$ sensitive tissues.	false
23386417.T7.T21	The normal 46,XY genital virilization depends on androgen receptor gene expression, which is tissue specific, and requires normal @CHEMICAL$ mRNA levels in @GENE$ sensitive tissues.	false
23386417.T10.T23	The aim of this study was to compare, by quantitative real time PCR, the amount of @CHEM-GENE$ mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the androgen receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening.	false
23386417.T10.T24	The aim of this study was to compare, by quantitative real time PCR, the amount of @CHEMICAL$ receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the @GENE$ mRNA levels observed in control phimosis subjects with eutopic urethral opening.	false
23386417.T11.T23	The aim of this study was to compare, by quantitative real time PCR, the amount of @CHEMICAL$ mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the @GENE$ receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening.	false
23386417.T11.T24	The aim of this study was to compare, by quantitative real time PCR, the amount of androgen receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the @CHEM-GENE$ mRNA levels observed in control phimosis subjects with eutopic urethral opening.	false
23386417.T12.T25	We observed significantly less @CHEM-GENE$ mRNA in the urethral mucosa of patients with hypospadias than in the controls (p=0.002).	false
23386417.T2.T14	The correlation between the level of @CHEM-GENE$ mRNA expression and the penile size was almost statistically significant only in hypospadias patients (r=0.47; p=0.053).	false
23386417.T4.T16	We also established the number of @CHEMICAL$ in exon 1 of the @GENE$ receptor gene by GeneScan analysis.	false
23386417.T4.T17	We also established the number of CAG repeats in exon 1 of the @CHEM-GENE$ gene by GeneScan analysis.	false
23386417.T5.T20	Our data suggest that a critical lower level of @CHEM-GENE$ mRNA expression could be a determining factor in the development of middle hypospadias.	false
23391443.T1.T10	The sCT released from NP stimulated @CHEMICAL$ production in human T47D breast cancer cells expressing @GENE$.	false
23395804.T7.T40	@CHEMICAL$ regulates transcription of the ion uptake @GENE$/Cl- cotransporter (ncc) gene in zebrafish gill.	false
23395804.T7.T41	Prolactin regulates transcription of the ion uptake @CHEM-GENE$ (ncc) gene in zebrafish gill.	false
23395804.T7.T42	Prolactin regulates transcription of the ion uptake @CHEMICAL$/Cl- cotransporter (@GENE$) gene in zebrafish gill.	false
23395804.T8.T40	@CHEMICAL$ regulates transcription of the ion uptake Na+/@GENE$ cotransporter (ncc) gene in zebrafish gill.	false
23395804.T8.T41	Prolactin regulates transcription of the ion uptake @CHEM-GENE$ (ncc) gene in zebrafish gill.	false
23395804.T8.T42	Prolactin regulates transcription of the ion uptake Na+/@CHEMICAL$ cotransporter (@GENE$) gene in zebrafish gill.	false
23395804.T2.T15	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), @GENE$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T16	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), @GENE$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T17	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEM-GENE$ (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (@GENE$; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; @GENE$), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T20	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), @GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T22	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T23	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.	false
23395804.T2.T24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.	false
23395804.T2.T25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.	false
23395804.T3.T15	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/@GENE$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T16	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/@GENE$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T17	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEM-GENE$ (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (@GENE$; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; @GENE$), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T20	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), @GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T22	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T23	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.	false
23395804.T3.T24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.	false
23395804.T3.T25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.	false
23395804.T4.T15	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T16	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T17	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$ (ncc; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (@CHEMICAL$; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; @CHEMICAL$), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T20	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEM-GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T22	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T23	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.	false
23395804.T4.T24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.	false
23395804.T4.T25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.	false
23395804.T5.T15	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T16	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T17	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$ (ncc; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (@CHEMICAL$; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; @CHEMICAL$), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T20	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEM-GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T22	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T23	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.	false
23395804.T5.T24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.	false
23395804.T5.T25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.	false
23395804.T6.T15	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T16	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T17	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$ (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (@CHEMICAL$; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; @CHEMICAL$), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T20	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$ (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (@CHEMICAL$; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T22	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; @CHEMICAL$), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T23	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and @CHEM-GENE$ (ecac; trpv6) transcripts within the gill.	false
23395804.T6.T24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @CHEMICAL$ channel (@GENE$; trpv6) transcripts within the gill.	false
23395804.T6.T25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @CHEMICAL$ channel (ecac; @GENE$) transcripts within the gill.	false
23395804.T1.T11	These results suggest that PRL signaling through PRL receptors in the gill regulates the expression of ncc, thereby linking this @CHEMICAL$ with an effector of @GENE$ uptake in zebrafish for the first time.	false
23395804.T1.T39	These results suggest that PRL signaling through @CHEMICAL$ in the gill regulates the expression of ncc, thereby linking this pituitary hormone with an effector of @GENE$ uptake in zebrafish for the first time.	false
23395804.T1.T10	These results suggest that PRL signaling through PRL receptors in the gill regulates the expression of @CHEMICAL$, thereby linking this pituitary hormone with an effector of @GENE$ uptake in zebrafish for the first time.	false
23395804.T1.T38	These results suggest that @CHEMICAL$ signaling through PRL receptors in the gill regulates the expression of ncc, thereby linking this pituitary hormone with an effector of @GENE$ uptake in zebrafish for the first time.	false
23397032.T1.T11	@CHEMICAL$ suppressed @GENE$ gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	CPR:4
23397032.T1.T12	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by @GENE$ without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T1.T13	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting @GENE$ expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T1.T14	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-@GENE$ complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T1.T15	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to @GENE$, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T1.T16	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with @GENE$. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T1.T17	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of @GENE$ counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T1.T18	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-@GENE$ antibody or IL-11 small interfering RNA.	false
23397032.T1.T19	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or @GENE$ small interfering RNA.	false
23397032.T2.T11	Dexamethasone suppressed @CHEMICAL$ gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @GENE$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T12	Dexamethasone suppressed IL-11 gene transcription enhanced by @CHEMICAL$ without affecting DFosB expression or Smad1 phosphorylation, and @GENE$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T13	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting @CHEMICAL$ expression or Smad1 phosphorylation, and @GENE$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T14	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-@GENE$ complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T15	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to @GENE$, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T16	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with @GENE$. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T17	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of @GENE$ counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T2.T18	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-@GENE$ antibody or IL-11 small interfering RNA.	false
23397032.T2.T19	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or @GENE$ small interfering RNA.	false
23397032.T3.T11	Dexamethasone suppressed @CHEMICAL$ gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T12	Dexamethasone suppressed IL-11 gene transcription enhanced by @CHEMICAL$ without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T13	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting @CHEMICAL$ expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T14	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-@CHEMICAL$ complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T15	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to @CHEMICAL$, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T16	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with @CHEMICAL$. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T17	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of @CHEMICAL$ counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	false
23397032.T3.T18	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @CHEMICAL$ on apoptosis of mPOBs, which was blunted by neutralizing anti-@GENE$ antibody or IL-11 small interfering RNA.	false
23397032.T3.T19	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @CHEMICAL$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or @GENE$ small interfering RNA.	false
23397032.T4.T20	These results demonstrate that @CHEMICAL$ and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and @GENE$ may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.	false
23397032.T4.T21	These results demonstrate that PTH(1-34) and GCs interact to regulate @CHEMICAL$ expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and @GENE$ may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.	false
23397032.T4.T22	These results demonstrate that PTH(1-34) and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that @CHEMICAL$ and @GENE$ may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.	false
23397032.T4.T23	These results demonstrate that PTH(1-34) and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and @CHEMICAL$ may regulate osteoblast differentiation and apoptosis via their effect on @GENE$ expression.	false
23402856.T15.T28	Number and area of preneoplastic foci positive for @CHEM-GENE$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.	false
23402856.T15.T29	Number and area of preneoplastic foci positive for @CHEMICAL$ S-transferase placental form (@GENE$) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.	false
23402856.T16.T28	Number and area of preneoplastic foci positive for @CHEM-GENE$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.	false
23402856.T16.T29	Number and area of preneoplastic foci positive for glutathione @CHEMICAL$-transferase placental form (@GENE$) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.	false
23402856.T18.T28	Number and area of preneoplastic foci positive for @CHEMICAL$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with @GENE$ or HCB alone.	CPR:3
23402856.T18.T29	Number and area of preneoplastic foci positive for glutathione S-transferase placental form (@CHEMICAL$) were consistently higher in these groups than the sum of individual values in the groups treated with @GENE$ or HCB alone.	CPR:3
23402856.T19.T28	Number and area of preneoplastic foci positive for @CHEMICAL$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or @GENE$ alone.	CPR:3
23402856.T19.T29	Number and area of preneoplastic foci positive for glutathione S-transferase placental form (@CHEMICAL$) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or @GENE$ alone.	CPR:3
23402856.T1.T30	Consistent with these findings, HEP and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @CHEMICAL$ induction, which may lead to more efficient metabolic activation of @GENE$ and HCB.	false
23402856.T20.T30	Consistent with these findings, @CHEMICAL$ and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @GENE$ induction, which may lead to more efficient metabolic activation of HEP and HCB.	false
23402856.T22.T30	Consistent with these findings, HEP and @CHEMICAL$ had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @GENE$ induction, which may lead to more efficient metabolic activation of HEP and HCB.	false
23402856.T2.T30	Consistent with these findings, HEP and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @CHEMICAL$ induction, which may lead to more efficient metabolic activation of HEP and @GENE$.	false
23402856.T3.T27	On the basis of these findings, we conclude that @CHEMICAL$ and HCB have additive and synergistic effects on the development of @GENE$-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.	CPR:3
23402856.T5.T27	On the basis of these findings, we conclude that HEP and @CHEMICAL$ have additive and synergistic effects on the development of @GENE$-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.	CPR:3
23402856.T6.T27	On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of @CHEMICAL$-positive foci and that higher risks are associated with a combination of residual @GENE$ pesticides in foods than with individual residual organochlorine pesticides.	false
23402856.T7.T27	On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of @CHEMICAL$-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual @GENE$ pesticides.	false
23403092.T9.T20	The food contaminant @CHEMICAL$ activates the @GENE$ in the intestine: interest of ex vivo models as an alternative to in vivo experiments.	CPR:3
23403092.T3.T14	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the @GENE$ ERK 1/2, p38 and JNK.	false
23403092.T3.T15	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the MAPK @GENE$, p38 and JNK.	false
23403092.T3.T16	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the MAPK ERK 1/2, @GENE$ and JNK.	false
23403092.T3.T17	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the MAPK ERK 1/2, p38 and @GENE$.	false
23403092.T2.T11	Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to @CHEMICAL$ lead to similar intestinal lesions and activation of @GENE$.	CPR:3
23403272.T19.T33	@CHEMICAL$ protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the @GENE$/heme oxygenase-1 pathway.	CPR:3
23403272.T19.T34	@CHEMICAL$ protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/@GENE$ pathway.	CPR:3
23403272.T20.T33	Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the @CHEMICAL$/@GENE$ oxygenase-1 pathway.	false
23403272.T20.T34	Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/@CHEM-GENE$ pathway.	false
23403272.T10.T29	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	CPR:4
23403272.T10.T30	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	CPR:4
23403272.T10.T31	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.	CPR:3
23403272.T10.T32	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.	CPR:3
23403272.T11.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T11.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T11.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.	false
23403272.T11.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T12.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T12.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T12.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.	false
23403272.T12.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T13.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T13.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T13.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.	false
23403272.T13.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T14.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEM-GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T14.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T14.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.	false
23403272.T14.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T15.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ (LDH) leakage, and enhanced production of the endogenous antioxidants, @GENE$ (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T15.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@CHEMICAL$) leakage, and enhanced production of the endogenous antioxidants, @GENE$ (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T15.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, @CHEMICAL$ (GSH) and @GENE$ (SOD) in EA.hy926 cells.	false
23403272.T15.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, @CHEMICAL$ (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T16.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (@GENE$) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T16.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@CHEMICAL$) leakage, and enhanced production of the endogenous antioxidants, glutathione (@GENE$) and superoxide dismutase (SOD) in EA.hy926 cells.	false
23403272.T16.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (@CHEMICAL$) and @GENE$ (SOD) in EA.hy926 cells.	false
23403272.T16.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (@CHEMICAL$) and superoxide dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T17.T29	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ dismutase (SOD) in EA.hy926 cells.	false
23403272.T17.T30	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@CHEMICAL$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ dismutase (SOD) in EA.hy926 cells.	false
23403272.T17.T31	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @CHEM-GENE$ (SOD) in EA.hy926 cells.	false
23403272.T17.T32	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @CHEMICAL$ dismutase (@GENE$) in EA.hy926 cells.	false
23403272.T18.T21	Treatment of these cells with @CHEMICAL$ significantly induced @GENE$ expression.	CPR:3
23403272.T1.T22	Moreover, @CHEMICAL$ promoted the nuclear translocation of @GENE$ (Nrf-2).	false
23403272.T1.T23	Moreover, @CHEMICAL$ promoted the nuclear translocation of nuclear factor erythroid 2 related factor-2 (@GENE$).	false
23403272.T2.T24	The @CHEMICAL$-induced @GENE$ expression was abrogated by Nrf2 siRNA.	CPR:3
23403272.T2.T25	The @CHEMICAL$-induced HO-1 expression was abrogated by @GENE$ siRNA.	false
23403272.T3.T26	Furthermore, inhibition of @CHEMICAL$ with @GENE$ (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.	CPR:4
23403272.T4.T26	Furthermore, inhibition of @CHEMICAL$ with zinc protoporphyrin IX (@GENE$) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.	CPR:4
23403272.T5.T26	Furthermore, inhibition of @CHEMICAL$ with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of @GENE$ against radiation-induced damage in EA.hy926 cells.	CPR:3
23403272.T6.T27	Our findings confirmed that @CHEMICAL$ protected EA.hy926 cells against radiation-induced injury through the @GENE$/HO-1 pathway.	CPR:3
23403272.T6.T28	Our findings confirmed that @CHEMICAL$ protected EA.hy926 cells against radiation-induced injury through the Nrf2/@GENE$ pathway.	CPR:3
23404093.T3.T10	The use of a combination of a @CHEMICAL$ @GENE$ receptor antagonist, dexamethasone and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	false
23404093.T3.T11	The use of a combination of a @CHEMICAL$ 5-HT3 receptor antagonist, dexamethasone and a @GENE$ antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	false
23404093.T4.T10	The use of a combination of a serotonin @CHEMICAL$ receptor antagonist, @GENE$ and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	false
23404093.T4.T11	The use of a combination of a serotonin 5-HT3 receptor antagonist, @CHEMICAL$ and a @GENE$ antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	false
23404093.T5.T12	@CHEMICAL$, a second-generation @GENE$ receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.	CPR:6
23404093.T5.T13	@CHEMICAL$, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation @GENE$ receptor antagonists appears to be the most effective agent in its class.	false
23404093.T6.T14	@CHEMICAL$, the first and only agent clinically available in the @GENE$ antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.	CPR:6
23404093.T6.T15	@CHEMICAL$, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the @GENE$ receptor antagonists and dexamethasone to control CINV.	false
23404093.T7.T14	Aprepitant, the first and only agent clinically available in the @CHEMICAL$ antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and @GENE$ to control CINV.	false
23404093.T7.T15	Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the @CHEMICAL$ receptor antagonists and @GENE$ to control CINV.	false
23404093.T8.T16	@CHEMICAL$ and netupitant are other @GENE$ antagonists that are currently in phase III clinical trials.	CPR:6
23404093.T9.T16	Rolapitant and @CHEMICAL$ are other @GENE$ antagonists that are currently in phase III clinical trials.	CPR:6
23409765.T3.T10	The case study of @CHEMICAL$ synthase (@GENE$) illustrates how such an equilibrium holds lessons for disease mechanisms, drug discovery, understanding drug side effects, and identifying proteins wherein drug discovery efforts might focus on quaternary structure dynamics.	false
23409765.T3.T9	The case study of @CHEM-GENE$ (PBGS) illustrates how such an equilibrium holds lessons for disease mechanisms, drug discovery, understanding drug side effects, and identifying proteins wherein drug discovery efforts might focus on quaternary structure dynamics.	false
23409765.T1.T6	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, HIV integrase, @GENE$, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T1.T4	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEM-GENE$, HIV integrase, pyruvate kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T1.T5	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, @GENE$, pyruvate kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T1.T7	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, HIV integrase, pyruvate kinase, and @GENE$. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T1.T8	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, HIV integrase, pyruvate kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of @GENE$ and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T2.T6	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, @CHEM-GENE$, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T2.T4	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$, HIV integrase, @GENE$ kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T2.T5	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, @CHEMICAL$, @GENE$ kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T2.T7	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, @CHEMICAL$ kinase, and @GENE$. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23409765.T2.T8	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, @CHEMICAL$ kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of @GENE$ and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	false
23411235.T11.T14	As part of a comprehensive study of the physiochemical and biological properties of @CHEMICAL$, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and @GENE$ cholesterol (LDL-C) oxidation assay.	false
23411235.T11.T15	As part of a comprehensive study of the physiochemical and biological properties of @CHEMICAL$, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and low-density lipoprotein cholesterol (@GENE$-C) oxidation assay.	false
23411235.T1.T14	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, @CHEMICAL$-linoleate model system and @GENE$ cholesterol (LDL-C) oxidation assay.	false
23411235.T1.T15	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, @CHEMICAL$-linoleate model system and low-density lipoprotein cholesterol (@GENE$-C) oxidation assay.	false
23411235.T2.T14	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-@CHEMICAL$ model system and @GENE$ cholesterol (LDL-C) oxidation assay.	false
23411235.T2.T15	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-@CHEMICAL$ model system and low-density lipoprotein cholesterol (@GENE$-C) oxidation assay.	false
23411235.T3.T14	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and @CHEMICAL$ @GENE$ (LDL-C) oxidation assay.	false
23411235.T3.T15	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and low-density lipoprotein @CHEMICAL$ (@GENE$-C) oxidation assay.	false
23411235.T10.T16	Moderate inhibitory effect of @CHEMICAL$-C oxidation by @GENE$ was observed.	CPR:4
23411279.T8.T13	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the @GENE$ pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	CPR:4
23411279.T8.T14	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild @GENE$ inhibitory activity.	CPR:4
23411279.T8.T10	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting @GENE$ (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	CPR:4
23411279.T8.T11	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate @GENE$ (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	CPR:4
23411279.T8.T12	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and @GENE$ (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	CPR:4
23411280.T11.T18	Inhibitory activity of Filipendula ulmaria constituents on recombinant @CHEM-GENE$.	false
23411280.T10.T12	@CHEMICAL$ (HDC) catalyses the formation of histamine, a bioactive @GENE$.	CPR:9
23411280.T10.T15	Histidine decarboxylase (@CHEMICAL$) catalyses the formation of histamine, a bioactive @GENE$.	CPR:9
23411280.T1.T12	@CHEM-GENE$ (HDC) catalyses the formation of histamine, a bioactive amine.	false
23411280.T1.T15	@CHEMICAL$ decarboxylase (@GENE$) catalyses the formation of histamine, a bioactive amine.	false
23411280.T8.T12	@CHEMICAL$ (HDC) catalyses the formation of @GENE$, a bioactive amine.	CPR:9
23411280.T8.T15	Histidine decarboxylase (@CHEMICAL$) catalyses the formation of @GENE$, a bioactive amine.	CPR:9
23411280.T2.T13	Agents that control @CHEMICAL$ activity are beneficial for treating @GENE$-mediated symptoms, such as allergies and stomach ulceration.	false
23411280.T3.T14	We searched for inhibitors of @CHEMICAL$ from the @GENE$ extract of the petal of Filipendula ulmaria, also called meadowsweet.	CPR:4
23414838.T6.T10	Discovery of a novel series of @CHEMICAL$ @GENE$ agonists.	CPR:5
23414838.T7.T10	Discovery of a novel series of quinolone @CHEM-GENE$ agonists.	false
23414838.T4.T8	High throughput screening led to the identification of a novel series of @CHEMICAL$ a7 nicotinic acetylcholine receptor (@GENE$) agonists.	CPR:5
23414838.T4.T9	High throughput screening led to the identification of a novel series of @CHEMICAL$ @GENE$ (nAChR) agonists.	CPR:5
23414838.T5.T8	High throughput screening led to the identification of a novel series of quinolone a7 nicotinic @CHEMICAL$ receptor (@GENE$) agonists.	false
23414838.T5.T9	High throughput screening led to the identification of a novel series of quinolone @CHEM-GENE$ (nAChR) agonists.	false
23416002.T7.T17	@CHEMICAL$ derived quinazolines as @GENE$/PKA inhibitors.	CPR:4
23416002.T7.T18	@CHEMICAL$ derived quinazolines as Rock/@GENE$ inhibitors.	CPR:4
23416002.T8.T17	Amino acid derived @CHEMICAL$ as @GENE$/PKA inhibitors.	CPR:4
23416002.T8.T18	Amino acid derived @CHEMICAL$ as Rock/@GENE$ inhibitors.	CPR:4
23416002.T5.T13	SAR and lead optimization studies for @CHEMICAL$ inhibitors based on @GENE$-derived quinazolines are described.	CPR:4
23416002.T6.T13	SAR and lead optimization studies for @CHEMICAL$ inhibitors based on amino acid-derived @GENE$ are described.	CPR:4
23416002.T1.T9	Studies demonstrated that these @CHEMICAL$ derived quinazolinones were mainly pan-@GENE$ inhibitors.	false
23416002.T2.T9	Studies demonstrated that these amino acid derived @CHEMICAL$ were mainly pan-@GENE$ inhibitors.	false
23416002.T3.T12	This is distinct from @CHEMICAL$ inhibitors based on non-@GENE$ derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.	CPR:4
23416002.T3.T14	This is distinct from Rock inhibitors based on non-@CHEMICAL$ derived quinazolinones, where high selectivity against @GENE$ could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.	CPR:4
23416002.T3.T15	This is distinct from Rock inhibitors based on non-@CHEMICAL$ derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of @GENE$, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.	false
23416002.T3.T16	This is distinct from Rock inhibitors based on non-@CHEMICAL$ derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair @GENE$ inhibition, and good human microsomal stability.	false
23416002.T4.T12	This is distinct from @CHEMICAL$ inhibitors based on non-amino acid derived @GENE$, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.	CPR:4
23416002.T4.T14	This is distinct from Rock inhibitors based on non-amino acid derived @CHEMICAL$, where high selectivity against @GENE$ could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.	CPR:4
23416002.T4.T15	This is distinct from Rock inhibitors based on non-amino acid derived @CHEMICAL$, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of @GENE$, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.	false
23416002.T4.T16	This is distinct from Rock inhibitors based on non-amino acid derived @CHEMICAL$, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair @GENE$ inhibition, and good human microsomal stability.	false
23416065.T17.T27	@CHEMICAL$-based design of a @GENE$ prodrug.	false
23416065.T5.T23	The @CHEMICAL$ inhibitor, @GENE$, is used in the clinic for its anti-inflammatory activity.	CPR:4
23416065.T2.T19	About 99% of a dose of @CHEMICAL$ is unavailable for reaction with the target enzyme, because diflunisal strongly binds to @GENE$ (HSA).	false
23416065.T2.T20	About 99% of a dose of @CHEMICAL$ is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (@GENE$).	false
23416065.T3.T19	About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because @CHEMICAL$ strongly binds to @GENE$ (HSA).	false
23416065.T3.T20	About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because @CHEMICAL$ strongly binds to human serum albumin (@GENE$).	false
23416065.T4.T21	To reduce the binding affinity of @CHEMICAL$ to @GENE$, we designed and synthesized the prodrug acetyldiflunisal.	false
23416065.T6.T21	To reduce the binding affinity of diflunisal to @CHEMICAL$, we designed and synthesized the prodrug @GENE$.	false
23416065.T10.T24	The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the @CHEMICAL$ and that upon binding, it acetylates @GENE$ 199.	false
23416065.T10.T22	The crystal structure of @CHEMICAL$ complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates @GENE$ 199.	false
23416065.T7.T24	The crystal structure of HSA complexed with @CHEMICAL$ and acetyldiflunisal revealed that acetyldiflunisal binds to the @GENE$ and that upon binding, it acetylates lysine 199.	false
23416065.T7.T22	The crystal structure of @CHEMICAL$ complexed with @GENE$ and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.	false
23416065.T8.T24	The crystal structure of HSA complexed with fatty acid and @CHEMICAL$ revealed that acetyldiflunisal binds to the @GENE$ and that upon binding, it acetylates lysine 199.	false
23416065.T8.T22	The crystal structure of @CHEMICAL$ complexed with fatty acid and @GENE$ revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.	false
23416065.T9.T24	The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that @CHEMICAL$ binds to the @GENE$ and that upon binding, it acetylates lysine 199.	false
23416065.T9.T22	The crystal structure of @CHEMICAL$ complexed with fatty acid and acetyldiflunisal revealed that @GENE$ binds to the IIA subdomain and that upon binding, it acetylates lysine 199.	false
23416065.T13.T25	The @CHEMICAL$ had twofold weaker binding affinity for @GENE$ as demonstrated by fluorescence quenching.	false
23416065.T14.T26	Reduced binding affinity means that @CHEMICAL$ is more easily released from @GENE$ into the circulation.	false
23416065.T1.T18	Taken together, our results not only provide a template for design of @CHEMICAL$-based prodrugs, but also pave the way toward more effective use of @GENE$ in the clinic.	false
23424204.T15.T32	Effect of @CHEMICAL$ on @GENE$ signal transduction and glucose oxidation in skeletal muscle of adult male albino rat.	false
23424204.T16.T32	Effect of bisphenol-A on @CHEMICAL$ signal transduction and @GENE$ oxidation in skeletal muscle of adult male albino rat.	false
23424204.T10.T24	In the present study, we investigated the possible effects of @CHEMICAL$ on @GENE$-signaling molecules and glucose oxidation in skeletal muscle of male rat.	false
23424204.T11.T24	In the present study, we investigated the possible effects of BPA on @CHEMICAL$-signaling molecules and @GENE$ oxidation in skeletal muscle of male rat.	false
23424204.T13.T17	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, @GENE$ and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T27	Although there was no change in the levels of insulin receptor (IR), @CHEMICAL$ (protein kinase B) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T28	Although there was no change in the levels of insulin receptor (IR), Akt (@CHEMICAL$) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T18	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and @GENE$ protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T25	Although there was no change in the levels of @CHEMICAL$ (IR), Akt (protein kinase B) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T26	Although there was no change in the levels of insulin receptor (@CHEMICAL$), Akt (protein kinase B) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T29	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEM-GENE$ (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T30	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (@GENE$) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T13.T31	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the @GENE$, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T17	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @CHEMICAL$ significantly decreased the IR, @GENE$ and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	CPR:4
23424204.T14.T27	Although there was no change in the levels of insulin receptor (IR), @CHEMICAL$ (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T28	Although there was no change in the levels of insulin receptor (IR), Akt (@CHEMICAL$) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T18	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @CHEMICAL$ significantly decreased the IR, Akt and @GENE$ protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	CPR:4
23424204.T14.T25	Although there was no change in the levels of @CHEMICAL$ (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T26	Although there was no change in the levels of insulin receptor (@CHEMICAL$), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T29	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T30	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (@CHEMICAL$) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	false
23424204.T14.T31	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @CHEMICAL$ significantly decreased the @GENE$, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	CPR:4
23424204.T2.T19	There was an increase in serum @CHEMICAL$ and decrease in serum @GENE$ levels but fasting blood glucose level remained unaltered.	false
23424204.T3.T19	There was an increase in serum @CHEMICAL$ and decrease in serum testosterone levels but fasting blood @GENE$ level remained unaltered.	false
23424204.T4.T20	In conclusion, @CHEMICAL$ has adverse effects on phosphorylation of @GENE$, GLUT4 translocation and (14)C-glucose oxidation.	CPR:4
23424204.T4.T21	In conclusion, @CHEMICAL$ has adverse effects on phosphorylation of Akt, @GENE$ translocation and (14)C-glucose oxidation.	CPR:4
23424204.T5.T20	In conclusion, BPA has adverse effects on phosphorylation of @CHEMICAL$, GLUT4 translocation and @GENE$ oxidation.	false
23424204.T5.T21	In conclusion, BPA has adverse effects on phosphorylation of Akt, @CHEMICAL$ translocation and @GENE$ oxidation.	false
23424207.T21.T41	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @GENE$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T21.T42	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @GENE$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T21.T43	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @GENE$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T21.T44	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @GENE$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T21.T45	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T21.T46	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T21.T47	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	CPR:4
23424207.T22.T41	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, @GENE$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T22.T42	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, @GENE$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T22.T43	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, @GENE$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T22.T44	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @GENE$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T22.T45	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T22.T46	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T22.T47	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T41	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEM-GENE$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T42	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, @GENE$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T43	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, @GENE$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T44	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and @GENE$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T45	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T46	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T23.T47	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T41	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T42	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @CHEMICAL$, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T43	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @CHEMICAL$ and testicular steroidogenic enzymes: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T44	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @CHEMICAL$: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T45	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEM-GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T46	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T24.T47	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	false
23424207.T25.T41	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T25.T42	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @CHEMICAL$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T25.T43	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @CHEMICAL$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T25.T44	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @CHEMICAL$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T25.T45	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T25.T46	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@CHEMICAL$), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T25.T47	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @CHEMICAL$ activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.	false
23424207.T26.T41	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T26.T42	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @CHEMICAL$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T26.T43	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @CHEMICAL$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T26.T44	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @CHEMICAL$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T26.T45	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T26.T46	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@CHEMICAL$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T26.T47	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @CHEMICAL$ activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.	false
23424207.T27.T40	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).	CPR:4
23424207.T27.T48	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (@GENE$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T49	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@GENE$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T52	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @GENE$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T53	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T56	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).	CPR:4
23424207.T27.T50	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @GENE$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T51	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@GENE$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T54	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T27.T55	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).	CPR:4
23424207.T28.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).	false
23424207.T28.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEM-GENE$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (@GENE$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), @GENE$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (@GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).	false
23424207.T28.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), @GENE$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (@GENE$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T28.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).	false
23424207.T29.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEM-GENE$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (@GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).	false
23424207.T29.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T29.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).	false
23424207.T31.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEM-GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).	false
23424207.T31.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T31.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).	false
23424207.T32.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ reductase (GR), glutathione (GSH), and @GENE$ (GST)).	false
23424207.T32.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEM-GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T32.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @CHEMICAL$ (GSH), and glutathione-S-transferase (@GENE$)).	false
23424207.T33.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @CHEMICAL$ (GSH), and @GENE$ (GST)).	false
23424207.T33.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T33.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), @GENE$ (GSH), and glutathione-S-transferase (GST)).	false
23424207.T34.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@CHEMICAL$), and glutathione-S-transferase (@GENE$)).	false
23424207.T34.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@CHEMICAL$), and @GENE$ (GST)).	false
23424207.T34.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T34.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), glutathione (@GENE$), and glutathione-S-transferase (GST)).	false
23424207.T35.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @CHEMICAL$-S-transferase (@GENE$)).	false
23424207.T35.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @CHEM-GENE$ (GST)).	false
23424207.T35.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T35.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), glutathione (GSH), and @GENE$-S-transferase (GST)).	false
23424207.T36.T40	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@CHEMICAL$-transferase (@GENE$)).	false
23424207.T36.T48	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T49	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T52	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T53	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T56	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @CHEM-GENE$ (GST)).	false
23424207.T36.T50	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T51	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T54	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23424207.T36.T55	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).	false
23425605.T2.T27	The @CHEM-GENE$ inhibitor a-methyltyrosine (300mM, 24h) completely abolished MeHg-induced DA release.	false
23425605.T3.T27	The @CHEMICAL$ inhibitor @GENE$ (300mM, 24h) completely abolished MeHg-induced DA release.	CPR:4
23425605.T4.T27	The @CHEMICAL$ inhibitor a-methyltyrosine (300mM, 24h) completely abolished @GENE$-induced DA release.	false
23425605.T5.T28	@CHEMICAL$ significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10mM), revealing that MeHg increases @GENE$ activity.	false
23425605.T6.T28	MeHg significantly increased DA precursor accumulation in cells treated with @CHEMICAL$ (10mM), revealing that MeHg increases @GENE$ activity.	false
23425605.T7.T28	MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10mM), revealing that @CHEMICAL$ increases @GENE$ activity.	CPR:3
23425605.T8.T28	MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10mM), revealing that MeHg increases @CHEM-GENE$ activity.	false
23428155.T2.T10	The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of @CHEMICAL$ analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low @GENE$ inhibition.	CPR:4
23428155.T3.T10	The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against @CHEMICAL$-resistant strains and low @GENE$ inhibition.	false
23428155.T5.T10	The solubility-driven structural modification of @CHEMICAL$ is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low @GENE$ inhibition.	false
23430109.T18.T38	Activity of @CHEMICAL$ against clinically-relevant AC220-resistant @GENE$ mutants of FLT3-ITD.	false
23430109.T18.T39	Activity of @CHEMICAL$ against clinically-relevant AC220-resistant kinase domain mutants of @GENE$-ITD.	false
23430109.T19.T38	Activity of ponatinib against clinically-relevant @CHEMICAL$-resistant @GENE$ mutants of FLT3-ITD.	false
23430109.T19.T39	Activity of ponatinib against clinically-relevant @CHEMICAL$-resistant kinase domain mutants of @GENE$-ITD.	false
23430109.T10.T27	Secondary point mutations in the @CHEM-GENE$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.	false
23430109.T10.T35	Secondary point mutations in the Fms-like @CHEMICAL$ kinase 3 (FLT3) tyrosine kinase domain (@GENE$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.	false
23430109.T10.T24	Secondary point mutations in the Fms-like @CHEMICAL$ kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @GENE$ inhibitors AC220 (quizartinib) and sorafenib.	false
23430109.T12.T27	Secondary point mutations in the @CHEM-GENE$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.	false
23430109.T12.T35	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) @CHEMICAL$ kinase domain (@GENE$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.	false
23430109.T12.T24	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) @CHEMICAL$ kinase domain (KD) are common causes of acquired clinical resistance to the @GENE$ inhibitors AC220 (quizartinib) and sorafenib.	false
23430109.T3.T27	Secondary point mutations in the @CHEMICAL$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors @GENE$ (quizartinib) and sorafenib.	false
23430109.T3.T35	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (@CHEMICAL$) are common causes of acquired clinical resistance to the FLT3 inhibitors @GENE$ (quizartinib) and sorafenib.	false
23430109.T3.T24	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @CHEMICAL$ inhibitors @GENE$ (quizartinib) and sorafenib.	CPR:4
23430109.T4.T27	Secondary point mutations in the @CHEMICAL$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (@GENE$) and sorafenib.	false
23430109.T4.T35	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (@CHEMICAL$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (@GENE$) and sorafenib.	false
23430109.T4.T24	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @CHEMICAL$ inhibitors AC220 (@GENE$) and sorafenib.	CPR:4
23430109.T5.T27	Secondary point mutations in the @CHEMICAL$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and @GENE$.	false
23430109.T5.T35	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (@CHEMICAL$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and @GENE$.	false
23430109.T5.T24	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @CHEMICAL$ inhibitors AC220 (quizartinib) and @GENE$.	CPR:4
23430109.T6.T25	@CHEMICAL$ (AP24534) is a @GENE$ inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	CPR:4
23430109.T6.T26	@CHEMICAL$ (AP24534) is a multikinase inhibitor with in vitro and clinical activity in @GENE$ inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	false
23430109.T6.T28	@CHEMICAL$ (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of @GENE$ mutation.	false
23430109.T7.T25	Ponatinib (@CHEMICAL$) is a @GENE$ inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	CPR:4
23430109.T7.T26	Ponatinib (@CHEMICAL$) is a multikinase inhibitor with in vitro and clinical activity in @GENE$ inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	false
23430109.T7.T28	Ponatinib (@CHEMICAL$) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of @GENE$ mutation.	false
23430109.T8.T25	Ponatinib (AP24534) is a @CHEMICAL$ inhibitor with in vitro and clinical activity in @GENE$ kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	false
23430109.T8.T26	Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in @CHEM-GENE$ inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	false
23430109.T8.T28	Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in @CHEMICAL$ kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of @GENE$ mutation.	false
23430109.T9.T29	@CHEMICAL$ has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in @GENE$.	false
23430109.T11.T30	We assessed the in vitro activity of @CHEMICAL$ against clinically relevant @GENE$-ITD mutant isoforms that confer resistance to AC220 or sorafenib.	false
23430109.T13.T30	We assessed the in vitro activity of ponatinib against clinically relevant @CHEMICAL$-ITD mutant isoforms that confer resistance to @GENE$ or sorafenib.	false
23430109.T14.T30	We assessed the in vitro activity of ponatinib against clinically relevant @CHEMICAL$-ITD mutant isoforms that confer resistance to AC220 or @GENE$.	false
23430109.T15.T32	"Substitution of the FLT3 ""gatekeeper"" @CHEMICAL$ with leucine (@GENE$) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."	false
23430109.T15.T33	"Substitution of the FLT3 ""gatekeeper"" @CHEMICAL$ with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the @GENE$ (AL) residue D835 conferred a high degree of resistance."	false
23430109.T15.T34	"Substitution of the FLT3 ""gatekeeper"" @CHEMICAL$ with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (@GENE$) residue D835 conferred a high degree of resistance."	false
23430109.T15.T31	"Substitution of the @CHEMICAL$ ""gatekeeper"" @GENE$ with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."	false
23430109.T16.T32	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with @CHEMICAL$ (@GENE$) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."	false
23430109.T16.T33	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with @CHEMICAL$ (F691L) conferred mild resistance to ponatinib, but substitutions at the @GENE$ (AL) residue D835 conferred a high degree of resistance."	false
23430109.T16.T34	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with @CHEMICAL$ (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (@GENE$) residue D835 conferred a high degree of resistance."	false
23430109.T16.T31	"Substitution of the @CHEMICAL$ ""gatekeeper"" phenylalanine with @GENE$ (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."	false
23430109.T17.T32	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with leucine (@CHEMICAL$) conferred mild resistance to @GENE$, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."	false
23430109.T17.T33	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with leucine (F691L) conferred mild resistance to @CHEMICAL$, but substitutions at the @GENE$ (AL) residue D835 conferred a high degree of resistance."	false
23430109.T17.T34	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with leucine (F691L) conferred mild resistance to @CHEMICAL$, but substitutions at the FLT3 activation loop (@GENE$) residue D835 conferred a high degree of resistance."	false
23430109.T17.T31	"Substitution of the @CHEMICAL$ ""gatekeeper"" phenylalanine with leucine (F691L) conferred mild resistance to @GENE$, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."	false
23430109.T1.T20	The switch control inhibitor @CHEMICAL$ was similarly inactive against @GENE$ AL mutations.	false
23430109.T2.T21	On the basis of its in vitro activity against @CHEMICAL$ TKI-resistant F691 substitutions, further clinical evaluation of @GENE$ in TKI-naive and select TKI-resistant FLT3-ITD+ AML patients is warranted.	false
23430109.T2.T22	On the basis of its in vitro activity against FLT3 TKI-resistant F691 substitutions, further clinical evaluation of @CHEMICAL$ in TKI-naive and select TKI-resistant @GENE$-ITD+ AML patients is warranted.	false
23432582.T11.T21	@CHEMICAL$ Cause G2/M Arrest Associated with the Modulation of @GENE$ and Chk2 in Human Breast Cancer MCF-7 Cells.	false
23432582.T11.T22	@CHEMICAL$ Cause G2/M Arrest Associated with the Modulation of CDK1 and @GENE$ in Human Breast Cancer MCF-7 Cells.	false
23432582.T10.T17	However, the involvement of the @CHEMICAL$-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor @GENE$.	false
23432582.T10.T18	However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan@CHEMICAL$ inhibitor @GENE$.	CPR:4
23432582.T9.T17	However, the involvement of the @CHEMICAL$-dependent pathway in the process of cell death induced by either @GENE$ 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk.	false
23432582.T9.T18	However, the involvement of the caspase-dependent pathway in the process of cell death induced by either @CHEMICAL$ 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan@GENE$ inhibitor z-VAD-fmk.	false
23432582.T2.T12	Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in @CHEMICAL$ levels could be detected in MCF-7 cells after @GENE$ 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.	false
23432582.T2.T19	Moreover, since reduced levels of @CHEMICAL$ and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after @GENE$ 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.	CPR:4
23432582.T2.T20	Moreover, since reduced levels of p21CIP1 and @CHEMICAL$ proteins but no change in p53 levels could be detected in MCF-7 cells after @GENE$ 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.	CPR:4
23432582.T3.T12	Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in @CHEMICAL$ levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that @GENE$ treated cells die from lethal mitosis.	false
23432582.T3.T19	Moreover, since reduced levels of @CHEMICAL$ and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that @GENE$ treated cells die from lethal mitosis.	false
23432582.T3.T20	Moreover, since reduced levels of p21CIP1 and @CHEMICAL$ proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that @GENE$ treated cells die from lethal mitosis.	false
23434223.T7.T11	A one-pot domino synthesis and discovery of highly functionalized @CHEMICAL$ as @GENE$ inhibitors.	CPR:4
23434223.T6.T10	These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and @CHEMICAL$ was found to be the most potent against @GENE$ with IC50 4.16 mmol/L.	CPR:4
23434223.T6.T8	These compounds were evaluated for their @CHEMICAL$ (AChE) inhibitory activity and @GENE$ was found to be the most potent against AChE with IC50 4.16 mmol/L.	false
23434223.T6.T9	These compounds were evaluated for their acetylcholinesterase (@CHEMICAL$) inhibitory activity and @GENE$ was found to be the most potent against AChE with IC50 4.16 mmol/L.	false
23434829.T10.T26	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEM-GENE$ for binding to integrin.	false
23434829.T10.T27	Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-@CHEMICAL$ (RGD) domain for binding to @GENE$.	false
23434829.T10.T24	@CHEMICAL$ (OPN), an extracellular matrix protein, has a functional arginine-glycine-@GENE$ (RGD) domain for binding to integrin.	false
23434829.T10.T25	Osteopontin (@CHEMICAL$), an extracellular matrix protein, has a functional arginine-glycine-@GENE$ (RGD) domain for binding to integrin.	false
23434829.T8.T26	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEM-GENE$ for binding to integrin.	false
23434829.T8.T27	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEMICAL$-glycine-aspartic acid (RGD) domain for binding to @GENE$.	false
23434829.T8.T24	@CHEMICAL$ (OPN), an extracellular matrix protein, has a functional @GENE$-glycine-aspartic acid (RGD) domain for binding to integrin.	false
23434829.T8.T25	Osteopontin (@CHEMICAL$), an extracellular matrix protein, has a functional @GENE$-glycine-aspartic acid (RGD) domain for binding to integrin.	false
23434829.T9.T26	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEM-GENE$ for binding to integrin.	false
23434829.T9.T27	Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-@CHEMICAL$-aspartic acid (RGD) domain for binding to @GENE$.	false
23434829.T9.T24	@CHEMICAL$ (OPN), an extracellular matrix protein, has a functional arginine-@GENE$-aspartic acid (RGD) domain for binding to integrin.	false
23434829.T9.T25	Osteopontin (@CHEMICAL$), an extracellular matrix protein, has a functional arginine-@GENE$-aspartic acid (RGD) domain for binding to integrin.	false
23434829.T11.T30	OPN increased the mRNA and protein expression of @CHEMICAL$ (P-gp), a subfamily of @GENE$-binding cassette transporter in a concentration- and time-dependent manner.	false
23434829.T11.T31	OPN increased the mRNA and protein expression of p-glycoprotein (@CHEMICAL$), a subfamily of @GENE$-binding cassette transporter in a concentration- and time-dependent manner.	false
23434829.T11.T32	OPN increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of @CHEM-GENE$ in a concentration- and time-dependent manner.	false
23434829.T11.T29	@CHEMICAL$ increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of @GENE$-binding cassette transporter in a concentration- and time-dependent manner.	false
23434829.T12.T36	@CHEMICAL$ (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and @GENE$ increased the drug pumping-out activity.	false
23434829.T13.T36	Daunomycin (@CHEMICAL$), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and @GENE$ increased the drug pumping-out activity.	false
23434829.T14.T38	OPN inhibited @CHEMICAL$-induced cell death, which was antagonized by @GENE$ monoclonal antibody.	false
23434829.T14.T37	@CHEMICAL$ inhibited @GENE$-induced cell death, which was antagonized by avb3 monoclonal antibody.	false
23434829.T1.T15	Long-term treatment with @CHEMICAL$ further enhanced the expression of @GENE$.	false
23434829.T2.T16	Knockdown of endogenous @CHEMICAL$ potentiated the @GENE$-induced apoptosis of PC-3 cells.	false
23434829.T3.T18	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including @CHEMICAL$, doxorubicin, actinomycin-D, and rapamycin, which are also @GENE$ substrates.	CPR:9
23434829.T3.T17	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including @GENE$, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.	false
23434829.T4.T18	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, @CHEMICAL$, actinomycin-D, and rapamycin, which are also @GENE$ substrates.	CPR:9
23434829.T4.T17	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including paclitaxel, @GENE$, actinomycin-D, and rapamycin, which are also P-gp substrates.	false
23434829.T5.T18	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, @CHEMICAL$, and rapamycin, which are also @GENE$ substrates.	CPR:9
23434829.T5.T17	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, @GENE$, and rapamycin, which are also P-gp substrates.	false
23434829.T6.T18	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and @CHEMICAL$, which are also @GENE$ substrates.	CPR:9
23434829.T6.T17	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and @GENE$, which are also P-gp substrates.	false
23434829.T7.T19	The animal studies also showed that @CHEMICAL$ knockdown enhanced the cytotoxic action of @GENE$.	false
23436791.T13.T21	A combination strategy to inhibit @CHEMICAL$: synergism between noncompetitive and @GENE$-competitive inhibitors.	false
23436791.T3.T15	Pim-1 is a @CHEM-GENE$ critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	false
23436791.T3.T14	@CHEMICAL$ is a @GENE$/threonine kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	false
23436791.T5.T15	Pim-1 is a @CHEM-GENE$ critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	false
23436791.T5.T14	@CHEMICAL$ is a serine/@GENE$ kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	false
23436791.T6.T19	In an effort to discover new potent @CHEMICAL$ inhibitors, a previously identified @GENE$-competitive indolyl-pyrrolone scaffold was expanded to derive structure-activity relationship data.	false
23436791.T7.T19	In an effort to discover new potent @CHEMICAL$ inhibitors, a previously identified ATP-competitive @GENE$ scaffold was expanded to derive structure-activity relationship data.	false
23436791.T1.T16	A synergistic effect in the inhibition of cell proliferation by @CHEMICAL$-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all @GENE$ inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.	false
23436791.T2.T16	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and @CHEMICAL$-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all @GENE$ inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.	false
23436791.T4.T16	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all @CHEMICAL$ inhibitors tested in showed synergism with the known anticancer agent, @GENE$.	false
23443628.T9.T14	PURPOSE: @CHEMICAL$ inhibitors and @GENE$ are the mainstay of pharmacological intervention for the cognitive symptoms of Alzheimer's disease (AD).	false
23452205.T4.T10	Introduction: The mGlu2 receptor, which belongs to the @CHEM-GENE$ (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology.	false
23452205.T4.T6	Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic @CHEMICAL$ receptors (mGlu) along with the @GENE$, has proven to be of particular importance in neuropharmacology.	false
23452205.T4.T7	Introduction: The @CHEMICAL$, which belongs to the group II subfamily of metabotropic @GENE$ receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology.	false
23452205.T1.T8	Preferentially expressed on presynaptic nerve terminals, the @CHEMICAL$ negatively modulates @GENE$ and GABA release and is widely distributed in the brain.	false
23452205.T2.T8	Preferentially expressed on presynaptic nerve terminals, the @CHEMICAL$ negatively modulates glutamate and @GENE$ release and is widely distributed in the brain.	false
23452205.T3.T9	High levels of @CHEMICAL$ are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where @GENE$ hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.	false
23454148.T12.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEM-GENE$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.	false
23454148.T12.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, @GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and @GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T12.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.	false
23454148.T13.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEM-GENE$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.	false
23454148.T13.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, @GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and @GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T13.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.	false
23454148.T14.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase @GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.	false
23454148.T14.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEM-GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and @GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T14.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.	false
23454148.T15.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and @GENE$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.	false
23454148.T15.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and @GENE$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEM-GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T15.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.	false
23454148.T16.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine @GENE$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.	false
23454148.T16.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine @GENE$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEM-GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T16.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.	false
23454148.T17.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.	false
23454148.T17.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEM-GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T17.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.	false
23454148.T19.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @CHEMICAL$ activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@CHEMICAL$ rats showed higher @GENE$ and depleted xanthine oxidase activities.	CPR:3
23454148.T19.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.	false
23454148.T19.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@CHEMICAL$ rats showed higher quinone reductase and depleted @GENE$ activities.	CPR:4
23454148.T20.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @CHEMICAL$ activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @CHEM-GENE$ and depleted xanthine oxidase activities.	false
23454148.T20.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.	false
23454148.T20.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @CHEMICAL$ reductase and depleted @GENE$ activities.	false
23454148.T21.T26	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T32	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @CHEMICAL$ activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T33	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @CHEMICAL$ and depleted @GENE$ oxidase activities.	false
23454148.T21.T27	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T29	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T30	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T31	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.	false
23454148.T21.T34	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @CHEM-GENE$ activities.	false
23454148.T2.T25	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated @CHEMICAL$ production in PM-MMC rats. Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing @GENE$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.	false
23454148.T4.T25	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated prostaglandin E2 production in PM-@CHEMICAL$ rats. Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing @GENE$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.	false
23454148.T5.T25	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated prostaglandin E2 production in PM-MMC rats. Conclusively, protein malnutrition alters CP, FU and @CHEMICAL$ metabolism in rat stomach by enhancing @GENE$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.	CPR:9
23454148.T7.T25	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated prostaglandin E2 production in PM-MMC rats. Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing @CHEMICAL$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of @GENE$, potentiating their gastrotoxicity.	false
23454527.T1.T10	@CHEMICAL$ (NAC, 33 mM) and the c-jun N-terminal kinase (@GENE$) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	false
23454527.T1.T9	@CHEMICAL$ (NAC, 33 mM) and the @GENE$ (JNK) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	false
23454527.T2.T10	N-acetylcysteine (@CHEMICAL$, 33 mM) and the c-jun N-terminal kinase (@GENE$) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	false
23454527.T2.T9	N-acetylcysteine (@CHEMICAL$, 33 mM) and the @GENE$ (JNK) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	false
23454527.T3.T10	N-acetylcysteine (NAC, 33 mM) and the c-jun @CHEMICAL$-terminal kinase (@GENE$) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	false
23454527.T3.T9	N-acetylcysteine (NAC, 33 mM) and the @CHEM-GENE$ (JNK) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	false
23454527.T4.T10	N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (@CHEMICAL$) inhibitor (@GENE$, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	CPR:4
23454527.T4.T9	N-acetylcysteine (NAC, 33 mM) and the @CHEMICAL$ (JNK) inhibitor (@GENE$, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.	CPR:4
23455312.T21.T37	Cerebrovascular Dilation via Selective Targeting of the @CHEMICAL$ Steroid-Recognition Site in the @GENE$ by a Novel Nonsteroidal Agent.	false
23455312.T22.T37	Cerebrovascular Dilation via Selective Targeting of the Cholane @CHEMICAL$-Recognition Site in the @GENE$ by a Novel Nonsteroidal Agent.	false
23455312.T10.T34	The @CHEM-GENE$ subunit is particularly abundant in vascular smooth muscle.	false
23455312.T14.T34	The @CHEM-GENE$ subunit is particularly abundant in vascular smooth muscle.	false
23455312.T11.T32	The endogenous steroid @CHEMICAL$ (LCA) dilates cerebral arteries via @GENE$ activation, which requires recognition by a BK b1 site that includes Thr169.	false
23455312.T11.T33	The endogenous steroid @CHEMICAL$ (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a @GENE$ site that includes Thr169.	false
23455312.T12.T32	The endogenous steroid lithocholic acid (@CHEMICAL$) dilates cerebral arteries via @GENE$ activation, which requires recognition by a BK b1 site that includes Thr169.	false
23455312.T12.T33	The endogenous steroid lithocholic acid (@CHEMICAL$) dilates cerebral arteries via BK channel activation, which requires recognition by a @GENE$ site that includes Thr169.	false
23455312.T13.T32	The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via @CHEMICAL$ activation, which requires recognition by a BK b1 site that includes @GENE$169.	false
23455312.T13.T33	The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a @CHEMICAL$ site that includes @GENE$169.	false
23455312.T9.T32	The endogenous @CHEMICAL$ lithocholic acid (LCA) dilates cerebral arteries via @GENE$ activation, which requires recognition by a BK b1 site that includes Thr169.	false
23455312.T9.T33	The endogenous @CHEMICAL$ lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a @GENE$ site that includes Thr169.	false
23455312.T18.T36	@CHEMICAL$ activated the @GENE$ cloned from rat cerebral artery myocytes with a potency (EC50 = 53 mM) similar to and an efficacy (*2.5 potentiation) significantly greater than that of LCA.	CPR:3
23455312.T19.T36	HENA activated the @CHEMICAL$ cloned from rat cerebral artery myocytes with a potency (EC50 = 53 mM) similar to and an efficacy (*2.5 potentiation) significantly greater than that of @GENE$.	CPR:3
23455312.T1.T23	@CHEMICAL$ failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets @GENE$ via the BK b1 steroid-sensing site.	CPR:3
23455312.T1.T24	@CHEMICAL$ failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets b1-containing BK channels via the @GENE$ steroid-sensing site.	false
23455312.T2.T23	HENA failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets @CHEMICAL$ via the BK b1 @GENE$-sensing site.	false
23455312.T2.T24	HENA failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets b1-containing BK channels via the @CHEMICAL$ @GENE$-sensing site.	false
23455312.T5.T25	@CHEMICAL$ failed to dilate the arteries from the @GENE$ knockout mouse, underscoring BK b1's role in HENA action.	false
23455312.T5.T26	@CHEMICAL$ failed to dilate the arteries from the KCNMB1 knockout mouse, underscoring @GENE$'s role in HENA action.	false
23455312.T6.T25	HENA failed to dilate the arteries from the @CHEMICAL$ knockout mouse, underscoring BK b1's role in @GENE$ action.	false
23455312.T6.T26	HENA failed to dilate the arteries from the KCNMB1 knockout mouse, underscoring @CHEMICAL$'s role in @GENE$ action.	false
23455312.T7.T28	Finally, carotid artery-infusion of @CHEMICAL$ (45 mM) dilated the pial cerebral arterioles via selective @GENE$ targeting.	false
23455312.T8.T29	In conclusion, we have identified for the first time a nonsteroidal agent that selectively activates @CHEMICAL$ by targeting the @GENE$-sensing site in BK b1, rendering vasodilation.	false
23455312.T8.T31	In conclusion, we have identified for the first time a nonsteroidal agent that selectively activates b1-containing BK channels by targeting the @CHEMICAL$-sensing site in @GENE$, rendering vasodilation.	false
23455597.T15.T21	Assessment of the abuse liability of @CHEMICAL$, a novel @GENE$ antagonist.	CPR:6
23455597.T16.T21	Assessment of the abuse liability of ABT-288, a novel @CHEM-GENE$ antagonist.	false
23455597.T10.T17	RATIONALE: @CHEMICAL$ antagonists, such as @GENE$, have been shown to possess cognitive-enhancing and wakefulness-promoting effects.	CPR:6
23455597.T2.T17	RATIONALE: @CHEM-GENE$ antagonists, such as ABT-288, have been shown to possess cognitive-enhancing and wakefulness-promoting effects.	false
23455597.T7.T18	CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to @CHEMICAL$ antagonists, indicates that @GENE$ is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard.	false
23455597.T7.T19	CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that @CHEMICAL$ is unlikely to possess a high potential for abuse in the human population and suggests that @GENE$ antagonists, as a class, are similar in this regard.	CPR:6
23456038.T2.T15	Additionally, a structural model of the @CHEM-GENE$ obtained by molecular dynamics simulation and energy minimization suggests that the phosphate moiety of phospho-S16 could compete with the phospho-substrate.	false
23456038.T3.T15	Additionally, a structural model of the @CHEMICAL$ obtained by molecular dynamics simulation and energy minimization suggests that the @GENE$ moiety of phospho-S16 could compete with the phospho-substrate.	false
23456038.T4.T15	Additionally, a structural model of the @CHEMICAL$ obtained by molecular dynamics simulation and energy minimization suggests that the phosphate moiety of @GENE$-S16 could compete with the phospho-substrate.	false
23456038.T5.T15	Additionally, a structural model of the @CHEMICAL$ obtained by molecular dynamics simulation and energy minimization suggests that the phosphate moiety of phospho-S16 could compete with the @GENE$-substrate.	false
23461378.T3.T12	Uptake of @CHEMICAL$ (5 nM) by @GENE$ was reduced by 82%-95%.	CPR:9
23461378.T1.T13	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), @GENE$ (84%-98%) and lopinavir (64%-89%).	CPR:9
23461378.T2.T13	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and @GENE$ (64%-89%).	CPR:9
23461378.T4.T13	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for @GENE$ (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).	CPR:9
23461378.T5.T13	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), @GENE$ (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).	CPR:9
23461378.T6.T13	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), @GENE$ (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).	CPR:9
23461841.T5.T20	A @CHEMICAL$ tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @GENE$, glucose, FFA and aldosterone.	false
23461841.T6.T20	A glucose tolerance test with 75 g @CHEMICAL$ load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @GENE$, glucose, FFA and aldosterone.	false
23461841.T8.T20	A glucose tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @CHEMICAL$, @GENE$, FFA and aldosterone.	false
23461841.T9.T20	A glucose tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @CHEMICAL$, glucose, FFA and @GENE$.	false
23461841.T2.T18	Since FFAs are known to be involved in the development of @CHEMICAL$ resistance, these results suggest that @GENE$ may be useful for lowering insulin resistance in PCOS patients.	false
23461841.T2.T19	Since FFAs are known to be involved in the development of insulin resistance, these results suggest that @CHEMICAL$ may be useful for lowering @GENE$ resistance in PCOS patients.	false
23466488.T38.T58	Oral l-glutamine increases active @CHEMICAL$ (7-36) amide secretion and improves glycemic control in stretpozotocin-@GENE$ induced diabetic rats.	false
23466488.T39.T58	Oral l-glutamine increases active @CHEMICAL$ (7-36) @GENE$ secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.	false
23466488.T40.T58	Oral @CHEMICAL$ increases active @GENE$ (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.	CPR:3
23466488.T41.T58	Oral l-glutamine increases active @CHEMICAL$ (7-36) amide secretion and improves glycemic control in @GENE$-nicotinamide induced diabetic rats.	false
23466488.T30.T57	It decreased blood @CHEMICAL$, stimulated @GENE$ secretion in type 2 diabetic patients.	false
23466488.T18.T54	The objective of the present investigation was to evaluate @CHEMICAL$ increases @GENE$ (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	CPR:3
23466488.T18.T55	The objective of the present investigation was to evaluate @CHEMICAL$ increases glucagon like peptide-1 (@GENE$) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	CPR:3
23466488.T22.T54	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) @GENE$ secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T22.T55	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) @GENE$ secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T23.T54	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in @GENE$-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T23.T55	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in @GENE$-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T24.T54	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in streptozotocin-@GENE$ (STZ-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T24.T55	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in streptozotocin-@GENE$ (STZ-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T25.T54	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (@GENE$-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T25.T55	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in streptozotocin-nicotinamide (@GENE$-NTM) induced diabetic Sprague Dawley rats.	false
23466488.T26.T54	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-@GENE$) induced diabetic Sprague Dawley rats.	false
23466488.T26.T55	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-@GENE$) induced diabetic Sprague Dawley rats.	false
23466488.T2.T42	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) @GENE$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T2.T45	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic @GENE$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T2.T46	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@GENE$, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T2.T47	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$, glutathione S transferase) were measured after 8week.	false
23466488.T2.T48	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$) were measured after 8week.	false
23466488.T2.T43	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) @GENE$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T2.T44	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon @GENE$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T3.T42	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T3.T45	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T3.T46	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T3.T47	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @CHEMICAL$, malondialdehyde, @GENE$, glutathione S transferase) were measured after 8week.	false
23466488.T3.T48	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @CHEMICAL$, malondialdehyde, glutathione peroxidase, @GENE$) were measured after 8week.	false
23466488.T3.T43	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T3.T44	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T4.T42	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T4.T45	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T4.T46	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T4.T47	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @CHEMICAL$, @GENE$, glutathione S transferase) were measured after 8week.	false
23466488.T4.T48	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @CHEMICAL$, glutathione peroxidase, @GENE$) were measured after 8week.	false
23466488.T4.T43	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T4.T44	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T5.T42	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T5.T45	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T5.T46	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T5.T47	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @CHEM-GENE$, glutathione S transferase) were measured after 8week.	false
23466488.T5.T48	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @CHEMICAL$ peroxidase, @GENE$) were measured after 8week.	false
23466488.T5.T43	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T5.T44	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.	false
23466488.T6.T42	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.	false
23466488.T6.T45	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.	false
23466488.T6.T46	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.	false
23466488.T6.T47	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @CHEMICAL$, @GENE$ S transferase) were measured after 8week.	false
23466488.T6.T48	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @CHEM-GENE$) were measured after 8week.	false
23466488.T6.T43	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.	false
23466488.T6.T44	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.	false
23466488.T12.T50	Plasma @CHEMICAL$, active GLP-1 (7-36) amide concentration and @GENE$ levels were measured after glucose loading.	false
23466488.T12.T49	Plasma @CHEMICAL$, active @GENE$ (7-36) amide concentration and insulin levels were measured after glucose loading.	false
23466488.T13.T50	Plasma glucose, active GLP-1 (7-36) @CHEMICAL$ concentration and @GENE$ levels were measured after glucose loading.	false
23466488.T13.T49	Plasma glucose, active @CHEMICAL$ (7-36) @GENE$ concentration and insulin levels were measured after glucose loading.	false
23466488.T14.T50	Plasma glucose, active GLP-1 (7-36) amide concentration and @CHEMICAL$ levels were measured after @GENE$ loading.	false
23466488.T14.T49	Plasma glucose, active @CHEMICAL$ (7-36) amide concentration and insulin levels were measured after @GENE$ loading.	false
23466488.T15.T51	The docking data indicated that @CHEMICAL$ bind to the @GENE$.	false
23466488.T16.T52	@CHEMICAL$ decreased plasma glucose, increased plasma and pancreatic @GENE$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	CPR:3
23466488.T16.T53	@CHEMICAL$ decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @GENE$ (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	CPR:3
23466488.T17.T52	l-glutamine decreased plasma @CHEMICAL$, increased plasma and pancreatic @GENE$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	false
23466488.T17.T53	l-glutamine decreased plasma @CHEMICAL$, increased plasma and pancreatic insulin, increased plasma and colonic active @GENE$ (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	false
23466488.T19.T52	l-glutamine decreased plasma glucose, increased plasma and pancreatic @CHEMICAL$, increased plasma and colonic active GLP-1 (7-36) @GENE$ secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	false
23466488.T19.T53	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @CHEMICAL$ (7-36) @GENE$ secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	false
23466488.T20.T52	l-glutamine decreased plasma glucose, increased plasma and pancreatic @CHEMICAL$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in @GENE$-nicotinamide induced diabetic rats.	false
23466488.T20.T53	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @CHEMICAL$ (7-36) amide secretion as well as decreased oxidative stress in @GENE$-nicotinamide induced diabetic rats.	false
23466488.T21.T52	l-glutamine decreased plasma glucose, increased plasma and pancreatic @CHEMICAL$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-@GENE$ induced diabetic rats.	false
23466488.T21.T53	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @CHEMICAL$ (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-@GENE$ induced diabetic rats.	false
23466526.T2.T18	ZEB2 @CHEM-GENE$ missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome.	false
23466526.T2.T17	@CHEMICAL$ @GENE$-finger missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome.	false
23466526.T1.T15	His1045Arg, identified in the highly conserved @CHEM-GENE$ of ZEB2.	false
23466526.T1.T16	His1045Arg, identified in the highly conserved C-@CHEMICAL$-finger (C-ZF) domain of @GENE$.	false
23470280.T11.T26	@CHEMICAL$ and @GENE$ enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala.	false
23470280.T5.T18	While these behaviors can be modulated by @CHEMICAL$ (CRF) and @GENE$ signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.	false
23470280.T5.T19	While these behaviors can be modulated by corticotropin releasing factor (@CHEMICAL$) and @GENE$ signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.	false
23470280.T6.T21	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEM-GENE$ agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	false
23470280.T6.T20	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, @GENE$ (DA) and the b-adrenergic receptor agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	false
23470280.T7.T21	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEMICAL$ agonist @GENE$ (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	false
23470280.T7.T20	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, dopamine (DA) and the b-adrenergic receptor agonist @GENE$ (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	false
23470280.T8.T21	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEMICAL$ agonist isoproterenol (@GENE$) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	false
23470280.T8.T20	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, dopamine (DA) and the b-adrenergic receptor agonist isoproterenol (@GENE$) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	false
23470280.T9.T21	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEMICAL$ agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic @GENE$ release.	false
23470280.T9.T20	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, dopamine (DA) and the b-adrenergic receptor agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic @GENE$ release.	false
23470280.T10.T12	While previous work from our lab suggests that CRFRs mediate the effect of @CHEMICAL$ on excitatory transmission in other subregions of the extended amygdala, blockade of @GENE$ in the CeAL failed to significantly alter effects of DA and ISO on glutamatergic transmission.	false
23470280.T10.T25	While previous work from our lab suggests that @CHEMICAL$ mediate the effect of @GENE$ on excitatory transmission in other subregions of the extended amygdala, blockade of CRFRs in the CeAL failed to significantly alter effects of DA and ISO on glutamatergic transmission.	false
23470280.T1.T12	While previous work from our lab suggests that CRFRs mediate the effect of catecholamines on excitatory transmission in other subregions of the extended amygdala, blockade of @CHEMICAL$ in the CeAL failed to significantly alter effects of DA and @GENE$ on glutamatergic transmission.	false
23470280.T1.T25	While previous work from our lab suggests that @CHEMICAL$ mediate the effect of catecholamines on excitatory transmission in other subregions of the extended amygdala, blockade of CRFRs in the CeAL failed to significantly alter effects of DA and @GENE$ on glutamatergic transmission.	false
23470280.T2.T13	These findings suggest that @CHEMICAL$ and @GENE$ enhancement of glutamatergic transmission onto CeAL neurons occurs via distinct mechanisms.	false
23470280.T3.T14	While @CHEMICAL$ increased spontaneous @GENE$ release in the CeAL, CRF caused no significant changes to optogenetically evoked glutamate release in this region.	false
23470280.T3.T15	While CRF increased spontaneous @CHEMICAL$ release in the CeAL, @GENE$ caused no significant changes to optogenetically evoked glutamate release in this region.	false
23470280.T4.T14	While @CHEMICAL$ increased spontaneous glutamate release in the CeAL, CRF caused no significant changes to optogenetically evoked @GENE$ release in this region.	false
23470280.T4.T15	While CRF increased spontaneous glutamate release in the CeAL, @CHEMICAL$ caused no significant changes to optogenetically evoked @GENE$ release in this region.	false
23470776.T3.T8	Environmental stress, @CHEM-GENE$ gene (OXTR) polymorphism, and mental health following collective stress.	false
23470776.T3.T9	Environmental stress, @CHEMICAL$ receptor gene (@GENE$) polymorphism, and mental health following collective stress.	false
23470776.T1.T5	We examined whether the @CHEM-GENE$ gene (OXTR) single nucleotide polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	false
23470776.T1.T6	We examined whether the @CHEMICAL$ receptor gene (@GENE$) single nucleotide polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	false
23470776.T2.T5	We examined whether the @CHEMICAL$ gene (OXTR) single @GENE$ polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	false
23470776.T2.T6	We examined whether the oxytocin receptor gene (@CHEMICAL$) single @GENE$ polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	false
23473037.T1.T9	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a @CHEM-GENE$.	false
23473037.T1.T8	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of @CHEMICAL$, corresponding to a @GENE$-to-proline mutation at residue 107.	false
23473037.T2.T9	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a @CHEM-GENE$.	false
23473037.T2.T8	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of @CHEMICAL$, corresponding to a leucine-to-@GENE$ mutation at residue 107.	false
23473037.T3.T11	Expression of SIRT1-@CHEMICAL$ in insulin-producing cells resulted in overproduction of @GENE$, cytokines, and chemokines.	false
23473037.T3.T14	Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of @CHEMICAL$, @GENE$, and chemokines.	false
23473037.T3.T15	Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of @CHEMICAL$, cytokines, and @GENE$.	false
23473037.T3.T10	Expression of @CHEMICAL$-L107P in insulin-producing cells resulted in overproduction of @GENE$, cytokines, and chemokines.	false
23473037.T3.T12	Expression of SIRT1-L107P in @CHEMICAL$-producing cells resulted in overproduction of @GENE$, cytokines, and chemokines.	false
23473679.T8.T11	Melanoma targeting property of a @CHEMICAL$-labeled lactam bridge-cyclized @GENE$ peptide.	false
23473679.T9.T11	Melanoma targeting property of a Lu-177-labeled @CHEMICAL$ bridge-cyclized @GENE$ peptide.	false
23473679.T6.T10	The purpose of this study was to determine the melanoma targeting property of @CHEM-GENE$ in B16/F1 melanoma-bearing C57 mice.	false
23473801.T12.T26	In the present study, @CHEMICAL$ (1 and 2mM) inhibited the @GENE$-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.	CPR:4
23473801.T12.T27	In the present study, @CHEMICAL$ (1 and 2mM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including @GENE$, arachidonic acid, and ADP.	false
23473801.T13.T26	In the present study, hinokitiol (1 and 2mM) inhibited the @CHEMICAL$-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, @GENE$, and ADP.	false
23473801.T13.T27	In the present study, hinokitiol (1 and 2mM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including @CHEMICAL$, @GENE$, and ADP.	false
23473801.T14.T26	In the present study, hinokitiol (1 and 2mM) inhibited the @CHEMICAL$-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and @GENE$.	false
23473801.T14.T27	In the present study, hinokitiol (1 and 2mM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including @CHEMICAL$, arachidonic acid, and @GENE$.	false
23473801.T15.T29	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, @GENE$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T15.T30	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@GENE$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T15.T31	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @GENE$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T15.T32	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@GENE$), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T15.T33	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @GENE$ in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T15.T34	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @GENE$-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T15.T28	@CHEMICAL$ inhibited the phosphorylation of @GENE$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	CPR:4
23473801.T16.T29	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, @CHEMICAL$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T16.T30	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@CHEMICAL$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T16.T31	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @CHEMICAL$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T16.T32	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@CHEMICAL$), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T16.T33	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @CHEMICAL$ in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T16.T34	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @CHEMICAL$-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T16.T28	Hinokitiol inhibited the phosphorylation of @CHEMICAL$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.	false
23473801.T17.T29	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, @CHEMICAL$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T17.T30	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@CHEMICAL$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T17.T31	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @CHEMICAL$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T17.T32	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@CHEMICAL$), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T17.T33	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @CHEMICAL$ in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T17.T34	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @CHEMICAL$-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T17.T28	Hinokitiol inhibited the phosphorylation of @CHEMICAL$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.	false
23473801.T18.T29	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, @CHEMICAL$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T18.T30	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@CHEMICAL$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T18.T31	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @CHEMICAL$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T18.T32	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@CHEMICAL$), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T18.T33	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @CHEMICAL$ in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T18.T34	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @CHEMICAL$-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T18.T28	Hinokitiol inhibited the phosphorylation of @CHEMICAL$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.	false
23473801.T19.T35	@CHEMICAL$ also reduced the @GENE$ activation and platelet aggregation stimulated by PDBu.	CPR:4
23473801.T3.T21	@CHEMICAL$ did not influence the binding of a fluorescent triflavin probe to the @GENE$ on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.	false
23473801.T4.T21	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the @CHEMICAL$ on platelet membrane, and neither @GENE$ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.	false
23473801.T5.T21	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the @CHEMICAL$ on platelet membrane, and neither ODQ nor @GENE$ significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.	false
23473801.T6.T21	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the @CHEMICAL$ on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the @GENE$-mediated inhibition of platelet aggregation.	false
23473801.T7.T23	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the PLCg2-@GENE$ cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.	CPR:4
23473801.T7.T24	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of @GENE$ and Akt.	CPR:4
23473801.T7.T25	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and @GENE$.	CPR:4
23473801.T7.T22	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the @GENE$-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.	CPR:4
23473801.T8.T23	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCg2-@CHEMICAL$ cascade and @GENE$ radical formation, followed by suppressing the activation of MAPKs and Akt.	false
23473801.T8.T24	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and @CHEMICAL$ radical formation, followed by suppressing the activation of @GENE$ and Akt.	false
23473801.T8.T25	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and @CHEMICAL$ radical formation, followed by suppressing the activation of MAPKs and @GENE$.	false
23473801.T8.T22	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the @CHEMICAL$-PKC cascade and @GENE$ radical formation, followed by suppressing the activation of MAPKs and Akt.	false
23474386.T4.T11	Novel @CHEMICAL$ derivatives as potent @GENE$ inhibitors.	CPR:4
23474386.T3.T5	A series of novel @CHEMICAL$ were designed, synthesized and biologically evaluated for @GENE$ inhibition.	false
23477419.T17.T21	Design, Synthesis, and Pharmacological Characterization of Novel @CHEMICAL$ Analogues as Extremely Potent @GENE$ Agonists.	CPR:5
23477419.T10.T20	Of the new compounds, Dmt(1)-(R)-bPro(2)-@CHEMICAL$(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).	false
23477419.T11.T20	Of the new compounds, Dmt(1)-(R)-bPro(2)-Trp(3)-@CHEMICAL$(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).	false
23477419.T8.T20	Of the new compounds, @CHEMICAL$(1)-(R)-bPro(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).	false
23477419.T9.T20	Of the new compounds, Dmt(1)-@CHEMICAL$(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).	false
23478260.T2.T5	We report that two common variants of @CHEMICAL$ (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for @GENE$34 and Gly36 to less frequently used codons.	false
23478260.T2.T6	We report that two common variants of high-temperature requirement A1 (@CHEMICAL$) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for @GENE$34 and Gly36 to less frequently used codons.	false
23478260.T2.T7	We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of @CHEMICAL$ that convert common codons for @GENE$34 and Gly36 to less frequently used codons.	false
23478260.T3.T5	We report that two common variants of @CHEMICAL$ (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and @GENE$36 to less frequently used codons.	false
23478260.T3.T6	We report that two common variants of high-temperature requirement A1 (@CHEMICAL$) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and @GENE$36 to less frequently used codons.	false
23478260.T3.T7	We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of @CHEMICAL$ that convert common codons for Ala34 and @GENE$36 to less frequently used codons.	false
23485402.T2.T19	In search of a basis for the impressive potency of an @CHEMICAL$ that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.	false
23485402.T2.T14	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @CHEMICAL$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM @GENE$ despite cleaving <20% of the SNAP-25.	false
23485402.T2.T15	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @CHEMICAL$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the @GENE$.	false
23485402.T2.T24	In search of a basis for the impressive potency of an endoprotease that cleaves @CHEMICAL$, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.	false
23485402.T2.T28	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, @CHEMICAL$ (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.	false
23485402.T2.T6	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (@CHEMICAL$), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.	false
23485402.T1.T8	Moreover, limited cleavage of SNAP-25 was conferred onto the @CHEMICAL$ from BoNT/E when fused to the @GENE$-terminus of BoNT/A.	false
23485402.T1.T10	Moreover, limited cleavage of SNAP-25 was conferred onto the protease from BoNT/E when fused to the @CHEMICAL$-terminus of @GENE$.	false
23485402.T1.T7	Moreover, limited cleavage of @CHEMICAL$ was conferred onto the protease from BoNT/E when fused to the @GENE$-terminus of BoNT/A.	false
23485402.T1.T9	Moreover, limited cleavage of SNAP-25 was conferred onto the protease from @CHEMICAL$ when fused to the @GENE$-terminus of BoNT/A.	false
23493372.T10.T30	@CHEMICAL$-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional @GENE$.	false
23493372.T11.T30	Dexamethasone-mediated changes in adipose @CHEMICAL$ metabolism are exaggerated, not diminished, in the absence of a functional @GENE$.	false
23493372.T6.T26	To understand the role of @CHEMICAL$ dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and GR(dim/dim) mice administered the potent GC @GENE$ (DEX).	false
23493372.T6.T27	To understand the role of GR dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and @CHEMICAL$(dim/dim) mice administered the potent GC @GENE$ (DEX).	false
23493372.T7.T26	To understand the role of @CHEMICAL$ dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and GR(dim/dim) mice administered the potent GC dexamethasone (@GENE$).	false
23493372.T7.T27	To understand the role of GR dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and @CHEMICAL$(dim/dim) mice administered the potent GC dexamethasone (@GENE$).	false
23493372.T8.T28	Absolute @CHEMICAL$ synthesis was increased in both wild-type and @GENE$(dim/dim) mice by DEX in the inguinal and epididymal fat depots.	false
23493372.T9.T28	Absolute triglyceride synthesis was increased in both wild-type and @CHEMICAL$(dim/dim) mice by @GENE$ in the inguinal and epididymal fat depots.	false
23493372.T1.T29	@CHEMICAL$(dim/dim) mice showed an exaggerated response to @GENE$ in both depots.	false
23493372.T2.T12	De novo lipogenesis was also greatly increased in both depots in response to @CHEMICAL$ in @GENE$(dim/dim), but not wild-type mice.	false
23493372.T3.T13	In contrast, the inhibitory effect of @CHEMICAL$ on bone and skin collagen synthesis rates was greater in wild-type compared with @GENE$(dim/dim) mice.	false
23493372.T4.T14	Wild-type mice were more sensitive to @CHEMICAL$-dependent decreases in @GENE$ sensitivity than GR(dim/dim) mice.	false
23493372.T4.T15	Wild-type mice were more sensitive to @CHEMICAL$-dependent decreases in insulin sensitivity than @GENE$(dim/dim) mice.	false
23493372.T5.T16	Wild-type and @CHEMICAL$(dim/dim) mice were equally sensitive to @GENE$-dependent decreases in muscle protein synthesis.	false
23493568.T4.T18	X-box binding protein 1 (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in b-cells has been reported to impair @CHEMICAL$ secretion leading to @GENE$ intolerance.	false
23493568.T4.T16	@CHEMICAL$ (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in b-cells has been reported to impair insulin secretion leading to @GENE$ intolerance.	false
23493568.T4.T17	X-box binding protein 1 (@CHEMICAL$) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in b-cells has been reported to impair insulin secretion leading to @GENE$ intolerance.	false
23493568.T5.T25	aXBPKO mice exhibited @CHEMICAL$ intolerance, mild @GENE$ resistance and an inability to suppress glucagon secretion following glucose stimulation.	false
23493568.T5.T24	a@CHEMICAL$KO mice exhibited @GENE$ intolerance, mild insulin resistance and an inability to suppress glucagon secretion following glucose stimulation.	false
23493568.T5.T26	aXBPKO mice exhibited @CHEMICAL$ intolerance, mild insulin resistance and an inability to suppress @GENE$ secretion following glucose stimulation.	false
23493568.T6.T25	aXBPKO mice exhibited glucose intolerance, mild @CHEMICAL$ resistance and an inability to suppress glucagon secretion following @GENE$ stimulation.	false
23493568.T6.T24	a@CHEMICAL$KO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress glucagon secretion following @GENE$ stimulation.	false
23493568.T6.T26	aXBPKO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress @CHEMICAL$ secretion following @GENE$ stimulation.	false
23493568.T1.T8	Interestingly, insulin treatment of aXBPKD cells reduced @CHEMICAL$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of @GENE$, while enhancing serine phosphorylation (pS(307)) of IRS-1.	false
23493568.T1.T31	Interestingly, @CHEMICAL$ treatment of aXBPKD cells reduced @GENE$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.	false
23493568.T1.T32	Interestingly, insulin treatment of a@CHEMICAL$KD cells reduced @GENE$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.	false
23493568.T1.T7	Interestingly, insulin treatment of aXBPKD cells reduced @CHEMICAL$ phosphorylation of @GENE$ (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.	false
23493568.T1.T9	Interestingly, insulin treatment of aXBPKD cells reduced @CHEMICAL$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of @GENE$.	false
23493568.T2.T8	Interestingly, insulin treatment of aXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of @CHEMICAL$, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.	false
23493568.T2.T31	Interestingly, @CHEMICAL$ treatment of aXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.	false
23493568.T2.T32	Interestingly, insulin treatment of a@CHEMICAL$KD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.	false
23493568.T2.T7	Interestingly, insulin treatment of aXBPKD cells reduced tyrosine phosphorylation of @CHEMICAL$ (pY(896)), and phosphorylation of Akt, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.	false
23493568.T2.T9	Interestingly, insulin treatment of aXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing @CHEMICAL$ phosphorylation (pS(307)) of @GENE$.	false
23493568.T3.T10	Consequently the a@CHEMICAL$KD cells exhibited blunted suppression of glucagon secretion following insulin treatment in the presence of high @GENE$.	false
23493568.T3.T11	Consequently the aXBPKD cells exhibited blunted suppression of @CHEMICAL$ secretion following insulin treatment in the presence of high @GENE$.	false
23493568.T3.T12	Consequently the aXBPKD cells exhibited blunted suppression of glucagon secretion following @CHEMICAL$ treatment in the presence of high @GENE$.	false
23494106.T15.T27	Toxicological profiles of selected synthetic @CHEMICAL$ showing high binding affinities to the @GENE$.	false
23494106.T16.T27	Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the @CHEM-GENE$.	false
23494106.T10.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (@CHEMICAL$) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T11.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; @CHEMICAL$ was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T4.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four @CHEMICAL$ compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T5.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (@CHEMICAL$, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T6.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, @CHEMICAL$, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T7.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, @CHEMICAL$ and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T8.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and @CHEMICAL$) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T9.T26	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one @CHEMICAL$ (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.	false
23494106.T1.T17	Furthermore, no impact on @CHEMICAL$ release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T1.T20	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, @CHEMICAL$/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T1.T24	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @CHEMICAL$ and JWH-122 which caused a decrease of TNFa and @GENE$/23p40.	CPR:4
23494106.T1.T18	Furthermore, no impact on cytokine release (i.e., on @CHEMICAL$, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T1.T19	Furthermore, no impact on cytokine release (i.e., on IL-10, @CHEMICAL$, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T1.T21	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/@CHEMICAL$ and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T1.T22	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and @CHEMICAL$ levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T1.T23	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @CHEMICAL$ and JWH-122 which caused a decrease of @GENE$ and IL-12/23p40.	CPR:4
23494106.T1.T25	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @CHEMICAL$ and JWH-122 which caused a decrease of TNFa and IL-12/@GENE$.	CPR:4
23494106.T2.T17	Furthermore, no impact on @CHEMICAL$ release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T2.T20	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, @CHEMICAL$/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T2.T24	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @CHEMICAL$ which caused a decrease of TNFa and @GENE$/23p40.	CPR:4
23494106.T2.T18	Furthermore, no impact on cytokine release (i.e., on @CHEMICAL$, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T2.T19	Furthermore, no impact on cytokine release (i.e., on IL-10, @CHEMICAL$, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T2.T21	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/@CHEMICAL$ and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T2.T22	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and @CHEMICAL$ levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.	false
23494106.T2.T23	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @CHEMICAL$ which caused a decrease of @GENE$ and IL-12/23p40.	CPR:4
23494106.T2.T25	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @CHEMICAL$ which caused a decrease of TNFa and IL-12/@GENE$.	CPR:4
23494802.T6.T15	@CHEMICAL$ Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and @GENE$ in Obese Individuals.	false
23494802.T6.T16	@CHEMICAL$ Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to @GENE$ and Oxidized LDL in Obese Individuals.	false
23494802.T3.T10	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-Hsp27) and oxLDL (anti-@GENE$) were investigated.	false
23494802.T3.T9	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-Hsp27) and @GENE$ (anti-oxLDL) were investigated.	false
23494802.T3.T7	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to @GENE$ (anti-Hsp27) and oxLDL (anti-oxLDL) were investigated.	false
23494802.T3.T8	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-@GENE$) and oxLDL (anti-oxLDL) were investigated.	false
23494944.T9.T18	@CHEMICAL$ markedly reduced AA performance and activities of @GENE$ (COX) and acetylcholinesterase (AChE) in all regions.	CPR:4
23494944.T9.T19	@CHEMICAL$ markedly reduced AA performance and activities of cytochrome c oxidase (@GENE$) and acetylcholinesterase (AChE) in all regions.	CPR:4
23494944.T9.T20	@CHEMICAL$ markedly reduced AA performance and activities of cytochrome c oxidase (COX) and @GENE$ (AChE) in all regions.	CPR:4
23494944.T9.T21	@CHEMICAL$ markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (@GENE$) in all regions.	CPR:4
23494944.T11.T13	GTLE pretreatment completely reversed the damaging effects of @CHEMICAL$ on AA and @GENE$ activity, markedly corrected COX and AChE activities, and moderately improved TGC.	CPR:4
23494944.T11.T14	GTLE pretreatment completely reversed the damaging effects of @CHEMICAL$ on AA and superoxide dismutase activity, markedly corrected @GENE$ and AChE activities, and moderately improved TGC.	CPR:4
23494944.T11.T15	GTLE pretreatment completely reversed the damaging effects of @CHEMICAL$ on AA and superoxide dismutase activity, markedly corrected COX and @GENE$ activities, and moderately improved TGC.	CPR:4
23494944.T2.T13	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and @CHEM-GENE$ activity, markedly corrected COX and AChE activities, and moderately improved TGC.	false
23494944.T2.T14	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and @CHEMICAL$ dismutase activity, markedly corrected @GENE$ and AChE activities, and moderately improved TGC.	false
23494944.T2.T15	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and @CHEMICAL$ dismutase activity, markedly corrected COX and @GENE$ activities, and moderately improved TGC.	false
23495999.T1.T18	By modulating expression levels of endogenous @CHEMICAL$ in primary cortical neurons, the frequency and amplitude of @GENE$ oscillations is modified, implying a key role for APP in maintaining neuronal calcium homeostasis essential for synaptic transmission.	false
23495999.T1.T20	By modulating expression levels of endogenous APP in primary cortical neurons, the frequency and amplitude of @CHEMICAL$ oscillations is modified, implying a key role for @GENE$ in maintaining neuronal calcium homeostasis essential for synaptic transmission.	false
23495999.T2.T18	By modulating expression levels of endogenous @CHEMICAL$ in primary cortical neurons, the frequency and amplitude of calcium oscillations is modified, implying a key role for APP in maintaining neuronal @GENE$ homeostasis essential for synaptic transmission.	false
23495999.T2.T20	By modulating expression levels of endogenous APP in primary cortical neurons, the frequency and amplitude of calcium oscillations is modified, implying a key role for @CHEMICAL$ in maintaining neuronal @GENE$ homeostasis essential for synaptic transmission.	false
23499825.T4.T6	Furthermore, the @CHEMICAL$ (11) selectively induced apoptosis in A549 cells without affecting the @GENE$ activity level.	false
23500058.T1.T17	Female C57BL/6 mice were exposed to dextran @CHEMICAL$ (DSS) and treated by intrarectal administration with either CD.siRNA @GENE$ or a control solution.	false
23500387.T11.T21	@CHEMICAL$ attenuates allergic airway inflammation by regulation of CD4(+)CD25(+) regulatory T cells (Tregs)/Th17 balance in @GENE$-sensitized mice.	false
23500387.T10.T12	The present study aimed to determine the protective effects and the underlying mechanisms of @CHEMICAL$ on @GENE$ (OVA)-induced allergic inflammation in a mouse model of allergic asthma.	false
23500387.T10.T14	The present study aimed to determine the protective effects and the underlying mechanisms of @CHEMICAL$ on ovalbumin (@GENE$)-induced allergic inflammation in a mouse model of allergic asthma.	false
23500387.T5.T17	A total of 60 mice were randomly assigned to six experimental groups: control, model, @CHEMICAL$ (2mg/kg), and curcumin (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and eosin (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	false
23500387.T6.T17	A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg), and @CHEMICAL$ (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and eosin (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	false
23500387.T7.T17	A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg), and curcumin (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by @CHEMICAL$ and eosin (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	false
23500387.T8.T17	A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg), and curcumin (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and @CHEMICAL$ (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	false
23500387.T9.T18	Our study demonstrated that @CHEMICAL$ inhibited @GENE$-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.	CPR:4
23500387.T9.T19	Our study demonstrated that @CHEMICAL$ inhibited OVA-induced increases in eosinophil count; @GENE$ level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.	CPR:4
23500387.T9.T20	Our study demonstrated that @CHEMICAL$ inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased @GENE$ level in bronchoalveolar lavage fluid.	CPR:3
23500387.T1.T13	Histological studies demonstrated that @CHEMICAL$ substantially inhibited @GENE$-induced eosinophilia in lung tissue.	CPR:4
23500387.T3.T15	The results in vivo show @CHEMICAL$-induced significantly broke Treg/Th17 balance; @GENE$ treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.	CPR:4
23500491.T12.T24	Structural Basis for the @CHEMICAL$-Induced Isomerization of @GENE$.	false
23500491.T1.T13	@CHEMICAL$ (KIFs) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of @GENE$.	false
23500491.T1.T19	Kinesin superfamily proteins (@CHEMICAL$) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of @GENE$.	false
23500491.T1.T22	Kinesin superfamily proteins (KIFs) are @CHEMICAL$ driven by the energy derived from the hydrolysis of @GENE$.	false
23500491.T2.T18	Previous studies have revealed that the @CHEMICAL$ binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of @GENE$ activity to guarantee the processive movement of dimeric KIFs.	false
23500491.T2.T20	Previous studies have revealed that the @CHEMICAL$ binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of ATPase activity to guarantee the processive movement of dimeric @GENE$.	false
23500491.T3.T21	Here, we report the first crystal structure of @CHEMICAL$ complexed with the non-hydrolyzable @GENE$ analog, AMPPNP (adenylyl imidodiphosphate), at 1.7A resolution.	false
23500491.T4.T21	Here, we report the first crystal structure of @CHEMICAL$ complexed with the non-hydrolyzable ATP analog, @GENE$ (adenylyl imidodiphosphate), at 1.7A resolution.	false
23500491.T5.T21	Here, we report the first crystal structure of @CHEMICAL$ complexed with the non-hydrolyzable ATP analog, AMPPNP (@GENE$), at 1.7A resolution.	false
23500491.T6.T23	By combining our structure with previously solved @CHEMICAL$ structures complexed with two @GENE$ analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.	false
23500491.T7.T23	By combining our structure with previously solved @CHEMICAL$ structures complexed with two ATP analogs, molecular snapshots during @GENE$ binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.	false
23500491.T8.T23	By combining our structure with previously solved @CHEMICAL$ structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the @GENE$-binding pocket during ATP binding is achieved by closure of the backdoor.	false
23500491.T9.T23	By combining our structure with previously solved @CHEMICAL$ structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during @GENE$ binding is achieved by closure of the backdoor.	false
23500550.T3.T16	Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that @CHEMICAL$-terminal @GENE$ peptides might be considered a promising bone anabolic therapy.	false
23500550.T1.T17	In addition, putative osteogenic actions of @CHEMICAL$ might be ascribed not only to its @GENE$-terminal domain but also to its PTH-unrelated C-terminal region.	false
23500550.T1.T4	In addition, putative osteogenic actions of PTHrP might be ascribed not only to its @CHEMICAL$-terminal domain but also to its @GENE$-unrelated C-terminal region.	false
23500550.T2.T17	In addition, putative osteogenic actions of @CHEMICAL$ might be ascribed not only to its N-terminal domain but also to its PTH-unrelated @GENE$-terminal region.	false
23500550.T2.T4	In addition, putative osteogenic actions of PTHrP might be ascribed not only to its N-terminal domain but also to its @CHEMICAL$-unrelated @GENE$-terminal region.	false
23504356.T1.T3	While studies of @CHEMICAL$, @GENE$, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics.	false
23504356.T2.T4	Newer lines of research, including cholinergic and glutamatergic agents and @CHEM-GENE$, will be of considerable interest in the future.	false
23510370.T1.T17	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), @CHEMICAL$ (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T18	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (@CHEMICAL$) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T11	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for @CHEMICAL$, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T12	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, @CHEMICAL$, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T13	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, @CHEMICAL$ (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T14	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (@CHEMICAL$/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T15	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/@CHEMICAL$/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T16	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/@CHEMICAL$), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T19	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, @CHEMICAL$, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T20	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, @CHEMICAL$, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T21	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, @CHEM-GENE$ (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T22	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (@GENE$), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T23	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), @GENE$ (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T24	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (@GENE$) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T25	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (PAX8) and @GENE$ (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T26	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (@GENE$), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	false
23510370.T1.T2	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the @GENE$ gene by in situ hybridization analysis.	false
23511016.T6.T11	Synthesis of a @CHEMICAL$ (Gd(3+))-conjugate of @GENE$ inhibitor pantoprazole for gastric wall imaging studies.	CPR:4
23511016.T7.T11	Synthesis of a DOTA (@CHEMICAL$)-conjugate of @GENE$ inhibitor pantoprazole for gastric wall imaging studies.	CPR:4
23511016.T8.T11	Synthesis of a DOTA (Gd(3+))-conjugate of @CHEMICAL$ inhibitor @GENE$ for gastric wall imaging studies.	CPR:4
23511016.T1.T10	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a @CHEMICAL$-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to @GENE$ in the stomach and colon.	false
23511016.T1.T9	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a @CHEMICAL$-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used @GENE$ inhibitor that binds to proton pumps in the stomach and colon.	CPR:4
23511016.T2.T10	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (@CHEMICAL$), with pantoprazole, which is a widely used proton pump inhibitor that binds to @GENE$ in the stomach and colon.	false
23511016.T2.T9	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (@CHEMICAL$), with pantoprazole, which is a widely used @GENE$ inhibitor that binds to proton pumps in the stomach and colon.	CPR:4
23511016.T3.T10	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with @CHEMICAL$, which is a widely used proton pump inhibitor that binds to @GENE$ in the stomach and colon.	false
23511016.T3.T9	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with @CHEMICAL$, which is a widely used @GENE$ inhibitor that binds to proton pumps in the stomach and colon.	CPR:4
23511125.T12.T25	@CHEMICAL$ inhibition reveals endogenous nicotinic modulation of @GENE$ inputs to CA1 stratum radiatum interneurons in hippocampal slices.	false
23511125.T8.T17	The involvement of brain @CHEM-GENE$ (nAChRs) in the neurotoxicological effects of soman, a potent acetylcholinesterase (AChE) inhibitor and a chemical warfare agent, is not clear.	false
23511125.T8.T22	The involvement of brain nicotinic @CHEMICAL$ receptors (@GENE$) in the neurotoxicological effects of soman, a potent acetylcholinesterase (AChE) inhibitor and a chemical warfare agent, is not clear.	false
23511125.T8.T13	The involvement of brain nicotinic @CHEMICAL$ receptors (nAChRs) in the neurotoxicological effects of soman, a potent @GENE$ (AChE) inhibitor and a chemical warfare agent, is not clear.	false
23511125.T8.T14	The involvement of brain nicotinic @CHEMICAL$ receptors (nAChRs) in the neurotoxicological effects of soman, a potent acetylcholinesterase (@GENE$) inhibitor and a chemical warfare agent, is not clear.	false
23511125.T10.T21	To test the hypothesis that AChE inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates @CHEMICAL$-dependent @GENE$ transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	false
23511125.T10.T20	To test the hypothesis that @CHEMICAL$ inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates nAChR-dependent @GENE$ transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	false
23511125.T11.T21	To test the hypothesis that AChE inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates @CHEMICAL$-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous @GENE$ excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	false
23511125.T11.T20	To test the hypothesis that @CHEMICAL$ inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates nAChR-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous @GENE$ excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	false
23511125.T9.T21	To test the hypothesis that AChE inhibition builds sufficient @CHEMICAL$ (ACh) in the brain and facilitates @GENE$-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	false
23511125.T9.T20	To test the hypothesis that @CHEMICAL$ inhibition builds sufficient @GENE$ (ACh) in the brain and facilitates nAChR-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	false
23511125.T1.T24	Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible @CHEMICAL$ inhibitor @GENE$ (100nM).	CPR:4
23511125.T7.T16	These results support the concept that AChE inhibition is able to recruit @CHEMICAL$-dependent @GENE$ transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of soman.	false
23511125.T7.T15	These results support the concept that @CHEMICAL$ inhibition is able to recruit nAChR-dependent @GENE$ transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of soman.	false
23511711.T12.T20	A Nanogram Dose of the @CHEMICAL$ Probe Substrate @GENE$ to Evaluate Drug Interactions.	CPR:9
23511711.T3.T18	The objective of the study was to establish an in vivo method for assessing @CHEMICAL$ (CYP3A) activity using therapeutically inert nanogram doses of @GENE$.	false
23511711.T3.T19	The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (@CHEMICAL$) activity using therapeutically inert nanogram doses of @GENE$.	false
23511711.T4.T15	We administered four escalating single doses of oral @CHEMICAL$ (0.0001-3 mg) to 12 healthy participants, stratified according to @GENE$ carrier status, to assess pharmacokinetics linearity.	false
23511711.T5.T16	We then evaluated the interactions with the @CHEMICAL$ inhibitor @GENE$ (400 mg q.d.) after nanogram and regular doses of midazolam.	CPR:4
23511711.T6.T16	We then evaluated the interactions with the @CHEMICAL$ inhibitor ketoconazole (400 mg q.d.) after nanogram and regular doses of @GENE$.	false
23511711.T10.T17	@CHEMICAL$ carrier status had no influence on midazolam oral clearance or its inhibition by @GENE$.	CPR:4
23511711.T9.T17	@CHEMICAL$ carrier status had no influence on @GENE$ oral clearance or its inhibition by ketoconazole.	CPR:9
23511711.T11.T13	This is the first study showing that @CHEMICAL$ pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess @GENE$ activity even in the presence of strong CYP3A inhibitors.	false
23511711.T11.T14	This is the first study showing that @CHEMICAL$ pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong @GENE$ inhibitors.	false
23511711.T1.T13	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of @CHEMICAL$ can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess @GENE$ activity even in the presence of strong CYP3A inhibitors.	false
23511711.T1.T14	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of @CHEMICAL$ can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong @GENE$ inhibitors.	false
23511711.T2.T13	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of @CHEMICAL$ in therapeutic doses and can be used to assess @GENE$ activity even in the presence of strong CYP3A inhibitors.	false
23511711.T2.T14	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of @CHEMICAL$ in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong @GENE$ inhibitors.	false
23512501.T13.T19	@CHEM-GENE$ Inducer Activity of Some Saudi Arabian Medicinal Plants.	false
23512501.T14.T19	@CHEM-GENE$ Inducer Activity of Some Saudi Arabian Medicinal Plants.	false
23512501.T7.T16	One such multifunctional cytoprotective enzyme is @CHEM-GENE$.	false
23512501.T8.T16	One such multifunctional cytoprotective enzyme is @CHEM-GENE$.	false
23512501.T10.T17	In this study, we prepared extracts of 27 Saudi Arabian medicinal plants which belong to 18 different plant families and tested their ability to induce @CHEM-GENE$ in murine hepatoma cells grown in microtiter plate wells.	false
23512501.T9.T17	In this study, we prepared extracts of 27 Saudi Arabian medicinal plants which belong to 18 different plant families and tested their ability to induce @CHEM-GENE$ in murine hepatoma cells grown in microtiter plate wells.	false
23512501.T11.T18	In addition to the Brassicaceae, a known source of @CHEM-GENE$, we found substantial inducer activity in extracts from the Apiaceae, Apocynaceae, and the Asteraceae families.	false
23512501.T12.T18	In addition to the Brassicaceae, a known source of @CHEM-GENE$, we found substantial inducer activity in extracts from the Apiaceae, Apocynaceae, and the Asteraceae families.	false
23512501.T5.T15	Thus, the @CHEM-GENE$ inducer activity of extracts of some Saudi Arabian medicinal plants indicates the presence of specific phytochemicals which have the potential to protect against chronic degenerative diseases.	false
23512501.T6.T15	Thus, the @CHEM-GENE$ inducer activity of extracts of some Saudi Arabian medicinal plants indicates the presence of specific phytochemicals which have the potential to protect against chronic degenerative diseases.	false
23512537.T9.T23	Metabolism of @CHEMICAL$ by @GENE$ Enzymes.	CPR:9
23512537.T4.T14	It is possible that variations in @CHEMICAL$ enzyme-mediated metabolism of @GENE$ may contribute to this phenomenon.	CPR:9
23512537.T5.T15	This hypothesis was explored by evaluating the contributions of @CHEMICAL$, and esterase enzymes in the metabolism of @GENE$ in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.	false
23512537.T5.T16	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and @CHEMICAL$ enzymes in the metabolism of @GENE$ in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.	CPR:9
23512537.T5.T17	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of @CHEMICAL$ in vitro and relating metabolism to changes in @GENE$ enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.	false
23512537.T5.T18	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of @CHEMICAL$ in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the @GENE$ in lung and liver cells.	false
23512537.T7.T19	@CHEMICAL$ and CYP3A5 metabolized @GENE$ via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.	CPR:9
23512537.T7.T20	CYP3A4 and @CHEMICAL$ metabolized @GENE$ via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.	CPR:9
23512537.T7.T21	CYP3A4 and CYP3A5 metabolized @CHEMICAL$ via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; @GENE$ did not metabolize BDP.	false
23512537.T8.T19	@CHEMICAL$ and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize @GENE$.	false
23512537.T8.T20	CYP3A4 and @CHEMICAL$ metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize @GENE$.	false
23512537.T8.T21	CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; @CHEMICAL$ did not metabolize @GENE$.	false
23512537.T1.T11	These studies show that @CHEMICAL$ and CYP3A5 metabolize @GENE$ to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.	CPR:9
23512537.T1.T12	These studies show that CYP3A4 and @CHEMICAL$ metabolize @GENE$ to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.	CPR:9
23512537.T2.T11	These studies show that @CHEMICAL$ and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence @GENE$ disposition in humans.	false
23512537.T2.T12	These studies show that CYP3A4 and @CHEMICAL$ metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence @GENE$ disposition in humans.	false
23512754.T12.T21	Effect of the Potent Antiviral @CHEMICAL$ on @GENE$ Production by Murine Macrophages Stimulated with HSV-2.	false
23512754.T8.T16	The antiherpetic action of @CHEMICAL$ was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the @GENE$ production using a bioassay and ELISA method.	false
23512754.T11.T17	In macrophages, levels of @CHEMICAL$, IFN-g, NO, IL-6 and IL-10 were increased by @GENE$ used alone or in combination with HSV-2.	CPR:3
23512754.T11.T18	In macrophages, levels of TNF-a, @CHEMICAL$, NO, IL-6 and IL-10 were increased by @GENE$ used alone or in combination with HSV-2.	CPR:3
23512754.T11.T19	In macrophages, levels of TNF-a, IFN-g, NO, @CHEMICAL$ and IL-10 were increased by @GENE$ used alone or in combination with HSV-2.	CPR:3
23512754.T11.T20	In macrophages, levels of TNF-a, IFN-g, NO, IL-6 and @CHEMICAL$ were increased by @GENE$ used alone or in combination with HSV-2.	CPR:3
23512754.T1.T13	Besides, @CHEMICAL$ not only synergized @GENE$ production combined with IFN-g, but also prolonged its expression in time.	CPR:3
23512754.T1.T14	Besides, @CHEMICAL$ not only synergized TNF-a production combined with @GENE$, but also prolonged its expression in time.	CPR:3
23512754.T2.T15	Results indicate that @CHEMICAL$ inhibits HSV-2 multiplication in epithelial cells and also increases @GENE$ production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.	CPR:3
23517558.T6.T8	Intestinal and hepatic first-pass extraction of the @CHEMICAL$ inhibitor @GENE$ in rats with chronic vascular catheters.	CPR:4
23517558.T2.T7	A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an @CHEMICAL$ inhibitor, @GENE$.	CPR:4
23517733.T14.T18	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on @GENE$ (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.	false
23517733.T14.T19	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (@GENE$)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.	false
23517733.T14.T20	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced @GENE$ (TNF-a) production by these cells.	false
23517733.T14.T21	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (@GENE$) production by these cells.	false
23517733.T15.T18	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on @GENE$ (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.	false
23517733.T15.T19	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (@GENE$)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.	false
23517733.T15.T20	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced @GENE$ (TNF-a) production by these cells.	false
23517733.T15.T21	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (@GENE$) production by these cells.	false
23517733.T16.T18	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on @GENE$ (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.	false
23517733.T16.T19	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (@GENE$)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.	false
23517733.T16.T20	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced @GENE$ (TNF-a) production by these cells.	false
23517733.T16.T21	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (@GENE$) production by these cells.	false
23519149.T9.T24	@CHEMICAL$ was shown to induce rapid oncosis in @GENE$-expressing cells.	false
23519149.T14.T25	We have shown that @CHEMICAL$ is more active in cells harboring epithelial phenotype with high @GENE$ and low vimentin expression.	false
23519149.T14.T26	We have shown that @CHEMICAL$ is more active in cells harboring epithelial phenotype with high E-cadherin and low @GENE$ expression.	false
23519149.T16.T27	In addition, high @CHEMICAL$ and Muc1 expression was correlated with sensitivity to @GENE$, whereas the presence of KRAS activating mutations was associated with resistance.	false
23519149.T16.T28	In addition, high ErbB3 and @CHEMICAL$ expression was correlated with sensitivity to @GENE$, whereas the presence of KRAS activating mutations was associated with resistance.	false
23519149.T16.T29	In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to @CHEMICAL$, whereas the presence of @GENE$ activating mutations was associated with resistance.	false
23519149.T2.T19	In DU-PM cells with acquired resistance to @CHEMICAL$, @GENE$ expression was decreased, while Bcl2 was increased.	CPR:4
23519149.T2.T20	In DU-PM cells with acquired resistance to @CHEMICAL$, ErbB3 expression was decreased, while @GENE$ was increased.	CPR:3
23521495.T1.T3	The use of peptide (@CHEM-GENE$) as ligands to stabilize and functionalize gold nanoparticles provides technical and operational convenience.	false
23523780.T1.T10	w-Agatoxin-IVA is a well known @CHEMICAL$ blocker and has been shown to affect presynaptic @GENE$ currents as well postsynaptic potentials.	false
23523780.T1.T5	@CHEMICAL$ is a well known P/Q-type Ca(2+) channel blocker and has been shown to affect presynaptic @GENE$ currents as well postsynaptic potentials.	false
23523780.T4.T10	w-Agatoxin-IVA is a well known @CHEM-GENE$ blocker and has been shown to affect presynaptic Ca(2+) currents as well postsynaptic potentials.	false
23523780.T4.T5	@CHEMICAL$ is a well known P/Q-type @GENE$ channel blocker and has been shown to affect presynaptic Ca(2+) currents as well postsynaptic potentials.	false
23523780.T3.T9	@CHEM-GENE$ play a vital role in presynaptic neurotransmitter release and thus play a role in action potential generation.	false
23523780.T2.T6	Administration of @CHEMICAL$, a @GENE$ inhibitor, isolated a single response to w-agatoxin, which was characterized by a reduction in network activity.	CPR:4
23523780.T2.T7	Administration of @CHEMICAL$, a GABAA inhibitor, isolated a single response to @GENE$, which was characterized by a reduction in network activity.	CPR:4
23523781.T14.T22	There was inconsistent stereological evidence of a loss of DA neurons, as identified by chromogenic or fluorescent-tagged antibodies to @CHEM-GENE$ in the substantia nigra pars compacta (SNpc).	false
23523781.T15.T23	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of @CHEMICAL$ stain or reduced immunolabeling of @GENE$-positive (TH(+)) neurons.	false
23523781.T15.T24	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of @CHEMICAL$ stain or reduced immunolabeling of tyrosine-hydroxylase-positive (@GENE$(+)) neurons.	false
23523781.T16.T23	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of silver stain or reduced immunolabeling of @CHEM-GENE$-positive (TH(+)) neurons.	false
23523781.T16.T24	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of silver stain or reduced immunolabeling of @CHEMICAL$-hydroxylase-positive (@GENE$(+)) neurons.	false
23523781.T6.T21	This study also suggests that even if the reduction in @CHEMICAL$(+) neurons reported by others occurs in PQ-treated mice, this apparent phenotypic change is unaccompanied by neuronal cell death or by modification of @GENE$ levels in the striatum.	false
23526814.T9.T15	@CHEMICAL$-Containing @GENE$ Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.	CPR:4
23526814.T1.T10	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T1.T11	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T1.T13	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.	false
23526814.T1.T12	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T2.T10	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T2.T11	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T2.T13	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.	false
23526814.T2.T12	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T3.T10	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @CHEMICAL$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other @GENE$ effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T3.T11	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@CHEMICAL$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other @GENE$ effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T3.T13	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other @CHEMICAL$ effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.	CPR:3
23526814.T3.T12	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @CHEMICAL$ at the nanomolar level, whereas the other @GENE$ effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T4.T10	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T4.T11	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T4.T13	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.	false
23526814.T4.T12	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T6.T10	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T6.T11	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T6.T13	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.	false
23526814.T6.T12	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23526814.T8.T10	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T8.T11	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	CPR:4
23526814.T8.T13	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.	false
23526814.T8.T12	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.	false
23528299.T6.T10	Discovery of a synthetic @CHEMICAL$ inhibitor @GENE$ as a potential anticancer agent.	CPR:4
23528299.T5.T8	@CHEMICAL$ is the first synthetic @GENE$ inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.	CPR:4
23528299.T1.T9	As a potent synthetic @CHEMICAL$ inhibitor (IC50=850nM, versus @GENE$ of 8.1mM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.	CPR:4
23528299.T2.T9	As a potent synthetic @CHEMICAL$ inhibitor (IC50=850nM, versus bestatin of 8.1mM), @GENE$ was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.	CPR:4
23528299.T3.T9	As a potent synthetic @CHEMICAL$ inhibitor (IC50=850nM, versus bestatin of 8.1mM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than @GENE$.	CPR:4
23530959.T5.T15	Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): @CHEMICAL$ Catalyzed Curing through Peptidyl-@GENE$.	false
23530959.T6.T15	Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): @CHEM-GENE$ Catalyzed Curing through Peptidyl-DOPA.	false
23530959.T1.T12	Both types of granules contain @CHEM-GENE$ that catalyzes oxidative cross-linking of L-DOPA.	false
23530959.T2.T12	Both types of granules contain @CHEMICAL$ that catalyzes oxidative cross-linking of @GENE$.	CPR:9
23530959.T3.T13	Co-secretion of @CHEM-GENE$ guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets.	false
23530959.T4.T14	@CHEM-GENE$ remains active long after the glue is fully cured, perhaps providing an active cue for conspecific larval settlement.	false
23535337.T11.T29	Disruption of AtWNK8 Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating @CHEMICAL$ Content and Activities of @GENE$ and Peroxidase.	false
23535337.T11.T31	Disruption of AtWNK8 Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating @CHEMICAL$ Content and Activities of Catalase and @GENE$.	false
23535337.T11.T30	Disruption of @CHEMICAL$ Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating @GENE$ Content and Activities of Catalase and Peroxidase.	false
23535337.T10.T12	@CHEM-GENE$ (WNKs) play important roles in plant growth and development.	false
23535337.T10.T18	With no @CHEMICAL$ kinases (@GENE$) play important roles in plant growth and development.	false
23535337.T2.T17	Here, we report that @CHEMICAL$ is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by @GENE$ and sorbitol treatment.	false
23535337.T3.T17	Here, we report that @CHEMICAL$ is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by NaCl and @GENE$ treatment.	false
23535337.T4.T19	Compared to the wild-type, the T-DNA knock-out @CHEMICAL$ mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the @GENE$ and sorbitol treatment, respectively.	false
23535337.T5.T19	Compared to the wild-type, the T-DNA knock-out @CHEMICAL$ mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the NaCl and @GENE$ treatment, respectively.	false
23535337.T6.T20	The @CHEMICAL$ mutant also accumulated 1.43-fold more @GENE$ than the wild-type in the sorbitol treatment.	false
23535337.T7.T20	The @CHEMICAL$ mutant also accumulated 1.43-fold more proline than the wild-type in the @GENE$ treatment.	false
23535337.T8.T21	Under @CHEMICAL$ and sorbitol stresses, @GENE$ (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	CPR:3
23535337.T8.T22	Under @CHEMICAL$ and sorbitol stresses, catalase (@GENE$) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	CPR:3
23535337.T8.T23	Under @CHEMICAL$ and sorbitol stresses, catalase (CAT) activity in @GENE$ mutant was 1.92- and 3.7-times of that in Col-0, respectively.	false
23535337.T9.T21	Under NaCl and @CHEMICAL$ stresses, @GENE$ (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	CPR:3
23535337.T9.T22	Under NaCl and @CHEMICAL$ stresses, catalase (@GENE$) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	CPR:3
23535337.T9.T23	Under NaCl and @CHEMICAL$ stresses, catalase (CAT) activity in @GENE$ mutant was 1.92- and 3.7-times of that in Col-0, respectively.	false
23535337.T1.T14	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @CHEMICAL$ and higher activities of @GENE$ and POD might result in the higher tolerance of WNK8 to osmotic stress.	false
23535337.T1.T15	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @CHEMICAL$ and higher activities of CAT and @GENE$ might result in the higher tolerance of WNK8 to osmotic stress.	false
23535337.T1.T27	Taken together, we revealed that maintaining higher @CHEMICAL$ and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @GENE$ and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.	false
23535337.T1.T28	Taken together, we revealed that maintaining higher CAT and @CHEMICAL$ activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @GENE$ and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.	false
23535337.T1.T13	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of @CHEMICAL$ enhances the tolerance to salt stress, and accumulating more @GENE$ and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.	false
23535337.T1.T16	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @CHEMICAL$ and higher activities of CAT and POD might result in the higher tolerance of @GENE$ to osmotic stress.	false
23536314.T7.T10	Immunofluorescence staining and western blotting demonstrated that @CHEMICAL$ treatment reduced GFAP and @GENE$ expression in the retinas of OLETF rats.	CPR:4
23536314.T7.T9	Immunofluorescence staining and western blotting demonstrated that @CHEMICAL$ treatment reduced @GENE$ and VEGF expression in the retinas of OLETF rats.	CPR:4
23537661.T1.T16	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEMICAL$ (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and @GENE$) without or with 0.5M (0.5MAhR).	CPR:5
23537661.T1.T17	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (@CHEMICAL$) agonists (non-ortho PCBs, PC-dibenzodioxins and @GENE$) without or with 0.5M (0.5MAhR).	false
23537661.T1.T9	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and @CHEMICAL$) without or with 0.5M (0.5M@GENE$).	false
23537661.T6.T16	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEM-GENE$ (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	false
23537661.T6.T17	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl @CHEMICAL$ receptor (@GENE$) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	false
23537661.T6.T9	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl @CHEMICAL$ receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5M@GENE$).	false
23537661.T7.T16	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEMICAL$ (AhR) agonists (@GENE$s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	CPR:5
23537661.T7.T17	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (@CHEMICAL$) agonists (@GENE$s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	false
23537661.T7.T9	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (@CHEMICAL$s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5M@GENE$).	false
23537661.T8.T16	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEMICAL$ (AhR) agonists (non-ortho PCBs, @GENE$ and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	CPR:5
23537661.T8.T17	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (@CHEMICAL$) agonists (non-ortho PCBs, @GENE$ and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	false
23537661.T8.T9	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, @CHEMICAL$ and PC-dibenzofurans) without or with 0.5M (0.5M@GENE$).	false
23538201.T5.T29	Phlebotomy and dietary @CHEMICAL$ restriction reduces @GENE$ in NAFLD/NASH patients.	false
23538201.T1.T20	Hepatic mRNA expression of @CHEMICAL$, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.	false
23538201.T1.T21	Hepatic mRNA expression of transferrin receptor 1 and 2, @CHEMICAL$, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.	false
23538201.T1.T22	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and @CHEMICAL$ were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.	false
23538201.T1.T23	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, @CHEMICAL$, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.	false
23538201.T1.T24	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, @CHEMICAL$, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.	false
23538201.T1.T25	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and @CHEMICAL$ mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.	false
23541399.T1.T6	Although the @CHEMICAL$ deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (androgen receptor, @GENE$, Rab11A).	false
23541399.T1.T5	Although the @CHEMICAL$ deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@GENE$, calmodulin, Rab11A).	false
23541399.T1.T7	Although the @CHEMICAL$ deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (androgen receptor, calmodulin, @GENE$).	false
23541399.T3.T6	Although the androgen deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@CHEMICAL$ receptor, @GENE$, Rab11A).	false
23541399.T3.T5	Although the androgen deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@CHEM-GENE$, calmodulin, Rab11A).	false
23541399.T3.T7	Although the androgen deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@CHEMICAL$ receptor, calmodulin, @GENE$).	false
23541670.T3.T11	Discovery of a series of novel @CHEMICAL$, as potent JAK3 @GENE$ inhibitors.	CPR:4
23541670.T3.T10	Discovery of a series of novel @CHEMICAL$, as potent @GENE$ kinase inhibitors.	CPR:4
23541670.T1.T8	We report the discovery of a novel series of ATP-competitive @CHEMICAL$ (JAK3) inhibitors based on the @GENE$ scaffold.	CPR:4
23541670.T1.T9	We report the discovery of a novel series of ATP-competitive Janus kinase 3 (@CHEMICAL$) inhibitors based on the @GENE$ scaffold.	CPR:4
23541670.T2.T8	We report the discovery of a novel series of @CHEMICAL$-competitive @GENE$ (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold.	false
23541670.T2.T9	We report the discovery of a novel series of @CHEMICAL$-competitive Janus kinase 3 (@GENE$) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold.	false
23542114.T7.T13	@CHEMICAL$ depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of @GENE$ pathway.	CPR:4
23542114.T5.T11	@CHEMICAL$ inhibited the phosphorylation and activation of AKT and STAT3 through @GENE$ signaling blockade.	CPR:4
23542114.T5.T9	@CHEMICAL$ inhibited the phosphorylation and activation of @GENE$ and STAT3 through Notch signaling blockade.	CPR:4
23542114.T5.T10	@CHEMICAL$ inhibited the phosphorylation and activation of AKT and @GENE$ through Notch signaling blockade.	CPR:4
23542114.T6.T12	These data show that the @CHEMICAL$ is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of @GENE$ pathway.	CPR:4
23546605.T3.T15	Here, we quantified expression of @CHEMICAL$ and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	false
23546605.T3.T16	Here, we quantified expression of INSL3 and its receptor @CHEMICAL$ in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	false
23546605.T3.T18	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). @CHEMICAL$ and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	false
23546605.T3.T19	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and @CHEMICAL$ mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	false
23546605.T3.T20	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with @CHEMICAL$ peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	false
23546605.T3.T21	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @CHEMICAL$-active follicles and @GENE$ peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	false
23546605.T1.T5	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of @CHEMICAL$ greatly attenuated expression of both INSL3 and its receptor while increasing @GENE$ secretion and expression of STAR and CYP11A1.	false
23546605.T1.T6	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both @CHEMICAL$ and its receptor while increasing @GENE$ secretion and expression of STAR and CYP11A1.	false
23546605.T1.T7	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptor while increasing @CHEMICAL$ secretion and expression of @GENE$ and CYP11A1.	false
23546605.T1.T8	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptor while increasing @CHEMICAL$ secretion and expression of STAR and @GENE$.	false
23546605.T2.T11	Moreover, in vivo, a significant cyclic variation in plasma INSL3 was observed during synchronized estrous cycles. INSL3 and @CHEMICAL$ followed a similar pattern, both increasing after luteolysis, before falling sharply after the @GENE$ surge.	false
23546605.T2.T10	Moreover, in vivo, a significant cyclic variation in plasma INSL3 was observed during synchronized estrous cycles. @CHEMICAL$ and @GENE$ followed a similar pattern, both increasing after luteolysis, before falling sharply after the LH surge.	false
23546605.T2.T9	Moreover, in vivo, a significant cyclic variation in plasma @CHEMICAL$ was observed during synchronized estrous cycles. INSL3 and @GENE$ followed a similar pattern, both increasing after luteolysis, before falling sharply after the LH surge.	false
23556445.T2.T13	Genomic variation in the @CHEMICAL$ gene is associated with b-thalassemia disease severity and @GENE$ treatment efficacy.	false
23556445.T1.T10	Aim: In this study we explored the association between genetic variations in MAP3K5 and @CHEMICAL$ genes, residing on chromosome 6q23, and disease severity in b-hemoglobinopathy patients, as well as the association between these variants with response to @GENE$ (HU) treatment.	false
23556445.T1.T9	Aim: In this study we explored the association between genetic variations in @CHEMICAL$ and PDE7B genes, residing on chromosome 6q23, and disease severity in b-hemoglobinopathy patients, as well as the association between these variants with response to @GENE$ (HU) treatment.	false
23561166.T6.T13	The high fat diet significantly increased hepatic mRNA expressions of @CHEMICAL$, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with @GENE$.	CPR:4
23561166.T6.T14	The high fat diet significantly increased hepatic mRNA expressions of PPARg, @CHEMICAL$ and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with @GENE$.	CPR:4
23561166.T6.T15	The high fat diet significantly increased hepatic mRNA expressions of PPARg, SREBP1C and @CHEMICAL$ genes in comparison to the control diet, which was subsequently reversed by supplementation with @GENE$.	CPR:4
23561166.T7.T16	In addition, @CHEMICAL$ supplementation significantly reduced hepatic mRNA abundance of @GENE$, ATPCL and G6Pase compared to the control group.	CPR:4
23561166.T7.T17	In addition, @CHEMICAL$ supplementation significantly reduced hepatic mRNA abundance of FAS, @GENE$ and G6Pase compared to the control group.	CPR:4
23561166.T7.T18	In addition, @CHEMICAL$ supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and @GENE$ compared to the control group.	CPR:4
23561166.T8.T19	Finally, epididymal mRNA abundance of @CHEMICAL$ was significantly increased by @GENE$ supplementation, compared to levels in the control and HF groups.	CPR:3
23561166.T9.T20	Enhancement of @CHEMICAL$ expression by @GENE$ was further confirmed in differentiated 3T3-L1 adipocytes.	CPR:3
23562060.T14.T21	Discovery of @CHEMICAL$: The first sub-micromolar, selective @GENE$ PAM.	false
23562060.T12.T18	This Letter describes the further chemical optimization of the @CHEMICAL$ PAM MLPCN probes @GENE$ and ML172.	false
23562060.T13.T18	This Letter describes the further chemical optimization of the @CHEMICAL$ PAM MLPCN probes ML129 and @GENE$.	false
23562060.T4.T15	An HTS campaign identified several weak @CHEMICAL$ PAMs (M5 EC50 >10mM) with a structurally related @GENE$ core that possessed a southern phenethyl ether linkage.	false
23562060.T4.T16	An HTS campaign identified several weak M5 PAMs (@CHEMICAL$ EC50 >10mM) with a structurally related @GENE$ core that possessed a southern phenethyl ether linkage.	false
23562060.T5.T15	An HTS campaign identified several weak @CHEMICAL$ PAMs (M5 EC50 >10mM) with a structurally related isatin core that possessed a southern @GENE$ linkage.	false
23562060.T5.T16	An HTS campaign identified several weak M5 PAMs (@CHEMICAL$ EC50 >10mM) with a structurally related isatin core that possessed a southern @GENE$ linkage.	false
23562060.T10.T19	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (@CHEMICAL$), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T10.T20	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (@CHEMICAL$), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T10.T17	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar @CHEMICAL$ PAM, ML326 (@GENE$), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T11.T19	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @CHEMICAL$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the @GENE$ CRC.	false
23562060.T11.T20	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @CHEMICAL$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the @GENE$ CRC.	false
23562060.T11.T17	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar @CHEMICAL$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the @GENE$ CRC.	false
23562060.T6.T19	While SAR within the HTS series was very shallow and unable to be optimized, grafting the @CHEMICAL$ linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T6.T20	While SAR within the HTS series was very shallow and unable to be optimized, grafting the @CHEMICAL$ linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T6.T17	While SAR within the HTS series was very shallow and unable to be optimized, grafting the @CHEMICAL$ linkage onto the ML129/ML172 cores led to the first sub-micromolar @GENE$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T7.T19	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the @CHEMICAL$/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T7.T20	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the @CHEMICAL$/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T7.T17	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the @CHEMICAL$/ML172 cores led to the first sub-micromolar @GENE$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T8.T19	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/@CHEMICAL$ cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T8.T20	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/@CHEMICAL$ cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T8.T17	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/@CHEMICAL$ cores led to the first sub-micromolar @GENE$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T9.T19	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, @CHEMICAL$ (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T9.T20	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, @CHEMICAL$ (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562060.T9.T17	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar @CHEMICAL$ PAM, @GENE$ (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.	false
23562076.T1.T10	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in @CHEMICAL$(-/-) mice also lacking adaptive immunity (T-bet(-/-)xRag2(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.	false
23562076.T1.T11	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (@CHEMICAL$(-/-)xRag2(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.	false
23562076.T1.T12	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)x@CHEMICAL$(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.	false
23562076.T1.T13	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)xRag2(-/-)), demonstrating that @CHEMICAL$ expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.	false
23562076.T1.T9	However, the favorable metabolic phenotype observed in @CHEMICAL$-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)xRag2(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.	false
23567243.T6.T12	Western blot assay demonstrated that @CHEMICAL$ decreased @GENE$ level and induced Bax translocation to cause cytochrome c release.	CPR:4
23567243.T6.T13	Western blot assay demonstrated that @CHEMICAL$ decreased Bcl-2 level and induced @GENE$ translocation to cause cytochrome c release.	CPR:3
23567243.T6.T14	Western blot assay demonstrated that @CHEMICAL$ decreased Bcl-2 level and induced Bax translocation to cause @GENE$ release.	CPR:3
23567243.T7.T17	Meanwhile, the alterations of @CHEMICAL$, p-CDK1 and p-cdc25c levels were also observed in response to @GENE$ treatment.	false
23567243.T7.T18	Meanwhile, the alterations of cyclin A and B1, @CHEMICAL$ and p-cdc25c levels were also observed in response to @GENE$ treatment.	false
23567243.T7.T19	Meanwhile, the alterations of cyclin A and B1, p-CDK1 and @CHEMICAL$ levels were also observed in response to @GENE$ treatment.	false
23570998.T15.T24	@CHEMICAL$ and rutin also increased @GENE$ activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).	CPR:3
23570998.T16.T24	Quercetin and @CHEMICAL$ also increased @GENE$ activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).	CPR:3
23570998.T17.T19	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like @GENE$, osterix, RunX2, osteoprotegerin and osteocalcin.	CPR:3
23570998.T17.T20	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, @GENE$, RunX2, osteoprotegerin and osteocalcin.	CPR:3
23570998.T17.T21	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, @GENE$, osteoprotegerin and osteocalcin.	CPR:3
23570998.T17.T22	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, @GENE$ and osteocalcin.	CPR:3
23570998.T17.T23	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and @GENE$.	CPR:3
23572520.T13.T21	@CHEMICAL$-nitrosation of @GENE$ is controlled by the conformation of a dynamic active-site helix.	false
23572520.T14.T21	S-nitrosation of @CHEM-GENE$ is controlled by the conformation of a dynamic active-site helix.	false
23572520.T8.T17	We used transient kinetic methods to determine a minimal mechanism for spontaneous GSNO-mediated transnitrosation of @CHEM-GENE$, a major detoxification enzyme and key regulator of cell proliferation.	false
23572520.T9.T18	C47 of @CHEMICAL$ is @GENE$-nitrosated in two steps, with the chemical step limited by a pre-equilibrium between the open and closed conformations of helix a2 at the active site.	false
23572520.T12.T19	Despite the presence of a @CHEMICAL$ at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using @GENE$ demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.	false
23572520.T12.T15	Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using @CHEMICAL$ demonstrate that GSNO binding does not precede S-nitrosation of @GENE$.	false
23572520.T12.T20	Despite the presence of a GSNO binding site at the active site of @CHEMICAL$, isothermal titration calorimetry as well as nitrosation experiments using @GENE$ demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.	false
23572520.T2.T19	Despite the presence of a @CHEMICAL$ at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede @GENE$-nitrosation of GSTP1-1.	false
23572520.T2.T15	Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede @CHEMICAL$-nitrosation of @GENE$.	false
23572520.T2.T20	Despite the presence of a GSNO binding site at the active site of @CHEMICAL$, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede @GENE$-nitrosation of GSTP1-1.	false
23578993.T27.T43	@CHEM-GENE$ (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T27.T44	@CHEMICAL$ aminotransferase (@GENE$), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T27.T45	@CHEMICAL$ aminotransferase (ALT), @GENE$ (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T27.T46	@CHEMICAL$ aminotransferase (ALT), Aspartate aminotransferase (@GENE$), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T27.T47	@CHEMICAL$ aminotransferase (ALT), Aspartate aminotransferase (AST), @GENE$ (ALP), Bilirubin were measured in serum.	false
23578993.T27.T48	@CHEMICAL$ aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (@GENE$), Bilirubin were measured in serum.	false
23578993.T28.T43	@CHEMICAL$ (ALT), @GENE$ aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T28.T44	Alanine aminotransferase (@CHEMICAL$), @GENE$ aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T28.T45	Alanine aminotransferase (ALT), @CHEM-GENE$ (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T28.T46	Alanine aminotransferase (ALT), @CHEMICAL$ aminotransferase (@GENE$), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	false
23578993.T28.T47	Alanine aminotransferase (ALT), @CHEMICAL$ aminotransferase (AST), @GENE$ (ALP), Bilirubin were measured in serum.	false
23578993.T28.T48	Alanine aminotransferase (ALT), @CHEMICAL$ aminotransferase (AST), Alkaline phosphatase (@GENE$), Bilirubin were measured in serum.	false
23578993.T29.T43	@CHEMICAL$ (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), @GENE$ were measured in serum.	false
23578993.T29.T44	Alanine aminotransferase (@CHEMICAL$), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), @GENE$ were measured in serum.	false
23578993.T29.T45	Alanine aminotransferase (ALT), @CHEMICAL$ (AST), Alkaline phosphatase (ALP), @GENE$ were measured in serum.	false
23578993.T29.T46	Alanine aminotransferase (ALT), Aspartate aminotransferase (@CHEMICAL$), Alkaline phosphatase (ALP), @GENE$ were measured in serum.	false
23578993.T29.T47	Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), @CHEMICAL$ (ALP), @GENE$ were measured in serum.	false
23578993.T29.T48	Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (@CHEMICAL$), @GENE$ were measured in serum.	false
23578993.T30.T51	@CHEMICAL$ (HP), lipid peroxidation (LPO), catalase (CAT), @GENE$ (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T30.T52	@CHEMICAL$ (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (@GENE$) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T30.T49	@CHEMICAL$ (HP), lipid peroxidation (LPO), @GENE$ (CAT), Glutathione peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T30.T50	@CHEMICAL$ (HP), lipid peroxidation (LPO), catalase (@GENE$), Glutathione peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T31.T51	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEM-GENE$ (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T31.T52	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEMICAL$ peroxidase (@GENE$) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T31.T49	Hydroxyproline (HP), lipid peroxidation (LPO), @CHEMICAL$ (CAT), @GENE$ peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T31.T50	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (@CHEMICAL$), @GENE$ peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T32.T51	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEMICAL$ (GPx) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T32.T52	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (@CHEMICAL$) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T32.T49	Hydroxyproline (HP), lipid peroxidation (LPO), @CHEMICAL$ (CAT), Glutathione peroxidase (GPx) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T32.T50	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (@CHEMICAL$), Glutathione peroxidase (GPx) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.	false
23578993.T33.T51	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEMICAL$ (GPx) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.	false
23578993.T33.T52	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (@CHEMICAL$) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.	false
23578993.T33.T49	Hydroxyproline (HP), lipid peroxidation (LPO), @CHEMICAL$ (CAT), Glutathione peroxidase (GPx) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.	false
23578993.T33.T50	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (@CHEMICAL$), Glutathione peroxidase (GPx) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.	false
23578993.T34.T53	@CHEMICAL$ (CYP 450 2E1), activity was determined as hydroxylation of @GENE$ in liver microsomes.	CPR:9
23578993.T34.T54	Cytochrome P450 2E1 (@CHEMICAL$), activity was determined as hydroxylation of @GENE$ in liver microsomes.	CPR:9
23578993.T1.T38	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and @GENE$) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	false
23578993.T1.T39	Serum markers of liver damage (AST, @CHEMICAL$, ALP and @GENE$) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	false
23578993.T1.T40	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and @GENE$) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	false
23578993.T3.T38	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and Bilirubin) were increased by @GENE$ and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	CPR:3
23578993.T3.T39	Serum markers of liver damage (AST, @CHEMICAL$, ALP and Bilirubin) were increased by @GENE$ and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	CPR:3
23578993.T3.T40	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and Bilirubin) were increased by @GENE$ and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	CPR:3
23578993.T4.T38	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and Bilirubin) were increased by CCl4 and @GENE$ intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	CPR:3
23578993.T4.T39	Serum markers of liver damage (AST, @CHEMICAL$, ALP and Bilirubin) were increased by CCl4 and @GENE$ intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	CPR:3
23578993.T4.T40	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and Bilirubin) were increased by CCl4 and @GENE$ intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	CPR:3
23578993.T5.T38	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with @GENE$ reversed such changes (p<0.001).	CPR:4
23578993.T5.T39	Serum markers of liver damage (AST, @CHEMICAL$, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with @GENE$ reversed such changes (p<0.001).	CPR:4
23578993.T5.T40	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with @GENE$ reversed such changes (p<0.001).	CPR:4
23578993.T10.T42	LPO was increased while as @CHEMICAL$, CAT and @GENE$ decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001).	false
23578993.T10.T41	LPO was increased while as @CHEMICAL$, @GENE$ and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001).	false
23578993.T12.T42	LPO was increased while as GSH, CAT and @CHEMICAL$ decreased by the administration of CCl4 and TAA (p<0.001); co-administration of @GENE$ restored these liver markers to normal levels (p<0.001).	CPR:3
23578993.T12.T41	LPO was increased while as GSH, @CHEMICAL$ and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of @GENE$ restored these liver markers to normal levels (p<0.001).	CPR:3
23583258.T11.T23	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory @CHEMICAL$, IL-6 and IL-8, caused by a mixture of @GENE$ representative of a high cholesterol diet.	CPR:3
23583258.T11.T24	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, @CHEMICAL$ and IL-8, caused by a mixture of @GENE$ representative of a high cholesterol diet.	CPR:3
23583258.T11.T25	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and @CHEMICAL$, caused by a mixture of @GENE$ representative of a high cholesterol diet.	CPR:3
23583258.T12.T23	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory @CHEMICAL$, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high @GENE$ diet.	CPR:3
23583258.T12.T24	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, @CHEMICAL$ and IL-8, caused by a mixture of oxysterols representative of a high @GENE$ diet.	CPR:3
23583258.T12.T25	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and @CHEMICAL$, caused by a mixture of oxysterols representative of a high @GENE$ diet.	CPR:3
23583258.T14.T26	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive @CHEMICAL$ species through the colonic @GENE$ NOX1 activation.	false
23583258.T14.T27	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive @CHEMICAL$ species through the colonic NADPH-oxidase @GENE$ activation.	false
23583258.T15.T26	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic @CHEM-GENE$ NOX1 activation.	false
23583258.T15.T27	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic @CHEMICAL$-oxidase @GENE$ activation.	false
23583258.T17.T30	@CHEMICAL$-dependent NOX1 activation, as well as @GENE$ synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.	CPR:3
23583258.T17.T29	@CHEMICAL$-dependent @GENE$ activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.	CPR:3
23583258.T2.T30	Oxysterol-dependent NOX1 activation, as well as @CHEMICAL$ synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular @GENE$ and flavonoids.	CPR:4
23583258.T2.T29	Oxysterol-dependent @CHEMICAL$ activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular @GENE$ and flavonoids.	CPR:4
23583258.T3.T30	Oxysterol-dependent NOX1 activation, as well as @CHEMICAL$ synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and @GENE$.	CPR:4
23583258.T3.T29	Oxysterol-dependent @CHEMICAL$ activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and @GENE$.	CPR:4
23583258.T4.T21	Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in @CHEMICAL$ synthesis induced by dietary @GENE$.	CPR:3
23583258.T4.T20	Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial @CHEMICAL$ down-regulation and was ineffective in interleukin synthesis induced by dietary @GENE$.	CPR:3
23583258.T10.T22	Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related @CHEMICAL$ induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary @GENE$.	false
23583258.T8.T22	Besides this direct activity, an excess of @CHEMICAL$ compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related @GENE$ induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.	CPR:4
23583258.T9.T22	Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking @CHEMICAL$-related @GENE$ induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.	CPR:3
23588308.T1.T5	A physiologically-based pharmacokinetic model was used to quantitatively predict the impact of @CHEMICAL$ on sensitive CYP3A4 substrates. Elevated @GENE$ AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of IL-6 was comparable to observed clinical data (59% versus 58%).	false
23588308.T1.T6	A physiologically-based pharmacokinetic model was used to quantitatively predict the impact of IL-6 on sensitive @CHEMICAL$ substrates. Elevated @GENE$ AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of IL-6 was comparable to observed clinical data (59% versus 58%).	false
23588308.T1.T7	A physiologically-based pharmacokinetic model was used to quantitatively predict the impact of IL-6 on sensitive CYP3A4 substrates. Elevated @CHEMICAL$ AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of @GENE$ was comparable to observed clinical data (59% versus 58%).	false
23588308.T2.T9	In virtual bone marrow transplant (BMT) patients, 500 pg/ml of @CHEMICAL$ resulted in increase in @GENE$ AUC that was in good agreement with the observed data (45% versus 39%).	false
23588308.T3.T11	In a different group of BMT patients treated with @CHEMICAL$, the magnitude of interaction with @GENE$ was under predicted ~3-fold.	false
23588312.T1.T20	A DPYD Variant (@CHEMICAL$) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. @GENE$ (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.	false
23588312.T1.T21	A @CHEMICAL$ Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. @GENE$ (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.	false
23588312.T1.T22	A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced @CHEMICAL$ Enzyme Activity. @GENE$ (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.	false
23588312.T4.T20	A DPYD Variant (@CHEMICAL$) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. 5-Fluorouracil (@GENE$) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.	false
23588312.T4.T21	A @CHEMICAL$ Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. 5-Fluorouracil (@GENE$) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.	false
23588312.T4.T22	A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced @CHEMICAL$ Enzyme Activity. 5-Fluorouracil (@GENE$) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.	false
23588312.T3.T7	The responses to @CHEMICAL$, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @GENE$ (DPD, encoded by the DPYD gene).	false
23588312.T3.T8	The responses to @CHEMICAL$, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (@GENE$, encoded by the DPYD gene).	false
23588312.T3.T9	The responses to @CHEMICAL$, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the @GENE$ gene).	false
23588312.T5.T7	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @CHEM-GENE$ (DPD, encoded by the DPYD gene).	false
23588312.T5.T8	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @CHEMICAL$ dehydrogenase (@GENE$, encoded by the DPYD gene).	false
23588312.T5.T9	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @CHEMICAL$ dehydrogenase (DPD, encoded by the @GENE$ gene).	false
23588312.T6.T13	The DPYD-@CHEMICAL$ variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 + 35 vs. 514 + 168 pmol @GENE$ min(-1) mg(-1); P = 0.00029).	false
23588312.T6.T12	The @CHEMICAL$-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 + 35 vs. 514 + 168 pmol @GENE$ min(-1) mg(-1); P = 0.00029).	false
23588312.T6.T14	The DPYD-Y186C variant was unique to individuals of African ancestry, and @CHEMICAL$ activity was 46% lower in carriers as compared with noncarriers (279 + 35 vs. 514 + 168 pmol @GENE$ min(-1) mg(-1); P = 0.00029).	false
23588312.T2.T16	In this study, 26% of the African Americans with reduced DPD activity were carriers of @CHEMICAL$. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.	false
23588312.T2.T17	In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding @CHEMICAL$ carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.	false
23588312.T2.T18	In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of @CHEMICAL$ showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.	false
23588312.T2.T15	In this study, 26% of the African Americans with reduced @CHEMICAL$ activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.	false
23588312.T2.T19	In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher @CHEMICAL$ activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.	false
23589329.T10.T30	@CHEMICAL$ inhibits autophagic flux activating the @GENE$-Keap1 pathway in a p62-dependent manner.	CPR:3
23589329.T10.T31	@CHEMICAL$ inhibits autophagic flux activating the Nrf2-@GENE$ pathway in a p62-dependent manner.	CPR:3
23589329.T10.T32	@CHEMICAL$ inhibits autophagic flux activating the Nrf2-Keap1 pathway in a @GENE$-dependent manner.	false
23589329.T5.T22	@CHEMICAL$ deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and @GENE$.	CPR:4
23589329.T5.T20	@CHEMICAL$ deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of @GENE$, Keap1, and LC3.	CPR:4
23589329.T5.T21	@CHEMICAL$ deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, @GENE$, and LC3.	CPR:4
23589329.T6.T23	Thus, @CHEMICAL$ activates @GENE$ through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2.	CPR:3
23589329.T6.T24	Thus, @CHEMICAL$ activates Nrf2 through a non-canonical mechanism (@GENE$-dependent), leading to a chronic, sustained activation of Nrf2.	false
23589329.T6.T25	Thus, @CHEMICAL$ activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of @GENE$.	CPR:3
23589329.T7.T26	In contrast, activation of @CHEMICAL$ by @GENE$ and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).	CPR:3
23589329.T7.T27	In contrast, activation of Nrf2 by @CHEMICAL$ and tert-butylhydroquinone depend upon @GENE$-C151 and not p62 (the canonical mechanism).	false
23589329.T7.T29	In contrast, activation of Nrf2 by @CHEMICAL$ and tert-butylhydroquinone depend upon Keap1-C151 and not @GENE$ (the canonical mechanism).	false
23589329.T8.T26	In contrast, activation of @CHEMICAL$ by sulforaphane and @GENE$ depend upon Keap1-C151 and not p62 (the canonical mechanism).	CPR:3
23589329.T8.T27	In contrast, activation of Nrf2 by sulforaphane and @CHEMICAL$ depend upon @GENE$-C151 and not p62 (the canonical mechanism).	false
23589329.T8.T29	In contrast, activation of Nrf2 by sulforaphane and @CHEMICAL$ depend upon Keap1-C151 and not @GENE$ (the canonical mechanism).	false
23589329.T3.T12	Collectively, these findings provide evidence that @CHEMICAL$ causes prolonged activation of @GENE$ through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers.	CPR:3
23589329.T3.T13	Collectively, these findings provide evidence that @CHEMICAL$ causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of @GENE$ found in certain human cancers.	CPR:3
23591044.T30.T53	@CHEMICAL$ and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.	false
23591044.T31.T53	Melatonin and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate @CHEM-GENE$ in the ovaries, oviducts, and uteri of adult rats.	false
23591044.T32.T53	Melatonin and @CHEMICAL$ intake exert opposite effects on circulating estradiol and progesterone and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.	false
23591044.T33.T53	Melatonin and ethanol intake exert opposite effects on circulating @CHEMICAL$ and progesterone and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.	false
23591044.T34.T53	Melatonin and ethanol intake exert opposite effects on circulating estradiol and @CHEMICAL$ and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.	false
23591044.T10.T38	We report the effects of ethanol intake and @CHEMICAL$ treatment (at doses of 100mg/100gBW/day) on sex hormones and @GENE$ in the ovaries, oviducts and uteri of ethanol-preferring rats.	false
23591044.T11.T38	We report the effects of ethanol intake and melatonin treatment (at doses of 100mg/100gBW/day) on sex hormones and @CHEM-GENE$ in the ovaries, oviducts and uteri of ethanol-preferring rats.	false
23591044.T12.T38	We report the effects of ethanol intake and melatonin treatment (at doses of 100mg/100gBW/day) on sex hormones and @CHEMICAL$ in the ovaries, oviducts and uteri of @GENE$-preferring rats.	false
23591044.T9.T38	We report the effects of @CHEMICAL$ intake and melatonin treatment (at doses of 100mg/100gBW/day) on sex hormones and @GENE$ in the ovaries, oviducts and uteri of ethanol-preferring rats.	false
23591044.T13.T39	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T13.T40	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T13.T41	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T13.T42	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).	false
23591044.T13.T43	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).	false
23591044.T13.T44	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).	false
23591044.T13.T45	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).	false
23591044.T14.T39	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T14.T40	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T14.T41	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T14.T42	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).	false
23591044.T14.T43	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).	false
23591044.T14.T44	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).	false
23591044.T14.T45	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).	false
23591044.T15.T39	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T15.T40	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T15.T41	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T15.T42	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).	false
23591044.T15.T43	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).	false
23591044.T15.T44	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).	false
23591044.T15.T45	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).	false
23591044.T16.T39	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T16.T40	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T16.T41	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).	false
23591044.T16.T42	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).	false
23591044.T16.T43	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).	false
23591044.T16.T44	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).	false
23591044.T16.T45	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).	false
23591044.T25.T46	Ovarian @CHEMICAL$ was not influenced by either treatment, and oviduct AR was reduced after @GENE$-melatonin combination.	false
23591044.T25.T47	Ovarian AR was not influenced by either treatment, and oviduct @CHEMICAL$ was reduced after @GENE$-melatonin combination.	CPR:4
23591044.T26.T46	Ovarian @CHEMICAL$ was not influenced by either treatment, and oviduct AR was reduced after ethanol-@GENE$ combination.	false
23591044.T26.T47	Ovarian AR was not influenced by either treatment, and oviduct @CHEMICAL$ was reduced after ethanol-@GENE$ combination.	CPR:4
23591044.T27.T48	Oviduct @CHEMICAL$, ER-b and uterine ER-b were down-regulated by either @GENE$ or melatonin.	CPR:4
23591044.T27.T49	Oviduct ER-a, @CHEMICAL$ and uterine ER-b were down-regulated by either @GENE$ or melatonin.	CPR:4
23591044.T27.T50	Oviduct ER-a, ER-b and uterine @CHEMICAL$ were down-regulated by either @GENE$ or melatonin.	CPR:4
23591044.T28.T48	Oviduct @CHEMICAL$, ER-b and uterine ER-b were down-regulated by either ethanol or @GENE$.	CPR:4
23591044.T28.T49	Oviduct ER-a, @CHEMICAL$ and uterine ER-b were down-regulated by either ethanol or @GENE$.	CPR:4
23591044.T28.T50	Oviduct ER-a, ER-b and uterine @CHEMICAL$ were down-regulated by either ethanol or @GENE$.	CPR:4
23591044.T1.T35	Conversely, ovarian PRA and PRB were positively regulated by @CHEMICAL$ and ethanol-melatonin combination, whereas @GENE$ was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T1.T51	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by @GENE$ and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T1.T52	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by @GENE$ and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T2.T35	Conversely, ovarian PRA and PRB were positively regulated by ethanol and @CHEMICAL$-melatonin combination, whereas @GENE$ was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T2.T51	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by ethanol and @GENE$-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T2.T52	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by ethanol and @GENE$-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T3.T35	Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-@CHEMICAL$ combination, whereas @GENE$ was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T3.T51	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by ethanol and ethanol-@GENE$ combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T3.T52	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by ethanol and ethanol-@GENE$ combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	false
23591044.T4.T35	Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas @CHEMICAL$ was down-regulated in the uterus and oviduct after @GENE$ consumption.	CPR:4
23591044.T4.T51	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after @GENE$ consumption.	false
23591044.T4.T52	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after @GENE$ consumption.	false
23591044.T5.T36	@CHEMICAL$ was increased in ovaries and uteri of @GENE$-treated rats.	CPR:3
23591044.T6.T37	@CHEMICAL$ and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of @GENE$ in female reproductive tissues.	false
23591044.T7.T37	Ethanol and @CHEMICAL$ exert opposite effects on E2 and P4, and they differentially regulate the expression of @GENE$ in female reproductive tissues.	false
23591044.T8.T37	Ethanol and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of @CHEM-GENE$ in female reproductive tissues.	false
23597507.T17.T23	Pha1b toxin prevents @CHEMICAL$-induced nociceptive behavior and mechanical hypersensitivity without acting on @GENE$ channels.	false
23597507.T10.T20	We also investigated the effect of Pha1b on @CHEMICAL$ transients in cultured dorsal root ganglia (DRG) neurons and HEK293 cells expressing the @GENE$ receptor.	false
23597507.T11.T21	Intraplantar or intrathecal administered Pha1b reduced both nocifensive behavior and mechanical hypersensitivity induced by @CHEMICAL$ similarly to that observed with SB366791, a specific @GENE$ antagonist.	false
23597507.T12.T21	Intraplantar or intrathecal administered Pha1b reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with @CHEMICAL$, a specific @GENE$ antagonist.	CPR:6
23597507.T16.T22	In contrast, w-conotoxin MVIIA (a selective @CHEM-GENE$ blocker) was effective only when administered intrathecally.	false
23597507.T7.T18	Moreover, Pha1b did not inhibit @CHEMICAL$-activated currents in patch-clamp recordings of HEK293 cells that expressed @GENE$ receptors.	false
23598363.T20.T52	Rescue of @CHEMICAL$-damaged oocytes from programmed cell death through inactivation of the @GENE$ family signaling network.	false
23598363.T11.T47	Recently, the c-Abl @CHEMICAL$ inhibitor @GENE$ (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.	CPR:4
23598363.T11.T46	Recently, the @CHEMICAL$ kinase inhibitor @GENE$ (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.	CPR:4
23598363.T12.T47	Recently, the c-Abl @CHEMICAL$ inhibitor imatinib mesylate (@GENE$) has become the focus of research as a fertoprotective drug against cisplatin.	CPR:4
23598363.T12.T46	Recently, the @CHEMICAL$ kinase inhibitor imatinib mesylate (@GENE$) has become the focus of research as a fertoprotective drug against cisplatin.	CPR:4
23598363.T13.T47	Recently, the c-Abl @CHEMICAL$ inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against @GENE$.	false
23598363.T13.T46	Recently, the @CHEMICAL$ kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against @GENE$.	false
23598363.T17.T48	We found that, before apoptosis, @CHEMICAL$ induces @GENE$ and TAp73 expression in the oocyte.	CPR:3
23598363.T17.T49	We found that, before apoptosis, @CHEMICAL$ induces c-Abl and @GENE$ expression in the oocyte.	CPR:3
23598363.T18.T21	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of @GENE$, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T18.T22	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T18.T23	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T18.T24	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T18.T25	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.	false
23598363.T19.T21	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of @GENE$, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:3
23598363.T19.T22	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T19.T23	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T19.T24	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T19.T25	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.	false
23598363.T1.T21	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of @CHEMICAL$, @GENE$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T1.T22	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:4
23598363.T1.T23	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:4
23598363.T1.T24	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:3
23598363.T1.T25	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.	CPR:4
23598363.T2.T21	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of @CHEMICAL$, imatinib inhibited the @GENE$-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	false
23598363.T2.T22	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:3
23598363.T2.T23	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:3
23598363.T2.T24	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.	CPR:4
23598363.T2.T25	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.	CPR:3
23598363.T3.T26	Surprisingly, the conditional deletion of @CHEM-GENE$, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.	false
23598363.T3.T27	Surprisingly, the conditional deletion of @CHEMICAL$63, but not @GENE$, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.	false
23598363.T3.T28	Surprisingly, the conditional deletion of @CHEMICAL$63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of @GENE$ and TAp73 caused by cisplatin.	false
23598363.T3.T29	Surprisingly, the conditional deletion of @CHEMICAL$63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and @GENE$ caused by cisplatin.	false
23598363.T4.T26	Surprisingly, the conditional deletion of @CHEMICAL$, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by @GENE$.	false
23598363.T4.T27	Surprisingly, the conditional deletion of Trp63, but not @CHEMICAL$, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by @GENE$.	false
23598363.T4.T28	Surprisingly, the conditional deletion of Trp63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of @CHEMICAL$ and TAp73 caused by @GENE$.	CPR:3
23598363.T4.T29	Surprisingly, the conditional deletion of Trp63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and @CHEMICAL$ caused by @GENE$.	CPR:3
23598363.T5.T30	These data suggest that @CHEMICAL$ is the master regulator of @GENE$-induced oocyte death.	false
23598363.T6.T31	The expression kinetics of @CHEMICAL$, c-Abl and TAp73 suggest that @GENE$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	false
23598363.T6.T32	The expression kinetics of TAp63, @CHEMICAL$ and TAp73 suggest that @GENE$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	false
23598363.T6.T33	The expression kinetics of TAp63, c-Abl and @CHEMICAL$ suggest that @GENE$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	false
23598363.T6.T34	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates @GENE$-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	CPR:3
23598363.T6.T35	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of @GENE$ and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	CPR:3
23598363.T6.T36	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and @GENE$ and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	CPR:3
23598363.T6.T37	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of @GENE$ by c-Abl-induced BAX expression.	CPR:3
23598363.T6.T38	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by @GENE$-induced BAX expression.	CPR:3
23598363.T6.T39	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced @GENE$ expression.	CPR:3
23598363.T7.T41	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting c-Abl @GENE$, which would otherwise activate TAp73-BAX-mediated apoptosis.	CPR:3
23598363.T7.T40	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting @GENE$ kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.	CPR:4
23598363.T7.T42	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate @GENE$-BAX-mediated apoptosis.	CPR:4
23598363.T7.T43	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-@GENE$-mediated apoptosis.	CPR:4
23598363.T8.T41	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting c-Abl @GENE$, which would otherwise activate TAp73-BAX-mediated apoptosis.	CPR:3
23598363.T8.T40	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting @GENE$ kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.	CPR:3
23598363.T8.T42	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting c-Abl kinase, which would otherwise activate @GENE$-BAX-mediated apoptosis.	CPR:3
23598363.T8.T43	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-@GENE$-mediated apoptosis.	CPR:3
23598363.T10.T45	Thus, imatinib and other c-Abl @CHEMICAL$ inhibitors provide an intriguing new way to halt @GENE$-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.	false
23598363.T10.T44	Thus, imatinib and other @CHEMICAL$ kinase inhibitors provide an intriguing new way to halt @GENE$-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.	false
23598363.T9.T45	Thus, @CHEMICAL$ and other c-Abl @GENE$ inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.	CPR:4
23598363.T9.T44	Thus, @CHEMICAL$ and other @GENE$ kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.	CPR:4
23598904.T23.T31	Suppression of @CHEMICAL$ expression is a common feature of @GENE$-resistant and manganese-resistant RBL-2H3 cells.	false
23598904.T24.T31	Suppression of @CHEMICAL$ expression is a common feature of cadmium-resistant and @GENE$-resistant RBL-2H3 cells.	false
23598904.T10.T27	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and @GENE$, respectively.	false
23598904.T5.T27	To clarify the roles of @CHEMICAL$ in hyperaccumulation of @GENE$ and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.	false
23598904.T6.T27	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and @GENE$ in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.	false
23598904.T7.T27	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, @GENE$-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.	false
23598904.T8.T27	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and @GENE$-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.	false
23598904.T9.T27	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to @GENE$ and MnCl2, respectively.	false
23598904.T18.T28	RBL-Cdr cells also showed cross-resistance to @CHEMICAL$ and AgNO3 probably due to enhanced expression of @GENE$.	false
23598904.T19.T28	RBL-Cdr cells also showed cross-resistance to HgCl2 and @CHEMICAL$ probably due to enhanced expression of @GENE$.	false
23598904.T21.T25	Among the possible transporters involved in the uptake of @CHEMICAL$ and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by @GENE$, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	CPR:9
23598904.T21.T29	Among the possible transporters involved in the uptake of @CHEMICAL$ and Mn(2+), the expression of @GENE$ (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	CPR:9
23598904.T21.T30	Among the possible transporters involved in the uptake of @CHEMICAL$ and Mn(2+), the expression of ZIP8 (@GENE$), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	CPR:9
23598904.T22.T25	Among the possible transporters involved in the uptake of Cd(2+) and @CHEMICAL$, the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by @GENE$, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	CPR:9
23598904.T22.T29	Among the possible transporters involved in the uptake of Cd(2+) and @CHEMICAL$, the expression of @GENE$ (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	CPR:9
23598904.T22.T30	Among the possible transporters involved in the uptake of Cd(2+) and @CHEMICAL$, the expression of ZIP8 (@GENE$), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	CPR:9
23598904.T1.T26	These results suggest that @CHEMICAL$ plays a pivotal role in the transport and toxicity of @GENE$ and Mn(2+) in RBL-2H3 cells.	CPR:9
23598904.T2.T26	These results suggest that @CHEMICAL$ plays a pivotal role in the transport and toxicity of Cd(2+) and @GENE$ in RBL-2H3 cells.	CPR:9
23601700.T3.T20	In the present work we show that reduction sensitive and @CHEMICAL$-stable heteromers can be reconstituted in vitro by mixing proMMP-9 with either serglycin, versican or @GENE$ isolated from various monocytic cell lines.	false
23601700.T3.T19	In the present work we show that reduction sensitive and @CHEMICAL$-stable heteromers can be reconstituted in vitro by mixing @GENE$ with either serglycin, versican or CSPGs isolated from various monocytic cell lines.	false
23601700.T4.T22	In addition, a strong but @CHEMICAL$-soluble proMMP-9*@GENE$ heteromer was formed.	false
23601700.T4.T21	In addition, a strong but @CHEMICAL$-soluble @GENE$*CSPG heteromer was formed.	false
23601700.T7.T24	As for the heteromer isolated from THP-1 cells, the in vitro reconstituted @CHEMICAL$-stable and SDS-soluble heteromers had a weaker binding to gelatin than the @GENE$ monomer.	false
23601700.T8.T24	As for the heteromer isolated from THP-1 cells, the in vitro reconstituted SDS-stable and @CHEMICAL$-soluble heteromers had a weaker binding to gelatin than the @GENE$ monomer.	false
23601700.T1.T13	However, the presence of @CHEMICAL$ inhibited the formation of the @GENE$-soluble heteromer, but not the SDS-stable reduction sensitive heteromer.	false
23601700.T2.T13	However, the presence of @CHEMICAL$ inhibited the formation of the SDS-soluble heteromer, but not the @GENE$-stable reduction sensitive heteromer.	false
23601710.T5.T11	Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of @CHEMICAL$ assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-@GENE$ moiety.	CPR:4
23601710.T6.T11	Optimization of a @CHEMICAL$ series of @GENE$ assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety.	CPR:4
23601710.T1.T7	Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of @CHEMICAL$ inhibitors of @GENE$ (CA) assembly are described.	CPR:4
23601710.T1.T8	Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of @CHEMICAL$ inhibitors of HIV capsid (@GENE$) assembly are described.	CPR:4
23601710.T4.T7	Detailed structure-activity relationships of the C3-@CHEMICAL$ moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of @GENE$ (CA) assembly are described.	false
23601710.T4.T8	Detailed structure-activity relationships of the C3-@CHEMICAL$ moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of HIV capsid (@GENE$) assembly are described.	false
23602986.T10.T24	The present work evaluated the effects of nicotine (@CHEMICAL$), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T10.T25	The present work evaluated the effects of nicotine (@CHEMICAL$), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T11.T24	The present work evaluated the effects of nicotine (NIC), @CHEMICAL$ (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T11.T25	The present work evaluated the effects of nicotine (NIC), @CHEMICAL$ (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T15.T24	The present work evaluated the effects of nicotine (NIC), cotinine (@CHEMICAL$), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T15.T25	The present work evaluated the effects of nicotine (NIC), cotinine (@CHEMICAL$), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T16.T24	The present work evaluated the effects of nicotine (NIC), cotinine (COT), @CHEMICAL$ (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T16.T25	The present work evaluated the effects of nicotine (NIC), cotinine (COT), @CHEMICAL$ (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T19.T24	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (@CHEMICAL$), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T19.T25	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (@CHEMICAL$), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T20.T24	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), @CHEMICAL$ (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T20.T25	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), @CHEMICAL$ (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T2.T24	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (@CHEMICAL$) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T2.T25	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (@CHEMICAL$) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T4.T24	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and @CHEMICAL$ (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T4.T25	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and @CHEMICAL$ (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T8.T24	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (@CHEMICAL$) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T8.T25	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (@CHEMICAL$) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T9.T24	The present work evaluated the effects of @CHEMICAL$ (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).	false
23602986.T9.T25	The present work evaluated the effects of @CHEMICAL$ (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).	false
23602986.T1.T23	Cotinine also increased the phosphorylation of @CHEMICAL$ in a similar fashion as @GENE$.	false
23602986.T21.T23	@CHEMICAL$ also increased the phosphorylation of @GENE$ in a similar fashion as nicotine.	false
23603059.T11.T29	@CHEMICAL$ upregulates the expression of @GENE$ in mouse aortic endothelial cells.	CPR:3
23603059.T6.T17	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 @CHEMICAL$ (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.	false
23603059.T6.T18	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (@CHEMICAL$) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.	false
23603059.T6.T21	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 @CHEMICAL$ subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.	CPR:3
23603059.T6.T19	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, @CHEMICAL$ and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.	false
23603059.T6.T20	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and @CHEMICAL$, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.	false
23603059.T6.T22	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, @CHEMICAL$ and AT1BR following @GENE$ (SA) treatment.	CPR:3
23603059.T6.T23	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and @CHEMICAL$ following @GENE$ (SA) treatment.	CPR:3
23603059.T8.T24	In addition, western blot analysis revealed that SA enhances the phosphorylations of @CHEM-GENE$ (JNK) and activated protein 1 (AP-1).	false
23603059.T8.T25	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun @CHEMICAL$-terminal kinases (@GENE$) and activated protein 1 (AP-1).	false
23603059.T8.T26	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun @CHEMICAL$-terminal kinases (JNK) and @GENE$ (AP-1).	false
23603059.T8.T27	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun @CHEMICAL$-terminal kinases (JNK) and activated protein 1 (@GENE$).	false
23603059.T1.T12	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific @CHEMICAL$ inhibitor, @GENE$, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.	CPR:4
23603059.T1.T13	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, @CHEMICAL$, strongly indicating that @GENE$ upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.	false
23603059.T1.T14	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, @CHEMICAL$, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the @GENE$ signaling pathway.	false
23603059.T1.T28	Finally, SA-induced @CHEMICAL$ expression was found to be prevented both by NAC and specific JNK inhibitor, @GENE$, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.	CPR:4
23603059.T2.T15	Taken together, our results indicate that @CHEMICAL$ indeed upregulates the @GENE$ expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.	CPR:3
23603059.T2.T16	Taken together, our results indicate that @CHEMICAL$ indeed upregulates the AT1R expression, thus highlighting a role of arsenic-induced aberrant @GENE$ signaling in the pathogenesis of hypertension.	false
23603059.T3.T15	Taken together, our results indicate that arsenic indeed upregulates the @CHEMICAL$ expression, thus highlighting a role of @GENE$-induced aberrant AT1R signaling in the pathogenesis of hypertension.	false
23603059.T3.T16	Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of @CHEMICAL$-induced aberrant @GENE$ signaling in the pathogenesis of hypertension.	CPR:3
23603382.T10.T17	The mRNA levels of SOD1, CAT, @CHEMICAL$ and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.	CPR:4
23603382.T10.T15	The mRNA levels of @CHEMICAL$, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.	CPR:4
23603382.T10.T16	The mRNA levels of SOD1, @CHEMICAL$, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.	CPR:4
23603382.T10.T18	The mRNA levels of SOD1, CAT, GPx and @CHEMICAL$ were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.	CPR:4
23603382.T9.T17	The mRNA levels of SOD1, CAT, @CHEMICAL$ and Txnrd1 were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.	CPR:3
23603382.T9.T15	The mRNA levels of @CHEMICAL$, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.	CPR:3
23603382.T9.T16	The mRNA levels of SOD1, @CHEMICAL$, GPx and Txnrd1 were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.	CPR:3
23603382.T9.T18	The mRNA levels of SOD1, CAT, GPx and @CHEMICAL$ were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.	CPR:4
23603382.T12.T19	The expressions of @CHEMICAL$ and HO-1 were significantly (P<0.05) increased in the @GENE$ group and reduced in the combined treatment group.	CPR:3
23603382.T12.T20	The expressions of HSP70 and @CHEMICAL$ were significantly (P<0.05) increased in the @GENE$ group and reduced in the combined treatment group.	CPR:3
23604720.T4.T12	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEM-GENE$ (AR) and galactitol formation in rat lenses with high levels of glucose.	false
23604720.T4.T13	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEMICAL$ reductase (@GENE$) and galactitol formation in rat lenses with high levels of glucose.	false
23604720.T5.T12	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEMICAL$ (AR) and @GENE$ formation in rat lenses with high levels of glucose.	false
23604720.T5.T13	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on aldose reductase (@CHEMICAL$) and @GENE$ formation in rat lenses with high levels of glucose.	false
23604720.T6.T12	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEMICAL$ (AR) and galactitol formation in rat lenses with high levels of @GENE$.	false
23604720.T6.T13	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on aldose reductase (@CHEMICAL$) and galactitol formation in rat lenses with high levels of @GENE$.	false
23604720.T9.T18	From the 10 isolated compounds, @CHEMICAL$ showed the most potent inhibition, with IC50 values of 0.30 and 0.67 mM for @GENE$ and rhAR, respectively.	CPR:4
23604720.T9.T19	From the 10 isolated compounds, @CHEMICAL$ showed the most potent inhibition, with IC50 values of 0.30 and 0.67 mM for rAR and @GENE$, respectively.	CPR:4
23604720.T10.T11	In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, @CHEMICAL$ showed competitive inhibition of @GENE$.	CPR:4
23608239.T16.T23	Enzyme activities such as @CHEM-GENE$, glutathione, catalase and lipid peroxidation were also determined in the stomach tissues.	false
23608239.T16.T24	Enzyme activities such as @CHEMICAL$ dismutase, glutathione, @GENE$ and lipid peroxidation were also determined in the stomach tissues.	false
23608239.T17.T23	Enzyme activities such as @CHEMICAL$, @GENE$, catalase and lipid peroxidation were also determined in the stomach tissues.	false
23608239.T17.T24	Enzyme activities such as superoxide dismutase, @CHEMICAL$, @GENE$ and lipid peroxidation were also determined in the stomach tissues.	false
23608239.T7.T21	Consequently significant changes were observed in enzyme activities such as @CHEMICAL$, CAT, @GENE$ and LPO in the stomach tissues when compared with ethanol control group.	false
23608239.T7.T22	Consequently significant changes were observed in enzyme activities such as SOD, @CHEMICAL$, @GENE$ and LPO in the stomach tissues when compared with ethanol control group.	false
23608239.T8.T21	Consequently significant changes were observed in enzyme activities such as @CHEMICAL$, CAT, GSH and LPO in the stomach tissues when compared with @GENE$ control group.	false
23608239.T8.T22	Consequently significant changes were observed in enzyme activities such as SOD, @CHEMICAL$, GSH and LPO in the stomach tissues when compared with @GENE$ control group.	false
23608535.T2.T21	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that MK2 catalytic activity directly regulated the promoters of the fast fiber-specific @CHEMICAL$ and the slow fiber-specific sarco/endoplasmic reticulum @GENE$-ATPase (SERCA) 2 gene.	false
23608535.T2.T19	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that @CHEMICAL$ catalytic activity directly regulated the promoters of the fast fiber-specific myosin heavy chain IId/x and the slow fiber-specific sarco/endoplasmic reticulum @GENE$-ATPase (SERCA) 2 gene.	false
23608535.T2.T22	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that MK2 catalytic activity directly regulated the promoters of the fast fiber-specific myosin heavy chain IId/x and the slow fiber-specific @CHEM-GENE$ gene.	false
23608535.T1.T3	These results link @CHEMICAL$ to the regulation of @GENE$ dynamics and identify enzymatic activity of MK2/3 as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in MK2/3(-/-) mice.	false
23608535.T1.T5	These results link MK2/3 to the regulation of @CHEMICAL$ dynamics and identify enzymatic activity of @GENE$ as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in MK2/3(-/-) mice.	false
23608535.T1.T7	These results link MK2/3 to the regulation of @CHEMICAL$ dynamics and identify enzymatic activity of MK2/3 as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in @GENE$(-/-) mice.	false
23611809.T10.T40	Recent observations revealed that @CHEM-GENE$ catalyzes N-glucuronidation of amine-containing compounds.	false
23611809.T3.T40	Recent observations revealed that @CHEMICAL$ catalyzes N-glucuronidation of @GENE$-containing compounds.	CPR:9
23611809.T11.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of @GENE$, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	CPR:9
23611809.T12.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, @GENE$, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	CPR:9
23611809.T13.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, @GENE$, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	CPR:9
23611809.T14.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, @GENE$, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	CPR:9
23611809.T15.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, @GENE$, diphenhydramine, tamoxifen, ketoconazole and midazolam.	CPR:9
23611809.T16.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, @GENE$, tamoxifen, ketoconazole and midazolam.	CPR:9
23611809.T17.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, @GENE$, ketoconazole and midazolam.	CPR:9
23611809.T18.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, @GENE$ and midazolam.	CPR:9
23611809.T19.T41	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and @GENE$.	CPR:9
23611809.T20.T42	These are drugs that were previously reported to be substrates for @CHEMICAL$ or UGT1A3 and that contain in their structure either @GENE$, cyclic amines, or an imidazole group.	false
23611809.T20.T43	These are drugs that were previously reported to be substrates for UGT1A4 or @CHEMICAL$ and that contain in their structure either @GENE$, cyclic amines, or an imidazole group.	false
23611809.T21.T42	These are drugs that were previously reported to be substrates for @CHEMICAL$ or UGT1A3 and that contain in their structure either tertiary aliphatic amines, @GENE$, or an imidazole group.	false
23611809.T21.T43	These are drugs that were previously reported to be substrates for UGT1A4 or @CHEMICAL$ and that contain in their structure either tertiary aliphatic amines, @GENE$, or an imidazole group.	false
23611809.T22.T42	These are drugs that were previously reported to be substrates for @CHEMICAL$ or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an @GENE$ group.	false
23611809.T22.T43	These are drugs that were previously reported to be substrates for UGT1A4 or @CHEMICAL$ and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an @GENE$ group.	false
23611809.T23.T44	@CHEMICAL$ was inactive in the glucuronidation of @GENE$, nortriptyline, carbamazepine and afloqualone.	false
23611809.T24.T44	@CHEMICAL$ was inactive in the glucuronidation of desipramine, @GENE$, carbamazepine and afloqualone.	false
23611809.T25.T44	@CHEMICAL$ was inactive in the glucuronidation of desipramine, nortriptyline, @GENE$ and afloqualone.	false
23611809.T26.T44	@CHEMICAL$ was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine and @GENE$.	false
23611809.T27.T45	This group of drugs contains @CHEMICAL$, and these results suggest that @GENE$ preferably conjugates tertiary amines.	false
23611809.T28.T45	This group of drugs contains secondary or primary amines, and these results suggest that @CHEMICAL$ preferably conjugates @GENE$.	CPR:9
23611809.T1.T29	This preference is partial because @CHEMICAL$ did not conjugate the @GENE$ in trifluoperazine.	false
23611809.T2.T29	This preference is partial because @CHEMICAL$ did not conjugate the tertiary cyclic amine in @GENE$.	false
23611809.T4.T30	Kinetic analyses revealed that the affinity and clearance of @CHEMICAL$ for @GENE$, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T4.T31	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for @CHEMICAL$, imipramine, and diphenhydramine are significantly higher than the corresponding values of @GENE$ and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T4.T32	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for @CHEMICAL$, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and @GENE$, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	false
23611809.T4.T33	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for @CHEMICAL$, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of @GENE$ toward these drugs are considerably higher.	CPR:9
23611809.T5.T30	Kinetic analyses revealed that the affinity and clearance of @CHEMICAL$ for amitriptyline, @GENE$, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T5.T31	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, @CHEMICAL$, and diphenhydramine are significantly higher than the corresponding values of @GENE$ and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T5.T32	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, @CHEMICAL$, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and @GENE$, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T5.T33	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, @CHEMICAL$, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of @GENE$ toward these drugs are considerably higher.	CPR:9
23611809.T6.T30	Kinetic analyses revealed that the affinity and clearance of @CHEMICAL$ for amitriptyline, imipramine, and @GENE$ are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T6.T31	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and @CHEMICAL$ are significantly higher than the corresponding values of @GENE$ and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T6.T32	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and @CHEMICAL$ are significantly higher than the corresponding values of UGT1A4 and @GENE$, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	CPR:9
23611809.T6.T33	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and @CHEMICAL$ are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of @GENE$ toward these drugs are considerably higher.	CPR:9
23611809.T9.T35	In conclusion, this study expands the understanding of the substrate specificity of @CHEMICAL$, highlighting its preference for @GENE$ with higher affinities and clearance values than those of UGT1A4 and UGT1A3.	CPR:9
23611809.T9.T36	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for @CHEMICAL$ with higher affinities and clearance values than those of @GENE$ and UGT1A3.	CPR:9
23611809.T9.T37	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for @CHEMICAL$ with higher affinities and clearance values than those of UGT1A4 and @GENE$.	CPR:9
23611835.T1.T14	@CHEMICAL$ (SB) is an @GENE$ (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	CPR:6
23611835.T1.T16	@CHEMICAL$ (SB) is an IL-8 receptor B (@GENE$) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	CPR:6
23611835.T1.T22	@CHEMICAL$ (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit @GENE$-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	CPR:4
23611835.T2.T20	Molecular docking studies suggested that SB has a good affinity towards @CHEMICAL$-binding site on @GENE$ subunit.	false
23611835.T3.T21	Of note, @CHEMICAL$ which is a close structural analogue of SB225002 with a potent @GENE$ antagonistic activity did not exhibit a similar antimitotic activity.	CPR:6
23611835.T4.T21	Of note, SB265610 which is a close structural analogue of @CHEMICAL$ with a potent @GENE$ antagonistic activity did not exhibit a similar antimitotic activity.	CPR:6
23614643.T4.T19	In this report, we utilized a library of @CHEMICAL$ that produce two and three GAG chains on the same scaffold, respectively, thus mimicking PGs, to examine the importance of GAG valency and chain type in regulating @GENE$/FGFR interactions in vivo in zebrafish.	false
23614643.T4.T20	In this report, we utilized a library of @CHEMICAL$ that produce two and three GAG chains on the same scaffold, respectively, thus mimicking PGs, to examine the importance of GAG valency and chain type in regulating FGF/@GENE$ interactions in vivo in zebrafish.	false
23614643.T1.T10	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor @CHEMICAL$, mRNA for the @GENE$ antagonist sprouty4, or FGF8 morpholino.	false
23614643.T1.T9	In support of this observation, elongation can be reversed by the @CHEMICAL$ inhibitor @GENE$, mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.	CPR:4
23614643.T1.T11	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor @CHEMICAL$, mRNA for the FGFR antagonist @GENE$, or FGF8 morpholino.	false
23614643.T1.T12	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor @CHEMICAL$, mRNA for the FGFR antagonist sprouty4, or @GENE$ morpholino.	false
23614643.T3.T13	Furthermore, expression of a multivalent but not a monovalent GAG containing @CHEMICAL$ proteoglycan recapitulates the elongation phenotype observed with the bivalent @GENE$.	false
23615471.T18.T39	@CHEMICAL$ Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of @GENE$ Signaling.	CPR:4
23615471.T10.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEM-GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T10.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T11.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEM-GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T11.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T12.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @CHEMICAL$, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEM-GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$ Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T12.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T13.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @CHEMICAL$, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$ Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @CHEMICAL$, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEM-GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T13.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T14.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @CHEMICAL$, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$ Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @CHEMICAL$, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$ @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @CHEMICAL$807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @CHEMICAL$807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T14.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @CHEMICAL$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T6.T19	Treatment with @CHEMICAL$ decreased protein abundance of @GENE$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T23	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, @GENE$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T24	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T30	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T31	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T20	Treatment with @CHEMICAL$ decreased protein abundance of Akt, @GENE$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T21	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, @GENE$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T22	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, @GENE$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T25	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T26	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T27	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T28	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T29	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T32	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T33	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T34	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T35	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	CPR:4
23615471.T6.T36	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	CPR:3
23615471.T7.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEM-GENE$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, @GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T7.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T8.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, @GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T8.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T9.T19	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEM-GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T30	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T20	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T21	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T22	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T25	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T28	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T32	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T33	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T34	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T35	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.	false
23615471.T9.T36	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.	false
23615471.T15.T37	Overexpression of @CHEMICAL$ or Akt2 in TW2.6 cells rescued growth inhibition caused by @GENE$ treatment.	false
23615471.T15.T38	Overexpression of Akt1 or @CHEMICAL$ in TW2.6 cells rescued growth inhibition caused by @GENE$ treatment.	false
23618921.T20.T39	Concurrent Regulation of the Transcription Factors @CHEMICAL$ and ATF4 Mediates the Enhancement of Glutathione Levels by the @GENE$ Fisetin.	false
23618921.T20.T40	Concurrent Regulation of the Transcription Factors Nrf2 and @CHEMICAL$ Mediates the Enhancement of Glutathione Levels by the @GENE$ Fisetin.	false
23618921.T21.T39	Concurrent Regulation of the Transcription Factors @CHEMICAL$ and ATF4 Mediates the Enhancement of Glutathione Levels by the Flavonoid @GENE$.	false
23618921.T21.T40	Concurrent Regulation of the Transcription Factors Nrf2 and @CHEMICAL$ Mediates the Enhancement of Glutathione Levels by the Flavonoid @GENE$.	false
23618921.T22.T39	Concurrent Regulation of the Transcription Factors @CHEMICAL$ and ATF4 Mediates the Enhancement of @GENE$ Levels by the Flavonoid Fisetin.	false
23618921.T22.T40	Concurrent Regulation of the Transcription Factors Nrf2 and @CHEMICAL$ Mediates the Enhancement of @GENE$ Levels by the Flavonoid Fisetin.	false
23618921.T13.T31	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are @GENE$ (Nrf2) and activating transcription factor 4 (ATF4).	false
23618921.T13.T32	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are NF-E2-related factor 2 (@GENE$) and activating transcription factor 4 (ATF4).	false
23618921.T13.T33	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are NF-E2-related factor 2 (Nrf2) and @GENE$ (ATF4).	false
23618921.T13.T34	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are NF-E2-related factor 2 (Nrf2) and activating transcription factor 4 (@GENE$).	false
23618921.T19.T35	Here we show that @CHEMICAL$ rapidly increases the levels of both @GENE$ and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.	CPR:3
23618921.T19.T36	Here we show that @CHEMICAL$ rapidly increases the levels of both Nrf2 and @GENE$ as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.	CPR:3
23618921.T19.T37	Here we show that @CHEMICAL$ rapidly increases the levels of both Nrf2 and ATF4 as well as @GENE$- and ATF4-dependent gene transcription via distinct mechanisms.	CPR:3
23618921.T19.T38	Here we show that @CHEMICAL$ rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and @GENE$-dependent gene transcription via distinct mechanisms.	CPR:3
23618921.T2.T26	Although @CHEMICAL$ greatly increases the stability of both Nrf2 and ATF4, only the effect on ATF4 is dependent on @GENE$ activity.	false
23618921.T2.T23	Although @CHEMICAL$ greatly increases the stability of both @GENE$ and ATF4, only the effect on ATF4 is dependent on protein kinase activity.	CPR:3
23618921.T2.T24	Although @CHEMICAL$ greatly increases the stability of both Nrf2 and @GENE$, only the effect on ATF4 is dependent on protein kinase activity.	CPR:3
23618921.T2.T25	Although @CHEMICAL$ greatly increases the stability of both Nrf2 and ATF4, only the effect on @GENE$ is dependent on protein kinase activity.	false
23618921.T3.T27	Using siRNA we found that @CHEMICAL$, but not Nrf2, is important for @GENE$'s ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T3.T28	Using siRNA we found that ATF4, but not @CHEMICAL$, is important for @GENE$'s ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T3.T29	Using siRNA we found that ATF4, but not Nrf2, is important for @CHEMICAL$'s ability to increase GSH levels under basal conditions whereas both @GENE$ and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T3.T30	Using siRNA we found that ATF4, but not Nrf2, is important for @CHEMICAL$'s ability to increase GSH levels under basal conditions whereas both ATF4 and @GENE$ appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T4.T27	Using siRNA we found that @CHEMICAL$, but not Nrf2, is important for fisetin's ability to increase @GENE$ levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T4.T28	Using siRNA we found that ATF4, but not @CHEMICAL$, is important for fisetin's ability to increase @GENE$ levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T4.T29	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase @CHEMICAL$ levels under basal conditions whereas both @GENE$ and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T4.T30	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase @CHEMICAL$ levels under basal conditions whereas both ATF4 and @GENE$ appear to cooperate to increase GSH levels under oxidative stress conditions.	false
23618921.T6.T27	Using siRNA we found that @CHEMICAL$, but not Nrf2, is important for fisetin's ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase @GENE$ levels under oxidative stress conditions.	false
23618921.T6.T28	Using siRNA we found that ATF4, but not @CHEMICAL$, is important for fisetin's ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase @GENE$ levels under oxidative stress conditions.	false
23618921.T6.T29	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase GSH levels under basal conditions whereas both @CHEMICAL$ and Nrf2 appear to cooperate to increase @GENE$ levels under oxidative stress conditions.	false
23618921.T6.T30	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase GSH levels under basal conditions whereas both ATF4 and @CHEMICAL$ appear to cooperate to increase @GENE$ levels under oxidative stress conditions.	false
23621358.T13.T20	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a @CHEMICAL$ (RBV) prodrug, exploiting the presence of @GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T13.T21	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a @CHEMICAL$ (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T15.T20	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (@CHEMICAL$) prodrug, exploiting the presence of @GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T15.T21	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (@CHEMICAL$) prodrug, exploiting the presence of carbohydrate receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T19.T20	GALACTOSYLATED MICELLES FOR A @CHEMICAL$ PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T19.T21	GALACTOSYLATED MICELLES FOR A @CHEMICAL$ PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T2.T20	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @CHEM-GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T2.T21	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @CHEMICAL$ receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	false
23621358.T3.T20	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @CHEMICAL$, i.e., ASGPR, were prepared starting from a @GENE$ conjugate.	false
23621358.T3.T21	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., @CHEMICAL$, were prepared starting from a @GENE$ conjugate.	false
23623750.T11.T50	Molecular and functional characterization of @CHEM-GENE$ in cynomolgus macaque.	false
23623750.T1.T12	@CHEM-GENE$ (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and FMO6P), but remain to be investigated in cynomolgus macaque.	false
23623750.T1.T28	@CHEMICAL$-containing monooxygenases (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including @GENE$ and FMO6P), but remain to be investigated in cynomolgus macaque.	false
23623750.T1.T32	@CHEMICAL$-containing monooxygenases (@GENE$), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and FMO6P), but remain to be investigated in cynomolgus macaque.	false
23623750.T1.T29	@CHEMICAL$-containing monooxygenases (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and @GENE$), but remain to be investigated in cynomolgus macaque.	false
23623750.T9.T33	@CHEMICAL$ sequences of cynomolgus @GENE$, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with human FMO1-5.	false
23623750.T9.T34	@CHEMICAL$ sequences of cynomolgus FMO1-5, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with @GENE$.	false
23623750.T10.T13	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized @CHEMICAL$, and @GENE$/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	false
23623750.T10.T14	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized @CHEMICAL$, and FMO1/@GENE$ and FMO3 also metabolized methimazole and trimethylamine, respectively.	false
23623750.T10.T15	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized @CHEMICAL$, and FMO1/FMO3 and @GENE$ also metabolized methimazole and trimethylamine, respectively.	false
23623750.T10.T46	@CHEMICAL$, FMO2, FMO3, and FMO5 metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	CPR:9
23623750.T10.T47	Cynomolgus FMO1, @CHEMICAL$, FMO3, and FMO5 metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	CPR:9
23623750.T10.T48	Cynomolgus FMO1, FMO2, @CHEMICAL$, and FMO5 metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	CPR:9
23623750.T10.T49	Cynomolgus FMO1, FMO2, FMO3, and @CHEMICAL$ metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	CPR:9
23623750.T2.T13	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and @CHEMICAL$/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.	CPR:9
23623750.T2.T14	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/@CHEMICAL$ and FMO3 also metabolized @GENE$ and trimethylamine, respectively.	CPR:9
23623750.T2.T15	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and @CHEMICAL$ also metabolized @GENE$ and trimethylamine, respectively.	CPR:9
23623750.T2.T46	@CHEMICAL$, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.	false
23623750.T2.T47	Cynomolgus FMO1, @CHEMICAL$, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.	false
23623750.T2.T48	Cynomolgus FMO1, FMO2, @CHEMICAL$, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.	false
23623750.T2.T49	Cynomolgus FMO1, FMO2, FMO3, and @CHEMICAL$ metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.	false
23623750.T3.T13	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and @CHEMICAL$/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.	CPR:9
23623750.T3.T14	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/@CHEMICAL$ and FMO3 also metabolized methimazole and @GENE$, respectively.	CPR:9
23623750.T3.T15	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and @CHEMICAL$ also metabolized methimazole and @GENE$, respectively.	CPR:9
23623750.T3.T46	@CHEMICAL$, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.	false
23623750.T3.T47	Cynomolgus FMO1, @CHEMICAL$, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.	false
23623750.T3.T48	Cynomolgus FMO1, FMO2, @CHEMICAL$, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.	false
23623750.T3.T49	Cynomolgus FMO1, FMO2, FMO3, and @CHEMICAL$ metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.	false
23623750.T4.T16	Rates of @CHEMICAL$ N-oxygenation (catalyzed by @GENE$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.	CPR:9
23623750.T4.T17	Rates of @CHEMICAL$ N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @GENE$ protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.	false
23623750.T4.T18	Rates of @CHEMICAL$ N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable @GENE$ expression.	false
23623750.T5.T16	Rates of benzydamine @CHEMICAL$-oxygenation (catalyzed by @GENE$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.	CPR:9
23623750.T5.T17	Rates of benzydamine @CHEMICAL$-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @GENE$ protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.	false
23623750.T5.T18	Rates of benzydamine @CHEMICAL$-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable @GENE$ expression.	false
23623750.T6.T16	Rates of benzydamine N-oxygenation (catalyzed by @CHEMICAL$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in @GENE$ N-oxygenation might be partly accounted for by the variable FMO3 expression.	false
23623750.T6.T17	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @CHEMICAL$ protein expression, indicating that the inter-animal variations in @GENE$ N-oxygenation might be partly accounted for by the variable FMO3 expression.	false
23623750.T6.T18	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in @CHEMICAL$ N-oxygenation might be partly accounted for by the variable @GENE$ expression.	CPR:9
23623750.T7.T16	Rates of benzydamine N-oxygenation (catalyzed by @CHEMICAL$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine @GENE$-oxygenation might be partly accounted for by the variable FMO3 expression.	false
23623750.T7.T17	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @CHEMICAL$ protein expression, indicating that the inter-animal variations in benzydamine @GENE$-oxygenation might be partly accounted for by the variable FMO3 expression.	false
23623750.T7.T18	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine @CHEMICAL$-oxygenation might be partly accounted for by the variable @GENE$ expression.	CPR:9
23623750.T8.T19	@CHEMICAL$ metabolized @GENE$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.	CPR:9
23623750.T8.T20	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of @GENE$ in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.	false
23623750.T8.T21	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of @GENE$ in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.	false
23623750.T8.T22	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus @GENE$, FMO2, FMO3, and FMO5 which were all functional.	CPR:9
23623750.T8.T23	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, @GENE$, FMO3, and FMO5 which were all functional.	CPR:9
23623750.T8.T24	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, @GENE$, and FMO5 which were all functional.	CPR:9
23623750.T8.T25	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and @GENE$ which were all functional.	CPR:9
23625910.T4.T31	Effect of paraoxonase 1 @CHEMICAL$ polymorphism on paraoxonase and acetylcholinesterase enzyme activities in Turkish population exposed to @GENE$.	false
23625910.T4.T30	Effect of @CHEMICAL$ 192 Q/R polymorphism on paraoxonase and acetylcholinesterase enzyme activities in Turkish population exposed to @GENE$.	false
23625910.T4.T32	Effect of paraoxonase 1 192 Q/R polymorphism on @CHEMICAL$ and acetylcholinesterase enzyme activities in Turkish population exposed to @GENE$.	false
23625910.T4.T33	Effect of paraoxonase 1 192 Q/R polymorphism on paraoxonase and @CHEMICAL$ enzyme activities in Turkish population exposed to @GENE$.	false
23625910.T2.T20	The aim of this study was to determine the effects of @CHEMICAL$ gene polymorphism and its effects on PON and AChE enzyme activities in individuals who were exposed to @GENE$ insecticides due to occupational reasons, and to profile the probability of susceptibility to organophosphorus compounds.	false
23625910.T2.T21	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on @CHEMICAL$ and AChE enzyme activities in individuals who were exposed to @GENE$ insecticides due to occupational reasons, and to profile the probability of susceptibility to organophosphorus compounds.	false
23625910.T2.T22	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on PON and @CHEMICAL$ enzyme activities in individuals who were exposed to @GENE$ insecticides due to occupational reasons, and to profile the probability of susceptibility to organophosphorus compounds.	false
23625910.T3.T20	The aim of this study was to determine the effects of @CHEMICAL$ gene polymorphism and its effects on PON and AChE enzyme activities in individuals who were exposed to organophosphorus insecticides due to occupational reasons, and to profile the probability of susceptibility to @GENE$ compounds.	false
23625910.T3.T21	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on @CHEMICAL$ and AChE enzyme activities in individuals who were exposed to organophosphorus insecticides due to occupational reasons, and to profile the probability of susceptibility to @GENE$ compounds.	false
23625910.T3.T22	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on PON and @CHEMICAL$ enzyme activities in individuals who were exposed to organophosphorus insecticides due to occupational reasons, and to profile the probability of susceptibility to @GENE$ compounds.	false
23625915.T10.T53	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @CHEMICAL$-activated Protein Kinase and p38beta @GENE$.	false
23625915.T10.T51	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @CHEM-GENE$ and p38beta Mitogen-activated Protein Kinase.	false
23625915.T10.T52	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @CHEMICAL$-activated Protein Kinase and @GENE$ Mitogen-activated Protein Kinase.	false
23625915.T10.T54	Store-operated Ca2+ Entry (SOCE) Induced by @CHEMICAL$ mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @GENE$-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.	false
23625915.T10.T55	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates @CHEMICAL$ Phosphorylation to inhibit SOCE in Endothelial Cells through @GENE$-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.	false
23625915.T11.T53	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta @GENE$.	false
23625915.T11.T51	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @GENE$ and p38beta Mitogen-activated Protein Kinase.	false
23625915.T11.T52	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and @GENE$ Mitogen-activated Protein Kinase.	false
23625915.T11.T54	Store-operated @CHEMICAL$ Entry (SOCE) Induced by @GENE$ mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.	false
23625915.T11.T55	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates @GENE$ Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.	false
23625915.T3.T12	The @CHEMICAL$ sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and @GENE$.	false
23625915.T3.T47	The @CHEMICAL$ sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through @GENE$ and Orai channels.	false
23625915.T3.T29	The @CHEMICAL$ sensor @GENE$ is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and Orai channels.	false
23625915.T8.T12	The Ca2+ sensor STIM1 is crucial for activation of store-operated @CHEMICAL$ entry (SOCE) through TRPC and @GENE$.	false
23625915.T8.T47	The Ca2+ sensor STIM1 is crucial for activation of store-operated @CHEMICAL$ entry (SOCE) through @GENE$ and Orai channels.	false
23625915.T8.T29	The Ca2+ sensor @CHEMICAL$ is crucial for activation of store-operated @GENE$ entry (SOCE) through TRPC and Orai channels.	false
23625915.T2.T34	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b @GENE$ (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T2.T36	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b mitogen-activated protein kinase (p38b @GENE$) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T2.T31	Here we show that SOCE activates @CHEM-GENE$ (AMPK); its effector p38b mitogen-activated protein kinase (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T2.T32	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (@GENE$); its effector p38b mitogen-activated protein kinase (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T2.T33	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector @GENE$ mitogen-activated protein kinase (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T2.T35	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b mitogen-activated protein kinase (@GENE$ MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T2.T37	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b mitogen-activated protein kinase (p38b MAPK) phosphorylates @GENE$, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	false
23625915.T4.T38	Activation of @CHEMICAL$ using @GENE$ resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.	CPR:3
23625915.T4.T39	Activation of AMPK using @CHEMICAL$ resulted in @GENE$ phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.	CPR:3
23625915.T4.T40	Activation of AMPK using @CHEMICAL$ resulted in STIM1 phosphorylation on serine residues and prevented @GENE$-induced Ca2+ entry.	CPR:4
23625915.T5.T38	Activation of @CHEMICAL$ using AICAR resulted in STIM1 phosphorylation on @GENE$ residues and prevented PAR-1-induced Ca2+ entry.	false
23625915.T5.T39	Activation of AMPK using AICAR resulted in @CHEMICAL$ phosphorylation on @GENE$ residues and prevented PAR-1-induced Ca2+ entry.	false
23625915.T5.T40	Activation of AMPK using AICAR resulted in STIM1 phosphorylation on @CHEMICAL$ residues and prevented @GENE$-induced Ca2+ entry.	false
23625915.T6.T38	Activation of @CHEMICAL$ using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced @GENE$ entry.	false
23625915.T6.T39	Activation of AMPK using AICAR resulted in @CHEMICAL$ phosphorylation on serine residues and prevented PAR-1-induced @GENE$ entry.	false
23625915.T6.T40	Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented @CHEMICAL$-induced @GENE$ entry.	false
23625915.T7.T41	Further, @CHEMICAL$ pretreatment blocked @GENE$-induced increase in permeability of mouse-lung microvessels.	CPR:4
23625915.T1.T46	Interestingly, SB203580, a selective inhibitor of @CHEMICAL$ MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and @GENE$ entry.	false
23625915.T1.T48	Interestingly, SB203580, a selective inhibitor of p38 @CHEMICAL$, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and @GENE$ entry.	false
23625915.T1.T49	Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked @CHEMICAL$ phosphorylation and led to sustained STIM1-puncta formation and @GENE$ entry.	false
23625915.T1.T50	Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained @CHEMICAL$-puncta formation and @GENE$ entry.	false
23625915.T9.T46	Interestingly, @CHEMICAL$, a selective inhibitor of @GENE$ MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.	CPR:4
23625915.T9.T48	Interestingly, @CHEMICAL$, a selective inhibitor of p38 @GENE$, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.	CPR:4
23625915.T9.T49	Interestingly, @CHEMICAL$, a selective inhibitor of p38 MAPK, blocked @GENE$ phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.	CPR:4
23625915.T9.T50	Interestingly, @CHEMICAL$, a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained @GENE$-puncta formation and Ca2+ entry.	false
23628605.T4.T25	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the @CHEMICAL$ side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, @GENE$ and ferredoxin.	false
23628605.T4.T26	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the @CHEMICAL$ side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, ferredoxin reductase and @GENE$.	false
23628605.T4.T24	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the @CHEMICAL$ side-chain cleavage enzyme, @GENE$, and its two electron-transfer partners, ferredoxin reductase and ferredoxin.	CPR:9
23628605.T8.T27	Several other steroidogenic enzymes, including @CHEM-GENE$, 11b-hydroxylase and aldosterone synthase also reside in mitochondria.	false
23628605.T8.T28	Several other steroidogenic enzymes, including @CHEMICAL$ dehydrogenase, @GENE$ and aldosterone synthase also reside in mitochondria.	false
23628605.T8.T29	Several other steroidogenic enzymes, including @CHEMICAL$ dehydrogenase, 11b-hydroxylase and @GENE$ also reside in mitochondria.	false
23628605.T9.T27	Several other steroidogenic enzymes, including @CHEMICAL$, 11b-hydroxylase and @GENE$ synthase also reside in mitochondria.	false
23628605.T9.T28	Several other steroidogenic enzymes, including 3b-hydroxysteroid dehydrogenase, @CHEMICAL$ and @GENE$ synthase also reside in mitochondria.	false
23628605.T9.T29	Several other steroidogenic enzymes, including 3b-hydroxysteroid dehydrogenase, 11b-hydroxylase and @CHEM-GENE$ also reside in mitochondria.	false
23628605.T10.T30	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of @CHEMICAL$. The access of cholesterol to the mitochondria is regulated by the @GENE$, StAR, serving as the acute regulator of steroidogenesis.	false
23628605.T10.T31	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of @CHEMICAL$. The access of cholesterol to the mitochondria is regulated by the steroidogenic acute regulatory protein, @GENE$, serving as the acute regulator of steroidogenesis.	false
23628605.T11.T30	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of vitamin D. The access of @CHEMICAL$ to the mitochondria is regulated by the @GENE$, StAR, serving as the acute regulator of steroidogenesis.	false
23628605.T11.T31	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of vitamin D. The access of @CHEMICAL$ to the mitochondria is regulated by the steroidogenic acute regulatory protein, @GENE$, serving as the acute regulator of steroidogenesis.	false
23628605.T1.T22	The precise fashion in which these proteins interact and move @CHEMICAL$ from the OMM to @GENE$, and the means by which cholesterol is loaded into the OMM, remain unclear.	CPR:9
23628605.T2.T22	The precise fashion in which these proteins interact and move cholesterol from the OMM to @CHEMICAL$, and the means by which @GENE$ is loaded into the OMM, remain unclear.	false
23628605.T3.T23	Human deficiency diseases have been described for @CHEMICAL$ and for all the mitochondrial steroidogenic enzymes, but not for the electron transfer proteins or for the components of the @GENE$ import machine.	false
23631440.T9.T21	@CHEMICAL$ Inhibitors Based on the @GENE$ Core.	CPR:4
23631440.T1.T11	New series of @CHEMICAL$, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine @GENE$ inhibitors (MMPIs) were designed, synthesized, and evaluated.	CPR:4
23631440.T3.T11	New series of pyrrolidine mercaptosulfide, @CHEMICAL$, and 3-mercapto-4-arylsulfonamido pyrrolidine @GENE$ inhibitors (MMPIs) were designed, synthesized, and evaluated.	CPR:4
23631440.T7.T11	New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and @CHEMICAL$ @GENE$ inhibitors (MMPIs) were designed, synthesized, and evaluated.	CPR:4
23631440.T2.T12	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several @GENE$ in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).	CPR:4
23631440.T2.T13	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including @GENE$ (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).	CPR:4
23631440.T2.T14	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), @GENE$ (~2 to 50 nM), and MMP-14 (~4 to 60 nM).	CPR:4
23631440.T2.T15	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and @GENE$ (~4 to 60 nM).	CPR:4
23631440.T4.T20	Our previous work with the @CHEMICAL$ functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the @GENE$ tested.	false
23631440.T5.T20	Our previous work with the mercaptosulfide functionality attached to both @CHEMICAL$ and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the @GENE$ tested.	false
23631440.T6.T20	Our previous work with the mercaptosulfide functionality attached to both cyclopentane and @CHEMICAL$ frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the @GENE$ tested.	false
23633618.T6.T11	A Structural Snapshot of @CHEMICAL$ in Complex with @GENE$ Provides Insights into Ligand Binding and Clusters of Conformational States.	false
23633618.T5.T8	An X-ray crystal structure of @CHEMICAL$ in complex with the drug @GENE$ was solved at 2.14 A resolution.	false
23633618.T3.T10	The @CHEMICAL$-@GENE$ structure is nearly superimposable on a previously solved closed structure in a ligand free state.	false
23638842.T7.T18	Protective Role of @CHEMICAL$ Bioactivated with @GENE$ in an Experimental Model of Multiple Sclerosis.	false
23638842.T3.T14	Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in @CHEMICAL$, which upon @GENE$ hydrolysis release the corresponding isothiocyanates.	CPR:9
23638842.T4.T14	Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon @CHEMICAL$ hydrolysis release the corresponding @GENE$.	CPR:9
23638842.T6.T15	acephala sabellica) bioactivated with @CHEMICAL$ (bioactive @GENE$) (10 mg/kg/day intraperitoneally), in an experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis.	false
23638842.T1.T8	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased @GENE$ translocation, pro-inflammatory cytokine production such as interleukin-1b (IL-1b), and apoptosis (Bax and caspase 3 expression).	CPR:4
23638842.T1.T9	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory @GENE$ production such as interleukin-1b (IL-1b), and apoptosis (Bax and caspase 3 expression).	CPR:4
23638842.T1.T10	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as @GENE$ (IL-1b), and apoptosis (Bax and caspase 3 expression).	CPR:4
23638842.T1.T11	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1b (@GENE$), and apoptosis (Bax and caspase 3 expression).	CPR:4
23638842.T1.T12	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1b (IL-1b), and apoptosis (@GENE$ and caspase 3 expression).	CPR:4
23638842.T1.T13	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1b (IL-1b), and apoptosis (Bax and @GENE$ expression).	CPR:4
23639191.T24.T45	Involvement of @CHEMICAL$ and phase II detoxifying enzyme system in neuroprotection mediated by the flavonoid @GENE$ isolated from Dracocephalum kotschyi.	false
23639191.T24.T46	Involvement of p-CREB and @CHEMICAL$ system in neuroprotection mediated by the flavonoid @GENE$ isolated from Dracocephalum kotschyi.	false
23639191.T16.T33	Herein, we investigated the effect of a natural neuroprotective flavonoid, @CHEMICAL$, on H2O2-induced disruption of @GENE$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T16.T34	Herein, we investigated the effect of a natural neuroprotective flavonoid, @CHEMICAL$, on H2O2-induced disruption of phase II detoxifying enzyme system and @GENE$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T16.T35	Herein, we investigated the effect of a natural neuroprotective flavonoid, @CHEMICAL$, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@GENE$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T17.T33	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on @CHEMICAL$-induced disruption of @GENE$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	CPR:4
23639191.T17.T34	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on @CHEMICAL$-induced disruption of phase II detoxifying enzyme system and @GENE$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	CPR:4
23639191.T17.T35	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on @CHEMICAL$-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@GENE$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	CPR:4
23639191.T18.T33	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of @CHEMICAL$ system and @GENE$ response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T18.T34	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEM-GENE$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T18.T35	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEMICAL$ response element binding protein (@GENE$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T19.T33	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of @CHEMICAL$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of @GENE$ for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T19.T34	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEMICAL$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of @GENE$ for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T19.T35	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@CHEMICAL$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of @GENE$ for 3h, followed by adding H2O2 (150mM) for 24h.	false
23639191.T20.T33	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of @CHEMICAL$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding @GENE$ (150mM) for 24h.	false
23639191.T20.T34	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEMICAL$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding @GENE$ (150mM) for 24h.	false
23639191.T20.T35	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@CHEMICAL$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding @GENE$ (150mM) for 24h.	false
23639191.T21.T36	The level of @CHEMICAL$, nuclear factor erythroid 2-related factor 2 (Nrf2), @GENE$ synthetase (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	false
23639191.T21.T37	The level of phosphorylated CREB, @CHEMICAL$ (Nrf2), @GENE$ synthetase (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	false
23639191.T21.T38	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (@CHEMICAL$), @GENE$ synthetase (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	false
23639191.T21.T39	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEM-GENE$ (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	false
23639191.T21.T40	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEMICAL$ synthetase (@GENE$) and heme oxygenase 1 (HO-1) were measured by western blot method.	false
23639191.T21.T41	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEMICAL$ synthetase (g-GCS) and @GENE$ (HO-1) were measured by western blot method.	false
23639191.T21.T42	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEMICAL$ synthetase (g-GCS) and heme oxygenase 1 (@GENE$) were measured by western blot method.	false
23639191.T6.T25	In @CHEMICAL$-treated cells, calycopterin also suppressed @GENE$ release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.	false
23639191.T7.T25	In H2O2-treated cells, @CHEMICAL$ also suppressed @GENE$ release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.	CPR:4
23639191.T8.T26	Moreover, @CHEMICAL$, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, @GENE$ and Nrf2, which play an important role in antioxidant capacity of the cell.	CPR:3
23639191.T8.T27	Moreover, @CHEMICAL$, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and @GENE$, which play an important role in antioxidant capacity of the cell.	CPR:3
23639191.T9.T26	Moreover, calycopterin, in presence of @CHEMICAL$ inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, @GENE$ and Nrf2, which play an important role in antioxidant capacity of the cell.	false
23639191.T9.T27	Moreover, calycopterin, in presence of @CHEMICAL$ inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and @GENE$, which play an important role in antioxidant capacity of the cell.	false
23639191.T10.T28	There was also an increase in @CHEMICAL$ and HO-1 levels in @GENE$ pretreated cells.	CPR:3
23639191.T10.T29	There was also an increase in g-GCS and @CHEMICAL$ levels in @GENE$ pretreated cells.	CPR:3
23639191.T11.T30	In the presence of @CHEMICAL$, calycopterin inhibited decrease in GSH level and @GENE$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.	false
23639191.T11.T31	In the presence of @CHEMICAL$, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.	false
23639191.T11.T32	In the presence of @CHEMICAL$, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.	false
23639191.T12.T30	In the presence of H2O2, @CHEMICAL$ inhibited decrease in GSH level and @GENE$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.	CPR:3
23639191.T12.T31	In the presence of H2O2, @CHEMICAL$ inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.	false
23639191.T12.T32	In the presence of H2O2, @CHEMICAL$ inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.	false
23639191.T13.T30	In the presence of H2O2, calycopterin inhibited decrease in @CHEMICAL$ level and @GENE$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.	false
23639191.T13.T31	In the presence of H2O2, calycopterin inhibited decrease in @CHEMICAL$ level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.	false
23639191.T13.T32	In the presence of H2O2, calycopterin inhibited decrease in @CHEMICAL$ level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.	false
23639191.T14.T30	In the presence of H2O2, calycopterin inhibited decrease in GSH level and @CHEMICAL$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, @GENE$, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.	false
23639191.T14.T31	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, @CHEMICAL$, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.	false
23639191.T14.T32	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, @CHEMICAL$, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.	false
23639191.T15.T30	In the presence of H2O2, calycopterin inhibited decrease in GSH level and @CHEMICAL$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against @GENE$-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.	false
23639191.T15.T31	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against @CHEMICAL$-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.	false
23639191.T15.T32	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against @CHEMICAL$-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.	false
23639249.T14.T29	@CHEMICAL$ stimulates Th17 differentiation enhancing phosphorylation of @GENE$ and STAT3 to worsen experimental autoimmune encephalomyelitis.	CPR:3
23639249.T14.T30	@CHEMICAL$ stimulates Th17 differentiation enhancing phosphorylation of c-Src and @GENE$ to worsen experimental autoimmune encephalomyelitis.	CPR:3
23639249.T4.T18	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by @GENE$ (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	CPR:3
23639249.T4.T19	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by @CHEMICAL$ (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @GENE$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	false
23639249.T4.T20	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by @CHEMICAL$ (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical @GENE$ ligand.	false
23639249.T5.T18	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (@GENE$), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	CPR:3
23639249.T5.T19	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (@CHEMICAL$), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @GENE$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	false
23639249.T5.T20	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (@CHEMICAL$), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical @GENE$ ligand.	false
23639249.T6.T18	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. @GENE$ increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	false
23639249.T6.T19	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. @CHEMICAL$ increased expression of @GENE$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	CPR:3
23639249.T6.T20	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. @CHEMICAL$ increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical @GENE$ ligand.	false
23639249.T7.T18	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as @GENE$ (TCDD), a prototypical AhR ligand.	false
23639249.T7.T19	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @CHEMICAL$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as @GENE$ (TCDD), a prototypical AhR ligand.	false
23639249.T7.T20	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as @CHEMICAL$ (TCDD), a prototypical @GENE$ ligand.	false
23639249.T8.T18	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (@GENE$), a prototypical AhR ligand.	false
23639249.T8.T19	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @CHEMICAL$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (@GENE$), a prototypical AhR ligand.	false
23639249.T8.T20	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (@CHEMICAL$), a prototypical @GENE$ ligand.	false
23639249.T10.T21	Activation of @CHEMICAL$, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and @GENE$.	CPR:3
23639249.T10.T22	Activation of STAT3, which is phosphorylated by the @CHEMICAL$ signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and @GENE$.	CPR:3
23639249.T9.T21	Activation of @CHEMICAL$, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by @GENE$ and TCDD.	CPR:3
23639249.T9.T22	Activation of STAT3, which is phosphorylated by the @CHEMICAL$ signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by @GENE$ and TCDD.	CPR:3
23639249.T11.T15	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.	false
23639249.T11.T16	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.	false
23639249.T11.T23	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by @GENE$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	CPR:3
23639249.T11.T24	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by @GENE$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T11.T25	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of @GENE$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T11.T27	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @GENE$ and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T11.T28	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @GENE$, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T12.T15	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.	false
23639249.T12.T16	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.	false
23639249.T12.T23	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and @GENE$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	CPR:3
23639249.T12.T24	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and @GENE$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T12.T25	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of @GENE$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T12.T27	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @GENE$ and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T12.T28	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @GENE$, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T13.T15	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.	false
23639249.T13.T16	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.	false
23639249.T13.T23	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @GENE$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T13.T24	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @GENE$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T13.T25	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of @CHEMICAL$ activity by @GENE$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	CPR:4
23639249.T13.T27	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both @GENE$ and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	CPR:4
23639249.T13.T28	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both c-Src and @GENE$, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	CPR:4
23639249.T1.T15	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @CHEMICAL$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.	CPR:3
23639249.T1.T16	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @CHEMICAL$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.	CPR:3
23639249.T1.T23	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T1.T24	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T1.T25	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of @CHEMICAL$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T1.T27	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @CHEMICAL$ and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T1.T28	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @CHEMICAL$, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T2.T15	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @CHEMICAL$ on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.	CPR:3
23639249.T2.T16	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @CHEMICAL$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.	CPR:3
23639249.T2.T23	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T2.T24	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T2.T25	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of @CHEMICAL$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T2.T27	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @CHEMICAL$ and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T2.T28	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @CHEMICAL$, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	false
23639249.T3.T17	Finally, we found that @CHEMICAL$ worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of @GENE$-producing cells in draining lymph nodes.	CPR:3
23639586.T4.T13	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, @GENE$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T4.T14	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, @CHEMICAL$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @GENE$ activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T4.T15	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, @CHEMICAL$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T4.T16	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, @CHEMICAL$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.	false
23639586.T5.T13	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum @GENE$, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T5.T14	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum @GENE$, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T5.T15	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum @CHEMICAL$, GSH/GSSG ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T5.T16	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum @CHEMICAL$, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.	false
23639586.T6.T13	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, @GENE$/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T6.T14	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, @GENE$/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T6.T15	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, @CHEMICAL$/GSSG ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T6.T16	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, @CHEMICAL$/GSSG ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.	false
23639586.T7.T13	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/@GENE$ ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T7.T14	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, GSH/@GENE$ ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T7.T15	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/@CHEMICAL$ ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T7.T16	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/@CHEMICAL$ ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.	false
23639586.T8.T13	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @GENE$-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T8.T14	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, GSH/GSSG ratio, @GENE$-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T8.T15	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @CHEM-GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.	false
23639586.T8.T16	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @CHEMICAL$-6-phosphatase and @GENE$ activities, liver glycogen.	false
23639586.T9.T13	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ carboxykinase activities, liver glycogen.	false
23639586.T9.T14	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ carboxykinase activities, liver glycogen.	false
23639586.T9.T15	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @CHEMICAL$ and @GENE$ carboxykinase activities, liver glycogen.	false
23639586.T9.T16	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @CHEM-GENE$ activities, liver glycogen.	false
23639586.T2.T12	These data suggest that TP treatment could alter the hepatic redox status, reduce serum @CHEMICAL$ and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in @GENE$ signaling pathway, glucose metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.	false
23639586.T3.T12	These data suggest that TP treatment could alter the hepatic redox status, reduce serum glucose and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in @CHEMICAL$ signaling pathway, @GENE$ metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.	false
23639626.T16.T36	@CHEMICAL$ induces the expression of @GENE$ in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.	CPR:3
23639626.T17.T36	TCDD induces the expression of @CHEMICAL$ in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on @GENE$ toxicity.	false
23639626.T11.T26	TCDD treatment of the cells largely prevented the activation of @CHEMICAL$, a regulator of translation initiation and substrate of the mammalian target of @GENE$ (mTOR).	false
23639626.T11.T27	TCDD treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the @CHEM-GENE$ (mTOR).	false
23639626.T11.T28	TCDD treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of @CHEMICAL$ (@GENE$).	false
23639626.T9.T26	@CHEMICAL$ treatment of the cells largely prevented the activation of @GENE$, a regulator of translation initiation and substrate of the mammalian target of rapamycin (mTOR).	false
23639626.T9.T27	@CHEMICAL$ treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the @GENE$ (mTOR).	false
23639626.T9.T28	@CHEMICAL$ treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of rapamycin (@GENE$).	false
23639626.T12.T31	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and IGF-I-induced @GENE$ and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."	CPR:4
23639626.T12.T32	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and IGF-I-induced AKT and @GENE$ activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."	CPR:4
23639626.T12.T29	"By ""working upwards"" from @CHEMICAL$, we observed that @GENE$ inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."	false
23639626.T12.T30	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and @GENE$-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."	CPR:4
23639626.T12.T33	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of @GENE$."	false
23639626.T13.T31	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced @CHEMICAL$ and ERK activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."	false
23639626.T13.T32	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and @CHEMICAL$ activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."	false
23639626.T13.T29	"By ""working upwards"" from @CHEMICAL$, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."	false
23639626.T13.T30	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and @CHEMICAL$-induced AKT and ERK activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."	false
23639626.T13.T33	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with @CHEMICAL$ phosphorylation of @GENE$."	false
23639626.T14.T34	This inhibition was mediated by a @CHEMICAL$-induced secreted factor which was identified as @GENE$ (IGFBP-4).	CPR:3
23639626.T14.T35	This inhibition was mediated by a @CHEMICAL$-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (@GENE$).	CPR:3
23639626.T1.T18	The induction of @CHEMICAL$ protein was dependent on a functional @GENE$ receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.	false
23639626.T1.T19	The induction of IGFBP-4 protein was dependent on a functional @CHEM-GENE$ and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.	false
23639626.T1.T20	The induction of IGFBP-4 protein was dependent on a functional @CHEMICAL$ receptor and was preceded by a rapid increase in the level of @GENE$ mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.	false
23639626.T1.T21	The induction of IGFBP-4 protein was dependent on a functional @CHEMICAL$ receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that @GENE$ is a previously unknown transcriptional target of TCDD in 5L cells.	false
23639626.T2.T18	The induction of @CHEMICAL$ protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of @GENE$ in 5L cells.	false
23639626.T2.T19	The induction of IGFBP-4 protein was dependent on a functional @CHEMICAL$ and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of @GENE$ in 5L cells.	false
23639626.T2.T20	The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of @CHEMICAL$ mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of @GENE$ in 5L cells.	CPR:4
23639626.T2.T21	The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that @CHEMICAL$ is a previously unknown transcriptional target of @GENE$ in 5L cells.	false
23639626.T3.T22	@CHEMICAL$ was not induced by @GENE$ in the parental cell line of 5L cells, Fao, and in various closely related rat hepatoma cell lines as well as in other unrelated cell types.	false
23639626.T4.T24	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing @CHEM-GENE$ leading to the induction of IGFBP-4 by TCDD.	false
23639626.T4.T23	The observations suggest that in 5L cells the @CHEMICAL$ gene may have got under the control of a promoter containing @GENE$ responsive element(s) leading to the induction of IGFBP-4 by TCDD.	false
23639626.T4.T25	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing @CHEMICAL$ responsive element(s) leading to the induction of @GENE$ by TCDD.	false
23639626.T5.T24	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing @CHEMICAL$ leading to the induction of IGFBP-4 by @GENE$.	false
23639626.T5.T23	The observations suggest that in 5L cells the @CHEMICAL$ gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by @GENE$.	false
23639626.T5.T25	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of @CHEMICAL$ by @GENE$.	CPR:3
2386945.T25.T46	Similar concentrations of these compounds blocked @CHEMICAL$-induced growth of MCF-7 cells, but @GENE$ (ER) interactions do not seem to be involved.	false
2386945.T25.T47	Similar concentrations of these compounds blocked @CHEMICAL$-induced growth of MCF-7 cells, but estrogen receptor (@GENE$) interactions do not seem to be involved.	false
2386945.T26.T46	Similar concentrations of these compounds blocked estradiol-induced growth of MCF-7 cells, but @CHEM-GENE$ (ER) interactions do not seem to be involved.	false
2386945.T26.T47	Similar concentrations of these compounds blocked estradiol-induced growth of MCF-7 cells, but @CHEMICAL$ receptor (@GENE$) interactions do not seem to be involved.	false
2386945.T1.T48	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 @CHEMICAL$, nor did pimozide interfere with the induction of progesterone receptors by @GENE$.	false
2386945.T1.T49	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @CHEMICAL$ by @GENE$.	false
2386945.T27.T48	@CHEMICAL$ and thioridazine had no effect on the estradiol binding properties of the MCF-7 @GENE$, nor did pimozide interfere with the induction of progesterone receptors by estradiol.	false
2386945.T27.T49	@CHEMICAL$ and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @GENE$ by estradiol.	false
2386945.T28.T48	Pimozide and @CHEMICAL$ had no effect on the estradiol binding properties of the MCF-7 @GENE$, nor did pimozide interfere with the induction of progesterone receptors by estradiol.	false
2386945.T28.T49	Pimozide and @CHEMICAL$ had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @GENE$ by estradiol.	false
2386945.T29.T48	Pimozide and thioridazine had no effect on the @CHEMICAL$ binding properties of the MCF-7 @GENE$, nor did pimozide interfere with the induction of progesterone receptors by estradiol.	false
2386945.T29.T49	Pimozide and thioridazine had no effect on the @CHEMICAL$ binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @GENE$ by estradiol.	false
2386945.T30.T48	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 @CHEMICAL$, nor did @GENE$ interfere with the induction of progesterone receptors by estradiol.	false
2386945.T30.T49	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did @CHEMICAL$ interfere with the induction of @GENE$ by estradiol.	false
2386945.T31.T48	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 @CHEMICAL$, nor did pimozide interfere with the induction of @GENE$ receptors by estradiol.	false
2386945.T31.T49	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @CHEM-GENE$ by estradiol.	false
2386945.T2.T34	Furthermore, @CHEMICAL$ also inhibited incorporation of [3H]thymidine into MCF-7 cells stimulated by @GENE$ in serum-free medium.	false
2386945.T3.T34	Furthermore, pimozide also inhibited incorporation of @CHEMICAL$ into MCF-7 cells stimulated by @GENE$ in serum-free medium.	false
2386945.T4.T35	The Ki for @CHEMICAL$ in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of @GENE$ (0.42 microM), insulin-like growth factor I (0.54 microM), and epidermal growth factor (0.43 microM).	false
2386945.T4.T36	The Ki for @CHEMICAL$ in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), @GENE$ (0.54 microM), and epidermal growth factor (0.43 microM).	false
2386945.T4.T37	The Ki for @CHEMICAL$ in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), insulin-like growth factor I (0.54 microM), and @GENE$ (0.43 microM).	false
2386945.T6.T38	@CHEMICAL$ also blocked cell growth and [3H]thymidine incorporation into the @GENE$-positive T47D and ZR75-1B human breast cancer cell lines and the ER-negative human breast cancer cell line, MDA-MB-231.	false
2386945.T6.T39	@CHEMICAL$ also blocked cell growth and [3H]thymidine incorporation into the ER-positive T47D and ZR75-1B human breast cancer cell lines and the @GENE$-negative human breast cancer cell line, MDA-MB-231.	false
2386945.T7.T38	Pimozide also blocked cell growth and @CHEMICAL$ incorporation into the @GENE$-positive T47D and ZR75-1B human breast cancer cell lines and the ER-negative human breast cancer cell line, MDA-MB-231.	false
2386945.T7.T39	Pimozide also blocked cell growth and @CHEMICAL$ incorporation into the ER-positive T47D and ZR75-1B human breast cancer cell lines and the @GENE$-negative human breast cancer cell line, MDA-MB-231.	false
2386945.T8.T40	Although numerous mechanisms of action of @CHEMICAL$ and thioridazine have been identified, both drugs are @GENE$ antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.	CPR:6
2386945.T9.T40	Although numerous mechanisms of action of pimozide and @CHEMICAL$ have been identified, both drugs are @GENE$ antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.	CPR:6
2386945.T12.T41	Inhibition of MCF-7 cell growth by the selective @CHEMICAL$ antagonists @GENE$ and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.	CPR:6
2386945.T12.T42	Inhibition of MCF-7 cell growth by the selective calmodulin antagonists @CHEMICAL$ and W-12 is consistent with a role for @GENE$ antagonism in the broad growth-inhibitory properties of pimozide.	false
2386945.T13.T41	Inhibition of MCF-7 cell growth by the selective @CHEMICAL$ antagonists W-13 and @GENE$ is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.	CPR:6
2386945.T13.T42	Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and @CHEMICAL$ is consistent with a role for @GENE$ antagonism in the broad growth-inhibitory properties of pimozide.	false
2386945.T15.T41	Inhibition of MCF-7 cell growth by the selective @CHEMICAL$ antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of @GENE$.	false
2386945.T15.T42	Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for @CHEMICAL$ antagonism in the broad growth-inhibitory properties of @GENE$.	CPR:4
2386945.T16.T43	We conclude that @CHEMICAL$ and thioridazine may be useful in the control of estradiol- and @GENE$-induced growth of ER-positive and ER-negative human breast tumors.	false
2386945.T16.T44	We conclude that @CHEMICAL$ and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of @GENE$-positive and ER-negative human breast tumors.	false
2386945.T16.T45	We conclude that @CHEMICAL$ and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and @GENE$-negative human breast tumors.	false
2386945.T17.T43	We conclude that pimozide and @CHEMICAL$ may be useful in the control of estradiol- and @GENE$-induced growth of ER-positive and ER-negative human breast tumors.	false
2386945.T17.T44	We conclude that pimozide and @CHEMICAL$ may be useful in the control of estradiol- and polypeptide hormone-induced growth of @GENE$-positive and ER-negative human breast tumors.	false
2386945.T17.T45	We conclude that pimozide and @CHEMICAL$ may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and @GENE$-negative human breast tumors.	false
2386945.T18.T43	We conclude that pimozide and thioridazine may be useful in the control of @CHEMICAL$- and @GENE$-induced growth of ER-positive and ER-negative human breast tumors.	false
2386945.T18.T44	We conclude that pimozide and thioridazine may be useful in the control of @CHEMICAL$- and polypeptide hormone-induced growth of @GENE$-positive and ER-negative human breast tumors.	false
2386945.T18.T45	We conclude that pimozide and thioridazine may be useful in the control of @CHEMICAL$- and polypeptide hormone-induced growth of ER-positive and @GENE$-negative human breast tumors.	false
2506486.T33.T44	Effects of @CHEM-GENE$ inhibitors on levels of catechols and homovanillic acid in striatum and plasma.	false
2506486.T34.T44	Effects of @CHEMICAL$ inhibitors on levels of @GENE$ and homovanillic acid in striatum and plasma.	false
2506486.T35.T44	Effects of @CHEMICAL$ inhibitors on levels of catechols and @GENE$ in striatum and plasma.	false
2506486.T10.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @CHEMICAL$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T10.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @GENE$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T10.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by clorgyline (4 mg/kg i.p.), MAO-B by @GENE$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T10.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @CHEMICAL$ by @GENE$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	CPR:4
2506486.T10.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @CHEMICAL$ (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T10.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @CHEMICAL$ (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T11.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @CHEMICAL$ (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T11.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T11.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T11.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @CHEMICAL$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T11.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @CHEMICAL$ and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	CPR:4
2506486.T11.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @CHEMICAL$ by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	CPR:4
2506486.T12.T42	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T12.T37	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T12.T38	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T12.T39	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T12.T40	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T12.T41	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T13.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @CHEMICAL$ by @GENE$ (40 mg/kg i.p.).	CPR:4
2506486.T13.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).	false
2506486.T13.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).	false
2506486.T13.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @CHEMICAL$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).	false
2506486.T13.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @CHEMICAL$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).	false
2506486.T13.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @CHEMICAL$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).	false
2506486.T14.T42	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T14.T37	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T14.T38	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T14.T39	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T14.T40	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T14.T41	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T21.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T21.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T21.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T21.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T21.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T21.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T27.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T27.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T27.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T27.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T27.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T27.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T2.T42	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T2.T37	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T2.T38	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T2.T39	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T2.T40	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T2.T41	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T32.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T32.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T32.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T32.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T32.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T32.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T8.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T8.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEM-GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T8.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T8.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T8.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T8.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T9.T42	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).	false
2506486.T9.T37	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by @GENE$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	CPR:4
2506486.T9.T38	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by @GENE$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	CPR:4
2506486.T9.T39	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T9.T40	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T9.T41	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).	false
2506486.T1.T36	The results suggest that most of the HVA in plasma is derived from deamination of @CHEMICAL$ by @GENE$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	CPR:9
2506486.T31.T36	The results suggest that most of the @CHEMICAL$ in plasma is derived from deamination of DA by @GENE$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	CPR:9
2506486.T3.T36	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that @GENE$ in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	false
2506486.T4.T36	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that @GENE$ in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	false
2506486.T5.T36	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of @GENE$ in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	false
2506486.T6.T36	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of @GENE$ after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	false
2506486.T7.T36	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with @GENE$ provide an improved but limited indication of central dopaminergic activity.	false
2554783.T1.T2	This lack of difference was unexpected since the genes for @CHEMICAL$ and esterase D, also called @GENE$ hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	false
2554783.T1.T3	This lack of difference was unexpected since the genes for catalase and @CHEMICAL$, also called @GENE$ hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	false
2554783.T1.T4	This lack of difference was unexpected since the genes for catalase and esterase D, also called @CHEM-GENE$, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	false
2751392.T9.T17	Developmental changes in @CHEM-GENE$ activity in young jaundiced male rats.	false
2751392.T1.T10	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, @CHEM-GENE$ (LDH-X), and serum testosterone levels.	false
2751392.T1.T11	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, @CHEMICAL$ dehydrogenase-X (@GENE$), and serum testosterone levels.	false
2751392.T2.T10	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, @CHEMICAL$ (LDH-X), and serum @GENE$ levels.	false
2751392.T2.T11	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, lactate dehydrogenase-X (@CHEMICAL$), and serum @GENE$ levels.	false
2751392.T3.T12	Testicular cytosolic @CHEMICAL$ activity was determined by oxidation of reduced @GENE$ (NADH).	false
2751392.T4.T12	Testicular cytosolic @CHEMICAL$ activity was determined by oxidation of reduced nicotinamide adenine dinucleotide (@GENE$).	false
2751392.T7.T15	@CHEMICAL$ activity and serum @GENE$ levels were similar for both genotypes at 180 days of age.	false
2751392.T8.T16	The delay of testicular maturation in the jaundiced males seems to be due to lower @CHEMICAL$ activity and serum @GENE$ levels.	false
2832297.T3.T17	@CHEMICAL$ modifies but does not block the @GENE$-induced ACTH response in patients with Addison's disease.	false
2832297.T3.T18	@CHEMICAL$ modifies but does not block the corticotropin-releasing hormone-induced @GENE$ response in patients with Addison's disease.	false
2832297.T1.T15	The effect of @CHEMICAL$ - a peripheral opiate agonist - on plasma @GENE$ response to Corticotropin-releasing Hormone (CRH) has been investigated in 6 patients with Addison's disease.	false
2832297.T1.T16	The effect of @CHEMICAL$ - a peripheral opiate agonist - on plasma ACTH response to @GENE$ (CRH) has been investigated in 6 patients with Addison's disease.	false
2832297.T1.T4	The effect of @CHEMICAL$ - a peripheral opiate agonist - on plasma ACTH response to Corticotropin-releasing Hormone (@GENE$) has been investigated in 6 patients with Addison's disease.	false
2832297.T2.T10	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of @GENE$ response to CRH was slightly delayed.	false
2832297.T2.T11	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to @GENE$ was slightly delayed.	false
2832297.T2.T7	After @CHEMICAL$ administration @GENE$ levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.	CPR:4
2832297.T2.T8	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then @GENE$ was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.	false
2832297.T2.T9	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an @GENE$ increase; the pattern of ACTH response to CRH was slightly delayed.	CPR:3
2857786.T1.T18	@CHEMICAL$ is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize @GENE$ as well.	CPR:6
2857786.T1.T20	@CHEMICAL$ is known to be an inhibitor of @GENE$, and recent data have shown this drug to antagonize muscarinic receptors as well.	CPR:4
2857786.T11.T21	@CHEMICAL$ was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the @GENE$ inhibitor neostigmine.	false
2857786.T12.T21	Ambenonium was a less potent antagonist of tissue responses to @CHEMICAL$, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the @GENE$ inhibitor neostigmine.	false
2857786.T13.T21	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with @CHEMICAL$) could be eliminated by prior treatment of tissues with the @GENE$ inhibitor neostigmine.	false
2857786.T14.T21	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the @CHEMICAL$ inhibitor @GENE$.	CPR:4
2857786.T15.T19	These data suggested that @CHEMICAL$ had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of @GENE$.	CPR:6
2857786.T15.T19	These data suggested that @CHEMICAL$ had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of @GENE$.	CPR:4
2857786.T15.T17	These data suggested that @CHEMICAL$ had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of @GENE$ and concomitant antagonism by blockade of muscarinic receptors.	CPR:4
2857786.T2.T19	These data suggested that ambenonium had a dual effect on tissue responses to @CHEMICAL$-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of @GENE$.	false
2857786.T2.T17	These data suggested that ambenonium had a dual effect on tissue responses to @CHEMICAL$-producing potentiation by blockade of @GENE$ and concomitant antagonism by blockade of muscarinic receptors.	CPR:5
2891463.T2.T28	However, @CHEMICAL$ produces less systemic beta 2- and possibly @GENE$ blockade than either timolol or levobunolol.	CPR:4
2891463.T3.T28	However, betaxolol produces less systemic beta 2- and possibly @CHEMICAL$ blockade than either @GENE$ or levobunolol.	CPR:4
2891463.T4.T28	However, betaxolol produces less systemic beta 2- and possibly @CHEMICAL$ blockade than either timolol or @GENE$.	CPR:4
2994716.T5.T10	@CHEMICAL$ sequence of the gene for @GENE$ (antihemophilic factor B).	false
2994716.T5.T11	@CHEMICAL$ sequence of the gene for human factor IX (@GENE$).	false
3004987.T5.T8	Autoradiography of @CHEMICAL$ gels of cross-linked @GENE$ showed only three protein bands specifically binding salmon calcitonin.	false
3094574.T26.T37	@CHEMICAL$ catalyzes an unusual oxidative decarboxylation of @GENE$.	CPR:9
3094574.T12.T27	@CHEMICAL$ usually catalyzes the conversion of @GENE$ to o-diphenols and oxidation of diphenols to the corresponding quinones.	CPR:9
3094574.T23.T27	@CHEMICAL$ usually catalyzes the conversion of monophenols to o-diphenols and oxidation of @GENE$ to the corresponding quinones.	CPR:9
3094574.T13.T29	None of the following enzymes tested catalyzed the new reaction: @CHEM-GENE$, ceruloplasmin, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T13.T31	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, @GENE$, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T13.T32	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, superoxide dismutase, @GENE$, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T13.T34	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and @GENE$.	false
3094574.T13.T30	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, @GENE$, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T13.T33	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @GENE$, and peroxidase.	false
3094574.T14.T29	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$, ceruloplasmin, @GENE$ dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T14.T31	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEM-GENE$, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T14.T32	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$ dismutase, @GENE$, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T14.T34	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$ dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and @GENE$.	false
3094574.T14.T30	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, @CHEMICAL$, @GENE$ dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T14.T33	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$ dismutase, ascorbate oxidase, @GENE$, and peroxidase.	false
3094574.T15.T29	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$, ceruloplasmin, superoxide dismutase, @GENE$ oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T15.T31	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$, @GENE$ oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T15.T32	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEM-GENE$, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T15.T34	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEMICAL$ oxidase, dopamine beta-hydroxylase, and @GENE$.	false
3094574.T15.T30	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, @CHEMICAL$, superoxide dismutase, @GENE$ oxidase, dopamine beta-hydroxylase, and peroxidase.	false
3094574.T15.T33	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEMICAL$ oxidase, @GENE$, and peroxidase.	false
3094574.T16.T29	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @GENE$ beta-hydroxylase, and peroxidase.	false
3094574.T16.T31	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$, ascorbate oxidase, @GENE$ beta-hydroxylase, and peroxidase.	false
3094574.T16.T32	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEMICAL$, @GENE$ beta-hydroxylase, and peroxidase.	false
3094574.T16.T34	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @CHEMICAL$ beta-hydroxylase, and @GENE$.	false
3094574.T16.T30	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, @CHEMICAL$, superoxide dismutase, ascorbate oxidase, @GENE$ beta-hydroxylase, and peroxidase.	false
3094574.T16.T33	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @CHEM-GENE$, and peroxidase.	false
3094574.T17.T35	@CHEM-GENE$ inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	false
3094574.T18.T35	@CHEMICAL$ inhibitors such as @GENE$, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	CPR:4
3094574.T19.T35	@CHEMICAL$ inhibitors such as phenylthiourea, @GENE$, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	CPR:4
3094574.T20.T35	@CHEMICAL$ inhibitors such as phenylthiourea, potassium cyanide, and @GENE$ inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	CPR:4
3094574.T21.T35	@CHEMICAL$ inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site @GENE$ of the enzyme in the catalysis.	false
3094574.T22.T36	@CHEMICAL$, a well-known competitive inhibitor of @GENE$, competitively inhibited the new reaction also.	CPR:4
3094574.T10.T28	Present studies demonstrate that @CHEMICAL$ will also catalyze quinone methide production with the same active site copper if a suitable substrate such as @GENE$ is provided.	CPR:9
3094574.T9.T28	Present studies demonstrate that @CHEMICAL$ will also catalyze @GENE$ production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.	CPR:9
3146348.T2.T13	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (@CHEMICAL$) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	CPR:4
3146348.T2.T15	The activation of @CHEMICAL$ [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	CPR:4
3146348.T2.T19	The activation of human [Glu1]plasminogen [@CHEMICAL$) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	CPR:4
3146348.T2.T23	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain @CHEMICAL$ (t-PA) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	CPR:4
3146348.T3.T13	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (@CHEMICAL$) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).	CPR:3
3146348.T3.T15	The activation of @CHEMICAL$ [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).	CPR:3
3146348.T3.T19	The activation of human [Glu1]plasminogen [@CHEMICAL$) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).	CPR:3
3146348.T3.T23	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain @CHEMICAL$ (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).	CPR:3
3146348.T4.T13	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (@CHEMICAL$) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).	CPR:3
3146348.T4.T15	The activation of @CHEMICAL$ [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).	CPR:3
3146348.T4.T19	The activation of human [Glu1]plasminogen [@CHEMICAL$) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).	CPR:3
3146348.T4.T23	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain @CHEMICAL$ (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).	CPR:3
3146348.T5.T16	@CHEMICAL$ functions as a result of its binding to @GENE$, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA.	false
3146348.T5.T17	@CHEMICAL$ functions as a result of its binding to [Glu1]Pg, with a Ki of approximately 9.0 mM, thereby rendering @GENE$ a less effective substrate for two-chain rec-t-PA.	false
3146348.T5.T18	@CHEMICAL$ functions as a result of its binding to [Glu1]Pg, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-@GENE$.	false
3146348.T9.T20	@CHEMICAL$ appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-t-PA, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of @GENE$.	false
3146348.T9.T21	Fibrinogen appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-@CHEMICAL$, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of @GENE$.	false
3146348.T10.T22	Analysis of the results of this paper reveals that normal plasma components, @CHEMICAL$ and @GENE$, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-t-PA, in in vitro systems.	false
3146348.T10.T24	Analysis of the results of this paper reveals that normal plasma components, @CHEMICAL$ and fibrinogen, exert major regulatory roles on the ability of @GENE$ to be activated by two-chain rec-t-PA, in in vitro systems.	false
3146348.T10.T25	Analysis of the results of this paper reveals that normal plasma components, @CHEMICAL$ and fibrinogen, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-@GENE$, in in vitro systems.	false
3146348.T1.T12	The presence of @CHEMICAL$ inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of @GENE$, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.	false
3146348.T1.T11	The presence of @CHEMICAL$ inhibits the stimulation of @GENE$ activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.	CPR:4
3146348.T1.T14	The presence of @CHEMICAL$ inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of @GENE$.	false
3812589.T12.T16	@CHEM-GENE$ activity was decreased when the assay was performed under both optimal and suboptimal reducing conditions, suggesting heterogeneity in the cblE disease.	false
6725552.T10.T27	We also analyzed the formation of 125I-@CHEMICAL$ -inhibitor complexes by sodium dodecyl sulfate @GENE$ gel electrophoresis (SDS-PAGE).	false
6725552.T8.T27	We also analyzed the formation of @CHEMICAL$-@GENE$ -inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).	false
6725552.T9.T27	We also analyzed the formation of 125I-@CHEMICAL$ -inhibitor complexes by @GENE$ polyacrylamide gel electrophoresis (SDS-PAGE).	false
6725552.T11.T28	In purified systems, the bimolecular rate constants for the reactions of @CHEMICAL$ with @GENE$-1-inhibitor, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	false
6725552.T11.T29	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with @CHEM-GENE$, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	false
6725552.T11.T30	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with @CHEMICAL$-1-inhibitor, @GENE$, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	false
6725552.T11.T31	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with @CHEMICAL$-1-inhibitor, alpha 2-antiplasmin, and @GENE$ were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	false
6725552.T12.T32	Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between @CHEMICAL$-@GENE$ and each of these three inhibitors.	false
6725552.T1.T14	This constant was reduced to 1.8 X 10(-2) min-1 when @CHEMICAL$ was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of @GENE$-1-inhibitor.	false
6725552.T1.T15	This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by @CHEMICAL$-deficient plasma that had been immunodepleted (less than 5%) of @GENE$-1-inhibitor.	false
6725552.T1.T16	This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of @CHEM-GENE$.	false
6725552.T2.T17	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-@GENE$ was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	false
6725552.T2.T18	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-Factor XIIf was found to form a complex with @GENE$, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	false
6725552.T2.T19	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with @GENE$ and antithrombin III.	false
6725552.T2.T20	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and @GENE$.	false
6725552.T3.T17	In addition, after inactivation in normal plasma, 74% of the active 125I-@CHEMICAL$ was found to form a complex with @GENE$-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	false
6725552.T3.T18	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with @CHEM-GENE$, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	false
6725552.T3.T19	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with @CHEMICAL$-1-inhibitor, whereas 26% of the enzyme formed complexes with @GENE$ and antithrombin III.	false
6725552.T3.T20	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with @CHEMICAL$-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and @GENE$.	false
6725552.T4.T21	Furthermore, 42% of the labeled enzyme was still complexed with @CHEM-GENE$ when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.	false
6725552.T4.T22	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$-1-inhibitor when 125I-@GENE$ was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.	false
6725552.T4.T23	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$.	false
6725552.T5.T21	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$ when @GENE$-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.	false
6725552.T5.T22	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when @CHEMICAL$-@GENE$ was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.	false
6725552.T5.T23	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when @CHEMICAL$-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$.	false
6725552.T6.T21	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$ when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$-1-inhibitor.	false
6725552.T6.T22	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-@CHEMICAL$ was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$-1-inhibitor.	false
6725552.T6.T23	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @CHEM-GENE$.	false
6725552.T7.T25	This study quantitatively demonstrates the dominant role of @CHEM-GENE$ in the inactivation of Factor XIIf in the plasma milieu.	false
6725552.T7.T26	This study quantitatively demonstrates the dominant role of @CHEMICAL$-1-inhibitor in the inactivation of @GENE$ in the plasma milieu.	false
7500004.T24.T38	@CHEMICAL$-dependent norepinephrine-induced currents in @GENE$-transfected HEK-293 cells blocked by cocaine and antidepressants.	false
7500004.T25.T38	Sodium-dependent norepinephrine-induced currents in @CHEMICAL$-transfected HEK-293 cells blocked by @GENE$ and antidepressants.	CPR:4
7500004.T26.T38	Sodium-dependent @CHEMICAL$-induced currents in @GENE$-transfected HEK-293 cells blocked by cocaine and antidepressants.	CPR:3
7500004.T27.T38	Sodium-dependent norepinephrine-induced currents in @CHEM-GENE$-transfected HEK-293 cells blocked by cocaine and antidepressants.	false
7500004.T13.T32	To explore the relationship between @CHEMICAL$ transport and ion permeation through the @GENE$, we established a human norepinephrine transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T13.T33	To explore the relationship between @CHEMICAL$ transport and ion permeation through the NE transporter, we established a @GENE$ (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T13.T34	To explore the relationship between @CHEMICAL$ transport and ion permeation through the NE transporter, we established a human norepinephrine transporter (@GENE$) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T15.T32	To explore the relationship between catecholamine transport and ion permeation through the @CHEM-GENE$, we established a human norepinephrine transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T15.T33	To explore the relationship between catecholamine transport and ion permeation through the @CHEMICAL$ transporter, we established a @GENE$ (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T15.T34	To explore the relationship between catecholamine transport and ion permeation through the @CHEMICAL$ transporter, we established a human norepinephrine transporter (@GENE$) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T16.T32	To explore the relationship between catecholamine transport and ion permeation through the @CHEMICAL$, we established a human @GENE$ transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T16.T33	To explore the relationship between catecholamine transport and ion permeation through the NE transporter, we established a @CHEM-GENE$ (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T16.T34	To explore the relationship between catecholamine transport and ion permeation through the NE transporter, we established a human @CHEMICAL$ transporter (@GENE$) cell line suitable for biochemical analysis and patch-clamp recording.	false
7500004.T18.T35	Stable transfection of @CHEMICAL$ cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and hNET-specific antibodies, (2) high-affinity, @GENE$-dependent transport of NE, and (3) inhibitor sensitivities similar to those of native membranes.	false
7500004.T18.T36	Stable transfection of hNET cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and @CHEMICAL$-specific antibodies, (2) high-affinity, @GENE$-dependent transport of NE, and (3) inhibitor sensitivities similar to those of native membranes.	false
7500004.T19.T35	Stable transfection of @CHEMICAL$ cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and hNET-specific antibodies, (2) high-affinity, Na(+)-dependent transport of @GENE$, and (3) inhibitor sensitivities similar to those of native membranes.	false
7500004.T19.T36	Stable transfection of hNET cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and @CHEMICAL$-specific antibodies, (2) high-affinity, Na(+)-dependent transport of @GENE$, and (3) inhibitor sensitivities similar to those of native membranes.	false
7500004.T20.T37	Whole-cell voltage-clamp of @CHEMICAL$-293 cells reveals @GENE$-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.	CPR:3
7500004.T21.T37	Whole-cell voltage-clamp of @CHEMICAL$-293 cells reveals NE-induced, @GENE$-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.	false
7500004.T22.T37	Whole-cell voltage-clamp of @CHEMICAL$-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and @GENE$ that are absent in parental cells.	CPR:4
7500004.T1.T28	In addition to NE-dependent currents, transfected cells posses an @CHEMICAL$-independent mode of charge movement mediated by @GENE$.	false
7500004.T23.T28	In addition to @CHEMICAL$-dependent currents, transfected cells posses an NE-independent mode of charge movement mediated by @GENE$.	false
7500004.T2.T29	@CHEMICAL$ antagonists without effect in non-transfected cells abolish both @GENE$-dependent and NE-independent modes of charge movement in transfected cells.	false
7500004.T3.T29	@CHEMICAL$ antagonists without effect in non-transfected cells abolish both NE-dependent and @GENE$-independent modes of charge movement in transfected cells.	false
7500004.T6.T31	To explain our observations, we propose that hNETs function as @CHEMICAL$ with an indefinite stoichiometry relating ion flux to @GENE$ transport.	false
7500004.T6.T30	To explain our observations, we propose that @CHEMICAL$ function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to @GENE$ transport.	CPR:9
7516184.T5.T13	The @CHEMICAL$-terminal portion of TSG-6 shows sequence homology to members of the cartilage link protein family of @GENE$.	false
7516184.T5.T28	The @CHEMICAL$-terminal portion of @GENE$ shows sequence homology to members of the cartilage link protein family of hyaluronan binding proteins.	false
7516184.T3.T16	The @CHEMICAL$-terminal half of TSG-6 contains a so-called @GENE$, characteristic for developmentally regulated proteins.	false
7516184.T3.T15	The @CHEMICAL$-terminal half of @GENE$ contains a so-called CUB domain, characteristic for developmentally regulated proteins.	false
7516184.T6.T22	The protein that binds TSG-6 was purified from human serum and identified as @CHEMICAL$ (I alpha I) by @GENE$-terminal microsequencing.	false
7516184.T6.T23	The protein that binds TSG-6 was purified from human serum and identified as inter-alpha-inhibitor (@CHEMICAL$) by @GENE$-terminal microsequencing.	false
7516184.T6.T21	The protein that binds @CHEMICAL$ was purified from human serum and identified as inter-alpha-inhibitor (I alpha I) by @GENE$-terminal microsequencing.	false
7516184.T1.T11	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/@CHEMICAL$ complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T1.T12	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by @CHEM-GENE$, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T1.T30	Experiments with recombinant TSG-6 and @CHEMICAL$ purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T1.T9	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/@CHEMICAL$ complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T1.T10	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The @CHEMICAL$/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T1.T29	Experiments with recombinant @CHEMICAL$ and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T1.T8	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the @CHEMICAL$/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T11	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/@CHEMICAL$ complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T12	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by @CHEMICAL$, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T30	Experiments with recombinant TSG-6 and @CHEMICAL$ purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T9	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/@CHEMICAL$ complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T10	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The @CHEMICAL$/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T29	Experiments with recombinant @CHEMICAL$ and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7516184.T2.T8	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the @CHEMICAL$/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)	false
7554708.T17.T25	BACKGROUND: The active metabolite of the anti-inflammatory drug @CHEMICAL$ has been characterized as a selective inhibitor of the inducible @GENE$ (PGHS).	CPR:4
7554708.T17.T28	BACKGROUND: The active metabolite of the anti-inflammatory drug @CHEMICAL$ has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (@GENE$).	CPR:4
7554708.T6.T25	BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible @CHEM-GENE$ (PGHS).	false
7554708.T6.T28	BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible @CHEMICAL$ H synthase (@GENE$).	false
7554708.T11.T30	METHODS: We measured the urinary excretion of products of platelet (@CHEMICAL$ [TXB2]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.	false
7554708.T12.T30	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [@CHEMICAL$]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.	false
7554708.T13.T30	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (@CHEMICAL$ [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.	false
7554708.T14.T30	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (prostaglandin IF2 alpha [@CHEMICAL$]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.	false
7554708.T15.T30	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) @CHEMICAL$ metabolism as in vivo indexes of the constitutive @GENE$ pathway.	false
7554708.T16.T31	Moreover, the production of @CHEMICAL$ during whole blood clotting was assessed as an index of the @GENE$ activity of platelet PGHS-1 ex vivo.	CPR:9
7554708.T16.T32	Moreover, the production of @CHEMICAL$ during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet @GENE$ ex vivo.	CPR:9
7554708.T4.T24	The daily administration of low-dose @CHEMICAL$ (40 mg), a selective inhibitor of platelet @GENE$, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.	CPR:4
7554708.T5.T24	The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet @CHEMICAL$, caused a cumulative inhibition of urinary @GENE$ and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.	CPR:9
7554708.T7.T24	The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet @CHEMICAL$, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood @GENE$ production that recovered with a timecourse consistent with platelet turnover.	CPR:9
7554708.T8.T26	CONCLUSIONS: @CHEMICAL$ does dose-dependently inhibit the @GENE$ activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.	CPR:4
7554708.T8.T27	CONCLUSIONS: @CHEMICAL$ does dose-dependently inhibit the cyclooxygenase activity of platelet @GENE$ of healthy subjects both in vivo and ex vivo.	CPR:4
7601910.T2.T22	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ (CREB).	false
7601910.T2.T23	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (@GENE$).	false
7601910.T2.T15	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (@GENE$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T2.T16	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), @GENE$ (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T2.T17	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (@GENE$), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T2.T18	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @GENE$ (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T2.T19	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (@GENE$), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T2.T20	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T2.T21	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (@GENE$), and cAMP response element binding protein (CREB).	false
7601910.T2.T24	This analysis revealed significant differences in the expression level of the @CHEM-GENE$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T22	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ (CREB).	false
7601910.T3.T23	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (@GENE$).	false
7601910.T3.T15	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (@CHEMICAL$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T16	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), @CHEMICAL$ (TGF beta 2), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T17	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (@CHEMICAL$), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T18	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @CHEM-GENE$ (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T19	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (@GENE$), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T20	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), @GENE$ (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T3.T21	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), retinoic acid receptor gamma (@GENE$), and cAMP response element binding protein (CREB).	false
7601910.T3.T24	This analysis revealed significant differences in the expression level of the @CHEMICAL$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T22	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ receptor gamma (RAR gamma), and @GENE$ (CREB).	false
7601910.T4.T23	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ receptor gamma (RAR gamma), and cAMP response element binding protein (@GENE$).	false
7601910.T4.T15	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (@CHEMICAL$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T16	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), @CHEMICAL$ (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T17	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (@CHEMICAL$), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T18	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @CHEMICAL$ (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T19	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (@CHEMICAL$), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T20	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEM-GENE$ (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T4.T21	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ receptor gamma (@GENE$), and cAMP response element binding protein (CREB).	false
7601910.T4.T24	This analysis revealed significant differences in the expression level of the @CHEMICAL$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	false
7601910.T5.T22	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @CHEM-GENE$ (CREB).	false
7601910.T5.T23	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @CHEMICAL$ response element binding protein (@GENE$).	false
7601910.T5.T15	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (@CHEMICAL$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T16	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), @CHEMICAL$ (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T17	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (@CHEMICAL$), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T18	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @CHEMICAL$ (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T19	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (@CHEMICAL$), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T20	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T21	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (@CHEMICAL$), and @GENE$ response element binding protein (CREB).	false
7601910.T5.T24	This analysis revealed significant differences in the expression level of the @CHEMICAL$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).	false
7703721.T3.T11	@CHEM-GENE$ in primary tumours and metastases of malignant melanoma.	false
7703721.T1.T5	The presence of @CHEMICAL$ (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the @GENE$ receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	false
7703721.T1.T8	The presence of estramustine binding protein (@CHEMICAL$), a 54 kD cytosolic glycoprotein, which is distinct from the @GENE$ receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	false
7703721.T1.T4	The presence of estramustine binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the @CHEM-GENE$, was investigated in a pilot study of primary malignant melanomas and their metastases.	false
7703721.T2.T5	The presence of @CHEM-GENE$ (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	false
7703721.T2.T8	The presence of @CHEMICAL$ binding protein (@GENE$), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	false
7703721.T2.T4	The presence of @CHEMICAL$ binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the @GENE$, was investigated in a pilot study of primary malignant melanomas and their metastases.	false
7714410.T22.T25	Preclinical efficacy of @CHEMICAL$, a potent, selective @GENE$ antagonist for topical ocular use.	CPR:6
7714410.T23.T25	Preclinical efficacy of emedastine, a potent, selective @CHEM-GENE$ antagonist for topical ocular use.	false
7714410.T21.T24	@CHEMICAL$ (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the @GENE$.	false
7714410.T2.T24	Emedastine (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the @CHEM-GENE$.	false
7756657.T1.T2	(2) Exposure histories vary in secondary 11q23 leukemia, as the only @CHEMICAL$ inhibitor was @GENE$ in one case, and, in another case, no topoisomerase II inhibitor was administered.	CPR:4
7756657.T1.T3	(2) Exposure histories vary in secondary 11q23 leukemia, as the only topoisomerase II inhibitor was @CHEMICAL$ in one case, and, in another case, no @GENE$ inhibitor was administered.	false
7825862.T12.T14	There are two isozymes of @CHEMICAL$ endoperoxide (PGH) synthase (cyclooxygenase) called PGH synthase-1 and -2 or @GENE$.	false
7825862.T12.T25	There are two isozymes of @CHEM-GENE$ (cyclooxygenase) called PGH synthase-1 and -2 or COX I and II.	false
7825862.T12.T32	There are two isozymes of @CHEMICAL$ endoperoxide (PGH) synthase (@GENE$) called PGH synthase-1 and -2 or COX I and II.	false
7825862.T12.T35	There are two isozymes of @CHEMICAL$ endoperoxide (PGH) synthase (cyclooxygenase) called @GENE$ or COX I and II.	false
7825862.T1.T13	@CHEMICAL$, piroxicam, and sulindac sulfide were found to preferentially inhibit @GENE$.	CPR:4
7825862.T2.T13	Indomethacin, @CHEMICAL$, and sulindac sulfide were found to preferentially inhibit @GENE$.	CPR:4
7825862.T3.T13	Indomethacin, piroxicam, and @CHEMICAL$ were found to preferentially inhibit @GENE$.	CPR:4
7825862.T5.T15	@CHEMICAL$, the active metabolite of Relafen, inhibits murine @GENE$ preferentially.	CPR:4
7825862.T6.T15	6-Methoxy-2-naphthylacetic acid, the active metabolite of @CHEMICAL$, inhibits murine @GENE$ preferentially.	CPR:4
7825862.T10.T16	Aspirin irreversibly inhibits @CHEMICAL$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (@GENE$) instead of PGH2.	false
7825862.T10.T17	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of @CHEMICAL$ causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (@GENE$) instead of PGH2.	CPR:9
7825862.T7.T16	@CHEMICAL$ irreversibly inhibits @GENE$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	CPR:4
7825862.T7.T17	@CHEMICAL$ irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of @GENE$ causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	false
7825862.T8.T16	Aspirin irreversibly inhibits @CHEMICAL$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, @GENE$ treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	false
7825862.T8.T17	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, @CHEMICAL$ treatment of @GENE$ causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	false
7825862.T9.T16	Aspirin irreversibly inhibits @CHEMICAL$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form @GENE$ (15-HETE) instead of PGH2.	false
7825862.T9.T17	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of @CHEMICAL$ causes this enzyme to form @GENE$ (15-HETE) instead of PGH2.	CPR:9
7902561.T3.T17	@CHEMICAL$ receptors mediate the satiating effect of @GENE$, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and sertraline cause anorexia is not clear.	false
7902561.T4.T17	@CHEMICAL$ receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which @GENE$ uptake inhibitors such as fluoxetine and sertraline cause anorexia is not clear.	false
7902561.T5.T17	@CHEMICAL$ receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as @GENE$ and sertraline cause anorexia is not clear.	false
7902561.T6.T17	@CHEMICAL$ receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and @GENE$ cause anorexia is not clear.	false
7902561.T10.T18	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and @CHEMICAL$ seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.	false
7902561.T11.T18	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of @CHEMICAL$ and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.	false
7902561.T12.T18	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or @CHEMICAL$ from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.	false
7902561.T14.T18	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of @CHEMICAL$, to stimulate directly @GENE$.	CPR:3
7902561.T7.T18	Anorexia induced by @CHEMICAL$, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.	false
7902561.T8.T18	Anorexia induced by (+)-amphetamine, @CHEMICAL$, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.	false
7902561.T9.T18	Anorexia induced by (+)-amphetamine, phentermine, @CHEMICAL$ and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.	false
7902561.T15.T19	It has been suggested that @CHEMICAL$ and D1 @GENE$ receptors are involved in their effect on food intake.	false
7902561.T15.T20	It has been suggested that beta- and alpha 1-adrenoceptors and @CHEM-GENE$ are involved in their effect on food intake.	false
8032658.T59.T70	Further characterization of @CHEM-GENE$ (putative 5-HT2B) in rat stomach fundus longitudinal muscle.	false
8032658.T59.T71	Further characterization of @CHEMICAL$ receptors (putative @GENE$) in rat stomach fundus longitudinal muscle.	false
8032658.T14.T60	1. The present study was undertaken to isolate and characterize pharmacologically homogeneous populations of @CHEM-GENE$ from a possible mixed receptor population mediating concentration of the longitudinal muscle of rat stomach fundus.	false
8032658.T7.T60	1. The present study was undertaken to isolate and characterize pharmacologically homogeneous populations of @CHEM-GENE$ from a possible mixed receptor population mediating concentration of the longitudinal muscle of rat stomach fundus.	false
8032658.T49.T69	Under these conditions, blockade of @CHEM-GENE$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.	false
8032658.T50.T69	Under these conditions, blockade of @CHEMICAL$ with @GENE$ (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.	CPR:4
8032658.T51.T69	Under these conditions, blockade of @CHEMICAL$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both @GENE$ (5-MeO-T) and tryptamine.	false
8032658.T52.T69	Under these conditions, blockade of @CHEMICAL$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (@GENE$) and tryptamine.	false
8032658.T53.T69	Under these conditions, blockade of @CHEMICAL$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and @GENE$.	false
8032658.T10.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), @GENE$, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T10.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), @GENE$, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T11.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, @GENE$ and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T11.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, @GENE$ and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T12.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and @GENE$ were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T12.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and @GENE$ were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T13.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst @GENE$, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	false
8032658.T13.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst @GENE$, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	false
8032658.T15.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, @GENE$ and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	false
8032658.T15.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, @GENE$ and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	false
8032658.T16.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and @GENE$ (8-OH-DPAT) were very weak or inactive.	false
8032658.T16.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and @GENE$ (8-OH-DPAT) were very weak or inactive.	false
8032658.T17.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (@GENE$) were very weak or inactive.	false
8032658.T17.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (@GENE$) were very weak or inactive.	false
8032658.T8.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including @GENE$ (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T8.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including @GENE$ (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T9.T61	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (@GENE$), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T9.T62	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (@GENE$), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	CPR:5
8032658.T44.T64	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of @CHEMICAL$ and yohimbine, the close pharmacological identity of @GENE$ in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.	false
8032658.T44.T65	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of @CHEMICAL$ and yohimbine, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned @GENE$ receptor is maintained.	false
8032658.T45.T64	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and @CHEMICAL$, the close pharmacological identity of @GENE$ in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.	false
8032658.T45.T65	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and @CHEMICAL$, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned @GENE$ receptor is maintained.	false
8032658.T46.T64	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and yohimbine, the close pharmacological identity of @CHEM-GENE$ in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.	false
8032658.T46.T65	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and yohimbine, the close pharmacological identity of @CHEMICAL$ receptors in rat stomach fundus and the recently cloned @GENE$ receptor is maintained.	false
8032658.T47.T66	@CHEMICAL$, which demonstrates some selectivity for @GENE$ in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.	false
8032658.T47.T67	@CHEMICAL$, which demonstrates some selectivity for 5-HT receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of @GENE$ function both in vitro and in vivo.	false
8032658.T48.T66	SB 200646, which demonstrates some selectivity for @CHEM-GENE$ in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.	false
8032658.T48.T67	SB 200646, which demonstrates some selectivity for @CHEMICAL$ receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of @GENE$ function both in vitro and in vivo.	false
8150771.T5.T20	Only strains of P. aeruginosa producing large amounts of @CHEMICAL$ may be resistant to both @GENE$ and cefepime.	false
8150771.T6.T20	Only strains of P. aeruginosa producing large amounts of @CHEMICAL$ may be resistant to both ceftazidime and @GENE$.	false
8294418.T20.T37	Phorbol esters and @CHEMICAL$ destabilize @GENE$ mRNA in vascular smooth muscle cells.	CPR:4
8294418.T3.T35	The mechanism by which @CHEMICAL$ (NE) down-regulates alpha 1B-adrenergic receptor (@GENE$) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
8294418.T3.T29	The mechanism by which @CHEMICAL$ (NE) down-regulates @GENE$ (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
8294418.T8.T35	The mechanism by which norepinephrine (@CHEMICAL$) down-regulates alpha 1B-adrenergic receptor (@GENE$) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
8294418.T8.T29	The mechanism by which norepinephrine (@CHEMICAL$) down-regulates @GENE$ (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
8294418.T1.T25	@CHEMICAL$, phorbol esters, and bradykinin each decreased @GENE$ mRNA levels by 70-80%.	CPR:4
8294418.T1.T24	@CHEMICAL$, phorbol esters, and @GENE$ each decreased alpha-AR mRNA levels by 70-80%.	false
8294418.T2.T25	NE, @CHEMICAL$, and bradykinin each decreased @GENE$ mRNA levels by 70-80%.	CPR:4
8294418.T2.T24	NE, @CHEMICAL$, and @GENE$ each decreased alpha-AR mRNA levels by 70-80%.	false
8294418.T4.T26	The @CHEMICAL$ inhibitor @GENE$ (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.	CPR:4
8294418.T5.T26	The @CHEMICAL$ inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (@GENE$) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.	CPR:4
8294418.T6.T26	The @CHEMICAL$ inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of @GENE$ and NE and decreased basal mRNA levels by 52 +/- 3%.	false
8294418.T7.T26	The @CHEMICAL$ inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and @GENE$ and decreased basal mRNA levels by 52 +/- 3%.	false
8294418.T10.T27	Neither ryanodine nor @CHEMICAL$ inhibited down-regulation of @GENE$ mRNA by NE.	CPR:3
8294418.T11.T27	Neither ryanodine nor EGTA inhibited down-regulation of @CHEMICAL$ mRNA by @GENE$.	CPR:4
8294418.T9.T27	Neither @CHEMICAL$ nor EGTA inhibited down-regulation of @GENE$ mRNA by NE.	CPR:3
8294418.T12.T28	@CHEMICAL$ caused @GENE$ mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.	CPR:4
8294418.T12.T30	@CHEMICAL$ caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal @GENE$ mRNA level.	CPR:4
8294418.T13.T28	Actinomycin D caused @CHEMICAL$ mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of @GENE$ to decrease basal alpha-AR mRNA level.	false
8294418.T13.T30	Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of @CHEMICAL$ to decrease basal @GENE$ mRNA level.	false
8294418.T14.T31	Both @CHEMICAL$ and phorbol esters increased the rate of @GENE$ mRNA degradation.	CPR:4
8294418.T15.T31	Both NE and @CHEMICAL$ increased the rate of @GENE$ mRNA degradation.	CPR:4
8294418.T16.T33	In @CHEMICAL$-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of @GENE$ mRNA.	CPR:4
8294418.T16.T32	In @CHEMICAL$-desensitized cells, phorbol esters and @GENE$ each caused the expected down-regulation of alpha-AR mRNA.	false
8294418.T17.T33	In NE-desensitized cells, @CHEMICAL$ and bradykinin each caused the expected down-regulation of @GENE$ mRNA.	CPR:4
8294418.T17.T32	In NE-desensitized cells, @CHEMICAL$ and @GENE$ each caused the expected down-regulation of alpha-AR mRNA.	false
8294418.T18.T21	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on @GENE$ mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8294418.T18.T22	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a @GENE$ substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8294418.T18.T23	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on @GENE$ gene transcription.	false
8294418.T18.T34	The @CHEMICAL$ inhibitor @GENE$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	CPR:4
8294418.T18.T36	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that @GENE$ exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8294418.T19.T21	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on @GENE$ mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8294418.T19.T22	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a @GENE$ substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8294418.T19.T23	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on @GENE$ gene transcription.	false
8294418.T19.T34	The @CHEMICAL$ inhibitor okadaic acid prolonged the normally transient effect of @GENE$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8294418.T19.T36	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that @GENE$ exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	false
8384716.T22.T45	Molecular cloning and functional expression of @CHEMICAL$-like rat and human @GENE$ receptor genes.	false
8384716.T22.T46	Molecular cloning and functional expression of 5-HT1E-like @CHEM-GENE$ genes.	false
8384716.T1.T24	Sequential polymerase chain reaction experiments were performed to amplify a unique sequence representing a @CHEM-GENE$ from rat hypothalamic cDNA.	false
8384716.T14.T35	Degenerate @CHEMICAL$ corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@GENE$, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T14.T36	Degenerate @CHEMICAL$ corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @GENE$, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T14.T37	Degenerate @CHEMICAL$ corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @GENE$; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T15.T35	Degenerate oligonucleotides corresponding to conserved @CHEMICAL$ from transmembrane domains III, V, and VI of known receptors [@GENE$, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T15.T36	Degenerate oligonucleotides corresponding to conserved @CHEMICAL$ from transmembrane domains III, V, and VI of known receptors [5-HT1A, @GENE$, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T15.T37	Degenerate oligonucleotides corresponding to conserved @CHEMICAL$ from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @GENE$; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T16.T35	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@CHEMICAL$, 5-HT1C, and 5-HT2; @GENE$ is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T16.T36	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @CHEMICAL$, and 5-HT2; @GENE$ is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T16.T37	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @CHEMICAL$; @GENE$ is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T17.T35	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@CHEMICAL$, 5-HT1C, and 5-HT2; 5-HT is @GENE$ (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T17.T36	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @CHEMICAL$, and 5-HT2; 5-HT is @GENE$ (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T17.T37	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @CHEMICAL$; 5-HT is @GENE$ (5-hydroxytryptamine)] were used as primers for the sequential reactions.	false
8384716.T18.T35	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@CHEMICAL$, 5-HT1C, and 5-HT2; 5-HT is serotonin (@GENE$)] were used as primers for the sequential reactions.	false
8384716.T18.T36	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @CHEMICAL$, and 5-HT2; 5-HT is serotonin (@GENE$)] were used as primers for the sequential reactions.	false
8384716.T18.T37	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @CHEMICAL$; 5-HT is serotonin (@GENE$)] were used as primers for the sequential reactions.	false
8384716.T19.T39	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (MR77) containing an @CHEMICAL$ encoding a 366-@GENE$ seven-transmembrane domain protein.	false
8384716.T19.T40	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (MR77) containing an intronless open reading frame encoding a @CHEM-GENE$.	false
8384716.T19.T38	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (@CHEMICAL$) containing an intronless open reading frame encoding a 366-@GENE$ seven-transmembrane domain protein.	false
8384716.T21.T41	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known @GENE$, rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.	false
8384716.T21.T42	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known rat 5-HT1A, @GENE$, rat 5-HT1D, and human 5-HT1E receptors, respectively.	false
8384716.T21.T43	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known rat 5-HT1A, rat 5-HT1B, @GENE$, and human 5-HT1E receptors, respectively.	false
8384716.T21.T44	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and @GENE$ receptors, respectively.	false
8384716.T6.T26	The specific binding is displaced by the selective 5-HT1D agonist @CHEMICAL$ but not by the mixed @GENE$ agonist 5-carboxyamidotryptamine.	false
8384716.T6.T25	The specific binding is displaced by the selective @CHEMICAL$ agonist @GENE$ but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.	CPR:5
8384716.T7.T26	The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed @CHEMICAL$ agonist @GENE$.	false
8384716.T7.T25	The specific binding is displaced by the selective @CHEMICAL$ agonist sumatriptan but not by the mixed 5-HT1A/1D agonist @GENE$.	false
8384716.T11.T28	HeLa cells transfected with the MR77 gene exhibited inhibition of @CHEM-GENE$ in response to serotonin.	false
8384716.T11.T27	HeLa cells transfected with the @CHEMICAL$ gene exhibited inhibition of @GENE$ cyclase in response to serotonin.	false
8384716.T12.T28	HeLa cells transfected with the MR77 gene exhibited inhibition of @CHEMICAL$ in response to @GENE$.	CPR:4
8384716.T12.T27	HeLa cells transfected with the @CHEMICAL$ gene exhibited inhibition of adenylate cyclase in response to @GENE$.	false
8384716.T13.T31	MR77 thus represents a @CHEM-GENE$ of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HT1E-like receptor.	false
8384716.T13.T32	MR77 thus represents a @CHEMICAL$ receptor of the @GENE$ class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HT1E-like receptor.	false
8384716.T13.T30	@CHEMICAL$ thus represents a @GENE$ receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HT1E-like receptor.	false
8384716.T13.T33	MR77 thus represents a @CHEMICAL$ receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, @GENE$ represents an additional 5-HT1E-like receptor.	false
8384716.T13.T34	MR77 thus represents a @CHEMICAL$ receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional @GENE$-like receptor.	false
8425287.T26.T40	The antiarrhythmic effects of exogenous @CHEMICAL$ and Valsalva on this form of VT may be due to receptor-mediated inhibition of @GENE$ or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	false
8425287.T26.T41	The antiarrhythmic effects of exogenous @CHEMICAL$ and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial @GENE$, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	false
8425287.T27.T40	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of @CHEM-GENE$ or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	false
8425287.T27.T41	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of @CHEMICAL$ cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial @GENE$, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	false
8425287.T28.T40	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of @CHEMICAL$ or to noncardiac receptor-mediated effects, i.e., exogenous @GENE$ may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	false
8425287.T28.T41	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous @CHEMICAL$ may modulate VT through alterations in autonomic tone by activation of arterial @GENE$, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	CPR:3
8425287.T42.T34	VT recurred with the addition of aminophylline, a @CHEMICAL$ @GENE$ antagonist.	false
8425287.T8.T34	VT recurred with the addition of @CHEMICAL$, a competitive @GENE$ antagonist.	CPR:6
8425287.T9.T34	VT recurred with the addition of aminophylline, a competitive @CHEM-GENE$ antagonist.	false
8425287.T10.T36	@CHEMICAL$ (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the @GENE$, terminated VT in four of four patients, an effect that was reversed by atropine.	false
8425287.T10.T35	@CHEMICAL$ (10 mg i.v.), a @GENE$ inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.	CPR:4
8425287.T11.T36	Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of @CHEMICAL$ at the @GENE$, terminated VT in four of four patients, an effect that was reversed by atropine.	false
8425287.T11.T35	Edrophonium (10 mg i.v.), a @CHEMICAL$ inhibitor that potentiates the effects of @GENE$ at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.	false
8425287.T13.T36	Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the @CHEMICAL$, terminated VT in four of four patients, an effect that was reversed by @GENE$.	CPR:4
8425287.T13.T35	Edrophonium (10 mg i.v.), a @CHEMICAL$ inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by @GENE$.	false
8425287.T19.T38	It can be identified by termination of the tachycardia in response to activation of the @CHEMICAL$ A1 or @GENE$, which results in inhibition of adenylate cyclase.	false
8425287.T19.T39	It can be identified by termination of the tachycardia in response to activation of the @CHEMICAL$ A1 or muscarinic cholinergic receptor, which results in inhibition of @GENE$.	false
8425287.T19.T37	It can be identified by termination of the tachycardia in response to activation of the @CHEM-GENE$ or muscarinic cholinergic receptor, which results in inhibition of adenylate cyclase.	false
8425287.T20.T38	It can be identified by termination of the tachycardia in response to activation of the adenosine A1 or @CHEMICAL$, which results in inhibition of @GENE$ cyclase.	false
8425287.T20.T39	It can be identified by termination of the tachycardia in response to activation of the adenosine A1 or muscarinic cholinergic receptor, which results in inhibition of @CHEM-GENE$.	false
8425287.T20.T37	It can be identified by termination of the tachycardia in response to activation of the @CHEMICAL$ or muscarinic cholinergic receptor, which results in inhibition of @GENE$ cyclase.	false
8566141.T17.T33	@CHEMICAL$ induces c-fos in rat striatum: reversal with dopamine D1 and @GENE$ antagonists.	false
8566141.T17.T31	@CHEMICAL$ induces @GENE$ in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.	CPR:3
8566141.T17.T32	@CHEMICAL$ induces c-fos in rat striatum: reversal with @GENE$ and NMDA receptor antagonists.	false
8566141.T18.T33	Amantadine induces c-fos in rat striatum: reversal with @CHEMICAL$ D1 and @GENE$ antagonists.	false
8566141.T18.T31	Amantadine induces @CHEMICAL$ in rat striatum: reversal with @GENE$ D1 and NMDA receptor antagonists.	false
8566141.T18.T32	Amantadine induces c-fos in rat striatum: reversal with @CHEM-GENE$ and NMDA receptor antagonists.	false
8566141.T19.T33	Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and @CHEM-GENE$ antagonists.	false
8566141.T19.T31	Amantadine induces @CHEMICAL$ in rat striatum: reversal with dopamine D1 and @GENE$ receptor antagonists.	false
8566141.T19.T32	Amantadine induces c-fos in rat striatum: reversal with @CHEMICAL$ and @GENE$ receptor antagonists.	false
8566141.T1.T24	@CHEMICAL$ (1-aminoadamantane) induced @GENE$ expression in the central, dorsal-medial and ventral-medial part of the striatum.	CPR:3
8566141.T2.T24	Amantadine (@CHEMICAL$) induced @GENE$ expression in the central, dorsal-medial and ventral-medial part of the striatum.	CPR:3
8566141.T3.T21	The distribution pattern of Fos induced by @CHEMICAL$ was more similar to those seen with dopaminomimetics than with @GENE$ antagonists.	false
8566141.T3.T20	The distribution pattern of @CHEMICAL$ induced by @GENE$ was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.	CPR:3
8566141.T4.T21	The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with @CHEM-GENE$ antagonists.	false
8566141.T4.T20	The distribution pattern of @CHEMICAL$ induced by amantadine was more similar to those seen with dopaminomimetics than with @GENE$ (NMDA) receptor antagonists.	false
8566141.T5.T21	The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with @CHEM-GENE$ antagonists.	false
8566141.T5.T20	The distribution pattern of @CHEMICAL$ induced by amantadine was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (@GENE$) receptor antagonists.	false
8566141.T10.T23	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEMICAL$ antagonist, MK-801, blocked @GENE$ induction of Fos in the striatum.	false
8566141.T10.T22	Pretreatment with the @CHEMICAL$ antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked @GENE$ induction of Fos in the striatum.	false
8566141.T10.T25	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked @CHEMICAL$ induction of @GENE$ in the striatum.	CPR:3
8566141.T6.T23	Pretreatment with the @CHEMICAL$ D1 receptor antagonist, SCH23390, and the @GENE$ antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	false
8566141.T6.T22	Pretreatment with the @CHEM-GENE$ antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	false
8566141.T6.T25	Pretreatment with the @CHEMICAL$ D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of @GENE$ in the striatum.	false
8566141.T7.T23	Pretreatment with the dopamine D1 receptor antagonist, @CHEMICAL$, and the @GENE$ antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	false
8566141.T7.T22	Pretreatment with the @CHEMICAL$ antagonist, @GENE$, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	CPR:6
8566141.T7.T25	Pretreatment with the dopamine D1 receptor antagonist, @CHEMICAL$, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of @GENE$ in the striatum.	CPR:4
8566141.T8.T23	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEM-GENE$ antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	false
8566141.T8.T22	Pretreatment with the @CHEMICAL$ antagonist, SCH23390, and the @GENE$ receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	false
8566141.T8.T25	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEMICAL$ receptor antagonist, MK-801, blocked amantadine induction of @GENE$ in the striatum.	false
8566141.T9.T23	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEMICAL$ antagonist, @GENE$, blocked amantadine induction of Fos in the striatum.	CPR:6
8566141.T9.T22	Pretreatment with the @CHEMICAL$ antagonist, SCH23390, and the NMDA receptor antagonist, @GENE$, blocked amantadine induction of Fos in the striatum.	false
8566141.T9.T25	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, @CHEMICAL$, blocked amantadine induction of @GENE$ in the striatum.	CPR:4
8566141.T11.T26	However, @CHEMICAL$ induction of @GENE$ in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.	CPR:3
8566141.T11.T27	However, @CHEMICAL$ induction of Fos in the striatum was unaffected by the @GENE$ antagonist, sulpiride.	false
8566141.T12.T26	However, amantadine induction of @CHEMICAL$ in the striatum was unaffected by the @GENE$ D2 receptor antagonist, sulpiride.	false
8566141.T12.T27	However, amantadine induction of Fos in the striatum was unaffected by the @CHEM-GENE$ antagonist, sulpiride.	false
8566141.T13.T26	However, amantadine induction of @CHEMICAL$ in the striatum was unaffected by the dopamine D2 receptor antagonist, @GENE$.	false
8566141.T13.T27	However, amantadine induction of Fos in the striatum was unaffected by the @CHEMICAL$ antagonist, @GENE$.	CPR:6
8566141.T14.T30	These results suggest that @CHEMICAL$ induction of Fos in the rat striatum is related to dopamine D1 and @GENE$.	false
8566141.T14.T28	These results suggest that @CHEMICAL$ induction of @GENE$ in the rat striatum is related to dopamine D1 and NMDA receptors.	CPR:3
8566141.T14.T29	These results suggest that @CHEMICAL$ induction of Fos in the rat striatum is related to @GENE$ and NMDA receptors.	false
8566141.T15.T30	These results suggest that amantadine induction of Fos in the rat striatum is related to @CHEMICAL$ D1 and @GENE$.	false
8566141.T15.T28	These results suggest that amantadine induction of @CHEMICAL$ in the rat striatum is related to @GENE$ D1 and NMDA receptors.	false
8566141.T15.T29	These results suggest that amantadine induction of Fos in the rat striatum is related to @CHEM-GENE$ and NMDA receptors.	false
8566141.T16.T30	These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and @CHEM-GENE$.	false
8566141.T16.T28	These results suggest that amantadine induction of @CHEMICAL$ in the rat striatum is related to dopamine D1 and @GENE$ receptors.	false
8566141.T16.T29	These results suggest that amantadine induction of Fos in the rat striatum is related to @CHEMICAL$ and @GENE$ receptors.	false
8697470.T1.T14	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @CHEMICAL$ (ATA), an inhibitor of platelet @GENE$/von Willebrand factor interaction (10 mg/kg i.v. bolus).	CPR:4
8697470.T1.T10	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual @CHEMICAL$ inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T1.T12	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and @CHEMICAL$ antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T1.T15	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @CHEMICAL$ (ATA), an inhibitor of platelet glycoprotein Ib/@GENE$ interaction (10 mg/kg i.v. bolus).	CPR:4
8697470.T1.T7	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of @CHEMICAL$ (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T1.T9	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against @CHEMICAL$ (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T2.T14	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@CHEMICAL$), an inhibitor of platelet @GENE$/von Willebrand factor interaction (10 mg/kg i.v. bolus).	CPR:4
8697470.T2.T10	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual @CHEMICAL$ inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T2.T12	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and @CHEMICAL$ antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T2.T15	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@CHEMICAL$), an inhibitor of platelet glycoprotein Ib/@GENE$ interaction (10 mg/kg i.v. bolus).	CPR:4
8697470.T2.T7	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of @CHEMICAL$ (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T2.T9	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against @CHEMICAL$ (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).	false
8697470.T4.T29	Infusion of @CHEMICAL$ failed to restore CFVs in ridogrel e @GENE$ treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by FVIIa was overcome by inhibition of platelet function.	false
8697470.T4.T30	Infusion of FVIIa failed to restore CFVs in ridogrel e @CHEMICAL$ treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by @GENE$ was overcome by inhibition of platelet function.	false
8697470.T5.T32	Activated partial thromboplastin time, and ex vivo platelet aggregation in response to @CHEMICAL$ and @GENE$, were not different after FVIIai infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.	false
8697470.T5.T33	Activated partial thromboplastin time, and ex vivo platelet aggregation in response to @CHEMICAL$ and thrombin, were not different after @GENE$ infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.	false
8710929.T13.T21	@CHEM-GENE$ have channel modes of conduction.	false
8710929.T1.T16	Members of the @CHEM-GENE$ gene family presumably function with fixed stoichiometry in which a set number of ions cotransport with one transmitter molecule.	false
8710929.T2.T18	Here we report channel-like events from a presumably fixed stoichiometry [@CHEMICAL$ (NE)+, Na+, and Cl-], human NE (hNET) in the @GENE$ gene family.	false
8710929.T2.T17	Here we report channel-like events from a presumably fixed stoichiometry [@CHEMICAL$ (NE)+, Na+, and Cl-], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.	false
8710929.T3.T18	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (@CHEMICAL$)+, Na+, and Cl-], human NE (hNET) in the @GENE$ gene family.	false
8710929.T3.T17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (@CHEMICAL$)+, Na+, and Cl-], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.	false
8710929.T4.T18	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, @CHEMICAL$, and Cl-], human NE (hNET) in the @GENE$ gene family.	false
8710929.T4.T17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, @CHEMICAL$, and Cl-], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.	false
8710929.T5.T18	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and @CHEMICAL$], human NE (hNET) in the @GENE$ gene family.	false
8710929.T5.T17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and @CHEMICAL$], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.	false
8710929.T6.T18	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human @CHEMICAL$ (hNET) in the @GENE$ gene family.	false
8710929.T6.T17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human @CHEMICAL$ (@GENE$) in the gamma-aminobutyric acid transporter gene family.	false
8710929.T7.T18	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human NE (hNET) in the @CHEM-GENE$ gene family.	false
8710929.T7.T17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human NE (@CHEMICAL$) in the @GENE$ transporter gene family.	false
8710929.T10.T19	These events are stimulated by NE and by guanethidine, an @CHEMICAL$ substrate, and they are blocked by @GENE$ and the antidepressant desipramine.	CPR:4
8710929.T11.T19	These events are stimulated by NE and by guanethidine, an @CHEMICAL$ substrate, and they are blocked by cocaine and the antidepressant @GENE$.	CPR:4
8710929.T8.T19	These events are stimulated by @CHEMICAL$ and by guanethidine, an @GENE$ substrate, and they are blocked by cocaine and the antidepressant desipramine.	CPR:9
8710929.T9.T19	These events are stimulated by NE and by @CHEMICAL$, an @GENE$ substrate, and they are blocked by cocaine and the antidepressant desipramine.	CPR:9
8710929.T12.T20	Voltage-clamp data combined with @CHEMICAL$ uptake data from these same cells indicate that @GENE$ have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).	CPR:9
8733007.T10.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T10.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T10.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T10.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @GENE$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T10.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @GENE$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T10.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T10.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @GENE$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @GENE$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T11.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T12.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @CHEMICAL$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T12.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @CHEMICAL$; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T12.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @CHEMICAL$; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T12.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T12.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T12.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @CHEMICAL$ (MR) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	CPR:6
8733007.T12.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@CHEMICAL$) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	CPR:6
8733007.T1.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @CHEMICAL$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T1.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @CHEMICAL$, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	CPR:6
8733007.T1.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @CHEMICAL$ antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	CPR:6
8733007.T1.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T1.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T1.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @CHEMICAL$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T1.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@CHEMICAL$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-@GENE$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEM-GENE$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T6.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @GENE$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of @GENE$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T7.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T15	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T13	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T14	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T18	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @GENE$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T19	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @GENE$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T20	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T8.T21	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	false
8733007.T2.T16	Although there is a high probability that the action of @CHEMICAL$ to cause cardiac fibrosis in this experimental model is an effect via non-epithelial @GENE$, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking MR occupancy by aldosterone and collagen deposition.	false
8733007.T2.T17	Although there is a high probability that the action of @CHEMICAL$ to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking @GENE$ occupancy by aldosterone and collagen deposition.	false
8733007.T3.T16	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial @CHEMICAL$, the locus of @GENE$ action remains to be established, as do the molecular mechanisms linking MR occupancy by aldosterone and collagen deposition.	false
8733007.T3.T17	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of @CHEMICAL$ action remains to be established, as do the molecular mechanisms linking @GENE$ occupancy by aldosterone and collagen deposition.	false
8733007.T4.T16	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial @CHEMICAL$, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking MR occupancy by @GENE$ and collagen deposition.	false
8733007.T4.T17	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking @CHEMICAL$ occupancy by @GENE$ and collagen deposition.	false
8740147.T32.T57	@CHEMICAL$ and debrisoquine are substrates of @GENE$ and potent inhibitors of monoamine oxidase in perfused lungs of rats.	CPR:9
8740147.T32.T58	@CHEMICAL$ and debrisoquine are substrates of uptake1 and potent inhibitors of @GENE$ in perfused lungs of rats.	CPR:4
8740147.T33.T57	Amezinium and @CHEMICAL$ are substrates of @GENE$ and potent inhibitors of monoamine oxidase in perfused lungs of rats.	CPR:9
8740147.T33.T58	Amezinium and @CHEMICAL$ are substrates of uptake1 and potent inhibitors of @GENE$ in perfused lungs of rats.	CPR:4
8740147.T34.T57	Amezinium and debrisoquine are substrates of @CHEMICAL$ and potent inhibitors of @GENE$ oxidase in perfused lungs of rats.	false
8740147.T34.T58	Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of @CHEM-GENE$ in perfused lungs of rats.	false
8740147.T1.T35	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal @CHEM-GENE$ (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	false
8740147.T1.T36	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal @CHEMICAL$ oxidase (@GENE$), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	false
8740147.T1.T40	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal @CHEMICAL$ oxidase (MAO), because it is a much more potent @GENE$ inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	false
8740147.T22.T35	Previous studies have resulted in the classification of @CHEMICAL$ as a selective inhibitor of neuronal @GENE$ (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	CPR:4
8740147.T22.T36	Previous studies have resulted in the classification of @CHEMICAL$ as a selective inhibitor of neuronal monoamine oxidase (@GENE$), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	CPR:4
8740147.T22.T40	Previous studies have resulted in the classification of @CHEMICAL$ as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent @GENE$ inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	CPR:4
8740147.T19.T50	In the present study, the effects of @CHEMICAL$ on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal @GENE$.	false
8740147.T20.T50	In the present study, the effects of amezinium on the deamination of @CHEMICAL$ were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal @GENE$.	false
8740147.T21.T50	In the present study, the effects of amezinium on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the @CHEMICAL$ transporter is non-neuronal @GENE$.	false
8740147.T23.T51	In addition, another drug that is both a substrate of @CHEMICAL$ and a MAO inhibitor, @GENE$, was investigated in the study.	CPR:9
8740147.T23.T52	In addition, another drug that is both a substrate of uptake1 and a @CHEMICAL$ inhibitor, @GENE$, was investigated in the study.	CPR:4
8740147.T24.T53	The first aim of the study was to show whether @CHEMICAL$ and debrisoquine are substrates of @GENE$ in rat lungs.	false
8740147.T25.T53	The first aim of the study was to show whether amezinium and @CHEMICAL$ are substrates of @GENE$ in rat lungs.	false
8740147.T26.T54	After loading of isolated perfused lungs with @CHEMICAL$ (@GENE$ and catechol-O-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T26.T55	After loading of isolated perfused lungs with @CHEMICAL$ (MAO and @GENE$ (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T26.T56	After loading of isolated perfused lungs with @CHEMICAL$ (MAO and catechol-O-methyltransferase (@GENE$) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T27.T54	After loading of isolated perfused lungs with 3H-noradrenaline (@CHEMICAL$ and @GENE$-O-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T27.T55	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEM-GENE$ (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T27.T56	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEMICAL$-O-methyltransferase (@GENE$) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T28.T54	After loading of isolated perfused lungs with 3H-noradrenaline (@CHEMICAL$ and catechol-@GENE$-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T28.T55	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEM-GENE$ (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T28.T56	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and catechol-@CHEMICAL$-methyltransferase (@GENE$) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	false
8740147.T29.T54	After loading of isolated perfused lungs with 3H-noradrenaline (@CHEMICAL$ and catechol-O-methyltransferase (COMT) inhibited), the efflux of @GENE$ was measured for 30 min.	false
8740147.T29.T55	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEMICAL$ (COMT) inhibited), the efflux of @GENE$ was measured for 30 min.	false
8740147.T29.T56	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and catechol-O-methyltransferase (@CHEMICAL$) inhibited), the efflux of @GENE$ was measured for 30 min.	false
8740147.T4.T38	In lungs perfused with 1 nmol/l @CHEMICAL$ (@GENE$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	false
8740147.T5.T38	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l @GENE$ caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	false
8740147.T6.T38	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of @GENE$ deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	false
8740147.T7.T38	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l @GENE$ caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	false
8740147.T8.T38	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of @GENE$ deamination, respectively.	false
8740147.T10.T39	When @CHEMICAL$ was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of @GENE$ by MAO-A in the lungs.	false
8740147.T10.T41	When MAO-B was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of @CHEMICAL$ by @GENE$ in the lungs.	false
8740147.T9.T39	When @CHEMICAL$ was also inhibited, 10 nmol/l @GENE$ caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs.	false
8740147.T9.T41	When MAO-B was also inhibited, 10 nmol/l @CHEMICAL$ caused 84% inhibition of the deamination of noradrenaline by @GENE$ in the lungs.	CPR:4
8740147.T11.T42	In contrast, in hearts perfused with 10 nmol/l @CHEMICAL$ under conditions where the amine was accumulated by @GENE$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T11.T44	In contrast, in hearts perfused with 10 nmol/l @CHEMICAL$ under conditions where the amine was accumulated by uptake2 (COMT, @GENE$ and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T11.T43	In contrast, in hearts perfused with 10 nmol/l @CHEMICAL$ under conditions where the amine was accumulated by uptake2 (@GENE$, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T12.T42	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by @CHEMICAL$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l @GENE$ had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T12.T44	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, @CHEMICAL$ and vesicular transport inhibited), 10 nmol/l @GENE$ had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T12.T43	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (@CHEMICAL$, uptake1 and vesicular transport inhibited), 10 nmol/l @GENE$ had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T13.T42	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by @CHEMICAL$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l @GENE$ caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T13.T44	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, @CHEMICAL$ and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l @GENE$ caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T13.T43	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (@CHEMICAL$, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l @GENE$ caused only 36% inhibition of deamination of noradrenaline.	false
8740147.T14.T42	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by @CHEMICAL$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of @GENE$.	false
8740147.T14.T44	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, @CHEMICAL$ and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of @GENE$.	false
8740147.T14.T43	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (@CHEMICAL$, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of @GENE$.	false
8740147.T15.T45	The results when considered with previous reports in the literature show that @CHEMICAL$ is about 1000 times more potent and debrisoquine is about 20 times more potent for @GENE$ inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.	CPR:4
8740147.T15.T46	The results when considered with previous reports in the literature show that @CHEMICAL$ is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by @GENE$.	CPR:9
8740147.T16.T45	The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and @CHEMICAL$ is about 20 times more potent for @GENE$ inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.	CPR:4
8740147.T16.T46	The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and @CHEMICAL$ is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by @GENE$.	CPR:9
8740147.T17.T47	@CHEMICAL$ is much less potent as a @GENE$ inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.	CPR:4
8740147.T17.T48	@CHEMICAL$ is much less potent as a MAO inhibitor in cells with the @GENE$, such as the myocardial cells of the heart.	CPR:9
8740147.T18.T49	The results also confirmed previous reports that @CHEMICAL$ is highly selective for @GENE$.	CPR:4
8836617.T18.T25	Role of @CHEM-GENE$ and mast cells in gaseous formaldehyde-induced airway microvascular leakage in rats.	false
8836617.T19.T25	Role of @CHEMICAL$ and mast cells in gaseous @GENE$-induced airway microvascular leakage in rats.	false
8836617.T10.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T10.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T10.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @CHEM-GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T11.T20	We have investigated the effects of @CHEMICAL$ [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @GENE$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	CPR:6
8836617.T11.T23	We have investigated the effects of @CHEMICAL$ [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T11.T24	We have investigated the effects of @CHEMICAL$ [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T12.T20	We have investigated the effects of CP-99,994 @CHEMICAL$, a @GENE$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	CPR:6
8836617.T12.T23	We have investigated the effects of CP-99,994 @CHEMICAL$, a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T12.T24	We have investigated the effects of CP-99,994 @CHEMICAL$, a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T13.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous @GENE$.	false
8836617.T13.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous @GENE$.	false
8836617.T13.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @CHEMICAL$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous @GENE$.	false
8836617.T5.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, @GENE$ (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T5.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, @CHEMICAL$ (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	CPR:6
8836617.T5.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, @CHEMICAL$ (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T6.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 @GENE$, a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T6.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 @CHEMICAL$, a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	CPR:6
8836617.T6.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 @CHEMICAL$, a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T7.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T7.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEM-GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T7.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T8.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and @GENE$ (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T8.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and @GENE$ (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T8.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and @CHEMICAL$ (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	CPR:6
8836617.T9.T20	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen @GENE$, a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T9.T23	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and ketotifen @GENE$, a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	false
8836617.T9.T24	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen @CHEMICAL$, a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	CPR:6
8836617.T3.T21	The increase in vascular permeability induced by @CHEMICAL$ in the rat airway was mediated predominantly by @GENE$ stimulation.	false
8836617.T4.T22	Activation of @CHEM-GENE$ and mast cells did not appear to play an important role in this airway response.	false
9486667.T16.T41	Molecular determinants of @CHEMICAL$ block of HERG @GENE$.	CPR:4
9486667.T16.T40	Molecular determinants of @CHEMICAL$ block of @GENE$ K+ channels.	CPR:4
9486667.T17.T41	Molecular determinants of dofetilide block of HERG @CHEM-GENE$.	false
9486667.T17.T40	Molecular determinants of dofetilide block of @CHEMICAL$ @GENE$ channels.	false
9486667.T13.T19	The human ether-a-go-go-related gene (HERG) encodes a @CHEMICAL$ channel with biophysical properties nearly identical to the @GENE$ (IKr).	false
9486667.T13.T25	The human ether-a-go-go-related gene (HERG) encodes a @CHEMICAL$ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (@GENE$).	false
9486667.T13.T33	The human ether-a-go-go-related gene (HERG) encodes a @CHEM-GENE$ with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr).	false
9486667.T13.T29	The human ether-a-go-go-related gene (@CHEMICAL$) encodes a @GENE$ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr).	false
9486667.T13.T30	The @CHEMICAL$ (HERG) encodes a @GENE$ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr).	false
9486667.T3.T19	The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the @CHEM-GENE$ (IKr).	false
9486667.T3.T25	The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @CHEMICAL$ current (@GENE$).	false
9486667.T3.T33	The human ether-a-go-go-related gene (HERG) encodes a @CHEMICAL$ with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @GENE$ current (IKr).	false
9486667.T3.T29	The human ether-a-go-go-related gene (@CHEMICAL$) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @GENE$ current (IKr).	false
9486667.T3.T30	The @CHEMICAL$ (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @GENE$ current (IKr).	false
9486667.T10.T28	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, @GENE$, and MK-499, at submicromolar concentrations.	CPR:4
9486667.T10.T26	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, @GENE$, and MK-499, at submicromolar concentrations.	CPR:4
9486667.T11.T28	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and @GENE$, at submicromolar concentrations.	CPR:4
9486667.T11.T26	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and @GENE$, at submicromolar concentrations.	CPR:4
9486667.T8.T28	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic @GENE$ drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.	CPR:4
9486667.T8.T26	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic @GENE$ drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.	CPR:4
9486667.T9.T28	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as @GENE$, E4031, and MK-499, at submicromolar concentrations.	CPR:4
9486667.T9.T26	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as @GENE$, E4031, and MK-499, at submicromolar concentrations.	CPR:4
9486667.T12.T31	By contrast, the closely related @CHEMICAL$ (BEAG) is 100-fold less sensitive to @GENE$.	false
9486667.T12.T32	By contrast, the closely related bovine ether-a-go-go channel (@CHEMICAL$) is 100-fold less sensitive to @GENE$.	false
9486667.T14.T34	To identify the molecular determinants for @CHEMICAL$ block, we first engineered chimeras between @GENE$ and BEAG and then used site-directed mutagenesis to localize single amino acid residues responsible for block.	false
9486667.T14.T35	To identify the molecular determinants for @CHEMICAL$ block, we first engineered chimeras between HERG and @GENE$ and then used site-directed mutagenesis to localize single amino acid residues responsible for block.	false
9486667.T15.T34	To identify the molecular determinants for dofetilide block, we first engineered chimeras between @CHEMICAL$ and BEAG and then used site-directed mutagenesis to localize single @GENE$ residues responsible for block.	false
9486667.T15.T35	To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and @CHEMICAL$ and then used site-directed mutagenesis to localize single @GENE$ residues responsible for block.	false
9486667.T1.T18	Thus, our results indicate that important determinants of @CHEMICAL$ binding are localized to the pore region of @GENE$.	false
9486667.T4.T22	Moreover, the reverse mutation BEAG @CHEMICAL$ increased the affinity of BEAG @GENE$ channels for dofetilide, whereas C-type inactivation could not be recovered.	false
9486667.T4.T24	Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG @CHEM-GENE$ for dofetilide, whereas C-type inactivation could not be recovered.	false
9486667.T4.T21	Moreover, the reverse mutation @CHEMICAL$ T432S increased the affinity of BEAG @GENE$ channels for dofetilide, whereas C-type inactivation could not be recovered.	false
9486667.T4.T23	Moreover, the reverse mutation BEAG T432S increased the affinity of @CHEMICAL$ @GENE$ channels for dofetilide, whereas C-type inactivation could not be recovered.	false
9486667.T5.T22	Moreover, the reverse mutation BEAG @CHEMICAL$ increased the affinity of BEAG K+ channels for @GENE$, whereas C-type inactivation could not be recovered.	false
9486667.T5.T24	Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG @CHEMICAL$ for @GENE$, whereas C-type inactivation could not be recovered.	false
9486667.T5.T21	Moreover, the reverse mutation @CHEMICAL$ T432S increased the affinity of BEAG K+ channels for @GENE$, whereas C-type inactivation could not be recovered.	false
9486667.T5.T23	Moreover, the reverse mutation BEAG T432S increased the affinity of @CHEMICAL$ K+ channels for @GENE$, whereas C-type inactivation could not be recovered.	false
9486667.T6.T27	Thus, the @CHEMICAL$ in position @GENE$ 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.	false
9486667.T7.T27	Thus, the serine in position @CHEMICAL$ 620 may participate directly in @GENE$ binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.	false
9521275.T3.T10	Treatment using a combination of @CHEMICAL$ and the @GENE$ inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than testosterone alone.	false
9521275.T4.T10	Treatment using a combination of testosterone and the @CHEMICAL$ inhibitor @GENE$ may have significantly better effects on sexual function and also seizure frequency than testosterone alone.	CPR:4
9521275.T5.T10	Treatment using a combination of testosterone and the @CHEMICAL$ inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than @GENE$ alone.	false
9525919.T16.T19	Identification of binding sites for @CHEMICAL$ and trifluoperazine on cardiac troponin C. The solution structure of @GENE$ (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.	false
9525919.T16.T22	Identification of binding sites for @CHEMICAL$ and trifluoperazine on cardiac troponin C. The solution structure of cardiac troponin C (@GENE$) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.	false
9525919.T16.T26	Identification of binding sites for @CHEMICAL$ and trifluoperazine on @GENE$. The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.	false
9525919.T17.T19	Identification of binding sites for bepridil and @CHEMICAL$ on cardiac troponin C. The solution structure of @GENE$ (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.	false
9525919.T17.T22	Identification of binding sites for bepridil and @CHEMICAL$ on cardiac troponin C. The solution structure of cardiac troponin C (@GENE$) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.	false
9525919.T17.T26	Identification of binding sites for bepridil and @CHEMICAL$ on @GENE$. The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.	false
9525919.T5.T20	For example, it is clear that the closed conformation of the regulatory @CHEMICAL$-terminal domain in Ca2+-bound @GENE$ (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.	false
9525919.T5.T21	For example, it is clear that the closed conformation of the regulatory @CHEMICAL$-terminal domain in Ca2+-bound cardiac troponin C (@GENE$) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.	false
9525919.T6.T20	For example, it is clear that the closed conformation of the regulatory N-terminal domain in @CHEMICAL$-bound @GENE$ (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.	false
9525919.T6.T21	For example, it is clear that the closed conformation of the regulatory N-terminal domain in @CHEMICAL$-bound cardiac troponin C (@GENE$) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.	false
9525919.T7.T20	For example, it is clear that the closed conformation of the regulatory N-terminal domain in Ca2+-bound @CHEMICAL$ (cTnC) presents a much different binding surface for @GENE$-sensitizing compounds than previously thought.	false
9525919.T7.T21	For example, it is clear that the closed conformation of the regulatory N-terminal domain in Ca2+-bound cardiac troponin C (@CHEMICAL$) presents a much different binding surface for @GENE$-sensitizing compounds than previously thought.	false
9525919.T10.T23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [@GENE$]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T10.T24	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [@CHEMICAL$]Met-labeled @GENE$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T11.T23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that @GENE$ and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T11.T24	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @CHEMICAL$ indicate that @GENE$ and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T12.T23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and @GENE$ bind to similar sites but only in the presence of Ca2+.	false
9525919.T12.T24	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @CHEMICAL$ indicate that bepridil and @GENE$ bind to similar sites but only in the presence of Ca2+.	false
9525919.T13.T23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of @GENE$.	false
9525919.T13.T24	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @CHEMICAL$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of @GENE$.	false
9525919.T8.T23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for @CHEMICAL$ and bepridil on @GENE$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T8.T24	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for @CHEMICAL$ and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @GENE$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T9.T23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and @CHEMICAL$ on @GENE$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T9.T24	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and @CHEMICAL$ on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @GENE$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	false
9525919.T14.T25	There are 3-4 drug binding sites in the @CHEMICAL$- and C-terminal domains of intact @GENE$ that exhibit fast exchange on the NMR time scale.	false
9525919.T15.T25	There are 3-4 drug binding sites in the N- and @CHEMICAL$-terminal domains of intact @GENE$ that exhibit fast exchange on the NMR time scale.	false
9525919.T4.T18	This subregion in @CHEMICAL$ makes a likely target against which to design new and selective @GENE$-sensitizing compounds.	false
9596079.T13.T28	Peripheral blood mononuclear cells express mutated @CHEMICAL$ mRNA in Gitelman's syndrome: evidence for abnormal @GENE$-sensitive NaCl cotransport.	false
9596079.T14.T28	Peripheral blood mononuclear cells express mutated @CHEMICAL$ mRNA in Gitelman's syndrome: evidence for abnormal thiazide-sensitive @GENE$ cotransport.	false
9596079.T10.T17	Genetic analysis has demonstrated complete linkage between the human @CHEMICAL$-sensitive sodium chloride cotransporter gene (@GENE$ or TSC) and Gitelman's syndrome (GS).	false
9596079.T10.T18	Genetic analysis has demonstrated complete linkage between the human @CHEMICAL$-sensitive sodium chloride cotransporter gene (NCCT or @GENE$) and Gitelman's syndrome (GS).	false
9596079.T10.T25	Genetic analysis has demonstrated complete linkage between the @CHEM-GENE$ gene (NCCT or TSC) and Gitelman's syndrome (GS).	false
9596079.T12.T17	Genetic analysis has demonstrated complete linkage between the human thiazide-sensitive @CHEMICAL$ cotransporter gene (@GENE$ or TSC) and Gitelman's syndrome (GS).	false
9596079.T12.T18	Genetic analysis has demonstrated complete linkage between the human thiazide-sensitive @CHEMICAL$ cotransporter gene (NCCT or @GENE$) and Gitelman's syndrome (GS).	false
9596079.T12.T25	Genetic analysis has demonstrated complete linkage between the @CHEM-GENE$ gene (NCCT or TSC) and Gitelman's syndrome (GS).	false
9596079.T9.T22	This study was performed to determine whether peripheral blood mononuclear cells (PBMC) express @CHEMICAL$ mRNA and whether defective PBMC @GENE$ cotransport could be demonstrated in GS.	false
9596079.T8.T21	Furthermore, functional evidence is provided that the underlying cause of GS is defective @CHEMICAL$ @GENE$ cotransport.	false
9631585.T5.T12	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with @CHEMICAL$ inhibitors, @GENE$ and mitoxantrone, and the alkylating agent, cyclophosphamide.	CPR:4
9631585.T6.T12	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with @CHEMICAL$ inhibitors, etoposide and @GENE$, and the alkylating agent, cyclophosphamide.	CPR:4
9631585.T7.T12	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with @CHEMICAL$ inhibitors, etoposide and mitoxantrone, and the alkylating agent, @GENE$.	false
9631585.T1.T8	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with @CHEMICAL$ inhibitors, @GENE$ and mitoxantrone, and an alkylating agent, cyclophosphamide.	CPR:4
9631585.T2.T8	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with @CHEMICAL$ inhibitors, etoposide and @GENE$, and an alkylating agent, cyclophosphamide.	CPR:4
9631585.T3.T8	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with @CHEMICAL$ inhibitors, etoposide and mitoxantrone, and an alkylating agent, @GENE$.	false
9673855.T1.T40	@CHEMICAL$ (deprenyl), a selective, irreversible inhibitor of @GENE$ (MAO-B) is widely used in the treatment of Parkinson's disease.	CPR:4
9673855.T1.T41	@CHEMICAL$ (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (@GENE$) is widely used in the treatment of Parkinson's disease.	CPR:4
9673855.T28.T40	Selegiline (deprenyl), a selective, irreversible inhibitor of @CHEM-GENE$ (MAO-B) is widely used in the treatment of Parkinson's disease.	false
9673855.T28.T41	Selegiline (deprenyl), a selective, irreversible inhibitor of @CHEMICAL$ oxidase type B (@GENE$) is widely used in the treatment of Parkinson's disease.	false
9673855.T2.T40	Selegiline (@CHEMICAL$), a selective, irreversible inhibitor of @GENE$ (MAO-B) is widely used in the treatment of Parkinson's disease.	CPR:4
9673855.T2.T41	Selegiline (@CHEMICAL$), a selective, irreversible inhibitor of monoamine oxidase type B (@GENE$) is widely used in the treatment of Parkinson's disease.	CPR:4
9673855.T25.T39	Unlike the nonselective @CHEMICAL$ inhibitors, @GENE$ does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.	CPR:4
9673855.T26.T39	Unlike the nonselective @CHEMICAL$ inhibitors, selegiline does not significantly potentiate @GENE$-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.	false
9673855.T11.T36	A low @CHEMICAL$ diet is recommended if selegiline is used together with nonselective @GENE$ inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.	false
9673855.T11.T37	A low @CHEMICAL$ diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible @GENE$ inhibitor, moclobemide.	false
9673855.T12.T36	A low tyramine diet is recommended if @CHEMICAL$ is used together with nonselective @GENE$ inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.	CPR:4
9673855.T12.T37	A low tyramine diet is recommended if @CHEMICAL$ is used together with nonselective MAO inhibitors or the selective, reversible @GENE$ inhibitor, moclobemide.	false
9673855.T13.T36	A low tyramine diet is recommended if selegiline is used together with nonselective @CHEMICAL$ inhibitors or the selective, reversible MAO-A inhibitor, @GENE$.	false
9673855.T13.T37	A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible @CHEMICAL$ inhibitor, @GENE$.	CPR:4
9710435.T25.T35	@CHEMICAL$ inhibits @GENE$-mediated Cl- secretion.	CPR:4
9710435.T1.T28	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of @CHEMICAL$ and salicylic acid on CFTR @GENE$ in excised, inside-out patches from L-cells were evaluated.	false
9710435.T1.T26	To determine whether this inhibition of ICl was due to the inhibition of @CHEMICAL$, the effects of @GENE$ and salicylic acid on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.	false
9710435.T1.T27	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of @CHEMICAL$ and salicylic acid on @GENE$ Cl- channels in excised, inside-out patches from L-cells were evaluated.	false
9710435.T2.T28	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and @CHEMICAL$ on CFTR @GENE$ in excised, inside-out patches from L-cells were evaluated.	false
9710435.T2.T26	To determine whether this inhibition of ICl was due to the inhibition of @CHEMICAL$, the effects of ibuprofen and @GENE$ on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.	false
9710435.T2.T27	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and @CHEMICAL$ on @GENE$ Cl- channels in excised, inside-out patches from L-cells were evaluated.	false
9710435.T3.T29	@CHEMICAL$ (300 microM) reduced @GENE$ Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).	CPR:4
9710435.T4.T30	Similarly, @CHEMICAL$ (3 mM) reduced @GENE$ Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).	CPR:4
9710435.T10.T32	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @CHEMICAL$ as well as basolateral membrane @GENE$ channels.	false
9710435.T10.T33	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @CHEM-GENE$.	false
9710435.T10.T31	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @CHEMICAL$ Cl- channels as well as basolateral membrane @GENE$ channels.	false
9710435.T6.T32	Based on these results, we conclude that the NSAIDs @CHEMICAL$ and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @GENE$ as well as basolateral membrane K+ channels.	CPR:4
9710435.T6.T33	Based on these results, we conclude that the NSAIDs @CHEMICAL$ and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @GENE$.	CPR:4
9710435.T6.T31	Based on these results, we conclude that the NSAIDs @CHEMICAL$ and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @GENE$ Cl- channels as well as basolateral membrane K+ channels.	CPR:4
9710435.T7.T32	Based on these results, we conclude that the NSAIDs ibuprofen and @CHEMICAL$ inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @GENE$ as well as basolateral membrane K+ channels.	CPR:4
9710435.T7.T33	Based on these results, we conclude that the NSAIDs ibuprofen and @CHEMICAL$ inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @GENE$.	CPR:4
9710435.T7.T31	Based on these results, we conclude that the NSAIDs ibuprofen and @CHEMICAL$ inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @GENE$ Cl- channels as well as basolateral membrane K+ channels.	CPR:4
9710435.T8.T32	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit @CHEMICAL$-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @GENE$ as well as basolateral membrane K+ channels.	false
9710435.T8.T33	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit @CHEMICAL$-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @GENE$.	false
9710435.T8.T31	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit @CHEMICAL$-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @GENE$ Cl- channels as well as basolateral membrane K+ channels.	false
9832994.T17.T27	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in @CHEMICAL$ and ACTH levels after i.v. @GENE$, pointing to a general state of arousal in these mCPP-treated animals.	CPR:3
9832994.T17.T28	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and @CHEMICAL$ levels after i.v. @GENE$, pointing to a general state of arousal in these mCPP-treated animals.	CPR:3
9832994.T18.T27	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in @CHEMICAL$ and ACTH levels after i.v. mCPP, pointing to a general state of arousal in these @GENE$-treated animals.	false
9832994.T18.T28	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and @CHEMICAL$ levels after i.v. mCPP, pointing to a general state of arousal in these @GENE$-treated animals.	false
9832994.T10.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @GENE$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T10.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @GENE$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T10.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @CHEMICAL$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T10.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @CHEMICAL$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9832994.T11.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @GENE$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T11.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @GENE$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T11.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @CHEMICAL$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T11.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @CHEMICAL$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9832994.T12.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @GENE$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T12.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @GENE$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T12.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @CHEMICAL$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T12.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @CHEMICAL$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9832994.T13.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @GENE$-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T13.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @GENE$-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T13.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @CHEMICAL$-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T13.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @CHEMICAL$-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9832994.T14.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist @GENE$.	false
9832994.T14.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist @GENE$.	false
9832994.T14.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @CHEMICAL$/5-HT2C antagonist @GENE$.	CPR:6
9832994.T14.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@CHEMICAL$ antagonist @GENE$.	CPR:6
9832994.T6.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as @GENE$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	CPR:6
9832994.T6.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as @GENE$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	CPR:6
9832994.T6.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as @CHEMICAL$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T6.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as @CHEMICAL$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9832994.T7.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and @GENE$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	CPR:6
9832994.T7.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and @GENE$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	CPR:6
9832994.T7.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and @CHEMICAL$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T7.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and @CHEMICAL$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9832994.T8.T23	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed @GENE$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T8.T24	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed @GENE$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	false
9832994.T8.T25	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed @CHEMICAL$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.	false
9832994.T8.T26	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed @CHEMICAL$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.	false
9851542.T23.T37	Pressor and bradycardic effects of @CHEMICAL$ and other @GENE$ inhibitors in the rat.	false
9851542.T19.T32	The cardiovascular effects of three different @CHEMICAL$ inhibitors: @GENE$, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.	CPR:4
9851542.T21.T32	The cardiovascular effects of three different @CHEMICAL$ inhibitors: physostigmine, @GENE$ and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.	CPR:4
9851542.T2.T32	The cardiovascular effects of three different @CHEMICAL$ inhibitors: physostigmine, tacrine and @GENE$ injected by intravenous (i.v.) route were compared in freely moving Wistar rats.	CPR:4
9851542.T12.T33	@CHEMICAL$ was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. @GENE$ inhibitors.	CPR:4
9851542.T17.T34	The @CHEMICAL$ antagonist @GENE$ or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	CPR:6
9851542.T17.T35	The alpha1-adrenoceptor antagonist @CHEMICAL$ or the @GENE$ antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T17.T36	The alpha1-adrenoceptor antagonist @CHEMICAL$ or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T18.T34	The @CHEMICAL$ antagonist prazosin or the @GENE$ V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T18.T35	The alpha1-adrenoceptor antagonist prazosin or the @CHEM-GENE$ antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T18.T36	The alpha1-adrenoceptor antagonist prazosin or the @CHEMICAL$ V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T20.T34	The @CHEMICAL$ antagonist prazosin or the vasopressin V1 receptor antagonist, @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T20.T35	The alpha1-adrenoceptor antagonist prazosin or the @CHEMICAL$ antagonist, @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	CPR:6
9851542.T20.T36	The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, @CHEM-GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T22.T34	The @CHEMICAL$ antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced @GENE$ pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T22.T35	The alpha1-adrenoceptor antagonist prazosin or the @CHEMICAL$ antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced @GENE$ pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T22.T36	The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] @CHEMICAL$ partially but significantly reduced @GENE$ pressor effect and mostly abolished it when administered concomitantly.	false
9851542.T3.T24	administration of the non-selective @CHEMICAL$ antagonist @GENE$ (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	CPR:6
9851542.T3.T25	administration of the non-selective muscarinic receptor antagonist @CHEMICAL$ (ID50 = 1.45 microg), the @GENE$ antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T3.T26	administration of the non-selective muscarinic receptor antagonist @CHEMICAL$ (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the @GENE$ antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T3.T27	administration of the non-selective muscarinic receptor antagonist @CHEMICAL$ (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the @GENE$ antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T4.T24	administration of the non-selective @CHEMICAL$ antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist @GENE$ (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T4.T25	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the @CHEMICAL$ antagonist @GENE$ (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	CPR:6
9851542.T4.T26	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist @CHEMICAL$ (ID50 = 4.33 microg), the @GENE$ antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T4.T27	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist @CHEMICAL$ (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the @GENE$ antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T5.T24	administration of the non-selective @CHEMICAL$ antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist @GENE$ (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T5.T25	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the @CHEMICAL$ antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist @GENE$ (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T5.T26	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the @CHEMICAL$ antagonist @GENE$ (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	CPR:6
9851542.T5.T27	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist @CHEMICAL$ (ID50 = 1.39 microg) and the @GENE$ antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	false
9851542.T6.T24	administration of the non-selective @CHEMICAL$ antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist @GENE$ (ID50 = 31.19 microg).	false
9851542.T6.T25	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the @CHEMICAL$ antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist @GENE$ (ID50 = 31.19 microg).	false
9851542.T6.T26	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the @CHEMICAL$ antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist @GENE$ (ID50 = 31.19 microg).	false
9851542.T6.T27	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the @CHEMICAL$ antagonist @GENE$ (ID50 = 31.19 microg).	CPR:6
9851542.T7.T28	Central injection of such @CHEMICAL$ antagonists did not affect @GENE$-induced bradycardia.	false
9851542.T8.T29	Our results show that @CHEMICAL$ inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central muscarinic M2 receptors inducing a secondary increase in sympathetic outflow and @GENE$ release.	false
9851542.T8.T30	Our results show that acetylcholinesterase inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central @CHEMICAL$ inducing a secondary increase in sympathetic outflow and @GENE$ release.	false
9876137.T8.T23	State-dependent @CHEMICAL$ block of @GENE$ isoforms, chimeras, and channels coexpressed with the beta1 subunit.	CPR:4
9876137.T9.T23	State-dependent cocaine block of @CHEM-GENE$ isoforms, chimeras, and channels coexpressed with the beta1 subunit.	false
9876137.T1.T10	@CHEMICAL$ block of @GENE$ and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	CPR:4
9876137.T1.T15	@CHEMICAL$ block of human cardiac (hH1) and @GENE$ was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	CPR:4
9876137.T7.T10	Cocaine block of @CHEMICAL$ and rat skeletal (mu1) muscle @GENE$ channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	false
9876137.T7.T15	Cocaine block of human cardiac (hH1) and @CHEM-GENE$ was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	false
9876137.T5.T13	@CHEMICAL$ block of @GENE$ was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.	CPR:4
9876137.T5.T14	@CHEMICAL$ block of hH1 channels was greater than block of @GENE$ at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.	CPR:4
9876137.T5.T16	@CHEMICAL$ block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of @GENE$ in this voltage range makes them more susceptible to cocaine block.	CPR:4
9876137.T6.T13	Cocaine block of @CHEMICAL$ was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to @GENE$ block.	false
9876137.T6.T14	Cocaine block of hH1 channels was greater than block of @CHEMICAL$ at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to @GENE$ block.	false
9876137.T6.T16	Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of @CHEMICAL$ in this voltage range makes them more susceptible to @GENE$ block.	CPR:4
